<SEC-DOCUMENT>0001493152-26-014692.txt : 20260401
<SEC-HEADER>0001493152-26-014692.hdr.sgml : 20260401
<ACCEPTANCE-DATETIME>20260401165059
ACCESSION NUMBER:		0001493152-26-014692
CONFORMED SUBMISSION TYPE:	424B3
PUBLIC DOCUMENT COUNT:		9
FILED AS OF DATE:		20260401
DATE AS OF CHANGE:		20260401

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Kairos Pharma, LTD.
		CENTRAL INDEX KEY:			0001962011
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				462993314
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B3
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-284569
		FILM NUMBER:		26829123

	BUSINESS ADDRESS:	
		STREET 1:		2355 WESTWOOD BLVD. #139
		CITY:			LOS ANGELES
		STATE:			CA
		ZIP:			90064
		BUSINESS PHONE:		818-404-5541

	MAIL ADDRESS:	
		STREET 1:		2355 WESTWOOD BLVD. #139
		CITY:			LOS ANGELES
		STATE:			CA
		ZIP:			90064
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B3
<SEQUENCE>1
<FILENAME>form424b3.htm
<DESCRIPTION>424B3
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Filed
Pursuant to Rule 424(b)(3)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Registration
Statement No. 333-284569</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Prospectus
Supplement No. 2</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(To
Prospectus Dated February 4, 2025)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; color: Red"><IMG SRC="form424b3_001.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Kairos
Pharma, Ltd.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2,500,000
shares of Common Stock Issuable Upon Exercise of the Pre-Funded Warrants</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>3,750,000
shares of Common Stock Issuable Upon Exercise of the Common Warrants</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>175,000
shares of Common Stock Issuable Upon Exercise of the Placement Agent Warrants</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
prospectus supplement No. 2 updates, amends and supplements the prospectus dated February 4, 2025 (as supplemented or amended from time
to time, the &ldquo;Prospectus&rdquo;), which forms a part of our Registration Statement on Form S-1, as amended (Registration No. 333-284569).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
prospectus supplement is being filed to update, amend and supplement the information in the Prospectus with the information contained
in our Annual Report on Form 10-K for the fiscal year ended December 31, 2025, originally filed with the Securities and Exchange Commission
on March 31, 2026 (the &ldquo;Annual Report&rdquo;). Accordingly, we have attached the Annual Report to this prospectus supplement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Prospectus relates to the offer for sale of an aggregate of 6,425,000 shares of common stock, par value $0.001 per share (&ldquo;common
stock&rdquo;), of Kairos Pharma, Ltd. (the &ldquo;Company&rdquo;), consisting of (i) 2,500,000 shares of common stock underlying the
pre-funded warrants, exercisable for $0.001 per share, and (ii) 3,750,000 shares of common stock underlying common stock purchase warrants,
each exercisable for $1.40 per share, all of which were issued to the investor in a private placement offering which closed on January
16, 2025 (the &ldquo;PIPE Offering&rdquo;). In addition, we are registering 175,000 shares of common stock, exercisable at $1.40 per
share, underlying common stock purchase warrants issued to Boustead Securities, LLC and D. Boral Capital LLC as compensation for their
services as co-placement agents for the PIPE Offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">You
should read this prospectus supplement in conjunction with the Prospectus, including any amendments or supplements to it. This prospectus
supplement is qualified by reference to the Prospectus, except to the extent that the information provided by this prospectus supplement
supersedes information contained in the Prospectus. This prospectus supplement is not complete without and may not be delivered or used
except in conjunction with, the Prospectus, including any amendments or supplements to it. You should keep this prospectus supplement
with your Prospectus for future reference.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
common stock is listed on NYSE American under the symbol &ldquo;KAPA.&rdquo; On March 31, 2026, the last reported sale price of our common
stock was $0.559 per share. We recommend that you obtain current market quotations for our common stock prior to making an investment
decision.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>We
are an &ldquo;emerging growth company&rdquo; under federal securities laws and are subject to reduced public company reporting requirements.
Investing in our securities involves a high degree of risk. See the section entitled &ldquo;Risk Factors&rdquo; beginning on page 11
of the Prospectus, and under similar headings in any amendments or supplements to the Prospectus, and beginning on page 25 of our Annual
Report on Form 10-K contained herein. </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Neither
the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined
if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
date of this prospectus is April 1, 2026.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>TABLE
OF CONTENTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left; background-color: rgb(204,238,255)">
  <TD STYLE="width: 100%"><A HREF="#form10-K_001">ANNUAL REPORT ON FORM 10-K FOR THE FISCAL YEAR ENDED DECEMBER 31, 2025</A></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="width: 100%"><DIV STYLE="border-top: Black 4pt solid; border-bottom: Black 1pt solid; font-size: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 18pt"><B><A NAME="form10-K_001"></A>UNITED
STATES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 18pt"><B>SECURITIES
AND EXCHANGE COMMISSION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 12pt"><B>Washington,
D.C. 20549 </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 18pt"><B>FORM
10-K</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9746;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ANNUAL
    REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 </B></FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the fiscal year ended December 31, 2025</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">or</FONT></P>



<P STYLE="margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>TRANSITION
    REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 </B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the transition period from ___ to ___</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Commission
file number: 001-42275</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 18pt"><B>KAIROS
PHARMA, LTD.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Exact
name of registrant as specified in its charter)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 49%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Delaware</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 49%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>46-2993314</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(State
                                            or other jurisdiction of</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">incorporation
    or organization)</FONT></P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(I.R.S
                                            Employer</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Identification
    No.)</FONT></P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2355
Westwood Blvd., #139</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Los
Angeles CA 90064</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Address
of principal executive offices) (Zip Code)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(310)
948-2356</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Registrant&#8217;s
telephone number, including area code)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Securities
registered pursuant to Section 12(b) of the Act:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 40%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Title
    of each class</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 16%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Trading
    Symbol(s)</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 40%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Name
    of each exchange on which registered</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common
    Stock, par value $0.001 per share</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">KAPA</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NYSE
    American</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Securities
registered pursuant to Section 12(g) of the Act: None</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes &#9744; No &#9746;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes &#9744; No &#9746;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange
Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)
has been subject to such filing requirements for the past 90 days. Yes &#9746; No &#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule
405 of Regulation S-T (&#167; 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant
was required to submit such files). Yes &#9746; No &#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting
company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221;
&#8220;smaller reporting company&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Large
    accelerated filer &#9744;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accelerated
    filer &#9744;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-accelerated
    filer &#9744;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Smaller
    reporting company &#9746;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Emerging
    growth company &#9746;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness
of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered
public accounting firm that prepared or issued its audit report. &#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant
included in the filing reflect the correction of an error to previously issued financial statements. &#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation
received by any of the registrant&#8217;s executive officers during the relevant recovery period pursuant to &#167;240.10D-1(b). &#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes &#9744; No &#9746;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
June 30, 2025, the last day of the Registrant&#8217;s most recently completed second fiscal quarter, the aggregate market value of Registrant&#8217;s
common shares held by non-affiliates was approximately $6.9 million based upon the closing sale price as reported on the NYSE American. This
calculation of market value has been made for the purposes of this report only and should not be considered as an admission or conclusion
by the Registrant that any person is in fact an affiliate of the Registrant.&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of March 31, 2026, the Registrant had 21,411,198 shares of Common Stock outstanding.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="width: 100%"><DIV STYLE="border-top: Black 1pt solid; border-bottom: Black 4pt solid; font-size: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>


<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&#160;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">TABLE
OF CONTENTS</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#sp_001">PART
    I</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">3</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    1</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#sp_002">Business</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">4</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    1A</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#sp_003">Risk
    Factors</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">25</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    1B</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#an_001">Unresolved
    Staff Comments</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">95</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    1C</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#an_002">Cybersecurity</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">95</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    2</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#an_003">Properties</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">95</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    3</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#an_004">Legal
    Proceedings</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">95</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    4</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#an_005">Mine
    Safety Disclosures</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">95</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#an_006">PART
    II</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">96</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    5</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#an_007">Market
    for the Registrant&#8217;s Common Equity, Related Shareholder Maters, and Issuer Purchases of Equity Securities</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">96</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    6</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#an_008">Reserved</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">97</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    7</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#mda_001">Management&#8217;s
    Discussion and Analysis of Financial Condition and Results of Operations</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">97</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    7A</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#mda_002">Quantitative
    and Qualitative Disclosures About Market Risk</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">108</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    8</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#an_011">Financial
    Statements and Supplementary Data</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">109</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    9</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#an_012">Changes
    in and Disagreements With Accountants on Accounting and Financial Disclosure</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">110</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    9A</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#an_013">Controls
    and Procedures</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">110</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    9B</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#an_014">Other
    Information</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">111</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    9C</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#an_015">Disclosure
    Regarding Foreign Jurisdictions that Prevent Inspections</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">111</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#an_016">PART
    III</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">112</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    10</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#an_017">Directors,
    Executive Officers and Corporate Governance</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">112</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    11</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#an_018">Executive
    Compensation</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">120</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    12</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#an_019">Security
    Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">122</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    13</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#an_020">Certain
    Relationships and Related Transactions, and Director Independence</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">122</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    14</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#an_021">Principal
    Accountant Fees and Services</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">123</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#an_022">PART
    IV</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">124</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    15</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#an_023">Exhibits
    and Financial Statement Schedules</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">124</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    16</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#an_024">Form
    10-K Summary</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">127</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#an_025">Signatures</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">128</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>


<!-- Field: Page; Sequence: 4; Options: NewSection; Value: 2 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><FONT STYLE="text-decoration: underline"><FONT ID="sp_001"></FONT>PART
I</FONT></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Disclosure
Regarding Forward-Looking Statements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Annual Report on Form 10-K (the &#8220;Annual Report&#8221;) contains &#8220;forward-looking statements&#8221; within the meaning of
Section 27A of the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), and Section 21E of the Securities Exchange
Act of 1934, as amended (the &#8220;Exchange Act&#8221;), and such forward-looking statements involve risks and uncertainties. Statements
about our future results of operations and financial position, business strategy, product candidates, planned preclinical and nonclinical
studies and clinical trials, results of preclinical and nonclinical studies, clinical trials, research and development costs, regulatory
approvals, timing and likelihood of success, as well as plans and objectives of management for future operations, are forward-looking
statements. These statements involve known and unknown risks, uncertainties, and other important factors that are in some cases beyond
our control and may cause our actual results, performance, or achievements to be materially different from any future results, performance
or achievements expressed or implied by the forward-looking statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Words
such as &#8220;could,&#8221; &#8220;may,&#8221; &#8220;will,&#8221; &#8220;should,&#8221; &#8220;likely,&#8221; &#8220;anticipates,&#8221;
&#8220;expects,&#8221; &#8220;intends,&#8221; &#8220;plans,&#8221; &#8220;projects,&#8221; &#8220;believes,&#8221; &#8220;estimates,&#8221;
and variations on such words, including similar expressions, are used to identify these forward-looking statements. Forward-looking statements
contained in this Annual Report include, but are not limited to, statements about:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    initiation, timing, progress and results of our preclinical and nonclinical studies and clinical trials, and our research and development
    programs, including the manufacture of clinical trial material and drug product for launch;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to successfully complete our ongoing and planned for clinical trials and obtain regulatory approval in the United States
    for our target drugs;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to retain the continued service of our key professionals and to identify, hire and retain additional qualified professionals
    as needed;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to advance product candidates into, and successfully complete, clinical trials;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    timing of and our ability to obtain and maintain regulatory approvals for our product candidates;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    ability to commercialize our product candidates, if approved;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    ability of our current in-development products, if approved, to successfully compete with other therapies, including therapies currently
    in development;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    pricing, coverage and reimbursement of our product candidates, if approved;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    implementation of our business model, strategic plans for our business, and product candidates;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    scope of protection we are able to establish and maintain for intellectual property rights covering our product candidates;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to identify additional product candidates and advance them into clinical development;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    estimates regarding expenses, capital requirements and needs for additional financing;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    financial performance; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">developments
    relating to our competitors and our industry.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>


<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
risks and uncertainties, all of which are difficult or impossible to predict accurately and many of which are beyond our control, include,
but are not limited to those made below under &#8220;Summary of Risk Factors&#8221; and in Item 1A. Risk Factors in this Annual Report.
You should carefully consider these risks, as well as the additional risks described in other documents we file with the Securities and
Exchange Commission (&#8220;SEC&#8221;). We also operate in a very competitive and rapidly changing environment. New risks emerge from
time to time and it is not possible for our management to predict all risks, nor can we assess the impact of all such risk factors on
our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained
in, or implied by, any forward-looking statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have based these forward-looking statements largely on our current expectations and projections about our business, the industry in which
we operate and financial trends that we believe may affect our business, financial condition, results of operations, and prospects and
these forward-looking statements are not guarantees of future performance or development. Forward-looking statements in this Annual Report
are based on management&#8217;s current views and assumptions regarding future events and speak only as of the date when made. Kairos
undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future
events, or otherwise, except as required by federal securities laws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, statements that &#8220;we believe&#8221; and similar statements reflect our beliefs and opinions on the relevant subject. These
statements are based upon information available to us as of the date of this Annual Report, and while we believe such information forms
a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate
that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are
inherently uncertain, and you are cautioned not to unduly rely upon these statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless
otherwise necessary or appropriate in the context, references in this Annual Report to &#8220;Kairos,&#8221; the &#8220;Company,&#8221;
&#8220;we,&#8221; &#8220;us,&#8221; and &#8220;our&#8221; refer to Kairos Pharma, Ltd., a Delaware corporation, and our wholly owned
subsidiary, Enviro Therapeutics, Inc., a California corporation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><FONT ID="sp_002"></FONT>ITEM
1. BUSINESS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Overview</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are a clinical-stage biopharmaceutical company advancing therapeutics for cancer patients that are designed to overcome key hurdles in
immune suppression and drug resistance. These therapeutics include antibodies and small molecules for the treatment of prostate cancer,
lung cancer, breast cancer, and glioblastoma. We are driven by innovative science to develop novel and transformative drug therapies
to treat cancer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
mission is to advance our portfolio of innovative therapeutics to target key mechanisms of therapeutic resistance and immune suppression
and transform the way cancer is treated. We have leveraged molecular insights of the mechanisms of therapeutic resistance and immune
suppression to develop a new class of novel drugs that we expect will target drug resistance and checkpoints of immune suppression. Our
seven-drug portfolio offers diversification and mitigates the overall exposure to many of the inherent risks of drug development. Our
proprietary technologies are licensed from Cedars-Sinai Medical Center, the largest academic medical center in the Western U.S. and ranked
number one in California and number two in the nation in U.S. News &amp; World Report&#8217;s Best Hospitals Honor Roll for 2022-2023.
As of the date of this Annual Report, our product candidates have not been approved as safe or effective by the FDA or any other comparable
foreign regulator.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
product portfolio currently consists of:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Five
    pre-clinical or clinical-trial stage drug candidates developed by us and designed to target immune response.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Two
    therapeutic agents developed by our Enviro Therapeutics, Inc. subsidiary and designed to increase anti-tumor response in conjunction
    with cancer therapies by addressing resistance to these agents.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
    variety of technologies licensed by our Enviro Therapeutics, Inc. subsidiary and consisting of compositions and methods for treating
    diseases and conditions by targeting CD105 and depleting mitochondrial DNA from the circulation.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>


<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Our
Science</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
human immune system can tell the difference between normal cells in the body and those it sees as &#8220;foreign,&#8221; which allows
it to focus an attack on the foreign cells while leaving the normal cells alone. To do this, our immune system uses &#8220;checkpoints&#8221;
- molecules on certain immune cells that need to be activated (or inactivated) to start an immune response. Cancer cells can find ways
to use these checkpoints to avoid being attacked by the immune system.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are developing small molecules that we believe can specifically target these central checkpoints. In addition, we are developing an activated
T cell therapy designed to target cancer stem cells.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
June of 2021, we announced the acquisition of Enviro Therapeutics, Inc. to incorporate their advanced pipeline of drug candidates in
Phase 1 and Phase 2 trials. The pipeline includes two therapeutic agents addressing what we believe to be significant unmet needs in
prostate and lung cancer markets and that we believe can help address cancer progression, in particular, in those cancers that develop
resistance to standard therapies.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a result, we have a pipeline of seven drugs. We have filed an Investigational New Drug, or IND, application with the FDA that has become
effective for ENV 105. As a result, we began a Phase 1 trial for non-small cell lung cancer in September 2023 and in September 2023 opened
a randomized Phase 2 trial for prostate cancer. We believe that the mechanism of action for ENV 105 may addresses the resistance mechanism
of tumor dormancy. This was only possible because ENV 105 targets both the cancer cells as well as its supportive non-cancer environment.
The advantage of targeting the unique environment supporting the tumor cells is that their capacity to adapt and evade therapy is significantly
lower than that of the cancer itself. As such, ENV 105 is designed to address resistance to chemotherapy, radiation therapy, androgen
targeted therapy, EGFR inhibitors, or checkpoint inhibition when given in combination. Interestingly, since the target of ENV 105, endoglin,
is upregulated by the tumor and supporting cells in response to androgen targeted therapy and EGFR inhibitors as a proven mechanism of
resistance, we believe the co-administration of ENV 105 specifically targets this mechanism of resistance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Through
the Enviro Therapeutics, Inc. acquisition, we also obtained ENV 205, a pre-clinical therapeutic for treating diseases and conditions
by depletion of mitochondrial DNA from circulation and for detection of mitochondrial DNA. We intend to use this antibody technology
to treat chemotherapy resistance and for cachexia, a common problem in the cancer patient population.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Our
Pipeline</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have sought to develop a broad portfolio of novel and transformative drug therapies to treat cancer. Our current portfolio consists of
seven drug therapies consisting of peptide and small molecule cancer immunotherapeutics KROS 101, 102, 201, 301 and 401 and therapeutic
agents ENV 105 and 205. We started three clinical trials in the fall of 2023 for KROS 201 and ENV 105.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">KROS
101 is a small molecule that targets the GITR ligand, a signal for T cell growth to remove a checkpoint barrier to fight a host of cancers.
Our second drug, KROS 201, is a T cell therapy activated by dendritic cells to treat glioblastoma, a deadly and common brain cancer.
Our ENV 105 drug seeks to address unmet medical needs in large markets of prostate and lung cancers. For example, the global prostate
cancer therapeutics market size was valued at USD 7.9 billion and at USD 1.7 billion for EGFR mutant non-small cell lung cancer. Our
ENV 105 biologic drug targets endoglin and addresses resistance to androgen targeted drugs and EGFR inhibitors. A Phase 2 trial involving
a heavily pre-treated population suffering from prostate cancer was initiated at Cedars-Sinai Medical Center. The primary objective of
the study was to measure the proportion of patients at two months who had either disease stabilization or regression (i.e. complete or
partial response), referred to as the clinical benefit rate. A clinical benefit rate of 62% was observed. This Phase 2 trial involved
the use of enzalutamide (Xtandi&#174;, Pfizer) and abiraterone (ZYTIGA&#174;, Janssen), two forms of hormone therapy that blocks the androgen
receptor and its target ligand, testosterone, respectively. These two agents are considered standard of care for nearly all recurrent
prostate cancer patients.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>


<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
trial accrued patients that were resistant to the very androgen targeted therapy (enzalutamide or abiraterone) that was given in the
trial in addition to ENV105. Importantly, ENV105 administration alone has no clinical benefit, based on pre-clinical findings (conducted
by us) and previous clinical findings (through trials performed by the National Cancer Institute). However, two agents that apparently
have no clinical effect, when combined result in halting tumor progression. The finding is well justified by numerous publications demonstrating
hormone therapy resistance develops through the induction of CD105, the target of ENV 105 [Placencio-Hickok et al. (2020) Endocrine Related
Cancer 27:1; Kato et al. (2020) Oncogene 38: 716; Smith et. al. (2023) Molecular Therapy 31: 78; Thiruvalluvanet. al. (2023) Cancers
14: 2491]. All the patients in the trial were not only resistant to the two hormone therapy agents, but the patients had all had at least
one other intervention after surgical or radiation progression. For some they had failed to respond to five other drugs. The responders
to the combination therapy were patients that had exceedingly few other options for survival. The study enrolled 11 patients prior to
closure, each of whom were enrolled in one of two arms (or specific treatments) in the clinical trial. Three patients were enrolled in
the abiraterone acetate arm and eight in the enzalutamide arm. Of these patients only two and six patients on each arm were considered
assessable, respectively (i.e. completed at least two months of therapy with imaging). Of the 11 patients enrolled in the trials, nine
were evaluable. This investigator-initiated trial closed to accrual prior to its planned enrollment of 40 patients due to limitation
of the drug supply from the manufacturer. The drug supply has since been expanded and obtained by Kairos Pharma. The primary objective
of the study was to measure the proportion of patients at two months who had either disease stabilization or regression (i.e., complete
or partial response), referred to as the clinical benefit rate. Disease status assessments were made by RECIST 1.1 or PCWG3 criteria.
One of the two patients on the abiraterone arm experienced a &lt;50% decline in his serum PSA concentration with disease stabilization
by scans. Four of the six patients on the enzalutamide arm experienced clinical benefit by three showing stabilization of disease, and
one showing decline in his serum PSA concentration and scan improvement. Grade 3 side effects consisting of hyponatremia, urinary retention,
and cellulitis were noted on the abiraterone arm. None of these grade 3 events were attributed to the use of ENV105. No grade 3 events
were noted on the enzalutamide arm. The most frequent grade 1-2 events occurring in at least two patients included anemia, nausea, and
gingival bleeding.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
three-gene panel was identified to serve as a companion biomarker for patient selection. There are no approved companion diagnostic tests
for ENV105. However, candidate biomarkers revealed in the previous Phase 2 trial will be verified in the new Phase 2 trial to better
predict patients that would best respond to the ENV105. Our Enviro Therapeutics, Inc. subsidiary will strive to co-develop companion
biomarkers with all drugs in its portfolio, enabling identification of potential drug responders prior to therapy. As of the date of
this Annual Report, our companion diagnostics are in development and have not been approved by the FDA. There is no guarantee that these
companion diagnostics will be approved by the FDA or comparable foreign regulatory agencies.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 21, 2024, the NIH announced that it was awarding Neil Bhowmick, PhD, our Chief Scientific Officer and also a Cedars-Sinai Professor
of Medicine, a grant of $3.2 million to support the development of the mechanism of action and companion biomarkers in research that
is being performed by Cedars-Sinai in conjunction with our ongoing Phase 2 trial for ENV105 (carotuximab) and apalutamide treating castrate
resistant prostate cancer patients. This funding will be used by Cedars-Sinai, through Dr. Bhowmick&#8217;s study, to test for the biomarkers
and genetic studies corollary studies to support our ongoing Phase 2 trial for ENV105, and also to help identify biomarker positive patients
who will potentially respond to ENV105 in a future Phase 3 trial. This supporting work is being carried out by Cedars-Sinai, through
Dr. Bhowmick&#8217;s laboratory. These corollary studies will not offset the costs of the clinical trial that Kairos anticipates expending.
The NIH funding will be dispersed to Cedars-Sinai and Dr. Bhowmick in stages during the Phase 2 trial for ENV105. The NIH grant does
not otherwise change the cost or management of the ongoing Phase 2 clinical trial.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>


<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">KROS
101 is a small molecule that induces trimerization of the GITR ligand and is the culmination of the pioneering work of Dr. Ramachandran
Murali, our Vice President of Research and Development, in 3D crystallography. KROS 201 consists of potent T cells that are stimulated
by dendritic cells in the test tube to target cancer stem cells. Our initial focus of KROS 201 is to treat glioblastoma. Dr. Yu runs
a lab that is known for its pioneering work in dendritic cell immunotherapy.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ENV
105 demonstrated an ability to target CD105 which is elevated in drug resistance in prostate cancer. Androgen therapy resistance in prostate
cancer is being targeted in the Phase 2 trial. EGFR antagonist resistance in lung cancer is being targeted in a Phase 1 trial. The ENV
105 Phase 2 trial in prostate cancer with apalutamide (Janssen) is a multicenter trial being conducted at Cedars-Sinai, University of
Utah, and City of Hope. The Phase 1 trial in lung cancer with Tagrisso (AstraZeneca) is being conducted at Cedars-Sinai.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are also developing KROS 102, KROS 301, and KROS 401. KROS 102 is a GITR ligand antagonist designed to increase inhibitory Treg functions
while hampering T effector cell numbers and function. KROS 301 is a tumor targeting small molecule and checkpoint inhibitor with two
distinct mechanisms of action resulting from blocking intranuclear localization of RelA, a key component of the NF-KB pathway. KROS 401
is a tumor microenvironment immune modulator and cyclic peptide inhibitor of IL-4 and IL-13 reversing tumor associated macrophage inhibition.
Both therapies reverse the mechanism of immune suppression at the tumor site.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Finally,
we are developing ENV 205, what we believe to be a first-of-its-kind biologic that targets prostate cancers that have become otherwise
resistant to chemotherapy. As of the date of this Annual Report, ENV 205 has not been approved by the FDA or any other comparable foreign
regulator. ENV 205 targets the excretion of mitochondrial DNA found elevated in circulation when patients are on chemotherapy. Higher
blood levels of mitochondrial DNA are not only associated with chemotherapy resistance, but more widely recognized as a mediator of cardiac
toxicity and other systemic inflammatory events contributing to the negative side effects of chemotherapy use. Thus, depleting mitochondrial
DNA with the administration of ENV 205 restores chemotherapy sensitivity with reduced toxic side effects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Addressing
these critical targets strike cancer at what we believe to be its most vulnerable point. The group of founding scientists generating
our initial drugs have combined their pioneering contributions in structural, biology, immunology, and cancer therapy to bring to unmet
medical needs what we believe are life changing therapeutics. As of the date of this Annual Report, aside from the clinical trials, which
are conducted off-site at third party facilities, our operations are all conducted virtually as we aim to be efficient in our deployment
of capital and leverage our history with premier academic medical centers to efficiently enroll and execute clinical trials.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>


<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Our
Development Pipeline and Programs</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
drug development programs for KROS 101, 102, 201, 301, and 401 as well as therapeutic agents ENV 105 and ENV 205 are summarized in the
following table.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="form10-k_001.jpg" ALT=""></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&#160;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Kairos-Developed
Products</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Kairos&#8217;
products consist of five pre-clinical or clinical-trial stage drug candidates developed by Kairos and designed to target immune response.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">KROS
101 is an orally available GITR (glucocorticoid-induced tumor necrosis factor receptor) ligand small-molecule antagonist designed to
deplete regulatory T cells (Tregs) and activate effector T cells to augment the antitumor immune response for the treatment of patients
with cancer. We are developing KROS 101 as a systemic immune modulator to address immunosuppressive activity of solid cancers and we
are currently working towards completing IND-enabling pharmacokinetic, toxicity and safety studies in 2024&#160;. KROS 101 stabilizes
the GITR ligand to signal GITR to impact cancer therapy. GITR is a powerful checkpoint that suppresses the immune response against cancer.
This checkpoint is a central switch that promotes &#8220;killer&#8221; effector T cell functions and hampers inhibitory regulatory T
cell (Treg) functions. Due to its central role in regulating Treg, GITR receptor complex is considered an optimal therapeutic target
for treating cancer. This may be the optimal complement to add to current checkpoint inhibitors as it shows a dose dependent effective
response in increasing the immune response. As a competitive antagonist, KROS 101 could be dosed to avoid the typical common side effects
of checkpoint inhibitors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe our GITR targeting small molecule has the potential to be a significant improvement over existing antibody treatments that have
been tested in clinical trials. When GITRL binds to the GITR on the surface of Treg cells, the suppressive activity of Treg cells against
effector T cells is reduced. While on the effector T cell, GITR-GITRL binding induces the proliferation of effector T cells. This receptor
is central to the regulation of the immune system.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Whereas
previous competitor therapeutics targeting GITR were antibodies that bind the receptor, our small molecule drug fits into the GITR ligand
stabilizing the three-pronged trimer structure. This structure enables the amplification of the GITR receptor trimer, leading to physiologic
signaling for T cell proliferation. The analogy is a digital signal rather than a limited analog signal. This powerful physiologic signal
can lead to exponential signaling of T cells to proliferate against cancer cells. In addition, the small molecule half-life enables reversibility,
allows for fine tuning to limit side effects. Having both agonist and antagonist molecules can reverse potential untoward effects. In
addition, this small molecule may also be given orally as a medication. The discovery of KROS 101 was the culmination of transformative
structural biology based on exclusive proprietary 3D crystallography first used to model GITR ligand by Kairos&#8217; scientists.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">KROS
101 is currently in pre-IND studies in development for a Phase 1 trial.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>


<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">KROS
102 is a GITR antagonist designed to increase the inhibitory regulatory T cell (Treg) functions, while hampering T effector cell numbers
and function. KROS 102 has been shown to decrease T effector cells and increase Treg cells in a dose dependent fashion to treat autoimmune
diseases. We are developing a novel GITR inhibitor that can impact the abnormal immune responses against one&#8217;s own body.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Due
to its central role in regulating Treg, the GITR receptor complex is an optimal therapeutic target to treat autoimmunity. By potently
and specifically inhibiting an immune response, this strategy may impact autoimmune diseases such as Crohn&#8217;s disease, multiple
sclerosis, and rheumatoid arthritis. KROS 102 has been shown to decrease T effector cells and increase Treg cells in a dose dependent
fashion. KROS 102 is currently in preclinical studies.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">KROS
201 is a proprietary technology for the production of activated T cells. Activated T cells (ATC) are killer T cells that are made from
a patient&#8217;s white blood cells in a cell culture by activating with cytokines or T cell activating signals and by priming dendritic
cells loaded with glioblastoma cancer stem cell specific antigens. Kairos generates activated T cells that will be infused intravenously
into patients with recurrent glioblastoma.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">KROS
201 begins with the activation of T cells using dendritic cells for the treatment of patients with glioblastoma. Activated T cells (ATC)
are killer T cells that are made from a patient&#8217;s white blood cells in a cell culture by activating with cytokines or T cell activating
signals and by priming dendritic cells loaded with glioblastoma cancer stem cell specific antigens. Cytotoxic and helper T cells are
generated in a cell manufacturing center and infused into patients with recurrent glioblastoma.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe KROS 201 has the potential to become a novel T cell therapy that allows a &#8220;plug and play&#8221; scenario where a patient&#8217;s
specific tumor can be addressed as well as the improvement of cancer treatment by stimulating patients&#8217; immune systems to generate
a long-term population of cytotoxic T cells &amp; helper T cells directed against the tumor.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
completed IND-enabling pharmacology and toxicology studies and submitted an IND application.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">KROS
301 is a tumor-targeting small molecule and checkpoint inhibitor with two distinct mechanisms of action resulting from blocking intranuclear
localization of RelA, a key component of the NF-KB pathway. NF-KB is a key component for cancer growth and drug resistance. KROS 301
targets tumor cells in in RelA/p65 biomarker positive solid tumors. The use of this biomarker enables choosing patients that will respond
to the drug enabling efficient clinical trials that are more likely to succeed. KROS 301 is in active pre-clinical development. Separate
approval will be required for the development and approval of a companion diagnostic. This approval may be delayed or not issued by the
FDA.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">KROS
401 is a tumor microenvironment immune modulator and cyclic peptide inhibitor of IL-4 and IL-13 reversing tumor associated macrophage
inhibition. KROS 401 reduced the M2 macrophage population and limits fibrosis of the pancreas due to anti-inflammatory process (Xue,
Nature Com. 2015). Other indications may include pulmonary fibrosis, Crohn&#8217;s disease, and other inflammatory conditions. KROS 401
blocks the IL4/IL13 cytokine immune receptors for triple negative breast cancer and in addition, it increases anti-tumor response in
conjunction with radiation therapy in an animal model.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Recently,
it became clear that macrophages in tumors are altered by the Th2 cytokines IL-4 and IL-13, inducing alternatively activated macrophages
or M2. Breast cancer associated tumor associated macrophages are mainly activated M2 macrophages. Thus, shifting the balance toward M1
macrophages will prevent tumor growth and enable T cell activation and killing, which is dependent on Th1 cytokines. We will target a
key Th2 cytokine pathway, IL-4, and IL-13 to block macrophage immunosuppression with KROS 401, thereby allowing T cells to access tumors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe there are significant advantages to KROS 401 as our peptide binds to IL13R alpha1 and IL4R alpha1 (type I) receptor complex and
blocks both IL-4 and IL-13 mediated signaling. The implication is that targeting IL-4Ralpha is predominantly for indications such as
asthma or eczema, while the type I is for macrophages/tumor growth (esp IL13R). KROS 401 is in preclinical development.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>


<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Enviro
and Enviro-Licensed or -Acquired Products</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Enviro&#8217;s
product portfolio includes two therapeutic agents at different stages of clinical development.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ENV
105 is a Phase 2 clinical stage therapeutic agent designed to address cancer progression. ENV 105 is an antibody therapeutic designed
for use by prostate cancer patients resistant to androgen-targeted therapy, which is being tested in a Phase 2 clinical trial. We began
accruing patients for the trial in September 2023. &#160;This multicenter randomized Phase 2 trial involving Cedars-Sinai Medical Center
and City of Hope in Los Angeles California and Huntsman Cancer Center in Utah is testing the combination of a third-generation androgen
targeted therapy, apalutamide (Janssen), with or without ENV 105 for prostate cancer patients that have developed resistance to at least
one other androgen targeted inhibitor (NCT05534646). Dr. Edwin Posadas is the principal investigator of this multi-institutional trial.
Dr. Posadas is Director of the Experimental Therapeutics Program and the Medical Director of the Urologic Oncology Program at the Samuel
Oschin Comprehensive Cancer Institute at Cedars-Sinai Medical Center. Companion biomarkers for efficient selection of patients to potentially
respond to the drug will be evaluated in this trial. The genetic biomarker potentially identifies responsive patients to ENV 105 prior
to therapy for a future Phase 3 trial. The companion biomarker would require a separate approval by the FDA. Prostate cancer is the most
common, non-cutaneous cancer affecting men in the United States and 1.2 million new cases registered worldwide. It is also the second
leading cause of cancer death in American males. Androgen targeted therapy accounts for USD 15 billion in sales in 8 primary markets.
Since nearly all patients eventually develop resistance to androgen targeted therapy, addressing this population with a drug targeting
endoglin (ENV 105) is of high value for this single indication. In clinical trials, ENV 105 has been shown to be reasonably well-tolerated
in patients as an adjunct to contemporary androgen targeted inhibitors (NCT03418324). Grade 3 hyponatremia, urinary retention, and cellulitis
were noted on the abiraterone arm. None of these were attributed to the use of ENV105. No grade 3 events were noted on the enzalutamide
arm. The most frequent grade 1-2 events occurring in at least two patients (listed as abiraterone, enzalutamide) included anemia, nausea,
and gingival bleeding. Careful mechanism-of-action studies have revealed that ENV 105 impacts a more ubiquitous means of cancer drug
resistance, cancer dormancy, the growth potential for this drug alone can be large. A Phase 1 EGFR antagonist resistant non-small cell
lung cancer targeted therapy combination of Tagrisso (osimertinib, AstraZeneca) and ENV 105 is at Cedars-Sinai Medical Center. The principal
investigator of this clinical trial is Dr. Karen L. Reckamp, Professor in Medicine, Director of the Division of Medical Oncology at Cedars-Sinai
Medical Center. We also expect targeted therapies to contribute to the growth of the prostate and EGFR-dependent non-small cell lung
cancer market, as immune therapies have not shown efficacy for these two cancer types.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ENV
205, an antibody fragment targeting mitochondrial DNA was shown to limit chemotherapy resistant prostate cancer in preclinical studies.
Mitochondrial DNA depletion limit inflammation-induced pro-tumorigenic activity and sensitizes prostate cancer to docetaxel. This biologic
is a first of its kind strategy of chemotherapy sensitization. The development of chemotherapy resistance is an unfortunate eventuality
for patients with solid tumors. ENV 205 has been shown to particularly sensitize tumors to docetaxel, a taxane class of chemotherapy.
Docetaxel is used to treat several cancers such as stomach cancer, breast cancer, non-small-cell lung cancer, prostate, and head and
neck cancer. Apart from restoring efficacy of docetaxel in certain resistant tumors, the use of ENV 205 allows for reduced dosing of
the chemotherapy required to achieve the same tumor cell killing. This is paradigm shifting in patient quality of life, limiting the
significant side-effects of chemotherapy. According to Business Research Insights, docetaxel market size $137 billion globally in 2024,
and is expected to reach $329 billion by 2033.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Our
Market Opportunity</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Global
cancer drug spending was valued at approximately $232 billion in 2024, and is expected to reach some $532 billion by 2031 driven largely
by the growth of targeted therapies and immuno-oncology (https://www.biospace.com/oncology-drugs-market-to-reach-usd-532-91-billion-by-2031-coherent-market-insights#:~:text=The%20global%20Oncology%20Drugs%20Market,report%20by%20Coherent%20Market%20Insights.).
Global immunotherapy market was valued at $226 billion by 2024 and is projected to grow at a CAGR of 11.9% from 2025 to 2030 (Grand View
Research). Increasing patient pool and higher mortality rates are augmenting the need for cancer immunotherapy globally. We are uniquely
positioned to advance our immunotherapies that may have the potential to transform the way cancer is treated using antibodies that target
CD105 to reverse drug resistance to prostate and lung cancer and activated T cells that target cancer stem cells that are the root of
glioblastoma. Our pipeline of immunotherapeutic agents that signals growth of effector T cells against cancer, and reverse immunosuppression
at the cancer site are being rapidly advanced to address large unmet needs in cancer immunotherapy.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>


<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ENV
105</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
broad application of ENV 105 as a complementary drug to support standard of care cancer therapy for many cancer types has revealed numerous
potential therapeutic strategies that have not been exhaustively explored in pre-clinical models. This is based on the identification
that ENV 105 acts on both the cancer cells and cancer associated fibroblastic cells, thus it complements many cancer epithelia-directed
therapies. However, we have focused on three indications in pre-clinical studies, two of which have matured to clinical trials: prostate
cancer (Phase 2 with androgen signaling inhibitors), lung cancer (Phase 1 with EGFR antagonist), and head and neck cancer (preclinical
with radiation or chemotherapy).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="text-decoration: underline">Prostate
cancer</FONT>: There are some 300,000 castrate resistant prostate cancer patients in the U.S. eligible to be given combination therapy of
ENV 105 + androgen signaling inhibitors for $5,000 per month (based on comparable neutralizing antibodies). This would suggest a potential
US$9 billion gross sales for ENV 105 for a six-month dose in the U.S. for this single indication. As a point of reference, androgen signaling
inhibitors on their own make up $10 billion market inclusive of Sanofi; Johnson and Johnson Services, Inc.; Pfizer, Inc.; Astellas Pharma,
Inc.; and Bayer AG - predicted to grow to $15 billion global market by 2027 of castrate resistant prostate cancer patients. None have
been approved to extend efficacy apart from chemotherapy (docetaxel and cabazitaxel) with undesirable toxicity profiles.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="text-decoration: underline">Lung
cancer</FONT>: There are approximately 30,466 patients with an EGFR driven non-small cell lung cancer annually in the U.S. The incidence
of EGFR driven NSCLC is most prevalent in non-smokers and those of east Asian descent, 35-40% of NSCLC - 341,633 patients annually in
Asia (China, India, Japan, S. Korea, Thailand, Philippines). To determine lung cancer market share for ENV 105, the current market share
for Tagrisso (US$3 billion annual sales for AstraZeneca) can be used as point of reference. Accordingly, ENV 105 could have a $1 billion
market share in the U.S. as a combination therapy with EGFR antagonists to improve or extend its efficacy.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="text-decoration: underline">Head
and neck cancer</FONT>: The capacity for ENV105 to complement both radiation and chemotherapy would suggest future clinical application
in many solid tumor types. For head and neck cancer, the World Health Organization estimates more than 550,000 new cases of and around
300,000 deaths per year. The rising consumption of alcohol and tobacco is a major factor behind estimated 7.9% increase in the head and
neck cancer by 2030. The global head &amp; neck cancer drug market is estimated to reach $8.1 billion in 2031. (See https://www.ihealthcareanalyst.com/global-head-neck-squamous-cell-carcinoma-drugs-market/).
Chemotherapy is the standard of care alone or in combination with radiation therapy, where toxicity is the greatest limitation. Administration
of ENV 105 enables lower radiation dosing to improve quality of life.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>KROS
101 and KROS 102</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Checkpoint
inhibitors are immunotherapeutic agents that block proteins that suppress a potent immune response of the body against cancers and other
&#8220;foreign&#8221; agents. KROS 101 and 102 are checkpoint inhibitors and agonists that enable T cells to expand and contract respectively.
The global immune checkpoint inhibitor market size was $47.4 billion in 2023 and anticipated to be $189.1 billion in 2032 with a CAGR
of 16,7% from 2024 to 2032 (Global Markets Insights; https://www.gminsights.com/industry-analysis/immune-checkpoint-inhibitors-market).
According to the same report, there was a $22.9 billion immune checkpoint inhibitors market in North America as of 2023.&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>KROS
201</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">KROS
201 is an activated T cell therapy that targets glioblastoma. T cell therapy market size is expected to be around $20.8 billion by 2030
from its value of $4.9 billion in 2021 with a CAGR of 20.4% during the forecast period 2022-2030 (Vision Research Reports).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>KROS
301</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
global small-molecule cancer therapies market size was valued at $175.3 billion in 2021 and is expected to have a CAGR of 5.44% from
2022 to 2030 (Grand View Research). KROS 301 is a small molecule that targets the NF-kB pathway in cancer to prevent cancer growth and
block checkpoint inhibitor expression of PD-L1.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>


<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>KROS
401</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
global peptide therapeutics market size was $117.3 billion in 2024 and is estimated to grow CAGR of 10.77% from 2025 to 2030 (Grand View
Research). KROS 401 is a cyclic peptide that blocks IL-4 and IL-13 receptors on tumor associated macrophage to reverse immune suppression
at the tumor site.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ENV
205</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cachexia
is debilitating disease of muscle wasting not treatable by nutrition supplementation associated with the death of 50% of all cancer,
20% of AIDS, and 30% of COPD patients, according to [Argil&#233;s et al. (2023) Nature Reviews Clinical Oncology 20:250-264]. Cachexia
is an underrecognized consequence of many chronic diseases. We believe ENV 205 is a molecule found to limit the process of muscle wasting
through the capture and excretion of mitochondrial DNA in circulation. Cachexia is considered an orphan disease in the U.S. and Europe,
increasing hospitalization costs and length of stay in several disease types. The specific cancer cachexia therapeutics market was over
$2 billion in 2022 worldwide, with an estimated growth to to over $4 billion by 2032, according to Market.US. The application of ENV
205 as cachexia therapeutic is further supported by the demonstrated restoration of docetaxel therapy sensitivity in resistant prostate
cancer models. Taxane-based therapy, inclusive of docetaxel, paclitaxel, and cabazataxel, is standard of care for majority of solid tumors
(inclusive of breast cancer, non-small cell lung cancer, advanced stomach cancer, head and neck cancer and metastatic prostate cancer).
Strong preclinical data suggest ENV 205 chemotherapy sensitization in a combination therapy setting and limit the development of cachexia
as a single agent.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
will aggressively pursue ENV 105 and ENV 205 in pre-clinical and clinical trials. Future therapeutic targets will be developed based
on the overriding mission to complement traditional cancer-targeted drugs with those that address the tumor microenvironment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Our
Strategy</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
goal is to unlock the power of the immune system on the two most pervasive problems in cancer treatment: (i) resistance to therapy and
(ii) immune suppression by cancer. We believe this road will lead to major improvement in the quality of life of cancer patients and
will transform the outcomes of patients. We seek to develop cutting-edge therapeutics for cancer patients that reverse the inhibitory
effects of cancer on the immune system. To this end, our strategy involves rapidly and efficiently advancing our existing portfolio of
innovative products through clinical development and leveraging our current industry-leading team. The strategy consists of the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
    multi-pronged toolkit of potent and life changing therapeutics with differing modalities, targets, and stages of development. Their
    commonality is targeting key mechanisms of drug resistance and immune suppression by cancer.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Leverage
    our academic research and clinical connections with our industry collaborations.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Complete
    enrollment of prostate patients in a randomized multi-institutional Phase 2 trial of ENV 105.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Complete
    enrollment in a Phase 1 trial of ENV105 for patients with non-small lung cancer on Tagrisso.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Initiate
    a Phase 1 trial of activated T cell therapy for KROS 201 in patients with glioblastoma.</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Complete
    pre-IND studies for the checkpoint inhibitor KROS 101.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Continue
    to advance our pipeline of immunotherapeutics for clinical trials.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Maintain
    a portfolio of innovative therapeutics to mitigate risk.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Leverage
    virtual infrastructure for efficient execution of collaborative clinical and translational research.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Utilize
    internal development capabilities to leverage close academic partnerships.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>


<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
particular, we intend to deploy an aggressive, three-pronged, growth strategy that we believe will help us develop our clinical pipeline
and maximize our success, consisting of strategic partnerships, commercial development, and portfolio optimization.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Strategic
    Partnerships</I></B> - We will focus on expanding our existing pipeline through establishing strategic partnerships with companies
    that have interesting products and technologies. We intend to focus on novel, early-stage and preclinical assets in a variety of
    therapeutic areas.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Commercial
    Development</I></B> - We expect to participate and assist in the commercial development activities of its assets with our strategic
    partners. Commercial development activities may include, but are not limited to, clinical development, market research, healthcare
    economics, market access, sales/marketing, and commercial launch strategies.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Portfolio
    Optimization</I></B> - We will continue to evaluate, prioritize, optimize, and make appropriate changes in our pipeline portfolio
    as market development dynamics and/or product opportunities change.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="form10-k_002.jpg" ALT=""></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&#160;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Our
Team</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Company is led by our CEO and Chairman, Dr. John S. Yu, our Chief Scientific Officer, Dr. Neil Bhowmick, our Vice President of Research
and Development, Dr. Ramachandran Murali, and our Chief Financial Officer, Mr. Doug Samuelson.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
Yu is a Professor and Clinical Chief in the Department of Neurosurgery and Director of the Brain Tumor Center at Cedars-Sinai Medical
Center in Los Angeles, California. Dr. Bhowmick is a Professor of the Department of Medicine and Director of the Cancer Biology Program
at Cedars-Sinai Medical Center. Dr. Murali is a structural biologist at Cedars-Sinai Medical Center, and the inventor, with others, of
three of the patented technologies licensed to Kairos.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Intellectual
Property</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Overview</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
Yu, Dr. Bhowmick and Dr. Murali have developed certain proprietary technology, and identified other proprietary technology developed
by researchers and Cedars, that the Company will pursue for commercialization. Proprietary technology invented and developed by doctors
and scientists and Cedars are owned by Cedars, and then optioned and/or licensed to such doctors and scientists, or other third parties,
for commercialization in partnership with Cedars. Kairos and its subsidiary Enviro have multiple such options and/or license agreements
with Cedars regarding proprietary technology that the Company is pursuing for commercialization, as described below.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>


<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
of our patent rights are subject to the license agreements between the patent owner and the Company, described below.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Kairos
Intellectual Property Agreements with Cedars-Sinai Medical Center</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Kairos
has entered into four Exclusive License Agreements with Cedars-Sinai Medical Center, which are sometimes referred to as the Kairos-Cedars
license agreements, which grant Kairos exclusive licensing rights (including the right to sublicense) with respect to certain patent
rights owned by Cedars to the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Method
    of generating activated T cells for cancer therapy, invented by Dr. John S. Yu and others.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Methods
    of use of compounds that bind to RelA of NFkB, invented by Dr. Ramanchandran Murali and others.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Composition
    and methods for treating fibrosis, invented by Dr. Ramanchandran Murali and others.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Compositions
    and methods for treating cancer and autoimmune diseases, invented by Dr. Ramanchandran Murali and others.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the exclusive license agreement in item 1 above, Kairos is required to pay (i) an initial license fee in the mid five-figures upon the
raising of $500,000 in capital, (ii) an annual maintenance fee in the low five-figures, (iii) royalties based on low single-digit percentage
of patent product sales and less than one percent of other sales and (iv) other non-royalty sublicense fees ranging from a mid-single-digit
to low double-digit percentage of such revenues shall be due and payable to Cedars, depending on the stage of FDA authorization at the
time the sublicense revenue is generated. Non-royalty sublicense revenue would be between 5% and 35% depending on the phase of FDA testing
of the product during which the sublicense agreement is signed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, Kairos is required to make payments to Cedars based on the following milestones: (i) successful completion of Phase 1 clinical
trial; (ii) the successful completion of Phase 2 clinical trial and receipt of U.S. Food and Drug Administration, or FDA, or equivalent
regulatory agency in another jurisdiction approval for a Phase 3 clinical trial; (iii) receipt of FDA approval; and (iv) cumulative net
sales exceeding $50,000,000. If all of these milestones are met, the required milestone payments will total $4,400,000.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
each of the exclusive license agreement in items 2, 3 and 4 above, Kairos is required to (i) pay an initial license fee of $15,000, (ii)
reimburse Cedars for patent protection costs ranging from the high four-figures to the mid-five-figures, (iii) pay an annual maintenance
fee in the low five-figures and (iv) pay royalties based on a low single-digit percentage of net sales. The royalty obligations as to
each product will terminate on a country-by-country basis concurrently with the expiration of the last to expire of a valid claim within
the patent rights that covers such product, including any term extensions thereof. There are no non-royalty expiration dates. Patent
expiration dates and specific jurisdictions of foreign patents that we in-license from Cedars-Sinai are listed in the Patent Table at
page 100 below.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Enviro
Intellectual Property Agreements with Cedars-Sinai Medical Center</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 16, 2020, Enviro entered into two Exclusive Option Agreements with Cedars-Sinai Medical Center that gives Enviro options to enter
into an Exclusive Agreement with Cedars which would grant Enviro exclusive licensing rights (including the right to sublicense) to certain
patent rights owned by Cedars with respect to (1) compositions and methods for treating diseases and conditions by depletion of mitochondrial
DNA from circulation for detection of mitochondrial DNA, and (2) sensitization of tumors to therapies through endoglin antagonism.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>


<!-- Field: Page; Sequence: 16; Value: 2 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
consideration of these agreements, Enviro agreed to pay option fees of $2,000 and $3,000, respectively. Enviro&#8217;s options expire
nine months from the effective date. On January 9, 2021 and January 11, 2021, the parties agreed to extend both nine-month option periods
for an additional six months. In consideration of these extensions, Enviro agreed to pay an extension fee of $500, and $1,000, respectively.
Enviro entered into two Exclusive License Agreements with Cedars-Sinai Medical Center on June 2, 2021. Enviro and Cedars entered into:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">an
    Exclusive License Agreement for Enviro to develop, manufacture, use and sell products utilized or derived from patent rights worldwide,
    which include one patent application in the United States related to the &#8220;Compositions and Methods for Treating Diseases and
    Conditions by Depletion of Mitochondrial DNA from Circulation and for Detection of Mitochondrial DNA&#8221; invented by Dr. Neil
    Bhowmick and others; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">an
    Exclusive License Agreement for Enviro to develop, manufacture, use and sell products utilized or derived from the patent rights
    and technical information worldwide, which include six patent applications in the United States, Australia, Canada, China, Europe
    and Japan related to the &#8220;Sensitization of Tumors to Therapies Through Endoglin Antagonism&#8221; invented by Dr. Neil Bhowmick
    and others.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
milestones agreed to were as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Completion
    of preclinical studies within two years of the effective date, as stipulated in the agreement thereof (the &#8220;Effective Date&#8221;);</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Completion
    of toxicology studies within two and a half years of the Effective Date;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Obtaining
    IND within three years of the Effective Date; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Beginning
    the Phase 1 trial within four years of the Effective Date.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of the date of this Annual Report, we have completed milestones 1, 2 and 3.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the two Enviro-Cedars license agreements, Enviro must meet certain milestones relating commercialization, and, if not met or extended,
Cedars may convert the exclusive licenses into non-exclusive licenses or to co-exclusive licenses, or terminate the licenses. In exchange
for each of the licenses, Enviro is obligated to pay an upfront license fee, plus an additional fee when Enviro has raised at least $250,000
in capital company-wide for any program or purpose; provided, however, that the Company will only have to pay such fee once between both
Enviro-Cedars license agreements. Enviro was also obligated to reimburse Cedars for the costs incurred for the prosecution of the patent
rights subject to the Enviro-Cedars license agreements prior to the date of execution of such agreements. The aggregate potential fees
that Enviro may have to pay in exchange for the licenses is approximately $690,000 as of December 31, 2024. &#160;Together, Kairos and
Enviro owed a total of approximately $950,000 to Cedars, of which $750,000 was converted into 312,500 shares of common stock, or 60%
of the IPO price, upon closing of the IPO. And on November 13, 2024, an additional $200,000 was converted into 150,830 shares of common
stock, using a conversion price equal to 60% of the closing price on November 13, 2024. Cedars will also be entitled to receive royalty
payments of a mid-single-digit percentage of net sales of products associated with the licensed patent right and less than one percent
of net sales of other products derived from Cedars&#8217; technical information, with a minimum royalty year in the low five-digits due
beginning on the third anniversary of the effective date of the license. To the extent Enviro derives non-royalty sublicensing revenues,
a high single-digit to low double-digit percentage of such revenues shall be due and payable to Cedars, depending on the stage of FDA
authorization at the time the sublicense revenue is generated. Non-royalty sublicense revenue would be between 5% and 35% depending on
the phase of FDA testing of the product during which the sublicense agreement is signed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Enviro
shall pay Cedars in connection with achieving certain milestones relating to products derived from the patent rights: (i) successful
completion of Phase 1 clinical trial; (ii) successful completion of Phase 2 clinical trial, receipt of FDA approval, and approval for
a Phase 3 clinical trial; (iii) FDA approval of a new drug application or biologics license applications; and (iv) cumulative net sales
exceeding $100,000,000. The maximum aggregate milestone payment for ENV 105 will be $7,150,000 when cumulative net sales have exceeded
$100,000,000. The last-to-expire of licensed patents is scheduled to expire on June 14, 2037. Patent expiration dates, specific jurisdictions
of foreign patents are listed in the Patent Table above.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>


<!-- Field: Page; Sequence: 17; Value: 2 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Enviro-Cedars license agreements will, unless sooner terminated, continue in effect on a country-by-country basis until the last to expire
of the patents covering the patent rights or future patent rights. Under the terms of the Enviro-Cedars license agreements, unless waived
by Cedars, the agreement shall automatically terminate: (a) if Enviro ceases, dissolves or winds up its business operations; (b) if performance
by either party jeopardizes the licensure, accreditation or tax exempt status of Cedars or the agreement is deemed illegal by a governmental
body; (c) within 30 days for non-payment of royalties or if of Enviro fails to undertake commercially reasonable efforts to exploit the
patent rights or future patent rights; (d) within 60 days of Enviro&#8217;s failure to cure any breach or default of a material obligation
under the agreements (e) within 90 days of Enviro&#8217;s failure to cure any breach or default of a material obligation under the agreements;
or (f) upon mutual written agreement of the parties.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">Effective April 17, 2025, Enviro, Kairos and Cedars
entered into a novation agreement pursuant to which the exclusive license was transferred from Enviro to Kairos, after which time Kairos
accepted and assumed all obligations and liabilities under the exclusive license agreements and Enviro was relived of any further liabilities
or obligations under the license agreements.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>License and Supply Agreement with Tracon Pharmaceuticals, Inc.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 21, 2021, Enviro, the Company&#8217;s formerly wholly-owned subsidiary, entered into an Enviro-Tracon license agreement with Tracon. Pursuant to the Enviro-Tracon license agreement, Tracon
grants to Enviro access to inactive IND filings for &#8220;TRC105&#8221; in the United States, ownership of &#8220;TRC105&#8221; stored
vials of drug product manufactured to GMP standards stored at Fisher Clinical or their designee, and assignment of Tracon&#8217;s patent
rights to its &#8220;CD105 technologies.&#8221;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the Enviro-Tracon license agreement, Enviro paid Tracon an upfront fee of $100,000, and was obligated to pay Tracon an additional
$500,000 upon its or its successor&#8217;s completion of one or more financings through the sale of equity (or debt convertible to
equity) in an amount of $10,000,000, and an additional $500,000 within 10 days of its or its successor&#8217;s completion of one or
more financings through the sale of equity (or debt convertible to equity) in an amount of $22,000,000. In addition, Enviro was
obligated to pay Tracon a royalty of 3% of net sales on a country-by-country basis of the products subject to the agreement, and
non-royalty payments of 3% of consideration for sublicensing fees. The royalty payments would terminate upon the completion of use
of the TRC105 product. The non-royalty payments would terminate upon payment of $500,000 after the financing of an aggregate amount
of $22,000,000 to the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prior
to becoming a wholly-owned subsidiary of the Company, Enviro issued Tracon equity ownership in Enviro equal to a number of shares of
restricted common stock of Enviro equal to 7% on a fully diluted and converted basis of all common and preferred shares of Enviro.
Thereafter, in connection with the Enviro-Kairos share exchange, the parties agreed that Tracon would receive, in exchange for its Enviro common
stock, 280,000 shares of the restricted common stock of Kairos (which was then equal to 1.41229% of the issued and outstanding shares of
Kairos on a fully diluted and converted basis). Under the Enviro-Tracon license agreement, until such time as Tracon has received all of the cash consideration (as described
above), Enviro or its successor in interest, shall issue to Tracon, without further consideration, any additional common stock of
Enviro, or such successor in interest, necessary so that Tracon maintains ownership of shares of Enviro, or such successor in
interest, equal to the Tracon-Enviro Equity on a fully diluted and converted basis of all stock in Enviro (or its successor).
However, as of the date of this Annual Report, all Tracon shares in Kairos have been sold and Tracon no longer has
an ownership interest in Kairos.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>


<!-- Field: Page; Sequence: 18; Value: 2 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the Enviro-Tracon license agreement, which was assumed by Kairos effective April 17, 2025 pursuant to a novation agreement, we
have exclusive licensing rights (which include the right to sublicense) to eight issued U.S. patents, four U.S. Utility or
provisional patent applications, 24 issued patents and 24 patent applications in foreign jurisdictions. Patent expiration dates,
specific jurisdictions of foreign patents are listed in the Patent Table below.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PATENT
TABLE</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Case</FONT></P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Number.Sub</FONT></P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Case</FONT></P></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Name
    of the Patent</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Patent</FONT></P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">No./Application
                                            No.</FONT></P></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Status
    (Patent granted or Patent application)</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Products
    or Technologies to which the Patents or Patent Applications Relate</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Type
                                            of Patent</FONT></P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Protection</FONT></P></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Expiration</FONT></P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Date</FONT></P></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Jurisdiction</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; width: 9%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">017431.501AU0</FONT></TD><TD STYLE="width: 1%; text-align: left"></TD><TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="width: 15%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">SENSITIZATION OF TUMORS TO THERAPIES
    THROUGH ENDOGLIN ANTAGONISM</FONT></TD><TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="vertical-align: top; width: 9%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">2017286561</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: left; width: 11%"><FONT STYLE="font-family: Times New Roman, Times, Serif">APPLICATION</FONT></TD><TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: left; width: 11%"><FONT STYLE="font-family: Times New Roman, Times, Serif">ENV 105</FONT></TD><TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="vertical-align: top; width: 11%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Both a Product
    and a Method of Treatment Patent</FONT></TD><TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left; width: 10%; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">2037-06-14</FONT></TD><TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="vertical-align: top; width: 8%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Australia</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">017313.004CA0</FONT></TD><TD STYLE="text-align: left"></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">COMPOSITIONS AND METHODS FOR TREATING CANCER
    AND AUTOIMMUNE DISEASES</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">3,108,796</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">APPLICATION</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">KROS 101 and KROS 102</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Both a Product and a Method
    of Treatment Patent</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">2039-08-08</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Canada</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">017313.005CA0</FONT></TD><TD STYLE="text-align: left"></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">METHOD OF GENERATING ACTIVATED T CELLS FOR
    CANCER THERAPY</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">3,150,273</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">APPLICATION</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">KROS 201</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Both a Product and a Method
    of Treatment Patent</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">2040-08-10</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Canada</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">017431.501CA0</FONT></TD><TD STYLE="text-align: left"></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">SENSITIZATION OF TUMORS TO THERAPIES THROUGH
    ENDOGLIN ANTAGONISM</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">3026066</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">APPLICATION</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">ENV 105</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Both a Product and a Method
    of Treatment Patent</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">2037-06-14</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Canada</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">017431.502CA0</FONT></TD><TD STYLE="text-align: left"></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">COMPOSITIONS AND METHODS FOR TREATING DISEASES
    AND CONDITIONS BY DEPLETION OF MITOCHONDRIAL OR GENOMIC DNA FROM CIRCULATION</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">3162518</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">APPLICATION</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">ENV 205</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Both a Product and a Method
    of Treatment Patent</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">2040-11-25</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Canada</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>


<!-- Field: Page; Sequence: 19; Value: 2 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Case
    Number.Sub Case</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Name
    of the Patent</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Patent
    No./Application No.</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Status
    (Patent granted or Patent application)</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Products
    or Technologies to which the Patents or Patent Applications Relate</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Type
    of Patent Protection</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Expiration
    Date</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Jurisdiction</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; width: 9%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">017313.004CN1</FONT></TD><TD STYLE="width: 1%; text-align: left"></TD><TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="width: 15%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">COMPOSITIONS AND METHODS FOR TREATING
    CANCER AND AUTOIMMUNE DISEASES</FONT></TD><TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="vertical-align: top; width: 9%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">2024104360758.0</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left; width: 11%; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">APPLICATION</FONT></TD><TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="vertical-align: top; width: 11%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">KROS 101 and
    KROS 102</FONT></TD><TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="width: 11%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Both a Product and a Method of
    Treatment Patent</FONT></TD><TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left; width: 10%; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">2039-08-08</FONT></TD><TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left; width: 8%; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">China</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">017431.501CN0</FONT></TD><TD STYLE="text-align: left"></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">SENSITIZATION OF TUMORS TO THERAPIES THROUGH
    ENDOGLIN ANTAGONISM</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">201780050000.4</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">APPLICATION</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">ENV 105</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Both a Product and a Method of Treatment Patent</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">2037-06-14</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">China</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">35882-714.7111</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">ANTIBODY FORMULATIONS
    AND USES THEREOF</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">201810659773.9</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">APPLICATION</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">ENV 105</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Both a Product and a Method of Treatment Patent</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">2033-09-05</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">China (People&#8217;s
    Republic)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">017313.004EP0</FONT></TD><TD STYLE="text-align: left"></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">COMPOSITIONS AND METHODS FOR TREATING CANCER
    AND AUTOIMMUNE DESEASES</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">19848154.1</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">APPLICATION</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">KROS 101 and KROS 102</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Both a Product and a Method of Treatment Patent</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">2039-08-08</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">European Patent</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">017313.005EP0</FONT></TD><TD STYLE="text-align: left"></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">METHOD OF GENERATING ACTIVATED T CELLS FOR
    CANCER THERAPY</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">20850517.2</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">APPLICATION</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">KROS 201</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Both a Product and a Method of Treatment Patent</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">2040-08-10</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">European Patent</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">017431.501EP0</FONT></TD><TD STYLE="text-align: left"></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">SENSITIZATION OF TUMORS TO THERAPIES THROUGH
    ENDOGLIN ANTAGONISM</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">17814046.3</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">APPLICATION</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">ENV 105</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Both a Product and a Method of Treatment Patent</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">2037-06-14</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">European Patent</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">017431.502EP0</FONT></TD><TD STYLE="text-align: left"></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">COMPOSITIONS AND METHODS FOR TREATING DISEASES
    AND CONDITIONS BY DEPLETION OF MITOCHONDRIAL OR GENOMIC DNA FROM CIRCULATION</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">20893032.1</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">APPLICATION</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">ENV 205</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Both a Product and a Method
    of Treatment Patent</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">2040-11-25</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">European Patent</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>


<!-- Field: Page; Sequence: 20; Value: 2 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Case
    Number.Sub Case</B></FONT></TD><TD STYLE="text-align: center; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Name
    of the Patent</FONT></TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Patent
    No./Application No.</FONT></TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Status
    (Patent granted or Patent application)</FONT></TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Products
    or Technologies to which the Patents or Patent Applications Relate</FONT></TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Type
    of Patent Protection</FONT></TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Expiration
    Date</FONT></TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Jurisdiction</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; width: 9%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">017313.002EP0</FONT></TD><TD STYLE="width: 1%; text-align: left"></TD><TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="vertical-align: top; width: 15%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">METHODS AND
    USE OF COMPOUNDS THAT BIND TO RELA OF NF-KB</FONT></TD><TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="vertical-align: top; width: 9%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">3303286</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left; width: 11%; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">GRANTED</FONT></TD><TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left; width: 11%; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">KROS 301</FONT></TD><TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="width: 11%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Both a Product and a Method of
    Treatment Patent</FONT></TD><TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left; width: 10%; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">2036-06-01</FONT></TD><TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="width: 8%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">France, Germany, Switzerland &amp;
    Liechtenstein, United Kingdom.</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">017313.003EP0</FONT></TD><TD STYLE="text-align: left"></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">COMPOSITIONS AND METHODS
    FOR TREATING FIBROSIS</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">3194446</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">GRANTED</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">KROS 401</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Both a Product and a Method of Treatment Patent</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">2035-09-18</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">France, Germany, Switzerland &amp; Liechtenstein,
    United Kingdom.</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">35882-714.741</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">ANTIBODY FORMULATIONS
    AND USES THEREOF</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">1538/DELNP/2015</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">GRANTED</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">ENV 105</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Both a Product and a Method of Treatment Patent</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">2033-09-05</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">India</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">35882-714.7611</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">ANTIBODY FORMULATIONS
    AND USES THEREOF</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">6445671</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">GRANTED</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">ENV 105</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Both a Product and a Method of Treatment Patent</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">2033-09-05</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">Japan</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">35882-714.7612</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">ANTIBODY FORMULATIONS
    AND USES THEREOF</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">6602446</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">GRANTED</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">ENV 105</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Both a Product and a Method of Treatment Patent</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">2033-09-05</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">Japan</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">017313.003JP0</FONT></TD><TD STYLE="text-align: left"></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">COMPOSITIONS AND METHODS
    FOR TREATING FIBROSIS</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">7095990</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">GRANTED</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">KROS 401</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Both a Product and a Method of Treatment Patent</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">2035-09-18</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">Japan</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">017313.003JP1</FONT></TD><TD STYLE="text-align: left"></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">COMPOSITIONS AND METHODS
    FOR TREATING FIBROSIS</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2020-148662</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">APPLICATION</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">KROS 401</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Both a Product and a Method of Treatment Patent</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">2035-09-18</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">Japan</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">017313.004JP0</FONT></TD><TD STYLE="text-align: left"></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">COMPOSITIONS AND METHODS
    FOR TREATING CANCER AND AUTOIMMUNE</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">7530346</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">GRANTED</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">KROS 101 and KROS 102</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Both a Product and a Method of Treatment Patent</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">2039-08-08</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">Japan</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">017313.004JP1</FONT></TD><TD STYLE="text-align: left"></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">COMPOSITIONS AND METHODS
    FOR TREATING CANCER AND AUTOIMMUNE</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2024-120839</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">APPLICATION</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">KROS 101 and KROS 102</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Both a Product and a Method of Treatment Patent</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">2039-08-08</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">Japan</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">017431.501JP0</FONT></TD><TD STYLE="text-align: left"></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">SENSITIZATION OF TUMORS TO THERAPIES THROUGH
    ENDOGLIN ANTAGONISM</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">7092684</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">GRANTED</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">ENV 105</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Both a Product and a Method of Treatment Patent</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">2037-06-14</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">Japan</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>


<!-- Field: Page; Sequence: 21; Value: 2 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Case
    Number.Sub Case</FONT></TD><TD STYLE="text-align: center; padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Name
    of the Patent</FONT></TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Patent
    No./Application No.</FONT></TD><TD STYLE="text-align: center; padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Status
    (Patent granted or Patent application)</FONT></TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Products
    or Technologies to which the Patents or Patent Applications Relate</FONT></TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Type
    of Patent Protection</FONT></TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Expiration
    Date</FONT></TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Jurisdiction</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; width: 9%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">017431.502JP0</FONT></TD><TD STYLE="width: 1%; text-align: left"></TD><TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="width: 15%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">COMPOSITIONS AND METHODS FOR TREATING
    DISEASES AND CONDITIONS BY DEPLETION OF MITOCHONDRIAL OR GENOMIC DNA FROM CIRCULATION</FONT></TD><TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="vertical-align: top; width: 9%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022-530781</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left; width: 11%; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">APPLICATION</FONT></TD><TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left; width: 11%; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">ENV 205</FONT></TD><TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="vertical-align: top; width: 11%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Both a Product
    and a Method of Treatment Patent</FONT></TD><TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left; width: 10%; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">2040-11-25</FONT></TD><TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left; width: 8%; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">Japan</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">017313.004KR0</FONT></TD><TD STYLE="text-align: left"></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">COMPOSITIONS AND METHODS FOR TREATING CANCER
    AND AUTOIMMUNE DISEASES</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10-2021-7006602</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">GRANTED</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">KROS 101 and KROS 102</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Both a Product and a Method of Treatment Patent</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">2039-08-08</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Korea, Republic of (KR)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">017313.004KR1</FONT></TD><TD STYLE="text-align: left"></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">COMPOSITIONS AND METHODS FOR TREATING CANCER
    AND AUTOIMMUNE DISEASES</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10-2025-7000546</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">APPLICATION</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">KROS 101 and KROS 102</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Both a Product and a Method of Treatment Patent</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">2039-08-08</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Korea, Republic of (KR)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">35882-714.911</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">ANTIBODY FORMULATIONS
    AND USES THEREOF</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MY-180157-A</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">GRANTED</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">ENV 105</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Both a Product and a Method of Treatment Patent</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">2033-09-05</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">Malaysia</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">35882-714.781</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">ANTIBODY FORMULATIONS
    AND USES THEREOF</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">368996</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">GRANTED</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">ENV 105</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Both a Product and a Method of Treatment Patent</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">2033-09-05</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">Mexico</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>


<!-- Field: Page; Sequence: 22; Value: 2 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Case
    Number.Sub Case</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Name
    of the Patent</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Patent
    No./Application No.</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Status
    (Patent granted or Patent application)</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Products
    or Technologies to which the Patents or Patent Applications Relate</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Type
    of Patent Protection</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Expiration
    Date</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Jurisdiction</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; width: 9%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">35882-714.861</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="width: 15%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">ANTIBODY FORMULATIONS AND USES
    THEREOF</FONT></TD><TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="vertical-align: top; width: 9%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">1501001224</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left; width: 11%; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">APPLICATION</FONT></TD><TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left; width: 11%; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">ENV 105</FONT></TD><TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="width: 11%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Both a Product and a Method of
    Treatment Patent</FONT></TD><TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left; width: 10%; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">2033-09-05</FONT></TD><TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left; width: 8%; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">Thailand</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">35882-706.202</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">ENDOGLIN ANTIBODIES</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">8,221,753</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">GRANTED</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">ENV 105</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">Product</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">2030-03-31</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">United States of America</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">35882-706.302</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">ENDOGLIN ANTIBODIES</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">9,150,652</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">GRANTED</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">ENV 105</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">Method of treatment</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">2029-09-30</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">United States of America</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">35882-706.401</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">ENDOGLIN ANTIBODIES</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">9,944,714</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">GRANTED</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">ENV 105</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">Composition of matter</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">2030-03-31</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">United States of America</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">35882-714.831</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">ANTIBODY FORMULATIONS AND USES THEREOF</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">10,195,281</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">GRANTED</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">ENV 105</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Product and Formulation</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">2034-12-25</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">United States of America</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">017313.002US0</FONT></TD><TD STYLE="text-align: left"></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">METHODS AND USE OF COMPOUNDS THAT BIND TO RELA
    OF NF-KB</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">10,881,641</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">GRANTED</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">KROS 301</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">Method of treatment</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">2037-11-30</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">United States of America</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">017313.002US1</FONT></TD><TD STYLE="text-align: left"></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">METHODS AND USE OF COMPOUNDS THAT BIND TO RELA
    OF NF-KB</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">10,195,281</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">GRANTED</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">KROS 301</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">Method of treatment</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">2037-11-30</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">United States of America</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">017313.003US0</FONT></TD><TD STYLE="text-align: left"></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">COMPOSITIONS AND METHODS FOR TREATING FIBROSIS</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">10,245,298</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">GRANTED</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">KROS 401</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Pharmaceutical composition</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">2035-09-18</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">United States of America</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>


<!-- Field: Page; Sequence: 23; Value: 2 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Case
    Number.Sub Case</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Name
    of the Patent</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Patent
    No./Application No.</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Status
    (Patent granted or Patent application)</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Products
    or Technologies to which the Patents or Patent Applications Relate</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Type
    of Patent Protection</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Expiration
    Date</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Jurisdiction</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; width: 9%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">017313.003US1</FONT></TD><TD STYLE="width: 1%; text-align: left"></TD><TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="width: 15%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">COMPOSITIONS AND METHODS FOR TREATING
    FIBROSIS</FONT></TD><TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="vertical-align: top; width: 9%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">11,547,738</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left; width: 11%; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">GRANTED</FONT></TD><TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left; width: 11%; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">KROS 401</FONT></TD><TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left; width: 11%; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">Method of
    treatment</FONT></TD><TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left; width: 10%; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">2035-09-18</FONT></TD><TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="vertical-align: top; width: 8%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">United States
    of America</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">017313.003US2</FONT></TD><TD STYLE="text-align: left"></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">COMPOSITIONS AND METHODS FOR TREATING FIBROSIS</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">18/093,667</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">APPLICATION</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">KROS 401</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Both a Product and a Method
    of Treatment Patent</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">2035-09-18</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">United States of America</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">017313.004US0</FONT></TD><TD STYLE="text-align: left"></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">COMPOSITIONS AND METHODS FOR TREATING CANCER
    AND AUTOIMMUNE DISEASES</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">17/266,488</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">APPLICATION</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">KROS 101 and KROS 102</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Both a Product and a Method of Treatment Patent</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">2039-08-08</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">United States of America</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">017313.005US0</FONT></TD><TD STYLE="text-align: left"></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">METHOD OF GENERATING ACTIVATED T CELLS FOR
    CANCER THERAPY</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">17/633,505</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">APPLICATION</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">KROS 201</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Both a Product and a Method of Treatment Patent</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">2040-08-10</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">United States of America</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">017431.501US1</FONT></TD><TD STYLE="vertical-align: top; text-align: left"></TD><TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">SENSITIZATION OF TUMORS
    TO THERAPIES THROUGH ENDOGLIN ANTAGONISM</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">17/685,040</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">APPLICATION</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">ENV 105</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Both a Product and a Method of Treatment Patent</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">2037-06-14</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">United States of America</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">017431.502US0</FONT></TD><TD STYLE="text-align: left"></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">COMPOSITIONS AND METHODS FOR TREATING DISEASES
    AND CONDITIONS BY DEPLETION OF MITOCHONDRIAL OR GENOMIC DNA FROM CIRCULATION</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">17/779,716</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">APPLICATION</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">ENV 205</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Both a Product and a Method
    of Treatment Patent</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">2040-11-25</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">United States of America</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&#160;</I></B></FONT></P>


<!-- Field: Page; Sequence: 24; Value: 2 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&#160;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Corporate
Reorganization</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Kairos
Pharma, Ltd. was originally incorporated on June 17, 2013 in the state of California as NanoGB13, Inc. The Company changed its name to
&#8220;Kairos Pharma, Ltd.&#8221; on July 15, 2016. On May 10, 2023, we filed a certificate of conversion with the Secretary of State
of the State of California, and on the same date, we also filed with the Delaware Secretary of State a certificate of conversion converting
the Company from a non-Delaware corporation to a Delaware corporation pursuant to section 265 of the Delaware General Corporation Law
t. In addition, on May 10, 2023, we filed a certificate of incorporation with the Secretary of State of the State of Delaware, thus completing
our conversion into a Delaware corporation. In conjunction with the Company&#8217;s conversion into a Delaware corporation, on May 10,
2023, the Company conducted a 1-for-2.5 Reverse Stock Split. After the Reverse Stock Split, there were 10,334,357 shares of our common
stock outstanding.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 13, 2019, Kairos entered into an Agreement of Merger with AcTcell Biopharma, Inc., or AcTcell, whereby the Company issued 5,045,000
shares of its common stock for all the issued and outstanding shares of AcTcell common stock. AcTcell was a California corporation that
was incorporated on July 22, 2019. AcTcell&#8217;s only asset at the merger date was an Exclusive License Agreement dated August 30,
2019 between AcTcell and Cedars-Sinai Medical Center. AcTcell had no liabilities at the merger date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">John
S. Yu, the Company&#8217;s Chairman, Chief Executive Officer and shareholder, was the sole owner of AcTcell. The acquisition of AcTcell
by Kairos was treated as a transaction between entities under common control resulting in the historical costs basis of AcTcell&#8217;s
assets and liabilities being recognized.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Enviro
was incorporated on November 15, 2019, under the law of the state of California and was an early-stage company that is focused on
the development of therapeutics targeting the tumor microenvironment to complement conventional and targeted therapies designed
against the cancer cells. Kairos&#8217;s Chairman, Chief Executive Officer and shareholder, Dr. Yu, was also a founder and
shareholder of Enviro.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 3, 2021, Kairos and Enviro entered into a share exchange agreement whereby Kairos acquired of all of the common stock of Enviro
in exchange for stock in Kairos. In the Enviro-Kairos share exchange, the Enviro shareholders exchanged 100% of the issued and outstanding
shares of Enviro (on a fully diluted basis) for 6,000,000 shares of newly issued restricted common stock of Kairos, which, as of the
closing of the Enviro-Kairos share exchange: (i) represented approximately twenty percent (20%) of the outstanding shares of capital
stock of the Company on a fully diluted basis, including all issued and outstanding convertible promissory notes, preferred stock, SAFEs,
other securities convertible into capital stock, stock options and warrants, and after giving effect to the issuance of the shares in
the Enviros-Kairos share exchange, and (ii) have voting power approximately equal to twenty percent (20%) of all shares eligible to vote
on matters by the shareholders of Kairos. At the closing of the Enviro-Kairos share exchange, Kairos issued each of Dr. Yu and Dr. Neil
Bhowmick (the other co-founder of Enviro) 1,860,000 of Kairos&#8217; restricted common stock in exchange for their shares of Enviro.
Kairos also issued Tracon Pharmaceutical, Inc., an unaffiliated third party, 280,000 shares of Kairos restricted common stock
in exchange from their shares of Enviro, which Tracon had received pursuant to a license and supply agreement between Enviro and Tracon,
pursuant to which Enviro had acquired certain licensing rights from Tracon.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
the closing of the Enviro-Kairos share exchange, prior to our 1-for-2.5 reverse split conducted in 2023 and including the newly issued
shares in that transaction, Kairos had approximately 19,825,957 shares of common stock issued and outstanding on a fully diluted basis
(including 18,825,957 outstanding shares of common stock, and 1,000,000 warrants exercisable into 1,000,000 shares of common stock).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">Effective April 17, 2025, the Company entered into novation agreements with Enviro and Enviro&#8217;s licensors,
Tracon and Cedars-Sinai Medical Center, pursuant to which the Company assumed all responsibilities, liabilities and obligations of Enviro
under such agreements and Enviro was released from all liability. At the same time, Enviro was dissolved.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Manufacturing</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
do not currently own or operate manufacturing facilities for the production of clinical or commercial quantities of our product candidates.
When we begin manufacturing, we intend to use vendors that are compliant with current cGMP, in pharmaceutical production. We expect that
commercial quantities of any compound and materials for our product candidates, if approved, will be manufactured in facilities and by
processes that comply with FDA and other regulations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Employees
and Human Capital Resources</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2025, we had one full-time employee, our Chief Financial Officer, and three part-time employees (including our executive
officers), each of whom is a part-time employee primarily engaged in research and development activities, and all hold M.D. or Ph.D.
degrees. Aside from our Chief Financial Officer, all officers and directors of the Company worked approximately 20 hours per week in
performance of their duties related to the Company. We consider our relationship with our employees to be good. None of our employees
is subject to a collective bargaining agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>


<!-- Field: Page; Sequence: 25; Value: 2 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
recognize that our continued ability to attract, retain and motivate exceptional employees is vital to ensuring our long-term competitive
advantage. Our employees are critical to our long-term success and are essential to helping us meet our goals. Among other things, we
support and incentivize our employees in the following ways:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Talent
    development, compensation, and retention:</I></B> We strive to provide our employees with a rewarding work environment, including
    the opportunity for growth, success, and professional development. We provide a competitive compensation and benefits package, including
    bonus and equity incentive plans, a 401(k) plan-all designed to attract and retain a skilled and diverse workforce.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Health
    and safety:</I></B> We support the health and safety of our employees by providing comprehensive insurance benefits, an employee
    assistance program, company-paid holidays, a personal time-off program, and other additional benefits which are intended to assist
    employees to manage their well-being.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Inclusion
    and diversity:</I></B> We are committed to efforts to increase diversity and foster an inclusive work environment that supports our
    workforce.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Recent
Financings</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><FONT STYLE="text-decoration: underline">Initial
Public Offering</FONT></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 17, 2024, we closed on our initial public offering (&#8220;IPO&#8221;) of 1,550,000 shares of common stock at $4.00 per share,
for gross proceeds of $6,200,000, following our listing on the NYSE American LLC, or NYSE American. Our IPO was underwritten by Boustead
Securities, LLC, acting as lead underwriter, with the underwriters receiving 7% cash compensation and warrants to purchase a total of
108,500 shares of common stock, exercisable at $4.80 per share.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><FONT STYLE="text-decoration: underline">Equity
Line of Credit Agreement</FONT></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 12, 2024, the Company and Helena Global Investment Opportunities I Ltd (&#8220;Helena&#8221;) entered into an equity line of
credit agreement (the &#8220;ELOC Agreement&#8221;), pursuant to which Helena agreed to purchase from the Company up to $30,000 shares
of common stock (the &#8220;ELOC Shares&#8221;). The Company issued 670,641 shares of restricted common stock (the &#8220;Commitment
Fee Shares&#8221;), valued at $900,000 (the &#8220;Issuance Value&#8221;) on the date of issuance, to Helena as the &#8220;Commitment
Fee&#8221; for entry into the ELOC Agreement. The ELOC Agreement will be available for the Company&#8217;s use at such time following
the filing, and subsequent effectiveness, of a resale registration statement registering the ELOC Shares for resale. Upon the effectiveness
of the resale registration statement (the &#8220;Effective Date&#8221;), the Commitment Fee shares will be subject to a &#8220;true-up&#8221;
pursuant to which, in the event the shares are valued at less than Issuance Value on the Effective Date, additional shares will be issued
to Helena to bring ensure the ELOC Shares equal the Issuance Value on the Effective Date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
ELOC Agreement will terminate upon the following events: (i) the first day of the month next following the 36-month anniversary of the
date of the ELOC Agreement or (ii) the date on which Helena has purchased the full $30,000,000 of ELOC Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
ELOC Agreement may be terminated by the Company after its commencement, at the Company&#8217;s discretion, provided that there are no
advance notices outstanding for which common stock has yet to be issued, and the Company has paid all amounts owed to Helena under the
ELOC Agreement, including the Commitment Fee Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><FONT STYLE="text-decoration: underline">January
2025 PIPE Offering</FONT></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 14, 2025, the Company entered into a securities purchase agreement (the &#8220;Purchase Agreement&#8221;) and registration rights
agreement (the &#8220;Registration Rights Agreement&#8221;) with the investor name therein (the &#8220;Investor&#8221;) for the sale
and issuance of 2,500,000 units (the &#8220;Pre-Funded Units&#8221;), with each Pre-Funded Unit consisting of a Pre-Funded Warrant to
purchase one share of common stock, exercisable for $0.001 per share, and a Common Warrant to purchase one and one half shares of common
stock, exercisable at $1.40 per share (the &#8220;January 2025 PIPE Offering&#8221;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>


<!-- Field: Page; Sequence: 26; Value: 2 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
advance of closing, on January 16, 2025, the Company and the Investor entered into an amended and restated purchase agreement (the &#8220;A&amp;R
Purchase Agreement&#8221;), which amended the terms of the Purchase Agreement to include a requirement that the Company obtain shareholder
approval prior to issuing in excess of 19.99% of the Company&#8217;s common stock and also amended the Common Warrants to make them immediately
exercisable and reduce the exercise period from 5.5 years to five years. Other terms of the agreements remained the same.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 16, 2025, the Company closed the January 2025 PIPE Offering for gross proceeds of $3,497,500 (or $1.399 per Pre-Funded Unit),
with an additional $2,500 payable upon the Investor&#8217;s exercise of the Pre-Funded Warrants in full.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Boustead
Securities, LLC (&#8220;Boustead&#8221;) and D. Boral Capital LLC (&#8220;D. Boral&#8221;) acted as co-placement agents for the January
2025 PIPE Offering. In conjunction therewith, on January 16, 2025, the Company entered into a Placement Agent Agreement with Boustead
(the &#8220;Placement Agent Agreement&#8221;). Under the terms of the Placement Agent Agreement, at closing the Company paid the Placement
Agents (i) a cash commission equal to 8% of the gross proceeds (including a 1% non-accountable expense fee) and (ii) warrants to purchase
a total of 175,000 shares of common stock, exercisable at $1.40 per share, with the total cash and warrant compensation split equally
between Boustead and D. Boral.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 20, 2025, the Company obtained the approval of 55.4% of the shareholders (the &#8220;Majority Shareholders&#8221;) for the issuance
in excess of 19.99% of the Company&#8217;s common stock at a price below market value, in compliance with Rule 713 of the NYSE American
LLC Company Guide. On February 10, 2025, the Company filed the definitive Schedule 14C and the shareholder approval became effective
on March 1, 2025.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><FONT STYLE="text-decoration: underline">January 2026 At-the-Market Offering</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">On January 12, 2026, we entered into an at-the-market (&#8220;ATM&#8221;)
offering agreement (the &#8220;ATM Agreement&#8221;) with H.C. Wainwright Co., LLC (the &#8220;Placement Agent&#8221;) for the sale, from
time to time, of up to $4,524,949 shares of our common stock. We registered the common stock offered under the ATM pursuant to prospectus
supplement filed in conjunction with our shelf registration statement on Form S-3 (SEC File No. 333-292686), which was declared effective
on January 23, 2026. Pursuant to the ATM Agreement, the Placement Agent is entitled to a placement agent fee of 3.0% of the gross sale
price of shares sold under the ATM.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><FONT ID="sp_003"></FONT>ITEM
1A. RISK FACTORS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Risks
Related to Our Financial Position and Capital Needs</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
are a small development-stage biopharmaceutical company with a limited operating history and no products approved for commercial sale.
We have incurred significant losses since our inception. We expect to incur losses over the next several years and may never achieve
or maintain profitability.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are a small development-stage biopharmaceutical company with a limited operating history and no products approved for commercial sale.
There can be no assurance that we will, or if we do, when we will, obtain approval to commercialize our products and potentially generate
revenue. We have incurred significant losses since our inception and we expect to incur losses over the next several years and may never
achieve or maintain profitability. Even if we achieve profitability, we may not be able to sustain or increase profitability on a quarterly
or annual basis. Our failure to become and remain profitable would depress the value of our common stock and could impair our ability
to raise capital, expand our business, maintain our research and development efforts, or continue our operations. A decline in the value
of our common stock could also cause you to lose all or part of your investment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>


<!-- Field: Page; Sequence: 27; Value: 2 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
require substantial additional funding to meet our financial needs and to pursue our business objectives. If we are unable to raise capital
when needed, we could be forced to delay, reduce, or altogether cease our current and future product development programs or future commercialization
efforts.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
will need to obtain substantial additional funding in connection with our continuing operations and planned activities. Our future capital
requirements will depend on many factors, including:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    timing, progress, and results of our ongoing and future clinical trials of our current in-development products;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    costs, timing, and outcome of regulatory review of our current in-development products and any of our future product candidates;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    scope, progress, results, and costs of identifying, obtaining, and conducting preclinical development, laboratory testing, and clinical
    trials of future product candidates that we may pursue;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    cost and timetable of manufacturing processes for development, clinical trials, and potential commercial use;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    number and development requirements of future product candidates that we may pursue;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    amount of funding that we receive under our non-dilutive funding opportunities, including government awards and government awards,
    if any, that we may apply for;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    costs and timing of future commercialization activities, including product manufacturing, marketing, sales, and distribution, for
    our current in-development products or any future product candidates that receive marketing approval;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    pricing and revenue, if any, received from commercial sales of our current in-development products or any future product candidates
    that receive marketing approval;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    costs and timing of preparing, filing, and prosecuting patent applications, maintaining, and enforcing our intellectual property
    rights, and defending any intellectual property-related claims;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    costs of operating as a public company; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    extent to which we acquire or in-license other product candidates and technologies.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Identifying
potential product candidates and conducting preclinical testing and clinical trials is a time-consuming, expensive, and uncertain process
that takes years to complete, and we may never generate the necessary data or results required to obtain regulatory approval and achieve
product sales. In addition, our current in-development products and any of our future product candidates, if approved, may not achieve
commercial success. Our commercial revenues, if any, will be derived from sales of drugs that we do not expect to be commercially available
for several years, if at all. Accordingly, we will need to continue to rely on additional financing to achieve our business objectives.
Adequate additional financing may not be available to us on acceptable terms, or at all. In addition, we may seek additional capital
due to favorable market conditions or strategic considerations even if we believe we have sufficient funds for our current or future
operating plans. If we are unable to raise capital when needed or on attractive terms, we could be forced to delay, reduce or altogether
cease our research and development programs or future commercialization efforts.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Raising
additional capital will likely cause dilution to our stockholders, restrict our operations, or require us to relinquish rights to our
current in-development products or technologies or any of our future product candidates.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Until
such time, if ever, as we can generate substantial product revenue, we expect to finance our cash needs through a combination of equity
offerings and debt financings. To the extent that we raise additional capital through the sale of equity or convertible debt securities,
your ownership interest will be diluted, and the terms of these securities may include liquidation or other preferences that adversely
affect your rights as a stockholder. Debt financing and preferred equity financing, if available, may involve agreements that include
covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures,
or declaring dividends.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we raise additional funds through collaborations, strategic alliances, or marketing, distribution, or licensing arrangements with third
parties, we may be required to relinquish valuable rights to our technologies, future revenue streams, research programs, or our current
in-development products or any future product candidates, or to grant licenses on terms that may not be favorable to us. If we are unable
to raise additional funds through equity or debt financings when needed, we may be required to delay, limit, reduce, or terminate our
development of our current in-development products or any future product candidate or future commercialization efforts or grant rights
to a third party to develop and market product candidates that we would otherwise prefer to develop and market ourselves.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Our
limited operating history may make it difficult for you to evaluate the success of our business to date and to assess our future viability.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have limited resources and limited operating history. There is only a limited basis upon which to evaluate our prospects for achieving
our intended business objectives. We have not yet demonstrated the ability to successfully complete a large-scale, pivotal clinical trial,
obtain marketing approval, manufacture a commercial scale product, arrange for a third party to do so on our behalf, or conduct sales
and marketing activities necessary for successful product commercialization. Consequently, predictions about our future success or viability
may not be as accurate as they could be if we had a history of successfully developing and commercializing pharmaceutical products.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>


<!-- Field: Page; Sequence: 28; Value: 2 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, as a business with a limited operating history, we may encounter unforeseen expenses, difficulties, complications, delays and
other known and unknown factors. We will eventually need to transition from a company with a research focus to a company capable of supporting
commercial activities. We may not be successful in such a transition and, as a result, our business may be adversely affected.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Because
of the numerous risks and uncertainties associated with drug development, we are unable to accurately predict the timing or amount of
expenses or when, or if, we will be able to achieve profitability. If we are required by regulatory authorities to perform studies in
addition to those currently expected, or if there are any delays in the initiation and completion of our clinical trials or the development
of our current in-development products or any of our future product candidates, our expenses could increase.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
may expend our limited resources to pursue a particular product candidate or indication and fail to capitalize on product candidates
or indications that may be more profitable or have a greater likelihood of success.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Because
we have limited financial and management resources, we focus on research programs and product candidates that we identify for specific
indications. As a result, we may forego or delay pursuit of opportunities with other product candidates or for other indications that
later prove to have greater commercial potential. Our resource allocation decisions may cause us to fail to capitalize on viable commercial
drugs or profitable market opportunities. Our spending on current and future research and development programs and product candidates
for specific indications may not yield any commercially viable products. If we do not accurately evaluate the commercial potential or
target market for a particular product candidate, we may relinquish valuable rights to that product candidate through collaboration,
licensing, or other royalty arrangements in cases in which it would have been more advantageous for us to retain sole development and
commercialization rights to such product candidate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Risks
Related to Development, Clinical Testing, Manufacturing and Regulatory Approval</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
are heavily dependent on the success of our initial drug candidates, which are still under clinical development, and if any of these
drugs does not receive regulatory approval or is not successfully commercialized, our business may be harmed.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
do not have any products that have gained regulatory approval by the FDA or comparable foreign regulatory authorities. As a result, our
business is dependent on our ability to successfully complete clinical development of, obtain regulatory approval for, and, if approved,
successfully commercialize one or more drug therapies in a timely manner. We cannot commercialize our drug therapies in the United States
without first obtaining regulatory approval from the FDA; similarly, we cannot commercialize our drug therapies outside of the United
States without obtaining regulatory approval from comparable foreign regulatory authorities. Before obtaining regulatory approvals for
the commercial sale of our drug therapies for a target indication, we must demonstrate with substantial evidence gathered in preclinical
studies and clinical trials, generally including two adequate and well-controlled clinical trials, and, with respect to approval in the
United States, to the satisfaction of the FDA, that a drug candidate is safe and effective for use for that target indication and that
the manufacturing facilities, processes and controls are adequate. Even if we were to successfully obtain approval of one of our drug
therapies from the FDA or comparable foreign regulatory authorities, any approval might contain significant limitations related to use
restrictions for specified age groups, warnings, precautions or contraindications, or may be subject to burdensome post-approval study
or risk management requirements. If we are unable to obtain regulatory approval for one or more of our drug therapies in one or more
jurisdictions, or any approval contains significant limitations, we may not be able to obtain sufficient funding or generate sufficient
revenue to continue the development of any other candidate that we may in-license, develop or acquire in the future. Furthermore, even
if we obtain regulatory approval for one of our drug therapies, we will still need to develop a commercial organization, establish commercially
viable pricing and obtain approval for adequate reimbursement from third-party and government payors. If we are unable to successfully
commercialize one or more of our drug therapies, we may not be able to earn sufficient revenue to continue our business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>


<!-- Field: Page; Sequence: 29; Value: 2 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>If
we are not able to obtain, or if there are delays in obtaining, required regulatory approvals, we will not be able to commercialize our
current in-development products or our future product candidates, and our ability to generate revenue will be materially impaired.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
current in-development products and our future product candidates and the activities associated with their development and commercialization,
including their design, testing, manufacture, safety, efficacy, record-keeping, labeling, storage, approval, advertising, promotion,
sale, and distribution, are subject to comprehensive regulation by the FDA and other regulatory agencies in the United States and by
comparable foreign regulatory authorities, with regulations differing from country to country. Failure to obtain marketing approval for
a product candidate will prevent us from commercializing the product candidate. We currently do not have any products approved for sale
in any jurisdiction. We as a company only have limited experience in filing and supporting the applications necessary to gain marketing
approvals and may rely on third-party contract research organizations to assist us in this process.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
time required to obtain approval, if any, by the FDA and comparable foreign authorities is unpredictable but typically takes many years
following the commencement of clinical trials and depends upon numerous factors, including the substantial discretion of the regulatory
authorities, government budget, and funding levels and statutory, regulatory, and policy changes. Average review times at the FDA have
fluctuated in recent years, and disruptions at the FDA and other agencies may slow the time necessary for new drugs to be reviewed and/or
approved. For example, over the last several years, including for 35 days beginning on December 22, 2018, the U.S. government has shut
down several times and certain regulatory agencies, including the FDA, have had to furlough nonessential employees and stop routine activities.
Events like this could significantly impact the ability of the FDA to timely review and process our regulatory submissions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Approval
policies, regulations, or the type and amount of clinical data necessary to gain approval may change during the course of a product candidate&#8217;s
clinical development. For instance, any reorganization and rededication of critical resources, at the FDA and within similar governmental
health authorities across the world, may impact the ability of new products and services from being developed or commercialized in a
timely manner. Regulations and requirements vary among jurisdictions, including in Europe and Japan. We have not obtained regulatory
approval for any product candidate, and it is possible that none of our current in-development products or any product candidates we
may seek to develop in the future will ever obtain regulatory approval. We are not permitted to market any product candidate in the United
States until we receive regulatory approval of an NDA from the FDA.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
order to obtain approval to commercialize a product candidate in the United States or abroad, we or our collaborators must demonstrate
to the satisfaction of the FDA or foreign regulatory agencies, that such product candidates are safe and effective for their intended
uses. Results from nonclinical studies and clinical trials can be interpreted in different ways. Even if we believe that the nonclinical
or clinical data for a product candidate is promising, such data may not be sufficient to support approval by the FDA and other regulatory
authorities. The FDA may also require us to conduct additional nonclinical studies or clinical trials for product candidates either prior
to or post-approval, and it may otherwise object to elements of our clinical development program.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have not submitted a marketing application for any product candidates in any country or region. Any marketing application must include
extensive preclinical, nonclinical, and clinical data and supporting information to establish the product candidate&#8217;s safety and
efficacy for each desired indication. The marketing application(s) must also include significant information regarding the chemistry,
manufacturing, and controls for the product candidate. Obtaining marketing authorization is a lengthy, expensive, and uncertain process.
The FDA, EMA, PMDA, TGA, and other comparable regulatory authorities have substantial discretion in the review and approval process and
may refuse to accept for filing any application or may decide that our data are insufficient for approval and require additional nonclinical,
clinical, or other studies. Foreign regulatory authorities have differing requirements for approval of drugs with which we must comply
prior to marketing. There can be no assurance that any foreign regulatory authorities will accept FDA approval as sufficient to support
approval in that country. Obtaining marketing approval for marketing of a product candidate in one country does not ensure that we will
be able to obtain marketing approval in other countries, but the failure to obtain marketing approval in one jurisdiction could negatively
affect our ability to obtain marketing approval in other jurisdictions. The FDA or any foreign regulatory bodies can delay, limit or
deny approval of our current in-development products or other future product candidates or require us to conduct additional nonclinical
or clinical testing or abandon a program for many reasons, including:</FONT></P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">disagreement
    with the design or implementation of our clinical trials;</FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>




<!-- Field: Page; Sequence: 30; Value: 2 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">negative
    or ambiguous results from our clinical trials or results that may not meet the level of statistical significance required by the
    FDA or comparable foreign regulatory agencies for approval (for example, otherwise positive clinical results may be called into question
    if patient reported outcomes introduce ambiguity due to factors such as co-morbidities and other underlying patient issues);</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">serious
    and unexpected drug-related side effects experienced by participants in our clinical trials or by individuals using drugs similar
    to our product candidates;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    inability to demonstrate to the satisfaction of the FDA or the applicable foreign regulatory body that our product candidates are
    safe and effective for the proposed indication;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">disagreement
    with the interpretation of data from nonclinical studies or clinical trials;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    inability to demonstrate the clinical and other benefits of our product candidates outweigh any safety or other perceived risks;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">requirements
    for additional nonclinical studies or clinical trials;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">disagreement
    regarding the formulation, labeling, and/or the specifications we propose for our product candidates; or</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
    in a policies, requirements, or regulations rendering our clinical data insufficient for approval.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Of
the large number of drugs in development, only a small percentage complete the FDA or foreign regulatory approval processes and are successfully
commercialized. The lengthy review process as well as the unpredictability of future clinical trial results may result in our failing
to obtain regulatory approval, which would significantly harm our business, financial condition, results of operations, and prospects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even
if we eventually receive approval of an NDA or foreign marketing application for our product candidates, the FDA, or the applicable foreign
regulatory agency may grant approval contingent on the performance of costly additional clinical trials, often referred to as Phase 4
clinical trials, and the FDA may require the implementation of a REMS, which may be required to ensure safe use of the drug after approval.
The FDA or the applicable foreign regulatory agency also may approve a product candidate for a more limited indication or patient population
than we originally requested, and the FDA or applicable foreign regulatory agency may not approve the labeling that we believe is necessary
or desirable for the successful commercialization of a product candidate. Any delay in obtaining, or inability to obtain, applicable
regulatory approval would delay or prevent commercialization of that product candidate and would materially adversely impact our business
and prospects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Preclinical
development is uncertain. Our preclinical programs may experience delays or may never advance to clinical trials, which would adversely
affect our ability to obtain regulatory approvals or commercialize these programs on a timely basis or at all.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Most
of our product candidates are still in the preclinical stage, and the risk of failure for such product candidates is high. In order to
obtain FDA approval to market a new biologic we must demonstrate proof of safety, purity and potency, including efficacy, in humans.
To meet these requirements, we will have to conduct adequate and well-controlled clinical trials. Before we can commence clinical trials
for a product candidate, we must complete extensive preclinical testing and studies that support our planned clinical trials in humans.
We cannot be certain of the timely completion or outcome of our preclinical testing and studies and cannot predict if the FDA will accept
our proposed clinical programs or if the outcome of our preclinical testing and studies will ultimately support the further development
of our current or future product candidates. As a result, we cannot be sure that we will be able to submit INDs or similar applications
for our preclinical programs on the timelines we expect, if at all, and we cannot be sure that submission of INDs or similar applications
will result in the FDA or other regulatory authorities allowing clinical trials to begin.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Conducting
preclinical testing is a lengthy, time-consuming and expensive process. The length of time of such testing may vary substantially according
to the type, complexity and novelty of the program, and often can be several years or more per program. Delays associated with programs
for which we are conducting preclinical testing and studies may cause us to incur additional operating expenses. The commencement and
rate of completion of preclinical studies and clinical trials for a product candidate may be delayed by many factors, including but not
limited to: an inability to generate sufficient preclinical or other in vivo or in vitro data to support the initiation of clinical studies;
delays in reaching a consensus with regulatory agencies on study design; any setbacks or delays on account of any pandemic; and the FDA
or foreign regulatory authorities not permitting the reliance on preclinical or other data from published scientific literature.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>


<!-- Field: Page; Sequence: 31; Value: 2 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Clinical
trials are expensive, time-consuming and difficult to design and implement, and involve an uncertain outcome.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
obtain the requisite regulatory approvals to commercialize any of our product candidates, we must demonstrate through extensive preclinical
studies and clinical trials that our product candidates are safe, pure and potent in humans. Clinical testing is expensive and can take
many years to complete, and its outcome is highly uncertain. Failure can occur at any time during the clinical trial process and our
future clinical trial results may not be successful. We may also experience numerous unforeseen events during our clinical trials that
could delay or prevent our ability to receive marketing approval or commercialize the product candidates we develop.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Failure
can occur at any time during the clinical trial process. Because the results of preclinical studies and early clinical trials are not
necessarily predictive of future results, our drug therapies may not have favorable results in later preclinical and clinical studies
or receive regulatory approval. We may experience delays in initiating and completing any clinical trials that we intend to conduct,
and we do not know whether planned clinical trials will begin on time, need to be redesigned, enroll patients on time or be completed
on schedule, or at all. Many of the factors that cause, or lead to, a delay in the commencement or completion of clinical trials may
also ultimately lead to the denial of marketing approval of our product candidates. Clinical trials can be delayed for a variety of reasons,
including delays related to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    FDA or other regulatory authorities may change the requirements for approval even after they have reviewed and commented on the design
    for our clinical trials;</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    FDA or comparable foreign regulatory authorities disagreeing as to the design or implementation of our clinical studies;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">obtaining
    regulatory approval to commence and/or continue to conduct a trial, including but not limited to obtaining IND approval by FDA;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">reaching
    an agreement on acceptable terms with prospective contract research organizations, or CROs, and clinical trial sites, the terms of
    which can be subject to extensive negotiation and may vary significantly among different CROs and trial sites;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">obtaining
    Institutional Review Board, or IRB, approval at each site, or Independent Ethics Committee, or IEC, approval at sites outside the
    United States;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">recruiting
    suitable patients to participate in a trial in a timely manner and in sufficient numbers;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">having
    patients complete a trial or return for post-treatment follow-up;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">imposition
    of a clinical hold by regulatory authorities, or IRBs, including as a result of unforeseen safety issues or side effects or failure
    of trial sites to adhere to regulatory requirements or follow trial protocols;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">clinical
    sites deviating from trial protocol, failing to adequately enroll study subjects, committing fraud or other violations of regulatory
    requirements, or dropping out of a trial, which can render data from that site unusable in support of regulatory approval;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">addressing
    patient safety concerns that arise during the course of a trial;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">adding
    a sufficient number of clinical trial sites; or</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">manufacturing
    sufficient quantities of our drug therapies for use in clinical trials.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
could also encounter delays if a clinical trial is suspended or terminated by us, the IRBs or IECs of the institutions in which such
trials are being conducted, the Data Safety Monitoring Board, or DSMB, for such trial or the FDA or other regulatory authorities. Such
authorities may impose such a suspension or termination due to a number of factors, including failure to conduct the clinical trial in
accordance with regulatory requirements or our clinical protocols, inspection of the clinical trial operations or trial site by the FDA
or other regulatory authorities resulting in the imposition of a clinical hold, unforeseen safety issues or adverse side effects, failure
to demonstrate a benefit from using a drug, changes in governmental regulations or administrative actions or lack of adequate funding
to continue the clinical trial. Furthermore, we rely on CROs and clinical trial sites to ensure the proper and timely conduct of our
clinical trials and, while we have agreements governing their committed activities, we have limited influence over their actual performance,
as described in &#8220;Item 1A Risk Factors- Risks Related to Our Dependence on Third Parties.&#8221;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>


<!-- Field: Page; Sequence: 32; Value: 2 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Treatment
of cancer patients with our oncology product candidates may be used in combination with other cancer drugs, such as other immuno-oncology
agents, monoclonal antibodies or other protein-based drugs or small molecule anti-cancer agent such as targeted agents or chemotherapy,
which can cause side effects or adverse events that are unrelated to our product candidate but may still impact the success of our clinical
trials. Additionally, our product candidates could potentially cause adverse events. The inclusion of critically ill patients in our
clinical trials may result in deaths or other adverse medical events due to other therapies or medications that such patients may be
using. As described above, any of these events could prevent us from obtaining regulatory approval or achieving or maintaining market
acceptance of our product candidates and impair our ability to commercialize our products. Because all of our product candidates are
derived from our platform technologies, a clinical failure of one of our product candidates may also increase the actual or perceived
likelihood that our other product candidates will experience similar failures.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Of
the large number of products in development, only a small percentage successfully complete the FDA or comparable foreign regulatory authorities&#8217;
approval processes and are commercialized. The lengthy approval process as well as the unpredictability of future clinical trial results
may result in our failing to obtain regulatory approval to market our product candidates, which would significantly harm our business,
financial condition, results of operations and prospects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even
if we eventually complete clinical testing and receive approval of a marketing application for our product candidates, the FDA or the
comparable foreign regulatory authorities may grant approval contingent on the performance of costly additional clinical trials, including
post-market clinical trials. The FDA or the comparable foreign regulatory authorities also may approve a product candidate for a more
limited indication or patient population than we originally request, and the FDA or comparable foreign regulatory authorities may not
approve the labeling that we believe is necessary or desirable for the successful commercialization of a product candidate. Any delay
in obtaining, or inability to obtain, applicable regulatory approval would delay or prevent commercialization of that product candidate
and would adversely impact our business and prospects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, the FDA or comparable foreign regulatory authorities may change their policies, adopt additional regulations or revise existing
regulations or take other actions, which may prevent or delay approval of our future product candidates under development on a timely
basis. Such policy or regulatory changes could impose additional requirements upon us that could delay our ability to obtain approvals,
increase the costs of compliance or restrict our ability to maintain any marketing authorizations we may have obtained.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we experience delays in the completion, or termination, of any clinical trial of our product candidates, the commercial prospects of
our product candidates will be harmed and our ability to generate product revenues from any of these product candidates will be delayed.
In addition, any delays in completing our clinical trials will increase our costs, slow down the development and approval process for
our product candidates and jeopardize our ability to commence product sales and generate revenues. Significant clinical trial delays
could also allow our competitors to bring products to market before we do or shorten any periods during which we have the exclusive right
to commercialize our product candidates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Future
legislation, and/or regulations and policies adopted by the FDA, the EMA, or comparable regulatory authorities, may increase the time
and cost required for us to conduct and complete clinical trials of our current in-development products or other future product candidates.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA has established regulations to govern the drug development and approval process, as have foreign regulatory authorities. The policies
of the FDA and other regulatory authorities may change and additional laws may be enacted or government regulations may be promulgated
that could prevent, limit, delay, or alternatively accelerate regulatory review of our current in-development products or other future
product candidates. Further, disruptions at the FDA and other agencies may prolong the time necessary for new drugs to be reviewed and/or
approved by necessary government agencies, which would adversely affect our business. For example, over the last several years, the U.S.
government has shut down several times and certain regulatory agencies, such as the FDA, have had to furlough critical employees and
stop critical activities. If a prolonged government shutdown occurs, it could significantly impact the ability of the FDA to timely review
and process our regulatory submissions, which could have a material adverse effect on our business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>


<!-- Field: Page; Sequence: 33; Value: 2 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Our
product candidates are based on novel technologies, which make it difficult to predict the timing, results and cost of product candidate
development and likelihood of obtaining regulatory approval.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have not yet succeeded and may not succeed in demonstrating efficacy and safety for any product candidates in clinical trials or in obtaining
marketing approval thereafter and use of our platform technologies may not ever result in marketable products. We may also experience
delays in developing a sustainable, reproducible, and scalable manufacturing process or transferring that process to commercial partners
or establishing our own commercial manufacturing capabilities, which may prevent us from completing our clinical trials or commercializing
any products on a timely or profitable basis, if at all.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Serious
adverse events, undesirable side effects or other unexpected properties of our product candidates may be identified during development
or after approval, which could lead to the discontinuation of our clinical development programs, refusal by regulatory authorities to
approve our product candidates or, if discovered following marketing approval, revocation of marketing authorizations or limitations
on the use of our product candidates thereby limiting the commercial potential of such product candidate.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
we develop our drug therapies and initiate clinical trials of our additional drug therapies, serious adverse events, or SAEs, undesirable
side effects, relapse of disease or unexpected characteristics may emerge causing us to abandon these product candidates or limit their
development to more narrow uses or subpopulations in which the SAEs or undesirable side effects or other characteristics are less prevalent,
less severe or more acceptable from a risk-benefit perspective or in which efficacy is more pronounced or durable. Should we observe
SAEs in our clinical trials or identify other undesirable side effects or other unexpected findings depending on their severity, our
trials could be delayed or even stopped, and our development programs may be halted entirely.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even
if our product candidates initially show promise in early clinical trials, the side effects of drug therapies are frequently only detectable
after they are tested in larger, longer and more extensive clinical trials or, in some cases, after they are made available to patients
on a commercial scale after approval. Sometimes, it can be difficult to determine if the serious adverse or unexpected side effects were
caused by the drug therapy or another factor, especially in oncology subjects who may suffer from other medical conditions and be taking
other medications. If serious adverse or unexpected side effects are identified during development or after approval and are determined
to be attributed to our product candidate, we may be required to develop a Risk Evaluation and Mitigation Strategy, or REMS, to ensure
that the benefits of treatment with such product candidate outweigh the risks for each potential patient, which may include, among other
things, a communication plan to health care practitioners, patient education, extensive patient monitoring or distribution systems and
processes that are highly controlled, restrictive and more costly than what is typical for the industry. Product-related side effects
could also result in potential product liability claims. Any of these occurrences may harm our business, financial condition and prospects
significantly.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, if one or more of our product candidates receives marketing approval, and we or others later identify undesirable side effects
or ADA caused by such products, a number of potentially significant negative consequences could result, including:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">regulatory
    authorities may suspend, withdraw or limit approvals of such product, or seek an injunction against its manufacture or distribution;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">regulatory
    authorities may require additional warnings on the label, including &#8220;boxed&#8221; warnings, or issue safety alerts, &#8220;Dear
    Healthcare Provider&#8221; letters, press releases or other communications containing warnings or other safety information about
    the product;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
    may be required to create a medication guide outlining the risks of such side effects for distribution to patients;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
    may be required to change the way a product is administered or conduct additional clinical trials;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    product may become less competitive, and our reputation may suffer;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
    may decide to remove the product from the marketplace; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
    may be subject to fines, injunctions or the imposition of civil or criminal penalties.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>


<!-- Field: Page; Sequence: 34; Value: 2 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Positive
results from preclinical studies and early-stage clinical trials may not be predictive of future results. Initial positive results in
any of our clinical trials may not be indicative of results obtained when the trial is completed or in later stage trials.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&#160;</I></B></FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
results of preclinical studies may not be predictive of the results of clinical trials. Preclinical studies and early-stage clinical
trials are primarily designed to test safety, to study pharmacokinetics and pharmacodynamics and to understand the side effects of product
candidates at various doses and schedules, and the results of any early-stage clinical trials may not be predictive of the results of
later-stage, large-scale efficacy clinical trials. In addition, initial success in clinical trials may not be indicative of results obtained
when such trials are completed. There can be no assurance that any of our current or future clinical trials will ultimately be successful
or support further clinical development of any of our product candidates. There is a high failure rate for drugs and biological products
proceeding through clinical trials. A number of companies in the pharmaceutical and biotechnology industries have suffered significant
setbacks in clinical development even after achieving promising results in earlier studies, and any such setbacks in our clinical development
could have a material adverse effect on our business and operating results.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even
if our clinical trials are completed, the results may not be sufficient to obtain regulatory approval for our product candidates. Data
obtained from preclinical and clinical activities are subject to varying interpretations, which may delay, limit or prevent regulatory
approval. In addition, the results of our preclinical studies may not be predictive of the results of outcomes in human clinical trials.
For example, our current or future product candidates may demonstrate different chemical, biological and pharmacological properties in
patients than they do in laboratory studies or may interact with human biological systems in unforeseen or harmful ways. Product candidates
in later stages of clinical trials may fail to show desired pharmacological properties or produce the necessary safety and efficacy results
despite having progressed through preclinical studies and initial clinical trials. Even if we are able to initiate and complete clinical
trials, the results may not be sufficient to obtain regulatory approval for our product candidates. In addition, we may experience regulatory
delays or rejections as a result of many factors, including changes in regulatory policy during the period of our product candidate development.
Any such delays could negatively impact our business, financial condition, results of operations and prospects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>As
an organization, we have limited experience designing and implementing clinical trials and we have never conducted pivotal clinical trials.
Failure to adequately design a trial, or incorrect assumptions about the design of the trial, could adversely affect the ability to initiate
the trial, enroll patients, complete the trial, or obtain regulatory approval on the basis of the trial results, as well as lead to increased
or unexpected costs and in delayed timelines.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
design and implementation of clinical trials is a complex process. We have limited experience designing and implementing clinical trials,
and we may not successfully or cost-effectively design and implement clinical trials that achieve our desired clinical endpoints efficiently,
or at all. A clinical trial that is not well designed may delay or even prevent initiation of the trial, can lead to increased difficulty
in enrolling patients, may make it more difficult to obtain regulatory approval for the product candidate on the basis of the study results,
or, even if a product candidate is approved, could make it more difficult to commercialize the product successfully or obtain reimbursement
from third-party payors. Additionally, a trial that is not well-designed could be inefficient or more expensive than it otherwise would
have been, or we may incorrectly estimate the costs to implement the clinical trial, which could lead to a shortfall in funding. We also
expect to continue to rely on third parties to conduct our clinical trials. If these third parties do not successfully carry out their
contractual duties, comply with regulatory requirements or meet expected deadlines, we may not be able to obtain marketing approval for
or commercialize our current or future product candidates we develop and our business could be materially harmed. Consequently, we may
be unable to successfully and efficiently execute and complete clinical trials that are required for biologics license application, or
BLA submission and FDA approval of our current or future product candidates. We may require more time and incur greater costs than our
competitors and may not succeed in obtaining regulatory approvals of product candidates that we develop.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Our
business is dependent on our ability to advance our current and future product candidates through clinical trials, obtain marketing approval
and ultimately commercialize them.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are early in our development efforts. Most of our product candidates are not yet in clinical trials. Our ability to generate product
revenues, which we do not expect will occur for several years, if ever, will depend heavily on the successful development and eventual
commercialization of our current product candidates and any other current or future product candidates we develop, which may never occur.
Our current product candidates and any future product candidates we develop will require additional preclinical or clinical development,
management of clinical, preclinical and manufacturing activities, marketing approval in the United States and other jurisdictions, demonstration
of effectiveness to pricing and reimbursement authorities, sufficient manufacturing supply for both preclinical and clinical development
and commercial production, building of a commercial organization and substantial investment and significant marketing efforts before
we generate any revenues from product sales.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>


<!-- Field: Page; Sequence: 35; Value: 2 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
clinical and commercial success of our current and future product candidates will depend on several factors, including the following:
timely and successful completion of preclinical studies and our clinical trials; sufficiency of our financial and other resources to
complete the necessary preclinical studies and clinical trials; our plans to successfully submit IND applications with the FDA for our
current and future product candidates; our ability to complete preclinical studies for current or future product candidates; successful
enrollment in, including maintaining or reaching target enrollment levels during the COVID-19 pandemic, and completion of clinical trials;
successful data from our clinical program that supports an acceptable risk-benefit profile of our product candidates in the intended
patient populations; our ability to establish agreements with third-party manufacturers on a timely and cost efficient manner; whether
we are required by the FDA or comparable foreign regulatory authorities to conduct additional clinical trials or other studies beyond
those planned or anticipated to support approval of our product candidates; acceptance of our proposed indications and the primary endpoint
assessments evaluated in the clinical trials of our product candidates by the FDA and comparable foreign regulatory authorities; receipt
and maintenance of timely marketing approvals from applicable regulatory authorities; successfully launching commercial sales of our
product candidates, if approved; the prevalence, duration and severity of potential side effects or other safety issues experienced with
our product candidates, if approved; entry into collaborations to further the development of our product candidates; obtaining and maintaining
patent and trade secret protection or regulatory exclusivity for our product candidates; acceptance of the benefits and uses of our product
candidates, if approved, by patients, the medical community and third-party payors; maintaining a continued acceptable safety, tolerability
and efficacy profile of the product candidates following approval; our compliance with any post-approval requirements imposed on our
products, such as post-marketing studies, a Risk Evaluation and Mitigation Strategy, or REMS, or additional requirements that might limit
the promotion, advertising, distribution or sales of our products or make the products cost prohibitive; competing effectively with other
therapies; obtaining and maintaining healthcare coverage and adequate reimbursement from third-party payors; and enforcing and defending
intellectual property rights and claims. There are multiple risks associated with developing companion diagnostics to ENV 105, ENV 205,
and KROS 301 and there is no guarantee that these companion diagnostics will be approved by the FDA or comparable foreign regulatory
agencies.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
factors, many of which are beyond our control, could cause us to experience significant delays or an inability to obtain regulatory approvals
or commercialize our current or future product candidates, and could otherwise materially harm our business. Successful completion of
preclinical studies and clinical trials does not mean that any of our current or future product candidates we develop will receive regulatory
approval. Even if regulatory approvals are obtained, we could experience significant delays or an inability to successfully commercialize
our current and any future product candidates we develop, which would materially harm our business. If we are not able to generate sufficient
revenue through the sale of any current or future product candidate, we may not be able to continue our business operations or achieve
profitability.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Interim,
topline and preliminary data from our clinical trials may change as more patient data become available and are subject to audit and verification
procedures that could result in material changes in the final data.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">From
time to time, we may publicly disclose preliminary, interim or topline data from our preclinical studies and clinical trials, which is
based on a preliminary analysis of then-available data, and the results and related findings and conclusions are subject to change as
patient enrollment and treatment continues and more patient data become available. Adverse differences between previous preliminary or
interim data and future interim or final data could significantly harm our business prospects. We may also announce topline data following
the completion of a preclinical study or clinical trial, which may be subject to change following a more comprehensive review of the
data related to the particular study or trial. We also make assumptions, estimations, calculations and conclusions as part of our analyses
of data, and we may not have received or had the opportunity to fully and carefully evaluate all data. As a result, the interim, topline
or preliminary results that we report may differ from future results of the same studies, or different conclusions or considerations
may qualify such results, once additional data have been received and fully evaluated. Topline data also remain subject to audit and
verification procedures that may result in the final data being materially different from the preliminary data we previously published.
As a result, interim, topline and preliminary data should be viewed with caution until the final data are available.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>


<!-- Field: Page; Sequence: 36; Value: 2 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Further,
others, including regulatory agencies, may not accept or agree with our assumptions, estimates, calculations, conclusions or analyses
or may interpret or weigh the importance of data differently, which could impact the value of the particular program, the approvability
or commercialization of the particular product candidate or product and our Company in general. In addition, the information we choose
to publicly disclose regarding a particular study or clinical trial is based on what is typically extensive information, and you or others
may not agree with what we determine to be material or otherwise appropriate information to include in our disclosure, and any information
we determine not to disclose may ultimately be deemed significant with respect to future decisions, conclusions, views, activities or
otherwise regarding a particular product candidate or our business. If the interim, topline, or preliminary data that we report differ
from actual results, or if others, including regulatory authorities, disagree with the conclusions reached, our ability to obtain approval
for and commercialize our product candidates, our business, operating results, prospects or financial condition may be harmed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
may face future business disruption and related risks resulting from pandemic, epidemic or outbreak of an infectious disease, any of
which could have a material adverse effect on our business.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
development of our drug candidates could be disrupted and materially adversely affected in the future by a pandemic, epidemic or outbreak
of an infectious disease like the outbreak of COVID-19. The spread of an infectious disease may result in the inability of our suppliers
to deliver components or raw materials on a timely basis or materially and adversely affect our collaborators and out-license partners&#8217;
ability to perform preclinical studies and clinical trials. In addition, hospitals may reduce staffing and reduce or postpone certain
treatments in response to the spread of an infectious disease. Such events may result in a period of business and manufacturing disruption,
and in reduced operations, any of which could materially affect our business, financial condition and results of operations. The extent
to which the coronavirus impacts our business will depend on future developments, which are highly uncertain and cannot be predicted,
including new information which may emerge concerning the severity of the coronavirus and the actions to contain the coronavirus or treat
its impact, among others.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Disruptions
at the FDA and other government agencies caused by funding shortages or global health concerns could hinder their ability to hire, retain
or deploy key leadership and other personnel, or otherwise prevent new or modified products from being developed, or approved or commercialized
in a timely manner or at all, which could negatively impact our business.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
ability of the FDA to review and approve new products can be affected by a variety of factors, including government budget and funding
levels, statutory, regulatory, and policy changes, the FDA&#8217;s ability to hire and retain key personnel and accept the payment of
user fees, and other events that may otherwise affect the FDA&#8217;s ability to perform routine functions. Average review times at the
agency have fluctuated in recent years as a result. In addition, government funding of other government agencies that fund research and
development activities is subject to the political process, which is inherently fluid and unpredictable. Disruptions at the FDA and other
agencies may also slow the time necessary for new biologics to be reviewed and/or approved by necessary government agencies, which would
adversely affect our business. For example, over the last several years, including for 35 days beginning on December 22, 2018, the U.S.
government has shut down several times and certain regulatory agencies, such as the FDA, have had to furlough critical FDA employees
and stop critical activities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
a prolonged government shutdown occurs, or if global health concerns continue to prevent the FDA or other regulatory authorities from
conducting their regular inspections, reviews, or other regulatory activities, it could significantly impact the ability of the FDA or
other regulatory authorities to timely review and process our regulatory submissions, which could have a material adverse effect on our
business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
may expend our limited resources to pursue a particular product candidate or indication and fail to capitalize on product candidates
or indications that may be more profitable or for which there is a greater likelihood of success.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Because
we have limited financial and managerial resources, we must prioritize our research programs and will need to focus our discovery and
development on select product candidates and indications. Correctly prioritizing our research and development activities is particularly
important for us due to the breadth of potential product candidates and indications that we believe could be pursued using our platform
technologies. As a result, we may forego or delay pursuit of opportunities with other product candidates or for other indications that
later prove to have greater commercial potential. Our resource allocation decisions may cause us to fail to capitalize on viable commercial
products or profitable market opportunities. Our spending on current and future research and development programs and product candidates
for specific indications may not yield any commercially viable products. If we do not accurately evaluate the commercial potential or
target market for a particular product candidate, we may also relinquish valuable rights to that product candidate through collaboration,
licensing or other royalty arrangements in cases in which it would have been more advantageous for us to retain sole development and
commercialization rights to such product candidate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>


<!-- Field: Page; Sequence: 37; Value: 2 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
may not be successful in our efforts to identify or discover additional product candidates in the future.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
research programs may initially show promise in identifying potential product candidates, yet fail to yield product candidates for clinical
development for a number of reasons, including:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    inability to design such product candidates with the properties that we desire; or</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">potential
    product candidates may, on further study, be shown to have harmful side effects or other characteristics that indicate that they
    are unlikely to be products that will receive marketing approval and achieve market acceptance.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
programs to identify new product candidates require substantial technical, financial and human resources. If we are unable to identify
suitable additional candidates for preclinical and clinical development, our opportunities to successfully develop and commercialize
therapeutic products will be limited.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>The
regulatory approval processes of the FDA and comparable foreign authorities are lengthy, time consuming, expensive, and inherently unpredictable,
and if we are ultimately unable to obtain regulatory approval for our drug therapy candidates, our business will be substantially harmed.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
time required to obtain approval by the FDA and comparable foreign authorities is unpredictable but typically takes many years following
the commencement of clinical trials and depends upon numerous factors, including the substantial discretion of the regulatory authorities.
In addition, approval policies, regulations or the type and amount of clinical data necessary to gain approval may change during the
course of a candidate&#8217;s clinical development and may vary among jurisdictions. We have not obtained regulatory approval for any
product candidate and it is possible that we will never obtain regulatory approval for any of our drug therapy candidates. We are not
permitted to market any of our product candidates in the United States until we receive regulatory approval of a NDA from the FDA. Our
ability to obtain approval by the FDA or other regulatory authorities can be adversely impacted for various reasons including:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
    may be unable to demonstrate to the satisfaction of the FDA or comparable foreign regulatory authorities that a candidate is safe
    and effective for its proposed indication;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">serious
    and unexpected drug-related side effects experienced by participants in our clinical trials or by individuals using drugs similar
    to our candidates, or other products containing the active ingredient in our candidates;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">negative
    or ambiguous results from our clinical trials or results that may not meet the level of statistical significance required by the
    FDA or comparable foreign regulatory authorities for approval;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
    may be unable to demonstrate that a candidate&#8217;s clinical and other benefits outweigh its safety risks;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    FDA or comparable foreign regulatory authorities may disagree with our interpretation of data from preclinical studies or clinical
    trials;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    data collected from clinical trials of our development candidates may not be acceptable or sufficient to support the submission of
    an NDA or other submission or to obtain regulatory approval in the United States or elsewhere, and we may be required to conduct
    additional clinical trials;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    FDA or comparable foreign authorities may disagree regarding the formulation, labeling and/or the specifications of our candidates;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    FDA or comparable foreign regulatory authorities may fail to approve or find deficiencies with the manufacturing processes or facilities
    of third-party manufacturers with which we contract for clinical and commercial supplies;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>


<!-- Field: Page; Sequence: 38; Value: 2 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    FDA or comparable foreign regulatory authorities may inspect and find deficiencies at the clinical trial sites we use to conduct
    our clinical studies; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    approval policies or regulations of the FDA or comparable foreign regulatory authorities may significantly change in a manner rendering
    our clinical data insufficient for approval.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prior
to obtaining approval to commercialize a candidate in the United States or abroad, we must demonstrate with substantial evidence from
well-controlled clinical trials, and to the satisfaction of the FDA or foreign regulatory agencies, that such candidates are safe and
effective for their intended uses. Results from preclinical studies and clinical trials can be interpreted in different ways. Even if
we believe the preclinical or clinical data for our candidates are promising, such data may not be sufficient to support approval by
the FDA and other regulatory authorities. A single-study approach is permissible in certain circumstances, particularly in oncology,
but such circumstances are exceptional and FDA may not agree with that proposed approach, and thus we may be required to conduct two
phase 3 trials.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA or any foreign regulatory bodies can delay, limit or deny approval of our candidates or require us to conduct additional preclinical
or clinical testing or abandon a program for many reasons, including:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    FDA or comparable foreign regulatory authorities may disagree with the adequacy of the design or implementation of our clinical trials;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    FDA or comparable foreign regulatory authorities may disagree with our safety interpretation of our drug;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    FDA or comparable foreign regulatory authorities may disagree with our efficacy interpretation of our drug; or</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    FDA or comparable foreign regulatory authorities may regard our CMC package as inadequate, and more particularly:</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">if
    our NDA does not include adequate tests by all methods reasonably applicable to show whether or not such drug is safe for use under
    the conditions prescribed, recommended, or suggested in the proposed labeling thereof;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">if
    the results of such tests show that such drug is unsafe for use under such conditions or do not show that such drug is safe for use
    under such conditions;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">if
    the methods used in, and the facilities and controls used for, the manufacture, processing, and packing of such drug are inadequate
    to preserve its identity, strength, quality, and purity;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">if
    the FDA determines that it has insufficient information to determine whether such drug is safe for use under such conditions;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">if
    based on information we submit and any other information before the FDA, the FDA determines there is a lack of substantial evidence
    that the drug will have the effect it purports or is represented to have under the conditions of use prescribed, recommended, or
    suggested in the proposed labeling thereof; or</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">if
    the FDA determines that our labeling is false or misleading in any particular way.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Of
the large number of drugs that enter clinical development, only a small percentage successfully complete the regulatory approval processes
and are approved and commercialized. This lengthy approval process, as well as the unpredictability of future clinical trial results,
may result in our failing to obtain regulatory approval to market of any of our drug therapy candidates, which would significantly harm
our business, results of operations and prospects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, the FDA or an applicable foreign regulatory agency also may approve a product candidate for a more limited indication or patient
population than we originally requested, the FDA or foreign regulatory agency may approve a product candidate with a label that does
not include the labeling claims necessary or desirable for the successful commercialization of that product candidate, or may require
warnings, other safety-related labeling information, or impose post-market safety requirements, including distribution restrictions,
that negatively impact the commercial potential of the drug. Any of the foregoing scenarios could materially harm the commercial prospects
for our product candidates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>


<!-- Field: Page; Sequence: 39; Value: 2 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Enrollment
and retention of patients in clinical trials is an expensive and time-consuming process and could be made more difficult or rendered
impossible by multiple factors outside our control.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
timely completion of clinical trials in accordance with their protocols depends, among other things, on our ability to enroll a sufficient
number of patients who remain in the study until its conclusion. We may encounter delays in enrolling, or be unable to enroll, a sufficient
number of patients to complete any of our clinical trials, and even once enrolled, we may be unable to retain a sufficient number of
patients to complete any of our trials. Patient enrollment and retention in clinical trials depends on many factors, including:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    patient eligibility criteria defined in the protocol;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    size of the patient population required for analysis of the trial&#8217;s primary endpoints;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    nature of the trial protocol;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    existing body of safety and efficacy data with respect to the product candidate;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    proximity of patients to clinical sites;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to recruit clinical trial investigators with the appropriate competencies and experience;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">clinicians&#8217;
    and patients&#8217; perceptions as to the potential advantages of the product candidate being studied in relation to other available
    therapies, including any new drugs that may be approved for the indications we are investigating;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">competing
    clinical trials being conducted by other companies or institutions;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to maintain patient consents;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    risk that patients enrolled in clinical trials will drop out of the trials before completion; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays
    or difficulties in enrollment and completion of studies due to any pandemic, epidemic or outbreak of an infectious disease.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Results
of preclinical studies, early clinical trials or analyses may not be indicative of results obtained in later trials.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
results of preclinical studies, early clinical trials or analyses of our product candidates may not be predictive of the results of later-stage
clinical trials. Product candidates in later stages of clinical trials may fail to show the desired safety and efficacy traits despite
having progressed through preclinical studies and initial clinical trials. A number of companies in the pharmaceutical industry have
suffered significant setbacks in advanced clinical trials due to lack of efficacy or adverse safety profiles, notwithstanding promising
results in earlier trials. In addition, conclusions based on promising data from analyses of clinical results may be shown to be incorrect
when implemented in prospective clinical trials. Even if our clinical trials for our drug therapy candidates are completed as planned,
we cannot be certain that their results will support the safety and efficacy sufficient to obtain regulatory approval.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Serious
adverse events or undesirable side effects caused by any of our drug therapy candidates could cause us or regulatory authorities to interrupt,
delay or halt clinical trials and could result in a more restrictive label or the delay or denial of regulatory approval by the FDA or
other comparable foreign authorities. Results of any clinical trial we conduct could reveal a high and unacceptable severity and prevalence
of side effects or unexpected characteristics.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
unacceptable side effects arise in the development of our candidates, we, the FDA or the IRBs at the institutions in which our studies
are conducted, or the DSMB, if constituted for our clinical trials, could recommend a suspension or termination of our clinical trials,
or the FDA or comparable foreign regulatory authorities could order us to cease further development of or deny approval of a product
candidate for any or all targeted indications. In addition, drug-related side effects could affect patient recruitment or the ability
of enrolled patients to complete a trial or result in potential product liability claims. In addition, these side effects may not be
appropriately recognized or managed by the treating medical staff. We expect to have to train medical personnel using our development
candidates to understand the side effect profiles for our clinical trials and upon any commercialization of any of our product candidates.
Inadequate training in recognizing or managing the potential side effects of our product candidates could result in patient injury or
death. Any of these occurrences may harm our business, financial condition and prospects significantly.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>


<!-- Field: Page; Sequence: 40; Value: 2 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally,
if one or more of our product candidates receives marketing approval, and we or others later identify undesirable side effects caused
by such products, a number of potentially significant negative consequences could result, including:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">regulatory
    authorities may withdraw approvals of such product;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">regulatory
    authorities may require additional warnings on the label, such as a &#8220;black box&#8221; warning or contraindication;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">additional
    restrictions may be imposed on the marketing of the particular product or the manufacturing processes for the product or any component
    thereof;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
    may be required to implement a Risk Evaluation and Mitigation Strategy, or REMS, or create a medication guide outlining the risks
    of such side effects for distribution to patients;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
    could be sued and held liable for harm caused to patients;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    product may become less competitive; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    reputation may suffer.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
of these events could prevent us from achieving or maintaining market acceptance of a product candidate, if approved, and could significantly
harm our business, results of operations and prospects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>The
market opportunities for any current or future product candidate we develop, if approved, may be limited to those patients who are ineligible
for established therapies or for whom prior therapies have failed, and may be small.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cancer
therapies are sometimes characterized as first-line, second-line or third-line, and the FDA often approves new therapies initially only
for third-line use. Second- and third-line therapies are administered to patients when prior therapy is not effective. The number of
patients who receive second- and third-line treatment is significantly smaller than the number of patients who receive first-line treatment.
We may initially seek approval for our product candidates we develop as second- or third-line therapies. If we do so, for those products
that prove to be sufficiently beneficial, if any, we would expect potentially to seek approval as a first-line therapy, but there is
no guarantee that any product candidate we develop, even if approved, would be approved for first-line therapy, and, prior to any such
approvals, we may have to conduct additional clinical trials.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
number of patients who have the types of cancer or autoimmune diseases we are targeting may turn out to be lower than expected. Even
if we obtain significant market share for any product candidate, if and when approved, if the potential target populations are small,
we may never achieve profitability without obtaining marketing approval for additional indications, including to be used as first- or
second-line therapy.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
have never obtained marketing approval for a drug therapy candidate and we may be unable to obtain, or may be delayed in obtaining, marketing
approval for any of our development candidates.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have never obtained marketing approval for a product candidate. It is possible that the FDA may refuse to accept for substantive review
any NDAs that we submit for our development candidates or may conclude after review of our data that our application is insufficient
to obtain marketing approval of our development candidates. If the FDA does not accept or approve our NDAs for our development candidates,
it may require that we conduct additional clinical, preclinical or manufacturing validation studies and submit that data before it will
reconsider our applications. Depending on the extent of these or any other FDA-required studies, approval of any NDA that we submit may
be delayed or may require us to expend more resources than we have available. It is also possible that additional studies, if performed
and completed, may not be considered sufficient by the FDA to approve our NDAs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
delay in obtaining, or an inability to obtain, marketing approvals would prevent us from commercializing our development candidates,
generating revenues and achieving and sustaining profitability. If any of these outcomes occur, we may be forced to abandon our development
efforts for our product candidates, which could significantly harm our business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Even
if we obtain FDA approval for any of our drug therapy candidates in the United States, we may never obtain approval for or commercialize
them in any other jurisdiction, which would limit our ability to realize their full global market potential.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
order to market any products in any particular jurisdiction, we must establish and comply with numerous and varying regulatory requirements
on a country-by-country basis regarding safety and efficacy. Approval by the FDA in the United States does not ensure approval by regulatory
authorities in other countries or jurisdictions. However, the failure to obtain approval in one jurisdiction may negatively impact our
ability to obtain approval elsewhere. In addition, clinical trials conducted in one country may not be accepted by regulatory authorities
in other countries, and regulatory approval in one country does not guarantee regulatory approval in any other country.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>


<!-- Field: Page; Sequence: 41; Value: 2 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Approval
processes vary among countries and can involve additional product testing and validation and additional administrative review periods.
Seeking foreign regulatory approval could result in difficulties and increased costs for us and require additional preclinical studies
or clinical trials which could be costly and time consuming. Regulatory requirements can vary widely from country to country and could
delay or prevent the introduction of our products in those countries. We do not have any product candidates approved for sale in any
jurisdiction, including in international markets, and we do not have experience in obtaining regulatory approval in international markets.
If we fail to comply with regulatory requirements in international markets or to obtain and maintain required approvals, or if regulatory
approvals in international markets are delayed, our target market will be reduced and our ability to realize the full market potential
of any product we develop will be unrealized.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Even
if we obtain regulatory approval for any development candidate, we will still face extensive and ongoing regulatory requirements and
obligations and any development candidates, if approved, may face future development and regulatory difficulties.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA and other federal and state agencies, including the U.S. Department of Justice, or the DOJ, closely regulate compliance with all
requirements governing prescription drug products, including requirements pertaining to marketing and promotion of drugs in accordance
with the provisions of the approved labeling and manufacturing of products in accordance with cGMP requirements. The FDA and DOJ impose
stringent restrictions on manufacturers&#8217; communications regarding off-label use and if we do not market our current in-development
products or our future product candidates for their approved indications, we may be subject to enforcement action for off-label marketing.
Violations of such requirements may lead to investigations alleging violations of the Food, Drug and Cosmetic Act and other statutes,
including the False Claims Act and other federal and state health care fraud and abuse laws as well as state consumer protection laws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
candidate for which we obtain marketing approval, along with the manufacturing processes, post-approval clinical data, labeling, packaging,
distribution, adverse event reporting, storage, recordkeeping, export, import, advertising and promotional activities for such product,
among other things, will be subject to extensive and ongoing requirements of and review by the FDA and other regulatory authorities.
These requirements include submissions of safety and other post-marketing information and reports, establishment registration and drug
listing requirements, continued compliance with current Good Manufacturing Practice, or cGMP, requirements relating to manufacturing,
quality control, quality assurance and corresponding maintenance of records and documents, requirements regarding the distribution of
samples to physicians and recordkeeping and Good Clinical Practice, or GCP, requirements for any clinical trials that we conduct post-approval.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even
if marketing approval of a product candidate is granted, the approval may be subject to limitations on the indicated uses for which the
product candidate may be marketed or to the conditions of approval, including a requirement to implement a REMS. If any of our product
candidates receive marketing approval, the accompanying label may limit the approved indicated use of the product candidate, which could
limit sales of the product candidate. The FDA may also impose requirements for costly post-marketing studies or clinical trials and surveillance
to monitor the safety or efficacy of a product. The FDA closely regulates the post-approval marketing and promotion of drugs to ensure
drugs are marketed only for the approved indications and in accordance with the provisions of the approved labeling. The FDA imposes
stringent restrictions on manufacturers&#8217; communications regarding off-label use, and if we market our products for uses beyond
their approved indications, we may be subject to enforcement action for off-label marketing. Violations of the Federal Food, Drug, and
Cosmetic Act, or FDCA, relating to the promotion of prescription drugs may lead to FDA enforcement actions and investigations alleging
violations of federal and state healthcare fraud and abuse laws, as well as state consumer protection laws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>


<!-- Field: Page; Sequence: 42; Value: 2 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, later discovery of previously unknown adverse events or other problems with our products, manufacturers or manufacturing processes
or failure to comply with regulatory requirements, may yield various results, including:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">litigation
    involving patients taking our product candidates;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">restrictions
    on such products, manufacturers, or manufacturing processes;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">restrictions
    on the labeling or marketing of products;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">restrictions
    on product distribution or use;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">requirements
    to conduct post-marketing studies or clinical trials;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">warning
    letters or untitled letters;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">withdrawal
    of the products from the market;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">refusal
    to approve pending applications or supplements to approved applications that we submit;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">recall
    of products;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">fines,
    restitution or disgorgement of profits or revenues;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">suspension
    or withdrawal of marketing approvals;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">refusal
    to permit the import or export of our products;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">damage
    to relationships with any potential collaborators;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">unfavorable
    press coverage and damage to our reputation;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">refusal
    to permit the import or export of our product candidates;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">product
    seizure; or</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">injunctions
    or the imposition of civil or criminal penalties.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Further,
the FDA&#8217;s policies may change, and additional government regulations may be enacted that could prevent, limit or delay regulatory
approval of our product candidates. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements
or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained, which
would adversely affect our business, prospects and ability to achieve or sustain profitability. We also cannot predict the likelihood,
nature or extent of government regulation that may arise from future legislation or administrative or executive action, either in the
United States or abroad.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Even
if we obtain marketing approvals for our current in-development products or any future product candidates, the terms of approvals and
ongoing regulation of such product candidates may limit how we manufacture and market the product candidates and compliance with such
requirements may involve substantial resources, which could materially impair our ability to generate revenue.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even
if marketing approval of any of our current in-development products or any future product candidates is granted, an approved product
and its manufacturer and marketer are subject to ongoing review and extensive regulation, including the potential requirements to implement
a risk evaluation and mitigation strategy or to conduct costly post-marketing studies or clinical trials and surveillance to monitor
the safety or efficacy of the product. We must also comply with requirements concerning advertising and promotion for any of our product
candidates for which we obtain marketing approval. Promotional communications with respect to prescription drugs are subject to a variety
of legal and regulatory restrictions and must be consistent with the information in the product&#8217;s approved labeling. Thus, we will
not be able to promote any products we develop for indications or uses for which they are not approved. In addition, manufacturers of
approved products and those manufacturers&#8217; facilities are required to comply with extensive FDA requirements including ensuring
that quality control and manufacturing procedures conform to cGMP, which include requirements relating to quality control and quality
assurance as well as the corresponding maintenance of records and documentation and reporting requirements. We and our contract manufacturers
could be subject to periodic unannounced inspections by the FDA to monitor and ensure compliance with cGMP.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accordingly,
assuming we receive marketing approval for one or more product candidates, we and our contract manufacturers will continue to expend
time, money, and effort in all areas of regulatory compliance, including manufacturing, production, product surveillance, and quality
control. If we are not able to comply with post-approval regulatory requirements, we could have the marketing approvals for our product
candidates withdrawn by regulatory authorities and our ability to market any future products could be limited, which could adversely
affect our ability to achieve or sustain profitability. Thus, the cost of compliance with post-approval regulations may have a negative
effect on our operating results and financial condition.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-compliance
by us or any future collaborator with regulatory requirements regarding safety monitoring or pharmacovigilance, and with requirements
related to the development of products for the pediatric population, can also result in significant financial penalties. Similarly, failure
to comply with regulatory requirements regarding the protection of personal information can also lead to significant penalties and sanctions.
Non-compliance with EU requirements regarding safety monitoring or pharmacovigilance, and with requirements related to the development
of products for the pediatric population, also can result in significant financial penalties. Similarly, failure to comply with the EU&#8217;s
requirements regarding the protection of personal information can also lead to significant penalties and sanctions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>


<!-- Field: Page; Sequence: 43; Value: 2 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
may seek a Breakthrough Therapy designation for one of our drug therapy candidates from the FDA. However, we might not seek such designation
or be granted the designation by the FDA if sought, and even if we are granted the designation, it may not lead to a faster development
or regulatory review or approval process.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may seek a Breakthrough Therapy designation for one or more of our drug therapy candidates. Breakthrough Therapy designation is a process
designed to expedite the development and review of drugs that are intended to treat a serious condition and preliminary clinical evidence
indicates that the drug may demonstrate substantial improvement over available therapy on a clinically significant endpoint(s). For purposes
of Breakthrough Therapy designation, clinically significant endpoint generally refers to an endpoint that measures an effect on irreversible
morbidity or mortality (IMM) or on symptoms that represent serious consequences of the disease. A clinically significant endpoint can
also refer to findings that suggest an effect on IMM or serious symptoms. For drugs that have been designated as breakthrough therapies,
interaction and communication between the FDA and the sponsor of the trial can help to identify the most efficient path for clinical
development while minimizing the number of patients placed in ineffective control regimens. Drugs designated as breakthrough therapies
by the FDA may also be eligible for fast-track designation (under a separate request), priority review, or accelerated approval, if supported
by clinical data at the time the NDA is submitted to the FDA. FDA encourages a Breakthrough Therapy designation request to be submitted,
and received by FDA, no later than the end-of-phase-2 meetings. Even if granted, accelerated approval status does not guarantee an accelerated
review or marketing approval by the FDA.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Designation
as a Breakthrough Therapy is within the discretion of the FDA both at the time of the submission of such a request, and during FDA&#8217;s
review of the drug and supporting data. Even if we believe that one of our candidates meets the criteria for designation as a Breakthrough
Therapy, the FDA may disagree and instead determine not to make such designation or may grant such a designation and subsequently rescind
the designation prior to approval. Even if we receive and maintain Breakthrough Therapy designation, the receipt of such designation
for a product candidate may not result in a faster development or regulatory review or approval process compared to drugs considered
for approval under conventional FDA procedures and does not assure ultimate approval by the FDA. In addition, even if one or more of
our product candidates qualify as breakthrough therapies, the FDA may later decide that the product candidates no longer meet the conditions
for qualification or decide that the time period for FDA review or approval will not be shortened.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Risks
Related to the Commercialization of Our Current In-Development Products and Our Future Product Candidates</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Even
if any of our current in-development products or any of our future product candidates receives marketing approval, it may fail to achieve
the degree of market acceptance by physicians, patients, third-party payors, and others in the medical community necessary for commercial
success.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even
if we obtain approvals from the FDA, the EMA, the PMDA, the TGA, or other comparable regulatory agencies and are able to initiate commercialization
of our current in-development products or any future product candidates we develop, the product candidate may not achieve market acceptance
among physicians, patients, and third-party payors and, ultimately, may not be commercially successful. The degree of market acceptance
of our product candidates, if approved for commercial sale, will depend on a number of factors, including:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the market size of any product candidate that obtains regulatory approval is significantly smaller than we anticipate, it may not achieve
market acceptance or commercial success. This could significantly and negatively impact our business, financial condition, and results
of operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>


<!-- Field: Page; Sequence: 44; Value: 2 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>If
we are unable to establish sales, marketing, and distribution capabilities for our current in-development products or our future product
candidates, or enter into sales, marketing, and distribution agreements with third parties, we may not be successful in commercializing
our product candidates, if and when they are approved.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
do not have a sales or marketing infrastructure and have limited experience in the sale, marketing, or distribution of pharmaceutical
products. To achieve commercial success for any product candidate for which we may obtain marketing approval, we will need to establish
a sales and marketing organization or enter into collaboration, distribution, and other marketing arrangements with one or more third
parties to commercialize such product candidate. In the United States, we intend to build a commercial organization to target areas with
the greatest incidence of treatments for cancers and other indications to which our drugs and therapies are targeted and recruit experienced
sales, marketing, and distribution professionals. The development of sales, marketing, and distribution capabilities will require substantial
resources, will be time-consuming, and could delay any product launch. We may decide to work with regional specialty pharmacies, distributors,
and/or multi-national pharmaceutical companies to leverage their commercialization capabilities to commercialize any product candidate
for which we may obtain regulatory approval outside of the United States.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the commercial launch of a product candidate for which we recruit a sales force and establish marketing and distribution capabilities
is delayed or does not occur for any reason, we would have prematurely or unnecessarily incurred these commercialization costs. This
may be costly, and our investment would be lost if we cannot retain or reposition our sales and marketing personnel. In addition, we
may not be able to hire a sales force in the United States that is sufficient in size or has adequate expertise to target the areas that
we intend to target. If we are unable to establish a sales force and marketing and distribution capabilities, our operating results may
be adversely affected.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Factors
that may inhibit our efforts to commercialize our drugs on our own include:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    inability to recruit, train, and retain adequate numbers of effective sales and marketing personnel;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    inability of sales personnel to obtain access to physicians or persuade adequate numbers of physicians to prescribe any future products;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    lack of complementary products to be offered by sales personnel, which may put us at a competitive disadvantage compared to companies
    with more extensive product lines;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">unforeseen
    costs and expenses associated with creating an independent sales and marketing organization; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">unforeseen
    costs and limitations with regard to setting up a distribution network.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we are unable to establish our own sales, marketing, and distribution capabilities in the United States and other jurisdictions in which
our current in-development products or any future product candidates are approved and, instead, enter into arrangements with third parties
to perform these services, our revenues and profitability, if any, are likely to be lower than if we were to sell, market, and distribute
any product candidates that we develop ourselves. We may not be successful in entering into arrangements with third parties to sell,
market, and distribute our product candidates or may be unable to do so on terms that are favorable to us. We likely will have limited
control over such third parties, and any of them may fail to devote the necessary resources and attention to sell and market our product
candidates effectively. If we do not establish sales, marketing, and distribution capabilities successfully, either on our own or in
collaboration with third parties, we will not be successful in commercializing any product candidates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Coverage
and adequate reimbursement may not be available for any of our in-development products or any future product candidates, which could
make it difficult for us to sell profitably, if approved.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Market
acceptance and sales of any product candidates that we commercialize, if approved, will depend in part on the extent to which reimbursement
for these drugs and related treatments will be available from third-party payors, including government health administration authorities,
managed care organizations and other private health insurers. Third-party payors decide which therapies they will pay for and establish
reimbursement levels. Third-party payors often rely upon Medicare coverage policy and payment limitations in setting their own coverage
and reimbursement policies. However, decisions regarding the extent of coverage and amount of reimbursement to be provided for any product
candidates that we develop will be made on a payor-by-payor basis. One payor&#8217;s determination to provide coverage for a drug does
not assure that other payors will also provide coverage and adequate reimbursement for the drug. Additionally, a third-party payor&#8217;s
decision to provide coverage for a therapy does not imply that an adequate reimbursement rate will be approved. Each payor determines
whether or not it will provide coverage for a therapy, what amount it will pay the manufacturer for the therapy, and on what tier of
its list of covered drugs, or formulary, it will be placed. The position on a payor&#8217;s formulary generally determines the co-payment
that a patient will need to make to obtain the therapy and can strongly influence the adoption of such therapy by patients and physicians.
Patients who are prescribed treatments for their conditions and providers prescribing such services generally rely on third-party payors
to reimburse all or part of the associated healthcare costs. Patients are unlikely to use our drugs, and providers are unlikely to prescribe
our drugs, unless coverage is provided, and reimbursement is adequate to cover a significant portion of the cost of our drugs and their
administration.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>


<!-- Field: Page; Sequence: 45; Value: 2 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
primary trend in the U.S. healthcare industry and elsewhere is cost containment. Third-party payors have attempted to control costs by
limiting coverage and the amount of reimbursement for particular medications. We cannot be sure that coverage and reimbursement will
be available for any drug that we commercialize and, if reimbursement is available, what the level of reimbursement will be. Inadequate
coverage and reimbursement may impact the demand for, or the price of, any drug for which we obtain marketing approval. If coverage and
adequate reimbursement are not available, or are available only to limited levels, we may not be able to successfully commercialize any
of our current in-development products and any future product candidates that we develop.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>If
we are unable to successfully develop any required companion diagnostic tests for our product candidates, experience significant delays
in doing so, or rely on third parties in the development of such companion diagnostic tests, we may be unable to realize the full commercial
potential of our product candidates.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
will strive to develop companion biomarkers for all drugs in
our portfolio and to evaluate whether a companion diagnostic test will be required for any of our product candidates. In general, the
FDA expects to review and approve simultaneously NDA and pre-market approval submissions for a therapeutic and its companion diagnostic,
respectively, so any delay in diagnostic approval could delay drug approval. On April 13, 2020, the FDA issued new guidance on developing
and labeling companion diagnostics for a specific group of oncology therapeutic products, including recommendations to support a broader
labeling claim rather than individual therapeutic products. We will continue to evaluate the impact of this guidance on our companion
diagnostic development and strategy. This guidance and future issuances from the FDA and other regulatory authorities may impact our
development of a companion diagnostic for our product candidates and result in delays in regulatory approval. We may be required to conduct
additional studies to support a broader claim. Also, to the extent other approved diagnostics are able to broaden their labeling claims
to include our approved drug products, if any, we may be forced to abandon any of our companion diagnostic development plans or we may
not be able to compete effectively upon approval, which could adversely impact our ability to generate revenue from the sale of our to
be approved products, if any, and our business operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may rely on third parties for the design, development, and manufacture of companion diagnostic tests for our product candidates that
require such tests. To be successful, we or our collaborators will need to address a number of scientific, technical, regulatory and
logistical challenges. If we or such third parties are unable to successfully develop companion diagnostics, or experience delays in
doing so, we may be unable to enroll enough patients for our current and planned clinical trials, the development of our product candidates
may be adversely affected or we may not obtain marketing approval, and we may not realize the full commercial potential of our product
candidates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Product
liability lawsuits against us could cause us to incur substantial liabilities and to limit commercialization of any products that we
may develop.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
use of any of our drug therapy candidates we may develop in clinical trials and the sale of any products for which we obtain marketing
approval exposes us to the risk of product liability claims. Product liability claims might be brought against us by patients, healthcare
providers, pharmaceutical companies or others selling or otherwise coming into contact with our products. On occasion, large judgments
have been awarded in class action lawsuits based on drugs that had unanticipated adverse effects. If we cannot successfully defend against
product liability claims, we could incur substantial liability and costs. In addition, regardless of merit or eventual outcome, product
liability claims may result in:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">impairment
    of our business</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">reputation
    and significant negative media attention;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">withdrawal
    of participants from our clinical trials;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">significant
    costs to defend the litigation;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">distraction
    of management&#8217;s attention from our primary business;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">substantial
    monetary awards to patients or other claimants;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">inability
    to commercialize THIO or any other product candidate;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">product
    recalls, withdrawals or labeling, marketing or promotional restrictions;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">decreased
    market demand for any product; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">loss
    of revenue.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>


<!-- Field: Page; Sequence: 46; Value: 2 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
product liability insurance coverage carry may not be sufficient to reimburse us for any expenses or losses we may suffer. We intend
to acquire insurance coverage to include larger clinical studies, different countries and the potential sale of commercial products;
however, we may be unable to obtain product liability insurance on commercially reasonable terms or in adequate amounts. A successful
product liability claim, or series of claims, brought against us could cause our share price to decline and, if judgments exceed our
insurance coverage, could adversely affect the results of our operations and business, including preventing or limiting the commercialization
of any product candidates we develop.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
hold $5 million in global product liability insurance coverage with a per incident limit of $5 million annually, which may not be adequate
to cover all liabilities that we may incur. &#160;We may need to increase our insurance coverage as we expand our clinical trials or
if we commence commercialization of any product candidates. Insurance coverage is increasingly expensive. We may not be able to obtain
or maintain insurance coverage at a reasonable cost or in an amount adequate to satisfy any liability that may arise, if at all. Product
liability insurance policies contain various exclusions, and we may be subject to a product liability claim for which we have no coverage.
We may have to pay any amounts awarded by a court or negotiated in a settlement that exceed our coverage limitations or that are not
covered by our insurance, and we may not have, or be able to obtain, sufficient capital to pay such amounts. Even if our agreements with
current or future collaborators entitle us to indemnification against losses, such indemnification may not be available or adequate should
any claim arise.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>There
are a variety of risks associated with marketing our current in-development products or any future product candidates internationally,
which could affect our business.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may seek regulatory approvals for ENV 105 and/or any of our product candidates outside of the United States and, accordingly, we expect
that we will be subject to additional risks related to operating in foreign countries if we obtain the necessary approvals, including:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">differing
    regulatory requirements and reimbursement landscapes in foreign countries;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    potential for so-called parallel importing, which is what happens when a local seller, faced with high or higher local prices, opts
    to import goods from a foreign market with low or lower prices rather than buying them locally;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">unexpected
    changes in tariffs, trade barriers, price and exchange controls, and other regulatory requirements;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">economic
    weakness, including inflation, or political instability in particular foreign economies and markets;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">compliance
    with tax, employment, immigration, and labor laws for employees living or traveling abroad;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">foreign
    taxes, including withholding of payroll taxes;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">foreign
    currency fluctuations, which could result in increased operating expenses and reduced revenues, and other obligations incident to
    doing business in another country;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">difficulties
    staffing and managing foreign operations;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">workforce
    uncertainty in countries where labor unrest is more common than in the United States;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">potential
    liability under the U.S. Foreign Corrupt Practices Act of 1977, as amended, or the FCPA, or comparable foreign regulations;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">challenges
    enforcing our contractual and intellectual property rights, especially in those foreign countries that do not respect and protect
    intellectual property rights to the same extent as the United States;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">production
    shortages resulting from any events affecting raw material supply or manufacturing capabilities abroad; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">business
    interruptions resulting from geo-political actions, including war and terrorism.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
and other risks associated with our international operations may compromise our ability to achieve or maintain profitability.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>



<!-- Field: Page; Sequence: 47; Value: 2 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Risks
Related to Our Dependence on Third Parties</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Our
employees and independent contractors, including principal investigators, clinical trial sites, contract research organizations, or CROs,
consultants, vendors, and any third parties we may engage in connection with development and commercialization, may engage in misconduct
or other improper activities, including noncompliance with regulatory standards and requirements, which could have a material adverse
effect on our business.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
employees and independent contractors, including principal investigators, clinical trial sites, consultants, vendors and any third parties
we may engage in connection with development and commercialization of our product candidates, could engage in misconduct, including intentional,
reckless or negligent conduct or unauthorized activities that violate: the laws and regulations of the FDA or other similar regulatory
requirements of other authorities, including those laws that require the reporting of true, complete and accurate information to such
authorities; manufacturing standards; data privacy, security, fraud and abuse and other healthcare laws and regulations; or laws that
require the reporting of true, complete and accurate financial information and data. Specifically, sales, marketing and business arrangements
in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud, misconduct, kickbacks, self-dealing
and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and
promotion, sales commission, customer incentive programs and other business arrangements. Activities subject to these laws could also
involve the improper use or misrepresentation of information obtained in the course of clinical trials, creation of fraudulent data in
preclinical studies or clinical trials or illegal misappropriation of drug product, which could result in regulatory sanctions and cause
serious harm to our reputation. It is not always possible to identify and deter misconduct by employees and other third parties, and
the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses
or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to comply with such laws or
regulations. Additionally, we are subject to the risk that a person or government could allege such fraud or other misconduct, even if
none occurred. If any such actions are instituted against us and we are not successful in defending ourselves or asserting our rights,
those actions could have a significant impact on our business and results of operations, including the imposition of significant civil,
criminal and administrative penalties, damages, monetary fines, disgorgements, possible exclusion from participation in Medicare, Medicaid,
other U.S. federal healthcare programs or healthcare programs in other jurisdictions, individual imprisonment, other sanctions, contractual
damages, reputational harm, diminished profits and future earnings, and curtailment of our operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
rely on single-sourced third parties to conduct the preclinical and nonclinical studies, clinical trials, and manufacture of our clinical
trial material for our current in-development products and our future product candidates, and those third parties may not perform satisfactorily,
including failing to meet deadlines for the completion of such studies, trials, and manufacturing services or failing to comply with
applicable regulatory requirements.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have engaged contract research organizations, or CROs, to conduct our ongoing and planned preclinical and nonclinical studies, clinical
trials and manufacture of our clinical trial material. We also expect to engage CROs for any of our other future product candidates that
may progress to clinical development. We expect to rely on CROs, as well as other third parties, such as clinical data management organizations,
medical institutions, and clinical investigators, to conduct those preclinical and nonclinical studies, clinical trials, and manufacture
of our clinical trial material. Currently, we rely on single source third-party research institutions, laboratories, clinical research
and manufacturing organizations for research and development. Agreements with such third parties might terminate for a variety of reasons,
including a failure to perform by the third parties. If we need to enter into alternative arrangements or fail to enter into alternative
arrangements in a timely manner, our product development activities would be delayed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
reliance on these third parties for research and development activities will reduce our control over these activities but will not relieve
us of our responsibilities. For example, we will remain responsible for ensuring that each of our clinical trials is conducted in accordance
with the general investigational plan and protocols for the trial. Moreover, the FDA requires us to comply with regulatory standards,
commonly referred to as good clinical practices, or GCPs, for conducting, recording, and reporting the results of clinical trials to
assure that data and reported results are credible and accurate and that the rights, integrity, and confidentiality of trial participants
are protected. Similar regulatory requirements apply outside the United States, including the International Council for Harmonisation
of Technical Requirements for the Registration of Pharmaceuticals for Human Use, or the ICH. We are also required to register certain
ongoing clinical trials and post the results of certain completed clinical trials on a government-sponsored database, ClinicalTrials.gov,
within specified timeframes. Failure to do so by us or third parties can result in FDA refusal to approve applications based on the clinical
data, enforcement actions, adverse publicity, and civil and criminal sanctions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>


<!-- Field: Page; Sequence: 48; Value: 2 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furthermore,
these third parties may also have relationships with other entities, some of which may be our competitors. If these third parties do
not successfully carry out their contractual duties, meet expected deadlines, or conduct our clinical trials in accordance with regulatory
requirements or our stated protocols, we will not be able to obtain, or may be delayed in obtaining, marketing approvals for our current
in-development products and our future product candidates and will not be able to, or may be delayed in our efforts to, successfully
commercialize such product candidates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, principal investigators for our clinical trials may serve as scientific advisors or consultants to us from time to time and
may receive cash compensation in connection with such services. If these relationships and any related compensation result in perceived
or actual conflicts of interest, or the FDA concludes that the financial relationship may have affected the interpretation of the trial,
the integrity of the data generated at the applicable clinical trial site may be questioned and the utility of the clinical trial itself
may be jeopardized, which could result in the delay or rejection by the FDA of any New Drug Application, or NDA, we submit. Any such
delay or rejection could prevent us from commercializing our current in-development products or any future product candidates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
will rely on third-party contract manufacturing organizations, or CMOs, for the production of clinical supply of our drug therapy candidates
and intend to rely on CMOs for the production of commercial supply our drug therapies, if approved. Our dependence on CMOs may impair
the development and commercialization of the drug, which would adversely impact our business and financial position.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have limited personnel with experience in manufacturing, and we do not own facilities for manufacturing. Instead, we rely on and expect
to continue to rely on CMOs for the supply of cGMP grade clinical trial materials and commercial quantities of any candidates we develop,
if approved. Reliance on CMOs may expose us to more risk than if we were to manufacture our product candidates ourselves. We intend to
have manufactured a sufficient clinical supply of our drug therapy substances to enable us to complete our clinical trials, and we have
also engaged a CMO to provide clinical and commercial supply of the drug product.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
facilities used to manufacture our product candidates must be inspected by the FDA and comparable foreign authorities. While we provide
oversight of manufacturing activities, we do not and will not control the execution of manufacturing activities by, and are or will be
essentially dependent on, our CMOs for compliance with cGMP requirements for the manufacture of our product candidates. As a result,
we are subject to the risk that our product candidates may have manufacturing defects that we have limited ability to prevent. If a CMO
cannot successfully manufacture material that conforms to our specifications and the regulatory requirements, we will not be able to
secure or maintain regulatory approval for the use of our product candidates in clinical trials, or for commercial distribution of our
product candidates, if approved. In addition, we have limited control over the ability of our CMOs to maintain adequate quality control,
quality assurance and qualified personnel. If the FDA or comparable foreign regulatory authority finds deficiencies with or does not
approve these facilities for the manufacture of our product candidates or if it withdraws any such approval or finds deficiencies in
the future, we may need to find alternative manufacturing facilities, which would delay our development program and significantly impact
our ability to develop, obtain regulatory approval for or commercialize our product candidates, if approved. In addition, any failure
to achieve and maintain compliance with these laws, regulations and standards could subject us to the risk that we may have to suspend
the manufacture of our product candidates or that obtained approvals could be revoked. Furthermore, CMOs may breach existing agreements
they have with us because of factors beyond our control. They may also terminate or refuse to renew their agreement at a time that is
costly or otherwise inconvenient for us. If we were unable to find an adequate CMO or another acceptable solution in time, our clinical
trials could be delayed, or our commercial activities could be harmed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>


<!-- Field: Page; Sequence: 49; Value: 2 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
rely on and will continue to rely on CMOs to purchase from third-party suppliers the raw materials necessary to produce our product candidates.
We do not and will not have control over the process or timing of the acquisition of these raw materials by our CMOs. Moreover, we currently
do not have any agreements for the production of these raw materials. Supplies of raw material could be interrupted from time to time
and we cannot be certain that alternative supplies could be obtained within a reasonable timeframe, at an acceptable cost, or at all.
In addition, a disruption in the supply of raw materials could delay the commercial launch of our product candidates, if approved, or
result in a shortage in supply, which would impair our ability to generate revenues from the sale of our product candidates. Growth in
the costs and expenses of raw materials may also impair our ability to cost effectively manufacture our product candidates. There are
a limited number of suppliers for the raw materials that we may use to manufacture our product candidates and we may need to assess alternative
suppliers to prevent a possible disruption of the manufacture of our product candidates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Finding
new CMOs or third-party suppliers involves additional cost and requires our management&#8217;s time and focus. In addition, there is
typically a transition period when a new CMO commences work. Although we generally have not, and do not intend to, begin a clinical trial
unless we believe we have on hand, or will be able to obtain, a sufficient supply of our product candidates to complete the clinical
trial, any significant delay in the supply of our product candidates or the raw materials needed to produce our product candidates, could
considerably delay conducting our clinical trials and potential regulatory approval of our product candidates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
part of their manufacture of our product candidates, our CMOs and third-party suppliers are expected to comply with and respect the proprietary
rights of others. If a CMO or third-party supplier fails to acquire the proper licenses or otherwise infringes the proprietary rights
of others in the course of providing services to us, we may have to find alternative CMOs or third-party suppliers or defend against
claims of infringement, either of which would significantly impact our ability to develop, obtain regulatory approval for or commercialize
our product candidates, if approved.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
performance failure or regulatory noncompliance on the part of CMOs could delay clinical development or marketing approval of our current
in-development products or any future product candidates or commercialization of such product candidates, resulting in additional losses,
and depriving us of potential product revenue.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Our
reliance on single-sourced third parties to manufacture our product candidates increases the risk that we will not have sufficient quantities
of our product candidates or products or such quantities at an acceptable cost, which could delay, prevent, or impair our development
or commercialization efforts.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
do not own or operate manufacturing facilities for the production of clinical or commercial supplies of the product candidates that we
are developing or evaluating, nor are we contemplating plans to do so. We have limited personnel with experience in drug manufacturing
and lack the resources and the capabilities to manufacture any of our product candidates on a clinical or commercial scale. We currently
rely on third parties, such as Fisher Clinical Services for drug supply and drug product manufacture of our current product candidate,
and our strategy is to continue to outsource all manufacturing of our product candidates and approved products, if any, to third parties.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
order to conduct clinical trials of our product candidates and prepare for commercialization, we will need to identify suitable manufacturers
with the capabilities to manufacture our compounds in large quantities in a manner consistent with existing regulations. Our future plans
include the identifying, qualifying, and contracting with a U.S. manufacturing site to manufacture ENV 105, assuming we have adequate
financial resources to pursue contingency manufacturing plans. Our current and future third-party manufacturers may be unable to successfully
increase the manufacturing capacity for any of our product candidates in a timely or cost-effective manner, or at all. In addition, quality
issues may arise during scale-up activities at any other time. If our manufacturers are unable to successfully scale up the manufacture
of our product candidates in sufficient quality and quantity, the development, testing, and clinical trials of that product candidate
may be delayed or infeasible, and regulatory approval or commercial launch of that product candidate may be delayed or not obtained,
which could significantly harm our business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
do not currently have any agreements with third-party manufacturers for the long-term commercial supply of our current in-development
products or any of our future product candidates. In the future, we may be unable to enter into agreements with third-party manufacturers
for commercial supplies of such product candidates or may be unable to do so on acceptable terms.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>


<!-- Field: Page; Sequence: 50; Value: 2 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even
if we are able to establish and maintain arrangements with third-party manufacturers, reliance on third-party manufacturers entails risks,
including:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">reliance
    on the third party for regulatory compliance and quality assurance;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    possible breach of the manufacturing agreement by the third party;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    possible misappropriation of our proprietary information, including our trade secrets and know-how; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    possible termination or nonrenewal of the agreement by the third party at a time that is costly or inconvenient for us.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Third-party
manufacturers may not be able to comply with current Good Manufacturing Practice, or cGMP, regulations or similar regulatory requirements
outside the United States. Our failure, or the failure of our third-party manufacturers, to comply with applicable regulations could
result in sanctions being imposed on us, including fines, injunctions, civil penalties, delays, suspension, or withdrawal of approvals,
license revocation, seizures, or recalls of product candidates or products, operating restrictions, and criminal prosecutions, any of
which could significantly and adversely affect supplies of our product candidates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
current in-development products and our future products and product candidates may compete with other product candidates and products
for access to manufacturing facilities. There are a limited number of manufacturers that operate under cGMP regulations and that might
be capable of manufacturing for us.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the third parties that we engage to supply any materials or manufacture product for our preclinical and nonclinical studies and clinical
trials should cease to continue to do so for any reason, we likely would experience delays in advancing these studies and trials while
we identify and qualify replacement suppliers, and we may be unable to obtain replacement supplies on terms that are favorable to us.
In addition, if we are not able to obtain adequate supplies of our current in-development products or any future product candidates or
the substances used to manufacture them, it will be more difficult for us to develop such product candidates and compete effectively.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
current and anticipated future dependence upon others for the manufacture of our product candidates may adversely affect our future profit
margins and our ability to develop product candidates and commercialize any products that receive marketing approval on a timely and
competitive basis.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
intend to continue to rely on third parties to conduct, supervise and monitor our clinical trials. If those third parties do not successfully
carry out their contractual duties, or if they perform in an unsatisfactory manner, it may harm our business.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
rely, and will continue to rely, on CROs, CRO-contracted vendors and clinical trial sites to ensure the proper and timely conduct of
our clinical trials, including our Phase 2 trials. Our reliance on CROs for clinical development activities limits our control over these
activities, but we remain responsible for ensuring that each of our trials is conducted in accordance with the applicable protocol and
legal, regulatory and scientific standards.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
and our CROs will be required to comply with the good laboratory practice requirements for our preclinical studies and GCP requirements
for our clinical trials, which are regulations and guidelines enforced by the FDA and are also required by comparable foreign regulatory
authorities. Regulatory authorities enforce GCP requirements through periodic inspections of trial sponsors, principal investigators
and clinical trial sites. If we or our CROs fail to comply with GCP requirements, the clinical data generated in our clinical trials
may be deemed unreliable and the FDA or comparable foreign regulatory authorities may require us to perform additional clinical trials
before approving our marketing applications. We cannot assure you that upon inspection by a given regulatory authority, such regulatory
authority will determine that any of our clinical trials comply with GCP requirements. In addition, our clinical trials must be conducted
with product produced under cGMP requirements. Accordingly, if our CROs fail to comply with these requirements, we may be required to
repeat clinical trials, which would delay the regulatory approval process.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
CROs are not our employees, and we do not control whether or not they devote sufficient time and resources to our clinical trials. Our
CROs may also have relationships with other commercial entities, including our competitors, for whom they may also be conducting clinical
trials, or other drug development activities, which could harm our competitive position. We face the risk of potential unauthorized disclosure
or misappropriation of our intellectual property by CROs, which may reduce our trade secret protection and allow our potential competitors
to access and exploit our proprietary technology. If our CROs do not successfully carry out their contractual duties or obligations,
fail to meet expected deadlines, or if the quality or accuracy of the clinical data they obtain is compromised due to the failure to
adhere to our clinical protocols or regulatory requirements or for any other reason, our clinical trials may be extended, delayed or
terminated, and we may not be able to obtain regulatory approval for, or successfully commercialize any product candidate that we develop.
As a result, our financial results and the commercial prospects for any product candidate that we develop would be harmed, our costs
could increase, and our ability to generate revenue could be delayed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>


<!-- Field: Page; Sequence: 51; Value: 2 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
our relationship with any CROs terminates, we may not be able to enter into arrangements with alternative CROs or do so on commercially
reasonable terms. Switching or adding additional CROs involves substantial cost and requires management&#8217;s time and focus. In addition,
there is a natural transition period when a new CRO commences work. As a result, delays occur, which can materially impact our ability
to meet our desired clinical development timelines. Though we intend to carefully manage our relationships with our CROs, there can be
no assurance that we will not encounter challenges or delays in the future or that these delays or challenges will not have an adverse
impact on our business, financial condition and prospects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>The
number and type of our collaborations could adversely affect our attractiveness to future collaborators or acquirers and the loss of,
or a disruption in our relationship with, any one or more collaborators could harm our business.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
any collaborations do not result in the successful development and commercialization of products or if one of our collaborators terminates
its agreement with us, we may not receive any future research and development funding or milestone or royalty payments under such collaborations.
If we do not receive the funding we expect under these agreements, our continued development of our product candidates could be delayed,
and we may need additional resources to develop additional product candidates. All of the risks relating to product development, regulatory
approval and commercialization described in this Annual Report also apply to the activities of any collaborators and there can be no
assurance that our collaborations will produce positive results or successful products on a timely basis or at all.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, subject to its contractual obligations to us, if one of our collaborators is involved in a business combination or otherwise
changes its business priorities, the collaborator might deemphasize or terminate the development or commercialization of our product
candidates. If a collaborator terminates its agreement with us, we may find it more difficult to attract new collaborators and the perception
of our business and our stock price could be adversely affected.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may in the future collaborate with additional pharmaceutical and biotechnology companies for development and potential commercialization
of therapeutic products. We face significant competition in seeking appropriate collaborators. Our ability to reach a definitive agreement
for a collaboration will depend, among other things, upon our assessment of the collaborator&#8217;s resources and expertise, the terms
and conditions of the proposed collaboration and the proposed collaborator&#8217;s evaluation of a number of factors. If we are unable
to reach agreements with suitable collaborators on a timely basis, on acceptable terms, or at all, we may have to curtail the development
of a product candidate, reduce or delay its development program or one or more of our other development programs, delay its potential
commercialization or reduce the scope of any sales or marketing activities, or increase our expenditures and undertake development or
commercialization activities at our own expense. If we elect to fund and undertake development or commercialization activities on our
own, we may need to obtain additional expertise and additional capital, which may not be available to us on acceptable terms or at all.
If we fail to enter into collaborations and do not have sufficient funds or expertise to undertake the necessary development and commercialization
activities, we may not be able to further develop our product candidates or bring them to market or continue to develop our programs,
and our business may be materially and adversely affected.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
are relying exclusively on the skills and expertise of our management team in conducting our business, not all of whom will devote all
of their time to managing the Company, and we currently only have one full-time employee, which may impede our ability to carry on our
business.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are relying exclusively on the skills and expertise of our management team in conducting our business. Not all of our management team
presently devotes all of their time to managing the Company. While our Chief Financial Officer serves on a full-time basis, we have no
other full-time employees, which may impede our ability to carry on our business. The lack of full-time employees among our officers
may very well prevent the Company&#8217;s operations from being efficient, and may impair the business progress and growth, which is
a risk to any investor. Our lack of full-time management may be an impediment to our business development. Without full-time officers,
aside from our Chief Financial Officer, we may not have sufficient time and effort devoted to our commercialization efforts, or efforts
to find and raise additional capital, or manage our business, which could impair our ability to succeed in our business plan and could
cause investment in our Company to lose value.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>


<!-- Field: Page; Sequence: 52; Value: 2 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
operate with a small team and our future success depends on our ability to retain key executives and to attract, retain, and motivate
qualified personnel.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
future success depends on our ability to retain our key officers and employees and to attract, retain and motivate highly qualified management
and scientific personnel.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
currently have limited personnel. As of the date of this Annual Report, we had three part-time employees, including our Chief Executive
officer, and our Chief Financial Officer was our only full-time employee. We are highly dependent on the management, research and development,
clinical, financial and business development expertise of Dr. Yu and Dr. Bhowmick. Each of them may currently terminate their employments
with us at any time. We do not maintain &#8220;key person&#8221; insurance for any of our executives or employees.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
will need to attract, hire and retain qualified officers and employees to achieve the Company&#8217;s objectives. Recruiting and retaining
qualified scientific personnel and sales and marketing personnel will be critical to our success. We may not be able to attract and retain
these personnel on acceptable terms given the competition among pharmaceutical, biotechnology and diagnostic companies for similar personnel.
Furthermore, current officers or employees may decide to leave the Company, and current or former officers or employees may decide to
sue the Company for owed but unpaid compensation. The loss of any of these persons&#8217; expertise would be difficult to replace and
could have a material adverse effect on our ability to achieve our business goals.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
limited personnel and resources may result in greater workloads for our employees compared to those at companies with which we compete
for personnel, which may lead to higher levels of employee dissatisfaction and turnover. Recruiting and retaining qualified research,
development, and business personnel and, if we progress the development of any of our current in-development products or any future product
candidates, commercialization, manufacturing, and sales and marketing personnel, will be critical to our success. The loss of the services
of our executive officers or other key employees could impede the achievement of our research, development and commercialization objectives
and seriously harm our ability to successfully implement our business strategy. Furthermore, replacing executive officers and key employees
may be difficult and may take an extended period of time because of the limited number of individuals in our industry with the breadth
of skills and experience required to successfully develop, gain regulatory approval of and commercialize our product candidates. Competition
to hire from this limited pool is intense, and we may be unable to hire, train, retain, or motivate these key personnel on acceptable
terms given the competition among numerous pharmaceutical and biotechnology companies for similar personnel. We also experience competition
for the hiring of research and development personnel from universities and research institutions. In addition, we rely on consultants
and advisors, including scientific and clinical advisors, to assist us in formulating our research and development and commercialization
strategy. Our consultants and advisors may have commitments under consulting or advisory contracts with other entities that may limit
their availability to us. If we are unable to continue to attract and retain high-quality personnel, our ability to pursue our growth
strategy will be limited.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
face substantial competition from large, well-funded, and experienced competitors, which may result in others discovering, developing
or commercializing products before or more successfully than we do.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
pharmaceutical and biotechnology industries are characterized by rapidly advancing technologies, intense competition, and a strong emphasis
on proprietary products. The immuno-oncology segment of the industry is in particular highly competitive. We face potential competition
from many different sources, including major pharmaceutical, specialty pharmaceutical, and biotechnology companies, academic institutions
and governmental agencies, and public and private research institutions. Regardless of the degree of success in development of our technology,
the Company faces competition from much larger enterprises and different technologies, disadvantages inherent in attempting to negotiate
licensing or other transactions with companies with vastly larger financial, scientific and other resources, lack of management experienced
in commercial business operations, reliance on contract laboratories and other third party service providers, lack of financial and other
resources, challenges to the validity of intellectual property, potential product liabilities, and regulatory risks including product
and reimbursement permits and regulations. Many of our competitors and potential competitors have substantially greater financial, technological,
managerial and research and development resources and experience than we do. We are aware of other products under development, which,
if successfully developed and commercialized, would compete with our products. We may be unable to keep pace with the rapid technological
changes in the biotechnology/medical device industry and as a result, our technologies may become obsolete. Smaller or early-stage companies
may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>


<!-- Field: Page; Sequence: 53; Value: 2 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
commercial opportunity could be reduced or eliminated if our competitors develop and commercialize medicines that are safer, are more
effective, have fewer or less severe side effects, are more convenient or are less expensive than any medicines we may develop. Our competitors
also may obtain FDA or other regulatory approval for their medicines more rapidly than we may obtain approval for ours, which could result
in our competitors establishing a strong market position before we are able to enter the market. In addition, our ability to compete
may be affected in many cases by insurers or other third-party payors seeking to encourage the use of generic medicines.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
have identified material weaknesses in our internal control over financial reporting. If we are unable to remediate these material weaknesses,
or if we identify additional material weaknesses in the future or otherwise fail to maintain effective internal control over financial
reporting, we may not be able to accurately or timely report our financial condition or results of operations, which may adversely affect
our business.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the preparation of our financial statements, we identified material weaknesses in our internal control over financial
reporting. A material weakness is a deficiency, or combination of deficiencies, in internal control over financial reporting, such that
there is a reasonable possibility that a material misstatement of the annual or interim financial statements will not be prevented or
detected on a timely basis. The material weaknesses are as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    did not design and maintain an effective control environment commensurate with our financial reporting requirements. Specifically,
    we lacked a sufficient complement of resources with (i) an appropriate level of accounting knowledge, experience and training to
    appropriately analyze, record and disclose accounting matters timely and accurately, and (ii) an appropriate level of knowledge and
    experience to establish effective processes and controls. Additionally, the lack of a sufficient number of professionals resulted
    in an inability to consistently establish appropriate authorities and responsibilities in pursuit of our financial reporting objectives,
    as demonstrated by, among other things, insufficient segregation of duties in our finance and accounting functions. This material
    weakness contributed to the following additional material weaknesses.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    did not design and maintain effective controls related to the period-end financial reporting process, including designing and maintaining
    formal accounting policies, procedures and controls to achieve complete, accurate and timely financial accounting, reporting and
    disclosures. Additionally, we did not design and maintain controls over the preparation and review of account reconciliations and
    journal entries, including maintaining appropriate segregation of duties.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    did not design and maintain effective controls related to the accounting for certain non-routine or complex transactions, including
    the proper application of U.S. GAAP to such transactions.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally,
    these material weaknesses could result in a misstatement of substantially all of our accounts or disclosures that would result in
    a material misstatement to the annual or interim financial statements that would not be prevented or detected.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    did not design and maintain effective controls over information technology, or IT, general controls for information systems that
    are relevant to the preparation of our financial statements. Specifically, we did not design and maintain (i) program change management
    controls to ensure that information technology program and data changes affecting financial IT applications and underlying accounting
    records are identified, tested, authorized and implemented appropriately, (ii) user access controls to ensure appropriate segregation
    of duties and that adequately restrict user and privileged access to financial applications, programs, and data to appropriate Company
    personnel, (iii) computer operations controls to ensure that critical batch jobs are monitored and data backups are authorized and
    monitored, and (iv) testing and approval controls for program development to ensure that new software development is aligned with
    business and IT requirements.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>


<!-- Field: Page; Sequence: 54; Value: 2 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
IT deficiencies did not result in adjustments to the financial statements. However, the IT deficiencies, when aggregated, could impact
maintaining effective segregation of duties, as well as the effectiveness of IT-dependent controls (such as automated controls that address
the risk of material misstatement to one or more assertions, along with the IT controls and underlying data that support the effectiveness
of system-generated data and reports) that could result in misstatements potentially impacting all financial statement accounts and disclosures
that would not be prevented or detected. Accordingly, management has determined the IT deficiencies in the aggregate constitute a material
weakness.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
address our material weaknesses, we are in the process of implementing measures designed to improve our internal control over financial
reporting and remediate the control deficiencies that led to the material weaknesses. These measures include (i) the ongoing hiring of
additional accounting personnel; (ii), initiating design and implementation of our financial control environment, including the establishment
of formal accounting policies and procedures, financial reporting controls and controls to account for and disclose complex transactions;
and (iii) initiating and designing IT controls to insure appropriate and restricted access to our accounting applications, programs,
and data.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are working to remediate the material weaknesses as efficiently and effectively as possible. We cannot assure you that there will not
be future material weaknesses in our internal control over financial reporting in the future. Any failure to maintain internal control
over financial reporting could severely inhibit our ability to accurately report our financial condition, results of operations, or cash
flows. If we fail to remediate our identified material weaknesses, or identify additional material weaknesses, in our internal control
over financial reporting investors may lose confidence in the accuracy and completeness of our financial reports, the market price of
our common stock could decline, and we could be subject to sanctions or investigations by the exchange we are listed on, the NYSE American,
the Securities and Exchange Commission, or SEC, or other regulatory authorities. Failure to remedy any material weakness in our internal
control over financial reporting, or to implement or maintain other effective control systems required of public companies, could also
restrict our future access to the capital markets.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
expect to expand our research, development, and business capabilities and potentially implement sales, marketing, and distribution capabilities,
and as a result, we may encounter difficulties in managing our growth, which could disrupt our operations.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
the clinical development of our current in-development products and any of our future product candidates progresses, we also expect to
experience significant growth in the number of our employees and the scope of our operations, particularly in the areas of research,
drug development, regulatory affairs and, if any of our current in-development products or any future product candidate receives marketing
approval, sales, marketing, and distribution. To manage our anticipated future growth, we must continue to implement and improve our
managerial, operational, and financial systems, expand our facilities, and continue to recruit and train additional qualified personnel.
Due to our limited financial resources and the limited experience of our management team in managing a company with such anticipated
growth, we may not be able to effectively manage the expansion of our operations or recruit and train additional qualified personnel.
The expansion of our operations may lead to significant costs and may divert our management and research and development resources. Any
inability to manage growth could delay the execution of our business plans or disrupt our operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>If
we engage in future acquisitions or strategic collaborations, this may increase our capital requirements, dilute our stockholders, cause
us to incur debt or assume contingent liabilities, and subject us to other risks.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">From
time to time, we may evaluate various acquisitions and strategic collaborations, including licensing or acquiring complementary drug
products, intellectual property rights, technologies, or businesses, as deemed appropriate to carry out our business plan. Any potential
acquisition or strategic collaboration may entail numerous risks, including:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">increased
    operating expenses and cash requirements;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    assumption of additional indebtedness or contingent liabilities;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>


<!-- Field: Page; Sequence: 55; Value: 2 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">assimilation
    of operations, intellectual property, and drug products of an acquired company, including difficulties associated with integrating
    new personnel;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    diversion of our management&#8217;s attention from our existing drug programs and initiatives in pursuing such a strategic partnership,
    merger, or acquisition;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">retention
    of key employees, the loss of key personnel and uncertainties in our ability to maintain key business relationships;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">risks
    and uncertainties associated with the other party to such a transaction, including the prospects of that party and their existing
    drugs or drug candidates and regulatory approvals; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    inability to generate revenue from acquired technology and/or drugs sufficient to meet our objectives in undertaking the acquisition
    or even to offset the associated acquisition and maintenance costs.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Risks
Related to Our Intellectual Property</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Our
exclusive licensing rights to our intellectual property are subject to agreements with third parties and we may not meet milestones set
forth in those agreements; our exclusive licensing rights may be terminated.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
agreements with Cedars-Sinai Medical Center  and Tracon Pharmaceuticals, Inc., which
were originally between each of Cedars-Sinai and Tracon and our subsidiary, Enviro Therapeutics, Inc., and which were assumed by the
Company effective April 17, 2025 pursuant to a novation agreement, are contingent on our ability to make payments and meet commercialization
goals, which we may not be able to meet based on innumerable factors. If we do not make such payments or meet such milestones, our exclusive
licensing rights to our intellectual property may be terminated. Even if we meet certain milestones, we may not be able to make the required
payments, which may cause us to breach such agreements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>If
we are unable to obtain and maintain patent and other intellectual property protection for our technology, or for any our current in-development
products or our future product candidates, or if the scope of the patent and other intellectual property protection obtained is not sufficiently
broad, our competitors could develop and commercialize technology and drugs similar or identical to ours, and our ability to successfully
commercialize our technology and product candidates may be impaired.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
do not own any issued patents and we in-license patents and patent applications for ENV 105, our lead drug compounds, and our success
depends in large part on our ability to obtain and maintain patent protection in the United States and other countries with respect to
ENV 105 and any of our future product candidates. We seek to protect our proprietary position by in-licensing intellectual property relating
to our product candidates including patent applications in the United States and abroad related to our technology and product candidates
that are important to our business. If we or our licensors do not adequately protect the intellectual property, we in-license or own,
competitors may be able to use our technologies and erode or negate any competitive advantage that we may have, which could harm our
business and ability to achieve profitability. To protect our proprietary positions, we and our licensors file patent applications in
the United States and abroad related to our novel technologies and product candidates that are important to our business. The patent
application and prosecution process is expensive and time-consuming. We and our current licensors and licensees, or any future licensors
and licensees may not be able to file and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely
manner. We or our current licensors and licensees, or any future licensors or licensees may also fail to identify patentable aspects
of our research and development before it is too late to obtain patent protection or fail to continue to prosecute patents relating to
our product candidates. Therefore, these and any of our in-licensed patents and patent applications may not be prosecuted and enforced
in a manner consistent with the best interests of our business. It is possible that defects of form in the preparation or filing of our
licensors&#8217; patents or our patent applications may exist, or may arise in the future, such as with respect to proper priority claims,
inventorship, claim scope, or patent term adjustments. If our current licensors and licensees, or any future licensors or licensees,
are not fully cooperative or disagree with us as to the prosecution, maintenance or enforcement of any patent rights, such patent rights
could be compromised and we might not be able to prevent third parties from making, using, and selling competing products. We cannot
predict whether the patent applications we and our licensors or licensees are currently pursuing will issue as patents in any particular
jurisdiction or whether the claims of any issued patents will provide sufficient protection from competitors. If there are material defects
in the form or preparation of our or our licensors&#8217; patents or patent applications, such patents or applications may be invalid
and unenforceable. Moreover, our competitors may independently develop equivalent knowledge, methods, and know-how and we may not be
able to prevent such competitors from commercializing such equivalent knowledge, methods, and know-how. Any of these outcomes could impair
our ability to prevent competition from third parties and could have a material adverse effect on our business, financial condition,
results of operations, or prospects. The patent position of biotechnology and pharmaceutical companies generally is highly uncertain
and has been the subject of much litigation in recent years. Changes in either the patent laws or interpretation of the patent laws in
the United States and other countries may diminish the value of our patents or narrow the scope of our patent protection. In addition,
the laws of foreign countries may not protect our rights to the same extent as the laws of the United States. No consistent policy regarding
the breadth of claims allowed in biotechnology and pharmaceutical patents has emerged to date in the United States or in many foreign
jurisdictions. In addition, the determination of patent rights with respect to pharmaceutical compounds and technologies commonly involves
complex legal and factual questions, which has in recent years been the subject of much litigation. As a result, the issuance, scope,
validity, enforceability, and commercial value of our patent rights are highly uncertain. Furthermore, recent changes in patent laws
in the United States, including the America Invents Act of 2011, and future changes in patent laws in or outside the United States may
affect the scope, strength, and enforceability of our patent rights or the nature of proceedings that may be brought by us related to
our patent rights.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>


<!-- Field: Page; Sequence: 56; Value: 2 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may not be aware of all third-party intellectual property rights potentially relating to our current in-development products or our future
product candidates. Publications of discoveries in the scientific literature often lag behind the actual discoveries, and patent applications
in the United States and other jurisdictions are typically not published until 18 months after filing, or in some cases not at all. Therefore,
we cannot be certain that we or our licensors were the first to make the inventions claimed in patents or pending patent applications
that we in-license or own, or that we or our licensors were the first to file for patent protection of such inventions. As a result,
the issuance, scope, validity, and commercial value of our patent rights cannot be predicted with any certainty. Moreover, we or our
licensors may be subject to a third-party pre-issuance submission of prior art to the U.S. Patent and Trademark Office, or USPTO, or
become involved in opposition, derivation, reexamination, <I>inter partes</I> review, or interference proceedings, in the United States
or elsewhere, challenging our patent rights or the patent rights of others. An adverse determination in any such submission, proceeding,
or litigation could reduce the scope of, or invalidate, our patent rights, allow third parties to commercialize our technology or product
candidates, and compete directly with us, without payment to us, or result in our inability to manufacture or commercialize product candidates
without infringing third-party patent rights.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
licensors&#8217; pending and future patent applications and our own pending and future patent applications may not result in patents
being issued that protect our technology or product candidates, in whole or in part, or which effectively prevent others from commercializing
competitive technologies and products. Even if our or our licensors&#8217; patent applications issue as patents, they may not issue in
a form that will provide us with any meaningful protection against competing products or processes sufficient to achieve our business
objectives, prevent competitors from competing with us or otherwise provide us with any competitive advantage. Our competitors may be
able to circumvent our in-licensed patents or any patents we may own in the future by developing similar or alternative technologies
or products in a non-infringing manner. Our competitors may seek to market generic versions of any approved products by submitting abbreviated
NDAs to the FDA in which they claim that patents licensed by us or may be owned by us in the future are invalid, unenforceable, and/or
not infringed. Alternatively, our competitors may seek approval to market their own products similar to or otherwise competitive with
our product candidates. In these circumstances, we may need to defend and/or assert our in-licensed or owned patents, including by filing
lawsuits alleging patent infringement. In any of these types of proceedings, a court, or other agency with jurisdiction may find our
in-licensed patents or any owned patents, should such patents issue in the future, invalid and/or unenforceable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
issuance of a patent is not conclusive as to its inventorship, scope, validity, or enforceability, and our in-licensed patents or patents
we may own in the future may be challenged in the courts or patent offices in the United States and abroad. Such challenges may result
in loss of exclusivity or freedom to operate or in patent claims being narrowed, invalidated or held unenforceable, in whole or in part,
which could limit our ability to stop others from using or commercializing similar or identical technology and product candidates, or
limit the duration of the patent protection of our technology and product candidates. In addition, given the amount of time required
for the development, testing, and regulatory review of new product candidates, patents protecting such candidates might expire before
or shortly after such candidates are commercialized. Any impairment of our intellectual property rights, or our failure to protect our
intellectual property rights adequately, could give third parties access to our technology and product candidates and could materially
and adversely impact our business, financial condition, results of operations, and prospects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>


<!-- Field: Page; Sequence: 57; Value: 2 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Our
internal computer systems, or those of our CROs or other contractors or consultants, may fail or suffer security breaches, which could
result in a material disruption of our product development programs.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Despite
the implementation of cyber security measures, our internal computer systems and those of our CROs and other contractors and consultants
are vulnerable to damage from computer viruses, unauthorized access, natural disasters, terrorism, war and telecommunication and electrical
failures. Such events could cause interruptions of our operations. For example, the loss of preclinical data or data from any future
clinical trial involving our product candidates could result in delays in our development and regulatory filing efforts and significantly
increase our costs. To the extent that any disruption or security breach were to result in a loss of, or damage to, our data, or inappropriate
disclosure of confidential or proprietary information, we could incur liability and the development of our product candidates could be
delayed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Our
proprietary information, or that of our customers, suppliers and business partners, may be lost or we may suffer security breaches.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the ordinary course of our business, we collect and store sensitive data, including intellectual property, clinical trial data, our proprietary
business information and that of our customers, suppliers and business partners, and personally identifiable information of clinical
trial subjects and employees, in our data centers and on our networks. The secure processing, maintenance and transmission of this information
is critical to our operations. Despite our security measures, our information technology and infrastructure may be vulnerable to attacks
by hackers or breached due to employee error, malfeasance or other disruptions. Although to our knowledge we have not experienced any
such material security breach to date, any such breach could compromise our network, or the networks of our CROs or other third-party
service providers, and the information stored there could be accessed, publicly disclosed, lost or stolen. Any such access, disclosure
or other loss of information could result in legal claims or proceedings, liability under laws that protect the privacy of personal information,
regulatory penalties, disrupt our operations, damage our reputation, and cause a loss of confidence in our products and our ability to
conduct clinical trials, which could adversely affect our business and reputation and lead to delays in gaining regulatory approvals
for our drugs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Our
rights to develop and commercialize our technology, our current in-development products, and our other future product candidates are
subject, in large part, to the terms and conditions of licenses granted to us by others, such as Cedars-Sinai Medical Center and Tracon
Pharmaceuticals, Inc. If we fail to comply with our obligations in the agreements under which we in-license or acquire development or
commercialization rights to products, technology, or data from third parties, we could lose such rights that are important to our business.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are heavily reliant upon licenses to certain patent rights and other intellectual property that are important or necessary to the development
of our current in-development products or our future product candidates. For example, we depend on license agreements from Cedars-Sinai
Medical Center and Tracon Pharmaceuticals, Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cedars-Sinai
and Tracon have relied upon, and any future licensors may have relied upon, third-party companies, consultants or collaborators, or on
funds from third parties such that our licensors are not the sole and exclusive owners of the patents we in-licensed. We have sublicensed
certain patents from Cedars-Sinai and Tracon. If third-party institutions such as Cedars-Sinai or Tracon fail to prosecute, maintain,
enforce, and defend such patents, or lose rights to those patents, the rights we have licensed may be reduced or eliminated, and our
right to develop and commercialize our current in-development products or our other future product candidates that are the subject of
such licensed rights could be adversely affected. Further development and commercialization of ENV 105, and development of any future
product candidates may, require us to enter into additional license or collaboration agreements. For example, our licensors or other
third parties may develop intellectual property covering ENV 105 which we have not licensed. Our future licenses may not provide us with
exclusive rights to use the licensed patent rights and other intellectual property or may not provide us with exclusive rights to use
such patent rights and intellectual property in all relevant fields of use and in all territories in which we wish to develop or commercialize
our current in-development products or our future product candidates in the future.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
license agreements with Cedars-Sinai and Tracon, and other intellectual property-related agreements we may enter into in the future may
impose diligence and other obligations, including payment of milestones and royalties. For example, our license agreement from Cedars
requires us to satisfy diligence requirements, including using commercially reasonable efforts to develop and commercialize products.
If we fail to comply with our obligations to our present or future licensors, those counterparties may have the right to terminate the
license agreements, in which event we might not be able to develop, manufacture, or market any product candidate licensed under the agreements,
which could materially adversely affect the value of the product candidate being developed under any such agreement and further involve
termination of our rights to important intellectual property or technology.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>


<!-- Field: Page; Sequence: 58; Value: 2 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
spite of our efforts, Cedars-Sinai, Tracon or any future licensors might conclude that we are in material breach of obligations under
our license agreements and may therefore have the right to terminate the license agreements, thereby removing our ability to develop
and commercialize product candidates and technology covered by such license agreements. If such in-licenses are terminated, or if the
underlying patents fail to provide the intended exclusivity, our competitors would have the freedom to seek regulatory approval of, and
to market, products identical to our product candidates and the licensors to such in-licenses could prevent us from commercializing product
candidates that rely upon the patents or other intellectual property rights which were the subject matter of such terminated agreements.
In addition, we may seek to obtain additional licenses from our licensors and, in connection with obtaining such licenses, we may agree
to amend our existing licenses in a manner that may be more favorable to the licensors, including by agreeing to terms that could enable
third parties (potentially including our competitors) to receive licenses to a portion of the intellectual property that is subject to
our existing licenses. Any of these events could have a material adverse effect on our business, financial condition, results of operations,
and prospects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
our license agreements with Cedars-Sinai and Tracon, and any future license agreements, disputes may arise regarding intellectual property
subject to a licensing agreement, including:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    scope of rights granted under the license agreement and other interpretation-related issues;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    extent to which our technology and processes infringe on intellectual property of the licensor that is not subject to the licensing
    agreement;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    sublicensing of patent and other rights under our collaborative development relationships;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    diligence obligations under the license agreement and what activities satisfy those diligence obligations;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    inventorship and ownership of inventions and know-how resulting from the joint creation or use of intellectual property by our licensors
    and us and our partners; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    priority of invention of patented technology.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, the license agreements involving intellectual property or technology from third parties are complex, and certain provisions
in such agreements may be susceptible to multiple interpretations. The resolution of any contract interpretation disagreement that may
arise could narrow what we believe to be the scope of our rights to the relevant intellectual property or technology or increase what
we believe to be our financial or other obligations under the relevant agreement, either of which could have a material adverse effect
on our business, financial condition, results of operations, and prospects. Moreover, if disputes over intellectual property that we
have licensed prevent or impair our ability to maintain our current licensing arrangements on commercially acceptable terms, we may be
unable to successfully develop and commercialize the affected product candidates, which could have a material adverse effect on our business,
financial condition, results of operations and prospects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
may not be successful in obtaining necessary rights to any product candidates we may develop through acquisitions and in-licenses.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
currently have rights to intellectual property, through licenses from third parties, to identify and develop product candidates. We may
find it necessary or prudent to obtain licenses from such third-party intellectual property holders in order to avoid infringing these
third-party patents. For example, many pharmaceutical companies, biotechnology companies, and academic institutions compete with us and
may be filing patent applications potentially relevant to our business. The licensing or acquisition of third-party intellectual property
rights is a competitive area, and several more established companies may pursue strategies to license or acquire third-party intellectual
property rights that we may consider attractive or necessary. These established companies may have a competitive advantage over us due
to their size, capital resources and greater clinical development and commercialization capabilities. In addition, companies that perceive
us to be a competitor may be unwilling to license rights to us. We also may be unable to license or acquire third-party intellectual
property rights on terms that would allow us to make an appropriate return on our investment or at all. If we are unable to successfully
obtain rights to required third-party intellectual property rights or maintain the existing intellectual property rights we have, we
may have to abandon development of the relevant program or product candidate, which could have a material adverse effect on our business,
financial condition, results of operations, and prospects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&#160;</I></B></FONT></P>


<!-- Field: Page; Sequence: 59; Value: 2 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->57<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&#160;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
may become involved in lawsuits to protect or enforce our owned or in-licensed patents or other intellectual property, which could be
expensive, time-consuming, and unsuccessful.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Competitors
or other third parties may infringe, misappropriate or otherwise violate our in-licensed issued patents or our other intellectual property
we may own. To counter such infringement, misappropriation, or other unauthorized use, we may be required to file infringement claims,
which can be expensive and time-consuming and divert the time and attention of our management and scientific personnel. Any claims we
assert against third parties could provoke these parties to assert counterclaims against us alleging that we infringe, misappropriate
or otherwise violate their patents, trademarks, copyrights, or other intellectual property. In addition, our in-licensed patents may
become involved in inventorship or priority disputes. Third parties may raise challenges to the validity of certain of our or our in-licensed
patent claims and may in the future raise similar claims before administrative bodies in the United States or abroad, even outside the
context of litigation. For example, we may be subject to a third-party pre-issuance submission of prior art to the USPTO, or become involved
in derivation, revocation, reexamination, post-grant review, or PGR, <I>inter partes</I> review, or IPR, interference proceedings, and
equivalent proceedings in foreign jurisdictions, such as opposition proceedings challenging any patents that we may own or in-license.
Such submissions may also be made prior to a patent&#8217;s issuance, precluding the granting of a patent based on one of our owned or
licensed pending patent applications. A third party may also claim that our potential future owned patents or licensed patent rights
are invalid or unenforceable in a litigation. The outcome following legal assertions of invalidity and unenforceability is unpredictable.
An adverse determination in any such submission, proceeding, or litigation could reduce the scope of, invalidate, or render unenforceable,
our potential future owned patents or licensed patent rights, allow third parties to commercialize our current in-development products
or our other future product candidates and compete directly with us, without payment to us, or result in our inability to manufacture
or commercialize products without infringing third-party patent rights In a patent infringement proceeding, there is a risk that a court
will decide that a patent we in-license is invalid or unenforceable, in whole or in part, and that we do not have the right to stop the
other party from using the invention at issue. There is also a risk that, even if the validity of such patents are upheld, the court
will construe the patent&#8217;s claims narrowly or decide that we do not have the right to stop the other party from using the invention
at issue on the grounds that our in-licensed patents do not cover the invention. An adverse outcome in a litigation or proceeding involving
our in-licensed patents could limit our ability to assert our in-licensed patents against those parties or other competitors and may
curtail or preclude our ability to exclude third parties from making and selling similar or competitive products. Similarly, in the future,
we expect to rely on trademarks to distinguish our current in-development products and any of our other future product candidates that
are approved for marketing, and if we assert trademark infringement claims, a court may determine that the marks we have asserted are
invalid or unenforceable, or that the party against whom we have asserted trademark infringement has superior rights to the marks in
question. In this case, we could ultimately be forced to cease use of such trademarks.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
any infringement litigation, any award of monetary damages we receive may not be commercially valuable. Furthermore, because of the substantial
amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information
could be compromised by disclosure during litigation. In addition, there could be public announcements of the results of hearings, motions,
or other interim proceedings or developments and if securities analysts or investors perceive these results to be negative, it could
have a substantial adverse effect on the price of our common stock. Moreover, there can be no assurance that we will have sufficient
financial or other resources to adequately file and pursue such infringement claims, which typically last for years before they are concluded.
Some of our competitors and other third parties may be able to sustain the costs of such litigation or proceedings more effectively than
we can because of their greater financial resources and more mature and developed intellectual property portfolios. Even if we ultimately
prevail in such claims, the monetary cost of such litigation and the diversion of the attention of our management and scientific personnel
could outweigh any benefit we receive as a result of the proceedings. Accordingly, despite our efforts, we may not be able to prevent
third parties from infringing, misappropriating, or successfully challenging our intellectual property rights. Uncertainties resulting
from the initiation and continuation of patent litigation or other proceedings could have a negative impact on our ability to compete
in the marketplace, which could have a material adverse effect on our business, financial condition, results of operations, and prospects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>


<!-- Field: Page; Sequence: 60; Value: 2 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->58<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Third
parties may initiate legal proceedings alleging that we are infringing misappropriating, or otherwise violating their intellectual property
rights, the outcome of which would be uncertain and could significantly harm our business.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
commercial success depends, in part, on our ability to develop, manufacture, market, and sell our current in-development products or
other future product candidates and use our proprietary chemistry technology without infringing, misappropriating or otherwise violating
the intellectual property of third parties. Numerous third-party U.S. and non-U.S. issued patents exist in the area of cancer therapies
and other therapies our drugs are targeted to treat.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
is a substantial amount of intellectual property litigation in the biotechnology and pharmaceutical industries, and we may become party
to, or threatened with, litigation, or other adversarial proceedings regarding intellectual property rights with respect to our technology
or product candidates, including interference proceedings before the USPTO. Third parties may assert claims against us based on existing
or future intellectual property rights. The outcome of intellectual property litigation is subject to uncertainties that cannot be adequately
quantified in advance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we are found to have infringed, misappropriated, or otherwise violated any third party&#8217;s intellectual property rights, we could
be forced, including by court order, to cease developing, manufacturing, or commercializing our current in-development products or other
future product candidates. Alternatively, we may be required to obtain a license from such third party in order to use technology and
continue developing, manufacturing or marketing product candidates that infringe or violate such third party&#8217;s intellectual property.
However, we may not be able to obtain any such required license on commercially reasonable terms or at all. Even if we were able to obtain
a license, it could be non-exclusive, thereby giving our competitors access to the same technologies licensed to us. We may also be required
to pay substantial ongoing royalty or license payments, fees, or comply with other unfavorable terms. In addition, we could be found
liable for monetary damages, including treble damages and attorneys&#8217; fees if we are found to have willfully infringed a patent
or other intellectual property right. A finding of infringement could prevent us from commercializing our current in-development products
or other future product candidates or force us to cease some of our business operations. Claims that we have misappropriated the confidential
information or trade secrets of third parties could have a similar negative effect on our business. Even if we were to prevail in such
a dispute, any litigation regarding our intellectual property could be costly and time-consuming and divert the attention of our management
and key personnel from our business operations. Furthermore, because of the substantial amount of discovery required in connection with
intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during
this type of litigation. During the court of litigation, there could be public announcements or the results of hearings, motions, or
other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could have a
substantial adverse effect on the price of our common stock. Negative publicity related to a decision by us to initiate such enforcement
actions against a customer or former customer, regardless of its accuracy, may adversely impact our other customer relationships or prospective
customer relationships, harm our brand and business and could cause the market price of our common stock to decline. Any of the foregoing
arising from uncertainty in legal proceedings could materially and adversely impact our business, financial condition, results of operations,
and prospects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
may be subject to claims by third parties asserting that we or our employees, consultants, and advisors have misappropriated </I></B>their
<B><I>intellectual property or claiming ownership of what we regard as our own intellectual property.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Many
of our employees, consultants, and advisors were previously employed at universities or other biotechnology or pharmaceutical companies,
including our competitors or potential competitors. Although we try to ensure that our employees, consultants, and advisors do not use
the proprietary information or know-how of third parties in their work for us, we may be subject to claims that we or such employees,
consultants, and advisors have inadvertently or otherwise used or disclosed intellectual property, including trade secrets or other proprietary
information, of any such individual&#8217;s former employer. We may also in the future be subject to claims that we have caused an employee
to breach the terms of his or her non-competition or non-solicitation agreement. Litigation may be necessary to defend against these
potential claims.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>


<!-- Field: Page; Sequence: 61; Value: 2 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->59<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, while it is our policy to require our employees and contractors who may be involved in the development of intellectual property
to execute agreements assigning such intellectual property to us, such employees and contractors may breach the agreement and claim the
developed intellectual property as their own. Further, we may be unsuccessful in executing such agreements with each party who, in fact,
conceives, or develops intellectual property that we regard as our own. The assignment of intellectual property rights may not be self-executing
and we may be forced to bring claims against third parties, or defend claims that they may bring against us, to determine the ownership
of what we regard as our intellectual property.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we fail in prosecuting or defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property
rights or personnel. A court could prohibit us from using technologies or features that are essential to our current in-development products
or other future product candidates if such technologies or features are found to incorporate or be derived from the trade secrets or
other proprietary information of the former employers. Even if we are successful in prosecuting or defending against such claims, litigation
could result in substantial costs and could be a distraction to management. In addition, any litigation or threat thereof may adversely
affect our ability to hire employees or contract with independent service providers. Moreover, a loss of key personnel or their work
product could hamper or prevent our ability to commercialize our product candidates. Any of the foregoing could have a material adverse
impact on our business, financial condition, results of operations, and prospects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Changes
in U.S. patent law could diminish the value of patents in general, thereby impairing our ability to protect our </I>products<I>.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
is the case with other pharmaceutical companies, our success is heavily dependent on our intellectual property rights, and particularly
on our in-licensed patent rights. Obtaining and enforcing patents in the pharmaceutical industry involves both technological and legal
complexity, and is therefore costly, time consuming and inherently uncertain. In addition, the U.S. has recently enacted and is currently
implementing wide-ranging patent reform legislation. Certain U.S. Supreme Court rulings have narrowed the scope of patent protection
available in certain circumstances and weakened the rights of patent owners in certain situations. In addition to increasing uncertainty
with regard to our ability to obtain rights to patents in the future, this combination of events has created uncertainty with respect
to the value of patents once rights are obtained. Depending on decisions by the U.S. Congress, the federal courts and the USPTO, the
laws and regulations governing patents could change in unpredictable ways that could further negatively impact the value of patent rights,
narrow the scope of available patent protection or weaken the rights of patent owners.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Any
trademarks we may obtain may be infringed or successfully challenged, resulting in harm to our business.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
expect to rely on trademarks as one means to distinguish any of our product candidates that are approved for marketing from the products
of our competitors. We have not yet selected trademarks for our product candidates and have not yet begun the process of applying to
register trademarks for our product candidates. Once we select trademarks and apply to register them, our trademark applications may
not be approved. Third parties who have prior rights to our trademarks or third parties who have prior rights to similar trademarks may
oppose our trademark applications, or otherwise challenge our use of the trademarks. In the event that our trademarks are successfully
challenged, we could be forced to rebrand our product candidates, which could result in loss of brand recognition and could require us
to devote resources to advertising and marketing new brands. At times, competitors may adopt trade names or trademarks similar to ours,
thereby diluting or impeding our ability to build brand identity and possibly leading to market confusion. Our competitors may infringe
our trademarks and we may not have adequate resources to enforce our trademarks and may not be able to prevent such third parties from
using and marketing any such trademarks.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, any proprietary name we propose to use with our current in-development products or any future product candidate in the United
States must be approved by the FDA, regardless of whether we have registered it, or applied to register it, as a trademark. The FDA typically
conducts a review of proposed product names, including an evaluation of the potential for confusion with other product names. If the
FDA objects to any of our proposed proprietary product names, we may be required to expend significant additional resources in an effort
to identify a suitable proprietary product name that would qualify under applicable trademark laws, not infringe the existing rights
of third parties and be acceptable to the FDA. If we are unable to establish name recognition based on our trademarks, we may not be
able to compete effectively and our business, financial condition, results of operations, and prospects may be adversely affected.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>


<!-- Field: Page; Sequence: 62; Value: 2 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->60<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>If
we are unable to protect the confidentiality of our proprietary information, know-how, and trade secrets, the value of our current in-development
products or other future product candidates could be adversely affected, and our business and competitive position would be harmed.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to seeking patent protection for our current in-development products or other future product candidates, we also rely on trade
secrets, including unpatented know-how, technology, and other proprietary information, to maintain our competitive position. We seek
to protect our trade secrets, in part, by entering into non-disclosure and confidentiality agreements with parties who have access to
them, such as our employees, corporate collaborators, outside scientific collaborators, contract manufacturers, consultants, advisors,
and other third parties. We also enter into confidentiality and invention or patent assignment agreements with our employees and consultants.
However, these agreements may be inadequate to protect our proprietary and intellectual property rights. Despite these efforts, any of
these parties may breach the agreements and disclose our proprietary information, including our trade secrets. In addition, we may not
be able to obtain adequate remedies for any such breaches. Although we use reasonable efforts to protect this proprietary information
and technology, we also cannot guarantee that we have entered into such agreements with each party that may have or have had access to
our confidential information, know-how, trade secrets, or other proprietary information or each individual who has developed intellectual
property on our behalf. Monitoring unauthorized uses and disclosures of our intellectual property is difficult, and we do not know whether
the steps we have taken to protect our intellectual property will be effective. Enforcing a claim that a party illegally disclosed or
misappropriated a trade secret is difficult, expensive, distracting to management, and time-consuming, and the outcome is unpredictable
and varied depending on the jurisdiction. In addition, some courts inside and outside the United States, in countries in which we operate
or intend to operate, are less willing, or unwilling, to protect trade secrets, know-how, and other proprietary information. Any claims
or litigation could cause us to incur significant expenses. Some third parties may be able to sustain the costs of complex litigation
more effectively than we can because they have substantially greater resources.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
employees, consultants, and other parties may unintentionally or willfully disclose our information or technology to competitors and
there can be no assurance that the legal protections and precaution taken by us will be adequate to prevent misappropriation of our technology
or that competitors will not independently develop technologies equivalent or superior to ours. Trade secrets and know-how can be difficult
to protect. Our competitors or other third parties may independently develop knowledge, methods and know-how equivalent to our trade
secrets. Additionally, competitors could purchase our product candidates and replicate some or all of the competitive advantages we derive
from our development efforts for technologies on which we do not have patent protection. If any of our trade secrets were to be lawfully
obtained or independently developed by a competitor, we would have no right to prevent them, or those to whom they communicate, from
using that technology or information to compete with us. If any of our trade secrets were to be disclosed to or independently developed
by a competitor, our competitive position would be harmed, which could have a material adverse effect on our business, financial condition,
results of operations, and prospects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>If
we or our licensors do not obtain patent term extension and data exclusivity for any product candidates we or our licensors may develop,
our business may be materially harmed.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Given
the amount of time required for the development, testing, and regulatory review of new product candidates, patents we license or may
own in the future protecting such candidates might expire before or shortly after such candidates are commercialized. As a result, our
intellectual property may not provide us with sufficient rights to exclude others from commercializing products similar or identical
to our product candidates. Depending upon the timing, duration, and specifics of any FDA marketing approval of any of our product candidates,
one or more of our in-licensed U.S. patents may be eligible for limited patent term extension under the Drug Price Competition and Patent
Term Restoration Action of 1984, or Hatch-Waxman Amendments. The Hatch-Waxman Amendments permit a patent extension term of up to five
years as compensation for patent term lost during the FDA regulatory review process. A patent term extension cannot extend the remaining
term of a patent beyond a total of 14 years from the date of product approval, only one patent may be extended and only those claims
covering the approved drug, a method for using it, or a method for manufacturing it may be extended. However, we may not be granted an
extension because of, for example, failing to exercise due diligence during the testing phase or regulatory review process, failing to
apply within applicable deadlines, failing to apply prior to expiration of relevant patents, or otherwise failing to satisfy applicable
requirements. Moreover, the applicable time period or the scope of patent protection afforded could be less than we request. If we are
unable to obtain patent term extension or term of any such extension is less than we request, our competitors may obtain approval of
competing products following our patent expiration, and our business, financial condition, results of operations, and prospects could
be materially harmed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>


<!-- Field: Page; Sequence: 63; Value: 2 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->61<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Obtaining
and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment, and other requirements
imposed by government patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Periodic
maintenance fees, renewal fees, annuity fees, and various other government fees on patents and applications will be due to be paid to
the USPTO and various government patent agencies outside of the United States over the lifetime of our owned or in-licensed patents and
applications. In certain circumstances, we rely on our licensing partners to pay these fees due to U.S. and non-U.S. patent agencies.
The USPTO and various non-U.S. government agencies require compliance with several procedural, documentary, fee payment, and other similar
provisions during the patent application process. We are also dependent on our licensors to take the necessary action to comply with
these requirements with respect to our licensed intellectual property. In some cases, an inadvertent lapse can be cured by payment of
a late fee or by other means in accordance with the applicable rules. There are situations, however, in which non-compliance can result
in abandonment or lapse of the patent or patent application, resulting in a partial or complete loss of patent rights in the relevant
jurisdiction. In such an event, potential competitors might be able to enter the market with similar or identical products or technology,
which could have a material adverse effect on our business, financial condition, results of operations, and prospects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
may not be able to protect our intellectual property rights throughout the world.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Filing,
prosecuting, and defending patents on product candidates in all countries throughout the world would be prohibitively expensive, and
our intellectual property rights in some countries outside the United States could be less extensive than those in the United States.
In some cases, we or our licensors may not be able to obtain patent protection for certain licensed technology outside the United States.
In addition, the laws of some foreign countries do not protect intellectual property rights to the same extent as federal and state laws
in the United States, even in jurisdictions where we or our licensors do pursue patent protection. Consequently, we may not be able to
prevent third parties from practicing our in-licensed inventions in all countries outside the United States, even in jurisdictions where
our licensors do pursue patent protection or from selling or importing products made using our inventions in and into the United States
or other jurisdictions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Competitors
may use our technologies in jurisdictions where we or our licensors have not pursued and obtained patent protection to develop their
own products and, further, may export otherwise infringing products to territories where we have patent protection, but enforcement is
not as strong as that in the United States. These products may compete with our current in-development products, our future product candidates,
and our preclinical programs. Our in-licensed patents or other intellectual property rights may not be effective or sufficient to prevent
them from competing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Many
companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The
legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents, trade secrets,
and other intellectual property protection, particularly those relating to biotechnology products, which could make it difficult for
us to stop the infringement of our in-licensed patents, if pursued and obtained, or the marketing of competing products in violation
of our proprietary rights generally. Proceedings to enforce our patent rights in foreign jurisdictions could result in substantial costs
and divert our efforts and attention from other aspects of our business, could put our in-licensed patents at risk of being invalidated
or interpreted narrowly and our in-licensed patent applications at risk of not issuing and could provoke third parties to assert claims
against us. We may not prevail in any lawsuits that we initiate, and the damages or other remedies awarded, if any, may not be commercially
meaningful. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant
commercial advantage from the intellectual property that we develop or license.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Many
countries have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties. In addition,
many countries limit the enforceability of patents against government agencies or government contractors. In these countries, the patent
owner may have limited remedies, which could materially diminish the value of such patent. If we or any of our licensors are forced to
grant a license to third parties with respect to any patents relevant to our business, our competitive position may be impaired, and
our business, financial condition, results of operations, and prospects may be adversely affected.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>


<!-- Field: Page; Sequence: 64; Value: 2 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->62<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Risks
Related to Healthcare Laws and Other Legal Compliance Matters</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>If
we successfully commercialize our current in-development products or one of our future product candidates, failure to comply with our
reporting and payment obligations under U.S. governmental pricing programs could have a material adverse effect on our business, financial
condition, and results of operations.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we participate in the Medicaid Drug Rebate Program, Part D, if and when we successfully commercialize a product candidate, we will be
required to report certain pricing information for such product candidate to the Centers for Medicare &amp; Medicaid Services, the federal
agency that administers the Medicaid and Medicare programs. We may also be required to report pricing information to the U.S. Department
of Veterans Affairs. If we become subject to these reporting requirements, we will be liable for errors associated with our submission
of pricing data, for failure to report pricing data in a timely manner, and for overcharging government payers, which can result in civil
monetary penalties under the Medicaid statute, the federal civil False Claims Act, and other laws and regulations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Our
current and future relationships with healthcare professionals, principal investigators, consultants, customers, and third-party payors
in the United States and elsewhere may be subject, directly or indirectly, to applicable anti-kickback, fraud and abuse, false claims,
physician payment transparency, health information privacy and security, and other healthcare laws and regulations, which could expose
us to penalties.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Healthcare
providers, physicians, and third-party payors in the United States and elsewhere will play a primary role in the recommendation and prescription
of any product candidates for which we obtain marketing approval. Our current and future arrangements with healthcare professionals,
principal investigators, consultants, customers, and third-party payors may expose us to broadly applicable fraud and abuse and other
healthcare laws, including, without limitation, the federal Anti-Kickback Statute and the federal False Claims Act, that may constrain
the business or financial arrangements and relationships through which we research, sell, market, and distribute any product candidates
for which we obtain marketing approval. In addition, we may be subject to physician payment transparency laws and patient privacy and
security regulation by the federal government and by the states and foreign jurisdictions in which we conduct our business. The applicable
federal, state, and foreign healthcare laws that may affect our ability to operate include the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    federal Anti-Kickback Statute, which prohibits, among other things, persons from knowingly and willfully soliciting, offering, receiving
    or providing remuneration, directly or indirectly, in cash or in kind, to induce or reward, or in return for, either the referral
    of an individual for, or the purchase, lease, order, or recommendation of, any good, facility, item or service, for which payment
    may be made, in whole or in part, under federal and state healthcare programs such as Medicare and Medicaid;</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">federal
    civil and criminal false claims laws, including the federal False Claims Act, which impose criminal and civil penalties, including
    through civil whistleblower or <I>qui tam</I> actions, against individuals or entities for, among other things, knowingly presenting,
    or causing to be presented, to the federal government, including the Medicare and Medicaid programs, claims for payment that are
    false or fraudulent or making a false statement to avoid, decrease, or conceal an obligation to pay money to the federal government;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>


<!-- Field: Page; Sequence: 65; Value: 2 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->63<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    federal civil monetary penalties statute, which imposes penalties against any person or entity who, among other things, is determined
    to have presented or caused to be presented a claim to a federal health program that the person knows or should know is for an item
    or service that was not provided as claimed or is false or fraudulent;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, which created additional federal criminal statutes
    that prohibit knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program or
    obtain, by means of false or fraudulent pretenses, representations or promises, any of the money or property owned by, or under the
    custody or control of, any healthcare benefit program, regardless of whether the payor is public or private, knowingly and willfully
    embezzling or stealing from a health care benefit program, willfully obstructing a criminal investigation of a health care offense
    and knowingly and willfully falsifying, concealing or covering up by any trick or device a material fact or making any materially
    false statements in connection with the delivery of, or payment for, healthcare benefits, items or services relating to healthcare
    matters;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">HIPAA,
    as amended by the Health Information Technology for Economic and Clinical Health Act of 2009, or HITECH, and their respective implementing
    regulations, which impose obligations on &#8220;covered entities,&#8221; including certain healthcare providers, health plans, and
    healthcare clearinghouses, as well as their respective &#8220;business associates&#8221; and their respective subcontractors that
    create, receive, maintain, or transmit individually identifiable health information for or on behalf of a covered entity, with respect
    to safeguarding the privacy, security, and transmission of individually identifiable health information;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    federal Physician Payments Sunshine Act, created under Section 6002 of Patient Protection and Affordable Care Act, as amended by
    the Health Care and Education Reconciliation Act, or collectively, the ACA, and its implementing regulations, created annual reporting
    requirements for manufacturers of drugs, devices, biologicals, and medical supplies for certain payments and &#8220;transfers of
    value&#8221; provided to physicians (defined to include doctors, dentists, optometrists, podiatrists, and chiropractors) and teaching
    hospitals, as well as ownership and investment interests held by physicians and their immediate family members. As of January 1,
    2022, these reporting obligations will extend to include transfers of value made in the previous year to certain non-physician providers
    such as physician assistants and nurse practitioners; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">analogous
    state and foreign laws, such as state anti-kickback and false claims laws, which may apply to sales or marketing arrangements and
    claims involving healthcare items or services reimbursed by non-governmental third-party payors, including private insurers; state
    and foreign laws that require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines
    and the relevant compliance guidance promulgated by the federal government or to adopt compliance programs as prescribed by state
    laws and regulations, or that otherwise restrict payments that may be made to healthcare providers; state and foreign laws that require
    drug manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers
    or marketing expenditures; state and local laws requiring the licensure of pharmaceutical sales representatives; and state and foreign
    laws governing the privacy and security of health information in certain circumstances, many of which differ from each other in significant
    ways and often are not preempted by HIPAA, thus complicating compliance efforts.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Further,
the ACA, among other things, amended the intent requirement of the federal Anti-Kickback Statute and certain criminal statutes governing
healthcare fraud. A person or entity no longer needs to have actual knowledge of the statute or specific intent to violate it. In addition,
the ACA provided that the government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback
Statute constitutes a false or fraudulent claim for purposes of the False Claims Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Efforts
to ensure that our future business arrangements with third parties will comply with applicable healthcare laws and regulations may involve
substantial costs. It is possible that governmental authorities will conclude that our business practices may not comply with current
or future statutes, regulations or case law involving applicable fraud and abuse or other healthcare laws. If our operations are found
to be in violation of any of these laws or any other governmental regulations that may apply to us, we may be subject to significant
civil, criminal, and administrative penalties, including, without limitation, damages, monetary fines, disgorgement, possible exclusion
from participation in Medicare, Medicaid, and other federal healthcare programs, contractual damages, reputational harm, diminished profits
and future earnings, additional reporting or oversight obligations if we become subject to a corporate integrity agreement or other agreement
to resolve allegations of non-compliance with the law and curtailment or restructuring of our operations, any of which could adversely
affect our ability to operate our business and pursue our strategy. If any of the physicians or other healthcare providers or entities
with whom we expect to do business, including future collaborators, are found not to be in compliance with applicable laws, they may
be subject to criminal, civil, or administrative sanctions, including exclusions from participation in government healthcare programs,
which could also affect our business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>


<!-- Field: Page; Sequence: 66; Value: 2 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->64<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, there has been increasing legislative and enforcement interest in the United States with respect to specialty drug pricing
practices. Specifically, there have been Congressional inquiries and proposed federal and state legislation designed to bring more transparency
to drug pricing, reduce the cost of prescription drugs under Medicare, review the relationship between pricing and manufacturer patient
programs and reform government program reimbursement methodologies for drugs. Moreover, payment methodologies may be subject to changes
in healthcare legislation and regulatory initiatives. We expect that additional U.S. federal healthcare reform measures will be adopted
in the future, any of which could limit the amounts that the U.S. federal government will pay for healthcare products and services, which
could result in reduced demand for our product candidates or additional pricing pressures.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Individual
states in the United States have also become increasingly aggressive in passing legislation and implementing regulations designed to
control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions
on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation
from other countries and bulk purchasing. Legally mandated price controls on payment amounts by third-party payors or other restrictions
could harm our business, results of operations, financial condition and prospects. In addition, regional healthcare authorities and individual
hospitals are increasingly using bidding procedures to determine what pharmaceutical products and which suppliers will be included in
their prescription drug and other healthcare programs. This could reduce the ultimate demand for our product candidates or put pressure
on our product pricing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
markets outside of the United States, reimbursement and healthcare payment systems vary significantly by country, and many countries
have instituted price ceilings on specific products and therapies. We cannot predict the likelihood, nature, or extent of government
regulation that may arise from future legislation or administrative action in the United States or any other jurisdiction. If we or any
third parties we may engage are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies,
or if we or such third parties are not able to maintain regulatory compliance, our product candidates may lose any regulatory approval
that may have been obtained and we may not achieve or sustain profitability.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Changes
in healthcare policies, laws, and regulations may impact our ability to obtain approval for, or commercialize our current in-development
products or our future product candidates, if approved.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the United States and some foreign jurisdictions there have been, and continue to be, several legislative and regulatory changes and
proposed reforms of the healthcare system in an effort to contain costs, improve quality, and expand access to care. In the United States,
there have been and continue to be a number of healthcare-related legislative initiatives, as well as executive, judicial, and Congressional
challenges to existing healthcare laws that have significantly affected, and could continue to significantly affect, the healthcare industry.
For example, on June 17, 2021, the U.S. Supreme Court dismissed a challenge on procedural grounds that argued the ACA is unconstitutional
in its entirety because the &#8220;individual mandate&#8221; was repealed by Congress. Thus, the Affordable Care Act will remain in effect
in its current form. Further, prior to the U.S. Supreme Court ruling, on January 28, 2021, President Biden issued an executive order
that initiated a special enrollment period for purposes of obtaining health insurance coverage through the ACA marketplace, which began
on February 15, 2021, and remained open through August 15, 2021. The executive order also instructed certain governmental agencies to
review and reconsider their existing policies and rules that limit access to healthcare, including among others, reexamining Medicaid
demonstration projects and waiver programs that include work requirements, and policies that create unnecessary barriers to obtaining
access to health insurance coverage through Medicaid or the ACA. It is possible that the Affordable Care Act will be subject to judicial
or Congressional challenges in the future. In addition, recently there has been heightened governmental scrutiny over the manner in which
manufacturers set prices for their marketed products, which has resulted in several U.S. Congressional inquiries and proposed and enacted
federal and state legislation designed to, among other things, bring more transparency to drug pricing, reduce the cost of prescription
drugs under government payor programs and review the relationship between pricing and manufacturer patient programs. Further, based on
a recent executive order, the Biden administration expressed its intent to pursue certain policy initiatives to reduce drug prices. We
expect that additional U.S. federal healthcare reform measures will be adopted in the future, any of which could limit the amounts that
the U.S. federal government will pay for healthcare products and services, which could result in reduced demand for our current in-development
products or our future product candidates or additional pricing pressures.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>


<!-- Field: Page; Sequence: 67; Value: 2 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->65<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
are subject to privacy and data security laws, rules, regulations, policies, industry standards, and contractual obligations, and our
failure to comply with them could harm our business.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
maintain a large quantity of sensitive information, including confidential business information and information related to our employees
and we expect to maintain personal information in connection with the conduct of our clinical trials. As such, we are subject to laws
and regulations governing the privacy and security of such information. In the United States, there are numerous federal and state privacy
and data security laws and regulations governing the collection, use, disclosure, and protection of personal information, including federal
and state health information privacy laws, federal and state security breach notification laws, and federal and state consumer protection
laws. The legislative and regulatory landscape for privacy and data protection continues to evolve, and there has been an increasing
focus on privacy and data protection issues, which may affect our business and is expected to increase our compliance costs and exposure
to liability. In the United States, numerous federal and state laws and regulations could apply to our operations or the operations of
our partners, including state data breach notification laws, state health information privacy laws, and federal and state consumer protection
laws and regulations, including Section 5 of the Federal Trade Commission Act, that govern the collection, use, disclosure, and protection
of health-related and other personal information. In addition, we may obtain health information from third parties, including research
institutions from which we obtain clinical trial data, that are subject to privacy and security requirements under HIPAA, as amended
by the Health Information Technology for Economic and Clinical Health Act, and the regulations promulgated thereunder. Depending on the
facts and circumstances, we could be subject to significant penalties if we obtain, use or disclose individually identifiable health
information in a manner that is not authorized or permitted by HIPAA.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Compliance
with these and any other applicable privacy and data security laws and regulations we may be subject to in the future is a rigorous and
time-intensive process, and we may be required to put in place additional mechanisms ensuring compliance with the new data protection
rules. If we fail to comply with any such laws or regulations, we may face significant fines and penalties that could adversely affect
our business, financial condition, results of operations or prospects. Any failure by us or our third-party processors to comply with
these data protection and privacy laws and regulations could result in significant government enforcement actions, which could include
civil, criminal, and administrative penalties, orders requiring that we change our practices, claims for damages, and other liabilities,
regulatory investigations and enforcement action, private litigation, significant costs of remediation, and adverse publicity, any of
which could negatively affect our operating results and business. Furthermore, the laws are not consistent, and compliance in the event
of a widespread data breach is costly. In addition, states are constantly adopting new laws or amending existing laws, requiring attention
to frequently changing regulatory requirements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">With
laws, regulations, and other obligations relating to privacy and data protection imposing new and relatively burdensome obligations,
and with the substantial uncertainty over the interpretation and application of these and other obligations, we may face challenges in
addressing their requirements and making necessary changes to our policies and practices and may incur significant costs and expenses
in an effort to do so. We are currently in the process of developing and updating our policies and procedures in accordance with requirements
under applicable data privacy and protection laws and regulations. We do not currently have any formal data privacy policies and procedures
in place and have not completed formal assessments of whether we are in compliance with all applicable data privacy laws and regulations.
Additionally, if third parties with which we work, such as vendors or service providers, violate applicable laws, rules or regulations
or our policies, such violations may also put our or our clinical trial and employee data, including personal data, at risk, and our
business, financial condition, results of operations, and prospects may be adversely affected.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&#160;</I></B></FONT></P>


<!-- Field: Page; Sequence: 68; Value: 2 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->66<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&#160;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Any
clinical trial programs we conduct or research collaborations we enter into in the European Economic Area may subject us to the General
Data Protection Regulation.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we conduct clinical trial programs or enter into research collaborations in the European Economic Area, or EEA, we may be subject to
the General Data Protection regulation, or GDPR. The GDPR applies extraterritorially and implements stringent operational requirements
for processors and controllers of personal data, including, for example, high standards for obtaining consent from individuals to process
their personal data, robust disclosures to individuals, a comprehensive individual data rights regime, data export restrictions governing
transfers of data from the EEA/European Union, or EU, to other jurisdictions, short timelines for data breach notifications, limitations
on retention of information, increased requirements pertaining to health data, other special categories of personal data and coded data
and additional obligations if we contract third-party processors in connection with the processing of personal data. The United Kingdom
has implemented its own version of the GDPR, which contains similar requirements. The GDPR provides that EU member states may establish
their own laws and regulations limiting the processing of personal data, including genetic, biometric or health data, which could limit
our ability to use and share personal data or could cause our costs to increase. If our or our partners&#8217; or service providers&#8217;
privacy or data security measures fail to comply with the GDPR requirements, we may be subject to litigation, regulatory investigations,
enforcement notices requiring us to change the way we use personal data and/or fines of up to 20 million Euros or up to 4% of the total
worldwide annual turnover of the preceding financial year, whichever is higher, as well as compensation claims by affected individuals,
negative publicity, reputational harm and a potential loss of business and goodwill.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Our
product candidates may be subject to government price controls that may affect our revenue.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
has been heightened governmental scrutiny in the United States and abroad of pharmaceutical pricing practices in light of the rising
cost of prescription drugs and biologics. In the United States, such scrutiny has resulted in several recent Congressional inquiries
and proposed and enacted federal legislation designed to, among other things, bring more transparency to product pricing, review the
relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for products.
At the state level, legislatures have become increasingly aggressive in passing legislation and implementing regulations designed to
control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions
on certain product access, and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation
from other countries and bulk purchasing. Outside of the United States, particularly in the European Union, the pricing of prescription
pharmaceuticals is subject to governmental control. In these countries, pricing negotiations with governmental authorities can take considerable
time after the receipt of marketing approval for a product. To obtain coverage and reimbursement or pricing approval in some countries,
we may be required to conduct a clinical trial that compares the cost-effectiveness of our current in-development products or our future
product candidates to other available therapies. If reimbursement of our product candidates is unavailable or limited in scope or amount,
or if pricing is set at unsatisfactory levels, our business could be harmed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>If
we fail to comply with environmental, health, and safety laws and regulations, we could become subject to fines or penalties or incur
costs that could harm our business.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are subject to numerous environmental, health, and safety laws and regulations, including those governing laboratory procedures and the
handling, use, storage, treatment, and disposal of hazardous materials and wastes. Our operations involve the use of hazardous materials,
including chemicals and biological materials. Our operations also produce hazardous waste products. We generally contract with third
parties for the disposal of these materials and wastes. We cannot eliminate the risk of contamination or injury from these materials.
In the event of contamination or injury resulting from our use of hazardous materials, we could be held liable for any resulting damages,
and any liability could exceed our resources. We also could incur significant costs associated with civil or criminal fines and penalties
for failure to comply with such laws and regulations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Although
we maintain workers&#8217; compensation insurance to cover us for costs and expenses, we may incur due to injuries to our employees resulting
from the use of hazardous materials, this insurance may not provide adequate coverage against potential liabilities. We do not maintain
insurance for environmental liability or toxic tort claims that may be asserted against us in connection with our storage or disposal
of biological or hazardous materials.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, we may incur substantial costs in order to comply with current or future environmental, health, and safety laws and regulations.
These current or future laws and regulations may impair our research, development, or production efforts. Our failure to comply with
these laws and regulations also may result in substantial fines, penalties or other sanctions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>


<!-- Field: Page; Sequence: 69; Value: 2 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->67<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
are subject to U.S. and certain foreign export and import controls, sanctions, embargoes, anti-corruption laws, and anti-money laundering
laws and regulations. Compliance with these legal standards could impair our ability to compete in domestic and international markets.
We can face criminal liability and other serious consequences for violations, which can harm our business.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are subject to export control and import laws and regulations, including the U.S. Export Administration Regulations, U.S. Customs regulations,
various economic and trade sanctions regulations administered by the U.S. Treasury Department&#8217;s Office of Foreign Assets Controls,
the FCPA, the U.S. domestic bribery statute contained in 18 U.S.C. &#167; 201, the U.S. Travel Act, the USA PATRIOT Act, and other state
and national anti-bribery and anti-money laundering laws in the countries in which we conduct activities. Anti-corruption laws are interpreted
broadly and prohibit companies and their employees, agents, contractors, and other collaborators from authorizing, promising, offering,
or providing, directly or indirectly, improper payments or anything else of value to recipients in the public or private sector.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may engage third parties to sell our current in-development products or our future product candidates outside the United States, to conduct
clinical trials, and/or to obtain necessary permits, licenses, patent registrations, and other regulatory approvals. We have direct or
indirect interactions with officials and employees of government agencies or government-affiliated hospitals, universities, and other
organizations. We can be held liable for the corrupt or other illegal activities of our employees, agents, contractors, and other collaborators,
even if we do not explicitly authorize or have actual knowledge of such activities. Any violations of the laws and regulations described
above may result in substantial civil and criminal fines and penalties, imprisonment, the loss of export or import privileges, debarment,
tax reassessments, breach of contract, and fraud litigation, reputational harm, and other consequences.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
rely, and expect to continue to rely, on third parties to conduct, supervise, and monitor our preclinical studies and clinical trials.
If those third parties do not perform satisfactorily, including failing to meet deadlines for the completion of such trials or failing
to comply with regulatory requirements, we may be unable to obtain regulatory approval for our product candidates or any other product
candidates that we may develop in the future.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
rely, and will rely, on third-party CROs, study sites and others to conduct, supervise, and monitor our preclinical studies and clinical
trials for our product candidates. We expect to continue to rely on third parties, such as CROs, clinical data management organizations,
medical institutions, and clinical investigators, to conduct our preclinical studies and clinical trials. Although we have agreements
governing their activities, we have limited influence over their actual performance and control only certain aspects of their activities.
The failure of these third parties to successfully carry out their contractual duties or meet expected deadlines could substantially
harm our business because we may be delayed in completing or unable to complete the studies required to support future approval of our
product candidates, or we may not obtain marketing approval for or commercialize our product candidates in a timely manner or at all.
Moreover, these agreements might terminate for a variety of reasons, including a failure to perform by the third parties. If we need
to enter into alternative arrangements, our product development activities would be delayed and our business, financial condition, results
of operations, stock price and prospects may be materially harmed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
reliance on these third parties for development activities will reduce our control over these activities. Nevertheless, we are responsible
for ensuring that each of our studies is conducted in accordance with the applicable protocol, legal, regulatory, and scientific standards
and our reliance on third parties does not relieve us of our regulatory responsibilities. For example, we will remain responsible for
ensuring that each of our trials is conducted in accordance with the general investigational plan and protocols for the trial. We must
also ensure that our preclinical trials are conducted in accordance with the FDA&#8217;s Good Laboratory Practice (GLP) regulations,
as appropriate. Moreover, the FDA and comparable foreign regulatory authorities require us to comply with standards, commonly referred
to as GCP guidelines, for conducting, recording, and reporting the results of clinical trials to assure that data and reported results
are credible and accurate and that the rights, integrity, and confidentiality of trial participants are protected. Regulatory authorities
enforce these requirements through periodic inspections of trial sponsors, clinical investigators, and trial sites. If we or any of our
third parties fail to comply with applicable GCPs or other regulatory requirements, we or they may be subject to enforcement or other
legal actions. For example, the data generated in our trials may not have been appropriately collected or documented, and thereby be
deemed unreliable and the FDA or comparable foreign regulatory authorities may conclude the study findings are not adequate and require
us to perform additional studies.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>


<!-- Field: Page; Sequence: 70; Value: 2 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->68<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, we will be required to report certain financial interests of our third-party investigators if these relationships exceed certain
financial thresholds or meet other criteria. The FDA or comparable foreign regulatory authorities may question the integrity of the data
from those clinical trials conducted by investigators who may have conflicts of interest.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
cannot assure you that upon inspection by a given regulatory authority, such regulatory authority will determine that any of our trials
complies with the applicable regulatory requirements. In addition, our clinical trials must be conducted with product candidates that
were produced under cGMP regulations. Failure to comply with these regulations may require us to repeat clinical trials, which would
delay the regulatory approval process. We also are required to register certain clinical trials and post the results of certain completed
clinical trials on one or more government-sponsored databases, e.g., ClinicalTrials.gov, within specified timeframes. Failure to do so
can result in enforcement actions and adverse publicity.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
third parties with which we work may also have relationships with other entities, some of which may be our competitors, for whom they
may also be conducting trials or other therapeutic development activities that could harm our competitive position. In addition, such
third parties are not our employees, and except for remedies available to us under our agreements with such third parties we cannot control
whether or not they devote sufficient time and resources to our ongoing clinical, non-clinical, and preclinical programs. If these third
parties do not successfully carry out their contractual duties, meet expected deadlines or conduct our preclinical studies or clinical
trials in accordance with regulatory requirements or our stated protocols, if they need to be replaced or if the quality or accuracy
of the data they obtain is compromised due to the failure to adhere to our protocols, regulatory requirements or for other reasons, our
trials may be repeated, extended, delayed, or terminated; we may not be able to obtain, or may be delayed in obtaining, marketing approvals
for our product candidates; we may not be able to, or may be delayed in our efforts to, successfully commercialize our product candidates;
or we or they may be subject to regulatory enforcement actions. As a result, our results of operations and the commercial prospects for
our product candidates would be harmed, our costs could increase and our ability to generate revenues could be delayed. To the extent
we are unable to successfully identify and manage the performance of third-party service providers in the future, our business, financial
condition, results of operations, stock price and prospects may be materially harmed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
any of our relationships with these third parties terminate, we may not be able to enter into arrangements with alternative providers
or to do so on commercially reasonable terms. Switching or adding additional third parties involves additional cost and requires management
time and focus. In addition, there is a natural transition period when a new third party commences work. As a result, delays could occur,
which could compromise our ability to meet our desired development timelines.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
will also rely on other third parties to store and distribute our product candidates for the clinical trials that we conduct. Any performance
failure on the part of our distributors could delay clinical development, marketing approval, or commercialization of our product candidates,
which could result in additional losses and deprive us of potential product revenue.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
have entered into, and may in the future enter into, certain collaboration agreements and strategic alliances to maximize the potential
of our product candidates, and we may not realize the anticipated benefits of such collaborations or alliances. We expect to continue
to form collaborations in the future with respect to our product candidates, but may be unable to do so or to realize the potential benefits
of such transactions, which may cause us to alter or delay our development and commercialization plans.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may form or seek other strategic alliances, joint ventures, or collaborations, or enter into additional licensing arrangements with third
parties that we believe will complement or augment our development and commercialization efforts with respect to product candidates we
develop. These transactions can entail numerous operational and financial risks, including exposure to unknown liabilities, disruption
of our business and diversion of our management&#8217;s time and attention in order to manage a collaboration. We also cannot be certain
that, following a strategic transaction or license, we will achieve the revenue or other anticipated benefits that led us to enter into
the arrangement. Additionally, the success of any collaboration arrangements may depend on the efforts and activities of our collaborators.
Collaborators generally have significant discretion in determining the efforts and resources that they will apply to these arrangements.
Disagreements between parties to a collaboration arrangement regarding clinical development and commercialization matters can lead to
delays in the development process or commercializing the applicable product candidate and, in some cases, termination of the collaboration
arrangement. These disagreements can be difficult to resolve if neither of the parties has final decision-making authority.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>


<!-- Field: Page; Sequence: 71; Value: 2 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->69<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>If
we are not able to establish future collaborations on commercially reasonable terms, we may have to alter our development and commercialization
plans for one or more of our other development programs.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
face significant competition in seeking appropriate additional collaborators. Our ability to reach a definitive agreement for any collaboration
will depend, among other things, upon our assessment of the collaborator&#8217;s resources and expertise, the terms and conditions of
the proposed collaboration and the proposed collaborator&#8217;s evaluation of a number of factors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we are unable to reach agreements with suitable collaborators on a timely basis, on acceptable terms, or at all, we may have to curtail
the development of a product candidate, reduce or delay its development program or one or more of our other development programs, delay
its potential commercialization or reduce the scope of any sales or marketing activities, or increase our expenditures and undertake
development or commercialization activities at our own expense. If we elect to fund and undertake development or commercialization activities
on our own, we may need to obtain additional expertise and additional capital, which may not be available to us on acceptable terms,
or at all. If we fail to enter into collaborations and do not have sufficient funds or expertise to undertake the necessary development
and commercialization activities, we may not be able to further develop our product candidates or bring them to market or continue to
develop our product platform and our business may be materially and adversely affected.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Our
current and any future collaborations are not a guarantee of success, and all collaborations are as risky, or riskier, than undertaking
the activities ourselves.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&#160;</I></B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">collaborators
    may not perform their obligations as expected;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">collaborators
    may not pursue development and commercialization of product candidates that achieve regulatory approval or may elect not to continue
    or renew development or commercialization programs based on clinical trial results, changes in the collaborators&#8217; strategic
    focus or available funding, or external factors, such as an acquisition, that divert resources or create competing priorities;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">collaborators
    may delay clinical trials, provide insufficient funding for a clinical trial program, stop a clinical trial or abandon a product
    candidate, repeat or conduct new clinical trials or require a new formulation of a product candidate for clinical testing;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">collaborators
    could fail to make timely regulatory submissions for a product candidate;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">collaborators
    may not comply with all applicable regulatory requirements or may fail to report safety data in accordance with all applicable regulatory
    requirements, which could subject them or us to regulatory enforcement actions;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">collaborators
    could independently develop, or develop with third parties, products that compete directly or indirectly with our products or product
    candidates if the collaborators believe that competitive products are more likely to be successfully developed or can be commercialized
    under terms that are more economically attractive than ours;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">product
    candidates discovered in collaboration with us may be viewed by our collaborators as competitive with their own product candidates
    or products, which may cause collaborators to cease to devote resources to the commercialization of our product candidates;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    collaborator with marketing and distribution rights to one or more of our product candidates that achieve regulatory approval may
    not commit sufficient resources to the marketing and distribution of such product candidate or product;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">disagreements
    with collaborators, including disagreements over proprietary rights, contract interpretation or the preferred course of development,
    might cause delays or termination of the research, development or commercialization of product candidates, might lead to additional
    responsibilities for us with respect to product candidates, or might result in litigation or arbitration, any of which would be time
    consuming and expensive;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">collaborators
    may not properly maintain or defend our intellectual property rights or may use our proprietary information in such a way as to invite
    litigation that could jeopardize or invalidate our intellectual property or proprietary information or expose us to potential litigation;
    and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">collaborators
    may infringe the intellectual property rights of third parties, which may expose us to litigation and potential liability.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, all of the risks relating to product development, regulatory approval and commercialization described in this Annual Report
also apply to the activities of any of our current or future collaborators.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Collaborations
with biopharmaceutical companies and other third parties often are terminated or allowed to expire by the other party. Any such termination
or expiration could adversely affect us financially and could harm our business reputation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>


<!-- Field: Page; Sequence: 72; Value: 2 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->70<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
any collaborations we have entered into or might enter into do not result in the successful development and commercialization of products
or if one of our collaborators subsequently terminates its agreement with us, we may not receive any future research funding or milestone
or royalty payments under such collaboration. If we do not receive the funding we expect under the agreements, our development of our
product candidates could be delayed and we may need additional resources to develop our product candidates and our product platform.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally,
if any collaborator of ours is involved in a business combination, the collaborator might deemphasize or terminate development or commercialization
of any product candidate licensed to it by us. If one of our collaborators terminates its agreement with us, we may find it more difficult
to attract new collaborators and our reputation in the business and financial communities could be adversely affected.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
face significant competition in seeking appropriate collaborators. Our ability to reach a definitive agreement for any collaboration
will depend, among other things, upon our assessment of the collaborator&#8217;s resources and expertise, the terms and conditions of
the proposed collaboration and the proposed collaborator&#8217;s evaluation of a number of factors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we are unable to reach agreements with suitable collaborators on a timely basis, on acceptable terms, or at all, we may have to curtail
the development of a product candidate, reduce or delay its development program or one or more of our other development programs, delay
its potential commercialization or reduce the scope of any sales or marketing activities, or increase our expenditures and undertake
development or commercialization activities at our own expense. If we elect to fund and undertake development or commercialization activities
on our own, we may need to obtain additional expertise and additional capital, which may not be available to us on acceptable terms,
or at all. If we fail to enter into collaborations and do not have sufficient funds or expertise to undertake the necessary development
and commercialization activities, we may not be able to further develop our product candidates or bring them to market or continue to
develop our product platform and our business may be materially and adversely affected.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Disruptions
at the FDA and other government agencies caused by funding shortages or global health concerns could hinder their ability to hire and
retain key leadership and other personnel, or otherwise prevent new products and services from being developed or commercialized in a
timely manner, which could negatively impact our business.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
ability of the FDA to review and approve new products can be affected by a variety of factors, including government budget and funding
levels, ability to hire and retain key personnel and accept the payment of user fees, and statutory, regulatory, and policy changes.
Average review times at the agency have fluctuated in recent years as a result. In addition, government funding of other government agencies
that fund research and development activities is subject to the political process, which is inherently fluid and unpredictable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Disruptions
at the FDA and other agencies may also slow the time necessary for new drugs to be reviewed and/or approved by necessary government agencies,
which would adversely affect our business. For example, over the last several years, including for 35 days beginning on December 22,
2018, the U.S. government has shut down several times and certain regulatory agencies, such as the FDA, have had to furlough critical
employees and stop critical activities. If a prolonged government shutdown occurs, it could significantly impact the ability of the FDA
to timely review and process our regulatory submissions, which could have a material adverse effect on our business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Separately,
the FDA and regulatory authorities outside the United States have and may adopt restrictions or other policy measures in response to
the COVID-19 pandemic that divert resources and delay their attention to any submissions we may make. If a prolonged government shutdown
occurs, or if global health concerns continue to prevent the FDA or other regulatory authorities from conducting their regular inspections,
reviews, or other regulatory activities, it could significantly impact the ability of the FDA or other regulatory authorities to timely
review and process our regulatory submissions, which could have a material adverse effect on our business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&#160;</B></FONT></P>


<!-- Field: Page; Sequence: 73; Value: 2 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->71<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&#160;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Risks
Related to Commercialization of Our Products</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>There
is no assurance that we will be able to obtain FDA approval and, even if we do, there is no assurance that either we, or our collaboration
partners, will be successful in commercializing any product candidate for which we receive regulatory approval, or experience significant
delays in doing so, our business will be materially harmed.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even
if we obtain FDA approval, there is no assurance that we, or our collaboration partners, will be successful in obtaining marketing approval
from applicable regulatory authorities for ENV 105 or any other product candidate. Our ability to generate revenues from any such products
will depend on our success in:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Successfully
    completing our Phase 1 and Phase 2 clinical trials and obtaining FDA approval for our product candidates;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">launching
    commercial sales of such products, whether alone or in collaboration with others;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">receiving
    approved labels with claims that are necessary or desirable for successful marketing, and that do not contain safety or other limitations
    that would impede our ability to market such products;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">creating
    market demand for such products through marketing, sales and promotion activities;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">hiring,
    training, and deploying a sales force or contracting with third parties to commercialize such products in the United States;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">creating
    partnerships with, or offering licenses to, third parties to promote and sell such products in foreign markets where we receive marketing
    approval;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">manufacturing
    such products in sufficient quantities and at acceptable quality and cost to meet commercial demand at launch and thereafter;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">establishing
    and maintaining agreements with wholesalers, distributors, and group purchasing organizations on commercially reasonable terms;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">maintaining
    patent and trade secret protection and regulatory exclusivity for such products;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">achieving
    market acceptance of such products by patients, the medical community, and third-party payors;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">achieving
    coverage and adequate reimbursement from third-party payors for such products;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">achieving
    patients&#8217; willingness to pay out-of-pocket in the absence of such coverage and adequate reimbursement from third-party payors;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">competing
    effectively with other therapies; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">maintaining
    a continued acceptable safety profile of such products following launch.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
the extent we are not able to do any of the foregoing, our business, financial condition, results of operations, stock price and prospects
will be materially harmed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
face significant competition from other biopharmaceutical and biotechnology companies, academic institutions, government agencies, and
other research organizations, which may result in others discovering, developing or commercializing products more quickly or marketing
them more successfully than us. If their product candidates are shown to be safer or more effective than ours, our commercial opportunity
may be reduced or eliminated.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
development and commercialization of cancer resistance products and immunotherapy products is characterized by rapidly advancing technologies,
intense competition and a strong emphasis on proprietary rights. We face competition with respect to our current product candidates,
and will face competition with respect to any product candidates that we may seek to develop or commercialize in the future, from major
biopharmaceutical companies, specialty biopharmaceutical companies, and biotechnology companies worldwide. Potential competitors also
include academic institutions, government agencies, and other public and private research organizations that conduct research, seek patent
protection, and establish collaborative arrangements for research, development, manufacturing, and commercialization.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">While
certain of our product candidates may be used in combination with other drugs with different mechanisms of action, if and when marketed
they will still compete with a number of drugs that are currently marketed or in development that also target cancer. To compete effectively
with these drugs, our product candidates will need to demonstrate advantages in clinical efficacy and safety compared to these competitors
when used alone or in combination with other drugs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>


<!-- Field: Page; Sequence: 74; Value: 2 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->72<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
commercial opportunities could be reduced or eliminated if our competitors develop and commercialize products that are safer, more effective,
have fewer or less severe side effects, are easier to administer or are less expensive alone or in combination with other therapies than
any products that we may develop alone or in combination with other therapies. Our competitors also may obtain FDA or comparable foreign
regulatory authorities&#8217; approval for their products more rapidly than we may obtain approval for ours, which could result in our
competitors establishing a strong market position before we are able to enter the market. In addition, our ability to compete may be
affected in many cases by third-party payors&#8217; coverage and reimbursement decisions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Many
of the companies with which we are competing or may compete in the future have significantly greater financial resources and expertise
in research and development, manufacturing, preclinical testing, conducting clinical trials, obtaining regulatory approvals, and marketing
approved products than we do. Mergers and acquisitions in the biopharmaceutical and biotechnology industries may result in even more
resources being concentrated among a smaller number of our competitors. Early-stage companies may also prove to be significant competitors,
particularly through collaborative arrangements with large and established companies. These third parties compete with us in recruiting
and retaining qualified scientific and management personnel and establishing clinical trial sites and patient registration for clinical
trials, as well as in developing or acquiring technologies complementary to, or necessary for, our programs. If we are unable to successfully
compete with these companies our business, financial condition, results of operations, stock price and prospects may be materially harmed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>If
we are unable to establish effective marketing, sales and distribution capabilities or enter into agreements with third parties to market
and sell our product candidates, if they are approved, the revenues that we generate may be limited and we may never become profitable.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
currently do not have a commercial infrastructure for the marketing, sale, and distribution of any products that we may develop. If and
when our product candidates receive marketing approval, we intend to commercialize our product candidates on our own or in collaboration
with others and potentially with pharmaceutical or biotechnology partners in other geographies. In order to commercialize our products,
we must build our marketing, sales, and distribution capabilities or make arrangements with third parties to perform these services.
We may not be successful in doing so. Should we decide to move forward in developing our own marketing capabilities, we may incur expenses
prior to product launch or even approval in order to recruit a sales force and develop a marketing and sales infrastructure. If a commercial
launch is delayed as a result of the FDA or comparable foreign regulatory authority requirements or other reasons, we would incur these
expenses prior to being able to realize any revenue from sales of our product candidates. Even if we are able to effectively hire a sales
force and develop a marketing and sales infrastructure, our sales force and marketing teams may not be successful in commercializing
our product candidates. This may be costly, and our investment would be lost if we cannot retain or reposition our sales and marketing
personnel.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may also or alternatively decide to collaborate with third-party marketing and sales organizations to commercialize any approved product
candidates, in which event, our ability to generate product revenues may be limited. To the extent we rely on third parties to commercialize
any products for which we obtain regulatory approval, we may receive less revenues than if we commercialized these products ourselves,
which could materially harm our prospects. In addition, we would have less control over the sales efforts of any other third parties
involved in our commercialization efforts, and could be held liable if they failed to comply with applicable legal or regulatory requirements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have no prior experience in the marketing, sale, and distribution of biopharmaceutical products, and there are significant risks involved
in building and managing a commercial infrastructure. The establishment and development of commercial capabilities, including compliance
plans, to market any products we may develop will be expensive and time consuming and could delay any product launch, and we may not
be able to successfully develop this capability. We will have to compete with other biopharmaceutical and biotechnology companies, including
oncology-focused companies, to recruit, hire, train, manage, and retain marketing and sales personnel, which is expensive and time consuming
and could delay any product launch. Developing our sales capabilities may also divert resources and management attention away from product
development.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>


<!-- Field: Page; Sequence: 75; Value: 2 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->73<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the event we are unable to develop a marketing and sales infrastructure, we may not be able to commercialize our product candidates,
which could limit our ability to generate product revenues and materially harm our business, financial condition, results of operations,
stock price and prospects. Factors that may inhibit our efforts to commercialize our product candidates include:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    inability to recruit, train, manage, and retain adequate numbers of effective sales and marketing personnel;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    inability of sales personnel to obtain access to physicians or educate adequate numbers of physicians on the benefits of prescribing
    our product candidates;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    inability to effectively oversee a geographically dispersed sales and marketing team;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    costs associated with training personnel, including sales and marketing personnel, on compliance matters and monitoring their actions;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">an
    inability to secure coverage and adequate reimbursement by third-party payors, including government and private health plans;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    unwillingness of patients to pay out-of-pocket in the absence of coverage and adequate reimbursement from third-party payors;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    clinical indications for which the products are approved and the claims that we may make for the products;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">limitations
    or warnings, including distribution or use restrictions, contained in the products&#8217; approved labeling;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    distribution and use restrictions imposed by the FDA or comparable foreign regulatory authorities or to which we agree as part of
    a mandatory REMS or voluntary risk management plan;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">liability
    for our personnel, including sales or marketing personnel, who fail to comply with applicable law;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    lack of complementary products to be offered by sales personnel, which may put us at a competitive disadvantage relative to companies
    with more extensive product lines; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">unforeseen
    costs and expenses associated with creating an independent sales and marketing organization or engaging a contract sales organization.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Even
if any of our product candidates receive marketing approval, they may fail to achieve the degree of market acceptance by physicians,
patients, hospitals, cancer treatment centers, third-party payors and others in the medical community necessary for commercial success.
The revenues that we generate from their sales may be limited, and we may never become profitable.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have never commercialized a product candidate for any indication. Even if our product candidates are approved by the appropriate regulatory
authorities for marketing and sale, they may not gain acceptance among physicians, patients, third-party payors, and others in the medical
community. If any product candidates for which we obtain regulatory approval does not gain an adequate level of market acceptance, we
could be prevented from or significantly delayed in achieving profitability. Market acceptance of our product candidates by the medical
community, patients, and third-party payors will depend on a number of factors, some of which are beyond our control. For example, physicians
are often reluctant to switch their patients and patients may be reluctant to switch from existing therapies even when new and potentially
more effective or safer treatments enter the market.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>


<!-- Field: Page; Sequence: 76; Value: 2 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->74<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Efforts
to educate the medical community and third-party payors on the benefits of our product candidates may require significant resources and
may not be successful. If any of our product candidates is approved but does not achieve an adequate level of market acceptance, we could
be prevented from or significantly delayed in achieving profitability. The degree of market acceptance of any product for which we receive
marketing approval will depend on a number of factors, including:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    efficacy of our product, including in combination with other cancer therapies;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    commercial success of any cancer therapies with which our product may be co-administered;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    prevalence and severity of adverse events associated with our product or those products with which it is co-administered;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    clinical indications for which our product is approved and the approved claims that we may make with respect to the product;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">limitations
    or warnings contained in the FDA-approved labeling of the product or the labeling approved by comparable foreign regulatory authorities,
    including potential limitations or warnings for our product that may be more restrictive than other competitive products;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
    in the standard of care for the targeted indications for our product, which could reduce the marketing impact of any claims that
    we could make following FDA approval or approval by comparable foreign regulatory authorities, if obtained;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    relative convenience and ease of administration of our product and any products with which it is co-administered;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    cost of treatment compared with the economic and clinical benefit of alternative treatments or therapies;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    availability of coverage and adequate reimbursement by third-party payors, such as private insurance companies and government healthcare
    programs, including Medicare and Medicaid;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    ability to have our product placed on approved formularies;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">patients&#8217;
    willingness to pay out-of-pocket in the absence of such coverage and adequate reimbursement from third-party payors;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    price concessions required by third-party payors to obtain coverage and adequate reimbursement;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    extent and strength of our marketing and distribution of our product;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    safety, efficacy, and other potential advantages over, and availability of, alternative treatments already used or that may later
    be approved;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">distribution
    and use restrictions imposed by the FDA or comparable foreign regulatory authorities with respect to our product or to which we agree
    as part of a REMS or voluntary risk management plan;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    timing of market introduction of our product, as well as competitive products;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to offer our product for sale at competitive prices;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    willingness of the target patient population to try new therapies and of physicians to prescribe these therapies;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    extent and strength of our raw material supplier and service provider support;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    actions of companies that market any products with which our product is co-administered;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    approval of other new products;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">adverse
    publicity about our product or any products with which it is co-administered, or favorable publicity about competitive products;
    and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">potential
    product liability claims.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>The
size of the potential market for our product candidates is difficult to estimate and, if any of our assumptions are inaccurate, the actual
markets for our product candidates may be smaller than our estimates. If the market opportunities for any product candidates we develop
are smaller than we believe they are, our potential revenues may be adversely affected, and our business may suffer.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
potential market opportunities for our product candidates are difficult to estimate and will depend in large part on the drugs with which
our product candidates are co-administered and the success of competing therapies and therapeutic approaches. In particular, the market
opportunity for cancer resistance drugs is hard to estimate given that it is an emerging field. Our projections of both the number of
people who have these diseases, as well as the subset of people with these diseases who have the potential to benefit from treatment
with our product candidates, are based on estimates. Our estimates of the potential market opportunities are predicated on many assumptions,
which may include industry knowledge and publications, third-party research reports, and other surveys. Although we believe that our
internal assumptions are reasonable, these assumptions involve the exercise of significant judgment on the part of our management, are
inherently uncertain, and their reasonableness has not been assessed by an independent source. These estimates may prove to be incorrect
and new studies may change the estimated incidence or prevalence of these diseases. The number of patients in the United States, Europe,
and elsewhere may turn out to be lower than expected, and patients may not be amenable to treatment with our product. If any of the assumptions
proves to be inaccurate, the actual markets for our product candidates could be smaller than our estimates of the potential market opportunities.
Additionally, because of the potential that any product candidates we develop could cure a target disease, we may not receive recurring
revenues from patients and may deplete the patient population prevalence through curative therapy.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>


<!-- Field: Page; Sequence: 77; Value: 2 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->75<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Risks
Related to Government Regulation</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>If
we fail to comply with federal and state healthcare laws, including fraud and abuse laws, we could face substantial penalties and our
business, financial condition, results of operations, stock price and prospects will be materially harmed.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
current and future arrangements with healthcare providers, third-party payors, customers, and others may expose us to broadly applicable
healthcare fraud and abuse, and other healthcare laws, which may constrain the business or financial arrangements and relationships through
which we research, as well as sell, market and distribute any products for which we obtain marketing approval. The applicable federal,
state and foreign healthcare laws and regulations that may affect our ability to operate include, but are not limited to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    federal Anti-Kickback Statute, which prohibits, among other things, individuals and entities from knowingly and willfully soliciting,
    receiving, offering or paying any remuneration (including any kickback, bribe, or rebate), directly or indirectly, overtly or covertly,
    in cash or in kind, to induce, or in return for, either the referral of an individual for, or the purchase, lease, order or recommendation
    of, any good, facility, item or service for which payment may be made, in whole or in part, under a federal healthcare program, such
    as the Medicare and Medicaid programs.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    federal civil and criminal false claims laws, including, without limitation, the civil FCA, and the federal Civil Monetary Penalties
    Law, which prohibit individuals or entities from, among other things, knowingly presenting, or causing to be presented, false or
    fraudulent claims for payment of federal funds, and knowingly making, or causing to be made, a false record or statement material
    to a false or fraudulent claim to avoid, decrease or conceal an obligation to pay money to the federal government.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Health Insurance Portability and Accountability Act of 1996 (HIPAA), which prohibits, among other things, knowingly and willfully
    executing, or attempting to execute, a scheme or artifice to defraud any healthcare benefit program or obtain, by means of false
    or fraudulent pretenses, representations, or promises, any of the money or property owned by, or under the custody or control of,
    any healthcare benefit program, regardless of the payor (e.g., public or private), willfully obstructing a criminal investigation
    of a healthcare offense, and knowingly and willfully falsifying, concealing or covering up by any trick or device a material fact
    or making any materially false, fictitious or fraudulent statements in connection with the delivery of, or payment for, healthcare
    benefits, items or services relating to healthcare matters.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    U.S. Federal Food, Drug and Cosmetic Act, which prohibits, among other things, the adulteration or misbranding of drugs, biological
    products and medical devices.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    federal physician payment transparency requirements, sometimes referred to as the Physician Payments Sunshine Act, created under
    the ACA and its implementing regulations, which require certain manufacturers of drugs, devices, biological products and medical
    supplies for which payment is available under Medicare, Medicaid or the Children&#8217;s Health Insurance Program (with certain exceptions)
    to report annually to the Centers for Medicare &amp; Medicaid Services (CMS) information related to payments or other transfers of
    value made to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors), other healthcare professionals
    (such as physician assistants and nurse practitioners), and teaching hospitals, as well as ownership and investment interests held
    by such physicians and their immediate family members.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Analogous
    state and foreign anti-kickback and false claims laws that may apply to sales or marketing arrangements and claims involving healthcare
    items or services reimbursed by non-governmental third-party payors, including private insurers, or that apply regardless of payor;
    state laws that require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines
    and the relevant compliance guidance promulgated by the federal government; state and local laws that require drug manufacturers
    to report information related to payments and other transfers of value to physicians and other healthcare providers or marketing
    expenditures; state laws that require the reporting of information related to drug pricing; and state and local laws requiring the
    registration of pharmaceutical sales representatives.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we or our operations are found to be in violation of any federal or state healthcare law, or any other governmental laws or regulations
that apply to us, we may be subject to penalties, including significant civil, criminal, and administrative penalties, damages, monetary
fines, disgorgement, imprisonment, suspension and debarment from government contracts, and refusal of orders under existing government
contracts, exclusion from participation in U.S. federal or state health care programs, additional reporting requirements and/or oversight
if we become subject to corporate integrity agreements or similar agreement to resolve allegations of non-compliance, contractual damages,
reputational harm, diminished profits and future earnings, and the curtailment or restructuring of our operations, any of which could
materially adversely affect our ability to operate our business and our financial results. If any of the physicians or other healthcare
providers or entities with whom we expect to do business is found not to be in compliance with applicable laws, it may be subject to
significant criminal, civil or administrative sanctions, including but not limited to, exclusions from participation in U.S. federal
or state healthcare programs, which could also materially affect our business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>


<!-- Field: Page; Sequence: 78; Value: 2 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->76<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Although
an effective compliance program can mitigate the risk of investigation and prosecution for violations of these laws, the risks cannot
be entirely eliminated. Moreover, achieving and sustaining compliance with such laws may prove costly. Any action against us for violation
of these laws, even if we successfully defend against it, could cause us to incur significant legal expenses and divert our management&#8217;s
attention from the operation of our business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>If
the government or third-party payors fail to provide adequate coverage, reimbursement and payment rates for our product candidates, or
if health maintenance organizations or long-term care facilities choose to use therapies that are less expensive or considered a better
value, our revenue and prospects for profitability will be limited.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
both domestic and foreign markets, sales of our products will depend in part upon the availability of coverage and adequate reimbursement
from third-party payors or placement on approved product formularies. Such third-party payors include government health programs such
as Medicare and Medicaid, managed care providers, private health insurers, and other organizations. Coverage decisions may depend upon
clinical and economic standards that disfavor new therapeutic products when more established or lower cost therapeutic alternatives are
already available or subsequently become available, even if our products are alone in a class. Third-party payors establish reimbursement
levels. Therefore, even if coverage is provided, the approved reimbursement amount may not be high enough to allow us to establish or
maintain a market share sufficient to realize a sufficient return on our or their investments. If reimbursement is not available, or
is available only to limited levels, our product candidates may be competitively disadvantaged, and we may not be able to successfully
commercialize our product candidates. Alternatively, securing favorable reimbursement terms may require us to compromise pricing and
prevent us from realizing an adequate margin over cost. Our failure to obtain or maintain timely or adequate pricing or formulary placement
of our products, or failure to obtain such formulary placement at favorable pricing may negatively impact our revenue.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
is significant uncertainty related to third-party payor coverage and reimbursement of newly approved therapeutics. Marketing approvals,
pricing, and reimbursement for new therapeutic products vary widely from country to country. Current and future legislation may significantly
change the approval requirements in ways that could involve additional costs and cause delays in obtaining approvals. Some countries
require approval of the sale price of a therapeutic before it can be marketed. In many countries, the pricing review period begins after
marketing or product licensing approval is granted. In some foreign markets, prescription biopharmaceutical pricing remains subject to
continuing governmental control even after initial approval is granted. As a result, we might obtain marketing approval for a product
in a particular country, but then be subject to price regulations that delay commercial launch of the product, possibly for lengthy time
periods, which may negatively impact the revenues we are able to generate from the sale of the product in that country. Adverse pricing
limitations may hinder our ability to recoup our investment in one or more product candidates, even if our product candidates obtain
marketing approval. Our ability to commercialize our product candidates will depend in part on the extent to which coverage and reimbursement
for these products and related treatments will be available from third-party payors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
significant trend within the healthcare industry is cost containment, both in the United States and elsewhere. Third-party payors, whether
foreign or domestic, or governmental or commercial, are developing increasingly sophisticated methods of controlling healthcare costs,
including use of formularies. Exclusion of a product from a formulary or other restrictions can significantly impact drug usage in the
patient population and beyond. Consequently, pharmaceutical companies compete to gain access to formularies for their products, typically
on the basis of unique product features, such as greater efficacy, better patient ease of use, or fewer side effects, as well as the
overall cost of the therapy. Certain third-party payors are requiring that companies provide them with predetermined discounts from list
prices, are using preferred drug lists to leverage greater discounts in competitive classes, are disregarding therapeutic differentiators
within classes, are challenging the prices charged for therapeutics, and are negotiating price concessions based on performance goals.
In addition, third-party payors are increasingly requiring higher levels of evidence of the benefits and clinical outcomes of new technologies,
benchmarking against other therapies, seeking performance-based discounts, and challenging the prices charged. We cannot be sure that
coverage will be available for any product candidate that we commercialize and, if available, that the reimbursement rates will be adequate.
If payors subject our product candidates to maximum payment amounts, or impose limitations that make it difficult to obtain reimbursement,
providers may choose to use therapies which are less expensive when compared to our product candidates. Additionally, if payors require
high copayments, beneficiaries may seek alternative therapies. We may need to conduct post-marketing studies in order to demonstrate
the cost-effectiveness of any products to the satisfaction of hospitals, other target customers and their third-party payors. Such studies
might require us to commit a significant amount of management time and financial and other resources. Our products might not ultimately
be considered cost-effective. Adequate third-party coverage and reimbursement might not be available to enable us to maintain price levels
sufficient to realize an appropriate return on investment in product development.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>


<!-- Field: Page; Sequence: 79; Value: 2 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->77<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, in the United States, no uniform policy of coverage and reimbursement for products exists among third-party payors. Therefore,
coverage and reimbursement for products can differ significantly from payor to payor. Further, we believe that future coverage and reimbursement
will likely be subject to increased restrictions both in the United States and in international markets. Third-party coverage and reimbursement
for our products or product candidates for which we receive regulatory approval may not be available or adequate in either the United
States or international markets, which could have a negative effect on our business, financial condition, results of operations, stock
price and prospects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
may also be delays in obtaining coverage and reimbursement for newly approved therapeutics, and coverage may be more limited than the
indications for which the product is approved by the FDA or comparable foreign regulatory authorities. Such delays have made it increasingly
common for manufacturers to provide newly approved drugs to patients experiencing coverage delays or disruption at no cost for a limited
period in order to ensure that patients are able to access the drug. Moreover, eligibility for reimbursement does not imply that any
therapeutic will be paid for in all cases or at a rate that covers our costs, including research, development, manufacture, sale, and
distribution. Interim reimbursement levels for new therapeutics, if applicable, may also not be sufficient to cover our costs and may
only be temporary. Reimbursement rates may vary, by way of example, according to the use of the product and the clinical setting in which
it is used. Reimbursement rates may also be based on reimbursement levels already set for lower cost products or may be incorporated
into existing payments for other services.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">An
inability to promptly obtain coverage and adequate reimbursement from third-party payors for any of our product candidates for which
we obtain marketing approval could have a material adverse effect on our operating results, our ability to raise capital needed to commercialize
products and our overall financial condition.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
are subject to new legislation, regulatory proposals and third-party payor initiatives that may increase our costs of compliance, and
adversely affect our ability to market our products, obtain collaborators, and raise capital.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the United States and some foreign jurisdictions, there have been a number of legislative and regulatory changes and proposed changes
regarding the healthcare system that could prevent or delay marketing approval of our product candidates, restrict or regulate post-approval
activities and affect our ability to profitably sell any products for which we obtain marketing approval. We expect that current laws,
as well as other healthcare reform measures that may be adopted in the future, may result in more rigorous coverage criteria and in additional
downward pressure on the price that we may receive for any approved products.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
example, the ACA was passed in March 2010 and substantially changed the way healthcare is financed by both governmental and private insurers,
and continues to significantly impact the United States pharmaceutical industry.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
have been executive, judicial and congressional challenges to certain aspects of the ACA. For example, legislation enacted in 2017, informally
titled the Tax Cuts and Jobs Act of 2017 (the Tax Act), includes a provision repealing, effective January 1, 2019, the tax-based shared
responsibility payment imposed by the ACA on certain individuals who fail to maintain qualifying health coverage for all or part of a
year that is commonly referred to as the &#8220;individual mandate.&#8221; On June 17, 2021 the U.S. Supreme Court dismissed a challenge
on procedural grounds that argued the ACA is unconstitutional in its entirety because the &#8220;individual mandate&#8221; was repealed
by Congress. Thus, the ACA will remain in effect in its current form. Further, prior to the U.S. Supreme Court ruling, on January 28,
2021, President Biden issued an executive order that initiated a special enrollment period for purposes of obtaining health insurance
coverage through the ACA marketplace. The executive order also instructed certain governmental agencies to review and reconsider their
existing policies and rules that limit access to healthcare, including among others, reexamining Medicaid demonstration projects and
waiver programs that include work requirements, and policies that create unnecessary barriers to obtaining access to health insurance
coverage through Medicaid or the ACA. In addition, on August 16, 2022, President Biden signed the Inflation Reduction Act of 2022 (the
IRA) into law, which among other things, extends enhanced subsidies for individuals purchasing health insurance coverage in ACA marketplaces
through plan year 2025. The IRA also eliminates the &#8220;donut hole&#8221; under the Medicare Part D program beginning in 2025 by significantly
lowering the beneficiary maximum out-of-pocket cost through a newly established manufacturer discount program. It is possible that the
ACA will be subject to judicial or Congressional challenges in the future. It is unclear how any such challenges and the healthcare reform
measures of the Biden administration will impact the ACA and our business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>


<!-- Field: Page; Sequence: 80; Value: 2 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->78<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
legislative changes have been proposed and adopted in the United States since the ACA. For example, through the process created by the
Budget Control Act of 2011, there are automatic reductions of Medicare payments to providers up to 2% per fiscal year, which went into
effect in April 2013 and, following passage of the Bipartisan Budget Act of 2018 (BBA) and the Infrastructure Investment and Jobs Act,
will remain in effect until 2031 unless additional Congressional action is taken.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, there have been a number of other legislative and regulatory proposals aimed at changing the biopharmaceutical industry. For
instance, the Drug Quality and Security Act of 2013 imposes obligations on manufacturers of biopharmaceutical products related to product
tracking and tracing. Further, manufacturers have product investigation, quarantine, disposition, and notification responsibilities related
to counterfeit, diverted, stolen, and intentionally adulterated products that would result in serious adverse health consequences of
death to humans, as well as products that are the subject of fraudulent transactions or which are otherwise unfit for distribution such
that they would be reasonably likely to result in serious health consequences or death.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Compliance
with the federal track and trace requirements may increase our operational expenses and impose significant administrative burdens. As
a result of these and other new proposals, we may determine to change our current manner of operation, provide additional benefits or
change our contract arrangements, any of which could have a material adverse effect on our business, financial condition, results of
operations, stock price and prospects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
has been heightened governmental scrutiny in the United States of pharmaceutical pricing practices in light of the rising cost of prescription
drugs and biological products. Such scrutiny has resulted in presidential executive orders, congressional inquiries and proposed and
enacted federal and state legislation designed to, among other things, bring more transparency to product pricing, review the relationship
between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for products.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
the federal level, the Trump administration used several means to propose or implement drug pricing reform, including through federal
budget proposals, executive orders and policy initiatives. For example, on July 24, 2020 and September 13, 2020, the Trump administration
announced several executive orders related to prescription drug pricing that attempt to implement several of the administration&#8217;s
proposals. The FDA concurrently released a final rule and guidance in September 2020, implementing a portion of the importation executive
order providing pathways for states to build and submit importation plans for drugs from Canada. Further, on November 20, 2020, the U.S.
Department of Health and Human Services (HHS) finalized a regulation removing safe harbor protection for price reductions from pharmaceutical
manufacturers to plan sponsors under Part D, either directly or through pharmacy benefit managers, unless the price reduction is required
by law. The rule also creates a new safe harbor for price reductions reflected at the point-of-sale, as well as a new safe harbor for
certain fixed fee arrangements between pharmacy benefit managers and manufacturers. The implementation of the rule has been delayed until
2032. In July 2021, the Biden administration released an executive order, &#8220;Promoting Competition in the American Economy,&#8221;
with multiple provisions aimed at prescription drugs. In response to Biden&#8217;s executive order, on September 9, 2021, HHS released
a Comprehensive Plan for Addressing High Drug Prices that outlines principles for drug pricing reform and sets out a variety of potential
legislative policies that Congress could pursue as well as potential administrative actions HHS can take to advance these principles.
In addition, the IRA directs the Secretary of HHS to establish a Drug Price Negotiation Program (the Program) to lower prices for certain
single-source prescription drugs and biologics covered under Medicare Parts B and D, based on criteria established under the IRA. Under
the Program, the Secretary of HHS will publish a list of &#8220;selected drugs,&#8221; and will then negotiate maximum fair prices (MFP)
with their manufacturers. Beginning in 2026, the first year of the Program, the number will be limited to 10 Part D drugs and biologics.
By 2029, and in subsequent years thereafter, the number will increase to 20 drugs and biologics covered under Part D and Part B. Agreements
between HHS and manufacturers will remain in place until a drug or biologic is no longer considered a &#8220;selected drug&#8221; for
negotiation purposes. Manufacturers who do not comply with the negotiated prices set under the Program will be subject to an excise tax
based on a percentage of total sales of a &#8220;selected drug&#8221; up to 95% and the potential of civil monetary penalties. Additionally,
on March 11, 2021, President Biden signed the American Rescue Plan Act of 2021 into law, which eliminates the statutory Medicaid drug
rebate cap, currently set at 100% of a drug&#8217;s average manufacturer price, for single source and innovator multiple source drugs,
beginning January 1, 2024.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>


<!-- Field: Page; Sequence: 81; Value: 2 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->79<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
the state level, legislatures have increasingly passed legislation and implemented regulations designed to control pharmaceutical and
biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and
marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk
purchasing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
new laws or regulations, including those that may result in additional reductions in Medicare and other healthcare funding, could have
a material adverse effect on customers for our products, if approved, and, accordingly, on our results of operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
expect that the ACA, as well as other federal and state healthcare reform measures that may be adopted in the future, may result in more
rigorous coverage criteria, increased regulatory burdens and operating costs, decreased net revenue from our biopharmaceutical products,
decreased potential returns from our development efforts, and additional downward pressure on the price that we receive for any approved
product. Any reduction in reimbursement from Medicare or other government healthcare programs may result in a similar reduction in payments
from private payors. The implementation of cost containment measures or other healthcare reforms may prevent us from commercializing
our products and being able to generate revenue, and we could be prevented from or significantly delayed in achieving profitability.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
are subject to the U.S. Foreign Corrupt Practices Act and other anti-corruption laws, as well as import and export control laws, customs
laws, sanctions laws and other laws governing our operations. If we fail to comply with these laws, we could be subject to civil or criminal
penalties, and other consequences, which could adversely affect our business, financial condition, results of operations, stock price
and prospects.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
operations are subject to anti-corruption laws, including the U.S. Foreign Corrupt Practices Act (FCPA) and other anti-corruption laws
that apply in countries where we do business. The FCPA and these other anti-corruption laws generally prohibit us and our employees and
intermediaries from authorizing, promising, offering, providing, soliciting, or receiving, directly or indirectly, corrupt or improper
payments or anything else of value to or from recipients in the public or private sector. We can be held liable for the corrupt or other
illegal activities of our personnel or intermediaries, even if we do not explicitly authorize or have prior knowledge of such activities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are also subject to other laws and regulations governing our international operations, including applicable import and export control
regulations, economic sanctions on countries and persons, anti-money laundering laws, customs requirements and currency exchange regulations,
collectively referred to as the trade control laws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
can provide no assurance that we will be completely effective in ensuring our compliance with all applicable anti-corruption laws or
other legal requirements, including trade control laws. If we are not in compliance with applicable anti-corruption laws or trade control
laws, we may be subject to criminal and civil penalties, disgorgement and other sanctions and remedial measures, and legal expenses,
which could have an adverse impact on our business, financial condition, results of operations, stock price and prospects. In addition,
we cannot predict the nature, scope or effect of future regulatory requirements to which our international operations might be subject
or the manner in which existing laws might be administered or interpreted. An investigation of any potential violations of anti-corruption
laws or trade control laws by U.S. or other authorities could also have an adverse impact on our reputation, our business, financial
condition, results of operations, stock price and prospects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
are subject to stringent and evolving U.S. and foreign laws, regulations, rules, contractual obligations, policies and other obligations
related to data privacy and security. Our actual or perceived failure to comply with such obligations could lead to regulatory investigations
or actions; litigation; fines and penalties; disruptions of our business operations; reputational harm; loss of revenue or profits; loss
of customers or sales; and other adverse business consequences.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the ordinary course of business, we process, generate, use, transfer, disclose, make accessible, protect, secure, dispose of, transmit,
and share (collectively, processing) personal data and other sensitive information, including proprietary and confidential business data,
trade secrets, intellectual property, data we collect about trial participants in connection with clinical trials, sensitive third-party
data, and patient information. Our data processing activities may subject us to numerous data privacy and security obligations, such
as various laws, regulations, guidance, industry standards, external and internal privacy and security policies, contracts, and other
obligations that govern the processing of personal data by us and on our behalf.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>


<!-- Field: Page; Sequence: 82; Value: 2 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->80<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may be subject to or affected by evolving federal, state and foreign data protection laws and regulations, such as laws and regulations
that address privacy and data security. In the United States, federal, state, and local governments have enacted numerous data privacy
and security laws, including data breach notification laws, personal data privacy laws, and consumer protection laws (e.g. Section 5
of the Federal Trade Commission Act). For example, HIPAA as amended by the Health Information Technology for Economic and Clinical Health
Act (HITECH), imposes specific requirements relating to the privacy, security, and transmission of individually identifiable health information.
We may obtain health information or other personal information from third parties, including research institutions from which we obtain
clinical trial data, that are subject to privacy and security requirements under HIPAA. While we do not believe that we are currently
acting as a covered entity or business associate under HIPAA and thus are not directly regulated under HIPAA, any person may be prosecuted
under HIPAA&#8217;s criminal provisions if it knowingly receives individually identifiable health information from a HIPAA-covered healthcare
provider or research institution that has not satisfied HIPAA&#8217;s requirements for disclosure of individually identifiable health
information under aiding-and-abetting or conspiracy principles.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain
states have also adopted data privacy and security laws and regulations, which govern the privacy, processing and protection of health-related
and other personal information. Such laws and regulations will be subject to interpretation by various courts and other governmental
authorities, thus creating potentially complex compliance issues for us and our future customers and strategic partners. For example,
the California Consumer Privacy Act of 2018 (CCPA) imposes obligations on covered businesses. These obligations include, but are not
limited to, providing specific disclosures in privacy notices and affording California residents certain rights related to their personal
data. The CCPA allows for statutory fines for noncompliance (up to $7,500 per violation). Although the CCPA exempts some data processed
in the context of clinical trials, the CCPA may increase compliance costs and potential liability with respect to other personal data
we may maintain about California residents. The California Privacy Rights Act of 2020 (CPRA), effective January 1, 2023, further expanded
the CCPA in California by adding additional consumer rights and obligations for businesses. In addition, the CPRA established the California
Privacy Protection Agency, which is tasked with CRPA implementation and enforcement, among other responsibilities. Other states have
enacted data privacy laws. For example, Virginia passed the Consumer Data Protection Act, and Colorado passed the Colorado Privacy Act,
both of which became effective in 2023. In addition, data privacy and security laws have been proposed at the federal, state, and local
levels in recent years, which could further complicate compliance efforts.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outside
the United States, an increasing number of laws, regulations, and industry standards apply to data privacy and security. For example,
the European Union&#8217;s General Data Protection Regulation (EU GDPR), the United Kingdom&#8217;s GDPR (UK GDPR), and the Swiss Federal
Act on Data Protection impose strict requirements for processing personal data. For example, under the EU GDPR, government regulators
may impose temporary or definitive bans on data processing, as well as fines of up to 20 million euros or 4% of annual global revenue,
whichever is greater. Further, individuals or consumer protection organizations authorized at law to represent their interests may initiate
litigation related to processing of individuals&#8217; personal data.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Compliance
with U.S. and foreign data protection laws and regulations could require us to take on more onerous obligations in our contracts, in
addition to direct compliance obligations under those laws. We may be directly or contractually subject to data privacy and security
obligations, including industry standards adopted by industry groups and may become subject to new data privacy and security obligations
in the future. For example, certain privacy laws, such as the EU GDPR and the CCPA, require companies to impose specific contractual
restrictions on their service providers. Moreover, clinical trial subjects about whom we or our potential collaborators obtain information,
as well as the providers who share this information with us, may contractually limit our ability to use and disclose the information.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the ordinary course of business, we may transfer personal data from Europe and other jurisdictions to the United States or other countries.
Europe and other jurisdictions have enacted laws requiring data to be localized or limiting the transfer of personal data to other countries.
In particular, Europe has significantly restricted the transfer of personal data to the United States and other countries whose privacy
laws it believes are inadequate. Other jurisdictions may adopt similarly stringent interpretations of their data localization and cross-border
data transfer laws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>


<!-- Field: Page; Sequence: 83; Value: 2 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->81<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Although
there are currently various mechanisms that may be used to transfer personal data from Europe to the United States in compliance with
law, such as the EU and UK&#8217;s standard contractual clauses, these mechanisms are subject to legal challenges, and there is no assurance
that we can satisfy or rely on these measures to lawfully transfer personal data to the United States.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
there is no lawful manner for us to transfer personal data from Europe or other jurisdictions to the United States, or if the requirements
for a legally-compliant transfer are too onerous, we could face significant adverse consequences, including the interruption or degradation
of our operations, the need to relocate part of or all of our business or data processing activities to other jurisdictions at significant
expense, increased exposure to regulatory actions, substantial fines and penalties, the inability to transfer data and work with partners,
vendors and other third parties, which could limit our ability to conduct clinical trial activities in Europe or elsewhere, and injunctions
against our processing or transferring of personal data necessary to operate our business. Some European regulators have prevented companies
from transferring personal data out of Europe for allegedly violating the GDPR and EU&#8217;s cross-border data transfer limitations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Obligations
related to data privacy and security are quickly changing in an increasingly stringent fashion, creating some uncertainty as to the effective
future legal framework. Additionally, these obligations may be subject to differing applications and interpretations, which may be inconsistent
or conflict among jurisdictions. Preparing for and complying with these obligations requires significant resources and may necessitate
changes to our information technologies, systems, and practices and to those of any third parties that process personal data on our behalf.
Although we endeavor to comply with all applicable data privacy and security obligations, we may at times fail (or be perceived to have
failed) to do so. We may also be bound by contractual obligations related to data privacy and security, and our efforts to comply with
such obligations may not be successful. Additionally, we publish privacy policies, self-certifications, and other documentation regarding
our collection, use and disclosure of personal information and/or other confidential information. Although we endeavor to comply with
our published policies, certifications, and documentation, we may at times fail to do so or may be perceived to have failed to do so.
Moreover, despite our efforts, our personnel or third parties upon whom we rely may fail to comply with such obligations. Such failures
can subject us to potential international, local, state and federal action if they are found to be deceptive, unfair, or misrepresentative
of our actual practices, which could negatively impact our business operations and compliance posture. For example, any failure by a
third-party processor to comply with applicable law, regulations, or contractual obligations could result in adverse effects, including
inability to or interruption in our ability to operate our business and proceedings against us by governmental entities or others. If
we fail, or are perceived to have failed, to address or comply with data privacy and security obligations, we could face significant
consequences. These consequences may include, but are not limited to, government enforcement actions (e.g., investigations, fines, penalties,
audits, inspections, and similar); litigation (including class-related claims); additional reporting requirements and/or oversight; bans
on processing personal data; orders to destroy or not use personal data; and imprisonment of company officials. Any of these events could
have a material adverse effect on our reputation, business, or financial condition, including but not limited to: loss of customers;
interruptions or stoppages in our business operations (including, as relevant, clinical trials); inability to process personal data or
to operate in certain jurisdictions; limited ability to develop or commercialize our products; expenditure of time and resources to defend
any claim or inquiry; adverse publicity; or revision or restructuring of our operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Violations
of or liabilities under environmental, health and safety laws and regulations could subject us to fines, penalties or other costs that
could have a material adverse effect on the success of our business.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are subject to numerous federal, state and local environmental, health and safety laws and regulations, including those governing laboratory
procedures, the handling, use, storage, treatment and disposal of hazardous materials and wastes and the cleanup of contaminated sites.
Our operations involve the controlled production, storage, use and disposal of hazardous and flammable materials, including chemicals
and biological materials such as infectious agents and various radioactive compounds. We would incur substantial costs as a result of
violations of or liabilities under environmental requirements in connection with our operations or property, including fines, penalties
and other sanctions, investigation and cleanup costs and third-party claims. Although we generally contract with third parties for the
disposal of hazardous materials and wastes from our operations, we cannot eliminate the risk of contamination or injury from these materials.
In the event of contamination or injury resulting from our use of hazardous materials, we could be held liable for any resulting damages,
and any liability could exceed our resources. We also could incur significant costs associated with civil or criminal fines and penalties,
as well as our curtailment of the use of these materials or even shutting down our facilities and operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>


<!-- Field: Page; Sequence: 84; Value: 2 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->82<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Although
we maintain workers&#8217; compensation insurance to cover us for costs and expenses we may incur due to injuries to our employees resulting
from the use of hazardous materials, this insurance may not provide adequate coverage against potential liabilities. While we maintain
insurance covering our manufacturing facility only, and not our other facilities, for environmental liability or toxic tort claims that
may be asserted against us in connection with our storage or disposal of biological or hazardous materials, such insurance coverage may
not be sufficient to cover extraordinary or unanticipated events at our manufacturing facility.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Risks
Related to Ownership of Our Common Stock</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Future
sales of our common stock, or the perception in the public markets that these sales may occur, could cause the market price for our common
stock to decline.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sales
of a substantial number of shares of our common stock in the public market could occur at any time, subject to the restrictions and limitations
described below. If our stockholders sell, or the market perceives that our stockholders intend to sell, substantial amounts of our common
stock in the public market, the market price of our common stock could decline significantly.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have reserved 1,650,000 shares of common stock for issuance under our 2023 Equity Incentive Plan, and we have issued a total of 80,000
restricted stock and/or restricted stocks to our independent directors and consultants. We cannot predict the effect, if any, that market
sales of shares of our common stock or the availability of shares of our common stock for sale will have on the market price of our common
stock prevailing from time to time. Sales of substantial amounts of shares of our common stock in the public market, or the perception
that those sales will occur, could cause the market price of our common stock to decline.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Such
shares are registered on Form S-8 and will be available for sale in the public market subject to vesting arrangements and exercise of
options, the lock-up agreements described above and, in the case of our affiliates, the restrictions of Rule 144 under the Securities
Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally,
the holders of certain shares of our common stock, or their transferees, have rights, subject to certain conditions, to require us to
file one or more registration statements covering their shares or to include their shares in registration statements that we may file
for ourselves or other stockholders. If we were to register the resale of those shares, they could be freely sold in the public market
without limitation. If these additional shares are sold, or if it is perceived that they will be sold, in the public market, the trading
price of our common stock could decline.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Financings
could adversely affect common stock ownership interest and rights in comparison with those of other security holders.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
board of directors, in accordance with our Certificate of Incorporation and Bylaws, has the power to issue additional shares of common
stock or preferred stock without stockholder approval. If additional funds are raised through the issuance of equity or convertible debt
securities, the percentage ownership of our existing stockholders will be reduced, and these newly issued securities may have rights,
preferences or privileges senior to those of existing stockholders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
board of directors may establish the rights, privileges, preferences and restrictions, including voting rights, of future series of stock
and to issue such stock without approval from our shareholders. The rights of holders of common stock may suffer as a result of the rights
granted to holders of preferred stock that may be issued in the future. In addition, we could issue preferred stock to prevent a change
in control of our Company, depriving common shareholders of an opportunity to sell their stock at a price in excess of the prevailing
market price.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>


<!-- Field: Page; Sequence: 85; Value: 2 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->83<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we issue any additional common stock or securities convertible into common stock, such issuance will reduce the proportionate ownership
and voting power of each other stockholder. In addition, such stock issuances might result in a reduction of the per share book value
of our common stock and result in what is more commonly known as dilution. We may issue further shares as consideration for the cash
or assets or services out of our authorized but unissued common stock that would, upon issuance, represent a majority of the voting power
and equity of our Company. The result of such an issuance would be those new stockholders and management would control our Company, and
persons unknown could replace our management at that time. Such an occurrence would result in a greatly reduced percentage of ownership
of our Company by our current stockholders, which could present significant risks to stockholders. The Company may raise capital in the
futures in &#8220;down rounds&#8221; at a lower per share price than the trading price for our stock, which would be dilutive to prior
investors, and there can be no assurance that future rounds will not be necessary that would be dilutive to investors in the current
round. Investors may experience dilution in any future financing conducted by the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
may not be able to maintain a listing of our common stock on NYSE American.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
must meet certain financial and liquidity criteria to maintain our listing on NYSE American. If we violate the listing requirements of
such stock exchange, or if we fail to meet any of such exchange&#8217;s continued listing standards, our common stock may be delisted.
In addition, our board of directors may determine that the cost of maintaining our listing on a national securities exchange outweighs
the benefits of such listing. A delisting of our common stock from NYSE American may materially impair our stockholders&#8217; ability
to buy and sell our common stock and could have an adverse effect on the market price of, and the efficiency of the trading market for,
our common stock. The delisting of our common stock could significantly impair our ability to raise capital and the value of your investment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>If
our shares of common stock become subject to the penny stock rules, it would become more difficult to trade our shares.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
SEC has adopted rules that regulate broker-dealer practices in connection with transactions in penny stocks. Penny stocks are generally
equity securities with a price of less than $5.00, other than securities registered on certain national securities exchanges or authorized
for quotation on certain automated quotation systems, provided that current price and volume information with respect to transactions
in such securities is provided by the exchange or system. If we do not maintain a listing on NYSE American or another national securities
exchange and if the price of our common stock is less than $5.00, our common stock could be deemed a penny stock. The penny stock rules
require a broker-dealer, before a transaction in a penny stock not otherwise exempt from those rules, to deliver a standardized risk
disclosure document containing specified information. In addition, the penny stock rules require that before effecting any transaction
in a penny stock not otherwise exempt from those rules, a broker-dealer must make a special written determination that the penny stock
is a suitable investment for the purchaser and receive (i) the purchaser&#8217;s written acknowledgment of the receipt of a risk disclosure
statement; (ii) a written agreement to transactions involving penny stocks; and (iii) a signed and dated copy of a written suitability
statement. These disclosure requirements may have the effect of reducing the trading activity in the secondary market for our common
stock, and therefore stockholders may have difficulty selling their shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>While
we are not a controlled company, our chairman of the board of directors presently has control over key decision making as a result of
his control of a majority of our voting stock and exercises significant voting power.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">John
S. Yu, our Chairman, and CEO, has the right to exercise voting rights with respect to an aggregate of 5,341,837 shares of common stock,
which represents approximately 36.00% of the voting power of our outstanding capital stock. &#160;As a result, Dr. Yu has the ability
to substantially control the outcome of matters submitted to our stockholders for approval, including the election of directors and any
merger, consolidation, or sale of all or substantially all of our assets. This could delay, defer, or prevent a change of control, merger,
consolidation, or sale of all or substantially all of our assets that our other stockholders support, or conversely this concentrated
control could result in the consummation of such a transaction that our other stockholders do not support. This could also discourage
a potential investor from acquiring our common stock due to the limited voting power of such stock relative to the shares of common stock
and might harm the market price of our common stock. In addition, Dr. Yu has the ability to substantially control the management and
major strategic investments of our Company as a result of his position as our CEO and his ability to control the election or replacement
of our directors. In the event of his death, the shares of our capital stock that Dr. Yu owns will be transferred to the persons or entities
that he designates. As a board member and officer, Dr. Yu owes a fiduciary duty to our stockholders and must act in good faith in a manner
he reasonably believes to be in the best interests of our stockholders. As a stockholder, even a controlling stockholder, Dr. Yu is entitled
to vote his shares in his own interests, which may not always be in the interests of our stockholders generally.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>


<!-- Field: Page; Sequence: 86; Value: 2 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->84<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Concentration
of ownership of our common stock among our existing executive officers, directors, and principal stockholders may prevent new investors
from influencing significant corporate decisions and matters submitted to stockholders for approval.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of the date of this Annual Report, our executive officers, directors, and current beneficial owners of 5% or more of our capital
stock and their respective affiliates hold, in the aggregate, beneficially own 37.2% of our outstanding common stock, based on
21,411,198 shares of our common stock outstanding as of March 31, 2026. &#160;As a result, these persons, acting together, would
be able to significantly influence all matters requiring stockholder approval, including the election and removal of directors, any
merger, consolidation, or sale of all or substantially all of our assets, or other significant corporate transactions. In addition,
these persons, acting together, may have the ability to control the management and affairs of our Company. Accordingly, this
concentration of ownership may harm the market price of our common stock by:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">delaying,
    deferring, or preventing a change in control;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">entrenching
    our management and/or the board of directors;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">impeding
    a merger, consolidation, takeover, or other business combination involving us; or</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">discouraging
    a potential acquirer from making a tender offer or otherwise attempting to obtain control of us.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, some of these persons or entities may have interests different than yours. For example, because many of these stockholders
purchased their shares at prices substantially below the price and have held their shares for a longer period, they may be more interested
in selling our Company to an acquirer than other investors, or they may want us to pursue strategies that deviate from the interests
of other stockholders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Provisions
in our corporate charter documents and under Delaware law could make an acquisition of our Company, which may be beneficial to our stockholders,
more difficult and may prevent attempts by our stockholders to replace or remove our current management.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Provisions
in our certificate of incorporation and our bylaws may discourage, delay or prevent a merger, acquisition, or other change in control
of our Company that stockholders may consider favorable, including transactions in which you might otherwise receive a premium for your
shares. These provisions also could limit the price that investors might be willing to pay in the future for shares of our common stock,
thereby depressing the market price of our common stock. In addition, because our board of directors is responsible for appointing the
members of our management team, these provisions may frustrate or prevent any attempts by our stockholders to replace or remove our current
management by making it more difficult for stockholders to replace members of our board of directors. Among other things, these provisions:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">allow
    the authorized number of our directors to be changed only by resolution of our board of directors;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">limit
    the manner in which stockholders can remove directors from the board of directors;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">establish
    advance notice requirements for stockholder proposals that can be acted on at stockholder meetings and nominations to our board of
    directors;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">require
    that stockholder actions must be effected at a duly called stockholder meeting and prohibit actions by our stockholders by written
    consent;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">limit
    who may call stockholder meetings;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">authorize
    our board of directors to issue preferred stock without stockholder approval, which could be used to institute a stockholder rights
    plan, or so-called &#8220;poison pill,&#8221; that would work to dilute the stock ownership of a potential hostile acquirer, effectively
    preventing acquisitions that have not been approved by our board of directors; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">require
    the approval of the holders of at least 66 2/3% of the votes that all our stockholders would be entitled to cast to amend or repeal
    certain provisions of our charter or bylaws.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>


<!-- Field: Page; Sequence: 87; Value: 2 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->85<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Moreover,
because we are incorporated in Delaware, we are governed by the provisions of Section 203 of the Delaware General Corporation Law, or
the DGCL, which prohibits a person who owns in excess of 15% of our outstanding voting stock from merging or combining with us for a
period of three years after the date of the transaction in which the person acquired more than 15% of our outstanding voting stock, unless
the merger or combination is approved in a prescribed manner. These provisions could discourage potential acquisition proposals and could
delay or prevent a change in control transaction. They could also have the effect of discouraging others from making tender offers for
our common stock, including transactions that may be in your best interests. These provisions may also prevent changes in our management
or limit the price that investors are willing to pay for our stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Our
certificate of incorporation provides that unless we consent in writing to the selection of an alternative forum, and except for actions
brought under the Securities Act or the Exchange Act, the Court of Chancery of the State of Delaware will be the exclusive forums for
substantially all disputes between us and our stockholders. In addition, our exclusive forum provision may result in increased costs
for investors to bring a claim.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
certificate of incorporation provides that unless we consent in writing to the selection of an alternative forum, and except for actions
brought under the Securities Act or the Exchange Act, the Court of Chancery of the State of Delaware is the exclusive forum for:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    derivative action or proceeding brought on our behalf;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    action asserting a breach of fiduciary duty;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    action asserting a claim against us arising pursuant to any provision of the DGCL or our certificate of incorporation or bylaws;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    action or proceeding to interpret, apply, enforce, or determine the validity of our certificate of incorporation, or our bylaws;
    and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    action asserting a claim against us or any of our directors, officers, employees, or agents that is governed by the internal-affairs
    doctrine.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
person purchasing or otherwise acquiring or holding any interest in shares of our capital stock is deemed to have received notice of
and consented to the foregoing provisions. These choice of forum provisions may limit a stockholder&#8217;s ability to bring a claim
in a judicial forum that it finds more favorable for disputes with us or with our directors, officers, other employees or agents, or
our other stockholders, which may discourage such lawsuits against us and such other persons or may result in additional expense to a
stockholder seeking to bring a claim against us. Alternatively, if a court were to find this choice of forum provision inapplicable to,
or unenforceable in respect of, one or more of the specified types of actions or proceedings, we may incur additional costs associated
with resolving such matters in other jurisdictions, which could adversely affect our business, results of operations, financial condition,
and prospects. In addition, our exclusive forum provision may result in increased costs for investors to bring a claim.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
choice of forum provision in our certificate of incorporation specifically excludes actions brought under the Securities Act or Exchange
Act. Section 27 of the Exchange Act creates exclusive federal jurisdiction over all claims brought to enforce any duty or liability created
by the Exchange Act or the rules and regulations thereunder. Consequently, this forum selection provision would not apply to suits brought
to enforce a duty or liability created by the Exchange Act or any other claim for which the U.S. federal courts have exclusive jurisdiction.
Moreover, Section 22 of the Securities Act creates concurrent jurisdiction for federal and state courts over all claims brought to enforce
any duty or liability created by the Securities Act or the rules and regulations thereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">While
the Delaware courts have determined that such choice of forum provisions are facially valid, a stockholder may nevertheless seek to bring
a claim in a venue other than those designated in the exclusive forum provisions, and there can be no assurance that such provisions
will be enforced by a court in those other jurisdictions. We note that investors cannot waive compliance with the federal securities
laws and the rules and regulations thereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>


<!-- Field: Page; Sequence: 88; Value: 2 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->86<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
will have broad discretion in the use of proceeds from selling of our securities and may invest or spend the proceeds in ways with which
you do not agree and in ways that may not increase the value of your investment.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
management will have broad discretion in the application of our cash, including the net proceeds from selling our securities, and could
spend the proceeds in ways that do not improve our results of operations or enhance the value of our common stock. The failure by our
management to apply these funds effectively could result in financial losses that could have a negative impact on our business, cause
the price of our common stock to decline, and delay the development of our current in-development products and planned pipeline and expansion
programs as well as commercial preparedness. Pending their use, we may invest our cash, including the net proceeds from our IPO and following
equity offerings, in a manner that does not produce value or that loses value.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
do not anticipate paying any cash dividends on our capital stock in the foreseeable future, and accordingly, stockholders must rely on
capital appreciation, if any, for any return on their investment.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
do not anticipate paying any cash dividends on our common stock in the foreseeable future. Instead, we plan to retain any earnings to
maintain and expand our existing operations. In addition, any future credit facility or debt securities may contain terms prohibiting
or limiting the amount of dividends that may be declared or paid on our common stock. If we do not pay cash dividends, you could receive
a return on your investment in our common stock only if you are able to sell your shares in the future and the market price of our common
stock has increased when you sell your shares. As a result, investors seeking cash dividends should not purchase our common stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>General
Risk Factors</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>The
trading price of our common stock may be volatile, and you could lose all or part of your investment.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
trading price of our common stock could be highly volatile and could be subject to wide fluctuations in response to various factors,
some of which are beyond our control, including limited trading volume. The stock market in general and the market for biopharmaceutical
companies in particular have experienced extreme volatility that has often been unrelated to the operating performance of particular
companies. As a result of this volatility, investors may not be able to sell their shares at or above the price paid for the shares.
In addition to the factors discussed under this &#8220;Item1A Risk Factors&#8221; section and elsewhere in this Annul Report, these factors
include:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    commencement, enrollment, or results of our planned and future clinical trials;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    loss of any of our key research, development, or management personnel;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">regulatory
    or legal changes or developments in the United States and other countries or in the status of our regulatory approvals;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    success of competitive products or technologies;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    emergence of new competitors or new technologies;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to develop and market new and enhanced products on a timely basis;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">adverse
    actions taken by regulatory agencies with respect to our clinical trials or manufacturers;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
    or developments in laws or regulations applicable to our current in-development products or any future product candidates;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>


<!-- Field: Page; Sequence: 89; Value: 2 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->87<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
    to our relationships with collaborators, manufacturers, or suppliers;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    results of our testing and clinical trials;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">disruption
    to our operations or those of other sources critical to our operations;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">unanticipated
    safety, tolerability, or efficacy concerns;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">announcements
    by us or our competitors of acquisitions, new products, significant contracts, commercial relationships or capital commitments;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">other
    announcements concerning our competitors or the pharmaceutical industry in general;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">actual
    or anticipated fluctuations in our operating results or those of our competitors;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
    in financial estimates or recommendations by securities analysts;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">potential
    acquisitions;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    results of our efforts to discover, develop, acquire, or in-license additional product candidates;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">commencement
    of, or our involvement in, litigation;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">dilutive
    issuances of our stock or the stock of our subsidiaries, or the incurrence of additional debt;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
    in our board of directors or management;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">adoption
    of new or different accounting standards;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    trading volume of our common stock on NYSE American;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">sales
    of our common stock by us, our executive officers and directors or our stockholders or the anticipation that such sales may occur
    in the future;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">general
    economic, political, and market conditions and overall fluctuations in the financial markets in the United States or the United Kingdom
    (including those relating to macroeconomic events, such as  wars in the Middle East and between Russia and Ukraine);</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">stock
    market price and volume fluctuations of comparable companies and, in particular, those that operate in the biopharmaceutical industry;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">general
    economic conditions and slow or negative growth of related markets; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">investors&#8217;
    general perception of us and our business.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
and other market and industry factors may cause the market price and demand for our common stock to fluctuate substantially, regardless
of our actual operating performance, which may limit or prevent investors from selling their shares of our common stock at or above the
price paid for the shares and may otherwise negatively affect the liquidity of our common stock. In addition, the stock market in general,
and biopharmaceutical companies in particular, have experienced extreme price and volume fluctuations that have often been unrelated
or disproportionate to the operating performance of these companies. Some companies that have experienced volatility in the trading price
of their shares have been the subject of securities class action litigation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>


<!-- Field: Page; Sequence: 90; Value: 2 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->88<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Any
lawsuit to which we are a party, regardless of merit, may result in an unfavorable judgment. We also may decide to settle lawsuits on
unfavorable terms. Any such negative outcome could result in payments of substantial damages or fines, damage to our reputation or adverse
changes to our business practices.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
lawsuit to which we are a party, regardless of the merit of such lawsuit, may result in an unfavorable judgment. We also may decide to
settle lawsuits on unfavorable terms. Any such negative outcome could result in payments of substantial damages or fines, damage to our
reputation or adverse changes to our business practices. Defending against litigation is costly and time-consuming and could divert our
management&#8217;s attention and our resources. Furthermore, during the course of litigation, there could be negative public announcements
of the results of hearings, motions, or other interim proceedings or developments, which could have a negative effect on the market price
of our common stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>If
equity research analysts do not publish research or reports, or publish unfavorable research or reports, about us, our business, or our
market, our stock price and trading volume could decline.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
trading market for our common stock will be influenced by the research and reports that equity research analysts publish about us and
our business. We do not currently have and may never obtain research coverage by equity research analysts. Equity research analysts may
elect not to provide research coverage of our common stock, and such lack of research coverage may adversely affect the market price
of our common stock. In the event we do have equity research analyst coverage, we will not have any control over the analysts or the
content and opinions included in their reports. The price of our shares could decline if one or more equity research analysts downgrade
our shares or issue other unfavorable commentary or research about us. If one or more equity research analysts ceases coverage of us
or fails to publish reports on us regularly, demand for our shares could decrease, which in turn could cause the trading price or trading
volume of our common stock to decline.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
incur significantly costs as a result of operating as a company whose common stock is publicly traded in the United States, and our management
are required to devote substantial time to new compliance initiatives.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a public company in the United States, we incur significant legal, accounting, and other expenses. These expenses will likely be even
more significant after we no longer qualify as an emerging growth company. The Sarbanes-Oxley Act, the Dodd-Frank Wall Street Reform
and Consumer Protection Act, the listing requirements of NYSE American, and other applicable securities rules and regulations impose
various requirements on public companies in the United States, including the establishment and maintenance of effective disclosure and
financial controls and corporate governance practices. Our senior management and other personnel will need to devote a substantial amount
of time to these compliance initiatives. Moreover, these rules and regulations will increase our legal and financial compliance costs
and will make some activities more time-consuming and costly. For example, we expect that these rules and regulations may make it more
difficult and more expensive for us to obtain director and officer liability insurance, which in turn could make it more difficult for
us to attract and retain qualified senior management personnel or members for our board of directors. We cannot predict or estimate the
amount of additional costs we may incur or the timing of such costs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">However,
these rules and regulations are often subject to varying interpretations, in many cases due to their lack of specificity, and, as a result,
their application in practice may evolve over time as new guidance is provided by regulatory and governing bodies. This could result
in continuing uncertainty regarding compliance matters and higher costs necessitated by ongoing revisions to disclosure and governance
practices.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to Section 404, public companies are required to furnish a report by our senior management on our internal control over financial reporting.
However, as we are presently an emerging growth company, so long as we remain in the status, or up to five years, we will not be required
to include an attestation report on internal control over financial reporting issued by our independent registered public accounting
firm. At such time as we will be required to prepare for eventual compliance with Section 404, we will be required to engage in a process
to document and evaluate our internal control over financial reporting, which is both costly and challenging. In this regard, we will
need to continue to dedicate internal resources, potentially engage outside consultants, and adopt a detailed work plan to assess and
document the adequacy of internal control over financial reporting, continue steps to improve control processes as appropriate, validate
through testing that controls are functioning as documented, and implement a continuous reporting and improvement process for internal
control over financial reporting. Despite our efforts, there is a risk that we will not be able to conclude, within the prescribed timeframe
or at all, that our internal control over financial reporting is effective as required by Section 404. Identifying material weaknesses
could result in an adverse reaction in the financial markets due to a loss of confidence in the reliability of our financial statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>


<!-- Field: Page; Sequence: 91; Value: 2 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->89<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Significant
disruptions of our information technology systems or data security incidents could result in significant financial, legal, regulatory,
business, and reputational harm to us.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are increasingly dependent on information technology systems and infrastructure, including mobile technologies, to operate our business.
In the ordinary course of our business, we collect, store, process, and transmit large amounts of sensitive information, including intellectual
property, proprietary business information, personal information, and other confidential information. It is critical that we do so in
a secure manner to maintain the confidentiality, integrity, and restricted availability of such sensitive information. We have also outsourced
elements of our operations, including elements of our information technology infrastructure, to third parties and, as a result, we manage
a number of third-party vendors who may or could have access to our computer networks or our confidential information. In addition, many
of those third parties in turn subcontract or outsource some of their responsibilities to other third parties. While all information
technology operations are inherently vulnerable to inadvertent or intentional security breaches, incidents, attacks, and exposures, the
accessibility and distributed nature of our information technology systems, and the sensitive information stored on those systems, make
such systems potentially vulnerable to unintentional or malicious, internal, and external attacks on our technology environment. Potential
vulnerabilities can be exploited from inadvertent or intentional actions of our employees, third-party vendors, business partners, or
by malicious third parties. Attacks of this nature are increasing in their frequency, levels of persistence, sophistication, and intensity,
and are being conducted by sophisticated and organized groups and individuals with a wide range of motives (including industrial espionage)
and expertise, including organized criminal groups, &#8220;hacktivists,&#8221; nation states, and others. In addition to the extraction
of sensitive information, such attacks could include the deployment of harmful malware, ransomware, denial-of-service attacks, social
engineering, and other means to affect service reliability and threaten the confidentiality, integrity, and availability of information.
In addition, the prevalent use of mobile devices increases the risk of data security incidents.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Significant
disruptions of our or our third-party vendors&#8217; or business partners&#8217; information technology systems or other similar data
security incidents could adversely affect our business operations and result in the loss, misappropriation, and unauthorized access,
use or disclosure of, or the prevention of access to, sensitive information, which could result in financial, legal, regulatory, business,
and reputational harm to us. In addition, information technology system disruptions, whether from attacks on our technology environment
or from computer viruses, natural disasters, terrorism, war, and telecommunication and electrical failures, could result in a material
disruption of our development programs and our business operations. For example, the loss of clinical trial data from ongoing, completed
or future clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or
reproduce the data. We cannot ensure that our data protection efforts and our investment in information technology, or the efforts or
investments of CROs, consultants or other third parties with which we work, will prevent breakdowns or breaches in our or their systems
or other cybersecurity incidents that cause loss, destruction, unavailability, alteration, dissemination of, or damage, or unauthorized
access to, our data, including personal data, assets, and other data processed or maintained on our behalf, that could have a material
adverse effect upon our reputation, business, operations, or financial condition.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">While
we have implemented security measures intended to protect our information technology systems and infrastructure, there can be no assurance
that such measures will successfully prevent service interruptions or security incidents. There is no way of knowing with certainty whether
we have experienced any data security incidents that have not been discovered. While we have no reason to believe this to be the case,
attackers have become very sophisticated in the way they conceal access to systems, and many companies that have been attacked are not
aware that they have been attacked. Any event that leads to unauthorized access, use, or disclosure of personal information, including
personal information regarding our patients or employees, could disrupt our business, harm our reputation, compel us to comply with applicable
federal and state breach notification laws and foreign law equivalents, subject us to time-consuming, distracting, and expensive litigation,
regulatory investigation and oversight, mandatory corrective action, require us to verify the correctness of database contents, or otherwise
subject us to liability under laws, regulations, and contractual obligations, including those that protect the privacy and security of
personal information. This could result in increased costs to us, and result in significant legal and financial exposure and reputational
harm. In addition, any failure or perceived failure by us or our vendors or business partners to comply with our privacy, confidentiality,
or data security-related legal or other obligations to third parties, or any further security incidents or other inappropriate access
events, may result in governmental investigations, enforcement actions, regulatory fines, litigation, or public statements against us
by advocacy groups or others, and could cause third parties, including clinical sites, regulators, or current and potential partners,
to lose trust in us, or we could be subject to claims by third parties that we have breached our privacy- or confidentiality-related
obligations. Moreover, data security incidents and other inappropriate access can be difficult to detect, and any delay in identifying
them may lead to increased harm of the type described above. Any of the foregoing could have a material adverse effect on our reputation,
business, operations, or financial condition.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>


<!-- Field: Page; Sequence: 92; Value: 2 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->90<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
are an &#8220;emerging growth company&#8221; and as a result of the reduced disclosure and governance requirements applicable to emerging
growth companies, our common stock may be less attractive to investors.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are an &#8220;emerging growth company&#8221; as defined in the JOBS Act. For so long as we remain an emerging growth company, we are
permitted by SEC rules and plan to rely on exemptions from certain disclosure requirements that are applicable to other SEC-registered
public companies that are not emerging growth companies. These exemptions include not being required to comply with the auditor attestation
requirements of Section 404, not being required to comply with the auditor requirements to communicate critical audit matters in the
auditor&#8217;s report on the financial statements, reduced disclosure obligations regarding executive compensation, and exemptions from
the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments
not previously approved. As a result, the information we provide stockholders will be different than the information that is available
with respect to other public companies. We have taken advantage of reduced reporting burdens in this Annual Report. In particular, in
this Annual Report, we have provided only two years of audited financial statements and we have not included all of the executive compensation
related information that would be required if we were not an emerging growth company. We cannot predict whether investors will find our
common stock less attractive if we rely on these exemptions. If some investors find our common stock less attractive as a result, there
may be a less active trading market for our common stock, and our stock price may be more volatile.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, the JOBS Act provides that an emerging growth company can take advantage of an extended transition period for complying with
new or revised accounting standards. This allows an emerging growth company to delay the adoption of certain accounting standards until
those standards would otherwise apply to private companies. We have elected to avail ourselves of this exemption and, therefore, we will
not be subject to the same requirements to adopt new or revised accounting standards as other public companies that are not &#8220;emerging
growth companies.&#8221;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
are also classified as a &#8220;smaller reporting company&#8221; and are exempt from certain disclosure requirements, which could make
our stock less attractive to potential investors.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Rule
12b-2 of the Exchange Act defines a &#8220;smaller reporting company&#8221; as an issuer that is not an investment company, an asset-backed
issuer, or a majority-owned subsidiary of a parent that is not a smaller reporting company and that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Had
    a public float of less than $250 million as of the last business day of its most recently completed fiscal quarter, computed by multiplying
    the aggregate number of worldwide number of shares of its voting and non-voting common equity held by non-affiliates by the price
    at which the common equity was last sold, or the average of the bid and asked prices of common equity, in the principal market for
    the common equity; or</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
    the case of an initial registration statement under the Securities Act or the Exchange Act for shares of its common equity, had a
    public float of less than $250 million as of a date within 30 days of the date of the filing of the registration statement, computed
    by multiplying the aggregate worldwide number of such shares held by non-affiliates before the registration plus, in the case of
    a Securities Act registration statement, the number of such shares included in the registration statement by the estimated offering
    price of the shares; or</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
    the case of an issuer who had annual revenue of less than $100 million during the most recently completed fiscal year for which audit
    financial statements are available, had a public float as calculated under paragraph (1) or (2) of this definition that was either
    zero or less than $700 million.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a &#8220;smaller reporting company&#8221; we are not required and may not include a Compensation Discussion and Analysis section in our
proxy statements; we provide only three years of business development information; provide fewer years of selected data; and have other
&#8220;scaled&#8221; disclosure requirements that are less comprehensive than issuers that are not &#8220;smaller reporting companies&#8221;
which could make our stock less attractive to potential investors, which could make it more difficult for you to sell your shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>


<!-- Field: Page; Sequence: 93; Value: 2 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->91<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>As
a &#8220;smaller reporting company,&#8221; we may at some time in the future choose to exempt our Company from certain corporate governance
requirements that could have an adverse effect on our public shareholders.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
NYSE American rules, a &#8220;smaller reporting company,&#8221; as defined in Rule 12b-2 under the Exchange Act, is not subject to certain
corporate governance requirements otherwise applicable to companies listed on NYSE American. For example, a smaller reporting company
is exempt from the requirement of having a compensation committee composed solely of directors meeting certain enhanced independence
standards, as long as the compensation committee has at least two members who do meet such standards. Although we have determined not
to avail ourselves of this or other exemptions from NYSE American requirements that are or may be afforded to smaller reporting companies
while we will seek to maintain our shares on NYSE American, in the future we may elect to rely on any or all of these exemptions. By
electing to utilize any such exemptions, our Company may be subject to greater risks of poor corporate governance, poorer management
decision-making processes, and reduced results of operations from problems in our corporate organization. Consequently, if we were to
avail ourselves of these exemptions, our stock price might suffer, and there is no assurance that we would be able to continue to meet
all continued listing requirements of NYSE American from which we would not be exempt, including minimum stock price requirements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><B><I>Changes in funding for or disruption at the
FDA, the SEC and other government agencies, including from government shut downs, or other disruptions to these agencies&#8217; operations
could hinder their ability to hire and retain key leadership and other personnel, delay the review and approval of regulatory submissions,
limit the development or implementation of regulatory programs, prevent new products and services from being developed or commercialized
in a timely manner or otherwise prevent those agencies from performing normal business functions on which the operation of our business
may rely, which could negatively impact our business</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">Federal agencies in the United States, including the
FDA and the SEC, operate pursuant to annual appropriations and other political and budgetary processes, and may from time to time be subject
to continuing resolutions, funding lapses, or other fiscal constraints. Without appropriation of sufficient funding to federal agencies,
our business operations related to our product development activities for the U.S. market could be impacted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">The ability of the FDA to review and approve new products
can be affected by a variety of factors, including government budget and funding levels, the ability to hire and retain key personnel
and accept the payment of user fees, and statutory, regulatory and policy changes. Average review times at the agency have fluctuated
in recent years and may continue to fluctuate as a results of these factor as a result. In addition, government funding of the SEC and
other government agencies on which our operations may rely, including those that fund research and development activities, is subject
to the political process, which is inherently fluid and unpredictable. For example, the Trump administration has issued executive orders
seeking to greatly reduce the size of the federal workforce, including through layoffs and severance packages offered to employees of
federal agencies within the executive branch and independent agencies, including the FDA. Any such reduction in personnel may result in
longer review times by the FDA and other agencies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">Disruptions at the FDA and other agencies may also
slow the time necessary for new product candidates to be reviewed and/or approved by necessary government agencies, which would adversely
affect our business. For example, over the last several years, the U.S. government has shut down several times, most recently in October
1, 2025 through November 12, 2025, and certain regulatory agencies, such as the FDA and the SEC, have had to furlough critical employees
and stop critical activities. If a prolonged government shutdown occurs again, or if global health concerns or shortages in resources
prevent the FDA or other regulatory authorities from conducting their regulatory inspections, reviews or other regulatory activities,
including formal or informal interactions with product developers, it could significantly impact the ability of the FDA to timely review
and process our regulatory submissions, which could have a material adverse effect on our business. Further, future government shutdowns
could impact our ability to access the public markets and obtain necessary capital in order to properly capitalize and continue our operations
or delay the review or effectiveness of required regulatory or securities filings.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><B><I>The U.S. Congress, the Trump administration,
or any new administration may make substantial changes to fiscal, tax, and other federal policies that may adversely affect our business.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">With the start of the Trump Administration in 2025,
U.S. policy changes have been implemented at a rapid pace and additional changes are likely. Changes to U.S. policy implemented by the
U.S. Congress, the Trump administration or any new administration have impacted and may in the future impact, among other things, the
U.S. and global economy, international trade relations, unemployment, immigration, healthcare, taxation, the U.S. regulatory environment,
inflation and other areas. Although we cannot predict the impact, if any, of these changes to our business, they could adversely affect
our business. Until we know what policy changes are made, whether those policy changes are challenged and subsequently upheld by the court
system and how those changes impact our business and the business of our competitors over the long term, we will not know if, overall,
we will benefit from them or be negatively affected by them.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I></I></B></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Recent
and potential future changes to U.S. and non-U.S. tax laws could materially adversely affect our Company.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Existing,
new, or future changes in tax laws, regulations, and treaties, or the interpretation thereof, in addition to tax policy initiatives and
reforms under consideration in the United States or internationally and other initiatives could have an adverse effect on the taxation
of international businesses. Furthermore, countries where we are subject to taxes, including the United States, are independently evaluating
their tax policy and we may see significant changes in legislation and regulations concerning taxation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Recently
enacted U.S. tax legislation has significantly changed the U.S. federal income taxation of U.S. corporations, including by reducing the
U.S. corporate income tax rate, limiting interest deductions, and revising the rules governing NOLs. Many of these changes are effective
immediately, without any transition periods or grandfathering for existing transactions. The legislation is unclear in many respects
and could be subject to potential amendments and technical corrections, as well as interpretations and implementing regulations by the
Treasury and Internal Revenue Service, or the IRS, any of which could lessen or increase certain adverse impacts of the legislation.
In addition, it is unclear how these U.S. federal income tax changes will affect state and local taxation, which often uses federal taxable
income as a starting point for computing state and local tax liabilities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
reduction of the corporate tax rate under the legislation may cause a reduction in the economic benefit of deferred tax assets available
to us.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2025, we had federal and state net operating loss, or NOLs, carryforwards of approximately $9.9 million. &#160;Under
the Tax Cuts and Jobs Act of 2017, or the Tax Act, as modified by the Coronavirus Aid, Relief, and Economic Security Act, or the CARES
Act, our NOLs generated in tax years beginning after December 31, 2020 may be carried forward indefinitely, but the deductibility of
such federal NOLs in tax years beginning after December 31, 2020, is limited to 80% of taxable income. This change may require us to
pay federal income taxes in future years despite generating a loss for federal income tax purposes in prior years. It is uncertain if
and to what extent various states will conform to the Tax Act or the CARES Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, under Sections 382 and 383 of the U.S. Internal Revenue Code of 1986, as amended, or the Code, if a corporation undergoes an
&#8220;ownership change,&#8221; generally defined as a greater than 50 percentage point change (by value) in its equity ownership by
certain stockholders over a three-year period, the corporation&#8217;s ability to use its pre-change NOLs and other pre-change tax attributes
(such as research and development tax credits) to offset its post-change income or taxes may be limited. We may have experienced ownership
changes in the past and may experience ownership changes in the future as a result of subsequent shifts in our stock ownership (some
of which may be outside our control). As a result, our ability to use our pre-change NOLs and tax credits to offset post-change taxable
income, if any, could be subject to limitations. Similar provisions of state tax law may also apply. In addition, at the state level,
there may be periods during which the use of NOLs is suspended or otherwise limited, which could accelerate or permanently increase state
taxes owed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>


<!-- Field: Page; Sequence: 94; Value: 2 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->92<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are unable to predict what tax reform may be proposed or enacted in the future or what effect such changes would have on our business,
but such changes, to the extent they are brought into tax legislation, regulations, policies or practices, could affect our effective
tax rates in the future in countries where we have operations and have an adverse effect on our overall tax rate in the future, along
with increasing the complexity, burden, and cost of tax compliance. While some of the changes made by the tax legislation may adversely
affect us in one or more reporting periods and prospectively, other changes may be beneficial on a going-forward basis. We intend to
work with our tax advisors and auditors to determine the full impact that the recent tax legislation as a whole will have on us.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
urge our stockholders to consult with their legal and tax advisors with respect to any such legislative changes and the potential tax
consequences of investing in or holding our common stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Changes
in accounting standards and subjective assumptions, estimates and judgments by management related to complex accounting matters may materially
impact reporting of our financial condition and results of operations.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accounting
principles generally accepted in the United States and related accounting pronouncements, implementation guidelines, and interpretations
we apply to a wide range of matters that are relevant to our business, such as accounting for long-lived asset impairment and share-based
compensation, are complex and involve subjective assumptions, estimates and judgments by our management. Changes in these rules or their
interpretation or changes in underlying assumptions, estimates or judgments by our management could significantly change or add significant
volatility to our reported or expected financial performance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>A
potential failure to maintain effective internal control over financial reporting in accordance with Section 404 of the Sarbanes-Oxley
Act could have a material adverse effect on our business, financial condition, and results of operations.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
management is responsible for establishing and maintaining adequate internal control over financial reporting. Internal control over
financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation
of financial statements in accordance with U.S. generally accepted accounting principles, or GAAP. Under standards established by the
Public Company Accounting Oversight Board, or PCAOB, a deficiency in internal control over financial reporting exists when the design
or operation of a control does not allow management or personnel, in the normal course of performing their assigned functions, to prevent
or detect misstatements on a timely basis. The PCAOB defines a material weakness as a deficiency, or combination of deficiencies, in
internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of annual or interim
financial statements will not be prevented, or detected and corrected, on a timely basis.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
will be required, pursuant to Section 404 of the Sarbanes-Oxley Act, to furnish a report by management on, among other things, regarding
the effectiveness of our internal control over financial reporting starting with the second annual report filed by the Company after
completion of our IPO and in each year thereafter. Our auditors, however, will not be required to attest to the effectiveness of our
internal control over financial reporting until we are no longer deemed an Emerging Growth Company, which will not be until after we
have been a public reporting company for five fiscal years or until we have annual gross revenues of more than $1.235 billion, whichever
occurs sooner. If we are unable to assert that our internal control over financial reporting is effective, or when required in the future,
investors may lose confidence in the accuracy and completeness of our financial reports, the market price of our common stock could be
adversely affected, and we could become subject to litigation or investigations by the stock exchange on which our common stock are listed,
the SEC or other regulatory authorities, which could require additional financial and management resources and could have a material
adverse effect on our business, financial condition, and results of operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>The
lack of public company experience of our management team could adversely impact our ability to comply with the reporting requirements
of U.S. securities laws, which could have a materially adverse effect on our business.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
officers have limited public company experience, which could impair our ability to comply with legal and regulatory requirements such
as those imposed by Sarbanes-Oxley Act. Such responsibilities include complying with federal securities laws and making required disclosures
on a timely basis. Any such deficiencies, weaknesses or lack of compliance could have a materially adverse effect on our ability to comply
with the reporting requirements of the Exchange Act, which is necessary to maintain our public company status. If we were to fail to
fulfill those obligations, our ability to continue as a U.S. public company would be in jeopardy in which event you could lose your entire
investment in our Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>


<!-- Field: Page; Sequence: 95; Value: 2 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->93<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
could be subject to securities class action litigation.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the past, when the market price of a stock has been volatile, holders of that stock sometimes have instituted securities class action
litigation against the company that issued the stock following a decline in the market price of their securities. This risk is especially
relevant for us because biotechnology companies have experienced significant share price volatility in recent years. Securities litigation
against us, regardless of the merits or outcome, could result in substantial costs and divert the time and attention of our management
from our business, which could have a material adverse effect on our business, financial condition, and results of operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Our
directors&#8217; liability to us and stockholders is limited; claims for indemnification by our directors and officers may reduce our
available funds to satisfy successful third-party claims against us and may reduce the amount of money available to us.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
certificate of incorporation and bylaws provide that we will indemnify our directors and officers, in each case, to the fullest extent
permitted by Delaware law. Pursuant to our bylaws and the DGCL, our directors will not be liable to the Company or any stockholders for
damages for any breach of fiduciary duty, except (i) acts that breach his or her duty of loyalty to the Company or its stockholders;
(ii) acts or omissions without good faith or involving intentional misconduct or knowing violation of the law; (iii) pursuant to Section
174 of the DGCL regarding director liability for unlawful payment of a dividend or unlawful stock purchase or redemption; or (iv) for
any transaction from which the director derived an improper personal benefit. Accordingly, we will have a much more limited right of
action against our directors that otherwise would be the case. This provision does not affect the liability of any director under federal
or applicable state securities laws. In addition, we have entered into indemnification agreements with each of our executive officers
and directors. The indemnification agreements provide the executive officers and directors with contractual rights to indemnification,
expense advancement and reimbursement, to the fullest extent permitted under the DGCL. The bylaws also require us, if so requested, to
advance expenses that such director or officer incurred in defending or investigating a threatened or pending action, suit or proceeding,
provided that such person will return any such advance if it is ultimately determined that such person is not entitled to indemnification
by us. Any claims for indemnification by our directors and officers may reduce our available funds to satisfy successful third-party
claims against us and may reduce the amount of money available to us.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Indemnity
provisions in various agreements potentially expose us to substantial liability for intellectual property infringement, data protection,
and other losses.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
agreements with third parties may include indemnification provisions under which we agree to indemnify them for losses suffered or incurred
as a result of claims of intellectual property infringement or other liabilities relating to or arising from our contractual obligations.
Large indemnity payments could harm our business and financial condition. Although we normally contractually limit our liability with
respect to such obligations, we may still incur substantial liability. Any dispute with a third party with respect to such obligations
could have adverse effects on our relationship with that third party and relationships with other existing or new partners, harming our
business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="background-color: white"><B><I>The capital
markets may experience periods of disruption, instability and economic uncertainty. Such market conditions may materially and adversely
affect the debt and equity capital markets, which may have a negative impact on our business and operations.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="background-color: white">From
time to time, capital markets may experience periods of disruption, instability and economic uncertainty. Such periods may result in,
among other things, write-offs, the re-pricing of credit risk, the failure of financial institutions or worsening general economic conditions,
any of which could materially and adversely impact the broader financial and credit markets and reduce the availability of debt and equity
capital for the market as a whole and, as a result, negatively affect our ability to access capital. Global financial markets have experienced
heightened volatility in recent years. In addition, social and political tensions in the U.S. and around the world may contribute to
increased market volatility, may have long-term effects on the U.S. and worldwide financial markets, and may cause economic uncertainties
or deterioration in the U.S. and worldwide. There can be no assurance these market conditions will not occur or worsen in the future,
including economic and political events in or affecting the world&#8217;s major </FONT>economies, such as the ongoing war between <FONT STYLE="font-weight: normal">Russia</FONT>
and Ukraine and continued conflicts and political unrest in the <FONT STYLE="font-weight: normal">Middle East</FONT> and South America.
Sanctions imposed by the U.S. and other countries in connection with hostilities between <FONT STYLE="font-weight: normal">Russia</FONT>
and Ukraine, the war in Iran, conflicts in the Middle East, and the tensions between China and Taiwan have caused additional financial
market volatility and affected the global economy. Concerns over future inflation volatility, economic recession, as well as interest
rate volatility and fluctuations in oil and gas prices resulting from global production and demand levels, as well as geopolitical tension,
have exacerbated market volatility. In addition, social unrest, changes regarding immigration and work permit policies and other political
and security concerns may not abate, which may cause the debt and equity capital markets and our business to be adversely affected both
within and outside of regions experiencing ongoing conflicts. Market uncertainty and volatility have also been magnified as a result
of uncertainties regarding actual and potential shifts in U.S. and foreign trade, economic and other policies, including with respect
to treaties and tariffs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT>Further,
volatility in the capital markets may make it difficult to raise equity capital or obtain debt financing, the results of which could cause
a material adverse effect on our business, financial condition and/or results of operations. If we are unable to raise additional capital,
we will not be able to fund our ongoing clinical trials and further develop our business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>


<!-- Field: Page; Sequence: 96; Value: 2 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->94<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><FONT ID="an_001"></FONT>ITEM
1B. UNRESOLVED STAFF COMMENTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">None.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><FONT ID="an_002"></FONT>ITEM
1C. CYBERSECURITY</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Risk
Management and Strategy</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<DIV><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
routinely assess material risks from cybersecurity threats, including any potential unauthorized occurrence on or conducted through our
information systems that may result in adverse effects on the confidentiality, integrity, or availability of our information systems
or any information residing therein. We conduct risk assessments at least annually to identify cybersecurity threats. These risk assessments
include identifying reasonably foreseeable potential internal and external risks, the likelihood of occurrence and any potential damage
that could result from such risks, and the sufficiency of existing policies, procedures, systems, controls and other safeguards we have
put in place to manage such risks. Our risk management process also encompasses cybersecurity risks associated with the use of our major
third-party vendors and service providers. For additional information regarding whether any risks from cybersecurity threats, including
as a result of any previous cybersecurity incidents, have materially affected or are reasonably likely to materially affect our company,
including our business strategy, results of operations, or financial condition, please refer to Item 1A &#8220;Risk Factors&#8221; in
this Annual Report on Form 10-K , including the risk factors entitled <I>&#8220;Our internal computer systems, or those of our CROs or
other contractors or consultants, may fail or suffer security breaches, which could result in a material disruption of our product development
programs,&#8221; and &#8220;Our proprietary information, or that of our customers, suppliers and business partners, may be lost or we
may suffer security breaches.&#8221; </I></FONT></P>

</DIV><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Governance</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">One
of the key functions of our Board of Directors is informed oversight of our risk management process, including risks arising from cybersecurity
threats. Our Board of Directors is responsible for monitoring and assessing strategic risk exposure, and our executive officers are responsible
for the day-to-day management of the material risks we face. Our Chief Financial Officer is primarily responsible for assessing and managing
material risks from cybersecurity threats on a day to day basis.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><FONT ID="an_003"></FONT>ITEM
2. PROPERTIES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
corporate address is 2355 Westwood Blvd. #139, Los Angeles, CA, 90064. This is the address of our registered agent. We currently do not
lease any properties, but if required, we believe that suitable additional or alternative space would be available in the future on commercially
reasonable terms. As of the date of this Annual Report, all of our operations are conducted virtually.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><FONT ID="an_004"></FONT>ITEM
3. LEGAL PROCEEDINGS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">From
time to time, we may become involved in material legal proceedings or be subject to claims arising in the ordinary course of our business.
Regardless of outcome, such proceedings or claims can have an adverse impact on us because of defense and settlement costs, diversion
of resources, and other factors, and there can be no assurances that favorable outcomes will be obtained. We are not presently party
to any legal proceedings material to our operations or of which any of our property is the subject, nor are we aware of any such proceedings
that are contemplated by a government authority.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><FONT ID="an_005"></FONT>ITEM
4. MINE SAFETY DISCLOSURES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></P>

<!-- Field: Page; Sequence: 97; Value: 2 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->95<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><FONT STYLE="text-decoration: underline"><FONT ID="an_006"></FONT>PART
II</FONT></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><FONT ID="an_007"></FONT>ITEM
5. MARKET FOR REGISTRANT&#8217;S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Market
Information</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
common stock is listed on the NYSE American LLC, or NYSE American, under the symbol &#8220;KAPA.&#8221;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Holders</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of March 31, 2026, we had 48 holders of record of our common stock and 21,411,198 shares of common stock issued and outstanding.
This number of holders of record does not represent the actual number of beneficial owners of our common shares because shares
are frequently held in &#8220;street name&#8221; by securities dealers and others for the benefit of individual owners who have the
right to vote their shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Dividends</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
do not anticipate declaring or paying, in the foreseeable future, any cash dividends on our capital stock. We intend to retain all available
funds and future earnings, if any, to fund the development and expansion of our business. Any future determination regarding the declaration
and payment of dividends, if any, will be at the discretion of our board of directors, subject to applicable laws, and will depend on
then-existing conditions, including our financial condition, operating results, contractual restrictions, capital requirements, business
prospects, and other factors our board of directors may deem relevant. In addition, our ability to pay cash dividends on our capital
stock in the future may be limited by the terms of any future debt or preferred securities we issue or any credit facilities we enter
into.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Securities
authorized for issuance under equity compensation plans.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table provides information about the Company&#8217;s common stock that may be issued under the Company&#8217;s 2023 Equity Incentive
Plan as of December 31, 2025.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold">Plan Category</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: justify">Number of securities to be issued upon exercise or vesting of outstanding options, warrants, &#160;rights and restricted stock units</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: justify">Weighted-average exercised price of outstanding options, warrants, rights and restricted stock units</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: justify">Number of securities remaining available for future issuance under equity compensation plans (excluding securities reflected in first column)</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 49%; font-size: 10pt; text-align: left">Equity compensation plans approved by stockholders</TD><TD STYLE="width: 2%; font-size: 10pt">&#160;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&#160;</TD><TD STYLE="width: 13%; font-size: 10pt; text-align: right">772,605</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&#160;</TD><TD STYLE="width: 2%; font-size: 10pt">&#160;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 13%; font-size: 10pt; text-align: right">1.05</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&#160;</TD><TD STYLE="width: 2%; font-size: 10pt">&#160;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&#160;</TD><TD STYLE="width: 13%; font-size: 10pt; text-align: right">877,395</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">Equity compensation plans not approved by security holders</TD><TD STYLE="font-size: 10pt">&#160;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&#160;</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="font-size: 10pt; text-align: left">&#160;</TD><TD STYLE="font-size: 10pt">&#160;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&#160;</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="font-size: 10pt; text-align: left">&#160;</TD><TD STYLE="font-size: 10pt">&#160;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&#160;</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="font-size: 10pt; text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt">Total</TD><TD STYLE="font-size: 10pt">&#160;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&#160;</TD><TD STYLE="font-size: 10pt; text-align: right">772,605</TD><TD STYLE="font-size: 10pt; text-align: left">&#160;</TD><TD STYLE="font-size: 10pt">&#160;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&#160;</TD><TD STYLE="font-size: 10pt; text-align: right">1.05</TD><TD STYLE="font-size: 10pt; text-align: left">&#160;</TD><TD STYLE="font-size: 10pt">&#160;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&#160;</TD><TD STYLE="font-size: 10pt; text-align: right">877,395</TD><TD STYLE="font-size: 10pt; text-align: left">&#160;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT>&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Recent
Sales of Unregistered Securities</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
below &#8220;Recent Developments - January 2025 PIPE Offering.&#8221;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Issuer
Purchases of Equity Securities</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">None.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>


<!-- Field: Page; Sequence: 98; Value: 2 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->96<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 45.35pt; text-indent: -45.35pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><FONT ID="an_008"></FONT>ITEM
6. [Reserved.]</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><FONT ID="mda_001"></FONT>ITEM
7. MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&#160;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(in
thousands, except for share amounts and per share data)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&#160;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>The
following discussion and analysis should be read in conjunction with our financial statements and related notes included elsewhere in
this Annual Report. This discussion and analysis and other parts of this Annual Report contain forward-looking statements based upon
current beliefs that involve risks, uncertainties and assumptions, such as statements regarding our plans, objectives, expectations and
intentions. Our actual results and the timing of selected events could differ materially from those described in or implied by these
forward-looking statements as a result of several factors, including those set forth under &#8220;Item 1A Risk Factors&#8221; and elsewhere
in this Annual Report. You should carefully read the &#8220;Item 1A Risk Factors&#8221; of this Annual Report to gain an understanding
of the important factors that could cause actual results to differ materially from our forward-looking statements. Please also see &#8220;Disclosure
Regarding Forward-Looking Statements.&#8221;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&#160;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Overview</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are a clinical-stage biopharmaceutical company advancing therapeutics for cancer patients that are designed to overcome key hurdles in
immune suppression and drug resistance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
mission is to advance our portfolio of innovative therapeutics to reverse key mechanisms of therapeutic resistance and immune suppression
and transform the way cancer is treated. We have leveraged molecular insights of the mechanisms of therapeutic resistance and immune
suppression to develop a new class of novel drugs that are designed to target drug resistance and checkpoints of immune suppression.
As of the date of this Quarterly Report, our product candidates have not been approved as safe or effective by the FDA or any other comparable
foreign regulator.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Since
inception, our operations have focused on organizing and staffing our Company, business planning, raising capital, acquiring and developing
our technology, establishing our intellectual property portfolio, identifying potential product candidates, and undertaking preclinical
and clinical studies and manufacturing. We do not have any products approved for sale and have not generated any revenue from product
sales.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Since
inception, we have incurred significant operating losses. Our net losses were $5,447 and $2,603 for the years ended December 31, 2025
and 2024, respectively. As of December 31, 2025, we had an accumulated deficit of $14,262. We expect to continue to incur significant
and increasing expenses and operating losses for the foreseeable future, as we advance our current and future product candidates through
preclinical and clinical development, manufacture drug product and drug supply, seek regulatory approval for our current and future product
candidates, maintain and expand our intellectual property portfolio, hire additional research and development and business personnel,
and operate as a public company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
will not generate revenue from product sales unless and until we successfully complete our clinical trials and obtain regulatory approval
for our product candidates. In addition, if we obtain regulatory approval for our product candidates and do not enter into a third-party
commercialization partnership, we will likely incur significant expenses related to developing our commercialization capability to support
product sales, marketing, manufacturing, and distribution activities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a result, we will need substantial additional funding to support our continuing operations and pursue our growth strategy. Until we can
generate significant revenue from product sales, if ever, we expect to finance our operations through a combination of public or private
equity offerings and debt financings and other sources, such as potential collaboration agreements, strategic alliances and licensing
arrangements. We may be unable to raise additional funds or enter into such other agreements or arrangements when needed on acceptable
terms, or at all. Our failure to raise capital or enter into such agreements as and when needed could have a material adverse effect
on our business, results of operations and financial condition. No assurance can be given that any future financing will be available
or, if available, that it will be on terms that are satisfactory to the Company. Even if the Company is able to obtain additional financing,
it may contain undue restrictions on our operations, in the case of debt financing, or cause substantial dilution for our stockholders,
in case of equity financing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 99; Value: 2 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->97<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Recent
Developments</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I><FONT STYLE="text-decoration: underline">Equity
Line of Credit Agreement (ELOC)</FONT></I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 12, 2024, we entered into an ELOC agreement (the &#8220;ELOC Agreement&#8221;) with Helena Global Investment Opportunities I
LTD (&#8220;Helena&#8221;), pursuant to which Helena agreed to purchase from the Company up to $30,000 of common stock (the &#8220;ELOC
Shares&#8221;), which the Company may exercise at any time following effectiveness of a registration statement at a price equal to the
95% of the lowest trading price during the three days following the Company&#8217;s notice to Helena to exercise the ELOC Agreement.
The Company issued 670,641 shares of restricted common stock (the &#8220;Commitment Fee Shares&#8221;) to Helena as a &#8220;Commitment
Fee&#8221; for the ELOC Agreement. The ELOC Agreement became available for the Company&#8217;s use following the filing and effectiveness
of a resale registration statement registering the ELOC Shares for resale. Following effectiveness of the resale registration statement
(the &#8220;Effective Date&#8221;), the Commitment Fee Shares were subject to a &#8220;true-up&#8221; pursuant to which, as the shares
are valued at less than $900 on the Effective Date, additional shares were issued to Helena to bring the ELOC Shares to the full $900
value.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
ELOC Agreement will terminate upon the following events: (i) the first day of the month next following the 36-month anniversary of the
date of the ELOC Agreement or (ii) the date on which Helena has purchased the full $30,000 of ELOC Shares.&#160;The ELOC Agreement may
also be terminated by the Company after its commencement, at the Company&#8217;s discretion, provided that there are no advance notices
outstanding for which common stock has yet to be issued, and the Company has paid all amounts owed to Helena under the ELOC Agreement,
including the Commitment Fee shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
the Company&#8217;s annual meeting of shareholders on June 10, 2025, a majority of the Company&#8217;s shareholders approved the issuance
in excess of 19.99% of the Company&#8217;s common stock at a price below market value, in accordance with the terms of the ELOC Agreement
and in compliance with Rule 713 of the NYSE American LLC Company Guide.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2025, in connection with its ELOC agreement with Helena, the Company sold 3,510,000 shares of its common
stock to Helena for net proceeds of $3,205. The shares were issued to Helena during the year ended December 31, 2025.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Boustead
Securities LLC (&#8220;Boustead&#8221;) and D. Boral Capital LLC (&#8220;D. Boral&#8221;) acted as placement agents (the &#8220;Placement
Agents&#8221;) in the ELOC offering and, following each exercise, are entitled to cash compensation of 7%, 1% non-accountable fees and
warrants equal to 7%. To date, the Placement Agents have received total cash compensation equal to $313,225 and a total of 245,750 warrants
to purchase common stock, exercisable at exercise prices of $0.40, $0.46 and $1.2308 per share, which warrants will expire five years
from the date of grant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I><FONT STYLE="text-decoration: underline">January
2025 PIPE Offering</FONT></I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 14, 2025, the Company entered into a securities purchase agreement (the &#8220;Purchase Agreement&#8221;) and registration rights
agreement (the &#8220;Registration Rights Agreement&#8221;) with the investor name therein (the &#8220;Investor&#8221;) for the sale
and issuance of 2,500,000 units (the &#8220;Pre-Funded Units&#8221;), with each Pre-Funded Unit consisting of a pre-funded warrant (the
&#8220;Pre-Funded Warrant&#8221;) to purchase one share of common stock, exercisable for $0.001 per share, and a common warrant (the
&#8220;Common Warrant&#8221;) to purchase one and one half shares of common stock, exercisable at $1.40 per share (the &#8220;January
2025 PIPE Offering&#8221;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 16, 2025, the Company closed the January 2025 PIPE Offering for a total purchase price of $3,498 (or $1.399 per Pre-Funded Unit),
with an additional $2 payable upon the Investor&#8217;s exercise of the Pre-Funded Warrants in full.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
advance of closing, on January 16, 2025, the Company and the Investor entered into an amended and restated Purchase Agreement (the &#8220;A&amp;R
Purchase Agreement&#8221;), which amended the terms of the Purchase Agreement to include a requirement that the Company obtain shareholder
approval prior to issuing in excess of 19.99% of the Company&#8217;s common stock and also amended the Common Warrants to make them immediately
exercisable and reduce the exercise period from 5.5 years to five years. Other terms of the Purchase Agreement and Common Warrants remained
the same.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 100; Value: 2 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->98<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Boustead
and D. Boral acted as co-placement agents for the January 2025 PIPE Offering. In conjunction therewith, on January 16, 2025, the Company
entered into a Placement Agent Agreement with Boustead (the &#8220;Placement Agent Agreement&#8221;). Under the terms of the Placement
Agent Agreement, at closing, the Company paid the Placement Agents (i) a cash commission equal to 8% of the gross proceeds (including
a 1% non-accountable expense fee) and (ii) warrants to purchase a total of 175,000 shares of common stock, exercisable at $1.40 per share,
with the total cash and warrant compensation split equally between the Placement Agents.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 20, 2025, the Company obtained the approval of 55.4% of the shareholders (the &#8220;Majority Shareholders&#8221;) for the issuance
in excess of 19.99% of the Company&#8217;s common stock at a price below market value, in compliance with Rule 713 of the NYSE American
LLC Company Guide. On February 10, 2025, the Company filed the definitive Schedule 14C and the shareholder approval became effective
on March 1, 2025.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I><FONT STYLE="text-decoration: underline">2026 At the Market Offering</FONT></I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">On January 12, 2026, we entered into an at-the-market
(&#8220;ATM&#8221;) offering agreement (the &#8220;ATM Agreement&#8221;) with H.C. Wainwright Co., LLC (the &#8220;Placement Agent&#8221;)
for the sale, from time to time, of up to $4,524,949 shares of our common stock. We registered the common stock offered under the ATM
pursuant to prospectus supplement filed in conjunction with our shelf registration statement on Form S-3 (SEC File No. 333-292686), which
was declared effective on January 23, 2026. Pursuant to the ATM Agreement, the Placement Agent is entitled to a placement agent fee of
3.0% of the gross sale price of shares sold under the ATM.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Components
of Results of Operations</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Net
Sales</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have not generated any sales to date. No revenue was recorded from any sources during the years ended December 31, 2025 and 2024.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Operating
Expenses</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
operating expenses consist of (i) research and development expenses and (ii) general and administrative expenses.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Research
and Development Expenses</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
Ramachandran Murali is our Vice President of Research and Development. Dr. Murali is a doctor and scientist at Cedars-Sinai Medical Center,
and is the inventor, with others, of three of the patented technologies that are subject to the Kairos-Cedars license agreements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are engaged in rolling out our Phase 1 and Phase 2 clinical trials for ENV 105 and a Phase 1 trial for KROS 201. In addition, we are
continuously performing preclinical research including animal models of disease, medicinal chemistry laboratory studies, formulation,
and toxicology and biodistribution studies. Our clinical development costs may vary significantly based on factors such as: per patient
trial costs; the number of trials required for approval; the number of sites included in the trials; the location where the trials are
conducted; the length of time required to enroll eligible patients; the number of patients that participate in the trials; the number
of doses that patients receive; the drop-out or discontinuation rates of patients; potential additional safety monitoring requested by
regulatory agencies; the duration of patient participation in the trials and follow-up; the cost and timing of manufacturing our product
candidates; the phase of development of our product candidates; and the efficacy and safety profile of our product candidates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
successful development and commercialization of product candidates is highly uncertain. This is due to the numerous risks and uncertainties
associated with product development and commercialization, including the following: the timing and progress of nonclinical and clinical
development activities; the number and scope of nonclinical and clinical programs we decide to pursue; raising necessary additional funds;
the progress of the development efforts of parties with whom we may enter into collaboration arrangements; our ability to maintain our
current development program and to establish new ones; our ability to establish new licensing or collaboration arrangements; the successful
initiation and completion of clinical trials with safety, tolerability and efficacy profiles that are satisfactory to the FDA or any
comparable foreign regulatory authority; the receipt and related terms of regulatory approvals from applicable regulatory authorities;
the availability of drug substance and drug product for use in production of our product candidate; establishing and maintaining agreements
with third-party manufacturers for clinical supply for our clinical trials and commercial manufacturing, if our product candidates are
approved; our ability to obtain and maintain patents, trade secret protection and regulatory exclusivity, both in the United States and
internationally; our ability to protect our rights in our intellectual property portfolio; the commercialization of our product candidates,
if and when approved; obtaining and maintaining third-party insurance coverage and adequate reimbursement; the acceptance of our product
candidate, if approved, by patients, the medical community and third-party payors; competition with other products; the impact of any
business interruptions to our operations, including the timing and enrollment of patients in our planned clinical trials, or to those
of our manufacturers, suppliers, or other vendors resulting from any pandemic or public health crisis; and a continued acceptable safety
profile of our therapies following approval.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 101; Value: 2 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->99<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
change in the outcome of any of these variables with respect to the development of our product candidates could significantly change
the costs and timing associated with the development of that product candidate. We may never succeed in obtaining regulatory approval
for any of our product candidates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>General
and administrative expenses</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">General
and administrative expenses consist primarily of salaries and related costs for personnel in executive, finance, corporate and business
development, as well as administrative functions. General and administrative expenses also include legal fees relating to patent, corporate,
IPO-related matters, and SEC reporting matters; professional fees for accounting, auditing, tax and administrative consulting services;
insurance costs; administrative travel expenses; marketing expenses and other operating costs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
anticipate that our general and administrative expenses will increase in the future as we increase our headcount to support our business
operations. We also anticipate that we will incur increased accounting, audit, legal, regulatory, compliance, and director and officer
insurance costs, as well as investor and public relations expenses associated with being a public company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Results
of Operations</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Comparison
of the Years Ended December 31, 2025 and 2024</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&#160;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes our results of operations for the years ended December 31, 2025 and 2024:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">December 31, <BR>2025</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">December 31, <BR>2024</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Revenues</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Operating expenses:</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; width: 60%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Research and
    development</FONT></TD><TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="width: 16%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">2,135</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="width: 16%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">414</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-align: left; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">General
    and administrative</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">3,437</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,929</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Total operating expenses</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">5,572</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">2,343</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Loss from operations</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(5,572</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(2,343</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Other income (expenses):</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Interest expense</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(35</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Financing costs</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(670</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Debt discount amortization</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(154</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Gain on settlement of accounts
    payable</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">599</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Interest
    income</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">125</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Total other income (expenses)</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">125</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(260</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Net loss</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(5,447</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(2,603</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 102; Value: 2 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->100<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&#160;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Research
and Development Expenses</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
table below summarizes our research and development expenses for the years ended December 31, 2025 and 2024:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">Research and
    Development Expenses:</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">December
    31, <BR>2025</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">December
    31, <BR>2024</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; width: 60%; text-align: left; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Clinical
    trial and related expenses</FONT></TD><TD STYLE="width: 2%; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; width: 16%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">2,135</FONT></TD><TD STYLE="width: 1%; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="width: 2%; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; width: 16%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">414</FONT></TD><TD STYLE="width: 1%; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Total research and development
    expenses</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">2,135</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">414</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development expenses were $2,135 and $414 for the years ended December 31, 2025 and 2024, respectively. The increase in R&amp;D expenses
in 2025 primarily related to our Phase 2 trial in prostate cancer beginning in 2024.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>General
and Administrative Expenses</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
table below summarizes our general and administrative expenses for the years ended December 31, 2025 and 2024:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">General and
    Administrative Expenses:</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">December
    31, <BR>2025</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">December
    31, <BR>2024</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; width: 60%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Stock-related
    expenses</FONT></TD><TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 16%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">341</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 16%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">219</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Officer and board compensation
    and wages</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">566</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">481</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Patent related expenses</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">75</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">134</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Legal expenses</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">202</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">149</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Accounting expenses</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">206</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">181</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Other professional service
    expenses and fees</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">510</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">242</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Fees relating to license
    agreements</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">138</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Insurance expenses</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">385</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">151</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Vendor advances amortization
    expense</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">871</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Intangible amortization
    expense</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">160</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">160</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-align: left; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Other
    expenses</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">121</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">74</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Total general and administrative
    expenses</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">3,437</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,929</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">General
and administrative expenses were $3,437 and $1,929 for the years ended December 31, 2025 and 2024, respectively. Significant changes
between periods consisted of the increase in other professional service expenses and fees, primarily related to being a publicly traded
company; the increase in insurance expenses, primarily D&amp;O; and the increase in vendor advance amortization expense in 2025, relating
to our vendor advances in 2025.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Other
Income (Expenses)</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
income (expenses) was $125 and $(260) for the years ended December 31, 2025 and 2024, respectively. In 2025, other income was interest
income earned from our money market account. In 2024, other expenses were interest expense of $35, financing costs of $670 and debt discount
amortization of $154, with other income relating to a gain on the settlement of accounts payable of $599.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Liquidity
and Capital Resources</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has experienced recurring losses from operations since inception and incurred a net loss of $5,447&#160;and used cash in operations
of $3,441&#160;during the year ended December 31, 2025. These factors raise substantial doubt about the Company&#8217;s ability to continue
as a going concern. The ability of the Company to continue as a going concern is dependent upon the Company&#8217;s ability to raise
additional funds and implement its strategies. The financial statements do not include any adjustments that might be necessary if the
Company is unable to continue as a going concern.&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 103; Value: 2 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->101<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2025, the Company had cash and short-term investments of $4,491. Until we can generate sufficient product revenue to
finance our cash requirements, which we may never do, we expect to finance our future cash needs through a combination of public or private
equity offerings and debt financings, or other capital sources such as potential collaborations, strategic alliances, licensing arrangements
and other arrangements. Based on our research and development plans, we expect that our existing cash balance may not enable us to fund
our planned operating expenses and capital expenditure requirements for at least the next 12 months from the date of filing of this Annual
Report. We have based this estimate on assumptions that may prove to be wrong, and we could exhaust our available capital resources sooner
than we expect. In addition, because the design and outcome of our anticipated and any future clinical trials is highly uncertain, we
cannot reasonably estimate the actual amounts necessary to successfully complete the development and commercialization of our current
products or any future product candidates. Additionally, although we have the ability to raise funds through our S-1 and S-3 registration
statements filed in 2025 and 2026, we may not receive some or all of these available proceeds, due to certain factors. The failure to
receive all or some of the proceeds would exhaust our available capital resources sooner than expected and will require us to obtain
further funding to achieve our business objectives.&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
assurance can be given that any future financing will be available or, if available, that it will be on terms that are satisfactory to
the Company. Even if the Company is able to obtain additional financing, it may contain undue restrictions on our operations, in the
case of debt financing, or cause substantial dilution for our shareholders, in the event of an equity financing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Cash
Flows</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
table below summarizes our cash flow activities for the years ended December 31, 2025 and 2024:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">December 31,</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">December 31,</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">Net cash provided by (used in):</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">2025</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">2024</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; width: 60%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Operating activities</FONT></TD><TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 16%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(3,441</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 16%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(3,955</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Investing activities</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-align: left; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Financing
    activities</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">6,660</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">5,134</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Net increase in cash and
    cash equivalents</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">3,219</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,179</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&#160;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Operating
Activities</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2025, we used cash from operating activities of $3,441, compared to $3,955 used during the year ended December
31, 2024. During the year ended December 31, 2025, we incurred a net loss of $5,447 and had non-cash expenses of $2,182, compared to
a net loss of $2,603 and non-cash expenses of $632 during the year ended December 31, 2024. The primary non-cash expense in 2025 was
the amortization of vendor advances of $2,170.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
net change in operating assets and liabilities during the year ended December 31, 2025 used cash of $806, compared to $1,984 used during
the year ended December 31, 2024. The primary use of cash relating to operating assets and liabilities during the year ended December
31, 2025, was the decrease in accounts payable and accrued expenses. The primary use of cash during the years ended December 31, 2024,
was the increase in vendor advances.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Financing
Activities</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2025, we provided cash from financing activities of $6,660, compared to $5,134 provided during the year ended
December 31, 2024. For the year ended December 31, 2025, cash provided by financing activities consisted of proceeds from our private
financing of $3,058 and proceeds of $3,602 from our ELOC. Net cash provided in 2024 was from net proceeds from our IPO of $5,524 and
proceeds from notes payable &#8211; officers of $142. Net cash used in 2024 consisted of the payment of deferred offering costs of $390
and the repayment of notes payable &#8211; officers of $142.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 104; Value: 2 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->102<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Debt
Agreements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Conversion
of Amounts Due to Related Parties</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2021, shareholders of the Company, and a company whose principal stockholder is also a stockholder of the
Company, advanced the Company $14. The advances accrued no interest, were unsecured and were due on demand. During the year ended December
31, 2022, the Company repaid $10&#160;of the advances, and as of December 31, 2023 and September 17, 2024 (the date of the closing of
the Company&#8217;s IPO), a total of $4&#160;was outstanding. During the three months ended September 30, 2024, the officers agreed to
automatically convert the principal into shares of the Company&#8217;s common stock upon the closing of the IPO transaction. Upon the
closing of the IPO, all of the principal automatically converted into&#160;1,664&#160;shares of the Company&#8217;s common stock based
on the conversion price of $2.40, which was 60% of the IPO closing price of $4.00. As of December 31, 2024, no principal or interest
was due on the advances.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&#160;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Notes
Payable to Officers</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&#160;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2024, the Company entered into note payable agreements with three of its officers in the aggregate total
of $142. The notes accrued interest at&#160;7.5% per annum, were unsecured and were due&#160;one year&#160;from the date of issuance.
During the year ended December 31, 2024, the principal of $142 and accrued interest of $3 were repaid in the form of stock. In connection
with the loans, the Company issued the officers&#160;36,270&#160;shares of the Company&#8217;s common stock. No amounts were owed to
the officers as of December 31, 2024.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&#160;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Convertible
Notes Payable</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&#160;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2022, the Company entered into several convertible note payable agreements with certain investors totaling
$675. The notes accrue interest at&#160;6% per annum, are unsecured and are due by April 2025.&#160;If the Company does not close an
IPO transaction within 12 months of the date of the note, the Company would have the choice of paying off the principal plus all accrued
and unpaid interest, or the note&#8217;s principal balance would increase to 110% of its original balance. The notes are convertible
at the option of the noteholders into shares of the Company&#8217;s common stock at a price per share as defined in the agreement or
will automatically be converted into shares of the Company&#8217;s common stock at 60% of the IPO price per share upon the closing of
an IPO transaction.&#160;The net proceeds to the Company relating to the convertible notes, was $564. As of December 31, 2022, $675&#160;of
principal was outstanding on the notes, in addition to $17&#160;of accrued and unpaid interest.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2023, no principal or interest payments were made on the notes and the notes accrued interest of $43. As
the Company did not close its IPO transaction within 12 months of the date of the notes, the notes&#8217; principal balance increased
to 110% of their original balance, or an increase of $68. As of December 31, 2023, $743&#160;of principal was outstanding on the notes
and $60&#160;of accrued and unpaid interest.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2024, as the Company had not closed its IPO transaction within 12 months of the date of issuance of the notes,
a portion of the notes&#8217; principal balance increased to 110% of their previous balance, or an increase of $49. As of September 17,
2024, $792&#160;of principal was outstanding on the notes and $92&#160;of accrued and unpaid interest.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
closing of the Company&#8217;s IPO on September 17, 2024, the principal amount of $792, plus the accrued and unpaid interest of $92,
totaling $884, automatically converted into&#160;368,371&#160;shares of the Company&#8217;s common stock based on the principal and accrued
interest due as of September 17, 2024. No principal or interest was owed on the notes as of December 31, 2024.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&#160;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Conversion
of Accounts Payable</I></B><I>&#160;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2024, the Company entered into an agreement with Cedars-Sinai Medical Center (&#8220;Cedars&#8221;) under
which Cedars agreed to convert $750&#160;of the total accounts payable due to them into&#160;312,500&#160;shares of the Company&#8217;s
common stock, with such conversion to occur upon the closing of the Company&#8217;s IPO. The conversion price of the shares was equal
to&#160;60% of the per share IPO price, or $2.40 per share. Upon the closing of the IPO, the shares were issued to Cedars and the debt
was converted.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 105; Value: 2 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->103<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Also,
during the year ended December 31, 2024, the Company entered into another agreement with Cedars under which Cedars agreed to convert
$200&#160;of the total accounts payable due to them into&#160;150,830&#160;shares of the Company&#8217;s common stock. The conversion
price of the shares was equal to&#160;60% of the closing price of the Company&#8217;s common stock on the date of the agreement, or $1.33
per share.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2024, the Company entered into an agreement with its Chief Financial Officer, under which the Chief Financial
Officer agreed to convert $172&#160;of the total accounts payable due to him into&#160;51,610&#160;shares of the Company&#8217;s common
stock with such conversion to occur upon the closing of the Company&#8217;s IPO.&#160;The conversion price of the shares was equal to
83% of the IPO price. Upon the closing of the IPO, the shares were issued to our Chief Financial Officer.&#160;No&#160;amounts were owed
to the Chief Financial Officer as of December 31, 2024.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Contractual
Obligations and Commitments</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&#160;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Kairos
Agreement with Prevail Infoworks, Inc.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
August 2024, the Company entered into a master service and technology agreement with Prevail Infoworks, Inc. (&#8220;Prevail&#8221;),
pursuant to which Prevail agreed to provide certain clinical research services to the Company. As part of the agreement, the Company
must make an advance payment of $900 to Prevail before they begin their services and, at such time as we notify Prevail to engage their
services related to the relevant clinical trial, or six months from the date of the agreement, pay approximately $80 per month during
the time Prevail performs clinical research services for the Company&#8217;s Phase 2 ENV 105 prostate and Phase 1 ENV 105 lung clinical
trials. The agreement with Prevail is subject to cancellation at any time upon 30 days&#8217; written notice to the other party. The
Company made the advance payment to Prevail in October 2024.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Kairos
Agreement with PreCheck Health Services, Inc.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 20, 2024, the Company entered into a bioassay services agreement (the &#8220;Bioassay Services Agreement&#8221;) with PreCheck
Health Services, Inc., a Florida-based corporation (&#8220;PreCheck&#8221;). Pursuant to the Bioassay Services Agreement, PreCheck will
provide certain biomarker screening services for the Company&#8217;s ongoing carotuximab (ENV105) clinical trials in order to assist
the Company in identifying lung and prostate cancer patients suitable to the Company&#8217;s ongoing Phase 1 clinical trials for lung
cancer patients and Phase 2 trials for patients with castrate resistant prostate cancer. In order to identify biomarkers for patient
screening and therapy monitoring using carotuximab (ENV105), PreCheck will utilize its SolidTumorCheck+ platform for the somatic gene
expression analysis of biopsy tissue samples derived from patients with lung and prostate cancer, as part of the Company&#8217;s ongoing
clinical trials. In furtherance of these efforts, PreCheck will develop a companion diagnostic to support its identification of such
patients with a three gene PCR analysis or other genetic analysis, which diagnostic test will then be developed and submitted to the
FDA for castrate-resistant prostate cancer patients and for lung cancer patients on Tagrisso. In exchange for PreCheck&#8217;s services,
and according to the terms of the Bioassay Services Agreement, the Company paid $900 to PreCheck as an advance for the future laboratory
services to be performed. The term of the agreement is one year from the effective date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Kairos
Agreement with CEO.CA Technologies Ltd.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 23, 2024, the Company entered into an advisory and consulting services agreement (the &#8220;CEO.CA Agreement&#8221;) with
CEO.CA Technologies Ltd., a Canadian company (&#8220;CEO.CA&#8221;), pursuant to which CEO.CA will provide certain internet-based financial
information and communications services for a period of one year for a services fee of $250. The service fee is an advance on future
services to be performed. The CEO.CA Agreement includes such services as strategic news placement, news releases, interviews, monthly
analytics and a video launch. The CEO.CA Agreement contains other customary clauses, including representations and warranties, indemnification
clauses and governing law clauses.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 106; Value: 2 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->104<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Kairos
Agreement with Belair Capital Advisors Inc.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 23, 2024, the Company entered into a strategic advisory agreement (the &#8220;Strategic Advisory Agreement&#8221;) with Belair
Capital Advisors Inc. (&#8220;BCA&#8221;). BCA, a venture capital and corporate finance advisory firm, has been a long-term investor
and advisor to the Company and frequently works with early-stage pharmaceutical companies. The strategic advisory services consist of
corporate strategy, market positioning and long-term growth plans within the pharmaceutical sector, digital marketing and engagement,
market research analysis and business development assistance, among other things. During the one-year term of the Strategic Advisory
Agreement, in exchange for its services, the Company will pay BCA $365 fee and will issue BCA 50,000 RSUs, which will vest at the end
of six months.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Kairos
Agreement with Cross Current Capital LLC</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 1, 2024, the Company entered into a consulting agreement (the &#8220;Consulting Agreement&#8221;) with Cross Current Capital
LLC, a limited liability company organized under the laws of Puerto Rico (&#8220;Cross Current&#8221;), and Alan Masley (the &#8220;Advisor&#8221;),
pursuant to which Cross Current agreed to provide certain financial and business consulting services to the Company including, but not
limited, to (a) help drafting a public company competitive overview, (b) help preparing and/or reviewing a valuation analysis, (c) help
in drafting marketing materials and presentations, (d) reviewing the Company&#8217;s business requirements and discuss financing and
businesses opportunities, (e) investor marketing, (f) investor relations introductions, (g) legal counsel introductions, (h) auditor
introductions, (i) investment banking and research introductions, (j) M&amp;A canvassing and ways to grow the business organically, and
(k) stand by capital markets advisory services. For the services rendered thereunder, the Company agreed to pay Cross Current $200,000
in cash and agreed to issue to the Advisor restricted shares of the Company&#8217;s common stock, issuable under the Company&#8217;s
2023 Equity Inventive Plan, in an amount equal to $500,000 (the &#8220;Shares&#8221;), which Shares will vest at the end of six months
after issuance. Should the Shares be valued at less than $500 on the date of vesting, the Shares will be subject to a &#8220;true-up&#8221;
pursuant to which additional shares will be issued to the holder to bring the value of to $500 as of that date (the &#8220;True-up Shares&#8221;)
and the True-up Shares will be deemed fully vested as of the date of issuance. The term of the Consulting Agreement is 24 months and
can be extended for another 12 months upon the written consent of both parties. The Company made the $200 payment in October 2024.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><FONT STYLE="text-decoration: underline">Exclusive
License Agreements with Cedars</FONT></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have entered into four Exclusive License Agreements with Cedars which grants us licensing rights with respect to certain patent rights
owned by Cedars as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Methods
    of use of compounds that bind to RelA of NFkB;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Composition
    and methods for treating fibrosis;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Compositions
    and methods for treating cancer and autoimmune diseases; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Method
    of generating activated T cells for cancer therapy.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 2, 2021, our wholly owned subsidiary, Enviro, entered into two Exclusive License Agreements with Cedars, which granted Enviro exclusive
licensing rights (which include the right to sublicense) with respect to certain patent rights owned by Cedars, as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">an
    Exclusive License Agreement (the &#8220;Enviro-Cedars License&#160;Agreement (Mitochondrial DNA)&#8221;) for Enviro to develop, manufacture,
    use and sell products utilized or derived from patent rights worldwide related to the &#8220;Compositions and Methods for Treating
    Diseases and Conditions by Depletion of Mitochondrial DNA from Circulation and for Detection of Mitochondrial DNA&#8221; invented
    by Dr. Neil Bhowmick and others; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">an
    Exclusive License Agreement, (the &#8220;Enviro-Cedars License Agreement (Endoglin Antagonism)&#8221; and, collectively with the
    Enviro-Cedars License Agreement (Mitochondrial DNA), the &#8220;Enviro-Cedars License Agreements&#8221;) for Enviro to develop, manufacture,
    use and sell products utilized or derived from the patent rights and technical information worldwide related to the &#8220;Sensitization
    of Tumors to Therapies Through Endoglin Antagonism&#8221; invented by Dr. Bhowmick and others.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><FONT STYLE="text-decoration: underline">Agreement
with former Chief Financial Officer</FONT></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have an agreement with our former Chief Financial Officer that requires us to pay $50 upon the completion of raising more than $900 in
a debt or an equity financing. $50 was owed as of December 31, 2024 and that amount was paid to the former CFO during the period ended
March 31, 2025.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 107; Value: 2 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->105<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><FONT STYLE="text-decoration: underline">Funding
Requirements</FONT></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
expect our expenses to increase substantially in connection with our ongoing research activities, particularly as we pursue the advancement
of our product candidates through clinical trials. In addition, we expect to incur additional costs associated with operating as a public
company. The timing and amount of our operating expenditures will depend on numerous variables, including: the initiation, progress,
timing, costs and results of the clinical trials for our product candidates or any future product candidates we may develop; the initiation,
progress, timing, costs and results of nonclinical studies for our product candidates or any future product candidates we may develop;
our ability to maintain our relationships with key collaborators; the outcome, timing and cost of seeking and obtaining regulatory approvals
from the FDA and comparable foreign regulatory authorities, including the potential for such authorities to require that we perform more
nonclinical studies or clinical trials than those that we currently expect or change their requirements on studies that had previously
been agreed to; the cost to establish, maintain, expand, enforce and defend the scope of our intellectual property portfolio, including
the amount and timing of any payments we may be required to make, or that we may receive, in connection with licensing, preparing, filing,
prosecuting, defending and enforcing any patents or other intellectual property rights; the effect of competing technological and market
developments; the costs of continuing to grow our business, including hiring key personnel and maintain or acquiring operating space;
market acceptance of any approved product candidates, including product pricing, as well as product coverage and the adequacy of reimbursement
by third-party payors; the cost of acquiring, licensing or investing in additional businesses, products, product candidates and technologies;
the cost and timing of selecting, auditing and potentially validating a manufacturing site for commercial-scale manufacturing; the cost
of establishing sales, marketing and distribution capabilities for any product candidates for which we may receive regulatory approval
and that we determine to commercialize; and our need to implement additional internal systems and infrastructure, including financial
and reporting systems.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">We expect that we will continue to require additional
funding to complete the clinical development and commercialization of our product candidates, if we receive regulatory approval, and
pursue in-licenses or acquisitions of other product candidates. If we receive regulatory approval for our product candidates, we expect
to incur significant commercialization expenses related to product manufacturing, sales, marketing and distribution, depending on where
we choose to commercialize ourselves.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Until
such time, if ever, as we can generate substantial product revenue, we expect to finance our cash needs through a combination of equity
and debt financings, collaborations, strategic alliances, and marketing, distribution or licensing arrangements with third parties. To
the extent that we raise additional capital through the sale of equity or convertible debt securities, ownership interest may be materially
diluted, and the terms of such securities could include liquidation or other preferences that adversely affect the rights of our current
common stockholder. Debt financing and preferred equity financing, if available, may involve agreements that include restrictive covenants
that limit our ability to take specified actions, such as incurring additional debt, making capital expenditures or declaring dividends.
If we raise funds through collaborations, strategic alliances or marketing, distribution or licensing arrangements with third parties,
we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates or grant
licenses on terms that may not be favorable to us. If we are unable to raise additional funds through equity or debt financings or other
arrangements when needed, we may be required to delay, reduce or eliminate our product development or future commercialization efforts,
or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Critical
Accounting Policies and Significant Judgments and Estimates</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations is based on our financial statements, which
have been prepared in accordance with accounting principles generally accepted in the United States, or GAAP. The preparation of these
financial statements requires us to make estimates, judgments and assumptions that affect the reported amounts of assets and liabilities,
disclosure of contingent assets and liabilities as of the date of the balance sheets and the reported amounts of expenses during the
reporting periods. In accordance with GAAP, we base our estimates on historical experience and on various other assumptions that we believe
are reasonable under the circumstances at the time such estimates are made. Actual results may differ materially from our estimates and
judgments under different assumptions or conditions. We periodically review our estimates in light of changes in circumstances, facts
and experience. The effects of material revisions in estimates are reflected in our financial statements prospectively from the date
of the change in estimate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 108; Value: 2 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->106<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
define our critical accounting policies as those accounting principles that require us to make subjective estimates and judgments about
matters that are uncertain and are likely to have a material impact on our financial condition and results of operations, as well as
the specific manner in which we apply those principles. While our significant accounting policies are more fully described in Note 2
to our unaudited financial statements appearing elsewhere in this Quarterly Report, we believe the following are the critical accounting
policies used in the preparation of our financial statements that require significant estimates and judgments.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Vendor
Advances</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&#160;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have entered into various contracts with service providers pursuant to which we pay the vendor an advance at the beginning of the contractual
period. These vendor advances could be paid by us either in cash or in shares of common stock, depending on the terms of the contract.
The advances are reduced by the accumulated value of the services performed by the vendor or are amortized on a straight-line basis over
the service period, whichever is shorter. As of December 31, 2024, advances to vendors totaled $3,115, with $2,615&#160;being paid in
cash and $500&#160;being paid with shares of our common stock. Amortization expense relating to the vendor advances during the year ended
December 31, 2024 was $256, with an unamortized balance of $2,859&#160;as of December 31, 2024. During the year ended December 31, 2025,
an additional advance to a vendor totaled $156, with the advance being paid with shares of our common stock, and amortization expense
relating to the vendor advances was $2,170, with an unamortized balance of $845&#160;as of December 31, 2025.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&#160;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Deferred
Offering Costs</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&#160;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Agreement
with Helena Global Investment Opportunities</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 12, 2024, we entered into an agreement with Helena Global Investment Opportunities I LTD (&#8220;Helena&#8221;) pursuant to
which we will have the right to issue and sell to Helena, from time to time, and Helena shall purchase from us, up to $30,000&#160;of
the Company&#8217;s shares of common stock (the &#8220;Equity Line of Credit&#8221;). The Equity Line of Credit became available to us
after we filed a registration statement on Form S-1 registering the shares issuable under the Equity Line of Credit and such registration
statement became effective. In exchange for the Equity Line of Credit, we are obligated to issue Helena a certain number of shares of
common stock, calculated using $900&#160;divided by the lowest one-day VWAP during the five trading days prior to entry into the agreement.
As a result, we issued Helena&#160;670,641&#160;shares of its common stock valued at $1,377&#160;on the date of issuance. We accounted
for the value of the shares issued as deferred offering costs. The shares vested on the date of the agreement, were issued to Helena,
and were subject to a &#8220;true up&#8221; based upon the value of the stock after we filed and obtained effectiveness of the registration
statement registering the ELOC shares for resale. At December 31, 2024, the balance of the deferred offering costs was $1,377.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 24, 2025, we issued another&#160;384,459&#160;shares of its common stock to Helena. The fair value of the shares on the date of
grant was $328. We recorded the fair value of the shares as deferred offering costs as of the same date. During the year ended December
31, 2025, we amortized $614&#160;of these costs as shares were issued under the agreement. As of December 31, 2025, the balance of the
deferred offering costs was $1,091.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&#160;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Research
and Development Expenses</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development expenses consist primarily of costs incurred in connection with the development of our product candidates. We expense
research and development costs as incurred.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
the end of each reporting period, we compare payments made to third-party service providers to the estimated progress toward completion
of the applicable research or development objectives. Such estimates are subject to change as additional information becomes available.
Depending on the timing of payments to the service providers and the progress that we estimate has been made as a result of the service
provided, we may record net prepaid or accrued expenses relating to these costs. As of December 31, 2024 and 2025, we have not made any
material adjustments to our prior estimates of accrued research and development expenses.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 109; Value: 2 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->107<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Stock-Based
Compensation</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company measures all stock options and other stock-based awards granted based on the fair value of the award on the date of the grant
and recognizes compensation expense for those awards over the requisite service period, which is generally the vesting period of the
respective award. The Company has elected to recognize forfeitures as they occur. The reversal of compensation cost previously recognized
for an award that is forfeited because of a failure to satisfy a service or performance condition is recognized in the period of the
forfeiture. Generally, the Company issues stock options with only service-based vesting conditions and records the expense for these
awards using the straight-line method over the requisite service period.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company classifies stock-based compensation expense in its statements of operations in the same manner in which the award recipient&#8217;s
payroll costs are classified or in which the award recipients&#8217; service payments are classified.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company was a private company until the listing of the Company&#8217;s common stock on the NYSE American on September 16, 2024 and the
subsequent closing of its IPO on September 17, 2024. The Company estimates the fair value of its common stock using an appropriate valuation
methodology, in accordance with the framework of the American Institute of Certified Public Accountants&#8217; Technical Practice Aid,
Valuation of Privately-Held Company Equity Securities Issued as Compensation. Each valuation methodology includes estimates and assumptions
that require the Company&#8217;s judgment. These estimates and assumptions include a number of objective and subjective factors, including
external market conditions, guideline public company information, the prices at which the Company sold its common stock to third parties
in arms&#8217; length transactions, the rights and preferences of securities senior to the Company&#8217;s common stock at the time,
and the likelihood of achieving a liquidity event such as an initial public offering or sale. Significant changes to the assumptions
used in the valuations could result in different fair values of stock options or warrants at each valuation date, as applicable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
fair value of each stock option or warrant grant is estimated using the Black-Scholes option-pricing model. The Company was a private
company and lacked company-specific historical and implied volatility information. Therefore, it estimated its expected stock volatility
based on the historical volatility of a publicly traded set of peer companies within the biotechnology industry with characteristics
similar to the Company. The expected term of the Company&#8217;s stock options has been determined utilizing the &#8220;simplified&#8221;
method for awards that qualify as &#8220;plain-vanilla&#8221; options. The expected term of stock options granted to non-employees is
equal to the contractual term of the option award. The risk-free interest rate is determined by reference to the U.S. Treasury yield
curve in effect at the time of grant of the award for time periods approximately equal to the expected term of the award. Expected dividend
yield is zero, based on the fact that the Company has never paid cash dividends and does not expect to pay any cash dividends in the
foreseeable future.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Commitments
and Contingencies</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">From
time to time, we may have certain contingent liabilities that arise in the ordinary course of business. We evaluate the likelihood of
an unfavorable outcome in legal or regulatory proceedings to which we are a party and record a loss contingency on an undiscounted basis
when it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. These judgments are subjective
and based on the status of such legal proceedings, the merits of our defenses, and consultation with legal counsel. Actual outcomes of
these legal proceedings may differ materially from our estimates. We estimate accruals for legal expenses when incurred as of each balance
sheet date based on the facts and circumstances known to us at that time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Off-Balance
Sheet Arrangements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&#160;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the years ended December 31, 2025 and 2024, we did not have, and we do not currently have, any off-balance sheet arrangements (as defined
under SEC rules).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&#160;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Recent
Accounting Pronouncements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
a description of recently issued accounting standards that may have a material impact on our financial statements or will otherwise apply
to our operations, please see Note 2 to our audited financial statements appearing elsewhere in this Annual Report.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Emerging
Growth Company Status</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
an &#8220;emerging growth company,&#8221; the Jumpstart Our Business Startups Act of 2012 permits us to take advantage of an extended
transition period to comply with new or revised accounting standards applicable to public companies until those standards would otherwise
apply to private companies. We have irrevocably elected to &#8220;opt out&#8221; of this provision and, as a result, we will comply with
new or revised accounting standards when they are required to be adopted by public companies that are not emerging growth companies.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><FONT ID="mda_002"></FONT>ITEM
7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a &#8220;smaller reporting company,&#8221; this item is not required.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>



<!-- Field: Page; Sequence: 110; Value: 2 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->108<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><FONT ID="an_011"></FONT>ITEM
8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&#160;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Index
to Financial Statements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Page</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A HREF="#FIN_001">Report
    of Independent Registered Public Accounting Firm -Weinberg and Company, P.A</A>. (PCAOB Firm ID: 572)</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-1</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&#160;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A HREF="#report">Report
    of Independent Registered Public Accounting Firm &#8211; Marcum LLP </A>(PCAOB Firm ID: 688)</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-2</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#FIN_002"><FONT STYLE="font-size: 10pt"><B>Consolidated
    Balance Sheets as of December 31, 2025 and 202</B>4</FONT></A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-3</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#FIN_003"><FONT STYLE="font-size: 10pt"><B>Consolidated
    Statements of Operations for the Years Ended December 31, 2025 and 202</B>4</FONT></A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-4</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#FIN_004"><FONT STYLE="font-size: 10pt"><B>Consolidated
    Statements of Changes in Stockholders&#8217; Equity (Deficit) for the Years Ended December 31, 2025 and 202</B>4</FONT></A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-5</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#FIN_005"><FONT STYLE="font-size: 10pt"><B>Consolidated
    Statements of Cash Flows for the Years Ended December 31, 2025 and 202</B>4</FONT></A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-6</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#FIN_006"><FONT STYLE="font-size: 10pt"><B>Notes
    to Consolidated Financial Statements</B></FONT></A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-7</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&#160;</B></FONT></P>


<!-- Field: Page; Sequence: 111; Value: 2 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->109<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&#160;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><FONT ID="FIN_001"></FONT>REPORT
OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
the Shareholders and Board of Directors of</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Kairos
Pharma, Ltd.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Opinion
on the Financial Statements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have audited the accompanying consolidated balance sheet of Kairos Pharma, Ltd. (the &#8220;Company&#8221;) as of December 31, 2025,
the related consolidated statements of operations, changes in shareholders&#8217; equity (deficit) and cash flows for the year  ended December 31, 2025, and the related notes <B>(</B>collectively referred to as the &#8220;financial statements&#8221;). In
our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December
31, 2025, and the results of its operations and its cash flows for the year ended December 31, 2025, in conformity with accounting principles
generally accepted in the United States of America.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Going
Concern</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. As more
fully described in Note 1, the Company has incurred significant losses and needs to raise additional funds to meet its obligations and
sustain its operations. These conditions raise substantial doubt about the Company&#8217;s ability to continue as a going concern. Management&#8217;s
plans in regard to these matters are also described in Note 1. The consolidated financial statements do not include any adjustments that
might result from the outcome of this uncertainty.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Basis
for Opinion</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s
financial statements based on our audit. We are a public accounting firm registered with the Public Company Accounting Oversight Board
(United States) (&#8220;PCAOB&#8221;) and are required to be independent with respect to the Company in accordance with the U.S. federal
securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain
reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company
is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audit
we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion
on the effectiveness of the Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
audit included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or
fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding
the amounts and disclosures in the financial statements. Our audit also included evaluating the accounting principles used and significant
estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audit provides
a reasonable basis for our opinion.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
Weinberg &amp; Company P.A.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weinberg
&amp; Company P.A.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have served as the Company&#8217;s auditor since 2025.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Los Angeles, CA</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
31, 2026</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<!-- Field: Page; Sequence: 112; Options: NewSection; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&#160;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT ID="report"></FONT><B>Report
of Independent Registered Public Accounting Firm</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
the Shareholders and Board of Directors of</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Kairos
Pharma, Ltd.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Opinion
on the Financial Statements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&#160;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have audited the accompanying consolidated balance sheet of Kairos Pharma, Ltd. (the &#8220;Company&#8221;) as of December 31, 2024,
the related consolidated statements of operations, shareholders&#8217; equity and cash flows for the year ended December 31, 2024, and
the related notes (collectively referred to as the &#8220;financial statements&#8221;). In our opinion, based on our audit, the financial
statements present fairly, in all material respects, the financial position of the Company as of December 31, 2024, and the results of
its operations and its cash flows for the year ended December 31, 2024, in conformity with accounting principles generally accepted in
the United States of America.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&#160;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Basis
for Opinion</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s
financial statements based on our audit. We are a public accounting firm registered with the Public Company Accounting Oversight Board
(United States) (&#8220;PCAOB&#8221;) and are required to be independent with respect to the Company in accordance with the U.S. federal
securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain
reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company
is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audit
we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion
on the effectiveness of the Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
audit included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or
fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding
the amounts and disclosures in the financial statements. Our audit also included evaluating the accounting principles used and significant
estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audit provides
a reasonable basis for our opinion.</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
<FONT STYLE="font-variant: small-caps">Marcum LLP</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Marcum
<FONT STYLE="font-variant: small-caps">LLP</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have served as the Company&#8217;s auditor from 2021 through 2025 (such date takes into account the acquisition of the attest business
of Marcum <FONT STYLE="font-variant: small-caps">llp</FONT> by CBIZ CPAs P.C. effective November 1, 2024).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Los Angeles, CA</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">April
15, 2025</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 113; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><FONT ID="FIN_002"></FONT>Kairos
Pharma, Ltd.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Consolidated
Balance Sheets</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(In
thousands, except for share amounts and par value data)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="display: none; vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">2025</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">2024</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">December
    31,</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">2025</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">2024</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">ASSETS</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Current Assets</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 60%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Cash and cash equivalents</FONT></TD><TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 16%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">4,491</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 16%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,272</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Vendor advances, net</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">845</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">2,859</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Prepaid expenses and other
    current assets</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">51</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">38</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Total
    Current Assets</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">5,387</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">4,169</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Deferred offering costs</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,091</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,377</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Intangible assets, net</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">62</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">222</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Total
    Other Assets</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,153</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,599</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">TOTAL
    ASSETS</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">6,540</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">5,768</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">LIABILITIES AND SHAREHOLDERS&#8217;
    EQUITY</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Current Liabilities</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Accounts payable and accrued
    expenses</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">199</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">992</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Total
    Current Liabilities</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">199</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">992</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Commitments and contingencies</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Shareholders&#8217; Equity</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Preferred stock, par value $0.001, 20,000,000
    shares authorized; no shares issued and outstanding, respectively;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Common stock, par value $0.001, 100,000,000
    shares authorized; &#160;20,821,353 and 13,736,597 shares issued and outstanding, respectively;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">21</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">14</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Additional paid-in capital</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">20,582</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">13,577</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Accumulated deficit</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(14,262</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(8,815</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Total
    Shareholders&#8217; Equity</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">6,341</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">4,776</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">TOTAL
    LIABILITIES AND SHAREHOLDERS&#8217; EQUITY</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">6,540</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">5,768</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying notes are an integral part of these consolidated financial statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>


<!-- Field: Page; Sequence: 114; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><FONT ID="FIN_003"></FONT>Kairos
Pharma, Ltd.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Consolidated
Statements of Operations</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(in
thousands, except for share amounts and per share data)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="display: none; vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">2025</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">2024</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Years
    Ended December 31,</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">2025</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">2024</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Revenues</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Operating expenses:</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; width: 60%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Research and
    development</FONT></TD><TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="width: 16%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">2,135</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="width: 16%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">414</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-align: left; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">General
    and administrative</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">3,437</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,929</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Total operating expenses</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">5,572</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">2,343</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Loss from operations</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(5,572</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(2,343</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Other income (expenses):</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Interest expense</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(35</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Debt discount amortization</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(154</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Financing costs</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(670</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Gain on settlement of accounts
    payable</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">599</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-align: left; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Interest
    income</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">125</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Total other income (expenses)</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">125</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(260</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">NET LOSS</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(5,447</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(2,603</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">BASIC AND DILUTED LOSS
    PER COMMON SHARE</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(0.30</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(0.23</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0pt; text-align: left; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">WEIGHTED-AVERAGE
    COMMON SHARES OUTSTANDING BASIC AND DILUTED</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">18,427,787</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">11,356,451</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying notes are an integral part of these consolidated financial statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>


<!-- Field: Page; Sequence: 115; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><FONT ID="FIN_004"></FONT>Kairos
Pharma, Ltd.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Consolidated
Statements of Shareholders&#8217; Equity (Deficit)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(in
thousands, except share amounts)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="display: none; vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Shares</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Amount</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Paid-in&#160;Capital</FONT></P></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Deficit</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Total</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Common
    Stock</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Additional</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Accumulated</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Shares</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Amount</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Paid-in&#160;Capital</FONT></P></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Deficit</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Total</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 35%; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">Balance, December 31, 2023</FONT></TD><TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="width: 9%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">10,562,640</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 9%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">11</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 9%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">4,123</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 9%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(6,212</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 9%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(2,078</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Issuance of common shares upon the closing
    of the initial public offering, net of offering costs</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,550,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">2</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;&#160;&#160;&#8239;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;4,650</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">4,652</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Issuance of common shares upon conversion of
    convertible notes payable and accrued interest</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">368,371</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">884</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">884</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Issuance of common shares upon conversion of
    accounts payable</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">514,940</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,789</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,789</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Issuance of common shares upon conversion of
    amounts due to related parties</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,664</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">7</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">7</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Issuance of common shares for deferred offering
    costs</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">670,641</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,877</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,878</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Fair value of warrants issued in connection
    with convertible notes payable</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">29</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">29</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Fair value of vested restricted stock units</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">68,341</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">218</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">218</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Net loss for the year
    ended December 31, 2024</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(2,603</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(2,603</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">Balance, December 31, 2024</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">13,736,597</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">14</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">13,577</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(8,815</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">4,776</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Proceeds from the sale of common shares and
    pre-funded warrants, net of offering costs</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">2,500,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">2</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">3,056</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">3,058</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Fair value of common shares issued for deferred
    offering costs</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">384,459</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">327</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">327</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Common shares issued for cash through equity
    line of credit, net of expenses</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">3,510,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">4</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">2,984</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">2,988</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Issuance of common shares recorded as a vendor
    advance</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">534,188</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">156</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">157</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Fair value of vested restricted stock units</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">144,707</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">482</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">482</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Issuance of common shares through cashless
    exercise of stock warrants</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">11,402</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Net loss for the year
    ended December 31, 2025</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(5,447</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(5,447</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Balance, December 31,
    2025</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">20,821,353</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">21</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">20,582</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(14,262</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">6,341</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying notes are an integral part of these consolidated financial statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>


<!-- Field: Page; Sequence: 116; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><FONT ID="FIN_005"></FONT>Kairos
Pharma, Ltd.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Consolidated
Statements of Cash Flows</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(In
thousands)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="display: none; vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">2025</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">2024</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Years
    Ended December 31,</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">2025</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">2024</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-decoration: underline; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Cash
    Flows from Operating Activities</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 60%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Net loss</FONT></TD><TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 16%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(5,447</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 16%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(2,603</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Adjustments to reconcile net loss to net cash
    used in operating activities:</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Amortization of intangible
    asset</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">160</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">160</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Amortization of vendor
    advances</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">2,170</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Amortization of debt discount</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">154</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Fair value of vested restricted
    stock units</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">482</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">218</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Fair value of common shares
    issued in connection with the conversion of accounts payable</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">670</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Fair value of warrants
    issued in connection with convertible notes payable</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">29</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Gain on settlement of accounts
    payable</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(599</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Changes in operating assets and liabilities:</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Vendor advances</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(2,358</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Prepaid expenses and other
    current assets</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(13</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(30</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-align: left; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Accounts
    payable and accrued expenses</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(793</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">404</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Net
    cash used in operating activities</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(3,441</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(3,955</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-decoration: underline; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Cash
    Flows from Financing Activities</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Proceeds from the sale and exercise of prefunded
    warrants</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">3,058</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Proceeds from the equity line of credit</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">3,602</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Proceeds from common stock issued for cash
    in connection with the closing of the initial public offering</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">5,524</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Proceeds from notes payable - officers</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">142</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Repayment of notes payable - officers</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(142</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Payment of deferred offering
    costs</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(390</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Net
    cash provided by financing activities</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">6,660</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">5,134</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Net increase in cash and cash equivalents</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">3,219</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,179</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Cash and cash equivalents,
    beginning of period</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,272</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">93</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Cash and cash equivalents,
    end of period</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">4,491</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,272</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-decoration: underline; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Supplemental
    cash flows disclosures:</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Interest paid</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">3</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Taxes paid</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-decoration: underline; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Supplemental
    non-cash financing disclosures:</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Common shares issued
    for deferred offering costs</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">327</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,377</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Common shares issued
    for vendor advances</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">157</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">500</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Reclassification of
    deferred offering costs to shareholders&#8217; equity</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">614</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">872</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Conversion of convertible
    notes payable and accrued interest to shareholders&#8217; equity</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">884</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Conversion of accounts
    payable to shareholders&#8217; equity</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,348</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Conversion of amounts
    due to related parties to shareholders&#8217; equity</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">4</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Issuance of convertible
    notes payable recorded as debt discount</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">49</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying notes are an integral part of these consolidated financial statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>


<!-- Field: Page; Sequence: 117; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><FONT ID="FIN_006"></FONT>KAIROS
PHARMA, LTD.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>FOR
THE YEARS ENDED DECEMBER 31, 2025 AND 2024</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(In
thousands, except for share amounts and per share data)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTE
1 &#8211; BASIS OF PRESENTATION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Organization
and Operations </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Kairos
Pharma, Ltd. (the &#8220;Company&#8221; or &#8220;Kairos&#8221;) was incorporated on June 17, 2013 under the laws of the state of California
as NanoGB13, Inc. The Company changed its name to Kairos Pharma, Ltd. on July 15, 2016 and subsequently converted into a Delaware corporation
under the same name, Kairos Pharma, Ltd., on May 10, 2023. The Company is an early-stage biotechnology company focused on the development
of immunotherapy and cell therapy treatments for oncology.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&#160;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Liquidity
and Capital Resources</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&#160;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets
and the settlement of liabilities and commitments in the normal course of business. As reflected in the accompanying consolidated financial
statements, the Company has experienced recurring losses from operations since inception and incurred a net loss of $5,447 and used cash
in operations of $3,441 during the year ended December 31, 2025. These factors raise substantial doubt about the Company&#8217;s ability
to continue as a going concern. The ability of the Company to continue as a going concern is dependent upon the Company&#8217;s ability
to raise additional funds and implement its strategies. The financial statements do not include any adjustments that might be necessary
if the Company is unable to continue as a going concern.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2025, the Company had cash and short-term investments of $4,491.
Until we can generate sufficient product revenue to finance our cash requirements, which we may never do, we expect to finance our
future cash needs through a combination of public or private equity offerings and debt financings, or other capital sources such as
potential collaborations, strategic alliances, licensing arrangements and other arrangements. Based on our research and development
plans, we expect that our existing cash balance may not enable us to fund our planned operating expenses and capital expenditure
requirements for at least the next 12 months from the date of filing of this Annual Report. We have based this estimate on
assumptions that may prove to be wrong, and we could exhaust our available capital resources sooner than we expect. In addition,
because the design and outcome of our anticipated and any future clinical trials is highly uncertain, we cannot reasonably estimate
the actual amounts necessary to successfully complete the development and commercialization of our current products or any future
product candidates. Additionally, although we have the ability to raise funds through our Form S-1 and S-3 registration statements
filed in 2025 and 2026, we may not receive some or all of these available proceeds, due to certain factors. The failure to receive
all or some of the proceeds would exhaust our available capital resources sooner than expected and will require us to obtain further
funding to achieve our business objectives.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
assurance can be given that any future financing will be available or, if available, that it will be on terms that are satisfactory to
the Company. Even if the Company is able to obtain additional financing, it may contain undue restrictions on our operations, in the
case of debt financing, or cause substantial dilution for our shareholders, in the event of an equity financing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><B>NOTE
2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><B>Basis
of Consolidation</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying consolidated financial statements and accompanying notes have been prepared in accordance with accounting principles generally
accepted in the United States of America (&#8220;U.S. GAAP&#8221;). The accompanying consolidated financial statements include the accounts
of the Company and its former wholly-owned subsidiary, Enviro Therapeutics, Inc. (&#8220;Enviro&#8221;) which was dissolved in October
2025. All intercompany balances and transactions have been eliminated in consolidation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>


<!-- Field: Page; Sequence: 118; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&#160;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Use
of Estimates</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
preparation of the financial statements in conformity with accounting principles generally accepted in the U.S. requires management to
make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities
at the financial statement date and reported amounts of revenue and expenses during the reporting period. Significant estimates are used
in the valuation of accruals for potential liabilities, amortization of vendor advances and deferred offering costs, valuations of stock-based
compensation, the realization of deferred tax assets, and impairment analysis and useful life for intangible assets among others. Actual
results could differ from these estimates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Concentration
of Credit Risk</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
instruments, which potentially subject the Company to concentration of credit risk, consist primarily of cash deposits. The Company maintains
deposits in federally insured financial institutions in excess of federally insured limits. Management believes that the Company is not
exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held. The
Company has not experienced any losses on deposits since its inception.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Cash
Equivalents</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company considers all highly liquid investments with original maturities of three months or less on the date of purchase to be cash equivalents.
The Company&#8217;s cash equivalents consisted of $4,326 in money market funds as of December 31, 2025. There were no cash equivalents
as of December 31, 2024. The underlying securities in the money market funds held by the Company are all government backed securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Intangible
Assets</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s intangible assets are stated at fair value as of the date acquired, less accumulated amortization. Amortization is calculated
based on the estimated useful lives of the assets, which were determined to be five years, using the straight-line method. The intangible
asset consists of a licensing agreement that the Company acquired through its acquisition of Enviro during the year ended December 31,
2021, with an acquisition cost of $800. Amortization expense relating to the intangible asset during the years ended December 31, 2025
and 2024 was $160, with an unamortized balance of $62 and $222 at December 31, 2025 and 2024, respectively.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Impairment
of Long-Lived Assets</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company applies the provisions of ASC Topic 360, <I>Property, Plant, and Equipment</I>, which addresses financial accounting and reporting
for the impairment of long-lived assets. A long-lived asset that is held and used should be tested for recoverability whenever events
or changes in circumstances indicate that the carrying amount of the asset group may not be recoverable. If the estimated undiscounted
future cash flows are less than the carrying value, an impairment determination is required. In that event, a loss is recognized based
on the amount by which the carrying amount exceeds the fair value of the long-lived assets. No impairment was recorded relating to the
Company&#8217;s intangible asset during the years ended December 31, 2025 and 2024.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>


<!-- Field: Page; Sequence: 119; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&#160;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Income
(Loss) Per Share</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic
loss per share is computed by dividing net loss applicable to common stockholders by the weighted average number of outstanding common
shares during the period. Shares of restricted stock are included in the basic weighted average number of common shares outstanding from
the time they vest. Diluted loss per share is computed by dividing the net loss applicable to common stockholders by the weighted average
number of common shares outstanding plus the number of additional common shares that would have been outstanding if all dilutive potential
common shares had been issued.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the years ended December 31, 2025 and 2024, the basic and diluted shares outstanding were the same, as potentially dilutive shares were
considered anti-dilutive. The potentially dilutive securities consisted of the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="display: none">SCHEDULE
OF POTENTIALLY DILUTIVE SECURITIES</FONT></FONT></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">December
    31, 2025</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">December
    31, 2024</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 56%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Warrants to purchase common
    stock</FONT></TD><TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="width: 18%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">4,281,038</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="width: 18%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">278,188</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Restricted stock units</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">772,605</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">172,000</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Total</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">5,053,643</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">450,188</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&#160;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Deferred
Offering Costs</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company capitalizes certain legal, professional, accounting and other third-party fees that are directly associated with in-process equity
issuances as deferred offering costs until such equity issuances are consummated. After consummation of the equity issuance, these costs
are recorded as a reduction in the capitalized amount associated with the equity issuance. Should the equity issuance be delayed or abandoned,
the deferred offering costs will be expensed immediately as a charge to operating expenses in the Company&#8217;s statement of operations.
As of December 31, 2024, the Company incurred $1,377 of deferred offering costs related to the Company&#8217;s pending equity line of
credit (&#8220;ELOC&#8221;) offering. During the year ended December 31, 2025, the Company issued common shares with a fair value of
$328 related to the ELOC. The Company&#8217;s registration statement registering the ELOC was declared effective on April 24, 2025, and
the Company will amortize these costs as cost of capital as funds are raised, based upon the Company&#8217;s estimate of the ultimate
funds raised under the ELOC. During the year ended December 31, 2025, $614 of deferred offering costs were amortized as cost of capital,
and as of December 31, 2025, total deferred offering costs were $1,091 related to the ELOC.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Fair
Value Measurements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company determines the fair value of its assets and liabilities based on the exchange price in U.S. dollars that would be received to
sell an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability
in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value maximize
the use of observable inputs and minimize the use of unobservable inputs. The Company uses a fair value hierarchy with three levels of
inputs, of which the first two are considered observable and the last unobservable, to measure fair value:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Level
    1 &#8212;</I> Quoted prices in active markets for identical assets or liabilities.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Level
    2 &#8212;</I> Inputs, other than Level 1, that are observable, either directly or indirectly, such as quoted prices for similar assets
    or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable
    market data for substantially the full term of the assets or liabilities.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Level
    3 &#8212;</I> Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of
    the assets or liabilities.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>


<!-- Field: Page; Sequence: 120; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
carrying amounts of financial instruments such as cash, and accounts payable and accrued liabilities, approximate the related fair values
due to the short-term maturities of these instruments.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash
equivalents consisted of money market funds at December 31, 2025. Money market funds were valued by the Company using quoted prices in
active markets for identical securities, which represent a Level 1 measurement within the fair value hierarchy.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Income
Taxes </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Income
tax expense is based on pretax financial accounting income. Deferred tax assets and liabilities are recognized for the expected tax consequences
of temporary differences between the tax bases of assets and liabilities and their reported amounts. Valuation allowances are recorded
to reduce deferred tax assets to the amount that will more likely than not be realized. The Company recorded a 100% valuation allowance
against its deferred tax assets as of December 31, 2025 and 2024.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for uncertainty in income taxes using a two-step approach to recognize and measure uncertain tax positions. The first
step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates that it is more likely
than not that the position will be sustained on audit, including resolution of related appeals or litigation processes, if any. The second
step is to measure the tax benefit as the largest amount that is more than 50 percent likely of being realized upon settlement. The Company
classifies the liability for unrecognized tax benefits as current to the extent that the Company anticipates payment (or receipt) of
cash within one year. Interest and penalties related to uncertain tax positions are recognized in the provision for income taxes.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&#160;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Patents
and Patent Application Costs </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Although
the Company believes that its patents and underlying technology have continuing value, the amount of future benefits to be derived from
the patents is uncertain. Patent costs are therefore expensed as incurred and are included in general and administrative expenses on
the accompanying consolidated Statements of Operations. Patent expenses were $79 and $134 during the years ended December 31, 2025 and
2024.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&#160;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Research
and Development Costs </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company expenses its research and development costs as incurred. Research and developments costs for the years ended December 31, 2025
and 2024 were $2,135 and $414, respectively.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&#160;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Research
Contract Costs and Accruals </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has entered into various research and development-related contracts with companies inside the United States. These agreements
are generally cancellable, and related costs are recorded as research and development expenses as incurred. The Company records accruals
for estimated ongoing research costs. When evaluating the adequacy of the accrued liabilities, the Company analyzes progress of the studies
or clinical trials, including the phase or completion of events, invoices received and contracted costs. Significant judgments and estimates
are made in determining the accrued balances at the end of any reporting period. Actual results could differ from the Company&#8217;s
estimates. The Company&#8217;s historical accrual estimates have not been materially different from the actual costs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&#160;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Stock-Based
Compensation </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company measures all stock options, certain warrants and other stock-based awards granted based on the fair value of the award on the
date of the grant and recognizes compensation expense for those awards over the requisite service period, which is generally the vesting
period of the respective award. The Company has elected to recognize forfeitures as they occur. The reversal of compensation cost previously
recognized for an award that is forfeited because of a failure to satisfy a service or performance condition is recognized in the period
of the forfeiture. Generally, the Company issues stock options with only service-based vesting conditions and records the expense for
these awards using the straight-line method over the requisite service period.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>


<!-- Field: Page; Sequence: 121; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company classifies stock-based compensation expense in its statements of operations in the same manner in which the award recipient&#8217;s
payroll costs are classified or in which the award recipients&#8217; service payments are classified.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&#160;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company was a private company until the completion of its IPO on September 17, 2024. Prior to the IPO, the Company estimated the fair
value of common stock using an appropriate valuation methodology, in accordance with the framework of the American Institute of Certified
Public Accountants&#8217; Technical Practice Aid, Valuation of Privately-Held Company Equity Securities Issued as Compensation. Each
valuation methodology includes estimates and assumptions that require the Company&#8217;s judgment. These estimates and assumptions include
a number of objective and subjective factors, including external market conditions, guideline public company information, the prices
at which the Company sold its common stock to third parties in arms&#8217; length transactions, the rights and preferences of securities
senior to the Company&#8217;s common stock at the time, and the likelihood of achieving a liquidity event such as an initial public offering
or sale. Significant changes to the assumptions used in the valuations could result in different fair values of stock options or warrants
at each valuation date, as applicable. Subsequent to September 17, 2024, the Company estimates the fair value of common stock based on
its historical trading price at the date of grants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
fair value of each stock option or warrant grant is estimated using the Black-Scholes option-pricing model. Until the completion of its
IPO, the Company was a private company and lacked company-specific historical and implied volatility information. Therefore, it estimated
its expected stock volatility based on the historical volatility of a publicly traded set of peer companies within the biotechnology
industry with characteristics similar to the Company. The expected term of the Company&#8217;s stock options has been determined utilizing
the &#8220;simplified&#8221; method for awards that qualify as &#8220;plain-vanilla&#8221; options or warrants. The expected term of
stock options or warrants granted to non-employees is equal to the contractual term of the option award. The risk-free interest rate
is determined by reference to the U.S. Treasury yield curve in effect at the time of grant of the award for time periods approximately
equal to the expected term of the award. Expected dividend yield is zero, based on the fact that the Company has never paid cash dividends
and does not expect to pay any cash dividends in the foreseeable future.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&#160;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Warrant
Instruments</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 24.45pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the instruments&#8217;
specific terms and applicable authoritative guidance in ASC 480 and ASC 815. The assessment considers whether the instruments are freestanding
financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and whether the instruments meet all
of the requirements for equity classification under ASC 815, including whether the instruments are indexed to the Company&#8217;s own
common stock and whether the instrument holders could potentially require net cash settlement in a circumstance outside of the Company&#8217;s
control, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted
at the time of warrant issuance and, for liability-classified warrants, at each reporting period end date while the warrants are outstanding.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&#160;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Marketing
and Advertising Costs </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Marketing
and advertising expenses were not material for the years ended December 31, 2025 and 2024.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Recent
Accounting Pronouncements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
November 2024, FASB issued ASU 2024-03 Income Statement&#8212;Reporting Comprehensive Income&#8212;Expense Disaggregation Disclosures
(Subtopic 220-40) Disaggregation of Income Statement Expenses. The guidance in ASU 2024-03 requires public business entities to disclose
in the notes to the financial statements, among other things, specific information about certain costs and expenses including purchases
of inventory; employee compensation; and depreciation and amortization expense for each caption on the income statement where such expenses
are included. The update is effective for annual reporting periods beginning after December 15, 2026, and interim reporting periods beginning
after December 15, 2027. Early adoption is permitted, and the amendments may be applied prospectively to reporting periods after the
effective date or retrospectively to all periods presented in the financial statements. We are currently evaluating the provisions of
this guidance and assessing the potential impact on our financial statement disclosures.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>


<!-- Field: Page; Sequence: 122; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
recent accounting pronouncements issued by the FASB, including its Emerging Issues Task Force, the American Institute of Certified Public
Accountants, and the Securities and Exchange Commission did not or are not believed by management to have a material impact on the Company&#8217;s
present or future consolidated financial statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTE
3 &#8211; VENDOR AGREEMENTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Vendor
Advances </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has entered into various contracts with service providers pursuant to which the Company pays the vendor an advance at the beginning
of the contractual period. These vendor advances could be paid by the Company either in cash or in shares of common stock, depending
on the terms of the contract. The advances are reduced by the accumulated value of the services performed by the vendor or are amortized
on a straight-line basis over the service period, whichever is shorter. As of December 31, 2024, advances to vendors totaled $3,115,
with $2,615 being paid in cash and $500 being paid with shares of the Company&#8217;s common stock. Amortization expense relating to
the vendor advances during the year ended December 31, 2024 was $256, with an unamortized balance of $2,859 as of December 31, 2024.
During the year ended December 31, 2025, an additional advance to a vendor totaled $156, with the advance being paid with shares of the
Company&#8217;s common stock, and amortization expense relating to the vendor advances was $2,170, with an unamortized balance of $845
as of December 31, 2025.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Vendor
advances consisted of the following at December 31, 2025, and 2024:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="display: none">SCHEDULE
OF VENDOR ADVANCES</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">December
    31, 2025</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">December
    31, 2024</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 56%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Prevail Infoworks (a)</FONT></TD><TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 18%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">900</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 18%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">900</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">PreCheck Health Services (b)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">900</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">900</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">CEO.CA Technologies (c)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">250</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">250</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Belair Capital Advisors (d)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">365</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">365</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Cross Current Capital
    (e)</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">856</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">700</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Vendor advances, gross</FONT></FONT></FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">3,271</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">3,115</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Less: accumulated amortization</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(2,426</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(256</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Vendor advances,
    net</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">845</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">2,859</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
remaining unamortized balance of $845 as of December 31, 2025, will be fully amortized during the year ending December 31, 2026.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I><FONT STYLE="text-decoration: underline">(a)</FONT></I></B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I><FONT STYLE="text-decoration: underline">Kairos
    Agreement with Prevail Infoworks, Inc.</FONT></I></B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 1, 2024, the Company entered into a master service and technology agreement with Prevail Infoworks, Inc. (&#8220;Prevail&#8221;),
pursuant to which Prevail agreed to provide certain clinical research services to the Company. As part of the agreement, the Company
was required to make an advance payment of $900 to Prevail before commencement of services and, at such time as we notify Prevail to
engage their services related to the relevant clinical trial, or six months from the date of the agreement, pay approximately $80 per
month during the time Prevail performs clinical research services for the Company&#8217;s Phase 2 ENV 105 prostate and Phase 1 ENV 105
lung clinical trials. The agreement with Prevail is subject to cancellation at any time upon 30 days&#8217; written notice to the other
party. The Company made the advance payment to Prevail in October 2024 and it is included in vendor advances on the accompanying Balance
Sheet as of December 31, 2025 and 2024. The unamortized balance of the advance was $500 as of December 31, 2025.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>


<!-- Field: Page; Sequence: 123; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I><FONT STYLE="text-decoration: underline">(b)</FONT></I></B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I><FONT STYLE="text-decoration: underline">Kairos
    Agreement with PreCheck Health Services, Inc.</FONT></I></B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 20, 2024, the Company entered into a bioassay services agreement (the &#8220;Bioassay Services Agreement&#8221;) with PreCheck
Health Services, Inc., a Florida-based corporation (&#8220;PreCheck&#8221;). Pursuant to the Bioassay Services Agreement, PreCheck will
provide certain biomarker screening services for the Company&#8217;s ongoing carotuximab (ENV105) clinical trials in order to assist
the Company in identifying lung and prostate cancer patients suitable to the Company&#8217;s ongoing Phase 1 clinical trials for lung
cancer patients and Phase 2 clinical trials for patients with castrate resistant prostate cancer. In exchange for PreCheck&#8217;s services,
and according to the terms of the Bioassay Services Agreement, the Company paid $900 to PreCheck as an advance for the future laboratory
services to be performed. The payment of $900 is included in vendor advances on the accompanying Balance Sheet as of December 31, 2025
and 2024. The term of the agreement is one year from the effective date. The advance was fully amortized as of December 31, 2025.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I><FONT STYLE="text-decoration: underline">(c)</FONT></I></B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I><FONT STYLE="text-decoration: underline">Kairos
    Agreement with CEO.CA Technologies Ltd.</FONT></I></B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 23, 2024, the Company entered into an advisory and consulting services agreement (the &#8220;CEO.CA Agreement&#8221;) with
CEO.CA Technologies Ltd., a Canadian company (&#8220;CEO.CA&#8221;), pursuant to which CEO.CA will provide certain internet-based financial
information and communications services for a period of one year for a services fee of $250. The service fee is an advance on future
services to be performed. The CEO.CA Agreement includes services such as strategic news placement, news releases, interviews, monthly
analytics and a video launch. The CEO.CA Agreement contains other customary clauses, including representations and warranties, indemnification
clauses and governing law clauses. The payment of $250 is included in vendor advances on the accompanying Balance Sheet as of December
31, 2025 and 2024. The advance was fully amortized as of December 31, 2025.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I><FONT STYLE="text-decoration: underline">(d)</FONT></I></B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I><FONT STYLE="text-decoration: underline">Kairos
    Agreement with Belair Capital Advisors Inc.</FONT></I></B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 23, 2024, the Company entered into a strategic advisory agreement (the &#8220;Strategic Advisory Agreement&#8221;) with Belair
Capital Advisors Inc. (&#8220;BCA&#8221;). BCA, a venture capital and corporate finance advisory firm, has been a long-term investor
and advisor to the Company and frequently works with early-stage pharmaceutical companies. The strategic advisory services provided by
BCA consist of corporate strategy, market positioning and long-term growth plans within the pharmaceutical sector, digital marketing
and engagement, market research analysis and business development assistance, among other things. During the one-year term of the Strategic
Advisory Agreement, in exchange for its services, the Company will pay BCA a $365 fee and will issue BCA 50,000 RSUs, which will vest
at the end of six months following the date of issuance. The payment of $365 is included in vendor advances on the accompanying Balance
Sheet as of December 31, 2025 and 2024. The advance was fully amortized as of December 31, 2025.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I><FONT STYLE="text-decoration: underline">(e)</FONT></I></B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I><FONT STYLE="text-decoration: underline">Kairos
    Agreement with Cross Current Capital LLC</FONT></I></B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 1, 2024, the Company entered into a consulting agreement (the &#8220;Consulting Agreement&#8221;) with Cross Current Capital
LLC, a limited liability company organized under the laws of Puerto Rico (&#8220;Cross Current&#8221;), and Alan Masley (the &#8220;Advisor&#8221;),
pursuant to which Cross Current agreed to provide certain financial and business consulting services to the Company including, but not
limited, to (a) help drafting a public company competitive overview, (b) help preparing and/or reviewing a valuation analysis, (c) help
in drafting marketing materials and presentations, (d) reviewing the Company&#8217;s business requirements and discuss financing and
businesses opportunities, (e) investor marketing, (f) investor relations introductions, (g) legal counsel introductions, (h) auditor
introductions, (i) investment banking and research introductions, (j) M&amp;A canvassing and ways to grow the business organically, and
(k) stand by capital markets advisory services. For the services rendered thereunder, the Company agreed to pay Cross Current $200 in
cash and agreed to issue to the Advisor $500 of restricted shares of the Company&#8217;s common stock under the Company&#8217;s 2023
Plan, which was calculated at 367,647 shares (the &#8220;Shares&#8221;) as of the date of the agreement and were issuable at December
31, 2024. The term of the Consulting Agreement is 24 months and can be extended for another 12 months upon the written consent of both
parties. The Company made the $200 payment in October 2024. The payment of $200 and the value of the shares issued of $500 are included
in vendor advances on the accompanying Balance Sheet as of December 31, 2025 and 2024.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>


<!-- Field: Page; Sequence: 124; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
367,647 shares issuable in 2024 were subject to a &#8220;true up&#8221; on April 1, 2025, at which time additional shares were either
issuable to the Advisor or to be returned by the Advisor to the Company in order to ensure the shares were valued at $500 as of April
1, 2025. Accordingly, on April 1, 2025, the Company issued an additional 166,541 shares of its common stock to the Advisor to bring the
value to $500. All the issuable shares were issued during the year ended December 31, 2025. The fair value of the additional shares on
the date of grant was $156. The Company recorded the fair value of the shares as a vendor advance as of the same date. The unamortized
balance of the advance was $345 at December 31, 2025.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTE
4 &#8211; DEFERRED OFFERING COSTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&#160;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Agreement
with Helena Global Investment Opportunities</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 12, 2024, the Company entered into an agreement with Helena Global Investment Opportunities I LTD (&#8220;Helena&#8221;) pursuant
to which the Company will have the right to issue and sell to Helena, from time to time, and Helena shall purchase from the Company,
up to $30,000 of the Company&#8217;s shares of common stock (the &#8220;Equity Line of Credit&#8221;). The Equity Line of Credit became
available to the Company after the Company filed a registration statement on Form S-1 registering the shares issuable under the Equity
Line of Credit and such registration statement became effective. In exchange for the Equity Line of Credit, the Company is obligated
to issue Helena a certain number of shares of common stock, calculated using $900 divided by the lowest one-day VWAP during the five
trading days prior to entry into the agreement. As a result, the Company issued Helena 670,641 shares of its common stock valued at $1,377
on the date of issuance. The Company accounted for the value of the shares issued as deferred offering costs. The shares vested on the
date of the agreement, were issued to Helena, and were subject to a &#8220;true up&#8221; based upon the value of the stock after the
company filed and obtained effectiveness of the registration statement registering the ELOC shares for resale. At December 31, 2024,
the balance of the deferred offering costs was $1,377.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 24, 2025, the Company issued another 384,459 shares of its common stock to Helena. The fair value of the shares on the date of
grant was $328. The Company recorded the fair value of the shares as deferred offering costs as of the same date. During the year ended
December 31, 2025, the Company amortized $614 of these costs as shares were issued under the agreement. As of December 31, 2025, the
balance of the deferred offering costs was $1,091.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTE
5 &#8211; SHAREHOLDERS&#8217; EQUITY</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><FONT STYLE="text-decoration: underline">Common
Stock</FONT></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I><FONT STYLE="text-decoration: underline">Authorized
Shares</FONT></I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s Certificate of Incorporation, as filed with the State of Delaware on May 10, 2023, following the Company&#8217;s conversion
from a California corporation into a Delaware corporation, authorizes the Company to issue up to 120,000,000 shares, consisting of 100,000,000
shares of common stock, par value of $0.001 per share, and 20,000,000 shares of preferred stock, par value $0.001 per share. Holders
of shares of common stock have full voting rights, one vote for each share held of record. Shareholders are entitled to receive dividends
as may be declared by the board of directors out of funds legally available and share pro rata in any distributions with shareholders
upon liquidation. Shareholders have no conversion, pre-emptive or subscription rights. All outstanding shares of common stock are fully
paid and non-assessable. As of December 31, 2025 and 2024, there were 20,821,353 and 13,736,597 shares of common stock issued and outstanding,
respectively, and no shares of preferred stock outstanding, respectively.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I><FONT STYLE="text-decoration: underline">Common
Stock Issued for Cash Upon Closing of the Company&#8217;s IPO</FONT></I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 17, 2024, the Company completed the IPO of its common stock in which the Company issued and sold 1,550,000 shares of its common
stock at a public offering price of $4.00 per share. The total gross proceeds of the IPO were $6,200 and the Company raised $5,524 in
net proceeds after deducting underwriting discounts and commissions and offering expenses payable by the Company, excluding deferred
offering costs of $872. The underwriters were granted a 45-day option to purchase up to an additional 232,500 shares of common stock
from the Company. No additional shares were sold under the 45-day option.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>


<!-- Field: Page; Sequence: 125; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 17, 2024, pursuant to the underwriting agreement, the Company issued common stock purchase warrants to the underwriters to
purchase up to 108,500 shares of the Company&#8217;s common stock, at an exercise price of $4.80 per share, subject to adjustments. The
warrants will be exercisable during the period commencing on March 16, 2025 and ending on September 17, 2029, and may be exercised on
a cashless basis under certain circumstances.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&#160;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I><FONT STYLE="text-decoration: underline">Common
Stock Issued Upon Conversion of Convertible Notes Payable and Accrued Interest</FONT></I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2022, the Company entered into several convertible note payable agreements with certain investors totaling
$675, with adjustments increasing the principal balance to $792 as of September 17, 2024, the date of the Company&#8217;s IPO. Upon closing
of the Company&#8217;s IPO, the principal amount of $792, plus the accrued and unpaid interest of $92, totaling $884, automatically converted
into 368,371 shares of the Company&#8217;s common stock based on the principal and accrued interest due as of September 17, 2024.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&#160;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I><FONT STYLE="text-decoration: underline">Common
Stock Issued Upon Conversion of Accounts Payable</FONT></I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2024, the Company entered into an agreement with Cedars-Sinai Medical Center (&#8220;Cedars&#8221;) under
which Cedars agreed to convert $750 of the total accounts payable due to them into 312,500 shares of the Company&#8217;s common stock,
with such conversion to occur upon the closing of the Company&#8217;s IPO. The conversion price of the shares was equal to 60% of the
per share IPO price, or $2.40 per share. Upon the closing of the IPO, the shares were issued to Cedars and the debt was forgiven. The
fair value of the shares was $1,250. The Company recorded the difference between the fair value of the shares and the debt forgiven as
a financing cost of $500, which was recorded during the year ended December 31, 2024.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Also,
during the year ended December 31, 2024, the Company entered into another agreement with Cedars under which Cedars agreed to convert
$200 of the total accounts payable due to them into 150,830 shares of the Company&#8217;s common stock. The conversion price of the shares
was equal to 60% of the closing price of the Company&#8217;s common stock on the date of the agreement, or $1.33 per share. The fair
value of the shares was $333. The Company recorded the difference between the fair value of the shares and the debt forgiven as a financing
cost of $133, which was recorded during the year ended December 31, 2024.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2024, the Company entered into an agreement with its Chief Financial Officer (&#8220;CFO&#8221;), under which
he agreed to convert $172 of the total accounts payable due to him into 51,610 shares of the Company&#8217;s common stock with such conversion
to occur upon the closing of the Company&#8217;s IPO. The conversion price of the shares was equal to 83% of the IPO price. Upon the
closing of the IPO, the shares were issued to the CFO. The fair value of the shares was $206. The Company recorded the difference between
the fair value of the shares and the accounts payable forgiven as a financing cost of $34, which was recorded during the year ended December
31, 2024. No amounts were owed to the CFO as of December 31, 2024.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
summary, during the year ended December 31, 2024, the company issued 514,940 shares of its common stock with a fair value of $1,789 relating
to the conversion of its account payable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&#160;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I><FONT STYLE="text-decoration: underline">Common
Stock Issued Upon Conversion of Amounts Due to Related Parties</FONT></I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2021, shareholders of the Company, and a company whose principal stockholder is also a stockholder of the
Company, advanced the Company $14. As of September 17, 2024, the date of the closing of the Company&#8217;s IPO, a total of $4 was outstanding.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2024, the officers agreed to automatically convert the principal into shares of the Company&#8217;s common
stock upon the closing of the IPO transaction. Upon the closing of the IPO, all of the principal automatically converted into 1,664 shares
of the Company&#8217;s common stock based on the conversion price of $2.40, which was 60% of the IPO closing price of $4. As the officers
received 666 additional shares based on the 40% discounted price, the fair value of those shares, $3, was recorded as a financing cost
during the year ended December 31, 2024. As of December 31, 2024, no principal or interest was due on the advances.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&#160;</I></B></FONT></P>


<!-- Field: Page; Sequence: 126; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&#160;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I><FONT STYLE="text-decoration: underline">Common
Stock Issued for Advances to Vendors</FONT></I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 1, 2024, the Company entered into a consulting agreement (the &#8220;Consulting Agreement&#8221;) with Cross Current Capital
LLC, a limited liability company organized under the laws of Puerto Rico (&#8220;Cross Current&#8221;), and Alan Masley (the
&#8220;Advisor&#8221;), pursuant to which Cross Current agreed to provide certain financial and business consulting services to the
Company. For the services rendered thereunder, the Company agreed to issue to the Advisor $500
of restricted shares of the Company&#8217;s common stock under the Company&#8217;s 2023 Plan, which was calculated at 367,647
shares (the &#8220;Shares&#8221;) as of the date of the agreement. The Shares were subsequently issued to Cross Current in 2025. The
value of the shares issued of $500
are included in Vendor Advances on the accompanying Balance Sheet as of December 31, 2025 and 2024 (see Note 3).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">The Shares  were subject to a &#8220;true up&#8221; on April 1, 2025, at which time additional shares were
either issuable to the Advisor or to be returned by the Advisor to the Company in order to ensure the shares were valued at $500
as of April 1, 2025. Accordingly, on April 1, 2025, the Company issued an additional 166,541
shares of its common stock to the Advisor to bring the value to $500.
The fair value of the additional shares on the date of grant was $157.
The Company recorded the fair value of the shares as a Vendor Advance as of the same date (see Note 3).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&#160;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I><FONT STYLE="text-decoration: underline">Common
Stock Issued for Cash Upon Closing of the Company&#8217;s Private Financing</FONT></I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&#160;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 14, 2025, the Company entered into a securities purchase agreement (&#8220;SPA&#8221;) and registration rights agreement with
an investor for the sale and issuance of 2,500,000 units (the &#8220;Pre-Funded Units&#8221;), with each Pre-Funded Unit consisting of
a pre-funded warrant to purchase one share of common stock, exercisable for $0.001 per share, and a common warrant to purchase one and
one half shares of common stock (an aggregate of 3,750,000), exercisable at $1.399 per share. On January 16, 2025, the Company closed
on the sale of the Pre-Funded Units for a total purchase price of $3,500 (or $1.40 per Pre-Funded Unit). Net proceeds received by the
Company relating to the financing, and subsequent exercise of prefunded warrants was $3,058.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
pre-funded warrants have an exercise price of $0.001 per share and are immediately exercisable and will expire when exercised in full.
The common warrants have an exercise price of $1.40 per share, will be exercisable six months from issuance and will expire five and
a half years from the issuance date. During the year ended December 31, 2025, the investor exercised 2,500,000 shares of the pre-funded
warrants and as of December 31, 2025, there were no pre-funded shares remaining unexercised.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I><FONT STYLE="text-decoration: underline">Common
Stock Issued for Cash Upon Exercise of the Company&#8217;s Equity Line of Credit (ELOC)</FONT></I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&#160;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2025, in connection with its ELOC agreement with Helena, the Company sold 3,510,000 shares of its common
stock to Helena for net proceeds of $2,988, which includes the allocation of deferred offering costs of $614. The shares were issued
to Helena during the year ended December 31, 2025.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I><FONT STYLE="text-decoration: underline">Adoption
of the 2023 Equity Incentive Plan</FONT></I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
July 2023, the Company&#8217;s board of directors and stockholders adopted the 2023 Equity Incentive Plan (the &#8220;2023 Plan&#8221;).
Under the 2023 Plan, the Company may grant incentive stock options to employees, including employees of any parent or subsidiary, and
nonstatutory stock options, stock appreciation rights, restricted stock awards, RSU awards, performance awards and other forms of stock
compensation to employees, directors and consultants, including employees and consultants of the Company&#8217;s affiliates. As approved,
a total of 1,650,000 shares of common stock were initially reserved for issuance under the 2023 Plan. As of December 31, 2025, and 2024,
a total of 877,395 shares and 1,478,000 remained available for issuance under the 2023 Plan, respectively.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>


<!-- Field: Page; Sequence: 127; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&#160;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I><FONT STYLE="text-decoration: underline">Grant
of Restricted Stock Units (RSUs)</FONT></I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
following table summarizes restricted common stock activity during the years ended December 31, 2024 and 2025:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="display: none">SCHEDULE
OF RESTRICTED COMMON STOCK ACTIVITY</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Number
                                            of</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Restricted
                                            Shares</B></FONT></P></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Fair
    Value</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Weighted
                                            Average</B></FONT></P>
                                                                               <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Grant
                                            Date Fair</B></FONT></P>
                                                                               <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Value</B></FONT></P></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unvested, December 31,
    2023</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8212;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8212;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8212;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 46%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</FONT></TD><TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="width: 14%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">240,341</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="width: 14%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">532</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="width: 14%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">2.21</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Vested</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(68,341</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(218</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">3.19</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Forfeited</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8212;</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8212;</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8212;</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unvested, December 31,
    2024</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">172,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">314</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1.83</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">745,312</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">981</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1.32</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Vested</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(144,707</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(482</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">3.33</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Forfeited</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8212;</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8212;</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8212;</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unvested,
    December 31, 2025</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">772,605</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">813</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1.05</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 8, 2025, the Company&#8217;s Compensation Committee of the board of directors approved the grant of an aggregate total of 667,940
RSUs to the Company&#8217;s executive officers and directors for their services to be performed from October 2025 to October 2026. The
RSUs were granted under the Company&#8217;s 2023 Equity Incentive Plan and were valued at $875 on the date of grant. Additionally, the
Company&#8217;s independent directors received an aggregate total of 57,252 RSUs, with a value of $75 on the date of grant. Each RSU
represents the right to receive one share of the Company&#8217;s common stock upon vesting. The RSUs will vest in full on October 8,
2026, the first anniversary following the grant date, subject to the recipient&#8217;s continuous service with the Company through such
vesting date. Notwithstanding the foregoing vesting schedule, in the event of a change in control of the Company (as defined in the Plan)
occurring prior to the vesting date, all unvested RSUs will become fully vested immediately upon the occurrence of such change in control.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 23, 2024, the Company entered into a strategic advisory agreement with Belair Capital Advisors Inc. (&#8220;Belair&#8221;).
During the one-year term of the agreement, in exchange for its services, the Company issued Belair 50,000 RSUs, which vest nine months
from the date of issuance. The fair value of the shares on the date of grant was $100, which value will be amortized over the one-year
service period of the agreement. None of these shares vested or were issued during the year ended December 31, 2024. During the years
ended December 31, 2025, the 50,000 RSUs vested and the shares were issued to Belair. As of December 31, 2025, no RSUs remained unvested.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
the closing of the Company&#8217;s IPO, the Company entered into agreements with each of its four officers. Such agreements provided
for annual grants of RSUs in accordance with the terms of the Company&#8217;s 2023 Equity Incentive Plan. The RSUs vest over one- or
two-year periods and are subject to full acceleration of vesting upon the sale of the Company. Upon the closing of the Company&#8217;s
IPO in September 2024, the Company granted the officers 92,000 RSUs. The fair value of the shares on the date of grant was $226. None
of these RSUs vested during the year ended December 31, 2024. During the years ended December 31, 2025, a total of 78,000 RSUs vested,
and the shares were issued to the officers. As of December 31, 2025, 14,000 RSUs remained unvested.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
the closing of the Company&#8217;s IPO, the Company entered into agreements with each of its three independent directors. The Company&#8217;s
policy provides that, upon initial election or appointment to its board of directors, each new non-employee director will be granted
a one-time grant, or Director Initial Grant, that will vest in substantially equal annual installments over a period of three years.
The Director Initial Grant is subject to full acceleration of vesting upon the sale of the Company, in accordance with the terms of the
Company&#8217;s 2023 Plan. In 2024, a total of 30,000 RSUs were granted to the directors. The fair value of the RSUs on the date of grant
was $43. None of the RSUs vested during the year ended December 31, 2024. During the years ended December 31, 2025, an additional 20,120
RSUs were granted to the Company&#8217;s new director with a fair value of $31. During the year ended December 31, 2025, a total of 16,707
shares vested, and 33,413 RSUs remained unvested.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>


<!-- Field: Page; Sequence: 128; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the years ended December 31, 2025, the Company recorded $482 of stock compensation-related expense for the fair value vesting of restricted
common stock. As of December 31, 2025, $813 of unamortized compensation remained.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&#160;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I><FONT STYLE="text-decoration: underline">Stock
Warrants</FONT></I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
table below summarizes the Company&#8217;s warrant activities for years ended December 31, 2024 and 2025:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="display: none">SCHEDULE
OF WARRANT ACTIVITY</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Number
                                            of</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Warrant</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Shares</B></FONT></P></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exercise</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Price</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Range</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Per
                                            Share</B></FONT></P></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Weighted</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Average</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exercise</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Price</B></FONT></P></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 46%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance, December
    31, 2023</FONT></TD><TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="width: 14%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">150,000</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 14%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">4.17</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 14%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">4.17</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">128,188</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.40
                                            &#8211; 4.80 </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">4.43</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cancelled</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8212;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8212;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8212;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercised</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8212;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8212;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8212;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Forfeited/Expired</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8212;</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8212;</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8212;</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance, December 31, 2024</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">278,188</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">2.40
                                            - 4.80</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">4.29</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">6,670,700</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">0.001
                                            &#8211; 1.40</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">0.87</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cancelled</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8212;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8212;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8212;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercised</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(2,517,850</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">0.001
                                            &#8211; 0.46</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">0.004</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Forfeited/Expired</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(150,000</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">4.17</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">4.17</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance,
    December 31, 2025</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">4,281,038</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">0.40
                                            &#8211; 4.80</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1.48</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Vested
    and exercisable, December 31, 2025</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">4,281,038</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">0.40
                                            &#8211; 4.80</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1.48</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes information concerning outstanding and exercisable warrants as of December 31, 2025:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="display: none">SCHEDULE
OF OUTSTANDING AND EXERCISABLE WARRANTS</FONT></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD COLSPAN="10" STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Warrants
    Outstanding</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD COLSPAN="10" STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Warrants
    Exercisable</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Range
                                            of</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exercise</B></FONT></P>
                                                                                                                                                                                                                                                                                                 <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Prices</B></FONT></P></TD><TD STYLE="text-align: center; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Number</FONT></P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Outstanding</FONT></P></TD><TD STYLE="text-align: center; padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: center; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Average</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Remaining</B></FONT></P>
                                                                                                                                                                                                                                                                                                <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Contractual</B></FONT></P>
                                                                                                                                                                                                                                                                                                <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Life
                                            (in years)</B></FONT></P></TD><TD STYLE="text-align: center; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: center; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Weighted</B></FONT></P>
                                                                               <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Average</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exercise</B></FONT></P>
                                                                                                                                                                                                                                                                                                <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Price</B></FONT></P></TD><TD STYLE="text-align: center; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: center; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Number</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exercisable</B></FONT></P></TD><TD STYLE="text-align: center; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: center; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Average</B></FONT></P>
                                                                               <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Remaining</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Contractual</B></FONT></P>
                                                                                                                                                                                                                                                                                                  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Life</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(in
                                            years)</B></FONT></P></TD><TD STYLE="text-align: center; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: center; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Weighted</B></FONT></P>
                                                                               <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Average</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exercise</B></FONT></P>
                                                                                                                                                                                                                                                                                                <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Price</B></FONT></P></TD><TD STYLE="text-align: center; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 14%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.40
                                            - 0.46</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">17,850</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">4.42</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">0.46</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">17,850</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">4.42</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">0.46</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.23
                                            - 2.40</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">4,154,688</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">4.02</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1.40</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">4,154,688</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">4.02</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1.40</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">4.80</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">108,500</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">3.75</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">4.80</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">108,500</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">3.75</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">4.80</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.40
                                            - 4.80</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">4,281,038</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">4.01</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1.48</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">4,281,038</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">4.01</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1.48</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>


<!-- Field: Page; Sequence: 129; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&#160;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I><FONT STYLE="text-decoration: underline">Warrant
Grants </FONT></I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 14, 2025, as amended on January 16, 2025, the Company entered into a securities purchase agreement (&#8220;SPA&#8221;) and registration
rights agreement with a select investor. In connection with the agreement, on January 16, 2025, the Company issued the investor a pre-funded
warrant to purchase up to 2,500,000 shares of the Company&#8217;s common stock at an exercise price of $0.001 per share. The warrant
is immediately exercisable and will expire when exercised in full. During the years ended December 31, 2025, the SPA investor exercised
2,500,000 shares of the pre-funded warrant, and as of December 31, 2025, there were no shares remaining unexercised. The investor also
received a warrant to purchase up to 3,750,000 shares of the Company&#8217;s common stock at an exercise price of $1.40 per share. The
warrant will be exercisable six months from the date of issuance (July 2025) and will expire five years from the issuance date. All the
warrant shares were exercisable as of December 31, 2025.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 16, 2025, the Company issued a warrant to purchase common stock to the underwriters of the SPA for the purchase of 175,000 shares
of the Company&#8217;s common stock at an exercise price of $1.40 per share. The warrant vested upon grant. The warrant was issued to
the underwriters as they were the placement agents for the SPA noted above. The warrant expires five years from the date of grant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
May and June 2025, the Company issued warrants to purchase common stock to the underwriters of the SPA for the purchase of 35,700 shares
of the Company&#8217;s common stock at exercise prices of $0.40 and $0.46 per share. The warrants vested upon grant. The warrants were
issued to the underwriters as they were the placement agents for the SPA noted above. The warrants expire five years from the date of
grant. During the year ended December 31, 2025, a total of 17,850 shares were exercised under a cashless exercise, leaving 17,850 shares
outstanding and exercisable. A total of 11,402 shares of the Company&#8217;s common stock were issued pursuant to cashless exercise.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
July 2025, the Company issued warrants to purchase common stock to the underwriters of the SPA for the purchase of 210,000 shares of
the Company&#8217;s common stock at an exercise price of $1.23 per share. The warrants vested upon grant. The warrants were issued to
the underwriters as they acted as placement agents for the SPA noted above. The warrants expire five years from the date of grant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 17, 2024, upon the closing of the IPO, the Company issued stock warrants to the participating underwriters for the purchase
of up to 108,500 shares of the Company&#8217;s common stock, at an exercise price of $4.80 per share, subject to adjustment. The warrants
will be exercisable during the period commencing on March 16, 2025, and ending on September 16, 2029, and may be exercised on a cashless
basis under certain circumstances.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 17, 2024, upon the closing of the IPO, the Company issued a stock warrant to the underwriters for the purchase of 19,688 shares
of common stock at an exercise price of $2.40 per share. The warrant vested upon grant. The warrant was issued to the underwriters as
they were the placement agents for the convertible notes payable (see Note 5). The Company valued the warrant using a Black-Scholes pricing
model with the following weighted average assumptions: fair value of the Company&#8217;s stock price of $2.46 per share, the expected
term of 2.5 years, volatility of 100%, dividend rate of 0%, and risk-free interest rate of 3.49%. The fair value of the warrant of $29
was recorded to General and Administrative expense during the year ended December 31, 2024. The warrant expires five years from the date
of grant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
intrinsic value for warrant shares outstanding as of December 31, 2025 was $4.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTE
6 &#8211; COMMITMENTS AND CONTINGENCIES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I><FONT STYLE="text-decoration: underline">Kairos
Exclusive License Agreements with Cedars-Sinai Medical Center (Cedars)</FONT></I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has entered into four Exclusive License Agreements with Cedars, each of which grants the Company licensing rights with respect
to certain patent rights owned by Cedars as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Methods
    of use of compounds that bind to RelA of NFkB;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Composition
    and methods for treating fibrosis;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Compositions
    and methods for treating cancer and autoimmune diseases; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Method
    of generating activated T cells for cancer therapy.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>


<!-- Field: Page; Sequence: 130; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
each of the exclusive license agreement in items 1, 2 and 3, the Company was required to pay an initial license fee of $5, reimburse
Cedars for patent protection costs ranging from approximately $9 to $61, pay an annual maintenance fee of $10, and pay royalties based
on 3.75% of net sales and pay other non-royalty sublicense fees ranging from 5% to 35% of sales of products. In addition, for items 1,
2 and 3, the Company is required to pay Cedars based on the following milestones:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$150
    upon the successful completing of Phase I clinical trial;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$250
    (for items 1 and 2) and $500 (for item 3) upon the successful completing of Phase II clinical trial for a product and receipt of
    Food and Drug Administration (&#8220;FDA&#8221;) approval for a Phase III clinical trial;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$1,500
    upon receipt of FDA approval of a new drug application or equivalent foreign regulatory approval in a non-United States major commercial
    market; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$250
    upon cumulative net sales exceeding $5,000.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the exclusive license agreement in item 4, the Company is required to pay an initial license fee of $50 upon raising $500 in capital,
pay an annual maintenance fee of $10, pay royalties based on 4.25% of patent product sales and 0.5% of other sales and pay other non-royalty
sublicense fees ranging from 5% to 35%. In addition, the Company is required to pay Cedars based on the following milestones:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$150
    upon the successful completing of Phase I clinical trial;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$250
    upon the successful completing of Phase II clinical trial and receipt of Food and Drug Administration (&#8220;FDA&#8221;) or equivalent
    regulatory agency in another jurisdiction approval for a Phase III clinical trial;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$1,500
    upon receipt of FDA approval of a new drug application; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$2,500
    upon cumulative net sales exceeding $50,000.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2025, no amounts were due under the Exclusive License Agreements between Cedars and the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I><FONT STYLE="text-decoration: underline">Enviro
Therapeutics</FONT></I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 2, 2021, the Company&#8217;s then-wholly owned subsidiary, Enviro, entered into two Exclusive License Agreements with Cedars,
which granted Enviro exclusive licensing rights (which include the right to sublicense) with respect to certain patent rights owned
by Cedars, as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">an
    Exclusive License Agreement (the &#8220;Enviro-Cedars License Agreement (Mitochondrial DNA)&#8221;) for Enviro to develop, manufacture,
    use and sell products utilized or derived from patent rights worldwide related to the &#8220;Compositions and Methods for Treating
    Diseases and Conditions by Depletion of Mitochondrial DNA from Circulation and for Detection of Mitochondrial DNA&#8221; invented
    by Dr. Neil Bhowmick and others; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">an
    Exclusive License Agreement (the &#8220;Enviro-Cedars License Agreement (Endoglin Antagonism)&#8221; and, collectively with the Enviro-Cedars
    License Agreement (Mitochondrial DNA), the &#8220;Enviro-Cedars License Agreements&#8221;) for Enviro to develop, manufacture, use
    and sell products utilized or derived from the patent rights and technical information worldwide related to the &#8220;Sensitization
    of Tumors to Therapies Through Endoglin Antagonism&#8221; invented by Dr. Neil Bhowmick and others.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
exchange for each of the licenses, pursuant to the terms of the Exclusive License Agreements, Enviro was required to pay an upfront
license fee in the mid four-figures and low-five figures, respectively. Enviro was also required to reimburse Cedars for the costs
in the mid-to-high six figures incurred in the prosecution of the patent rights subject to the Enviro-Cedars License Agreements
prior to the date of execution of such agreements, and certain costs and fees then outstanding aggregating in the low-six figures
owed by Kairos pursuant to the Kairos-Cedars License Agreements. Pursuant to the Enviro-Cedars License Agreements, Cedars was also
to receive royalty payments of a mid-single-digit percentage of net sales of products associated with the licensed patent right and
less than one percent of net sales of other products derived from Cedars&#8217; technical information, with a minimum annual royalty
fee in the low five-digits due beginning on the third anniversary of the effective date of the Enviro-Cedars License Agreements. To
the extent Enviro derived non-royalty sublicensing revenues, a high single-digit to low double-digit percentage of such revenues
would be due and payable to Cedars, with the actual percentage of such revenues dependent on the stage of FDA authorization at the
time the sublicense revenue is generated.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>


<!-- Field: Page; Sequence: 131; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Enviro
was also required to pay Cedars in connection with achieving the following Payment Milestones relating to products derived from the patent
rights: successful completion of a Phase I clinical trial; successful completion of a Phase II clinical trial, receipt of FDA approval,
and approval for a Phase III clinical trial; FDA approval of an NDA or BLA; cumulative net sales exceeding $50,000; and cumulative net
sales exceeding $100,000. If all of these payment milestones are met among both of the Exclusive License Agreements, the required
milestone payments would total in the mid-to-high seven-figures.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the Exclusive License Agreements, Enviro was obligated to meet the following Commercialization Milestones. Pursuant to the
Enviro-Cedars License Agreement (Endoglin Antagonism), Enviro was obligated to (1)
obtain an IND for a patent product within 1 year of the effective date of the agreement, (2) commence a Phase II trial within 2
years of the effective date of the agreement, and (3) submit an NDA or BLA to the FDA or equivalent regulatory agency in another
jurisdiction within 7 years of the effective date of the agreement. Pursuant to the Enviro-Cedars License Agreement (Mitochondrial
DNA), Enviro was obligated to (1) complete preclinical studies of a patent product within 2 years of the effective date of the
agreement, (2) complete toxicology studies within 2.5 years of the effective date of the agreement, (3) obtain IND within 3 years of
the effective date of the agreement, (4) begin a Phase I trial within 4 years of the effective date of the agreement, and (5) submit
an NDA or BLA to the FDA or equivalent regulatory agency in another jurisdiction within 7 years of the effective date of the
agreement. If the Commercialization Milestones are not met or extended, Cedars may convert the exclusive licenses into non-exclusive
licenses or to a co-exclusive licenses or terminate the licenses.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Exclusive License Agreements will, unless sooner terminated, continue in effect on a country-by-country basis until the last of the
patents covering the patent rights or future patent rights expires. Under the terms of the Enviro-Cedars License Agreements, unless waived
by Cedars, the agreements would automatically terminate: (a) if Enviro ceases, dissolves or winds up its business operations; (b) if
performance by either party jeopardizes the licensure, accreditation or tax exempt status of Cedars or the agreement is deemed illegal
by a governmental body; (c) within 30 days for non-payment of royalties or if Enviro fails to undertake commercially reasonable efforts
to exploit the patent rights or future patent rights; (d) within 60 days of Cedars&#8217; failure to cure any breach or default of a
material obligation under the agreements; (e) within 90 days of Enviro&#8217;s failure to cure any breach or default of a material obligation
under the agreements; or (f) upon mutual written agreement of the parties.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><B><I><FONT STYLE="text-decoration: underline">Novation Agreements</FONT></I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><B><I>&#160;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">On October 1, 2025, the Board of Directors approved
the entry of Kairos and Enviro into a novation agreement (the &#8220;Cedars Novation Agreement&#8221;) with Cedars. The Cedars Novation
Agreement was entered into on October 1, 2025, but effective as of April 17, 2025, for purposes of transferring the exclusive license
of two patents from Enviro, as the original licensee, to Kairos, as the new licensee. As the new licensee of the two patents, Kairos accepted
and assumed all obligations and liabilities that may arise under the Exclusive License Agreements from Enviro and Enviro is relieved of
all of its liabilities and obligations under the license agreements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">In addition, on October 1, 2025, the Board approved
the Company&#8217;s entry into a novation agreement (the &#8220;Tracon Novation Agreement&#8221;) with Tracon Pharmaceuticals, Inc. (the
&#8220;Tracon&#8221;) and Enviro pursuant to which Enviro&#8217;s rights and obligations under the license and supply agreement between
Tracon, Enviro and Kairos, originally dated May 21, 2021, as amended to date (the &#8220;Tracon License Agreement&#8221;), were transferred
from Enviro to Kairos and Enviro was relieved of any further liabilities or obligations under the license and supply agreement. Under
the Tracon License Agreement, Tracon had granted Enviro exclusive access to its TRC105 and CD105 technologies, which Kairos has now assumed
pursuant to the Tracon Novation Agreement.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I><FONT STYLE="text-decoration: underline">Agreement
with Lonza Sales AG</FONT></I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 12, 2025, the Company entered into an amendment (the &#8220;Lonza Amendment&#8221;) to the sales agreement with Lonza Sales
AG (&#8220;Lonza&#8221;), originally dated February 14, 2008, pursuant to which the Company agreed to purchase and Lonza agreed to
testing of standards and the preparation to manufacture ENV105 antibody to be used in the Company&#8217;s Phase 2 clinical trial.
The Company agreed to pay a total of $1,143
in consideration, which will be paid over time as each of the 13 stages of the Lonza Amendment are completed. As of December 31, 2025, Lonza&#8217;s testing and preparation of the ENV105 antibody had yet to be completed and
the Company had yet to make any payments to Lonza.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&#160;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I><FONT STYLE="text-decoration: underline">Legal
Matters</FONT></I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&#160;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
the Company&#8217;s knowledge, it is not currently the subject of any material legal proceeding. In the future, the Company may be involved
in actual and/or threatened legal proceedings, claims, investigations and government inquiries arising in the ordinary course of our
business, including legal proceedings, claims, investigations and government inquiries involving intellectual property, data privacy
and security, other torts, illegal or objectionable content, consumer protection, securities, employment, contractual rights, civil rights
infringement, false or misleading advertising, or other legal claims relating to our business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&#160;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTE
7 &#8211; INCOME TAXES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred
income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial
reporting purposes and the amounts used for income tax purposes. A full valuation allowance is established against all net deferred tax
assets as of December 31, 2025 and 2024 based on estimates of recoverability. While the Company has optimistic plans for its business
strategy, it determined that such a valuation allowance was necessary given the current and expected near-term losses and the uncertainty
with respect to its ability to generate sufficient profits from its business model. Because of the impacts of the valuation allowance,
there was no income tax expense or benefit for the years ended December 31, 2025 and 2024.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>


<!-- Field: Page; Sequence: 132; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
reconciliation of the differences between the effective and statutory income tax rates for the years ended December 31, 2025 and 2024
are shown below:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; display: none; text-align: justify">SCHEDULE OF RECONCILIATION OF THE DIFFERENCES BETWEEN THE EFFECTIVE AND STATUTORY INCOME TAX RATES<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="display: none; vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Amount</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Percent</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Amount</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Percent</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">2025</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">2024</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Amount</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Percent</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Amount</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Percent</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 40%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Federal statutory rates</FONT></TD><TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 11%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(1,144</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="width: 11%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">21.0</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">%</FONT></TD><TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 11%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(547</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="width: 11%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">21.0</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">%</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">State income taxes</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(381</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">7.0</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">%</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(182</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">7.0</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">%</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Other</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">%</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(13</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">0.5</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">%</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Valuation allowance against
    net deferred tax assets</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,525</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(28.0</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)%</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">742</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(28.5</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)%</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Effective rate</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">%</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">%</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
December 31, 2024 and 2023, the significant components of the deferred tax assets are summarized below:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="display: none">SCHEDULE OF SIGNIFICANT COMPONENTS OF THE DEFERRED TAX ASSETS AND LIABILITIES</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">2025</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">2024</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-decoration: underline; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Deferred income
    tax assets:</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; width: 56%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Net operating
    loss carryforwards</FONT></TD><TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 18%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">2,766</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 18%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,199</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-align: left; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Capitalized
    R&amp;D expenses</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">482</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">90</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 20pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Total deferred income tax
    assets</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">3,248</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,289</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-align: left; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Less:
    valuation allowance</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(3,009</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(841</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 20pt; text-align: left; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Total
    net deferred income taxes</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">239</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">448</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-decoration: underline; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Deferred income
    tax liabilities:</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Amortization of intangibles</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(17</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(62</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-align: left; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Accrual
    to cash</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(222</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(386</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 20pt; text-align: left; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Total
    deferred income tax liabilities</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(239</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(448</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Total deferred income
    tax assets</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2025, the Company has net operating loss (&#8220;NOL&#8221;) carryforwards of approximately $9,900 and are subject to
IRS code section 382 limitations. Of the total federal net operating loss, approximately $9,600 has an indefinite carryforward period
as of December 31, 2025. The remaining federal and California net operating loss carryforwards will expire through December 31, 2045,
unless previously utilized. NOL carryforwards may be subject to limitation under Sections 382 of the Internal Revenue Code, and similar
state provisions which limit the amount carryforwards that can be utilized to offset future taxable income. In general, an ownership
change, as defined by Sections 382, results from transactions increasing ownership of certain stockholders in the stock of the corporation
by more than 50 percentage points over a three-year period. The Company does not anticipate performing a complete analysis of the limitation
on the annual use of the net operating loss carryforwards until the time that it anticipates it will be able to utilize these tax attributes.
This could impose an annual limit or reduction on the Company&#8217;s ability to utilize net operating loss carryforwards and could cause
U.S. federal income taxes to be paid earlier than otherwise would be paid if such limitations were not in effect. The U.S. federal net
operating loss carryforwards are stated before any such anticipated limitations. If a change in ownership were to have occurred, the
Company&#8217;s NOL carryforwards could be eliminated or restricted.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&#160;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTE
8 &#8211; GAIN ON SETTLEMENT OF ACCOUNTS PAYABLE </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 17, 2024, the Company entered into a Settlement Agreement with the Company&#8217;s former outside legal counsel. In connection
with the agreement, the law firm agreed to settle the amount the Company owed them, which totaled $749, in exchange for a payment of
$150. This resulted in a gain of $599 for the Company. In October 2024, the Company made the $150 payment to the law firm. As of December
31, 2024, no amounts were owed to the law firm.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&#160;</B></FONT></P>


<!-- Field: Page; Sequence: 133; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&#160;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTE
9 &#8211; SEGMENT INFORMATION </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company operates and manages its business as one reportable segment and operates as a clinical-stage biopharmaceutical company. The Company&#8217;s
current focus is on developing immunotherapy and cell therapies for the treatment of cancer. The Company&#8217;s Chief Operating Decision
Maker (&#8220;CODM&#8221;) is the Chief Executive Officer, who reviews financial information presented and decides how to allocate resources
based on net income (loss). Net income (loss) is used for evaluating financial performance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Significant
segment expenses include research and development, officer compensation, insurance, and stock-based compensation. Operating expenses
include all the remaining costs necessary to operate our business, which primarily include external professional services and other administrative
expenses. The following table presents the significant segment expenses and other segment items regularly reviewed by our CODM:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="display: none">SCHEDULE
OF SEGMENT EXPENSES</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="display: none; vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">2025</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">2024</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Years
    ended December 31,</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">2025</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">2024</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">Revenue</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8212;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8212;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">Less:</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 60%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Research and development, less
    officer compensation</FONT></TD><TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="width: 16%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,837</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="width: 16%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">414</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Officer compensation and wages</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">716</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">119</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Insurance</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">385</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">151</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Stock-based compensation</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">482</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">218</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Operating expenses</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">2,152</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,441</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Other income (expenses)</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">125</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(260</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">NET
    LOSS</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(5,447</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(2,603</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTE
10 &#8211; SUBSEQUENT EVENTS </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
January 2026, the Company filed a shelf registration statement on Form S-3 (SEC File No. 333-292686) registering up to $75 million
in aggregate securities and, in conjunction therewith, filed a prospectus supplement for the sale of up to $4.5
million of common stock pursuant to an At the Market Offering Agreement (the &#8220;ATM Agreement&#8221;) with H.C. Wainwright and
Co., LLC (the &#8220;Placement Agent&#8221;). Under the ATM Agreement, the Placement Agent will be entitled to 3.0% of the gross
proceeds of any sales made under the ATM Agreement. As a result of the ATM offering, subsequent to December 31, 2025, the Company
raised $385 through the sale of 589,845 shares of its common stock.</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 2, 2026, the Company entered into a binding term sheet with Celyn Therapeutics, Inc., a privately held biotechnology company, regarding
a proposed asset acquisition of CL-273, an investigational, reversible, wild type sparing pan EGFR small molecule inhibitor being developed
by Eilean Therapeutics for EGFR mutant non-small cell lung cancer. Pursuant to the term sheet, the Company will receive 100% of the development, manufacturing, commercialization rights,
patent prosecution and patent filing rights worldwide to CL-273 in exchange for upfront payment of 16.5% of the Company&#8217;s outstanding
capital stock, with such stock to be issued in the form of Common Stock or convertible preferred stock, and milestone payments of (i)
$15 million payable at NDA or BLA FDA, with such payment to be made in combination of cash and stock and (ii) 2% royalties from net revenue
generated from sales in the U.S. for the life of the intellectual property. Closing is subject to satisfactory completion of due diligence
and negotiation of a definitive acquisition agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">On March 27, 2026, the Company entered into an additional statement
of work to the sales agreement with Lonza Sales AG (&#8220;Lonza&#8221;), originally dated February 14, 2008, pursuant to which the Company
agreed to purchase and Lonza agreed to testing of standards and the preparation to manufacture ENV105 antibody to be used in the Company&#8217;s
Phase 2 clinical trial. The Company agreed to pay an approximate total of $2,000 in consideration, which will be paid over time as each
of the 13 stages of the Lonza Amendment are completed. See Note 6 for further details.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>


<!-- Field: Page; Sequence: 134; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><FONT ID="an_012"></FONT>ITEM
9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
discussed in Form 8-K filed with the SEC on April 28, 2025 (the &#8220;Form 8-K&#8221;), which is incorporated herein by reference&#65292;on
April 23, 2025, the Audit Committee of the Company selected Weinberg and Company, P.A. (&#8220;Weinberg&#8221;) to serve as the Company&#8217;s
independent registered public accounting firm for the review of its Quarterly Reports on Form 10-Q and Annual Report on Form 10-K for
the fiscal year ending December 31, 2025. As a result, the Audit Committee dismissed Marcum LLP (&#8220;Marcum&#8221;) and Marcum would
no longer serve as the Company&#8217;s independent registered public accounting firm, effective as of April 23, 2025.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Marcum&#8217;s
audit report on our financial statements for the years ended December 31, 2024 and 2023 contained no adverse opinion or disclaimer of
opinion, nor was it qualified or modified as to uncertainty, audit scope or accounting principles, except that the audit report on the
financial statements of the Company for the year ended December 31, 2023 was modified as to contain uncertainty about the Company&#8217;s
ability to continue as a going concern.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the years ended December 31, 2024 and 2023 and through the date of the Form 8-K, the Company had no &#8220;disagreements&#8221; (as defined
in Regulation S-K, Item 304(a)(1)(iv) and the related instructions) with Marcum on any matter of accounting principles or practices,
financial statement disclosure, or auditing scope or procedures, which disagreements if not resolved to the satisfaction of Marcum would
have caused them to make reference thereto in their reports on the financial statements for such periods.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
were no reportable events as defined in item 304(a)(1)(v) of Regulation S-K for the years ended December 31, 2024 or 2023 except for
the material weaknesses in internal control over financial reporting for the fiscal years ended December 31, 2024 and 2023, as disclosed
in Part II, Item 9A of the Company&#8217;s Annual Report on Form 10-K for the years ended December 31, 2024 and 2023.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the years ended December 31, 2024 and 2023, prior to retaining Weinberg, the Company did not consult with Weinberg regarding either:
(i) the application of accounting principles to a specified transaction, either contemplated or proposed, or the type of audit opinion
that might be rendered on the Company&#8217;s financial statements, and neither a written report nor oral advice was provided to the
Company that Weinberg concluded was an important factor considered by the Company in reaching a decision as to the accounting, auditing
or financial reporting issue; or (ii) any matter that was the subject of a &#8220;disagreement&#8221; or a &#8220;reportable event&#8221;
(as those terms are defined in Item 304(a)(1)(iv) and (a)(1)(v) of Regulation S-K, respectively).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><FONT ID="an_013"></FONT>ITEM
9A. CONTROLS AND PROCEDURES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Evaluation
of Disclosure Controls and Procedures</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
term &#8220;disclosure controls and procedures,&#8221; as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act, refers to
controls and procedures that are designed to ensure that information required to be disclosed by a company in the reports that it files
or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC&#8217;s
rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that such
information is accumulated and communicated to a company&#8217;s management, including its principal executive and principal financial
officers, as appropriate to allow for timely decisions regarding required disclosure. Under the supervision and with the participation
of our management, including our Chief Executive Officer and Chief Financial Officer, we conducted an evaluation of the effectiveness
of our disclosure controls and procedures as of December 31, 2025. Based on this evaluation, our Chief Executive Officer and Chief Financial
Officer concluded that our disclosure controls and procedures were not effective at a reasonable assurance level as of December 31, 2025.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>


<!-- Field: Page; Sequence: 135; Options: NewSection; Value: 110 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->110<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
designing and evaluating our disclosure controls and procedures, management recognizes that disclosure controls and procedures, no matter
how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the disclosure controls
and procedures are met. Additionally, in designing disclosure controls and procedures, our management necessarily was required to apply
its judgment in evaluating the cost-benefit relationship of possible disclosure controls and procedures. The design of any system of
controls is also based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any
design will succeed in achieving its stated goals under all potential future conditions; over time, controls may become inadequate because
of changes in conditions, or the degree of compliance with policies or procedures may deteriorate. Because of the inherent limitations
in a control system, misstatements due to error or fraud may occur and not be detected.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Management&#8217;s
Annual Report on Internal Control over Financial Reporting</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2025, our management carried out an evaluation of the effectiveness of the design and operation of our disclosure controls
and procedures. Such evaluation was carried out by our Chief Financial Officer under the supervision of our Chief Executive Officer.
Based on this evaluation, management concluded that our disclosure controls and procedures were, and continue to be, ineffective as of
December 31, 2025. Based on the foregoing, our management concluded that our internal controls over the following financial reporting
areas to be material weaknesses:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Due
    to our size and stage of development, segregation of all conflicting duties is not always possible or economically feasible. During
    the year, we lacked sufficient review procedures and segregation of duties such that proper review had not been performed by someone
    other than the preparer, including manual journal entries, and that process documentation is lacking for review and monitoring controls
    over the financial statements closing process.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
have been no changes in the Company&#8217;s internal control over financial reporting during the three months ended December 31, 2025
that has materially affected, or is reasonably likely to materially affect, the Company&#8217;s internal control over financial reporting.
Management will continue to monitor and evaluate the effectiveness of our internal controls and procedures over financial reporting as
necessary.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Changes
in Internal Control over Financial Reporting</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
have been no changes in our internal control over financial reporting (as defined in Rules 13a-15(f) or 15d-15(f) of the Exchange Act)
that occurred during the period covered by this Annual Report that materially affected, or are reasonably likely to materially affect,
our internal control over financial reporting. However, the Company will continue to monitor and work to address the underlying causes
of material weaknesses and control deficiencies. Such material weaknesses and control deficiencies will not be fully remediated until
the Company has concluded that its internal controls are operating effectively for a sufficient period of time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><FONT ID="an_014"></FONT>ITEM
9B. OTHER INFORMATION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I><FONT STYLE="text-decoration: underline">10b5-1
Plan</FONT></I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 16, 2025, John S. Yu, the Company&#8217;s Chief Executive Officer and Chairman of the Board of Directors, adopted a Rule 10b5-1
trading plan. Mr. Yu&#8217;s Rule 10b5-1 trading plan is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) and
provides for the potential sale of up to 3,500,000 shares of the Company&#8217;s common stock at specified limit prices ranging from
$2.50 to $8.00 per share from March 16, 2026 to December 31, 2026.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><FONT ID="an_015"></FONT>ITEM
9C. DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
Applicable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>


<!-- Field: Page; Sequence: 136; Value: 110 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->111<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><FONT STYLE="text-decoration: underline"><FONT ID="an_016"></FONT>PART
III</FONT></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><FONT ID="an_017"></FONT>ITEM
10 - DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Executive
Officers and Directors</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Set
forth in the table below are the name, age, title of each executive officer and director, followed by a detailed description of their
business experience and qualifications.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 40%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Name</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 6%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Age
    </B>&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 50%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Position(s)</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">John
    S. Yu, M.D.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">61</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer and Chairman of the Board</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Neil
    Bhowmick, Ph.D.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">54</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Scientific Officer</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ramachandran
    Murali. Ph.D.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">65</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Vice
    President of Research and Development</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Doug
    Samuelson</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">66</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Financial Officer</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hyun
    W. Bae, M.D.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">56</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Independent
    Director</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hansoo
    Michael Keyoung, M.D., Ph.D.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">51</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Independent
    Director</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Rahul
    Singhvi, Sc.D., MBA</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">60</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Independent
    Director</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>John
S. Yu, M.D., CEO and Chairman of the Board of Directors</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
Yu, our co-founder, Chairman and Chief Executive Officer, is a medical clinician and investigator. Since 2019, Dr. Yu has also served
as the Chief Financial Officer and a director of our wholly owned subsidiary, Enviro. Dr. Yu is committed to advancing Kairos&#8217;s
pipeline to tackle the most unmet needs in cancer: resistance to cancer therapeutics and the suppressed immune response in cancer. As
the Professor of Neurosurgery and Director of Surgical Neuro-Oncology at Cedars-Sinai Medical Center, where he has worked since January
1998 until present, he has dedicated his medical career to the development of immunotherapy for cancer and glioblastoma. Dr. Yu is the
co-inventor of the GITR and activated T cell technology. Dr. Yu earned his bachelor&#8217;s degree from Stanford University in 1985 and
spent a year at the Sorbonne in Paris studying French literature while completing a fellowship in immunology at the Institut Pasteur
in Paris, and earned his medical degree from Harvard Medical School in 1990 and a master&#8217;s degree from the Harvard University Department
of Genetics in 1990, before pursuing a neurosurgical residency at Massachusetts General Hospital in Boston. His portfolio has included
26 research grants, 10 patents, seven FDA-approved investigational drugs and 17 IRB approved clinical trials. We believe Dr. Yu, with
his substantial experience in cancer research as both a clinician and investigator, is qualified to serve on our board of directors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Neil
Bhowmick, Ph.D., Chief Scientific Officer</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
Bhowmick, our Chief Scientific Officer, has more than 20 years of broad biochemistry experience filing and prosecuting patents in therapeutics
and devices, published in peer-reviewed journals (110 publications) leading foundational and pre-clinical cancer studies, obtaining regulatory
approvals, and conducting clinical trials. Dr. Bhowmick discovered the role of fibroblasts in cancer therapy resistance and has used
this finding to extend the time of cancer remission in multiple cancer types in preclinical and clinical examples as a founder and CEO
of Enviro Therapeutics Inc. He trained at Vanderbilt University and is the Professor of Medicine at Cedars-Sinai Medical Center and Director
of the Cancer Biology Program at Cedars-Sinai Cancer. He is on the Editorial Board of four scientific journals and charter member of
a NIH grant study section. Dr. Bhowmick was a Consultant at Celgene (currently Bristol Myers Squibb, a New York Stock Exchange-listed
company) in 2009, Xencor Inc., a Nasdaq-listed company, from 2019 to 2020 and at Tracon, a Nasdaq-listed company, from 2014 to 2019.
He currently serves on the Scientific Advisory Board of FibroBiologics. Dr. Bhowmick has received NCI/NIH funding for over 15 years,
has been cited over 15,000 times, and holds six patents for biomarker detection platforms and stromal targeted therapeutics (inclusive
of ENV 105 and ENV 205<B>).</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>


<!-- Field: Page; Sequence: 137; Value: 110 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->112<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Ramachandran
Murali, Ph.D., Vice President of Research and Development</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
Murali, our Vice President of Research and Development, is an established structural biologist with expertise in macromolecular crystallography,
computational biology, drug discovery, immunology, and cancer biology. Using these skills, Dr. Murali advanced a unique technology for
creating small peptidomimetics and small molecule drugs that target protein-protein/DNA interactions for diagnostic and therapeutic applications
in areas like cancer biology, immunotherapy, and autoimmune pathologies. Dr. Murali co-founded three biotech startup companies, including
Xcyte Therapeutics, a cancer immunotherapy company founded in Seattle, WA in 1996, Ception Therapeutics, Inc, an immunotherapeutic pharmaceutical
company founded in Philadelphia, PA in 2003 and Nidus, CA, a immunotherapeutic company founded in Los Angeles, CA in 2005. Dr. Murali&#8217;s
accomplishments also include developing small molecule agonist/antagonists for numerous cell surface receptor complexes, including members
of the TNFR super family. Recently, he targeted various transcription factors, such as Onecut-2, for cancer therapy. Dr. Murali has over
10 years of experience in collaborating with several biotech companies and is a co-inventor of more than 10 patents. Dr. Murali obtained
his doctoral degree in Biophysics from the University of Madras, one of the pioneering institutes for structural biology in India. Upon
graduation, he completed his post-doctoral training at Columbia University and the Wistar Institute (Philadelphia, PA). Later, he joined
the University of Pennsylvania as a faculty member and rose to the position of Associate Professor. He is currently a Professor in the
Department of Biomedical Sciences, Research Division of Immunology at Cedars-Sinai Medical Center (Los Angeles, CA).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Doug
Samuelson, Chief Financial Officer</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr.
Samuelson has served as our external Chief Financial Officer since 2019. Mr. Samuelson is a finance and accounting professional with
over 25 years of experience. From 2016 to 2022, Mr. Samuelson served as the Chief Financial Officer of Wellness Center USA, Inc. in Tucson,
Arizona. From 2016 to March 2020, Mr. Samuelson served as the Director of Accounting of Second Sight Medical Products, Inc., and in this
position, managed all accounting functions, including all general ledger close functions, tax reporting, external audit responsibilities,
banking and technical accounting issues. From 2018 to 2019, Mr. Samuelson served as the Chief Financial Officer of AdvaVet, Inc., in
Los Angeles, California, the U.S. subsidiary of Swedish pharmaceutical company, Oasmia Pharmaceutical AB (NASDAQ: OASM). From 2016 to
2018, Mr. Samuelson was the Chief Financial Officer of Solis Tek, Inc. (OTC: GNAL), where he handled all financial reporting with the
SEC. Mr. Samuelson obtained a Bachelor of Science in Accounting from University of Utah, College of Business, and obtained a Master of
Science in Computer Science from California State University, Northridge, School of Engineering. He is also a Certified Public Accountant
in the State of California.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Hyun
W. Bae, M.D., Independent Director</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
Hyun W. Bae has served on our board of directors as an independent director since September 9, 2020. Dr. Bae is an orthopaedic surgeon
in private practice in Santa Monica, California, and has been appointed Professor in Orthopaedic Surgery at Cedars-Sinai Medical Center,
the Director of Cedars&#8217; Education and Fellowship program, and a clinical partner of the Orthopaedic Stem Cell and Tissue Engineering
Laboratory. Since 2010, Dr. Bae has served as the Chief Medical Officer and a director of Prosidyan, a company that develops proprietary
fiber-based bioactive glass products. Dr. Bae has served as a Scientific Advisory Board Member of Mesoblast since 2008, Engage Surgical
since 2018, and Spine Biopharma since 2019. He also served as a Scientific Advisory Board Member of Tissuegene from 2008 to 2015. Dr.
Bae is a 20-year veteran of the drug development industry and is a renowned researcher and inventor. He was principal investigator for
four FDA-approved randomized clinical trials and has completed 30 clinical studies throughout his career. Dr. Bae also has authored 60
published scientific papers, written five review articles and holds 30 patents. Dr. Bae obtained a Biomechanics degree from Columbia
University and a Doctor of Medicine degree, cum laude, from Yale University and is a former NIH Howard Hughes Research Fellow in Bethesda,
Maryland. We believe that Dr. Bae is qualified to serve on our board of directors because of his industry and technical experience, including
his operational experience in drug discovery and development, and service on multiple company boards.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>


<!-- Field: Page; Sequence: 138; Value: 110 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->113<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Hansoo
Michael Keyoung, M.D., Ph.D., Independent Director</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
Hansoo Michael Keyoung has served on our board of directors as an independent director since our IPO in September 2024. For over 20 years,
Dr. Keyoung has led a successful career as a physician, healthcare executive, and investor in the United States, Europe and Asia. Since
2017, Dr. Keyoung has served as the head of North America for CBC Group, a healthcare-dedicated private equity firm with over $4 billion
in assets under management. He has served as Board Chair of AffaMed Therapeutics since 2019, a director of Graybug Vision, a Nasdaq-listed
company, since 2019, and a director of InxMed since 2019. From 2015 to 2017, Dr. Keyoung also served as the Chief Executive Officer of
Genexine, a KOSDAQ-listed biotech company with a $1 billion plus market cap focused on developing innovative biologic drugs for cancer
and rare diseases. During his tenure as Chief Executive Officer of Genexine, he successfully helped lead clinical development in Europe
and Asia, raised $100 million in equity, and set up partnerships with Merck, Fosun Pharma, Tasly Pharma, and Kalbe Pharma. From 2013
to 2015, he also served as President of Catalyst Biosciences, a Nasdaq-listed company and a clinical-stage hemophilia and ophthalmology
company that partnered with Pfizer, MedImmune, and Isu Abxis. Additionally, he has experience advising Eli Lilly, Bausch &amp; Lomb,
and Samsung Electronics/Biologics on Asian expansion, global drug development and commercial partnership strategies. Dr. Keyoung has
a Doctor of Medicine degree and a Doctor of Philosophy degree in neuroscience and neurology from Cornell University Weill Medical College
and Memorial Sloan Kettering. He was also a Biomedical Fellow at Rockefeller University and Memorial Sloan Kettering. We believe that
Dr. Keyoung is qualified to serve on our board of directors because of his extensive experience serving in management and on boards of
directors of public company, his experience in private equity investing in healthcare companies, and his extensive advisory work to industry-leading
healthcare companies.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Rahul
Singhvi, Sc.D., MBA, Independent Director</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
Rahul Singhvi has served on our board of directors as an independent director since December 10, 2024. Dr. Singhvi is a global leader
in the Life Sciences industry and is cofounder of the US based biomanufacturing company, Resilience (National Resilience, Inc.). Prior
to cofounding Resilience in 2020, from October 2019 to July 2020, Dr. Singhvi was an Operating Partner at Flagship Pioneering, where
he founded and operated companies launched from Flagship&#8217;s innovation foundry, Flagship Venture Labs. Before joining Flagship,
from September 2013 until October 2019, Rahul was the Chief Operating Officer at the Vaccine Business Unit of Takeda Pharmaceutical Co
Ltd. (NYSE: TAK) where he led worldwide vaccine manufacturing operations. Before joining Takeda, from August 2005 to April 2011, Dr.
Singhvi was President and CEO of Novavax, Inc. (Nasdaq:NVAX) where he led the company&#8217;s transformation into a global vaccine player.
Dr. Singhvi&#8217;s career began at Merck &amp; Co in 1994, where he held several positions in R&amp;D and manufacturing. Dr. Singhvi
serves on the Board of Trustees of the Keck Graduate Institute, and on the Board of Directors for Codexis (Nasdaq:CDXS), and Garuda Therapeutics
(private). Dr. Singhvi graduated as the top ranked chemical engineer from the Indian Institute of Technology, Kanpur, India and obtained
both his M.S. and Sc.D. degrees in chemical engineering from MIT. He received an MBA from the Wharton School of the University of Pennsylvania,
where he graduated as a Palmer Scholar. Because of Dr. Signhvi&#8217;s experience and knowledge in the operation and leadership of early-stage
public healthcare companies, we believe he will be able to provide valuable insights and contributions to our Board.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Family
Relationships</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
are no family relationships among our directors and executive officers.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Composition
of Our Board of Directors</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
business and affairs are organized under the direction of our board of directors, which consists of four members, each of whom are elected
to serve for one year <FONT STYLE="background-color: white">terms to hold office until the next annual meeting of our stockholders and
until a successor is appointed and qualified, or until their removal, resignation, or death</FONT>. The primary responsibilities of our
board of directors are to provide oversight, strategic guidance, counselling, and direction to our management. Our board of directors
meets on a regular basis and additionally as required.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Director
Independence </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
board of directors has undertaken a review of the independence of each director. Based on information provided by each director concerning
her or his background, employment and affiliations, including family relationships, our board of directors has determined that three
of our four directors, each of Drs. Bae, Keyoung and Singhvi, are &#8220;independent&#8221; directors in accordance with the rules and
regulations of NYSE American.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>


<!-- Field: Page; Sequence: 139; Value: 110 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->114<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Involvement
in Certain Legal Proceedings </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
the best of our knowledge, none of our directors or executive officers has, during the past ten years:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">been
    convicted in a criminal proceeding or been subject to a pending criminal proceeding (excluding traffic violations and other minor
    offences); </FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">had
    any bankruptcy petition filed by or against the business or property of the person, or of any partnership, corporation or business
    association of which he was a general partner or executive officer, either at the time of the bankruptcy filing or within two years
    prior to that time; </FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">been
    subject to any order, judgment, or decree, not subsequently reversed, suspended or vacated, of any court of competent jurisdiction
    or federal or state authority, permanently or temporarily enjoining, barring, suspending or otherwise limiting, his involvement in
    any type of business, securities, futures, commodities, investment, banking, savings and loan, or insurance activities, or to be
    associated with persons engaged in any such activity; </FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">been
    found by a court of competent jurisdiction in a civil action or by the Securities and Exchange Commission or the Commodity Futures
    Trading Commission to have violated a federal or state securities or commodities law, and the judgment has not been reversed, suspended,
    or vacated; </FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">been
    the subject of, or a party to, any federal or state judicial or administrative order, judgment, decree, or finding, not subsequently
    reversed, suspended or vacated (not including any settlement of a civil proceeding among private litigants), relating to an alleged
    violation of any federal or state securities or commodities law or regulation, any law or regulation respecting financial institutions
    or insurance companies including, but not limited to, a temporary or permanent injunction, order of disgorgement or restitution,
    civil money penalty or temporary or permanent cease-and-desist order, or removal or prohibition order, or any law or regulation prohibiting
    mail or wire fraud or fraud in connection with any business entity; or </FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">been
    the subject of, or a party to, any sanction or order, not subsequently reversed, suspended or vacated, of any self-regulatory organization
    (as defined in Section 3(a)(26) of the Exchange Act (15 U.S.C. 78c(a)(26))), any registered entity (as defined in Section 1(a)(29)
    of the Commodity Exchange Act (7 U.S.C. 1(a)(29))), or any equivalent exchange, association, entity or organization that has disciplinary
    authority over its members or persons associated with a member. </FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>The
Board of Directors&#8217; Role in Risk Oversight</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
board of directors oversees that the assets of our Company are properly safeguarded, that the appropriate financial and other controls
are maintained, and that our business is conducted wisely and in compliance with applicable laws and regulations and proper governance.
Included in these responsibilities is the board of directors&#8217; oversight of the various risks facing our company. In this regard,
our board of directors seeks to understand and oversee critical business risks. Our board of directors does not view risk in isolation.
Risks are considered in virtually every business decision and as part of our business strategy. Our board of directors recognizes that
it is neither possible nor prudent to eliminate all risk. Indeed, purposeful and appropriate risk-taking is essential for our company
to be competitive on a global basis and to achieve its objectives.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">While
the board of directors oversees risk management, company management is charged with managing risk. Management communicates routinely
with the board of directors and individual directors on the significant risks identified and how they are being managed. Directors are
free to, and indeed often do, communicate directly with senior management.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
board of directors administers its risk oversight function as a whole by making risk oversight a matter of collective consideration;
however, much of the work is delegated to committees, which will meet regularly and report back to the full board of directors. We have
established a standing audit committee, compensation committee and nominating and corporate governance committee of our board of directors.
The audit committee will oversee risks related to our financial statements, the financial reporting process, accounting and legal matters,
the compensation committee will evaluate the risks and rewards associated with our compensation philosophy and programs, and the nominating
and corporate governance committee will evaluate risk associated with management decisions and strategic direction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>


<!-- Field: Page; Sequence: 140; Value: 110 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->115<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Committees
of Our Board of Directors</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
board of directors has established an audit committee, a compensation committee, and a nominating and corporate governance committee,
each of which is made up of independent directors. The composition and responsibilities of each of the committees of our board of directors
are described below. Members serve on these committees until their resignation or until otherwise determined by our board of directors.
Each committee has adopted a written charter that satisfies the application rules and regulation of the SEC and the NYSE American rules
and regulations, which have been posted to our website at https://kairospharma.com. Our board of directors may establish other committees
as it deems necessary or appropriate from time to time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Audit
Committee</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
audit committee consists of Dr. Michael Keyoung, Dr. Hyun W. Bae and Dr. Rahul Singhvi, each of whom our board of directors has determined
satisfies the independence requirements under the NYSE American rule and regulations and Rule 10A-3(b)(1) of the Exchange Act. The chair
of our audit committee is Dr. Michael Keyoung, whom our board of directors has determined is an &#8220;audit committee financial expert&#8221;
within the meaning of SEC regulations. Each member of our audit committee can read and understand fundamental financial statements in
accordance with applicable requirements. In arriving at these determinations, the board of directors has examined each audit committee
member&#8217;s scope of experience and the nature of their employment in the corporate finance sector.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
primary purpose of the audit committee is to discharge the responsibilities of our board of directors with respect to our corporate accounting
and financial reporting processes, systems of internal control and financial-statement audits, and to oversee our independent registered
accounting firm. Specific responsibilities of our audit committee include:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">helping
    our board of directors oversee our corporate accounting and financial reporting processes;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">managing
    the selection, engagement, qualifications, independence and performance of a qualified firm to serve as the independent registered
    public accounting firm to audit our financial statements;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">discussing
    the scope and results of the audit with the independent registered public accounting firm, and reviewing, with management and the
    independent accountants, our interim and year-end operating results;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">developing
    procedures for employees to submit concerns anonymously about questionable accounting or audit matters;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing
    related person transactions;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">obtaining
    and reviewing a report by the independent registered public accounting firm at least annually, that describes our internal quality
    control procedures, any material issues with such procedures, and any steps taken to deal with such issues when required by applicable
    law; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">approving
    or, as permitted, pre-approving, audit and permissible non-audit services to be performed by the independent registered public accounting
    firm.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Compensation
Committee</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
compensation committee consists of Dr. Singhvi, Dr. Keyoung and Dr. Bae. The chair of our compensation committee is Dr. Singhvi. Our
board of directors has determined that each member of our compensation committee is independent under the NYSE American rules and regulations
and as a &#8220;non-employee director&#8221; as defined in Rule 16b-3 promulgated under the Exchange Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>


<!-- Field: Page; Sequence: 141; Value: 110 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->116<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
primary purpose of our compensation committee is to discharge the responsibilities of our board of directors in overseeing our compensation
policies, plans and programs, and to review and determine the compensation to be paid to our executive officers, directors and other
senior management, as appropriate. Specific responsibilities of our compensation committee include:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing
    and approving the compensation of our chief executive officer, other executive officers, and senior management;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing
    and recommending to our board of directors the compensation paid to our directors;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing
    and approving the compensation arrangements with our executive officers and other senior management;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">administering
    our equity incentive plans and other benefit programs;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing,
    adopting, amending, and terminating, incentive compensation and equity plans, severance agreements, profit sharing plans, bonus plans,
    change-of-control protections, and any other compensatory arrangements for our executive officers and other senior management;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing,
    evaluating, and recommending to our board of directors&#8217; succession plans for our executive officers; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing
    and establishing general policies relating to compensation and benefits of our employees, including our overall compensation strategy,
    including base salary, incentive compensation, and equity-based grants, to assure that it promotes stockholder interests and supports
    our strategic and tactical objectives, and that it provides for appropriate rewards and incentives for our management and employees.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Nominating
and Corporate Governance Committee</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
nominating and corporate governance committee consists of Dr. Singhvi, Dr. Bae and Dr. Keyoung. The chair of our nominating and corporate
governance committee is Dr. Singhvi. Our board of directors has determined that each member of the nominating and corporate governance
committee is independent under the NYSE American rules and regulations, a non-employee director, and free from any relationship that
would interfere with the exercise of his or her independent judgment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Specific
responsibilities of our nominating and corporate governance committee include:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">identifying
    and evaluating candidates, including the nomination of incumbent directors for reelection and nominees recommended by stockholders,
    to serve on our board of directors;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">considering
    and making recommendations to our board of directors regarding the composition and chairmanship of the committees of our board of
    directors;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">instituting
    plans or programs for the continuing education of our board of directors and orientation of new directors;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">developing
    and making recommendations to our board of directors regarding corporate governance guidelines and matters; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">overseeing
    periodic evaluations of the board of directors&#8217; performance, including committees of the board of directors and management.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stockholders
of record may also nominate director candidates for our annual meetings of stockholders by following the procedures set forth in our
bylaws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>


<!-- Field: Page; Sequence: 142; Value: 110 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->117<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Code
of Business Conduct and Ethics</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have adopted a written Code of Business Conduct and Ethics that applies to all our employees, officers, and directors. This includes
our principal executive officer, principal financial officer, and principal accounting officer or controller, or persons performing similar
functions. The full text of our Code of Business Conduct and Ethics has been posted on our website at www.kairospharma.com. We intend
to disclose on our website any future amendments of our Code of Business Conduct and Ethics or waivers that exempt any principal executive
officer, principal financial officer, principal accounting officer or controller, persons performing similar functions, or our directors
from provisions in the Code of Business Conduct and Ethics. Information contained on, or accessible through, our website is not a part
of this prospectus, and the inclusion of our website address in this prospectus is only an inactive textual reference.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Insider
Trading Policy</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have adopted an insider trading policy which prohibits our directors, officers and employees from engaging in transactions in our common
stock while in the possession of material non-public information; engaging in transactions in the stock of other companies while in possession
of material non-public information that they become aware of in performing their duties; and disclosing material non-public information
to unauthorized persons outside our company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
insider trading policy restricts trading by directors, officers and certain key employees during blackout periods, which generally begin
three weeks prior to the last day of each fiscal quarter and ending three business days following the date the Company&#8217;s financial
results are publicly disclosed and the Form 10-Q or the Form 10-K is filed. Additional blackout periods may be imposed with or without
notice, as the circumstances require.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, directors, officers and employees are expressly prohibited from making certain transactions, including short-term trading,
short sales, options trading, trading on margin, and hedging, unless such transaction is specifically approved in advance by the administrator
of our insider trading policy.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">While
we have not adopted a formal policy governing insider trading restrictions on the Company itself, as a matter of practice the Company
observes the same procedures and restrictions, including the potential existence of material non-public information, with respect to
transactions by the Company in its securities, including repurchases of common stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Compensation
Committee Interlocks and Insider Participation</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">None
of the members of the compensation committee is currently, or has been at any time, one of our executive officers or employees. None
of our executive officers currently serves, or has served during the last calendar year, as a member of the board of directors or compensation
committee of any entity that has one or more executive officers serving as a member of our board of directors or compensation committee.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Non-Employee
Director Compensation</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Compensation
for non-employee directors is determined by the board of directors. Each non-employee director receives an annual cash compensation of
$50,000, payable in quarterly instalments in arrears, plus an additional $10,000 cash compensation for the chair of the audit committee.
In addition, our policy provides that, upon initial election or appointment to our board of directors, each new non-employee director
will be granted a one-time grant, or Director Initial Grant, of $50,000 of RSUs, with the number of RSUs issued calculated as of the
grant date, which will vest in substantially equal annual instalments over a period of three years. The Director Initial Grant is subject
to full acceleration of vesting upon the sale of our Company, in accordance with the terms of our 2023 Equity Incentive Plan. Employee
directors receive no additional compensation for their service as a director.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>


<!-- Field: Page; Sequence: 143; Value: 110 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->118<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
reimburse our directors for all reasonable out-of-pocket expenses incurred for their attendance at meetings of our board of directors
or any committee thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
current non-employee directors earned the following compensation for their service during fiscal year ended December 31, 2025:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Name</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&#160;</B></FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Fees<FONT STYLE="text-decoration: underline"><BR>
    </FONT>Earned or<FONT STYLE="text-decoration: underline"><BR>
    </FONT>Paid in<FONT STYLE="text-decoration: underline"><BR>
    </FONT>Cash<FONT STYLE="text-decoration: underline"><BR>
    </FONT>($)</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&#160;</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&#160;</B></FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Stock<FONT STYLE="text-decoration: underline"><BR>
    </FONT>Awards<FONT STYLE="text-decoration: underline"><BR>
    </FONT>($)<SUP>(3)</SUP></B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&#160;</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&#160;</B></FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Option<FONT STYLE="text-decoration: underline"><BR>
    </FONT>Awards<FONT STYLE="text-decoration: underline"><BR>
    </FONT>($)</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&#160;</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&#160;</B></FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Non-Equity<FONT STYLE="text-decoration: underline"><BR>
    </FONT>Incentive Plan<FONT STYLE="text-decoration: underline"><BR>
    </FONT>Compensation<FONT STYLE="text-decoration: underline"><BR>
    </FONT>($)</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&#160;</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&#160;</B></FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>All
    Other<FONT STYLE="text-decoration: underline"><BR>
    </FONT>Compensation ($)</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&#160;</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&#160;</B></FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Total<FONT STYLE="text-decoration: underline"><BR>
    </FONT>($)</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&#160;</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 52%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hyun
    W. Bae<SUP>(1)</SUP></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; width: 4%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">50,000</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; width: 4%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12,400</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; width: 4%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; width: 4%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; width: 4%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; width: 4%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">62,400</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hansoo
    Michael Keyoung<SUP>(1) </SUP></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">60,000</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12,400</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">72,400</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Rahul
    Singhvi<SUP>(2)</SUP></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">50,000</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">18,750</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">68,750</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    entered into director agreements with Dr. Bae and Dr. Keyoung, effective September 16, 2024, the date of our initial listing on the
    NYSE American.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    entered into a director agreement with Dr. Singhvi upon his appointment on December 10, 2024.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
    non-employee director received RSUs which vest annually in one-third increments over a period of three years.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
certificate of incorporation contains provisions limiting the liability of directors, and our bylaws provide that we will indemnify each
of our directors and officers to the fullest extent permitted under Delaware law. Our certificate of incorporation and bylaws will also
provide our board of directors with discretion to indemnify our employees and other agents when determined appropriate by the board of
directors. In addition, we have entered into indemnification agreements with each of our directors and executive officers, which will
require us to indemnify them.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Delinquent
Section 16(a) Reports</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
16(a) of the Exchange Act requires our executive officers and directors, and persons who own more than 10% of our common stock, to file
reports regarding ownership of, and transactions in, our securities with the SEC and to provide us with copies of those filings.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
the Company&#8217;s knowledge, based solely on our review of the copies of such forms furnished to us and written representations by
our officers and directors regarding their compliance with applicable reporting requirements under Section 16(a) of the Exchange Act,
we believe that all Section 16(a) filing requirements for our executive officers, directors and 10% stockholders were met during the
year ended December 31, 2025, except for the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 20%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Name</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; width: 2%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 20%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Late
    Reports</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; width: 2%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 32%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Date
    of Earliest Transaction</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; width: 2%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 22%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Date
    Filed</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">John
    S Yu</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form
    4</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">01/01/2025</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">02/24/2025</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form
    4</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10/08/2025</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11/26/2025</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ramachandran
    Murali</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form
    4</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">01/01/2025</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">02/24/2025</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form
    4</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10/08/2025</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11/26/2025</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Neil
    Bhowmick</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form
    4</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">01/01/2025</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">04/07/2025</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form
    4</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10/08/2025</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">12/30/2025</FONT></P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Doug
    Samuelson</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form
    4</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10/08/2025</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11/26/2025</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Rahul
    Singhvi</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form
    4</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10/08/2025</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11/26/2025</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Michael
    Hansoo Keyoung</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form
    4</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">09/16/2025</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11/26/2025</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hyun
                                            W. Bae</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form
    4</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">09/16/2025</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12/23/2025</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&#160;</B></FONT></P>


<!-- Field: Page; Sequence: 144; Value: 110 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->119<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&#160;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><FONT ID="an_018"></FONT>ITEM
11 - EXECUTIVE COMPENSATION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
named executive officers for the years ended December 31, 2025 and 2024 were Dr. Yu, Dr. Bhowmick, Dr. Murali and Mr. Samuelson.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&#160;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Summary
Compensation Table</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Set
forth below is the summary compensation table for our named executive officers for the years ended December 31, 2024 and 2025. We are
currently a &#8220;emerging growth company&#8221; and a &#8220;smaller reporting company&#8221; as defined under SEC rules and, as a
result, we are required to include only two years of compensation disclosure, rather than three years, in this table.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Name
    and principal position</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Year</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Salary<BR>
    ($)</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Bonus<BR>
    ($)</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Stock
    Awards<BR> ($)</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Option
    Awards<BR> ($)</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Non-Equity
    Incentive Plan Compensation ($)</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Nonqualified
    Deferred Compensation Earnings<BR> ($)</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">All
    Other Compensation<BR> ($)</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Total<BR>
    ($)</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 28%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">John S. Yu</FONT></TD><TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="width: 4%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">2024</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="width: 4%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">51,301</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="width: 4%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="width: 4%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">34,440</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="width: 4%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="width: 4%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="width: 4%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="width: 4%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="width: 4%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">85,741</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">2025</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">200,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">87,500</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">75,415</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">362,915</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Neil Bhowmick</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">2024</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">29,315</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">34,440</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">72,755</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">2025</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">106,250</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">50,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">69,165</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">225,415</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Ramachandran Murali</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">2024</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">23,452</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">34,440</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">63,892</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">2025</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">87,500</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">40,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">62,915</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">190,415</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Doug Samuelson</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">2024</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">14,657</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">123,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">137,657</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">2025</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">62,500</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">50,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">142,250</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">254,750</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&#160;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Employment
Agreements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
of our executive officers has entered into an employment agreement with us. The executive officers will each receive compensation on
an annual basis in cash, payable in monthly installments commencing at the completion of our IPO, as well as an initial restricted stock
grant of RSUs. As may be decided from time to time by our Compensation Committee, our executive officers may be entitled to various target
bonuses. The terms of the employment agreements are as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Employment
Agreement with John Yu, MD</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 27, 2023, we entered enter into an employment agreement with our Chief Executive Officer and Chairman of the Board, John Yu,
M.D. Dr. Yu&#8217;s employment agreement became effective upon consummation of our IPO. Under the terms of his employment agreement,
Dr. Yu will receive base compensation of $175,000 per year. Dr. Yu also received 14,000 RSUs, which will vest annually in substantially
equal installments over a period of three years. In addition, Dr. Yu will be entitled to receive an annual cash or stock bonus, as may
be determined by the compensation committee of the board of directors. Should Dr. Yu terminate his employment for &#8220;Good Reason,&#8221;
as defined in his employment agreement, he will be entitled to his then applicable base salary for period of six months, subject to his
continued compliance with certain requirements of his employment agreement. Dr. Yu will also be entitled to standard benefits that may
be offered by the Company from time to time, including 30 days&#8217; paid vacation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Employment
Agreement with Doug Samuelson</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 27, 2023, we entered into an employment agreement with our Chief Financial Officer, Mr. Doug Samuelson, which became effective
upon consummation of our IPO. Under the employment agreement, Mr. Samuelson will be entitled to receive (i) a base salary equal to $50,000
per year, payable in monthly installments; (ii) an annual grant of 50,000 RSUs, which RSUs will be issued each year on the anniversary
date of our IPO, with each grant becoming fully vested after 12 months; and (iii) such number of RSUs equal to 1.2 times the amount of
outstanding invoices then owed to Mr. Samuelson according to his current consulting agreement, with such number of RSUs to be calculated
at our IPO per share purchase price. In addition, in the event of &#8220;Change of Control,&#8221; as such term is defined in his employment
agreement, Mr. Samuelson will be entitled to receive 250,000 RSUs, which number shall include all RSUs Mr. Samuelson has received up
until the date of the Change of Control, and which shall all vest immediately upon issuance. Mr. Samuelson will also be entitled to receive
an annual cash or stock bonus, as may be determined by the compensation committee of the board of directors and will be entitled to standard
benefits that may be offered by the Company from time to time, including 30 days&#8217; paid vacation and six months&#8217; severance
in the event his employment is terminated without cause.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 145; Value: 110 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->120<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Employment
Agreement with Neil Bhowmick, MD</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 27, 2023, we entered into an employment agreement with our Chief Scientific Officer, Neil Bhowmick, M.D., which became effective
upon the consummation of our IPO. Under Dr. Bhowmick&#8217;s employment agreement, Dr. Bhowmick will receive a base salary equal to $100,000
per year, payable in monthly installments, and 14,000 RSUs, which RSUs will vest annually over a period of three years. In addition,
Dr. Bhowmick will be entitled to receive an annual cash or stock bonus, as may be determined by the board of directors or a committee
thereof. Dr. Bhowmick will also be entitled to standard benefits that may be offered by the Company from time to time, including 30 days&#8217;
paid vacation and six months&#8217; severance in the event his employment is terminated without &#8220;Good Cause&#8221; in accordance
with the terms of his employment agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Employment
Agreement with Ramachandran Murali, MD</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 27, 2023, we entered into an employment agreement with our Vice President of Research and Development, Ramachandran Murali,
MD, which became effective upon consummation of our IPO. Under Dr. Murali&#8217;s employment agreement, Dr. Murali will receive base
compensation of $80,000 per year and will receive an initial grant of 14,0000 RSUs, which RSUs will vest annually in substantially equal
installments over a period of three years. In addition, Dr. Murali will be entitled to receive an annual cash or stock bonus, as may
be determined by the board of directors or a committee thereof. Dr. Murali will also be entitled to standard benefits that may be offered
by the Company from time to time, including 30 days&#8217; paid vacation and six months&#8217; severance in the event his employment
is terminated without &#8220;Good Cause&#8221; in accordance with the terms of his employment agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Equity-Based
Incentive Awards</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
July 2023, we adopted our 2023 Equity Incentive Plan, which reserved 1,650,000 shares of common stock for issuance under the 2023 Equity
Incentive Plan. The equity-based incentive awards granted under the 2023 Equity Incentive Plan are designed to align our interests and
those of our stockholders with those of our employees and consultants, including our executive officers. Our board of directors or an
authorized committee thereof is responsible for approving equity grants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Outstanding
Equity Awards at Fiscal Year End</B></FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Outstanding
Equity Awards</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Outstanding
Equity Awards at December 31, 2025</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table provides information regarding outstanding equity awards held by our named executive officers as of December 31, 2025.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD>&#160;</TD><TD>&#160;</TD>
    <TD STYLE="text-align: center">&#160;</TD><TD STYLE="font-weight: bold">&#160;</TD>
    <TD COLSPAN="14" STYLE="font-weight: bold; text-align: center">Options</TD><TD STYLE="font-weight: bold">&#160;</TD><TD STYLE="font-weight: bold">&#160;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center">Restricted Stock Unit Awards</TD><TD STYLE="font-weight: bold">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold">Name</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Grant Date</TD><TD STYLE="padding-bottom: 1pt">&#160;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Number of Securities Underlying Options (#)</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Vested</B></FONT></P></TD><TD STYLE="padding-bottom: 1pt">&#160;</TD><TD STYLE="padding-bottom: 1pt">&#160;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Number of Securities Underlying Options (#)</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Unvested</B></FONT></P></TD><TD STYLE="padding-bottom: 1pt">&#160;</TD><TD STYLE="padding-bottom: 1pt">&#160;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Option</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exercise</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Price</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>($)</B></FONT></P></TD><TD STYLE="padding-bottom: 1pt">&#160;</TD><TD STYLE="padding-bottom: 1pt">&#160;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Option</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Expiration</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>date</B></FONT></P></TD><TD STYLE="padding-bottom: 1pt">&#160;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&#160;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Number of Securities Underlying RSUs (#) Vested</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&#160;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&#160;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Number of Securities Underlying RSUs (#) Unvested</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 34%; text-align: left">John S. Yu</TD><TD STYLE="width: 2%">&#160;</TD>
    <TD STYLE="width: 10%; text-align: center"><P STYLE="margin: 0">10/08/2025</P></TD><TD STYLE="width: 2%">&#160;</TD>
    <TD STYLE="width: 1%; text-align: left">&#160;</TD><TD STYLE="width: 5%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&#160;</TD><TD STYLE="width: 2%">&#160;</TD>
    <TD STYLE="width: 1%; text-align: left">&#160;</TD><TD STYLE="width: 5%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&#160;</TD><TD STYLE="width: 2%">&#160;</TD>
    <TD STYLE="width: 1%; text-align: left">&#160;</TD><TD STYLE="width: 5%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&#160;</TD><TD STYLE="width: 2%">&#160;</TD>
    <TD STYLE="width: 1%; text-align: left">&#160;</TD><TD STYLE="width: 5%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&#160;</TD><TD STYLE="width: 2%">&#160;</TD>
    <TD STYLE="width: 1%; text-align: left">&#160;</TD><TD STYLE="width: 5%; text-align: right"><P STYLE="margin: 0; text-indent: 0.5in">-</P></TD><TD STYLE="width: 1%; text-align: left">&#160;</TD><TD STYLE="width: 2%">&#160;</TD>
    <TD STYLE="width: 1%; text-align: left">&#160;</TD><TD STYLE="width: 5%; text-align: right">190,840</TD><TD STYLE="width: 1%; text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&#160;</TD><TD>&#160;</TD>
    <TD STYLE="text-align: center">09/16/2024</TD><TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&#160;</TD><TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&#160;</TD><TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&#160;</TD><TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&#160;</TD><TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD><TD STYLE="text-align: right">7,000</TD><TD STYLE="text-align: left">&#160;</TD><TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD><TD STYLE="text-align: right">7,000</TD><TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Doug Samuelson</TD><TD>&#160;</TD>
    <TD STYLE="text-align: center"><P STYLE="margin: 0">10/08/2025</P></TD><TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&#160;</TD><TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&#160;</TD><TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&#160;</TD><TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&#160;</TD><TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&#160;</TD><TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD><TD STYLE="text-align: right">152,672</TD><TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&#160;</TD><TD>&#160;</TD>
    <TD STYLE="text-align: center">09/16/2024</TD><TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&#160;</TD><TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&#160;</TD><TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&#160;</TD><TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&#160;</TD><TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD><TD STYLE="text-align: right">50,000</TD><TD STYLE="text-align: left">&#160;</TD><TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Neil Bhowmick</TD><TD>&#160;</TD>
    <TD STYLE="text-align: center"><P STYLE="margin: 0">10/08/2025</P></TD><TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&#160;</TD><TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&#160;</TD><TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&#160;</TD><TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&#160;</TD><TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&#160;</TD><TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD><TD STYLE="text-align: right">171,756</TD><TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&#160;</TD><TD>&#160;</TD>
    <TD STYLE="text-align: center">09/16/2024</TD><TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&#160;</TD><TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&#160;</TD><TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&#160;</TD><TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&#160;</TD><TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD><TD STYLE="text-align: right">7,000</TD><TD STYLE="text-align: left">&#160;</TD><TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD><TD STYLE="text-align: right">7,000</TD><TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Ramachandran Murali</TD><TD>&#160;</TD>
    <TD STYLE="text-align: center"><P STYLE="margin: 0">10/08/2025</P></TD><TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&#160;</TD><TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&#160;</TD><TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&#160;</TD><TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&#160;</TD><TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&#160;</TD><TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD><TD STYLE="text-align: right">152,672</TD><TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&#160;</TD><TD>&#160;</TD>
    <TD STYLE="text-align: center">09/16/2024</TD><TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&#160;</TD><TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&#160;</TD><TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&#160;</TD><TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&#160;</TD><TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD><TD STYLE="text-align: right">7,000</TD><TD STYLE="text-align: left">&#160;</TD><TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD><TD STYLE="text-align: right">7,000</TD><TD STYLE="text-align: left">&#160;</TD></TR>
  </TABLE>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Emerging
Growth Company Status</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are an &#8220;emerging growth company,&#8221; as defined in the JOBS Act. As an emerging growth company we will be exempt from certain
requirements related to executive compensation, including the requirements to hold a nonbinding advisory vote on executive compensation
and to provide information relating to the ratio of total compensation of our chief executive officer to the median of the annual total
compensation of all of our employees, each as required by the Investor Protection and Securities Reform Act of 2010, which is part of
the Dodd-Frank Wall Street Reform and Consumer Protection Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Clawback
Policy</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a public company, if we are required to restate our financial results due to our material noncompliance with any financial reporting
requirements under the federal securities laws as a result of misconduct, the Chief Executive Officer and Chief Financial Officer may
be legally required to reimburse our Company for any bonus or other incentive-based or equity-based compensation they receive in accordance
with the provisions of section 304 of the Sarbanes-Oxley Act of 2002, as amended. As such, on March 1, 2024 we adopted a clawback policy,
entitled, &#8220;Policy for Recovery of Erroneously Awarded Compensation.&#8221;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 146; Value: 110 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->121<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><FONT ID="an_019"></FONT>ITEM
12 - SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth information regarding beneficial ownership of our capital stock as of March 31, 2026 by:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">each
    person, or group of affiliated persons, known by us to beneficially own more than 5% of our common stock;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">each
    of our directors and named executive officers; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">all
    of our current executive officers and directors as a group.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have determined beneficial ownership in accordance with the rules and regulations of the SEC, and the information is not necessarily
indicative of beneficial ownership for any other purpose. Except as indicated by the footnotes below, we believe, based on information
furnished to us, that the persons and entities named in the table below have sole voting and sole investment power with respect to all
shares that they beneficially own, subject to applicable community property laws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Applicable
percentage ownership is based on 21,411,198 shares of our common stock outstanding as of March 31, 2026.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless
otherwise indicated, the address for each beneficial owner listed in the table below is 2355 Westwood Blvd. #139, Los Angeles, California
90064.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">Name of Beneficial
    Owner</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Number
    of Shares Beneficially<BR> Owned (#) (2)</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Percentage
    of Shares Beneficially Owned (%)</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Greater than 5% Holders:</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 60%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Technomedics Management
    and Systems, Inc.<SUP>(1)</SUP></FONT></TD><TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="width: 16%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,139,027</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="width: 16%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;5.3</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Directors and Named Executive
    Officers:</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">John S. Yu, M.D. <SUP>(3)</SUP></FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">5,347,170</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;25.0</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Ramachandran Murali, Ph.D.</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">142,191</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;**</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Neil Bhowmick, Ph.D.</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,135,316</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;5.3</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Douglas Samuelson</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">140,367</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">**</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Hyun W. Bae, M.D</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">49,855</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">**</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hansoo Michael Keyoung, M.D.</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">5,569</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">**</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Rahul Singhvi, Sci.D., MBA</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">5,569</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">**</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">All directors and executive officers as a group
    (7 persons)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">6,826,037</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;31.9</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">**
Represents beneficial ownership of less than 1%.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)
Manfred Mosk exercises voting and investment power of all shares held by Technomedics Management and Systems, Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)
Does not include restricted stock units issued under the Company&#8217;s 2023 Equity Incentive Plan which remain subject to vesting.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">(3) The Yu Family trust owns 5,316,572
shares and John Yu owns 30,598 shares of our common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><FONT ID="an_020"></FONT>ITEM
13 - CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following includes a summary of transactions since January 1, 2023 to which we have been a party in which the amount involved exceeded
or will exceed the lesser of $120,000 as of December 31, 2025, and in which any of our directors, executive officers or, to our knowledge,
beneficial owners of more than 5% of our capital stock or any member of the immediate family of any of the foregoing persons had or will
have a direct or indirect material interest, other than equity and other compensation, termination, change in control and other arrangements,
which are described under &#8220;Executive Compensation.&#8221; We also describe below certain other transactions with our directors,
executive officers and stockholders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Loans
and Advances from Related Parties</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
August 2024, the Company borrowed $0.04 million from one of its officers. The loans accrue interest at 7.5% interest per annum, are unsecured,
and are due in August 2025.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
April and May 2024, the Company borrowed $0.1 million from three of its officers. The loans accrue interest at 7.5% per annum, are unsecured,
and are due in April 2025. The officers holding notes payable have since agreed to convert the outstanding loans and principal into shares
of common stock of the company, converting at the IPO per share purchase price, following completion of the IPO.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2021, stockholders of the Company, and a company whose principal stockholder is also a stockholder of the
Company, advanced the Company $0.01 million, which was all outstanding at December 31, 2021. The advances accrue no interest, are unsecured
and are due on demand. As of December 31, 2021, $0.01 million was owed on the advances. During the year ended December 31, 2022, the
Company repaid $0.01 million of the advances, and as of December 31, 2022 and 2023, and June 30, 2024, a total of $0.004 was outstanding.&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>


<!-- Field: Page; Sequence: 147; Value: 110 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->122<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Policies
and Procedures for Transactions with Related Persons </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
request for us to enter into a transaction with an executive officer, director, nominee for election as a director, beneficial owner
of more than 5% of any class of our common stock, or any member of the immediate family of any of the foregoing persons, in which the
amount involved exceeds $120,000 (or, if less, 1% of the average of our total assets in a fiscal year) and such person would have a direct
or indirect interest, must be presented to our board of directors or our audit committee for review, consideration and approval. In approving
or rejecting any such proposal, our board of directors or our audit committee is to consider the material facts of the transaction, including
whether the transaction is on terms no less favorable than terms generally available to an unaffiliated third party under the same or
similar circumstances and the extent of the related person&#8217;s interest in the transaction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><FONT ID="an_021"></FONT>ITEM
14 - PRINCIPAL ACCOUNTANT FEES AND SERVICES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Fees
Paid to Auditors</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table represents fees for professional audit services for the audit of the Company&#8217;s annual financial statements for
the fiscal years ended December 31, 2025 and 2024, rendered by Weinberg and Company, P.A., the Company&#8217;s current independent registered
public accounting firm, and Marcum LLP, the Company&#8217;s prior independent registered public accounting firm.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center; padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: center; padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">Weinberg
    and Company, P.A.</FONT></TD><TD STYLE="text-align: center; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: center; padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">Marcum
    LLP</FONT></TD><TD STYLE="text-align: center; padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">(in thousands)</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">Fiscal
    year ended December 31,</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Fiscal
    year ended December 31</B></FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">2025</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">2024</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">2025</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>2024</B></FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 40%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Audit fees <SUP>1</SUP></FONT></TD><TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 11%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;50,150</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="width: 11%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 11%; text-align: right">10,000</TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="width: 11%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;144,200</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Audit-related fees <SUP>2</SUP></FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><P STYLE="margin: 0">16,000</P></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><P STYLE="margin: 0">59,740</P></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Tax fees</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">All other fees</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Total fees</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;50,150</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right">26,000</TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;203,940</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 24pt; text-align: justify; text-indent: -24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Audit
                                            fees consist of fees for the audit of the Company&#8217;s annual financial statements for
                                            2024 and 2025 and services in connection with registration statements filed in 2024 and 2025.
                                            Audit fees also include fees related to the reviews of interim financial information included
                                            in Forms 10-Q and for consent or comfort letter procedures performed in conjunction with
                                            registration statements or completing financial transactions during the respective fiscal
                                            years.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Audit
Committee Pre-approval Policies</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
policy has been for the Audit Committee to pre-approve all audit, audit-related and non-audit services performed by our independent auditors
and to subsequently review the actual fees and expenses paid to our independent auditors. Accordingly, the Audit Committee pre-approved
all audit, audit-related and non-audit services performed by our independent auditors and subsequently reviewed the actual fees and expenses
paid to our former auditor, Marcum LLP, during fiscal 2023 and 2024 and the actual fees and expenses paid to our current auditor, Weinberg
and Company, P.A. during fiscal year 2025.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>


<!-- Field: Page; Sequence: 148; Value: 110 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->123<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><FONT STYLE="text-decoration: underline"><FONT ID="an_022"></FONT>PART
IV</FONT></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><FONT ID="an_023"></FONT>ITEM
15. EXHIBITS AND FINANCIAL STATEMENT SCHEDULES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
    Number</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify; width: 0.1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Description</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">1.1</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1962011/000149315226001909/ex1-2.htm" STYLE="-sec-extract: exhibit">At the Market Offering Agreement, dated January 12, 2026, by and between Kairos Pharma,Ltd. and H.C. Wainright Co., LLC (incorporated by reference to Exhibit 1.2 to the Company&#8217;s Registration Statement on Form S-3 filed on January 12, 2026).</A></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1962011/000149315223034915/ex3-5.htm" STYLE="-sec-extract: exhibit">Certificate
    of Incorporation of Kairos Pharma, Ltd. filed with the Secretary of State of the State of Delaware, dated May 10, 2023 (incorporated
    by reference to Exhibit 3.5 to the Company&#8217;s Registration Statement on Form S-1, filed on August 16, 2024).</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1962011/000149315223034915/ex3-6.htm" STYLE="-sec-extract: exhibit">Bylaws
    of Kairos Pharma, Ltd. (Delaware) (incorporated by reference to Exhibit 3.6 to the Company&#8217;s Registration Statement on Form
    S-1, filed on August 16, 2024).</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1962011/000149315224017318/ex4-1.htm" STYLE="-sec-extract: exhibit">Form
    of Representative&#8217;s Warrant (incorporated by reference to Exhibit 4.1 to the Company&#8217;s Registration Statement on Form
    S-1, filed on August 16, 2024).</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1962011/000149315225002048/ex4-1.htm" STYLE="-sec-extract: exhibit">Form
    of Pre-Funded Warrant (incorporated by reference to Exhibit 4.1 to the Company&#8217;s Current Report on Form 8-K filed January 14,
    2025).</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.3</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1962011/000149315225002832/ex4-2.htm" STYLE="-sec-extract: exhibit">Form
    of Common Warrant (incorporated by reference to Exhibit 4.2 to the Company&#8217;s Current Report on Form 8-K filed January 17, 2025).</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.4</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1962011/000149315225002832/ex4-3.htm" STYLE="-sec-extract: exhibit">Form
    of Placement Agent Warrants (incorporated by reference to Exhibit 4.3 to the Company&#8217;s Current Report on Form 8-K filed January
    17, 2025).</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">4.5</P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><A HREF="https://www.sec.gov/Archives/edgar/data/1962011/000164117225006509/ex4-5.htm" STYLE="-sec-extract: exhibit">Description of Securities (incorporated by reference to Exhibit 4.5 to the Company&#8217;s Amendment No. 1 to its Annual Report on Form 10-K/A filed April 28, 2025)</A></P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1962011/000149315223034915/ex10-1.htm" STYLE="-sec-extract: exhibit">Exclusive
    Option Agreement, dated March 16, 2020, between Cedars-Sinai Medical Center and Enviro Therapeutics, Inc. (re Depletion of Mitochondrial
    DNA) (incorporated by reference to Exhibit 10.1 to the Registration Statement filed on August 16, 2024).</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1962011/000149315223034915/ex10-2.htm" STYLE="-sec-extract: exhibit">Amendment
    to Exclusive Option Agreement, dated January 11, 2021, between Cedars-Sinai Medical Center and Enviro Therapeutics, Inc. (re Depletion
    of Mitochondrial DNA). (incorporated by reference to Exhibit 10.2 to the Registration Statement filed on August 16, 2024).</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.3</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1962011/000149315223034915/ex10-3.htm" STYLE="-sec-extract: exhibit">Exclusive
    Option Agreement, dated March 16, 202, between Cedars-Sinai Medical Center and Enviro Therapeutics, Inc. (re Sensitization of Solid
    Tumors) (incorporated by reference to Exhibit 10.3 to the Registration Statement filed on August 16, 2024).</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.4</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1962011/000149315223034915/ex10-4.htm" STYLE="-sec-extract: exhibit">Amendment
    to Exclusive Option Agreement, dated January 9, 2021, between Cedars-Sinai Medical Center and Enviro Therapeutics, Inc. (re Sensitization
    of Solid Tumors) (incorporated by reference to Exhibit 10.4 to the Registration Statement filed on August 16, 2024).</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.5</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1962011/000149315223034915/ex10-5.htm" STYLE="-sec-extract: exhibit">Exclusive
    License Agreement, dated June 21, 2021, between Cedars-Sinai Medical Center and Enviro Therapeutics, Inc. (re Compositions and Methods
    for Treating Diseases and Conditions by Depletion of Mitochondrial or Genomic DNA from Circulation and for Detection of Mitochondrial
    or Genomic DNA) (incorporated by reference to Exhibit 10.5 to the Registration Statement filed on August 16, 2024).</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.6</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1962011/000149315223034915/ex10-6.htm" STYLE="-sec-extract: exhibit">Exclusive
    License Agreement, dated June 2, 2021, between Cedars-Sinai Medical Center and Enviro Therapeutics, Inc. (re Sensitization of Tumors
    to Therapies Through Endoglin Antagonism) (incorporated by reference to Exhibit 10.6 to the Registration Statement filed on August
    16, 2024).</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.7</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1962011/000149315223034915/ex10-7.htm" STYLE="-sec-extract: exhibit">Exclusive
    License Agreement, dated August 30, 2019, between Cedars-Sinai Medical Center and Kairos Pharma, Ltd. (as successor to AcTcell Biopharma,
    Inc.) (re Methods of generating activated T cells for cancer therapy) (incorporated by reference to Exhibit 10.7 to the Registration
    Statement filed on August 16, 2024).</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.8</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1962011/000149315223034915/ex10-8.htm" STYLE="-sec-extract: exhibit">Amendment
    to Exclusive License Agreement, dated June 17, 2021, between Cedars-Sinai Medical Center and Kairos Pharma, Ltd. (re Methods of generating
    activated T cells for cancer therapy) (incorporated by reference to Exhibit 10.8 to the Registration Statement filed on August 16,
    2024).</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.9</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1962011/000149315223034915/ex10-9.htm" STYLE="-sec-extract: exhibit">Exclusive
    License Agreement, dated October 1, 2017, between Cedars-Sinai Medical Center and Kairos Pharma, Ltd. (re Methods of use of compounds
    that bind to RelA of NFkB) (incorporated by reference to Exhibit 10.9 to the Registration Statement filed on August 16, 2024).</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.10</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1962011/000149315223034915/ex10-11.htm" STYLE="-sec-extract: exhibit">Amendment
    to Exclusive License Agreement, dated June 17, 2021, between Cedars-Sinai Medical Center and Kairos Pharma, Ltd. (re Methods of use
    of compounds that bind to RelA of NFkB) (incorporated by reference to Exhibit 10.11 to the Registration Statement filed on August
    16, 2024).</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.11</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1962011/000149315223034915/ex10-12.htm" STYLE="-sec-extract: exhibit">Exclusive
    License Agreement, dated October 1, 2017, between Cedars-Sinai Medical Center and Kairos Pharma, Ltd. (re Composition and Methods
    for Treating Fibrosis) (incorporated by reference to Exhibit 10.12 to the Registration Statement filed on August 16, 2024).</A></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>


<!-- Field: Page; Sequence: 149; Value: 110 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->124<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.12</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1962011/000149315223034915/ex10-13.htm" STYLE="-sec-extract: exhibit">Amendment
    to Exclusive License Agreement, dated June 17, 2021, between Cedars-Sinai Medical Center and Kairos Pharma, Ltd. (re Composition
    and Methods for Treating Fibrosis) (incorporated by reference to Exhibit 10.13 to the Registration Statement filed on August 16,
    2024).</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.13</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1962011/000149315223034915/ex10-14.htm" STYLE="-sec-extract: exhibit">Exclusive
    License Agreement, dated March 12, 2019, between Cedars-Sinai Medical Center and Kairos Pharma, Ltd. (re Composition and Methods
    for Treating Cancer and Autoimmune Diseases) (incorporated by reference to Exhibit 10.14 to the Registration Statement filed on August
    16, 2024).</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.14</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1962011/000149315223034915/ex10-15.htm" STYLE="-sec-extract: exhibit">Amendment
    to Exclusive License Agreement, dated June 17, 2021, between Cedars-Sinai Medical Center and Kairos Pharma, Ltd. (re Composition
    and Methods for Treating Cancer and Autoimmune Diseases) (incorporated by reference to Exhibit 10.15 to the Registration Statement
    filed on August 16, 2024).</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.15</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1962011/000149315223034915/ex10-16.htm" STYLE="-sec-extract: exhibit">License
    and Supply Agreement, dated May 21, 2021, between Tracon Pharmaceuticals, Inc., Enviro Therapeutics, Inc., and Kairos Pharma, Ltd.
    (incorporated by reference to Exhibit 10.16 to the Registration Statement filed on August 16, 2024)</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.16</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1962011/000149315223034915/ex10-17.htm" STYLE="-sec-extract: exhibit">First
    Amendment to Exclusive License Agreement, dated April 18, 2021, between Cedars-Sinai Medical Center and Enviro Therapeutics, Inc.
    (re Methods for Treating Diseases and Conditions by Depletion of Mitochondrial or Genomic DNA) (incorporated by reference to Exhibit
    10.17 to the Registration Statement filed on August 16, 2024).</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.17</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1962011/000149315223034915/ex10-18.htm" STYLE="-sec-extract: exhibit">Second
    Amendment to Exclusive License Agreement, dated October 11, 2022, between Cedars-Sinai Medical Center and Enviro Therapeutics, Inc.
    (re Sensitization of Tumors to Therapies Through Endoglin Antagonism) (incorporated by reference to Exhibit 10.18 to the Registration
    Statement filed on August 16, 2024).</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.18</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1962011/000149315223034915/ex10-20.htm" STYLE="-sec-extract: exhibit">Form
    of Subscription Agreement for 6% Convertible Notes (incorporated by reference to Exhibit 10.20 to the Registration Statement filed
    on August 16, 2024).</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.19</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1962011/000149315223034915/ex10-21.htm" STYLE="-sec-extract: exhibit">Form
    of 6% Convertible Note (incorporated by reference to Exhibit 10.21 to the Registration Statement filed on August 16, 2024).</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.20</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1962011/000149315223034915/ex10-22.htm" STYLE="-sec-extract: exhibit">Form
    of Investor Rights and Lock-Up Agreement for 6% Convertible Notes (incorporated by reference to Exhibit 10.22 to the Registration
    Statement filed on August 16, 2024).</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.21</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1962011/000149315223034915/ex10-23.htm" STYLE="-sec-extract: exhibit">Kairos
    Pharma, Ltd. 2023 Equity Incentive Plan (incorporated by reference to Exhibit 10.23 to the Registration Statement filed on August
    16, 2024).</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.22</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1962011/000149315223034915/ex10-24.htm" STYLE="-sec-extract: exhibit">Form
    of Director Offer Letter (incorporated by reference to Exhibit 10.24 to the Registration Statement filed on August 16, 2024).</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.23</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1962011/000149315223034915/ex10-25.htm" STYLE="-sec-extract: exhibit">Form
    of Employment Agreement for John Yu (incorporated by reference to Exhibit 10.25 to the Registration Statement filed on August 16,
    2024).</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.24</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1962011/000149315223034915/ex10-26.htm" STYLE="-sec-extract: exhibit">Form
    of Employment Agreement with Doug Samuelson (incorporated by reference to Exhibit 10.26 to the Registration Statement filed on August
    16, 2024).</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.25</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1962011/000149315223034915/ex10-27.htm" STYLE="-sec-extract: exhibit">Form
    of Employment Agreement for Neil Bhowmick (incorporated by reference to Exhibit 10.27 to the Registration Statement filed on August
    16, 2024).</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.26</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1962011/000149315223034915/ex10-28.htm" STYLE="-sec-extract: exhibit">Form
    of Employment Agreement for Ramachandran Murali (incorporated by reference to Exhibit 10.28 to the Registration Statement filed on
    August 16, 2024).</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.27</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1962011/000149315223034915/ex10-29.htm" STYLE="-sec-extract: exhibit">Form
    of Indemnification Agreement between Kairos Pharma, Ltd. and each of its directors (incorporated by reference to Exhibit 10.29 to
    the Registration Statement filed on August 16, 2024).</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.28</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1962011/000149315224017318/ex10-30.htm" STYLE="-sec-extract: exhibit">Conversion
    Agreement, dated March 7, 2024, between Cedars-Sinai Medical Center, Kairos Pharma, Ltd. and Enviro Therapeutics, Inc. (incorporated
    by reference to Exhibit 10.30 to the Registration Statement filed on August 16, 2024).</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.29</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1962011/000149315224017318/ex10-31.htm" STYLE="-sec-extract: exhibit">Second
    Amendment to the Exclusive License Agreement to Methods and Use of Compounds that Bind to RelA of NF-kB, dated March 7, 2024, between
    Kairos Pharma Ltd. and Cedars-Sinai Medical Center (incorporated by reference to Exhibit 10.31 to the Registration Statement filed
    on August 16, 2024).</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.30</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1962011/000149315224017318/ex10-32.htm" STYLE="-sec-extract: exhibit">Second
    Amendment to the Exclusive License Agreement to Composition and Methods for Treating Fibrosis with Kairos Pharma Ltd, dated March
    7, 2024, between Kairos Pharma, Ltd. and Cedars-Sinai Medical Center (incorporated by reference to Exhibit 10.32 to the Registration
    Statement filed on August 16, 2024).</A></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>


<!-- Field: Page; Sequence: 150; Value: 110 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->125<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.31</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1962011/000149315224017318/ex10-33.htm" STYLE="-sec-extract: exhibit">Second
    Amendment to the Exclusive License Agreement to Compositions and Methods for Treating Cancer and Autoimmune Diseases, dated March
    7, 2024, between Kairos Pharma, Ltd. and Cedars-Sinai Medical Center (incorporated by reference to Exhibit 10.33 to the Registration
    Statement filed on August 16, 2024).</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.32</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1962011/000149315224017318/ex10-34.htm" STYLE="-sec-extract: exhibit">Third
    Amendment to Exclusive License to Compositions and Methods for Treating Diseases and Conditions by Depletion of Mitochondrial or
    Genomic DNA, dated March 7, 2024, between Enviro Therapeutics, Inc. and Cedars-Sinai Medical Center(incorporated by reference to
    Exhibit 10.34 to the Registration Statement filed on August 16, 2024).</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.33</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1962011/000149315224017318/ex10-35.htm" STYLE="-sec-extract: exhibit">Third
    Amendment to the Exclusive License Agreement to Sensitization of Tumors to Therapies Through Endoglin Antoganism, dated March 7,
    2024, between Enviro Therapeutics, Inc. and Cedars-Sinai Medical Center (incorporated by reference to Exhibit 10.35 to the Registration
    Statement filed on August 16, 2024).</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.34</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1962011/000149315224017318/ex10-36.htm" STYLE="-sec-extract: exhibit">Form
    of Loan Agreement between the Company and Certain Officers (incorporated by reference to Exhibit 10.36 to the Registration Statement
    filed on August 16, 2024).</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.35</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1962011/000149315224032896/ex10-37.htm" STYLE="-sec-extract: exhibit">Master
    Services Agreement, dated August 1, 2024, between Kairos Pharma Limited and Prevail InfoWorks, Inc. (incorporated by reference to
    Exhibit 10.37 to the Registration Statement filed on August 16, 2024) <SUP>(1)</SUP></A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.36</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1962011/000149315224032896/ex10-38.htm" STYLE="-sec-extract: exhibit">Amendment
    to Loan Agreement, dated August 16, 2024, between the Company and John S. Yu (incorporated by reference to Exhibit 10.38 to the Registration
    Statement filed on August 16, 2024).</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.37</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1962011/000149315224032896/ex10-39.htm" STYLE="-sec-extract: exhibit">Amendment
    to Loan Agreement, dated August 16, 2024, between the Company and Doug Samuelson (incorporated by reference to Exhibit 10.39 to the
    Registration Statement filed on August 16, 2024).</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.38</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1962011/000149315224032896/ex10-40.htm" STYLE="-sec-extract: exhibit">Amendment
    to Loan Agreement, dated August 16, 2024, between the Company and Neil Bhowmick (incorporated by reference to Exhibit 10.40 to the
    Registration Statement filed on August 16, 2024).</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.39</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1962011/000149315224037958/ex10-1.htm" STYLE="-sec-extract: exhibit">Bioassay
    Services Agreement, dated September 20, 2024, between the Company and PreCheck (incorporated by reference to Exhibit 10.1 to the
    Company&#8217;s current Report on Form 8-K filed on September 24, 2024).</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.40</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1962011/000149315224038590/ex10-1.htm" STYLE="-sec-extract: exhibit">Form
    of Advertising Services Agreement, dated September 23, 2024, between the Company and CEO.CA Technologies, Inc. (incorporated by reference
    to Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K filed on September 27, 2024).</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.41</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1962011/000149315224038590/ex10-2.htm" STYLE="-sec-extract: exhibit">Form
    of Advisory &amp; Consulting Agreement, dated September 23, 2024, between the Company and Belair Capital Advisors Inc. (incorporated
    by reference to Exhibit 10.2 to the Company&#8217;s Current Report on Form 8-K filed on September 27, 2024).</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.42</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1962011/000149315224039586/ex10-1.htm" STYLE="-sec-extract: exhibit">Consulting
    Agreement, dated October 1, 2024, between Kairos Pharma, Ltd, Cross Current Capital LLC and Alan Masley (incorporated by reference
    to Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K filed October 4, 2024).</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.43</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1962011/000149315224045671/ex10-5.htm" STYLE="-sec-extract: exhibit">Purchase
    Agreement, dated November 12, 2024, by and between Kairos Pharma, Ltd. and Helena Global Investment Opportunities I Ltd. (incorporated
    by reference to Exhibit 10.5 to the Company&#8217;s Quartey Report on Form 10-Q, filed on November 14, 2024).</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.44</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1962011/000149315224045671/ex10-6.htm" STYLE="-sec-extract: exhibit">Second
    Conversion Agreement, dated November 13, 2024, by and between Kairos Pharma, Ltd. and Cedars-Sinai Medical Center. (incorporated
    by reference to Exhibit 10.6 to the Company&#8217;s Quartey Report on Form 10-Q, filed on November 14, 2024).</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.45</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1962011/000149315224045671/ex10-7.htm" STYLE="-sec-extract: exhibit">Third
    Amendment to Exclusive License Agreement (Cancer Autoimmune), dated November 13, 2024, by and between Kairos Pharma, Ltd. and Cedars-Sinai
    Medical Center. (incorporated by reference to Exhibit 10.7 to the Company&#8217;s Quartey Report on Form 10-Q, filed on November
    14, 2024).</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.46</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1962011/000149315224045671/ex10-8.htm" STYLE="-sec-extract: exhibit">Fourth
    Amendment to Exclusive License Agreement (Depletion of DNA), dated November 13, 2024, by and between Kairos Pharma, Ltd. and Cedars-Sinai
    Medical Center and Enviro Therapeutics, Inc (incorporated by reference to Exhibit 10.8 to the Company&#8217;s Quartey Report on Form
    10-Q, filed on November 14, 2024).</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.47</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1962011/000149315224045671/ex10-9.htm" STYLE="-sec-extract: exhibit">Third
    Amendment to Exclusive License Agreement (Fibrosis), dated November 13, 2024, by and between Kairos Pharma, Ltd. and Cedars-Sinai
    Medical Center. (incorporated by reference to Exhibit 10.9 to the Company&#8217;s Quartey Report on Form 10-Q, filed on November
    14, 2024).</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.48</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1962011/000149315224045671/ex10-10.htm" STYLE="-sec-extract: exhibit">Third
    Amendment to Exclusive License Agreement (RelA of NF-kB), dated November 13, 2024, by and between Kairos Pharma, Ltd. and Cedars-Sinai
    Medical Center. (incorporated by reference to Exhibit 10.10 to the Company&#8217;s Quartey Report on Form 10-Q, filed on November
    14, 2024).</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.49</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1962011/000149315224045671/ex10-11.htm" STYLE="-sec-extract: exhibit">Fourth
    Amendment to Exclusive License Agreement (Sensitization of Solid Tumors), dated November 13, 2024, by and between Enviro Therapeutics
    Inc. and Cedars-Sinai Medical Center. (incorporated by reference to Exhibit 10.11 to the Company&#8217;s Quartey Report on Form 10-Q,
    filed on November 14, 2024).</A></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>


<!-- Field: Page; Sequence: 151; Value: 110 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->126<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.50</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1962011/000149315224045671/ex10-12.htm" STYLE="-sec-extract: exhibit">Form
    of the Amendment No.1 to the Employment Agreement by and between Kairos Pharma, Ltd and Doug Samuelson (incorporated by reference
    to Exhibit 10.12 to the Company&#8217;s Quartey Report on Form 10-Q, filed on November 14, 2024).</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.51</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1962011/000149315224045671/ex10-13.htm" STYLE="-sec-extract: exhibit">Form
    of the Amendment No.1 to the Employment Agreement by and between Kairos Pharma, Ltd and Dr. Ramachandran Murali (incorporated by
    reference to Exhibit 10.13 to the Company&#8217;s Quartey Report on Form 10-Q, filed on November 14, 2024).</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.52</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1962011/000149315224045671/ex10-14.htm" STYLE="-sec-extract: exhibit">Form
    of the Amendment No.1 to the Employment Agreement by and between Kairos Pharma, Ltd and Dr. Neil Bhowmick (incorporated by reference
    to Exhibit 10.14 to the Company&#8217;s Quartey Report on Form 10-Q, filed on November 14, 2024).</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.53</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1962011/000149315224045671/ex10-15.htm" STYLE="-sec-extract: exhibit">Form
    of Amendment No. 1 to Employment Agreement by and between Kairos Pharma, Ltd. and John S. Yu (incorporated by reference to Exhibit
    10.15 to the Company&#8217;s Quartey Report on Form 10-Q, filed on November 14, 2024).</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.54</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1962011/000149315224049994/ex10-1.htm" STYLE="-sec-extract: exhibit">Director
    Offer Letter, dated December 10, 2024, between Kairos Pharma, Ltd. and Rahul Singhvi (incorporated by reference to Exhibit 10.1 to
    the Current Report on Form 8-K filed on December 13, 2024).</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.55</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1962011/000149315225002048/ex10-1.htm" STYLE="-sec-extract: exhibit">Form
    of Securities Purchase Agreement (incorporated by reference to Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K filed
    January 14, 2025).</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.56</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1962011/000149315225002048/ex10-2.htm" STYLE="-sec-extract: exhibit">Form
    of Registration Rights Agreement (incorporated by reference to Exhibit 10.2 to the Company&#8217;s Current Report on Form 8-K filed
    January 14, 2025).</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.57</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1962011/000149315225002048/ex10-3.htm" STYLE="-sec-extract: exhibit">Form
    of Lock-up Agreement (incorporated by reference to Exhibit 10.3 to the Company&#8217;s Current Report on Form 8-K filed January 14,
    2025).</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.58</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1962011/000149315225002832/ex10-1.htm" STYLE="-sec-extract: exhibit">Form
    of Amended and Restated Securities Purchase Agreement (incorporated by reference to Exhibit 10.1 to the Company&#8217;s Current Report
    on Form 8-K filed January 17, 2025).</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.59</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1962011/000149315225002832/ex10-3.htm" STYLE="-sec-extract: exhibit">Placement
    Agent Agreement, dated January 16, 2025, between Kairos Pharma, Ltd. and Boustead Securities LLC (incorporated by reference to Exhibit
    10.3 to the Company&#8217;s Current Report on Form 8-K filed January 17, 2025).</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.60</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1962011/000164117225014905/ex99-1.htm" STYLE="-sec-extract: exhibit">Services
    Agreement, dated June 10, 2025, between Kairos Pharma Ltd and the Company and Barretto Pacific Corporation (incorporated by reference
    to Exhibit 99.1 to the Company&#8217;s Current Report on Form 8-K filed June 12, 2025).</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.61</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1962011/000149315225017208/ex10-1.htm" STYLE="-sec-extract: exhibit">Novation
    Agreement between Kairos Pharma, Ltd., Enviro Therapeutics, Inc. and Cedars-Sinao Medical Center (incorporated by reference to Exhibit
    10.1 to the Company&#8217;s Current Report on Form 8-K filed October 7, 2025).</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.62</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1962011/000149315225017208/ex10-2.htm" STYLE="-sec-extract: exhibit">Novation
    Agreement between Kairos Pharma Ltd, Enviro Therapeutics, Inc. and Tracon Pharmaceuticals, Inc. (incorporated by reference to Exhibit
    10.2 to the Company&#8217;s Current Report on Form 8-K filed October 7, 2025).</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT>10.63</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1962011/000149315225018145/ex10-1.htm" STYLE="-sec-extract: exhibit">Form of Restricted Stock Unit Grant Agreement (incorporated by refere<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">nce to Exhibit 10.1 to the Current Report on Form 8-K filed October 15, 2025).</FONT></A></TD></TR>

<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">10.64</FONT></TD>
    <TD STYLE="text-align: justify">&#160;</TD>
    <TD STYLE="text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1962011/000149315225017208/ex10-1.htm"><FONT STYLE="font-size: 10pt">Novation Agreement, dated October 7, 2025 but effective April 17, 2025, between Kairos Pharma, Ltd, Enviro Therapeutics, Inc. and Tracon Pharmaceuticals, Inc. (incorporated by reference to the Current Report on Form 8-K filed October 7, 2025).</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">10.65</FONT></TD>
    <TD STYLE="text-align: justify">&#160;</TD>
    <TD STYLE="text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1962011/000149315225017208/ex10-2.htm"><FONT STYLE="font-size: 10pt">Novation Agreement, dated October 7, 2025, between Kairos Phrma, Ltd., Enviro Therapeutics, Inc. and Tracon Pharmaceuticals, Inc. (incorporated by reference to the Current Report on Form 8-K filed October 7, 2025).</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">10.66</FONT></TD>
    <TD STYLE="text-align: justify">&#160;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1962011/000149315225023276/ex10-3.htm" STYLE="-sec-extract: exhibit">Form of Amendment No. 83 to Sales Agreement, dated November 12, 2025, between Kairos Pharma Ltd. and Lonza Sales AG (incorporated by reference to Exhibit 10.3 to the Quarterly Report on Form 10-Q filed November 14, 2025).</A></FONT></TD></TR>

<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><P STYLE="margin: 0">10.67</P></TD>
    <TD STYLE="text-align: justify">&#160;</TD>
    <TD STYLE="text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1962011/000149315225018145/form8-k.htm" STYLE="-sec-extract: exhibit">Form of Restricted Stock Unit Grant Agreement (incorporated by reference to Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K filed October 15, 2025).</A></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT>10.68</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.1in">&#160;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1962011/000149315226008435/ex10-1.htm" STYLE="-sec-extract: exhibit">Term Sheet, dated March 2, 2026, by and between Kairos Pharma, Ltd. and Celyn Therapeutics, Inc. (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K filed March 2, 2026).</A></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">10.69</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><A HREF="#EX_001">Statement of Work 86 to the Lonza Sales Agreement, dated March 27, 2026, between Kairos Pharma, Ltd. and Lonza Sales AG.*</A></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">14.1</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1962011/000164117225004920/ex14-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Code of Business Conduct and Ethics (incorporated by reference to Exhibit 14.1 to the Company&#8217;s Amendment No. 1 to its Annual Report on Form 10-K/A filed April 29, 2025).</FONT></A></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">19.1</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1962011/000164117225004920/ex19-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Insider Trading Policy (incorporated by reference to Exhibit 19.1 to Amendment No. 1 to the Company&#8217;s Annual Report on Form 10-K/A filed on April 29, 2025).</FONT></A></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: transparent">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.1*</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><A HREF="#EX_002"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consent of Weinberg and Company, P.A.</FONT></A></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: transparent">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.2*</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><A HREF="#EX_003"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consent of Marcum LLP</FONT></A></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: transparent">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">31.1*</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><A HREF="#EX_004"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</FONT></A></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: transparent">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">31.2*</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><A HREF="#EX_005"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</FONT></A></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: transparent">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">32.1**</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><A HREF="#EX_007"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certification of Chief Executive Officer Pursuant to 18 U.S.C. Section 1350, As Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</FONT></A></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: transparent">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">32.2**</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><A HREF="#EX_008">Certification of Chief Financial Officer Pursuant to 18 U.S.C. Section 1350, As Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</A></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: transparent">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: justify"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">97.1</P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify">&#160;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><A HREF="https://www.sec.gov/Archives/edgar/data/1962011/000164117225006509/ex97-1.htm" STYLE="-sec-extract: exhibit">Policy for Recovery of Erroneously Awarded Compensation, adopted March 1, 2024 (incorporated by reference to Exhibit 97.1 to the Company&#8217;s Amendment No. 1 to its Annual Report on Form 10-K/A filed April 29, 2025)</A></P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.INS</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Instance Document</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.SCH</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Taxonomy Extension Schema Document</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.CAL</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Taxonomy Extension Calculation Linkbase Document</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.DEF</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Taxonomy Extension Definition Linkbase Document</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.LAB</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Taxonomy Extension Label Linkbase Document</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.PRE</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Taxonomy Presentation Linkbase Document</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">104</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cover
    Page Interactive Data File (embedded within the Inline XBRL document)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain
    information contained in this exhibit has been redacted because (i) it is not material and (ii) it is the type of information that
    the company normally treats as private or confidential.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*
Filed herewith.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">**
Furnished herewith.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><FONT ID="an_024"></FONT>ITEM
16. FORM 10-K SUMMARY</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">None.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>


<!-- Field: Page; Sequence: 152; Value: 110 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->127<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><FONT ID="an_025"></FONT>SIGNATURES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Company has duly caused this Annual Report to
be signed on its behalf by the undersigned, thereunto duly authorized.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">KAIROS
    PHARMA, LTD.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 47%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    John S. Yu</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">John
    S. Yu</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
                                            Executive Officer and</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chairman
    of the Board of Directors</FONT></P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
    March 31, 2026</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Principal
    Executive Officer</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirements of the Securities Exchange Act of 1934, this Annual Report has been signed below by the following persons on behalf
of the registrant and in the capacities and on the dates indicated.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 30%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Signature</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Title</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 16%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Date</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    John S. Yu</I></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chairman
    of the board of directors,</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">John
    S. Yu</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 31,
    2026</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(principal
    executive officer)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Doug Samuelson</I></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Financial Officer</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Doug
    Samuelson</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(principal
    financial and accounting officer)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 31,
    2026</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Hyun W. Bae</I></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hyun
    W. Bae</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 31,
    2026</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/Hansoo
    Michael Keyoung</I></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hansoo
    Michael Keyoung</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 31,
    2026</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Rahul Singhvi</I></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Rahul
    Singhvi</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 31,
    2026</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>


<!-- Field: Page; Sequence: 153 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->128<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="margin: 0; text-align: right"><B><A NAME="EX_001"></A>Exhibit 10.69</B></P>

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"><IMG SRC="ex10-69_001.jpg" ALT=""></P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 154 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"><IMG SRC="ex10-69_002.jpg" ALT=""></P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 155 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"><IMG SRC="ex10-69_003.jpg" ALT=""></P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 156 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"><IMG SRC="ex10-69_004.jpg" ALT=""></P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 157 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"><IMG SRC="ex10-69_005.jpg" ALT=""></P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 158 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="EX_002"></A>Exhibit
23.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CONSENT
OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
consent to the incorporation by reference in the Registration Statements on Form S-3 (File No. 333-292686), Form S-1 (File Nos. 333-286662
and 333-284569) and Form S-8 (File No. 333-282391), of our report dated March 31, 2026, (which report contains an explanatory paragraph
describing conditions that raise substantial doubt about Kairos Pharma, Ltd.&rsquo;s ability to continue as a going concern) relating
to the financial statements of Kairos Pharma, Ltd. as of December 31, 2025 and for the year then ended, included in this Annual Report
on Form 10-K for the year ended December 31, 2025.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
Weinberg &amp; Company, P.A.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Los
Angeles, California</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
31, 2026</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 159 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>
<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="EX_003"></A>Exhibit
23.2</B></FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>CONSENT
OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
consent to the incorporation by reference in the Registration Statement on Forms S-1 (Nos. 333-284569 and 333-286662), Form S-3 (No.
333-292686) and Form S-8 (No. 333-282391) of our report dated April 15, 2025, with respect to the consolidated financial statements of
Kairos Pharma, Ltd. included in this Annual Report on Form 10-K for the year ended December 31, 2024.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
<FONT STYLE="font-variant: small-caps">Marcum llp</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Los
Angeles, CA</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
31, 2026</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 160 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>
<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="EX_004"></A>Exhibit
31.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CERTIFICATION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I,
John S. Yu, certify that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.
I have reviewed this Annual Report on Form 10-K for the fiscal year ended December 31, 2025 of Kairos Pharma, Ltd. (the &ldquo;registrant&rdquo;);</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.
Based on my knowledge, this Annual Report does not contain any untrue statement of a material fact or omit to state a material fact necessary
to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the
period covered by this Annual Report;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.
Based on my knowledge, the financial statements, and other financial information included in this Annual Report, fairly present in all
material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented
in this Annual Report;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.
The registrant&rsquo;s other certifying officers and I are responsible for establishing and maintaining disclosure controls and procedures
(as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act
Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision,
to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others
within those entities, particularly during the period in which this Annual Report is being prepared;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under
our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements
for external purposes in accordance with generally accepted accounting principles;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c.
Evaluated the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented in this Annual Report our conclusions
about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this Annual Report based on
such evaluation; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d.
Disclosed in this Annual Report any change in the registrant&rsquo;s internal control over financial reporting that occurred during the
registrant&rsquo;s fourth fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant&rsquo;s
internal control over financial reporting; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.
The registrant&rsquo;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial
reporting, to the registrant&rsquo;s auditors and the audit committee of the registrant&rsquo;s board of directors (or persons performing
the equivalent functions):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are
reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial information;
and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s
internal control over financial reporting.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
    March 31, 2026</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    John S. Yu</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">John
    S. Yu</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal
    Executive Officer)</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 161 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>
<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="EX_005"></A>Exhibit
31.2</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CERTIFICATION
PURSUANT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I,
Douglas Samuelson, certify that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.
I have reviewed this Annual Report on Form 10-K of Kairos Pharma, Ltd.:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary
to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the
period covered by this report;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material
respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this
report;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.
The registrant&rsquo;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures
(as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act
Rules 13a-15(r) and 15d-15(r) for the registrant and have:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision,
to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others
within those entities, particularly during the period in which this report is being prepared;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under
our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements
for external purposes in accordance with generally accepted accounting principles;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c.
Evaluated the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions
about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation;
and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d.
Disclosed in this report any change in the registrant&rsquo;s internal control over financial reporting that occurred during the registrant&rsquo;s
most recent fiscal quarter (the registrant&rsquo;s fourth fiscal quarter in the case of an annual report) that has materially affected,
or is reasonably likely to materially affect, the registrant&rsquo;s internal control over financial reporting; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.
The registrant&rsquo;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial
reporting, to the registrant&rsquo;s auditors and the audit committee of the registrant&rsquo;s board of directors (or persons performing
the equivalent functions):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are
reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial information;
and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s
internal control over financial reporting.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
March 31, 2026</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 47%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Douglas Samuelson</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Douglas
    Samuelson</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Financial Officer</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<I>Principal
    Financial and Accounting Officer</I>)</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 162 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="EX_007"></A>Exhibit
32.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CERTIFICATION
PURSUANT TO</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>18
U.S.C. SECTION 1350,</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>AS
ADOPTED PURSUANT TO</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SECTION
906 OF THE SARBANES-OXLEY ACT OF 2002</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the Annual Report of Kairos Pharma, Ltd. (the &ldquo;Company&rdquo;) on Form 10-K for the fiscal year ended December
31, 2025, as filed with the Securities and Exchange Commission on the date hereof (the &ldquo;Report&rdquo;), I, John S. Yu, Chief Executive
Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of
2002, that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)
The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)
The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations
of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
March 31, 2026</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    John S. Yu</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">John
    S. Yu</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal
    Executive Officer)</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>


<!-- Field: Page; Sequence: 163 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="EX_008"></A>Exhibit
32.2</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CERTIFICATION
PURSUANT TO</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>18
U.S.C. SECTION 1350,</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>AS
ADOPTED PURSUANT TO</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SECTION
906 OF THE SARBANES-OXLEY ACT OF 2002</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the Annual Report of Kairos Pharma, Ltd. (the &ldquo;Company&rdquo;) on Form 10-K for the fiscal year ended December
31, 2025, as filed with the Securities and Exchange Commission on the date hereof (the &ldquo;Report&rdquo;), I, Doug Samuelson, Chief
Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley
Act of 2002, that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)
The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)
The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations
of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
March 31, 2026</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Doug Samuelson</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Doug
    Samuelson</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Financial Officer</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal
    Financial Officer)</FONT></TD></TR>
  </TABLE>
<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Page; Sequence: 164; Options: Last -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>form424b3_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 form424b3_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !% )T# 2(  A$! Q$!_\0
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M\L8_NY_B/L*YVY^(+-;G[-9E92/O2-E0?PZURZ&_UC4]L9::\N/E!)Z9ZGV
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
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>form10-k_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 form10-k_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %6 G # 2(  A$! Q$!_\0
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M-'E_X3+0I;/5(CYEK_J[P#O]?7U]:QK82E2:J;P?WG3A\PKUDZ5[37EHR?\
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M&!_\*^QJ2A8MK[(I4+K<^2H=,U(8/]GWHQ_TP?\ PK0ATW4!C-C=_P#?EO\
M"OJ6DQ6L<>U]DY)Y>I_:/FR'3[X?\N5S_P!^F_PKH/#UG=)KVGL]K.JBX0DF
M,@ 9KW/ I"!5RS*3BX\NYRK)XJ:ES;',>*]9O[.'[+IEG<2W$@YECB++&/\
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MNJ@\:;>9_P"N+?X4?V-JO(_LV\YZ_N6KW0UR?CSQ2WAG1%EMROVR:0+$K#/
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M<L/45A7/AZ.:\EN(KN2W,LAD<18&25"_T_6O 3-+G_72_P#?9IIFES_K9/\
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M$T?B: -&BL[\31^)H T:*SOQ-'XF@#1HK._$T?B: -&BL[GU/YU(LSKWS]:
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MLO\ ORO^%5]1?<AYQ'^3\3YG++D_,/SJ,LN/O#\Z^F_^$=T4G_D$67_?A?\
M"C_A'=$_Z!%C_P!^%_PJU@I=R'FT7]G\3YAWKG[P_.HRR_WA^=?4/_".:'_T
M"+'_ +\+_A1_PC>A_P#0'L?^_"_X52PC[D/-(O[)\N,ZY^\/SJ,LN?O#\Z^I
M_P#A&M#/_,'L?^_"_P"%'_"-Z%_T!K#_ ,!U_P *M89]R'F,7]D^5BZX^\OY
MU&77^\OYU]6_\(UH7_0&L/\ P'7_  I/^$8T'_H#6'_@.O\ A5+#VZF<L<GT
M/E NN[[P_.F.Z_WE_.OK+_A&-!_Z MA_X#K_ (4?\(OH/_0%T_\ \!U_PJO8
MON9/&)]#Y*WK_>7\Z877/WA^=?7'_",: /\ F"Z?_P" Z_X4?\(OX?\ ^@)I
M_P#X#)_A5*DT0\2GT/D9G7^\/SIA9<'YA^=?7G_"+>'_ /H":?\ ^ R?X4A\
M+>'SQ_8>G'_MV3_"J]F0Z_D?*>EZ%JVN2"/2].N+H]VC3Y1]6/ _.O0=%^"6
MIW)636K^&S0\F*#]X_Y]!7OL-O#!$L4,,<<2\*B* H_ 5)M3^Z/RJE%&3JM[
M'"Z!\.?#/AZ5)[:R\ZZ3D7$[;V!]NPKK,U>VI_='Y4;$_NC\JLS*-%7]B?W!
M^5&Q/[H_*@"A15[:G]T?E2[$_N#\J *%%7MJ?W!^5&U/[@_*@"C15[:G]T?E
M1M3^X/RH HT5>VI_='Y4;4_NC\J *-%7MJ?W1^5&U/[@_*@"C15[:G]T?E1M
M3^ZOY4 4:54=C\JYJ[M3^Z/RIV10!66U/\38^E3)$B'@<^M/W"C(H ^<_CQ_
MR/%K_P!>2_\ H1KRWGL"?H*]2^/'_(\6O_7DO_H1KBO#VLV^E6NK0S"0->0I
M'&Z*3MPV3G#*1D<?S!KUJ+:I*QR3^-F%F@G!Q_.N_G\;Z+>3H;C2I?*=W:X5
M44>81M,1'H?EPWM6)INOV4$-\;N&;?<R12M&JB19)%DWELG!4'ICFJYY6O87
M*NYS?//!_+I5[1?^0[IW_7U%_P"A"NCU?Q38:CI5Y:'[3(TBKY;E-C/(#]]R
M&P1CC:0?7-<YHO\ R'=._P"OJ+_T(4^9N+;06LS[0'6D9,D'<1CTI1UI<BO&
M.PC\K@C>W/?TI?+YSN;IC%.W+ZBC</44 ,\K@?.W!SG-+Y?7YVYIVY?44;AZ
MB@!NPY!W'CMZT;#@C>W7K3MR^HHW+ZB@!NPY)W-R,8]*3RSQ\[<=_6GY'K2T
M 1F,G/SMD]_2EV'(.X],8I^0*3<OK0 SRSMQO;KUI2AR?G;G]*=N7U%&1ZT
M,\L_+\[<?K1Y9P1O;FGEAZTF1ZT )M.[.YNF,4GEG &]N/UIVY?44N10 SRS
M\WSMS^E+Y?(.X\4[<* 0: &>6<8WM]:7RSDG<>:=D49% #/+X'S-Q^M*8R<_
M,>?TI^129% 7&[.<[CTI/+. -[=:?D4N10!'Y?)^<\_I2B/!'S'C]:=D4N10
M!'Y9P1O;DT;.<[SZ8I^129H :(SQ\[''ZT>6>?G;G]*?10 S8<@[FX'YTGEG
M'^L;.>M244 ,V')(8\_I1Y9^7YVX_6GYHH 9Y9P1O;D]:-ASG><8Z4^B@"/R
MS@#S&X[T>6?F^=N?TJ2B@!NP@CYST_.D\LXQO/UJ2B@!A0Y)W$<4FPX'[P\?
MK4E% $>PX/[QN?TI=G(.X\=O6GT4 1^6=H'F-UZTNPY)WGGMZ4^B@"/8>/G/
M'7WH,9P1YC<GKQ4E% #-AW9WG&,8I/+; _>-P<YXYJ2B@"/8?F^=N?TI=AR#
MO.!VI]% $?EG&/,;.<YI=AW$[SSV]*?10!'L/'[QN.OO1Y9P1O;GOZ5)10 S
M8=V=YQZ4FPX'[PY'?UJ2B@"/8>?G//L.*-C?*?,/'7WJ2B@"/RVVD>8<YZX%
M+L.XG><$=,"GT4 1B-@ /,;CV'-&QOF_>'GITXJ2B@"/8<@[S@#IZTGEMC'F
M'.>N!4M% $>QLGYSR.!QQ0$/'[PG'7CK4E% $1C;!'F')/!P.*<$.[.XD8Z4
M^B@#YR^/'_(\6O\ UY+_ .A&O+J]1^/'_(\6O_7DO_H1KRZO8H?PT<=3XF%%
M%%;$!5W1?^0[IW_7U%_Z$*I5=T7_ )#NG?\ 7U%_Z$*F7PL:W/M#O574+B2W
ML9Y8H7EE5#LC09+-V JR:Y W_B.*[U#R[=I@MTPB22(A1"!D;2 ,D],Y->&=
MQ"^L>*$TIL::?M4<95F:(DL_S'< #@C"C@?WA4DFM:Y;WCA;"6:)D^7,#_(-
MS?-QUX"_+UYJ)-:\31O/-)IT@0N"L;0MA0%&4!SP.IWGCC&*BTS7_$&J6[7T
M,"R!G"(B1L$3DY)&<DC(SSZ4 22>)-<AD^TSZ8\-O#%EXS&PWEF0*0>F<L?E
MZC!J[JFLZYIUQ(L>G&Z4F$*D4+$<_?.[V/2FR7FM7FF:A<)$\5S!"L20JF09
M<Y9@I!SQMQU]JHP7OC#RMK02%I!&%D,*C9M.7../O#UZ>U "7GBW6+6^^Q1Z
M?%+=?9A.855MV2>!_P !')JVNK>(S,1_9X8L20/*8)&-JD9/\1SD=J?$?$<-
M@;N0*]RUV@"F$/(L&[YAQC@\$=<>]$FH>(+C2!,MG)%<+.!LCC*EEQR,')P#
MQGOC- %CPSXAGUR]U*.2.*(6KJ@09W _-G/Y?SKIQ7'K>>(Q*?\ B7P1K(V=
MT41#*>,%CGG'(]ZZ#19;R;2;62_XNFC!E!CV8;O\O:@!FO37=OHE[+8 M=I$
M3$ FX[OIWKFI=4\0+(\44-R[M#^Z(M\)G:/F+$9SG(QVXXKMRH/45@:I?:S:
MWA6QLDGMUC!)*DL6.>>#T&!QU.: *%K>>)+?5KE+BU:YMT3$0&%W,%C).['J
MS?7';%4T\2Z_;J9)M)=HB)9&D>-T$85<A<8SU[GKVK4LM2U^613-IL9A(P 5
M,1;J0YSG:, ?+U&>M5EU7Q-*AVZ;$H7<")(6&\C<1CGIA5'/]Z@".'Q#XAEG
M,::+^[,6Y9V1U#'=@-MZCCG!.:@NO$7B2*X=H=%D<1Q%?*\M@I.1\^['/?@<
MBI8=3\27NL6X>QGM+2.Y*N=F \>1][/I@\CUI]UJ_B4S"&#3,(_G!I!&P,6
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M_,5M?^_;5[1252PU-=#-YAB']H\6/P5U0C_D+VO_ '[:F?\ "D=5/_,8M/\
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MTS0?,R>%]N:DHH C^?(X'OS1\^"=HSV&:D-)0 WY\]!C'K29DP/E7/?FGTM
M$9,G/RCVYZTOSY'RCWYI]&: (_WF/NKG/K1\^X_*".W-29HS0!'^\^7@>_-&
M9,'Y5SGCFI*,T 1_/G[HQCUI,R8'R#.>>:ES10!'E\GY1[<TN9,CY1COS3Z*
M (R9,'"KGMS1E\]!C'KWJ2DH 9F3 ^5<]^:,R?-\J_[//6GT4 ,^?(^48[\T
M9DP/E&?K3Z* (R7R<*,8XYZT?O,K\H]^>E244 1GS.<*/;FE^?/W1C'K3Z*
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MN-.8L[",+#DA6). 2?8$]*JKXYN'B>==(D,0X5=^&9MV,\C 7!'XT =OFEK
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M,5I[*)/,SKF\;K)-:R264Q\I7$F+C'F$Q^7Z<#')]37/:-C^WM/QP/M4>/\
MOH52Q5W1?^0[IW_7U%_Z$*'%13L%[L^T!UI3TI!UI:\4[3)OKR]BU?3[:!;<
MPW!?S#(&W *,G&./SK'NO&EO$QACLIVD)D5#\I4;#M)89R!GMUQS75L@8@D#
M(Z'TJ,VD!;=Y,6=V[.P=?7ZT <U-XGN(;2UD6Q$DDZ22?*X !5T7&#U)W?AB
MG1>,;::[%JFG71?"9R% !8\CKV]?:NE,$9VY1#MY7('%)]FBW[Q$F_&-VT9_
M.@#E(O'EE/*D<5E<NSL1P5R><#'/.?T[UTFEZA'JEA'>P ^3+DH3_$N>"/8T
MO]FVHG\X6\7F;#'N" $*>2/QJ>W@2V@2&) D4:A45>@ Z"@"6BBB@ K#UW17
MU983'=&WEB#@/MW8#8R1Z'C@UN44 <C-X/>6X>8:E(JR.7*;>!DDY'/7G'XF
MH7\#RM:B)-4>(XV[D0C XZ<\=,_6NTHH XUO!<C.\@U$F1MP^=2?E+A]N<Y(
M)!S]:E_X0XJ?,349Q.%P)22>Q'3..]=;24 9VAZ<VE:3!9/.T[1!OWC=3EB<
M?AG'X5??'6G51U'2[;4XO*N?-,?<)*R9^NTC-)[!IU*.I^*='TG/VJ]3S!_R
MSC.YOR%<7JWQ,:9'AT^Q78>-]QSG_@-=3_P@'AO)_P")>3G_ *;/_C1_PK_P
MU_T#S_W]?_&N"M#%3TBTD>KAZF IV=2,I/Y6/&;BX>ZG>:4(';D[%"C\A4)K
MVS_A7_AK_H'G_OZ_^-'_  K_ ,,_] \_]_G_ ,:\[^S*KWDCVUGV'2LHO\#Q
M$]::W2O;S\/O#!_YAQ_[_/\ XTG_  KSPQ_T#?\ R,_^--99475">?4/Y7^!
MX8U-;I7NO_"O/"__ $#/_(S_ .-(?AUX7/73/_(S_P"-:++JG=&;SRB_LO\
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M?]VCR(_[M %*BKOD1_W:/(C_ +M %*BKOD1_W:/(C_NT 4J*N^1'_=H\B/\
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M<9V/UQC% $E%,WG)&UN!G..M)O/R_(W/MTH DHJ,R'!.Q^#CI2AB6QM/3.:
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M$2H\Q 6 (!8 G/3BH_M]OY_D^;'YFTMC=V!P>?J<5BW_ (7T^ZNVO+B5DD(
M#G VX4*,$].F?K66W@C3'W1R:C([[E! **.,8!48R<#GN>M '8O=11QN[2(%
MC!+G=]W'7--2\AEA$J2(8RH;=NX (R,_@:YD^&;+F%-6D5#DD )\REL@%L<G
M(Z]>U5H=#T33K%X4U5F74'1HI#B0L5.0,<@KGC!&.U '717UO,A:*:-E#;"0
MW1LXQ1]OMS.T FC\U%#,N>@SC^AKA;W3O"TC,DFL!'AE624*N S$L!G &?OD
M#Z>U:3>#89H/-M=0=F:$QQN43848[LD ?,>?O=30!U+7D*D;I$YQC#9ZG _
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M_P#"UM*Z_8;O]*0_%G2A_P N-W_X[_C7E!J)JM9A6(EDV&Z7^\]:/Q<TD?\
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M+6H97N'B\Q2EKY@VY]:PO^%Q?#__ )]KC_P7UW4JTU!)1,)03=[GSE_P$_\
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M_P"/2W_[_BO?LOSA>@XYZT;GROR]>O/2K6%IHS>95GO8^?&^%'BT]+2W_P#
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M51_&VD)/M9YECVYW-&P))(P N,G(.<^E6-7DTG3I(FO+59#<':-L>YF/RJ
M.N<J*P#JGADV-Q)'I(81G>@*%?,'!!5ORX[4 =$WB;3OLTDRR2%%4LI,9 D
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M[3)[4GVE_:HJ* )?M+^U+]ID]JAHH F^TR>U'VE_:H:* )?M#^U'VA_:HJ*
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M[:M<]/\ 6&F_\)AX7  _MNU&#G_6FJ5'#^1#Q>-ZM_=_P#DS\&[)O^8O<_\
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M%_,]>!?;RJ9S^E+\^3A5QBO'?^%D>(O^>EM_WY_^O2'XD^(A_P M+;_OS_\
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M:7PH9+2.%K#R=DH9Y48%08\#=CJV_D>@KE-%&W7=.!()%U$,C_>%-_LC5/\
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ME&K^)6O8P,?9MFX+_P #/-=W]E4@99L#MZ4GV5<_>:MDK''*;D5Q15G[,O\
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M7FUIIU[J"SM:6[RB!0\I7&$!. 3GWXKT*6'IN"E(YY5)<UD>\_\ "_\ 0O\
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M%1&=)07^S8*2 ?*HR?3OTSQVJ_=WOBBQLKBZ50R(C%4>++,3T8X/&.. ,<T
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M;AC%>\?$7X7:AXU\00ZC:ZE:VJ1P"(I+&S$D$G/'UKD?^&?M:_Z#MA_WY?\
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M.N>)#);I'I:XDCW,[PLH5\X*XS_#Z_Q=178QAA& Y!8#!(& 31L'J:4# Q0
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
7%%%% $$\"S; Q(VN'&#W%2KWHHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>form10-k_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 form10-k_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $S G # 2(  A$! Q$!_\0
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M5UP/ )]*QG!P=F;0J1J*Z'BBD!%+4F@4444 %%%07-S#:P///(L<2#+,QX%
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M2^+(7B:U=%Q H* #HIHN ^/Q'=L^=L>W^[70V%\E]#O PP^\*X*)^!S73>'
MS22R?P$8_&D,Z.D- I#S0!5O]2L],MC<7MU%;PC^.1L"FV.IV6J6XN+&ZBN(
MB<!XVR,UY9\<-+U2Y@TZ]MT>6QMPPF5?X"?XB/IFF_!'2]2MX[Z_GCDBL+A5
M$0?_ ):'^\!^7-:^RC[/FN9\SY[#_C'I^H27=C?)&\EFD91@HR$;.<G\*R_A
M58WTWB5;R)'6UCC8228PK9Z#WKUSQ& WAO4=P!'V9\ C(Z&L3X98/@+3F  )
M4Y]^36BK6HM&+IIU$[F+X_\ !MW?WAU?3U$C!!YT1.,X[@_2N?\ !OA*[UJX
MAOI,)8(^2W=R#T KV&_XTZY]?*;W[5S'PT4CP; &4J?,?((QWJHXB:I.(I4$
MZB9@^.?#MXFJ-J=K"TL4H&\+R5(XKGM(TN\U:Y2.WA8J3AG(X7\:]KG ,+Y'
M\)KE?A\I&B3[E(;[2_48XJX8N4:=C&IA8RJ7.8\36,EAJJQD$1>4JQGU &*R
M588Z$Y].]>O:AIEIJ4'E74*NHZ$]17*^$]'LI9KN>2+>\$Y5"QR *Z*6,2IV
M:V.6K@G[31[CAKLFA:-:6@3?=E,X8\**JP>+]01]T@CD3/*@8.*S_$\<D/B"
M<N#AL%2?3VK,5N.#[5O1P]*<>:74YJN(JPER1>QZSI][%?VJ3Q'AAT/:KE<U
MX/CDCTG<^0'<E01VKH@PSUKQJL5";2/>H3<J:<MQYK.N-=TJTNQ:7%_;QW!Z
M1LX!J^3D<=>U?.GB'1]7@\4SVUQ!*]U<2DP'J9 >F/I69L?1+_/$=C<D<$5X
M!J]E>V>L7,-W$XF:4D$@G?D]17MGAZVN;/P_96]X2UQ'$ ^3G'MFN?\ %Z@^
M)?#61G-P0>,\4 6_!NFSKX0%K?*P$^[$;=54]!7"ZQX7O]&O5C*K)%,Y6)@?
MO$]B*]C&,FN5\:9:;1MH)Q=@\#.* (?#?A*6QTZZ^V$">ZCV87^ 5QM]I-YI
M<[0W$+JH;"L.C#M7L6<CUKF_&0W6%H5!/^DIT&3UIW P/#V@WKPW%Y)&8\1,
ML0/!8FL-=R.4<;64X(->NI]Q1[#%<SXKTRT6S-XL(6<NJEAWR>] C T$.^K0
ME>D9W.WH,5O77BB1YBMJBK$#@.PR6K1_LJ"UT.:.SA"O)$>>Y.*X:(["%/5>
M"* .UTW7#/((K@*"> R\ UO"O/[+=+/&B#YRPQ[5WX.  >N* '57N[RWL;=[
MBZGCAA099Y&P!4VX5YI\:=)U75/"<7]FQO*D,V^>)#RRX].^*<8W=@;T.[TS
M7-+UF-GTZ_@NE3[QB?.*\_\ C1INHWNA6D]G&\EO;REIT09[<''M7%_ _2M3
M;Q"^IQ))'IBQ,DCGA9&[ #OBO?I5S$^1G*D8K1_NJBMJ0USQU/FWX<:;J-]X
MRT^:RCD"02;YI1D!5[@GWKU;XC^";KQ&D%]IP5KR %#&QQO7T!]:;\)(RGA^
M^W(5)O9.JX.,UZ%53K/GYD9QIKEY6?.WA;P5JGB&^>)5$5O!(([B1SRN.JBN
MZ^(?A"YEBM+[386F6WB$+Q+UVCH:U/AJ&7^WMRL,W[D9&,\FNZP,Y[54\1+G
M3[$JA'E:?4^=-.TN_P!2NOLMI;2/*&PWRXV9[GTKI_%^BSZ-'ID1YA2#RRW8
M/WKK_!"E==\2;D(_TK@D8]:ZN^L+74;=K>ZB65&ZJU:RQ;4TWT,(X6\&CPA&
M&"2<>]=_I6MOX<\+PK(A>YG<M%$>R^II/#WAO3G\4:I#);%HK1AY*O\ =Y_G
M53QW;R6^MPOM(A>,",@<#'45TRK1K25-[',J<Z*<T2P^-]4$H=A"R?W-N.*[
MK1M7BU>R$\?!Z,I[&O'T(KOO ,4JVMU*01&[@+[XSFEC*%.,.:(82O4E4M+8
M[4T"F[A2@CUKR#V5N.HHS10,\X^*7Q#;P7IT5O8JDFJ70/E[^B+W8UX%-X]\
M5W%T;I]>O!)G=A'PH^@]*[3X_6-S#XIL+UP3;2V^Q&QP&!SBO*%YQBO3P]*+
MC<PE)WL?07PI^*%WKU\-"UUE>[*%K>X QYGJI'KWK9\<6MS+\2/!LL-O(\43
MR>8ZJ2$Z8R>U>*_"ZRN+WXB:0(%)\F0RR$=%4#G_  KZ&\1^+VT3Q;H6C+;1
MRKJ3LK2,^#'C':N:I'EJ>Z7%W6I;UK7-2TV:46NCM<0Q)YCSM(%&.X%5)_%R
M31:>+#3FN[R[0R)"2%V =3FH?%L6NWUU'96ED\FF ;IC'(%,O^S[5!)IVJ0W
M>F:S8Z4$>"%K9[$R#(7/!!J%&-KLEMWL6I?&LZZ1+>Q:66>VD,=W$TN/)/UQ
MS2:QXJO;""*Y;1TEMI%1HW:<<L1T QU%5?\ A'M3?PQK1EA'V_49/-$*MD+T
MP :36K+5+RTBL'T(7"Q1 03K/CRWVX)--*%Q-NQV=K<2SV,<TT!BE9-QBSDK
MQTKFI_%-W;7<(U#1&ALYIO*21Y 6W>NW']:LV/AZY6VL)+O4KS[1;QJ'2.3"
M2$9//KZ5B-!K]UX@%]J.C//#$V+:)9@J1#^\1W-1%1NRG>QHWGC*>*>\^R:8
M]Q9V3;+B?>!M/? [XJ74/$EXL2SV>CM=67E"8S22!5(([<&LF;2M=L!JNGVE
MBL]OJ,AD68O_ *O=]X$4FK:;KRVUEHT%D\^F6\2+,T<@0SD#D9/05=H:"?-8
MU(_%TDE[I:KII%GJ 4Q3M(,C(Y&W';I4'BOPU9FTGU&"%UN!SMCZ,?7%27.G
MWUW<>'YTTX6T=K(3)#O!\M<8'3K6[KFH?V5I,]YY?F^6,[?6A2Y9IP(G!3@^
M<R=(T33]%T]=2D5FD$0D9GZKQDUS&H>*+^^N&:*9H8?X53@D?6NQUKS=0\)R
M-""'DA#[1Z8R17F*'C/3^E=^$@JLG*IJSS<7-TDHPT1T6F>)K^RF4RS--%GY
ME?D_G7HMK<)=6\<T9RCC(KQY#SQ]!7J7A^)X-$MDEX8+DY[9K/'THQU6A>7U
M9R;BV8'P[@F@MM7$T3QDWSD;QC(KMO2N<\*>(V\10WKM D1M[AH0%;.X#O71
M=^,\_I7F'L'*^$898I]:,L;)NO6()&,CMBHM0\67^F2F2YT61+%91&96E&XY
M.,[:T]!UF35Y-05XA&+:X,2X/W@*YO4H-?OM?6XN]'>YL8'_ '%LLP4$_P!X
MYZU<$KZD3;Z&G?\ BN6"^NH=/TMKM;5!)<RAPH _+DXJ2?Q/>2VT-SI>D/=P
M20F5I&E"!1W'?FLR;3M;TV_U)[&P6XBU-.#OP86(YSZU!?:1K]KHUCHUE;-+
M;!,W4D;A6?N5!/05KRQ(O(UD\57EY8P7>F:(\XD0M(S2! F.V>];.@:NFMZ5
M'>I&T6259&.=I'49KD]1A\02Z-;:;IVCM9VN")524%MH_A#>_K73^&XW@TF.
M%].-AY9*K$7#G'KFHE&*6A2NV10H_P#PF=Q(4.S[,!N[$YK9N;:*ZB:&9 R-
MUJC'J;/K\NG>4-J1"3?GGK6F/NUD:')_V%;IKBVR^;]G,9<Y]?3-;%Y<PZ1:
M)%"H!;[H_K4C:AC6EL/*&6C\P/GI63XD1ENH9CDQE-OT- "1:A<R-N:4Y]JV
M+&\,WR2?>KF('QC%;&G$O<H!VZTP&^.(Y)O!6KQQ(SNULP557))]JC\!1R0^
M!M(25&21;<!E<8(^HJ]XCU4Z+X>O=36-96MXBZHQP'/I3/#&L?V]X;L-4:-(
MFN(@Y13D*?2GKR$:<UR;Q"C/X>U%44LQMW 4#))P:Q/AQ#-;^ M-CGC:.15.
M488(Y-=#JUVUAI%W>(@9H(FD"GN0.E9OA+6Y?$?A>SU66%(I)P28TZ#!QQ1]
MD+>\9][XKOK";?=:+)'8^;Y/FM*-Q). 0*6^\5RV]Y<VVFZ4UW%9@-<NKA O
M? 'K69?P:]?:\+F[T9KBRMV_T>W68*N?[Q]ZFN=/US3KW538V*W,6J /O9\>
M2^,'/KBME&)%W<TKGQ->26L-UIFE/=6SP^<93($4#N/K567QA/'HL.JVFDA[
M1X]SN\P380<8QCDU0OM(UZTT:PT.SMFFLHXP+EXW"LY)R5!["K%W#J$VDPV#
M>%@UHJX$2W RC#H3ZT*,;";D=/H]_/J6F17=Q;&V>49$9;) [5E>#XI(X]2\
MR-ES=-C<.HJUX5T^]TS0HK?4'W3 D@;MVP=AFG^'M9;6$O&:%8_)F,8V]\=Z
MAO1I#:7,FRSJFCVFK1!+F,DC[K+P17+:+X;@GO[M;E)#'!)M0-QN'OZUW/:L
MC3M4.HS7T A$9@<IN!ZU5*K.,7%/0QK4:<I*36ISFL>(I4G:ST\^5#%\I8=?
MPK,@UK4;>0.MT[<Y*MR#6?<H\-[/'*#O#G.: >.M>W2HT^1*U[]3P:E>HIMI
MV/3-&U1=4LA-C:XX<>AKFO$D,\GQ%\,R1PR-$@DW,%^5>.YJYX+C=;2XE;(1
MV&W/?WJ?5?$K:;XKTG1_)1UOMVZ0MRF!7A5HJ-1I'T>'FYTTY'2GH:Y[5(G?
MQ=H;^66C19BS 9 .WBNASVS63>:F]MKVG:<L:LMV)"S$_=VC-9&XNKZA>V21
M+8:<UY+(<??"A?J:PU\:1G2I9Y[!Q>17/V;[/N!S)['^M:'BE]9&GK#HT.Z6
M0XDDSC8OM[USB:%J,NBPI;Z6;2YL[A+@"64,;AOXLFMH*-M3*3=]#:M?%ES(
MUU:W.DRQ:C#&)%MED#>8I[@T[3/$EQ>:Q_96IZ9]DN&B\U!Y@<%1^'!K/@M=
M=DU2]\0/IZQ7(MQ#;VN_))[DFJVC:7K,DMV+^PECO;Q&#W[2AA&.P5>PIN,
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M5**VUN[UD:S<Z<('L[9DBM_,R96(]>U5=(M=<75)K[4=':>[F#*)C, D2XZ
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M9-1RG2]SJ6/"NM0:QI21!-KPJ(W0_2JNI>";>ZG::UF,#,<E<97-7?#/AM=
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M25#<3Q6T)EE<(@(!8^YP/UIV\ X/'IF@"2BJMS=PVWEB63:7<1J,=6/:K(/
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MK:WBWW%K<PEEWPK(N#*"0./?D9]*O7>L16.EI?SPS;'94V(FXJ6( SCMD]:
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MI,4 <Q)X-T^3[2 9H_M*1J=K8VE3]X>A/>M6?3()[6WM2&$,#HRA3_=Z"M(
M#M2X% '-?\(I$$G1;R4^8=H#8(5.?E&?K3KOPK97-S9REI0;6(1 ;OO*"",_
MB*Z+: <XHP/2@#GT\):<JH,-A(S&![$8_K4:^$+/85DGF=FP"V>H"A1^0 KI
M  .@HV@=J .7NO"5H;5TAR9?F92[8!)&.35WP[IMQIEI.MU('FGG:9BO09 &
M.@]*V]H]*-H]* %HHHH **** "L'5_#D.L7L5Q-/,HBQB-6^4X.>E;U&* .6
MF\&63P-%'--#NB,+8Q]PJ%(_("M.70[.:Y>X= TKVXMPQ RJ\]/3K6K@&C%
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M1>.XT)\^,LQG:,Q9PZ #GMSSQ^-=BD*K&L9^95Z;N32-:6S/N:"(MG.2@ZT
M<M_PF<L3O]ITV6.)8Q)N60,3D$@ ?0?A5F#Q7Y^F1W@MMIDG\E0\@"9P#DMV
M'/I71^1">L2?D*B^SVXB\GR8_+SG;M&W- '*1^,+BUMII+VW&"\GV=A)PX5@
M,<#CKP>]21^-@R&8V,GD%%*-NZL54X([ ;NM=4UK;LFQH(ROH5&*AGLK>:W:
M(QJB$;?D&#B@#F#X[1'5&LG=]\B.(G##Y&VG8?XC^7%.B\47LR:G<1Q0LMO
MDD48E#9)]2.GTK?L-(LM/@6"&%2JL7!?YCN/4YJXEK;H'"01KO\ O84#/UH
MP]/\1_;M2%F80I.1N60-R "<@= <\&NA7I4:6T$;ETB16QC<% .*EH *:0.]
M.J-F(R>E $(L+41)$+= B JHQT!ZCZ53/A[2"S_\2^#Y\9^7KBN:L=9U6&*:
M*V!O)P[,T\V[RV &?E&,J3TQZU))XIU5?(MY++$TK%6*1M@ CA@?49[^E '4
MQ:380^=Y=K$GG##X'44Q=+M(I)66$!94V.O\)'TKFH[[5!H+O++.A-S&DLFP
METB(7<0/SYH?7[BUO([*P6>[MG&?M$RMDYZ[3C^'KSUH Z:'1M/@0K':1A2I
M3!'\)ZCZ&I(=,LK:5)(;6*-TC\I65<%4_NCVKEX-2O[?1EGN99U*W,2NS(6(
M0XS4]QXHNO,>"SM#)*"V RM@ %0&)QW#$X]J -R31M.D:%GLX28/]7\O"]Z=
M!I%A;P2PQVL:QRG,@Q][ZUSB^*=06^LK>>VCC\V=(7#*V7W9^93C  QT/-/.
MH&+4KV2]N[N.>&5A!;I&Q1X\<< <]^<T ;LVAZ9.[O)91%G8.S;>20,<_A5B
M/3[2.19$MXU9<@$+TSC/\A^5<G:^*M8N420::"BG$@VL"_S ?*#TX/Z4-XLU
M)?LFRSCE\\L7 1U\K&,1G(^]R>>G% ';8 Z45G:-<W=YIT5Q>(L<LF3L4'Y1
MV!SWK1H *0TM-?M0!1CT73897ECLH5=SEF"]3S_B:AE\/Z2[!FT^ MQ@[>F,
M8_D/RKG[6X\00&2\!WI).8EBE).1OX;C[H"]N])%XLU*:5UDLEMT$VSS71\(
M,G@@#J<<$>M &M:>%;""XN991YQG 4AD V@$D8Q]36FNDV"QA%M(@HQ@!?08
M'Z5RT6M:Q!$XCMS,X=V+3!L;06( _# %31^([U)722$Q(-[_ +R-V9\$_*N!
M_.@#H8=&TZWE$L5I$L@;>& P0>F::="TMIGF-C"6<DL=O!)Z\>]<_I6OZC?>
M?=RV[(([=P(R&",P;@CC/(Q4-IXKU#<+BZB"V[QJ=ODN&#<Y]>,B@#KFT^T9
MR[6Z%BVXDCDG&,_E31IEB(XH_LL>R)=D8V\*/0?E7&7'B75+F6%D@:((K.]N
MJ.)&_=[ADXQC)Q4Q\6ZGY4\C6 C6*4(0R.6 R01M Y/';B@#J&T;3GG$S6<1
MD!)W;>3GO^M,?0M+<R%K*$[UVO\ +U%7XF+JI[$9YJ44 98T+2Q*)#8PF3;M
MW%>U6+33K.RDD>VMXXS)RY5<9JY10 #I37.%)%.HH SM-O+B^MFDGLYK1@[+
MLD()(!X;@]ZQ+S5M5@URZ6!#):6JJ\JG;C;@DX.<[NF!TKJB.*9L3GY5^;KQ
MUH Y(>.-DDD<M@ZLD6]L/T. >?;D<TK^*+J"[;=$LNYD6.*)]RY8'^/Z@5U1
MMH"6<PQDD;22HY'I34MH% 588P%Z87I0!SB^+6:15\@+(Q"E9) J(?GSEO\
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M#TH XJTO_%<Z12R6VP(V'1X@ID&1R>>.,_E0VJ>)<6OEV\K;\F;?;@8;(^7
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MP_$=/>MJZUNT@LY[E)ED$,1E9$.21T_G44'B+3WAC=[B)'.%9,YVL1G'X9H
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M'=5=LS8SRW/7D9'3BM=M>TU>)+R-2$,A#=E'6F7>M_9Y;)8;.6XCO&VQR(0
M#@GG/L* *-YX4@O)K^=R#-<R(RL2<(HQD?CBJTGAB^^WHT=]BV0OMC+G(0YP
MOOUZUL+XATY@SBY7RE 8R9X]/Z=:MZ??)J$<LB+A8Y6CZYS@]: .<TOPOJ-I
MJ-I<3ZB\B1*,H'.%P.G(^;/KQ6KI.C/I^I7-TTJN)L\ =.<UM@ 4N*  =***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BB@T 0I,DCNJ.K%#A@#DJ?>J5
MYK-M97T5I*7\V1=XVKD 9QDU-::59V,]S-;P*DEU)YDS#^)O\BJ&IZ']OU6&
M]$D0:.,QE9(M_!/4<C!H 33O$]CJ4A6 MC ;><8 .<9].!FM(7ULQ4)<1G*[
ML;NH]:P#X+M%MQ#',\9"*FY5'.%*\^O6HIO!HO)TFGOF&U,;8H]B@X.>,XQS
MTH Z=+N&508YXWR<##=ZK'5[,7CVIN$$B)YC'/"C..3]:R+'09K;74NY2IAB
MAP!&-JO)TW;>V!QFJDO@@2+*BWQ 9/+7"<E=VX[B.2<GK0!TRZC:2.R)=1%D
M?RR-W1O2HDU>V;4)[+S )(<!BQ &3V^M8$G@@-Y:K?NL:.LA&WEF '.<^U:5
MSX9M;K4'O'=ED<DG:,$$H5SGUYH U/M]J%W-<Q!<[<[QUJO?ZW9:=;Q7$TQ,
M4LGE(8QNRV"?Z&L:+P7:LC^?.)"T1B $>U5Z<@>O'6KO_",6AL[:U<[X8;LW
M(0@8/!&WZ<T 6[/7+&_C=X;A=L?W@QP<>M6OMMN Q\^,A1N/S#@>M8-UX1MY
MC*T$S6[OO^XHZ-C@^PQ53_A!8O),?VY_]6J@@$%F4DC=SR.>V* .BO-7L[ 1
M-<3867.PJ,YQUZ4\ZG:*[H;J/?&0'7=R"1D#ZD5F2>&8)-/LK3SG46H;:1WW
M#GK1<^&8)]3:\>08)#;0G.X(R@D]^&_2@#1EU:UBC1FDR790%'4;C@9%7Q7)
MV_@U(]0%R]]*X55"KCT*D9_+]:ZL=: '4444 )VK-U71K75TC6YW$1[@ IQD
M,,$5I'@5S_B/79M%FT]EC1K>61OM+-U2-1DL/>@!+?PG8VP3R998R%9'*X'F
M*<9!X]ATJ4>%].4OA& >(Q$9_A.,_P#H(K&L?'8.5OK8JYFDV"')Q$, ,?<Y
MJ5/&2K<RO)'LM=B-&.K$%7.>.GW1UH OCPCIS;A)YSH 512V JG.1Z]S5&^\
M(;T46<VV63*RS/\ >*X  &.. !4E[XPCMU$/E&.ZDA+H"0P5L$@''J%-6'U6
M]EU,VL,MM;I#!'-(TPR9-W7 [ >OK0 NE^'(;6*_$AS]J< [?X5  P/3/)/N
M:DD\*V#JH3S(QD[]I^^I()4_D*HIXWLI2WDVT\N&/W1P5&<MS]#Q0GCFV#!9
M;652TK)'M.XLHQ\V.WWAQ0!HQ>&-.A\G9&P,3 J<^C%OYFEN?#MM<3W+&>=(
M;HYN(%;"R-C&?4< =/2K6EZD-3M!<K$T<9=E7<>6P2,_I6A@4 <RO@O3EA\J
M-Y8^&5VC(!=3C@_D.>M26OA#3;6YDN$\UG9L_,V<8SCZ]3UKHMHHQ0!@V_AB
MSM;)[>"21'9F;SN"PR<XYXQ^%-3PEI<47EA)"-FS+-D__KKH,"C:#0!@:?X4
ML--OFO(FE>5I/,RYSS@C^IK?'2C I: "DVBJ.JZD=+L);K[/-<>61^[A7+$$
MXX%6T<LBG&"PSSVH =M![48'I7#P^-[O:QN+>%5?RU@8$X+MC*D^OI6AI6OW
MMS<6\=P;:5;E9&58LAXMI/WO8XQ]: .HP">E&T>@KD+'QCY=D)-0BDWY)?:!
M\I).U<#KTZU/J?B>ZM9],B2V2,7R$EY3\L'( +8[<_GB@#J,#THP/2N&B\7Z
MD]W<6QBMU(E,22R*55?GVANO(X/T.*GN?$FIV\TD+O;-';S!9KE%W?*0#]W/
MO@D=.* .RR.E* *YC5]>N[.^2.U>WF7R3(\.#N5<9WD^F<<5%:^(M1D^R[Q:
MNANQ!+(,\AER-OOGK0!U9 /44O:N>U/Q$;:2:&",Y@D19)&Q@9/( [\=ZJ?\
M)YI_V5KCRY0BN%^88W YY'TQTH ZVD!YQ7+MXVLTE2-X)EWL0#C/ .,_G4^D
M>('U77)K=(]ENMJLR9()8EV&?;ITH Z*D89%(#FD<D=/K0!F?V!8B 0^7\@E
M,W'=LYY]:HR^$+"0%6EGZ_)R,QKG) _$GGK4;>,K7[5<V\<$DTL+A J'[^<_
MET-)%XK6^U"Q@M86$4TNQW? _@WX Z]Q0 ]_!VFO=I<,\IV,6"EN!N)/]35C
M3_#%CIU_]LB+M-MP=P')Q@G\@*S;'Q8RM/\ ;HWW"=U^4#]VN]E7_>^[^%37
M_B"_-IITUA9GS+LN5C8;F('3..F: )Y/"=K):M:?:[D6F<QPAAM3)R?J.3P:
M7_A$-+6T6V59 JDD'=SDC'6J,/C$P073:E;F.2%V"[3\K8."![YS4D_CBQ@S
MF*4Y5&0=W# $?SH L2^#M/GN'GF9Y97C*2,V/GXQGVZ]JUI]/@N'MG?.;=]\
M8'&#@C^1JB-9,US:K$H$4]FUR"PY&,?XUA:=XXFE2RCO+6-+J2W$CQ(>I;&P
MJ3_"0>] &I>>#=,O;-+5O-2)8Q'M1NJC/'ZFMG3K"'3H## &"%R_S'/6L6+Q
M=:R7$<7D3*K$*TG96P3CWZ'I4)\42V]]=?:5#0_\N\42\R+G .?7GD'I0!UF
M:,URA\;VJ6GGS6TL62-JN1EQG!(^E6M"UJ?5+V='VF%5W)A<'':@#H:*** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ K+O]:LM-N8H;J3:TOW?_KUJ
M5G7NA:?J%U%<74 DECY4D]^WY4 9%UXRT]=+EN[822.L9D6,H02 N<GVP>M)
MJ?B:6QO5M8K+SC]F$Y()'7\.@QZUI7'AC2;F/9);?*5V':Q!*XP5^F .*NMI
MUJS2,T8)DB$+>Z>E &-%XLTY[.*>9S$79492N"I./TY%./B[259 TY4LY3#+
MR,'&<>F:MW/AK2;MD::U!V$$<D9P !G\A31X7T@3><+4>;OW;\G)YSCZ>U $
M=[KR6)O3+ [K:F,'9R6+]*C/BFP&^3YA$@.YB,$D,%( /7DUISZ59W N!)%G
M[0 )3G[V.E5I_#>E7-NL$MJ"B@@<G(R<GGZT +I.J)J@N'B ,:. C+_$"H(/
MMUK3 X%5[/3K73XO*M8A&G'RCV&*M4 )@4FP9SBG44 )M'I05!I:* $VB@ "
MEHH **** #K4,MK!/CS8E? (&X9X/!J8]*86P1DT 5SI=BSHYM8MR'*G;TIJ
M:/IT8<)9P@.<M\O7@C^1/YU:#9H+$8H J+HVFH05LH00,9V]O\FGSZ7974D<
MDUM&[Q_<8CD?_6]JL;\#D@#U-*&XZT 5DTRRCW;+:,;CN/R]32'2K L&-I%N
MW!LA<<^M6&E"@EB /<XIOFY?:",CJ,\T .2&.) L:A%'0+P!SFI*C\SD#(R1
MT/4^]*6P,YH ?13-YW8_.E)/M0 ZBF$GL:19-PR",=B.: )**C,F,\@#')]*
M4-D4 .*@TT@#UI]1L"2<'GU]* *WV"S"[/LT17(;:4&,KT/U%.MM-LK1F>WM
MHXV;[Q5>37&Z=J6N:?:10-:M++M+MOC.7)!);/;!P,5L7.I:Y!9V[Q6J32_9
M3-*H0C<^.$'I0!M'2[ R"0VD)=1M#;1P*DDLK:5=LD*,NPI@C/RGJ/IQ7)V_
MB+6Y44R6@0A2R?NB?./I_L__ %JE.OZS<F=[2SVQ1QR,IDC(+L ,#\R?KB@#
MHVTNQ9"C6L14@C&WMG/\ZB_L73?+2+[%#L1MRC;W_K7.G7?$/VBY@%B@:,*J
MLR'&2RC=QU&"3CVJQ;:MK2KJ$EU$,Q0!HHO*VY.<,V>_KB@#<?3+)[K[0;6,
MSD;2^WDC'3Z4Z&PM+:)(X;>-(U;>JJO /K]:Y"/6=5O9%N$B>;R&:,B-2BN>
M",^GI3+G6M:DN+28(8TBD?<PA;;RA^0COR ,^] '9-86DLYG>WB:4X!8KR<<
MTTZ/IS)L:SA*EM^"O&?6N277M:M+F-?L$A:XGW.KH2%4A1P?;)-.B\0:\R^<
M\1"&/&W[/P#O + ]P >E '7'3;-GC=K:,M&24.W[I/7%+;Z=9VDCR6]M'$[\
M,RC!-<O_ &SXDE"O%:QHF=N7B/S<$[O8<#\ZNZ1K>I7VMSVMQ9/%;I&"&9,8
M;/(S0!T@ %-?'>G FFR8/7TH IQZ;8QR/(EI$&<Y8[>O^?ZT)IMC'<"=;2%9
M5&%=5Y'T/TKF%N[FU-W<2+>SZO$\F+<9\ME_A]MNW!^N:33[K5[[6+.XGCE2
M)BN\*,*0/,Y([?PT =7_ &;9/(LK6L1=<E6V=,\FIQ;0@H1&H*#"8'W?I7*K
MK]Y8V<P,$\TR7<X96C)(3<VS'MC%))KNO11O-):(L3LRK^[.8@"/G/KGTH Z
M2?3K*9&62TB<-U!7K4?]DZ?(26LX22H7.WG Z#\*YUM5O-3T&SN9?-2W:X*W
M+VRD,4!P#CJ >]1R:[J%G-]ETJTN+BW6%BDERAR3C(YZX[4 =B+6!2I$2@JN
MQ2!T7T^E5Y=,L'0*]I 0$$8R@X7T^E<_)K>N0221/:AWA5MH6,_Z0W8#^[4N
MC:OK.H30"YMTBAVLSN5Y;&,#';G/Y4 ;D-E:KL"6T:A,%<*!M(Z8I?[,L?/D
MG^RQ^;)R[;>37'6FI:YIL1C-N9YF+R8:-LRDD]\_+CCBNOTR2ZDL87O-OGLH
M9PHP ?2@!9=*L)U"RVD3@=,KTJ:*U@@),42(2,?*,<5-10 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%(: %II8@FJ-E+J+7%X+R.%81+_HQC.2R8
M_B]^M8^N27$>N:>\/FR)D*8$#!3DC+$CT% '4#I17):CXDU:VNI;:#3@TBQ"
M?;G<40\$''?//TJLWB?75%NJZ:7=X6+9C(4G!(.?P''O0!V98]J7-<MJ4NOX
M0VH1W-@YD)!4>9CC;C//M59=;UY%-O%9[I @0;XS\F /G8]\\T =EDTN>*XM
MM<UBWNIX(X"XBC9B'B/)[$$=?7%3P:WKDDT9-JK6XE1"_EE3*&8 L!VP#F@#
MJR^&Q2[N*XNXO=6TW4]1E6)I5EE)C8QD[@H&(QS@9)/S>U3:G=:O+X9EF>-H
MYS<@!(E88C![GK^- '6[SG']*-_>N GN-;@^U36[74EI*8841 28B<9=21G'
M4&K+?VW<V.H"2:[AEM L",@ \]MX8N..F.* .VW'&<\4X$UP=])J3ZC>HL]Y
M$Q+J[;242+"["!]<_K74Z!++-HUN\T;1.005<DG@XSSZ]: -2BBB@ HHHH 0
M]*Y;Q8&^V:6ZWWV5H9'D#%]H+!> P[@]/QKJ3TJE?WMG8VC7-Y(B0K@%F&>I
MP* .!L-?U.*W@A:[CADQDAG5E&2Q;<>N1P!]:F/BC5GN+=S=6L:2 EDW@A/8
M^O'(KM;R]L]/M/M-QCR5&2RIO.#T/':GVT]M=VZ3P@;'&X;DVDCZ'F@#@KC5
MM0DL95FU:.8M@! 5!& #D'USFG_\)-JBM;"*]A,)).^0KO/(X<#MCTKMC?V*
M7ZV9*^<<87;Z@XY_ U!;:UI=W</;V\@:2-MI4QD<\C(XY'!YH Y?4]8@E\/6
ML-Q<K=WCN?,D60#R<Y^; (SCM5."6V-S=Q27C+NAD5IVN,&5<#RP.>""":]%
M'E$YV)QQG XJ&&ZM;KSO*VD0R&-SC&&'4?K0!QMDL<OB+3)$U-"OV=/-4R$L
M'5<!5Y[Y)/TK<\06FIZEHTULF(I#.A1H)"&V Y)]JW<Q*?NJ.^<"@.A.01[<
M]Z .$%OXK@N[B^C1A/=",2H'W+$%W#Y0>.<*3]:GU;4M=TRW\VXNBC2M)L1
MF>,;  >H/YUW.P>_-(T:-C<H..F1F@#BUNO%;3S;XR(2RG$:KG9ZIGOZYS3X
MD\16?AC3HK*/=>9<3B7!89)()]_;WKLM@SFC8,YH X*]M?$U[;[IA)&\T?SQ
MQ8QDJ< _0XKJ](2^CBEAOG,ACDVQR'JZ8!S6EM%)LQTH >.E-*@G-.HH ;L'
MO1M&.].HH 9Y:G'M2[%X]J=10 S8/>FR01RQM'(@=",%6&01[U+10!7MK*VL
MX?)MH4ACSG;&H49_"I=B^]/HH 9L4TNP$YQS3J* &[!G.* H'2G44 (!2-]
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MS?H\!92%W<@AQ_-03]:=I?A[5+&^M;DSN/+VQR@S%@Z#=G]2M '7,RH-S':
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M1[9)%RJR+SG.![<]!6D/#NFA=JVX7Y_,!4D$'V]![4_^P=-";/LD>S?OVD9
M8'(/X&@"II_BG3=3^T>0T@$"-)(70J-HX//UJAIOC6WN[8M)"S3F4HD5N"YV
M[2P8^GR@UN)HMC&+A5@4)<?ZU>S?AVJO>^&M.OKF":6(!HCGY/EW<$ ''UH
MH3^,;0V[O:QRDYVQR21D(S8SMSZXJ>#Q3:-$[,DK"(9ED1#L0]@3ZFIH/"^F
M0W,\_D!FE;.#T7C' [<5+)X=TV4G?;*<KM('&1UYQUH S(_&=G< R)%,MN&0
M>:Z$!L@G ]^*F/C&P0A6ANE8#+@PGY%.,,?0'(J['X=TR,*JVJ8"[<?U/OR:
M=%H&G0(R1VR@,,'/)(SGK^% #M-UBVU2.5[?>!&YC8.I4Y'M6@#D54L],M;
M2"VC">8VYSG))_&K8&!0 M%%% !1110 AZ&L/Q$EU]FMFM+JX@/VA$?R0#E2
M>:W:84R1Z4 <2OB'5M+M)1-9M=$,3'*6Y"[POS>G7-377B[4+:T^TOIG!D")
M&IR6.W<3G&![=S78&)6&" 1Z$4TPH<$@9'3B@#CCXTN]D[QZ>)MFX;8F),>'
M5?FXXSG/X&GR>+KQK A;(1WKG]VARRE=I._@=.,5U<-G!;H4BC558EB .I/6
MI/(3CY5X&!QVH Y&#Q+?$JK0+RK2;Y&(5R.-J\=>_/:MS0]4DU338[F2+RV)
M*LO7!^O?\*T?(3CY5XZ<=*<L:J,#@4 /HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *#Q12'I0 @?UXI#
M(1T4FJ-D-2^T79OC;F$R?Z,(@=P3_:SWS6/KFFW^H:Y ;>YD@MX[<LS*3RV>
M@P<?G0!TP?(!X_"E+XKA1J/B73-(M8!:-<3"*,[MIXXY0^X]:?+K?B8/MBL4
M(\]AYC*0,<84#WYSVXH [??SVI/,_#ZUSEZ-46+6)+<R)*%C:%L9 X&[:._>
MJ$NHZ]%:M<FW,CD,(]JE=HXP2.: .SW_ $I!(#CU[CTKB[&^UY+ZUDEM&5;J
M91,A4G:.A([ 4LLNMZ;J%ZT49=9KAFB8H3O/ 5.O (SS[4 =GOYQCFCS#Z<5
MR>H_\)#<Z(ODL(KUKL[0!M"QC/7GN._J:R)+36WOEN+47D4(!1%=LR!_+/!Y
MQMSW]<8H ]#WGTHW^U<!<P3R1@VAU&&$1 W1E5B&D'0 =?J1QTK<DAO+C3-&
ME"7$$D5S&TL0?)V\YW>HZ&@#HP^>G6G Y%<#'::I/;ZBBF]241DN2_)E$F5V
M^VW.:[R(?NUSUP,T /HHHH **** "H)+J&*2..25$>4[4#, 6.,X%3U@Z[HG
M]KS63%P@MB[JW.Y6*X5A[@T ;$4\<Z!HV#*>ZFI V3QS7#6GAOQ!!#!";]%=
M5YEC8J%Y;<-O^UD'/;%::Z+JL&G3V\6H-RV55N21QD;NH[_G0!N_VA;%P@G0
ML6V8SSNZX_2IFF5/OL%^IQ7&VOAC5%B_UR1'S#(B[RVPX8=?Q'Y4]M UF[O%
MNKB9%?E %D)"+\G;U.UOIF@#L-^#TXI=XSC^O6N-F\/Z\SPG^UF;;,<A3SL&
M-I^N <_6DU>VU67Q&L=NTY60H1(,JL:A2&'H<G!H [/?@9I/-&2,C([9KC7\
M.ZY]I14U$);B 1L0Y+,<<\^N<G--N/#.JJ96@N=TCHJ(YE/R@.QP0>HP1^5
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 (.M+110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
6444 %%%% !1110 4444 %%%% '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>ex10-69_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex10-69_001.jpg
M_]C_X  02D9)1@ ! 0$ 9 !D  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" 2/ X0# 2(  A$! Q$!_\0
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MR1CYN,#(&2>C7G5&*E22,<Y4=0#W(/>@">BFHV]0P! .>#[$CM]*=0 4444
M%%%% !1D#J<45'+T&>F[G\FZT 29'J.>GO16=%/&;UH>0R1\9QM.>3MP3C[P
M!R%.0<YR*T:/\K@%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MJ-GYQG\0'1KC2HP#^I4W<8R-KD\X7"J3A=V!N90"1SABI"YD.(_G*BZC) /
M.<,2"A'0'<N0 3D'=@C:21@@G^=7X>Z9^T[XP\6_#[QKJ?[5?[55O>?'[_@I
MI_P4\_8^\5^&D\016W@3X>_LZZ/X9_X* 0_!.\\ ^%3X5LX_#.M_"KQ7\&/A
M)XT\ ?%J2Z_X2B\83>$Y/$FH^#=:T#1M,\1UG]HK_@H#XO\ V=/&WQ=U_7/B
M1\.K3X+^+/V*OV#?VB&U+5?''PHTVR\7_#'QS<S_ /!17]J?P_XK\,?#/QWX
MO\.^ /'6N>)? /PST/\ :"\*^$-:'@GX5Z+\0_B+H$WA5K1_&^@ ']-ZZYHT
M'BQ-$EU328M;U#2[_5[#16U&Q36K[2=)N]-T_5M4L]+,XO[G3=,O]7TJSU'4
M(K=K*RNM3TZVNKB*>\MXWZE;J-FV@.#R<,C(0 0I)5@#C<RJ#CYB?ER!FOY!
MU^(_[5S:;<_&#X:?$3Q+\7=>\,?LS_\ !2+0O@3\9/A1)\8_VCO$O@/X&W_[
M3'_!,4>,;?P)\5_C#\"/AOK/[3OC#X8^&Y_CGXD^$/C)OA[XO/C>+PAH?AS0
M]5^*=UX8U*;5?2/B'\>8],\>^"_#G@']M+]K/5O^">VK_MO?LI>$)?VAX/B1
M\3?$7B?4=0\2?LM?MJ^(OVD/A)H?Q_N-,E^(.N?!72]2\"_L[>*/B1XET[7;
MVP^"?B'7O'3Z7XO\$S^%M5A\" ']6)N5QD(S=!E=I4Y4,"#N 8%2OS)N ) )
M&16+KGBWPWX9M[&[\1Z[H_A^SU+6-$\/:==ZWJNG:1:W_B#Q+J5OHWAS0;*X
MU&ZMH;O6]>UB\M-*T;2[=Y+W5=2NH+&PAN+F5(F_DR^)7QP_:=M_!OPE?Q=\
M>?C'X,_9/NM._;[B^ WQV\=?%G]J7X2>,OB.GAG]I#2M)_99\3>,O'WP&^$G
MQ%^+7Q/\<V'[/@\0:A^S_P"!?BIIIT_]HS3;2T\6^(?"_P 7?$TENE?J[^US
M8_%7QA^PC^P\_P 13J?CKXP+^U?_ ,$@?%'Q6U/0/A_X@\)S:EXITG]K3]FK
MQ'\3_%TGPZU/14\0_#W2H;VU\2>)M9T+Q!IFFWG@C2XKVQUTV+:5=QH ?H^G
M[3G[.4OBFW\#1?'KX+2^-KSQ//X)M/!L7Q7^'\GBNZ\96U_=Z5<^$K;PZGB)
MM7N/$]MJMA>Z7/X?AM)-6CU*TNK)[,3V\R)[2+I#C"R-EBB@1N"Q7.XJ&5<J
MNUOF'RMM^4L&4G^63QUXT\#?$K]@?]K_ /X)[>%O!WQ(\2_MM?$K]LG_ (*.
M67P5\$6GP'^,-JW@WXB>/?\ @I5\??B7\$/CVWQ4N?A]8_#;PGX7^&.C>(O!
M/QY7XFR^.K.QTC0-+M!HNI77B"XTG0[S]^O"-OX=US2/VK=(^$_C+XF>(/&%
M[\2?'.E^(Q\0]0^(AT_P1\5;SX3>!;>S\._#";QY8Z?I^F_#.TTJ3PEKVFQ_
M#:74?A]:>*-:\4W-EJ7_  D$_B2VM0#JD_:O_9CEM/%E]#^T)\$I[/P'X:U'
MQGXUNHOBKX$>V\)^$=)UR^\,:IXI\0W(U_[/I'AS3O$VFZAX<O\ 7+Z6#2[+
M7K*YT>YNXM1ADME(?VL/V8)]$\<>)8OVB/@BWAWX9:=INK_$?76^*7@F/2?
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M&?MC?M8>,Y/#'P;\8^&_#WC+_@G9X]^#=[X)TWPG^T7\-M0UC7_AQ;I^RO\
M"V#XM>*M/M9;?6D\)?:?&=Y/9>%X]0M?#K:<FOW,_LGC_P :^$OC_P# ']H?
MX=>+_P!H;_@I[^TOX0EUGX ^-=8TS2_V$XOV?OB=\,O!W@G]HKP)XJU7Q9\+
MK[Q!^QI\&;#XJV6FPVFD:M\0_!^DZ?\ $KXG7GPR\->([OX;^#K[Q/>V\=P
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M+^'</@0Z(/&5UXEO_AG>P?$"VL[70IT?P;YOB/S1I-O/=1^H?#/XM_#GXS>
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M#X;\.:=JFMW^I7@CN]1O62Q%EH>A:;J_B+7KK3="TC4]0M/S]L?@!^T1X_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MP&M7N3UAC Z]2R8_D:W*PK<C^VKP#9\T2$_,&8E<#[O50/8]1G'KNT %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 445#+(R;=H
M!R&/.>VWICZT 344 @@$=",CZ&B@ J$0J)?-!.2<D>ORE1], GI^-344 %)N
M7.W(W>F1G\OPI:C\H>;YN3G;MQQCZ^N>V?3B@"2BBB@ HHHH **** "BBB@
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M:P2PP2NGXC_M4?\ !<RY_9U^)_[7=GX=_8O^(_Q6_9S_ & ?&GP6\#?M??M
M6WQ;\ ^ M7\&:[\;X_#TF@+\+O@IXEL)_%/Q<L=+;Q5H5I?W46L^$Y-2OKMI
M/#]OJNE&WU:X /Z!:*_$7]H'_@K/\5O!'Q^^-?PC_9;_ ."?7QS_ &U_"'[)
M^K_"3P_^U5\0/A?XZ\)^&?$'A'Q3\7M'T[Q9IG@CX)_"35]*U3Q/^T-XT\+>
M ]9L?%WCG1O#]]X<@\(VY^R:YJ=@BS7R?M7I=VE_IUE?1I=1QWEM#=QQ7UK/
M8WL,=Q&LR0WME=)'=6=Y"KB*ZM+F..XMKA)()D62-@ "_1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !13'<1KN/3('YTX$$ CH: %INU<@[1D9(..03U/XTZB@ HHI&.U68]%!
M/Y#- "T4U'5QE3G!P?K3J (8XV4MN<MD8'YGGZXQTZ<T1HZLQ9@0<X^8DC+$
MGJ!_^OZU-10 4444 %%%% !1110 4444 %%%% !1110!&)$+E,_,"!C!R<C.
M<8Z>_3WJ2JP5A<LVTE6 &[' PI[^YP,59H .M0F&( D(,@9')ZCIWY_'KWJ4
MD@$@$^PZU38W&YOO;,GHO./KP/;D$\=1Q@ ='/MR9&)R%(X[\[L8 ]1Q5NJ$
M8C)/F$ ;1MR<=SG'X8S5^@"-)4=BJDY )(((Z$ ]?<TYG" $YY.. 3R>F<=/
MQI%C16+*,$C!_$@_S%*^W WXQD8S_>[8]_2@#E[/;_PDM\5_BMT/4\[4C!]N
M.![]LUU5<K8A3XCO\')6W0XZD*PC'/MD#DCK@5U5 !1110 4444 %%%% #7=
M4&YLXSC@$_RH5@ZAEY!SCMT)'\Q0RJXPPR/ZTJJ% 5> ,X_$Y_K0 M%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?S4
M_P#!<:']F2S^//[&_B#]J;1OVR_V;?#V@:3\55^&_P#P5/\ V-_%'B[1]=_9
ME\=:TVCQW/PB^(VE_#[P%X[UIO"/Q/T[3[:Z@UGQ!I<^FPO#J%I8HFCW'C_4
M;#\6OVIK3X]?M8_\$9?^"B/B'XKK\3?VR_@[^SC^UQ^S_P"(?V#?VNOBO^SU
MK'P\^/'Q:^%R^,O 7AKXV_$_5?!=EX=\,:UXWT'P=X%\0>(_ ^G_ !1UGPS]
MJ\0>%)_$Z71TT:,VG^'_ ._7R0&9U+ MG<-[;3DDYQZY)^F2.@&(FLXF?S27
M$N"-ZRR*3G;U*,A&0N"5VG:=HP@"@ _SV_\ @JQJW[,/QOU_XP?#']EW]CCP
M#!X'M?\ @G/\,;7]A?XF^+OV=OVV/CC\0/C%X,M[/4_$6CZ#_P $_P#X3^%=
M-\,?#G]E5?AAXB34;3XM_%'QI9)KRZA::EK&O^'?$>AW'B"VM_K6U^'W@JP_
MX*6_LE_&_4/A=<0_'/\ :L_X()_"VQ_9K^/_ (D^#WCWQ1J&K_\ !4";3(?!
MW@GQGXP\8)X:UJP\$?%_0_AGI5CH^N>+_B)>^&O^$;T6PL(?$NM6%W-I<DO]
MN0@ !P\F2 "?.ER2%5<D[L%BJKD[02<^K9@> B0A/,"2DM)LDD52TC,)"2#Q
ME2,$89,+M(QR ?Y]G_!.KX"RM+\/['PYI7BWX=?M'_!O]@G]OKP[^V_X+\&?
M\$[/V@_A;XX\;:[X[^$.LZ'?^!?VV_VI?BO\?;W0?CI\1M4^-EQH?Q0^#UU\
M./ASXMEU>YTBZTJWTOP#H$6GVVF^H_LN?\$T/@?<:A_P;(_\)#^QA:7-G\5O
MAG^UK)^W'-KGPC\1WUGX[N/#_P (M%\9?#KP_P#M12ZKHUU8ZMH-M\2HH9/"
M?A+XI++H4D5C%X9T2PC\.6*:;'_>2]NK[=Q8[3D9DDX(Z. & #CG####^$C)
MRJVZ+N(+[F4*Q+O\VU=H+$DECCC<Y9L<9X% '^?WK7[*?QZ\/_LG? _3[7X&
M_$'3?V0OV;?^"V'[>VN?$KX.:I^R5XY_:0\+^$?A1K][)8_LU_%)?V/TU/P/
MKWQD_9]\ :MJ>M3W.D^&;Z71(7\2OK8L->:UO=*NO4Q^PWK/C;]DG]B_PWI/
MP'_:3^(GP"^+_P#P<,_ +XW>(/@W\1/V(8/V>O!W@;X%7WASQ?X:^+_CKP9^
MSKX-\>?&_5O@G^R!XQO9?M5M9_%!_A['IMC>W]Q?>%])T?Q'!?ZO_=3-;$M&
MX\\LIX,<\BD8W$!@7 =?G8!3E0#RO"@$=H?,\R5I&)CVDM(P;D@X.PCH1N7D
M^6W,>T\@ _BI_:._X)X>/-6^!W_!R[\&/@U^Q?K5CX<\7?%/]ECXG_L9> -!
M^ TVC^$?%7B'P_\ #;19/B'XN_9?T:;PS::'K/B:V">,M,OM3^%,=QJ4>H:G
M>:'8NEYJ:6$_[>>/_ACXM_:Q_P""*7Q1^#7[(_PE\>_LJ>//BO\ LG?$/X:_
M#+X0?$GX7M^S)XPT#Q6EIJF@:UX4UGX?:K:Z(OP[LOBEJMGKEG!K-[;:=8W>
MD^-HO&,EQ!:ZG/>G]F_[/M_1_J)9EP3OY39(OEXWL5\O;MR<=:F6UB4CY20I
MW ,S$;N>2"<,3DDELDMSQ0!_(I^S/^SMKGQP_:^_X)0W?P5_X)G_ !?_ &#?
M!W[$'P/^+OP^_;F\<?&'X(^'O@OX7^)V@>*_@[IWP^LOV=?#=Y#=78_:N\*^
M(?B2OB3Q?J/BF\M]9\/PV-_/XW:^3Q#K^IH/T9_X(!?LU^*?V;/V'O$^A?$G
MX"WGP*^)NL_M-?M,ZIK.FZS\-=/^'/B[7/!3_&/Q9J/PXOKJSMK"PO+WPW#X
M9U%$\$+,\VFV&C2QVOAXII/V7S/W,-G$JMMCR<EP,LV6.T]&=01E%(4L ",C
M!ID=LXVD!U4$?)O9>0>6"Y8#.2>O))/4T ?R ^$?^"=G[1.H?\%^/B-X.\4?
M!_QA)_P39L_BW^T;_P % M,\<7_@F]A^%WB?X\?M0_LG?#_X%^-O#4/C)HY-
M'N_$5GXOU'Q-JY\/)-%/_P 26;4I(W3SXA\G_L"_\$UO^"DWCC]E[_@JCX ^
M)/@KX@_"7X^?#_\ 86\(?\$P_P!AWQ?XXT*^^&?_  M#X.^ /'OQH\>:_IOA
MGQ#K;PVTWAOXBP3^#O!UGXMM)]/T"*PUN&\N[B&.WFO8/[LQ8P?+\I.S&S+R
M'9\I0A 7PBLC,C*H"L&.\,>:D^SQKG8H7(((&0""SL>!QDM)(Q.,DL3G)- [
MZ6/Y,?V3/@7XO^)O[=7[!WQ6^ __  3T^-W[!/PX_8Y_82^-_P $OVOM1^)G
MP6TWX$V'QO\ $WC;X?>&_"WPW^!'@R/3[R2_^/VF>!?B%H6O?$>'QU;VFJ>&
M9&-IJXUYM9U'3;6[^//"'_!,#XK^"/\ @W=_9D^&_P +_P!C[QM\)?VZ?'W[
M1/P&U/\ :%O?"'P=M[+]I*/2? O[7_BSQ+I'C7X@2W.GVOBO4=)^'?A4:!XK
MT*/5'OM-\/Z<-+86UIIANKJW_N.^Q0<?*<JJ*#O<_*A!48)QD%0P..&RPP2:
M?]EAPJ^6NT'/OG).1CH=Q+$C'S'(P<4"/Q*_X(Z?!KXQ_L>6_P"U?^Q+\6?A
M7XBNI?A9\>?$_P 5OA_^VC/X6BL]-_;?\$_'K4KKQJGQ#^(GC6V>Y/B?]I/P
M)J+W?@?XOMK#1W<EK9>%Y='>[TZ&>5/Q%_X*1?L2_M?_ !,_;&_;G\5-^QS^
MT5\9?VN?B=\5OV3]9_X)6_M>_!^]T'2OV9/@/X#^#^MZ7KL:_M Q_P#"9:5X
M-TS7/AWJ\_BQ]4O_ (V?#OXC:OXG?49(O"0T?07LII_[;3 8P?)^4LS8.2P4
MMN<L0QQRP'.>">.3R);JP#,I4L0[KN8Y?##!4Y4 ;B1@9R!R<4 ?P^_M]_\
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M>&?^"5?Q%^#7AKX3Z7^RK^V]X[_9]\4^&OV./V?_ -BOXR>*5^"?PV^(UO\
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M'+]O[]MS]C#P_P#&+2_VK/A;^RQXD\>I^PQ^UO\ M@? #6_@'XG^+,7@6_\
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MCMK7@/2?AA\0?'_[./B+X?6$7Q9\!>&-0UF_\':1\3?!/Q8^&_Q6^'_B;6/
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MA]_P3U_;[^#MU^RUH?Q ^&FM>.OAQXLU']L'XQZ&_P $OCIX*TS5['PS\/\
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M'/@^_E_:/^-]E^S99>'/A[I&GZ)XX\2W8T)+GX?ZJ=$^)UQ+8^$_%0LM2O=
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MX#ZEX6\'_!S0/#_PWUB]\=>'/!LVCZ=K&K:=I>N:L+C3_$5YI^A( ?T*Z?\
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MX*\9^')X[35O"][&]AK46K:. >QWW_!77X21>'OABFC?L\_M6>)?C/\ $O\
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M'_$G]HSPO8^(?&WP+^-,WQ%^&?PFO/">E^.='T>7]G_XD>/[?0?C#H6K>/?
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M/QK\2/@%XXB\8VFJ2W3VL&B6-M\'-2T\Z3<6TE^]QK]O<I>*MO.C@'Q7J?\
MP6&\(^)/ O[/FK?L_P#P-U7XF^/OC?\  ;PU^T=J_P //BG\;?@S^S-8_"'X
M=^)M>\3>#=(TWQGX\^*FO'2-;^(.K_$+P7XZ\&>&_"O@&R\20WMYX)\0:SK^
MN>&O# T?5=4T=&_X*QZK\8;OX$>'?V3_ -DCXB_'SX@_'/X,_''XM+X7UCXJ
M_"SX5:)\+KO]G/XW>'_V?OC%X$^)OC6_U#Q7H$>K^'?B;K5UX;TC5_  \;Z;
MXIU"RM[K1'F\*WW_  D]GX#9?\$6?&W@'PM^SGJW@;6OV+_C#\4/A+^SW?\
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MCX[?&GPOHZ>.OCIX*^'N@7L-IX<T>^M_")UB[T/P_JGC^?QKJ&F)<SNS2O\
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M/IV_SZ5+%+YF?EQC!_ ]/Y&I H7. !DY..Y/?ZU##&R;MV.0H&#G[N[/8>M
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MB2 18HH KI%N&902V>[$C /'!) (P#G&<\YR339H=VU%4%#G<#TX_O9SG()
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M21CGC.0  ^B@"HD3I,IVC8"^W'\*L.!]<@YSG&1CCI;HHH *:45CDJ":=10
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M47_@G(Q!A_;:_9JE=E*JD?Q:\*2,[85F$:)?EY&Z-A$)*G=C'-3-_P %0O\
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M"50D@2(2);?\$V[F(--'^]Q'-*D?*,Y;%??E% 'P5_PLK_@ID3S^QQ^Q8%R
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MA2,JN25W_+39?'O_  4O:0"W_95_8@BB.,R7'[>GQUF=!C+9CA_X)T)O*_=
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M!C# DXX(QC/H* (YW))BP-IP2<G.,%CQW'RX)S@9'>JQR,90&/:YY/&4R N
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M[(O@+Q8K:AJ.NP66FV_A_P 9_#KX@Z7+#XKNM,EO?[)O;C3OMMC>V5U<U_\
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M110 4444 %? _P 1TW?\%+?V17VG>/V+_P!OE1UQ\_QB_P""?!P<C!.<@<\
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MBOA8?$G_ (*(D+C]D3]D[)!!3_AN[XF;UQD8X_83*L<@#.[JZYQM8AC?$/\
MX*/>;LB_9+_8Z'S$AI/V\OB]@+@9)5/V 6<%68!E$94 J0Q)  !]V45\-?\
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M.)/X@M/L%Q)'J >RNHS<-;FRG62UNIE7]K(5"Q@ Y'(Z@CC@X(ZC(SU/7L,
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M)HWP"^%'C^#P)\&M;^$_QJ\6?&_P=XVO)OB'X_O-?^(ECK/BW7+34/%VEO\
M\(A<_8[:/PWILLD=A%KMVVFMU8#[<_::_P""AOPN_93\>_$SP)\0?!?Q$URZ
M^&_[-/A7]HB"\\#V6DZS=^.+OQ_\=$_9Z^'WP>\(:%=:G97MW\1_&_Q+U'PW
MHV@R:E+8^'5N/$-B+_7]-MXKNX3XI_:Q_P""C?[;OP]_9S^*.I:;^P7\7_@!
M\=_!OQ+_ &-[70/^$D^('P*^('PX\9?#'X^?M)^$/AAXBL/"WQ>T[6M2^%\'
MQ2MU.J?#7Q-X!UJ:/6O VH>.O"GQ(TFZ\1^"[=_$,>GX\_X)K?M9?M.^+_C!
M\3?VI_VE_@AX;\?_ !!_9K^%?P?^&</[-WP8\9Z9X<^#OQ,^ W[4-A^U)\*?
MBR9?B=\3?$>I?$JU'Q!\/^%M3\6>#=1E\)0W%AITWABPU&.*>X\27O7_ !6_
M8I_X*$_M+_"'XZ:)^T)^U9\ 8OB'XFTWX"_\*%^'WPA^#GQ T;]F?P;XT_9]
M^//A3]H2U^(_Q2TOQC\2_$_Q2\7>)/BCXD\&Z%X&UVU\.^+_  UH_@?X=VKV
M>C6OB;Q#<OKC(#Z@_;N_:H^(?[+'["?Q-_:5T#P!IT/QCTKPK\/M&\&_#CQ;
MK$6JZ#H/QH^,WCCP/\*/!6B^--7\*7$L&L>&O"/Q$\?:0WBN^T&_6VU'0M)O
MO[)OX!J$=Q#Y#H?[%G[:WPM\7?"?XG>"/^"CWQT^-7Q$M_'/@U_VC? 7[2EA
M\+!^SA\6?AE=3V]M\5;'X8_#KX4_"'P_K7P&\9Z5:22:W\&]1\+^);RQLK^Q
MM] ^)A\;66HWFM0_6_QL_9\M/VK/V5/&O[.?[14ML\OQB^%)\$_$W5?A7<:E
MH5IHGBS4M-LY;_Q5\+[GQ!->:KIC^%O&<$'B3P/<:Y]MO;2;3-);4TO'BN(I
MOC;3_P!DG_@HU\3M4^%7@;]JK]M'X,Z_\!/A)\0?AS\2=:O?V;_@3X^^"?[0
M7[26K_"?6M.\4^"] ^+OC'6?C?X[\(^ O"&I>*]%T'7_ (F:1\*_#5I=^/;;
M3;KPO::GX4\-:SJEA. <_K7_  58U?2E\7_&FV_9'^)FK?L$?#KXU:W\#/&?
M[8L?Q'^&EG>6M]X5^+,OP-\9_%GP[\ O.E\;^)O@#X ^*]KJ7AWQ/X_BUJQ\
M2C1-'USQQHWP\UOPKIC:@G@O[;__  4;_:&O?@]\6M7_ &?/@+\3_"OP/\%_
MM<?"7]EN+]L_0/B?\--/UJ/XB^$/VU/A9\$?C$MC\&M7MKW6O^%+7'B.'QW\
M#=4^)1U>\\27&NG4)[7X?P>$9(_&]IZMXB_X)D_M):IX-\>_LA:;^TC\)K#_
M ()W?$GXY>)_B_KW@*Y^!WBF_P#VG]&\%_$'XXS_ +0?Q$_9T\+_ !8D^,5O
M\,HOAYXB\=:CK^AZ;XOU3X47_BWPU\-_$5WX8M+:]U32M(\1P4OBM_P3%_:A
M\8:!\3?V>O '[6GPQ\#_ +'OQ&_:KM/VPT\':U^SSJWBCX[>&?&.H_M2^'?V
MM/'OP@TOXE6/QB\->!)?A)XA^+=CXC\2Z/J%U\-%\=:/%XA3PI=:MJ^@V,KW
M@!3^,?\ P6[^&?PI\??&"=/AYX*U;]GK]GKXH^)?A-\8OB?J?[5/P1\'?&FU
MU[P!XGN/!GQ:\2_#;]E+7;]?'_Q!\ ?"?Q):ZQ:>(;Z_\1>"?&/B>'PWKFI?
M"WP1X]TR/0KSQ!^XUG(LRPR))YL4D0EAD#;T>-U#12*_)821E7#,06R"P5OE
M'XC^(/\ @E'\5--^*/Q9G^#WQ6_91\+_  8^-?QO\6?'K5M5^*'["OP_^,W[
M5WPD\0?%'QLWQ"^,OA;X0_&3Q)XRM?AU?Z%XS\5ZEXMU/PEJ7Q8^#OQ!U'X9
M1^+)M+LH?$^D:#X?LK+]PK>&.*-!'&(PJ!%13\J(GRHB]MJ* JG )4#(!R*
M)#&C'<5&>I.!S^G\J3RD_NK_ -\H?YJ3^=244 0M&>B 8.=PPHYSG(^7J3G/
MK0D2\LRKN/&1W4+M /;H2#P*FHH C$,0X"+Z=*>0",8X'0=/Y4M% $9BC(P5
M7 Y' .".XR#_ (5\'_%-,?\ !1_]BS@[1^RI^W^,"*,KE_B)^P4RYDV;XB55
ML*CHDGS;PQ5"OWI7P3\5B#_P4C_8I7<0?^&6?V_6"81D95\=_L&JS;B"Z2(T
MBJH0J&1Y=ZM\I !]!?'GX ^#_P!HCPE9>!?'6N?%70?#UEXETSQ0ES\'OC;\
M7/@)XJDOM,M+^R@M)_&WP6\8>!O&,^B2KJ=Q/?Z ^O+H^HW,%E/>V<\UG;20
M_P W?P\^&%QX2_X)*?\ !2G]K'2_C3^US>?'SX:^$_\ @L-\*_!?C'Q7^VE^
MU)X[A\->&O@S\9OCYX!^&-QHGAWQG\6-:\(6?C#P7X6^'7A*R\/^/[;0;?QA
M9ZCI\^M0ZN-7U"YNV_JUDW;?E!)#*0 0,X8$@D\#(SUX]??\X;'_ ()W^'X/
MV%/VI?V'IOB?XAET3]J&Y_;4N]:^(3^']+&M>$V_;0\?_%#X@^(4TO0TOY-/
MU(>"KSXH7UAI!N[ZW.K1:7!<7BVC7+QQ 'XR>"]0T>__ &BOV+OAS^Q#H?\
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M\*?AQHLZ33:-X-\):;9W%[>W;7>H7?::3^R]X TWXQ?M)_&6\?6_$6H?M3>
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MU>ZCM?L]_P#!,SP3\"/'GPB\6:O^T'^T_P#'K0?V:?#WB#PO^RE\,_CGXQ\
M:SX%_9TTG7_#5QX#>?PL/!?PZ\%^*_'GBC1_AM=WWPR\,^-_C+XH^(WBO0/
M6JZQI=EJAO\ 7M?U34@#],H?]4G).!C+'<QP2.6P-QXY; SUP,XJ6F(I50IQ
MD9'&<8SQU]NO3GL*?0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M 'P#_P % C&/"O[,DF7!C_;Y_8L#8&<M/\;O#UF@'(^4F?YSV4$C)XK[[C38
M@7ODD\YY)Y/X]?J37P#_ ,%!$>3P?^S7L'3]OK]B%^P.V+]H'PJTAY_V58X!
MR5Z<G%??L;%E.1M(9E SGA3@<B@"2BBB@ HHHH **** "BBB@ HHHH ****
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M=7P"C?=MR70([/(#\NU23@#-?><DD:^8SQ$*F3DJ5+'<5X&-S$Y[9!XP,XR
M"HI<!?F2-05"(?E?  (+<?=8\ '&:9R7")D?O5\U7QO;#<OU( R!D*>_ QP)
M(G*X9!G<H)!#<@@88CJ. .O')Y[EPBC4K<;0'DP68GO][/H,L 0,D=L>COK?
MY@<EI21_\)!J08<+$Y;DC&9/K[_F<>E=BT$<D3;06W*0 S$@@\'@Y_SC'-<U
MIT:#6]0+ +YL(7<3C+2N' !)P6)4D 9)VG V@XZU%"*%!Z>O4Y).3]2?\*&^
M9W IP6D2IM,94!L@;F(RN0" 2<'U(QN[],"T(HQGY1R<G]?\:DR,XR,^G?\
MSR**0$8BC&<(!DEC]6.2?_K=!VQ4E%% !3!&JL7&=S9SR<<D$\=.PI]% !11
M10 4444 %%%% !1110 5\"?%=2/^"D7[$\H!V+^RY_P4 B8=<R2>.OV$I0,G
MH2+>0A1CC)P0#C[[KX0^*MG=2?\ !1+]BZ[CMYGM+;]F[]N\74Z0N\%O+<>+
M?V*8[4S3*I2*6989T@5V!E42A0Q0[0#[OHHHH **** "BBB@ HHHH **;O0[
M<,IW,57YA\S*&+*O/+ *Q('("MGH<#.B??=5_P!Y@O\ ,B@!U%59;ZQA0237
MEK%&3@/+<0QH3Z!G<*3[ YJH^O:''GS-9TF/ W'?J-FF%_O'=,./?I0!JT5S
M<OC'PA#CSO%7AN+< 1YNN:9'D'H1NNAD'(P15,_$+P K,C>./!X=>60^)M%#
M*,D993>Y'*L.0.01V- '845PK_%#X9Q*SR?$3P+&BY+,_B[0$50.I9FU  8[
MY(Q6-+\<_@G!GS_C%\+(<$@^;\0?"4>",D@[]77! !)'L: /4Z*\7F_:0_9X
MMPQG^/7P7@",%<S?%'P/&$8G 5B^NJ%8G@ X.>U5&_:@_9I4$M^T/\#% ZEO
MBUX! 'U)\04 >YT5X!)^UA^RS$6$O[2OP C*_>$GQD^'2%?]X-XC!'XU2G_;
M"_9*MBXG_:C_ &=(3&-T@F^-WPSB*+D+N?S/$R[1N95R<#<P'4B@#Z,HKYAF
M_;:_8TM\BX_:V_9B@(QD3?'SX51<GD#Y_%8P2.1GK6=<_MX_L.V>/M?[9?[*
M-KG(_P!)_:)^$,&"" 1^]\8+G!.#CH>* /J^BOB^Y_X*0?\ !/"S++>_MZ?L
M7VC(<.MS^U)\#X2O^\)?'*%3[$"L";_@J7_P3)MY#%/_ ,%%OV$XI "?+;]K
MCX B0 $ ED_X3_<HR0,D8SQ0!]WT5^?T_P#P5;_X)BP$@_\ !13]AZ7Y3+FW
M_:E^"M]B/S#$&_T+QK,-OF#R@<_ZS*Y)PM,;_@JO_P $VBF^+]NS]E6X3/\
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MX;R@A,;V7R_$3<+N7<2<#(SQ5D_\%2?^"<2!3_PW9^RE,7&Y$M_C?X NI'0
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M7GQG_P""=4)WH&V)(;3]M>_51,5 #(9-@<%U0A@H!^@M(P!!!Z$$'G'!X/\
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MWFA2P^--4T3XAW7B#7?"7ASXM/K*>'O%VG?;?#-A!JV@65QI_P Y^*O@[=>
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M'N_*+_@G3^Q__:/A^34/VA/V5[J^U?2?^""'_!*SX!Z'+\6O@W<RWT7BG3?
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MOA^\U'1UO;F#VWX>_P#!4?\ 89^*'A3XN>./"GQ]TZV\.? SX='XP_$T^-_
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MX"]>H).._<FI&(52V,E02/4X[9P>O2JX7SR)"=H4@;>2& .[.3MZYQT/3/-
M'P1XW$:?\%1?V<W*;I%_8 _;75?W39*?\-$?L!;E-QDJ<ML(BV%ARX(!P?O6
M...0.H$BCC<&R,]<=0#Z_P"17PGXW##_ (*@_LT;@NV7]@G]N(QDNV2UO^T-
M_P $\S,"GF[0 +B#Y_().['F@#8WWN,=L?GF@!:*3(/0@_C2T 1RNR+E0">>
M,$_CQV'<=^WH5C8LBL>I&3CCGT_#I22/L7.,Y(7!)'7Z _RQ[U&D^YE79MSG
MG)XX)Z%!WP.O>@ \R02[, J6QG!Z8S^F0">A/Z6*KO/M<KLSM[Y/<>R''<=>
M<5)')YBYQ@Y(QDG^8'\J )**** "BBB@ Z]:H30(JG<"ZN0,# (.=X(],%>U
M7ZKW/^K'^]ZXYV/CF@"N?]((BW/'M!.1@].GW@<G!Y.<G'-,:-4)1]\@3HPX
M[!B2!QGYL9'4#';F5YOW>$C8/@8**K$'())PWRKD?,QRO8]<TD(=I!YVTR8R
M_P HP& & #O;)4$ Y48.<9Q0 1P!U#*2HZC./7!]<D$<D\GKSFFRKL*(WED@
M_*VW+X.2P Y4,P'#.-K;<'U%IY@C%-A. ",$<@G!XSQ@D#GKGC.#BL^9"7"8
M4@#),9+;<ACC<"P''&1_B ,8\H2H.W*A=B[G)!  :/A<,0VX\<D@9Z,+M%@-
MM5V.&B#&:0@GC:0 W)&<XXQD<Y!6,AB0OR#.PLJA>H&W@,V>HQGIGIUQ!LD7
M)>+8P4EG,B$MEV0;R2-K=-H!*CY3UR!I%+3;;LN[Z_Y:[ ?"G_!0]HU^!?PW
M=RR;/VY?^";VYS&ZAI#^WQ^SJNQ6<*[D%_F/S'+?-\IS7W++;12>?"4@)9I8
MY(2JYDA?*,A,D@$BR1DHZ2!E<.5(",P/Q'_P4.C9?@+X #2>0O\ PVW_ ,$X
M-CQNGFLS?M_?LVQJ'^616\QY$1E4!V4L P;83]9?$O7+OPK\/?'?BC3#I[:K
MX5\&^,/$=B=3BN)[%;[1= U/4[+[=!;36UW-9BZMHC<QVUS;7#VPE2&ZAD96
MIMV3Z[_H >'?AO\ #[PK?/J7A;P#X'\+ZM<0RQS:IX:\+>']&U-K=V3S8'O-
M)T^SN61RL7FH9BCA5RI;81-K?PZ\!^*=7\/ZYXD\$^#_ !)K7A.X>]\*ZKXA
M\*Z%K6I>&KR1D=[KP]J.HZ=->Z-.SJCM)I<]K(SKYCR%SNK\0?@3^VG_ ,%
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M%CFMKN&6WN;>>%+B&>WF4QSV\\,T;Q30R1L\4L<T;QNC.LB.&=3_ #/>'/\
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MI^H>./ WA/7?%OBOQ_I_@+P7XF\0>&?AJGAKPWK=QI<GTUXI_P""<WP7\1_
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MS5X+_;;\:?L^Z'^T9_P1>^&?[4_QE\9>%_@W\$/%GB?6?B_>VW_$]\;^&O\
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ML<OE7>GZYX8\5Z%K&A:SIE];6]Y9:AIUS#-"NU7;TJOPE_X)67VH^'?V_?\
M@NA\&](C,?PL\*?MK?"GXM^&8X4E.G6OQ(_:%_9^T#Q?\:X+*9F, NKSQ)HN
MCZ]K5E;J@AU76KB^N ]QJ#R']VJ "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH 0J&Z@''/-+TZ444 %%%% !1110!\'?$9D
MC_X*8_LDL[ONF_8<_P""A$,48B4*IC^.G_!-.>:03B-I"Y157R3(L6!YFUI
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M +1@<#@9Z\#)&>* &2 ;F!D&]@H*;1@D895R">^,G)'./HHPH  ;A5! &27
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MHH **** "HIC* #'R<\@ $GCC[W&,\'D'D5+10 @S@9ZX&?KWI'=4&6.!_\
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M9.3G\S2D2;2_&QFC4+GA2)&!('N2.W\J $'TP.PX&!Z8'  [ < 8%,.<!E5
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M['%O;&X=AY=Q$NH_![5KF-88QM$,EU,)&8NSE<1K=/[*7[6LI4R_\%0OVEX
M$566Q^!'[",6YQMW.3??LNZIC=AAM7A2V>@% 'Z!45\$Q_LG_M,E<77_  4[
M_:YD;;@&W^$W_!/VT )&"<+^QK*2^,XRS(K88#C!D_X8]^.#@&3_ (*7_MS;
MP,@Q:!^P1!&6*@$M%_PPU*,%MS! VQ<A1\H"@ ^\J*^#5_8[^-'[PM_P4K_;
MN9GV\G2?V"PJ;3N)C1/V'%5-^64J?,4#;UQD.7]C[XV*CHO_  4L_;I!;!21
M]#_8(DDCQC*<_L.%'#=V()&, <DT ?>%%?!?_#(/Q[C5_*_X*:_MN;F&%,_@
M[]@*<+TYVM^Q&F3QUW#J<8S4D?[)W[1L:NH_X*:?MALS;E#R_#3]@!R$.,8'
M_#%X D7'$@"YR=RG- 'WA17P@O[*/[2";PO_  4T_:^8$L4,OPN_X)_2%6;N
M2/V,%#*N 0A55'(P=V T?LF_M&,JB?\ X*:?MBL "'\GX:_\$_[=FY/S!D_8
MN8J2.F6< =@>* /O&BO@V+]D#XZAC]H_X*8?MOSH0<*GA?\ 8(MRI+!B=T7[
M$>[)P5 .Y5!( Z$,7]C?XS!]\G_!2S]O&53D&(Z;^PA'&!\P&&A_8@CE##(;
M/FL254%B,B@#[UHKX&'[%_Q=W9?_ (*4?M[O@* 2/V(D4;4920L/[%408R%@
MTF]2 R*8]HW*TG_#&/Q9QD_\%(?V]'.Y#M9_V*TR%(R"T7[&2E4?!W[3NP?D
MVG&T ^]:*^$!^QI\4FA:.3_@HI^W:S,Q;S1>?L?QS "19%53;_L@0Q!0%\G[
MFYHR?,+NS/2-^QE\2VW[O^"A/[=1WL[$C6_V5HR-_54$?[)R!$7.$";=O&W!
M H ^\**^!_\ AB7Q^V[S/^"A'[>C#:H"#Q;^S9%N*N''SP?LP0R*3M",0XW(
M2I!R2:TG[#7C%V>23]OC]OB9G/W!\4/@S:*NZ8R,RK9?L^VZ*4W%40 H8P(B
M H% 'Z T5\"M^PQXB?'F_MW_ +?,Y&>5^+/PNM,9QR18_!.S5N,@ J0,DXW8
M8!_84U9XPDG[</[?#E6+AA\;/!L#L6))5FM/A3 "J X52",8'. : /OJBOS_
M !^P5='YI?VUOV_)74,%;_AH:PA!WL&),=KX MX"5 *+OB(52VWYMK"0_L#V
MC B3]L#]OF7*@!A^U#K\#*>0[ 6NBVZEGX+!@R1[?W"Q9;> ??E%?GZO[ &F
MY4-^UO\ M]L%(R6_:T\;KO"@##>79JV&(W$J5;)(R%.V@?\ !/KP]_'^U3^W
M[+^[6,$_ME?%J(@Y0-+BVU"!6D94Y+AU&YS&B,Y:@#] J*^!?^'?GA'"AOVF
M?V]W(*$N?VUOCI&7V$G!$/B=$&_.UPB)E0,8(R7Q?\$^_ J"59_VB?V\[T22
M/*C3?MT?M)VS0%X_+,<7]F^/;',0_P!8B3&<)(-RXR5(!]Z.Q7&$9LY^[V^M
M)Y@P/E8$@G!&,8ZY+%5_\>YKX)A_X)Z?#N)&27]H+]O:\+*BL\_[?/[5<3GR
MQM!4V?Q/M!&S]9&C5"S<GI4D?_!/?X;Q<M\=_P!O&XQ*LJ[_ /@H!^UR-H3
M$0$?Q9@#QLN599=Y;EV?S,/0!]X"8L<"-B02.J#I_P "Z>G)![$TAGP2#&V0
M,D J2!US@$G& 3TYP<9KX3_X=Z_"@JP;XT?MWG<Q;_E(C^VPA7))V@Q?'-,*
M,XV\@   G -/'_!/;X2M%Y,OQ@_;ID168@/_ ,%%/VX \FX]9)HOCQ'*0O\
M"F_8,#Y>Y /NM9"?^6;@>I'MD<#YCGV'UZ&G;Q_=?_O@U\)#_@GE\&BH5_BO
M^W3( ,$O_P %'OV\22,Y .W]H=1@'@  <=<U"W_!.SX*D\?%']N8@C!_XV1_
MM\1=<@@"/]HH8'H001T& !0!]X&4@_ZN0CCD(3R?89/Z8[DT]6)&2K*?0@Y_
M3/\ .O@-?^"<'P- Q)\4?V[;I-P;R[O_ (*7_P#!0::,'=]X9_:3+ J#QS@;
M1CGK*_\ P3A^ K,&_P"%B_MP9 9<#_@I-_P4$PP<8)<-^TH0Q7JN<[6Y'(%
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MHZ*0=P)YXY.1GO1*66,$$@Y4?GP0?S_.H0P"F12#-SN' RH.,D>R@')/0DT
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M*<@YP?H2#^HKY"_8I_97TK]BS]G#P/\ LWZ'X_\ &/Q2TOP3K_Q<\0?\)_\
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M4?C-\?\ P_\ L\_%C7O@_P#%+Q!X8_:X^'GA\_LX^ ?'GBSQ#X/\7ZK\*O!
M\&_$3PY;VEMX:T;XB>.]!UW6?$D'@S[TO/\ @D;\*O&$/QCN_C)^T-^UO\<?
M'7QU^"_PR^!'Q#^)GQ(^('PY_P"$FD\ ?"'XIW/Q?\'6/A;2?!7PH\'^!?",
M\7B6\N;/5FT/PE:V?B"RN=2U'5]/G\6ZUK/BF^[+Q-_P2^^'>N>/_'_B#0OV
MA_VQ?AA\*/B[\3IOC%\6OV8/A/\ &JP\$? CQW\0M8UF+7_'.K^;9^#I_C3X
M%TSXI>(A=^(_BOX4^%WQ@\">&/'^MZOKVJ:SI<MQX@\1#5@#ZC_:;^"?AS]I
MGX1:K\'O%WC7X@>#? WC/7?!O_"7CX<^+(_ OB+Q_P"$=*\4:+XAUWX0WGB,
M16^N:3X5^+VE:;/X$\<#PWJ?A[Q9>>#]9UW2M"\0:-<WSW<?YL_\$I-''PC^
M._[=7P(N_@]K?[(%EIU_\ _B]\,_V))/%VE_$7P3\,_A1XS\(^+/ Q^-'PZ\
M8^%]9UKP/:6WQL^)7PQ\?:;XT^&?@B:/2_ ?BGX:/K-_'<ZUX_OM3U#]+_VH
M_P!F+X;_ +5_PKNOA3\2!XHTZS7Q/X3^('A+QKX \277@[XF?#+XG_#S7K+Q
M5\._B?\ #3QA:)+-X:\;>"?$FG66J:-J,EO?:=*B7&E:UI.LZ%J.IZ3><?\
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M$C4_"NI^([2_M+C3;.=;B)9)E*,6DVW?LK[?KV[].P<L_P"5?^!+R]>X]O\
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MB_9V_:4E<.,9++%\(79<YSRN,=.!FG#_ (*4?L?2%HE\>_$)WC597C3]FO\
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M^UK"6\P##2?!73I4RN!OP('P5 *-R3@D,#-U?V^/@S+B6+X9_MLR'>JK(/\
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M2)&/^":/[6:Y"_ZSXL?L *H)^\&*?ME2M\O&XJ&SGY<U]U44 ?"O_#4?[3;
M!/\ @FO^TX&8#!D^,?["BJI(SB1HOVK9V&,$$QQR\],KEA#+^T[^U>06LO\
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M)W-P"I/&"<9[#M['^8'PN/'7_!2]Y-W_  S+^PO'C#,K?MQ?'N4J=H"Y\O\
MX)_+&&_A)4NJ+M+-^\(%@>-_^"FS#*_LU?L(@=/F_;@^/S$G<!G*?\$^B #\
MQQDD' YY-?3OQ3^(-G\+/AK\1_B=>Z5>ZYI_P[\">*/'=]I.G76EZ??:EI_A
M'1+K7;VSM+[6[S3=%M+B6VL9@EQJ5_:6<.2T\\:+D;G@/QUX9^(W@CP?\0_
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M5D2%8P 1LSEA]_-<,8S+Y !+1HRLQ$BM@,.5#95T;<K;<-D<*""(UE,@#>8
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M0Z:+IYXO,^_O _Q6^'/Q)UKXGZ!X&\36GB36_@MX_/PP^*6G6D=_'+X-\?\
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MUU@2^ _B5X-UY=2T2?4-+$6K"U:]74+6[M(/4RW!P"2!TZ$]0.N,<@C/;!H
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MYF9LY("E&<:M]UP+-%&0?RS^%%( HHHH **** "BBB@ HHHH ^!O^"E'F_\
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M>'/".?$%M?[O#6@Z/H#!M,TRRM86TUN!^&]]^R/JM_\ \%!_%'[(&L?ML?\
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M:1/I;ZFUE-IDTMA) UK(\3 '\W/[1T^OZUXZ_;)\/^&OCC\/O %QXZ_X+'>
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MFA^P_P"#-0_9EU_XLZ;\%?VKO&'Q3^*_[*,>@_!KQ?\ %QOV<[KQI^T/XO\
M@;I?A.'XGZM8^#O#'Q;^$.I>*?@=X@TM-$U_3-6\/3>&Y;+2[C1GM9K/3?H2
M_P#V5OBQ??\ !/K_ (*+>+/B]\+;.S_:4_;%_9H\<:+J7P(\'ZV_Q/@\!^%O
MAY^SKJGPK^!OP5TC4;:UATCQ9XUTO3X+W6_%%QX1TJWT+5/B?XPUZV\+P7=C
M#IM]J'[C>3%Q^ZCXQCY%XVY"XXXV@D#TR<=:!%$"6$488L7+!%!+DY+$@9+$
M\ENI/.:;E)IJ]DW?1+36[UWU\V!_.#XQ_P""8GQF_:(_X)V_%[Q!XFUM]?\
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MS2T4 )M .0 #C&<<X]/\/2C /4 _A2T4 (%"C &!UH(!Z@'Z@'^=+10&^XF
M.@ _"C '0 ?A2T4!ML( !T '_P!?FJK0R[F*[2"Q(R2#R<_IG%6Z* &(N$56
MP2 ,^F1R/RIX ' X'/Z\T44 %%%% 'P!\75S_P %*?V(FXPO[*?_  4&##(^
MZWCS]@K/&02,A<X4@$C)!QG[_KX ^+A/_#RO]B9<G!_9(_X*%$+@X+CXB?\
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M!'&.E #Z*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MG[47QO\ &NMZOX=^$?A_Q%\.?'OP4^._PJ^$&M6/CZ+Q#\7K#7-+A^">M?\
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MDD/_ (^V>Y[_ /ZJ^"_^"D[K'^S1X<9G,:_\-D_\$VE+*NX_O/\ @HS^RJF
M,'[^[86Z*&W' &:^]$_B'8.V/Q.X_P#CQ/\ *@!]%%% !1110 4444 %%%%
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M9/;VI(9C*6!&,#(_[Z=?Y**L4 %%%% !1110 4444 %%%% !44DFT KASG!
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M' _;'_X)O.%D7<A:/_@HK^RNZ;EXR R@X!!XX(."/O).AX'WFZ=\,02??(H
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M#TC#]ZO[+?\ P4#C0ERH$<GC/]A9Y05"D-EH8CN+*4"G;G<17Z T 5-AM\E
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M$P.#D@$G//4J3C'4U-(VZ'<.,^61ZC+*?S%.=EC4;@3R%X&><'M] :0@21
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MY!-_P7=_X):Z?X:35_$7[3UAX0\7S0(+SX&>)/ /Q-M?VC-)\1%EMKOP/=_
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MQ7>:EIZI ?A_IG@G3[9Y;4W KZ2_X**)\3O$G[,FO?";X17U[X<\7_'WQO\
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M9?M_A7Q-XHUK7[!&CCB#-+*YF'R+^Q2*-J'J=BC/J .,#H.OZU^./@J* _\
M!=KX\WVJ"-=1B_X)@_ ZV\+0&*U,\WAVX_:+^(TWB5K6>,RRF--=ATB*^2Y>
MT:<R:<([>ZC@26#]==5\0:1X?TJ^UK6]0L=(T31K"ZU+6=;U6^L]-TC1],TZ
M![G4-3U34[Z:WLK'3[*UBEN+F]N9XK>&&-Y972-6<-N]O)6 M7E[%;P7$MPZ
M6]O;))-<7,\R000P0*TDL\\TA5(8(D21Y9I&2.-4+,X 8C\W_A'_ ,%=?V$O
MC9\?]*_9M^&WQ6U;7_%WBC4_$GASX;^.#\/?'NG? WXP>+O!=E=ZGXR\'_"#
MXX:CX=M?AM\1O$/AO2[.?5+F#PUK][9:Q8JT_A:^U\1RB/Y-U73/%O\ P6E\
M6ZG8Z?XL\9_#[_@D?X.U>[T;4)O#$^K^#?%?_!3+Q':)/%K<6G>,--NM+\4>
M'?V+?#=^8]#74/#LNFWOQ\U6S\0)9ZC_ ,(?9Z;J@]5_X*S_ +.#Z=_P3NN=
M=_9W\,Z1X,\:?L"^(/AK^UO^SIX<\%V*>'M'\/:A^S+J2>)=0\-:9INDBS6'
M1M7^&8\;^&[K1K1X5U>WU,6$[$2R.YN]%V5M]?\ @@?L6DBNH;(&>P.>1U''
M7!ZCJ.-P4Y :TI#[%0M@@,1N^7(!!/RD8P?[V>F >WX>>-/C%\;?^"C/QF\.
M? K]C7]I?Q7^R?\ !_P5^S;\'OVH?CW\:OAWX7\+>+/BQJWB;]J+PWKWB/\
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M110 4444 %%%% !1110 4444 %%,DD$8!()R<<?G_+)QWQ3E8,H89P1D9X-
M"T444 %%%!. 2>@Y- !14'VA/1_^^>/SS4] !@>@HHHH *K^1_I'VC>W^K,>
MS/R8+!MV.S Y (XV\$=ZL44 )@'J ?PJ)Y1&ZIMZA>00  3MYXZ#']*FJ*21
M$.&!)P&X7.!DXY^H- 'P1\8(PW_!2#]B1^=R?LN?M_A0"<?/XS_89!RH.">!
MC(XR<$9Y^_*_/_XPL/\ AY'^P^V2&_X9<_X* E><#'_"8_L,$[ACJ#M(.0!@
MY!R,?H!0 45%,C.%VG&&R><=C@\>A[=ZD'  )R0!SZ^] $8ES(8]I&,\YXX
M/3WR/SJ6DP,@X&1T/?GBEH **** "BBB@ HHHH *AF1G0!>H.?\ QUAQ[\U-
M10!5D0)&K* CAE!*\$C.",]<'O4>[]W\H8N7^=QC^]_$QXSLQ@=>@ Q5B?\
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M;%S_ 'MTL809SRQ (4D?>\7FY8R>@Q]WWS]TGV^N?:@":BBB@ HHHH ****
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M 2-L1E9#(-\D:#(VJ[J6VCYA]\%S&\I3+,7^961LYP2@3!&[([@G((/'< N
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M0!]%T5\SR?MI?L<PX\W]K']FB(%MF9/CO\+$ ?LGS>*A\QP<*,G@U6_X;?\
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MP(4 KM(;!!P@_P""I/\ P3RQQ^V3^S[*2<#[/\0-+G XR0XA>4J0 2<D8[T
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MD0P%)7_86-W8L'7;C&/E(SG.>I.>W3'?- R6HI=X4%/7YO\ =P<G/M_6I:*
M*Z3*JJ)&^?&6Z<$\XZX. >.O'>IU8, PZ'I_*JTT2@%\G)8<':1R0,#Y<XQT
MYI(Y&4*" (AD;R",]<8.[!)/MSR: +=% ((!'((R#Z@T4 %%%% !1110 5%,
M[(H*C)W8/< 8)R?8$#-2U3-RXR/+R03@\XZ\=J ))\F'H3NV;L#G!(SQVY_'
MM415&1"P4."%PQ"D#>0, _Q8Q@#V/I4L_P T2DY!W(WRDYZY('0^O7'O59=C
M2(H)W$,V' ^7;]TYR"6#!2!V'M0 +(Q01X!3+#.1G*DL3P.F<$#N/U:K'Y&7
M:7P&X(/(&2&]#C. >X[8IS +(,*,J6)VL@5MXZ[<E\GG/&2>F:8=H_U42JQR
M.J$DGTRH9<#=P"#CKTH >6\Y@WF(-Q"JA7) 7DAN2"?F.!@#.,DYJ)8]GF+A
MN2-[;%7)P& ;;@;QD D\G@9-*BL@(8;264KDC'1%&3]5STY'3G. J/.D9_WC
MJN% =L'(!Q@%5(SGG[PP<?P@ 'Y]_P#!4C2+37_V*/B%H6H3ZM!IWB'XE?LN
M>'+Z;P_KNK^&M9@M-?\ VL/@AI5W-HGB7P[>Z9X@\.ZQ#!=O)INNZ%J>GZSH
MUYY.HZ7>VM];P7$>[>?\$Z_V??M$L[>.OVX7>[FNKJX,?_!3#_@HYL7>[S,J
MQ1_M4#9&KR,L$$(58T40PJ"RHV9_P4U>X_X8X\7^3&R2Q?&']D>8+'@HQ@_:
M^^!$L@5CM8AXU*OD;]NXAP2N/ODR(9Y%+ + TY+87<#,&R!*1F%02?FR% ^]
M@+N !^7_ , /V8OV+/VEO@]\._CU\%/C!^W%XH^%/Q3\-1>*/ _B67_@HO\
M\%,/#[Z[X?NKF>&*ZDT;Q1^TMIFMV*RS6LK+%J6GVET1&DAC6-T>3VB7_@GC
M\ O)4KX__;:B1 BCRO\ @I/_ ,%#(PR*YV[F_P"&GR'&&)W.2S* 6;O7Y\_\
M$>_VC?A5I'_!)+]C3X?>%_BW\%M6^.UE^S:VD^$_A/>?%+P*_C+5_B-:0>*I
M/#_A-_"LFN_VU/JE_JT-K9/8Q67VN;SYF$,"1E&^+OV9/%OPXT7P?_P2;_:+
M^!/[77Q:^-7[=G[5?QD^#/AG]K?P/XA_:>^(7Q2?XJ:7XW\ ^*=8_;.\.?$;
M]F;6/B!J/@#X-:?^RW/I_B+Q!H(\(_#?P++\'-<^'/A[P)-))'K=_INM@'[>
MVW_!/GX%76H7-O<>+?VU(;6%B([A/^"C7_!0N R2%8X2KW:?M-H]P=L48"R3
M.RLH9#\QW:\G_!/+]GV*(Q/XV_;5\@.NYI/^"D?_  4.()<A5 +?M/MN#,P3
M;GEB !SFOP1_9!\,VW@'X+_\$=/VJ_$O[2'[1NJ>+OVI?B/\9_AK^U-XR^)_
M[5_Q<USP5XN^!6M?LI?MN?%BZ\/ZSH>O^.U\"^$])^$6K?!CPAJ_@KQEX2TS
MPUXD\+?V'>ZM)XDN;Z_O=0DZK]D_6?V5K?Q!\>_V\/A_^TE\:/AW\ ?A9^S9
M\=IOV7_@/9?MV_&3]I7]HSXQ^ O#/PZ\2^*/'7[8NM_ W]H+X^?%?2;#7M3\
M+>'=1NOV8_@[K'@RQN]*\/VS_$CXP6-OKWB31_"?PY /V^?_ ()V_L],2?\
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M+2S:7@!UO[-OP9_8-_:M\-^)?$OP7^)O[<US-X&\5W/@3XB^"/&7[<7_  5
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M_@_NSL*@#]II$ 7:%+!0S%3DL&+,C?\ !.;]FE4:0Z[^UN%VOO=_^"AO_!0
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MB^._VFM['JHD_9M\6L"!@C._"GD8]Z /%?VD?V3_ /@G;^RA\!OBG^T;\6_
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M>O\ P3/_ &+44I_PJ?774F,D/\9_CM+DQ$,G^L^)TAX*C/0-@AMP.#_*+?\
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MSXS+.QSRSEF/&2<#'WBGW$XQ\J\<\<#CD \>X!]J4D#J0,<')'!]* /@H_\
M!,']A/;L7]G[157RVCPGB[XC1ML8Y9 Z>,58(QY90<$@$\@5 ?\ @ES^P:S(
M[_L]:&SQ[-K?\);\1]RA&+)\Q\9DG868\YSD^M??F1TR,^F1WZ?G2D@=2!]?
M;K^5 'P0O_!+_P#8.5G=?V=_#I9QABWB;X@.&] P;Q:P(';C@<"F-_P2Z_8%
MDYD_9H\$.2,-NU#Q<V_/7?N\1GS,_P 6_=NY!R*^^L@]#FB@#X&C_P""7/\
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M0>W7OUQ^7-&1ZCGIR* *6Z;+*HD(4E"<Y)P2"P.,@G!R00>F,$9J>-'"@EY
M3]Y6.< 9V@;LX(ZDCEOXL\ 3$@=2!GIDT9'J/SH C92#DR-M[\@>PZ#U/8 D
MXSQP4 !;Y9FY &,YZ'.1P#G'!YY[YI\@#H5+  XYX.,$-WXYQ^55 JI,JY!V
MLN3@#JI(Z<8].F<'CC) )'+K(B@N%;9DY)P6;!&[/' ';'/O4QC)_P"6D@YS
MP5X]N5/'US4E(1D$'H01^= $0*=#*3D]<X__ %51'F##%YLC/6238V22,X;
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M_P!MS]MK]FZW\<^"M%\87&F_#WP/^R]\/=,\5>%]:\9>6-8L8]=\1:AK4/\
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M5_#G4/%>AZXFJ:1K]I8^+M+TJ^L+:3PM>^4Z/_P3L_:S\,^)+?\ :&TSX_\
MP,U?]JFW_;>^)W[6GEZO\)O']A\!I_"'QD_92\%_LI^(O@Q/HFF_$>7QZ/\
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M@.B^,/A[+HE]+K/AKQ?HBWFI@'T#X[_:\L_@%_P3WU;]M3Q[XE\#?M&KX-^
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M'4$!1D_W?3GK754V[NX!1112 **** *\,<B$[@,%?[Q.#QGC'?ZX&/>K%%%
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M[<C'?/M7P+\9WC7_ (*-?L-K( 3)^SA^WRL6021*NO?L9OD$ @#R5F4Y(SN
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MX8X#);_M\_LT7#J.1\[K$5CP<F0K@$X!^ZTS@YX)9_RW''Z8_P#UT .HHHH
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MJ?V &D<=?*7]O?\ 9I:5?^VD8://;=FONF+!4XZ>9-U]1-(#^N<>U $E%%%
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M>#OAO\-_"RZA)!9GQ+\0/'7B#P_X1T)KJ:.TBU'5HKJ\>.SMKF2/Z$K\T_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH ***CDD$:%R"P&,[1DXSU '7'I0!)377>K+ZC'/\ G\O>
ME5@RAAG!&1G@X/M2.VU6;KM&<?3K^/\ 6@!L:>6NW.>6.<8ZG/Z#BGD\$CG
M)_$#I48;SHFP,;@R\GC.".V>,U$I\EA&<MO8-G/0,=H ![ KGCL: /@/XSR1
M'_@HU^PD6),Q_9Z_;X\ADP4!75?V/2^YB%*MMQMP.<'/%?H#%*9-V5*[<?CG
M/\L5\!_&IL?\%%_V%XL,5?\ 9X_;V;:I 7*:M^QZ 67&2<2,JX(P6.0>,??D
M4@?< NW&#V((.<'CZ']* ):J_9SG.X9))/ '4DXZ=.@[5-))Y84XSDX[#MFB
M.029XVD=02#_ "_"@"'!R+;IM0,'QV!& ??/'?CGKQ2?9C_>'_?(//Y5;HH
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MWF*I^.G[&/F>1ND*L/VTOV?PH5DY&=PW#.=FYC@*37W].DBAG .#(Q^5@&V
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M &A]IMH;.Y>OE8;*]];M^K;?7S9VM6;72-HKTC&*7W6L_-.^MSX0^"'C"_\
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M[/\ ?8#Z X_4Y/XT /HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MA%!<Y8J "<<4YHX&)9HU8E0A<C<[("VT,2/G7YFP&)'S'CFOB71?&O[3VI_
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M.60%1RPK] VRY99=BJ#E&4_-P^1D'/4 9. ,\4@$@_UG_ &_]"2IY>5P>A9
M?8;AV[\X!'H:@XB^:-O,8_+M..%/).  >"H'ISCJ14K$M&I8;<LA8>@W@CU[
MXX[9/I0!S.BLW]LZR#@@NF#CD%2W?OP0/88Q765R^C[3JNJ $'D-P0>LC#MV
M_K744WT]%^0!12%E!"DC)Z#//^>#]<4M( HHHH **** "BBB@ HHHH ****
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M\6]%+?*I8,V0"*^[(\889S^\DSD8.2Y..O/7@^F.,B@"2BBB@ HHHH ****
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MK34E2&)]_&78\]"IQGZG&>/7 J(A2WEE2VUD=7;"J4"MSN&<9/ &#D@G(SP
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M)CAC@B/XH,0Q*@ 'NR]CN'W]10!\ P?MY:I.8@/V&OV_8S,KO'YWP.\)0@!
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ME_;1\?N^R/\ X)^_MU,,L#*WAC]FR&,;59RV+C]I^&1@VW8NU&)=D&,9(^[
M<@'U /YC-+0!\'+^VI\06"M_P[W_ &[U4C/S>&OV9@0.1AE_X:C+@]\;<],C
MJ*5/VT_B"[$?\.^/V[54$#>_AO\ 9F49(!QM_P"&I#(>^6"; 1@G.,_>%&!Z
M4 ?!-S^VS\0+<X3_ ()Z?MZ73%6?;;^%OV:3M"$?*SS?M1P1%W!.P*YZ'/.
M96_;2^(X4L/^">'[=[G* (NB_LJAOF&2V7_:O5"%_BPP(/ !-?>-% 'P?_PV
MC\21M_XUX?MW.2P4[=&_934#.?F._P#:Q "C')R3Z YX5?VS_B81(6_X)V?M
MW(4SA6TW]DIBXR<%/+_:WD5L\<%E;N5&<#[OHH ^"O\ AM/XFO\ ZO\ X)T_
MMY$@;BK:3^R7&<>S3?M<PH3VVAF8=2N.:A_X;5^*QB:9?^";W[>S!&*"+[#^
MQRD\F,_-&DG[9*808ZR!=VY2H(S7WW1@>G^?\D_G0!\%1_MG_%J0C'_!-K]O
M/!17W/\ \,4PCY@#M*R_MI*X=<X92O!S@D"GG]LSXN^:D:?\$U_V\6$C;1*;
MC]B%(DX)+2F3]M575>"!A&). !R*^\J3 /4 _A0!\*1_MB_&"17<?\$VOVZE
M"%AB34/V'$9@AP61#^VQN8-U3C<PYVCG#I?VPOC%%")O^';?[<\F0"L<6I_L
M,O,6/17C_P"&UP4R<9;D+U8K@@?=.!TP,>F*6@#X3A_; ^-$Y0)_P38_;AB+
M9_X^=<_88@50.I=F_;48+CL 22> #5D_M7_'ERPM_P#@FY^V$V "ANO'?["-
MD'SG@>;^V8V&XR%(R?;!K[CP/3_/7^?-% 'PK+^U1^TJK+Y7_!-3]J-T,>YG
MD^,'[!D6UR<",@?M=RYW#!5U)4DX)%4C^U5^U.P+1_\ !,S]I%!N 5;KXX_L
M,1/(FTGS$%M^U)>IC.!AI%/.>V#][T$ ]0#]: /@L?M/_M8R+(8_^";OQJ@9
M44Q+J'[0'['L(DD/WX7:P^.>I^7)&<;BHDC.3M9B #"?VEOVS)%!A_X)O_$!
M#SD7O[3/[,</0@#8;/QSJ(8,/F!;9P/FPWRU]]44 ? @_:6_;.P^_P#X)Q>-
MD*#(/_#3O[-9C;H2 Q\7*ZMM)QOC5"PP75#YE21_M,?M@F".:;_@G'\2%=RP
M>T@_:2_9;FNHBN<!C)\1[>S<L,, EXQ","P#94?>]% 'P?'^T]^U?C]]_P $
MWOC8/WB(?(^/O['LP 8$M(3+\=+7Y$("X ,K%AMC(!(<_P"U!^U/&R*?^";/
M[0%PK9S)9_'+]BQTB !_UOVS]HZQ?). !$DPP<LRXQ7W=28!Z@'\* /A"']J
M7]J61MK_ /!,_P#:2MQ\N7G^-O[#ACR?O!#;_M13R-LP=^^-.VS=SB#_ (:J
M_:G,HC7_ ()F?M'[3)L,K?'+]AH1JOF(IE95_:B>;8(F><A8FD\N-E"&1E0_
M>V!Z#\J7 ]!_D8_EQ]* /A2W_:>_:FG7,G_!.#X[V;G.([OXZ_L:E@<9 8V7
M[0=ZH/8[2X')R1S2R?M,_M5 ,(_^"=7QB\Q0IS<?'W]D>&W;=V22+XUW,^X'
MKYEK&O\ =9J^ZJ* /Q;_ &V/CQ^TYXB^"7ANP\1?L&_$+PMI\?[57[ >I1ZA
MJ'[0'[,ES;W-_I/[=W[.&K:?H\@L?B3.]N^O:A8VVAV=TZM;QWE_#)=-;6J3
M7,?UT/VD?VLFW^3_ ,$[_BD")]I^U?M"?LL1;HB<&9/LOQ3O>BC<(I!&Q! +
M!L@2_P#!1#'_  SQX4!\OY_VRO\ @F^A,JLR#S/^"B7[+*;F50S$KNRN!PP4
M\ 9'V%XIN)[+PKXDO;662&YM-$UN[@GCP)8;BVL+J6&6+((#Q31HR9!!*C*D
M$B@#XYD_:._:[QB#_@GC\03)YX39<_M%_LT0*8<9:=6@\>WC$@\>48U8]=PI
MA_:)_;&8OY?_  3X\2[!]QI?VFO@ A)QG#B+6IPC \8#..ASCI^,'P.^%W[1
M;_\ !'GX:?\ !2+P;_P4 _;3A_:ETK]ARS_:TOK+XI_&)/BW^S_X\\:>'_A2
M?BCXB\#>.O@YXUT"[T2#X>>-Y-'N_#=S-X5N_#GBWPCINJG5?#7B2#4K(M>_
M57Q^_P""MOQ1^#GP[TSXSV7P!_9L\.?"(_L[?#3X_6NI_M1?MZ^!_P!FKXA?
M&X>-OAA8_$_7O W[,_PX?X;?$S4O%NK^"[&]7PI)K'Q-U;X6V?B?QY#=>&-"
MBNK&SNO$D8!]W_\ #1?[9V#_ ,:\?$8(QRW[4'P "#@$J[#5F96&<85'4G^(
M#FG?\-#?MI/D0_\ !/N^4X&TW?[4_P $X5#G(\N0VB7[(V< ;$E!SUR,5^:5
MM_P5.^(_@+XU_MT_'WXF^$-+D_83^%'[$G["?[0?PPL'^*.A:;\2K;6/VCK7
MXB7'@FR;P5K'@+0?#&A^)?C)XMU&/P1XRU7Q9\8K?PA\-E^&GAC7$U;5-,\5
M:P?#GJ?[.7_!6/Q9\>OB=XD_9VTCP;^Q/XZ_:"\0? GXA_'#X$Z'^S/_ ,%
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M@NH+*@_8(8-B,L^#(A)4( 0V]?NZ6+S-N#C;GGZX[?A^GO4H& !UP!R?;O\
M6@#X,D^*W_!1_++;_L8_LF2,) H\W_@H#\1H@5()+_N_V!+AASPJ%-S=3M I
MO_"U?^"DV&S^QA^R(K ';_QL%^)A&[L&_P"-?2D#/7&3[=Q][44 ? P^*?\
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M:OX<TFR\4VLNO?'346T"ZUW0-(U&UM]0?49/W @B\I6R%#R.\LFS[N]R2>2
M6QPH9@#M51@  4\1H-N% *\ @ $# &!CH"!@BGT %%%% !1110 5^?W[1!)_
M;A_X)T@HK+_;/[6+"0C#12+\"RB>6_8O&\N8P,.-TA(,6#^@-?!/[0B;_P!M
MS_@GE)\P,>H_M6=&PNP_!.!"'&1G+[648., \<F@#J/^"A_[,OB+]LO]B?\
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M+\8^-+S2O@I>ZEX9TV3PUK=Y\-AXLTC6_L.G^'=*\/\ @3P;=W>EVWZ$6/\
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ME?CS^UO^TE^W3^SKK/BKXU-'^SYI'P-T+]HKX"? ?X+_ +-NH^&]>\7?'/\
M:\T_XN>)/AGX4U?7O"/Q8TCXHZ-I?PW^)+:WXR\8Q?#SX7-\'/'(CTWX7:OX
MC\<:F/#GB>/5_!W#G]N/]JU]:OOVFT3X,Q?L6:7_ ,%$K;]@1_A2_@[Q?/\
M&2Y\,G]I6T_8HN/VF1\;+3XB?\(K'./VFKU+NT^%;?!ZZTN?X-VRW,OCH>,K
MY?L8!^WU&1ZBOQIU+]I/]O/X2_M"?LNZ;\>'_9RB\+?M<?M'?%CX.Z'^R=X"
M\->)M1^-'PF^#?@3P7\5O'&B?M"7'QVA^*&KZ)\2%T+P_P" O".K_&;3%^#G
M@WPKX9_X6GH/A'2]>MO%%CI\_C/R[]@#_@I;X]_;)^,?PIO;#XY?LIZU\/\
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MVD^#M?7POXZO[WXD>+IM5U^VA\*Z NC:R ?M5D>HZXZ]_3ZT9'J/S%?SM?M
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M/TSV '21# \M1NW9/.."&R,GMD@XI=K"%5P=P* @<\AQD^XX)SZ<U,N<#/7
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M^(H-/U.U9+G3KZ72-5NTM;V ^?:SF.:$K(@)^2/%O_!-[]EGQIXE^,?B_6O
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MK?PS^,NA^ O!MS\?_&_P]OC^UU\"/AEI>G6NF?$CX?>!M-L_!.N^ _C!JGB
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MJ* /QAUG]D[]O:T_;#U3]I.SA_8X^+^A>";V/P)^RIH7Q?\ '?[0.ER_LQ_
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M]#U]JF. RP@JT9.U^W&68\*556#;1D@Y P!UISQ1*A9,%D4E1OSSZ 9Z'I0
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MZC% $E% ((R#D'D$="/6B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M>&=!\._&_P#:0\::-X-\9>([C0],T?X9^"!!I5E>^(?&/A!O%6A6UUO>"O\
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M05IX@\ Q^$?'NGZ#\,/B?X;UKPCH>BZY=7>F^+/ ^K6=_K5QHWA'0T32M/L
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *, = !110 4444 ! /4
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MHH **** "H(XW1R6;*X('/N"/KP",G^M3TUW6-2S$@#T!)Y] ,DT 1RQ;AE
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MK\\?BKI]EK/_  5!_8H234IH;SPA^QI_P4,\7QZ7;O&!?O>_%3_@GOX,@EU
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBD9@H+'H.OXG% "T5")XR0 3DD 8&>2<#IFIJ "BF)(LF2ISC&>,=>E/H
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MQC'F>[LDKOS=KOU!N[;LE=WLME?HO);+R"BBBJ$%%%% !1110 4444 %%%%
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M23RU=%P<L-IY&1M"MC:,#:1QTXY':@#X&_X*0$1_LX^$%1Q#N_;:_P""9$;
M.<[6_P""D?[*.Y5#!AD_(IP"<$J,;@:^_ @D=U;.U69@1C@LQR#D$$'&>F1C
M&:^ /^"CV^/]G/P85E9_._;D_P""8,> BR# _P""E'[)TDNY?F)7RE))&64*
M2!@EA]^F1HG? !WY/.> K/QE<COGDCDXH :@61C"&D!7+ECC<2"%Y.-O\6/7
MWX-6RH"*F<#* 'KDJ00/QQ3$5$;?Y@R0>"5XW$-]>W>GR?=##G#H1^+!?ZT
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M]'^Q%\ F\&?%GX<WND>*M1\#?&W6-:OO'_AE_&OB;2K/4]%\1_#3X<_"+7/
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MEDC/*.AI\7[ G@:,H3^T/^W4Y5E8^9^V[^T:X?:02&!\= %6Q\RJ%!R0,#&
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M1VQ@$9Y)S4\K1KM,BYZX. <<<]\C/ R/QQ3(X625FXV%-J\DD?-G!R/Y9]*
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M%% !1110 4444 %%%% !1110 4444 %%%% !1143S(C!#G+ $8 QRP4=QW-
M$M%0RK*6!C. %((S@$D@],'T]14U !1110 4444 0&-C(7SA=RD#)Y "Y[XZ
M@Y!'/KSQ/4!23S"P(V%D)&>RA<\8Z\''(J8D*"QZ $GZ 9H " >H!^H!IDD@
MC X))SQG' ZG/MD<>]$<BR E<\=<C'6G,BN,, 0#GGUH =14$2R@GS&R,84
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MY]W'RHF5N1N 51R0 H &!VXQTZ_6HX)C(Y4L&P@;(& #G&.V?Y4 3JB*254
MG.3WY.<4K,%&XYQD#CKR0!^IIU1-)&24).0PR/=6!'3MD"@#G-%='U/5F7DE
MT!.,'AG S[8'&>>F.*ZBN2T+;_:NL;.GFIQSQS)US[^_]*ZV@ HHHH ****
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M  '&#@$D'! YSGMC(QC@TID9V"N2@SM8$8!! W9!XQU4],$\GI4:JP5RJL
M[\@D#EMJ<^P4\?PGC&02 .=V8?.1D [<<=?USP/R&.<YF=E0 P 9)&2JY^7!
M(['ACT/0D$9XXK@,0I ))Y(!8%/E_B '&2, G!Z"GH[Q@[4P& *@@Y51_"P'
M\09LD8!PP)QG@ O#D ^H'\JA>,*2Z*2S, W/0,PW$#VZX]S[8F!R ?4 _G39
M"0N0<'<@_-U!_,&@#F-"&W4M73)(5D.2-I)9Y"3C /0#KQZ>_55RFA,7U/66
M8C=YB+CV#28XS_G\*ZN@ HHHH **** "BBB@ HIN]2=H(SR,?3K3J "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ I RDX# D9R 03P<'CV/!]#2U$L05V?NV<CMR0?SX_/- $M%,
MD8JC,H)('  SWQ^G7\*@264NH*<$X)]!ZT 6J*** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBH(YB[E" ,!CD$GHP7TQSG(YH 8;89+F1E).<C@ D\<9(
MQTX/4\FJ\BE7V LV['[SL,#/S%'0Y.-HQT'.03FK&XS$QD!1DG<#DC8<9P<=
M3QU[U R;'=002,$LQQD;0>3GJ,D#M@<XZT ..YL'&%4<L7W'#8.X@DN>!G!)
M8]SFF8';!(Q@D=5R=IPP(P1R P/'!YYIAWMTD( X :-5VC'0,?F  &220<8/
M?%.Z$EM@#K@$-E4 "X(/ &,?*>/OGMU $)"_>SS_ '54]/4*J+WXR#[8Q4J2
M@[HP68%2SAE *Q[6!*X.<DCT[ =Z?%&S@MO*\X&T9#+U5P2>C DCVQ4<T<JD
M[7D8% ,#H<L<YYZ[?H,=:=]$NU_Q EMSAW!/ 50"?XAS\WMSQWSGK4TL:R;=
MQ7C/!&>N.>H]/\XJB"^U@R%=XQ@9WX4@[D7OR<'D8]>M!YR206P<D'C'8;>@
MQQSWQR.32 TE^Z.<\#GUXZ_C3)?N?\"3_P!#7^?2FR2>4BD ')"\Y 'RD]@?
M3%#G=$K'(R8FP#CDLO!]0,]/:@#D_#K[]4UD<#;(G&<D_O)AD]*[*N,\/E5U
M;600H+RH!@$=&<] ,#.?7GGG(('9TVK.S ****0!1110 4444 0B+$IEW'+9
M!&.,<=.>O YQZ^M3444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1140E!D,>T@@GG(P0!DG]1^?M0!+1110 4444 %%%% $$
M<3([$D$-G'7(^;/(Z<@\XXR.E3T44 %5WN%1F4J>,>G.1G/7IC'O[58I"JDY
M*J3ZD F@"NH,KK*#M4$#&3N^7MP<8/<>A]34TA(C<@X(1B".H.#S3@ .  !Z
M 8I>O6@"O;]'P<_,.^>P]_\ /X58I  .@ ^@ _E2T (0#U /4<@'@]1SZ]Z7
MITHIDC[ IP2"V.".."<\]> : 'T4U&#JK#HPR/IV_.G4 %%%% !1110 4444
M %%%,61&.%8$C/'? ./YT )+LVYD!(R!QD\GV%5Q"LC$A<1D$*P)#*<8. >?
MO G!R.XQWF9X7&'(P#G:W!RI[C\/RJK+(8B&7S#&6 18AN!&0&( S@9))/;D
MD<<@#=OEDH<DIU/<AN0<^F ,#C;SD]ZD7SS'MB"JIW$ME2QW'L,\$'/))!&>
M.E02,VV64HS$$%$?:6&XHJD$9&.#ZG@#(Q3DD8*J[]O"DJNU#N8#=P!ECNSN
MZX]30 +&\9*O]X[6SN+%ASC=_",,#A4P!@<D4_K3'9<J)&W$] V3D=^ ">W'
M!Y&>@-6U6W*!PJ[1@9(QCH.?3J/ZT 5V)*.IR20-IP.N>02   !R.^>AJ./8
M02HP#U7LI/5%]% P0  ,D\5-+LS^ZQC:<[>F>V/]KKGVQ4ZK;L<*$)QG ':@
M"!6E8@(Y)(+#E0,*P4Y.W .3D#N.?:K#!EB7)(8&,$C'4LH(Z=.>/H.O=ENC
M+N9PP9B3STQGCCUP!^'>I9?N?\"C_P#1BT <OH6YM3U=V[RH,]SM,@_D*ZRN
M1T!B=2U=>,"92/7):7-==3;3>BMY %%%%( HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH ***K(Q,Y7>2HW8&>#@ C^9_+V- %FBBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ IH1 Q8*-Q.2><YY_QIU% !1110 4444 %%%% !1110 4444 %%
M%02>9YB[=^W"YQT^\=V??;C'OB@">BBB@ IK(K@!AD#D=?Z4ZB@"*1&"!8L@
M@C ! XSD\D'_ "?85#MN?4_]])_\34B^;YS9SL_3&!C;[Y^]4] #(PP0!_O<
MYYSW/?W'7MZ =*?110 4444 %%%% !46V.([R2,Y7))(R3D_3.,YJ6HY%5E
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!%'$(R2"3G.<@>
MI/8#IG'T SDC-2T44 %%)D9QS^1_GC%+0 44F0.I _&ER#T.: "BBB@"&9V0
M#8,DG'0GMP,#N3TJ4<@$\$@9_P GFEHH 9(@D7:20,@\8[=N<\'H?;ICK0H5
M L>X9' !(!..>GT.3Q[T2/Y:[L9Y  ]R<#]:J1L&F#8(+,3C!_N$?3J?UYH
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M#T%=?0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M3UI:* &NI9&4$ D8R>W/7ZCM[TV*/RUQG)SDGIG]3_\ 7J2B@ HHHH ****
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MP2/YTS &!N1QTXSD$=R#V]QW(JQ+#\A6)1\P((S[<$9[YQWX X&:KQB(%BZ
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHJ&02F1=APGR[N1GAB3U]1BIJ "F/(L>-V>3@ #)XZT^FLBN,, 0#GGUH 9&
MZ.2%4@XR<KC/-2TQ8T0Y48R,'&>?_P!7^-/H **** #KUI  .@ ^@Q_*EHH
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MMR.6^Z&XY[GGCWQ4+)(V05;/&"  .#NSE<@DGN!SP!CBIXT67YY5#NGRY*8
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M1110 4444 %,\Q-Q3<-PQQGG)[?7C^G6GU&8E+^9\V[(/7C(&.GTH DHHHH
M**** "BBB@ HHHH **** "BBB@ HHHH ***3(]1^?IU_*@!:AG_U? )^9>@)
MZ'/;V%3=>E)D9QD9],C/Y4 9_1E8<.IP-P.!N^4[AP<8/MZ@U(TQ=2I"@.H
MR<-@CGCGGGIDXXY/6FN-URR\A7VC<.@VJ<C/3)/R_7CK4WV=.06);C!."5^G
MID#]..E $2.T08* 06+9.3@GKP,9''J,>_=&9G8.K9)0+N1"0,DDC!!YZ=>Q
MQ4WV8?WW_,5-'&(P0"3DYR>O0#^E %-(U;<&)3@;<C"CD?=#8.<?+QQ@Y/4B
MK]5;G'R=_E?MG!.W'TZ'!]C5J@ J.7[G_ D_]#6DE<QJ"H!)8#G/3!/;GM36
M.^$$CDF/(]]Z@_3^E '-Z P-_JX(.1.N">AYD)(YY'.,XZ@BNE,(,@ER0<@D
M=0<+M'?C@G\^G%<MH+$ZIJPQPD@&<]R\C>G'7U['\.OH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "J C(N_,4C#LWFID9PJ.B-C(^7L<@DD@C !%7Z
MA$*B4RY^8\$[4!*\X4L%W%1DX!)_08 )J*** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BJ_FMYNS"@;L9(8<8S],GH/4]J
ML4 %%%% !4,LC(5VKN!#9&#U&W'(!]_;\JFHH **** "BBB@ HHHH **** "
MBBB@ JF;9B3\Z\DG[N3R<]2<_K5RB@! , #T ''3BJO'VHY"=, [?F)50<Y]
ML_@!^=NH1*#*8PO*YRQX[#IQSUQU_G0!+E?4?F.O_P"NJ\BA7,VY<+@E<9)(
M]R>,DXR.E02_ZZ0<X&P@ D<L.?S/X4]$X$N?E4G*\DD X&,M@Y//0$=LGB@"
M3[4H'SJ5DX^0GGG&.<8Y!R.*EC?S 3C;@XQG/8'M]:12LH)V@'H"PR<=CR ?
M7C/;K4(<6Y\M\MN.X,HX QM&1Z_+ZXYX- %NBJS7* =&)]",9Y_'^56: "HY
M>$X_O)_Z,6AY BA@"V3C"@DXP><>G&/J::[!HQCJ3&< YQET)&1UQD?F#CF@
M#FM!Q]OU7IGS_P ?O25U=<CH)!U+50'4GS 2H!RF9)."<CD@>G&>F1SUU !1
M2$@=?Y&@D#J0/_UXH 6HI91%MR,[LX&0.@R:E) Y-! /4 _6@"*67RP#M+9)
MZ''09J13E0<8R <'J,C.#]*3*L>Q(!ZCL<9Z_A0&4  $  <?0#^@_( ^AH =
M12 @C/:EH **0D#@]^!U_P ]Z,CGVZ_EGKTH 6BD) &>U&X8SGCU_P _7\.]
M "T4F1D#/)Y%+0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1129'//3K[4 +11UHH ***"< G
MT&: "BHHY1)G (QCK[Y]O;_]52$@8SWZ4 +12%@.I_R>GY_X^AH!!Z&@!:**
M* "BBB@ HHHH ,@=3BBHI8S(% .,'GKT/T(Z>GZCN]5VJJ]< #/J>Y[]3S0
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MO ?QC^)GPETG]K#4/!GA&R^&_BOQQ^R]X1\51>-_B7\,?"NM?#30='U9]?\
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M #6;:I;!.!D@>G<_@.?PH1@Z*X! 89 /7%.(!!!&0>"#T(]#2      #@ #
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M?8D?T_QI)5+(P7DG;C/LP/\ 2B)2J!6X(+9QTY8GCZ@Y_GS0!)1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MF?NI^Q.W'4$<-GUZ@XJ.%U7?N8+E@0">?NBFPNB,XR0I";2_!."V>>G&1TH
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M]*LF2?LN?]U<K^1(;/KV_'BI!'R^Z3<K  +\HVC.<!@%8CZY^O:ILCU'YB@
M7[H/J >!CJ/2D<@#GOP/J>E.J.7[G_ H_P#T8M ',: "+[4SGY3(F!SD8#@Y
M/?/)]174EU#!2P#'@#OV_P 1_G-<GH.3J.K#>V!.I"]OO29[]^>WK]:Z@P@R
M"7.#D$C&0< J._'!/Y]\4 34444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !112,P49)P.G0G^6: %HJM%+(2PE4#,K+%LR<IP0S9Z8R 2/RX)
MJS0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% #695QN(&3@9[G_ #WZ"G5')&)-N21C/09R#C(_0<TD
MC-&@V ''R\YX[ \#D#ODCZT 2T57AE:0X88(7.<8!/'KT(SC'/?GCF?(Z9&?
M3-  S!1EC@#&2?<X_F: P894@CU'TS_6FR*&0J3MSCGTP01U]2,41J%4*#N
MSS]3D]/?/TZ4 /HHHH **,@]"#10!')&L@ ;/&<8..M(Y9$41@DC:HXSQP.>
M14I('4@?6HI7*(&4!N1W/0GM@'J,\_X\ #E8B,-(0N 2Q/ &.N>> !3P00""
M"",@CD$'H0>X-1X$T6&& ZX(Z_Y]?\YIRJ$4*.BC H 23_5N ,DJP ^H(J&&
M/*MD,A)[?*2I4?7C)/T/O5FFN2$8CJ%8CZ@$B@"I)#M8!$9EVG)(W8.> /3
MSD>X_! BG/G;D'&W)VY(SN]>F5_/ZU8BEW@[AM(..3UX[9QSUSQ2RQB3 W;2
M,X[Y!QD8_+GM^- %6./!S-E /ND,4#9+#!VD!E*XX?('/05:(CE 7.<'=\I'
M49&<C(/7\Z214<+EPNTYSD8/'/7(Z=\''I2QH$!PV0W)Z'GIG( [4 -C$BNR
M<>4B@)_>)(&,GH<#=GISBIZK/.RLRA 0IQDG'8'^M3HQ9%8C&1G H =129&<
M9&?3/-+0 4444 %%%% !4%P,Q]&)W#:5&2#@Y/\ WSN'<<]*42Y_A_(\=O4
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M-WX'./I5<9",<MB,#(W-G^(8'.."OX]J -&BLV-6EW*6R& VAB2%+)YBG'?
M('.<D9Z'%6FFV C83M8)P0.H&#].10!8HJLUU$I&2<'." >V,_S%0),&=)!G
M9)(R@9/&% )P>.K9X /!]: -"BH!.&<*%."<!LCW[=>QJ5VV(SXSM!..F<4
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(4 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>ex10-69_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex10-69_002.jpg
M_]C_X  02D9)1@ ! 0$       #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" 24 X0# 2(  A$! Q$!_\0
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MX6M3H>I:S-HLOPIM_@;X?BU77M%AL8F\2VPU^P@T2"/5KE9KI-.4WF/^R?\
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MGQ7X<\>>)?V@_B#\.&\?Q7EU8ZIJ,OB7X9:QX5U62/48=1\/W5OJ+P( =O\
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M%^U/^T7J]OJ'@&!].^)%K^T=:?M46MIX4@TR]UZ]MO#EWX1D_:-L[K^VYSK
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M&Y\-_P#"B[:TAMVM;[^VO^$ENKB^N8)K%'G /R,\/?\ !:>?Q9^SAXF_:/\
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MZ** "BBB@ J&9)&V[&(QNSABO7&.G7H:FHH 0#Y0".P!'7MR/?\ K0JJH"J
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M@ 98;CD[\8P3@8!YX.:;G%[IM>:7X:^GX@0O:;PZ6\DT.X!F>,GEB6'S%L]
M!@8."2<=<R6VEPP$G:23\Q;S'W&7@&3.[AF&X$YZ$J/E.*F5Y%)P'YP#N3/3
M/ICU]_;'.;$+R-]\8X.?E*X/R\<^Y(]\5G?M>W8"1HU=0K#(&,=N@P.E0R1
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MD <8H L4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MQR!M7&?P-1QR&,$A4)8 L54IDC/) +=<GJ>/7'1Z67?KIY]_0"Q%([DAE"C
M(X89_/C\J<D01BP8G((P<<;B">@'<5+12 9(@D7:20,@\8[?6FMF*(;?F*[0
M,@G(+@'@8Z GIZ4LKF-=P&>0,<]_H#_GWI4;<JDX!(S@'IS_ )S[T *C%D5B
M,$CD<C'/3GFA_N-_NM_(TZFO]QO]UOY&@"&BBB@!\LHB )&<DCJ!T&>]2 Y
M/3(!H(!Z@'Z@'^=53#*23O'))^\_&>W!'2@"W59Y/,8P@8). V01E<-R!@X(
M&/K5A00J@G)"@$^I P34<L>]<+A6W*=W0X!!/(&>0,4 .C4H@4G)&>1QU)/]
M:CDG$;;=N> <[@.OUIAAD)!#@83:>6Y;<I)X]0"/7FC<(_D=?,8<EN#P2<#+
M<\4 *MRA)4C:<9&6!SR1U'3D8I/M0_N?^/+43,AD5P@& !M^4$_>S[<Y'Y?2
MI?-C'_++]$_QH ADC>+:%=1NSDX(SMQUY]_YU9BE+D*5P0N=V00<8!(^N<T1
MQ%=V\A\XQG)QC.3\V<9R.GI5=4+L54@$%SGD<!L8&WGN/;B@"_3)/N'ZK_Z$
M*CBC=&)9@1M(QECSD'/S$^A_.I)/N'WP/S('Z4 <KX<&VZU0=<WCMGZ*!T_$
M].U=;7(Z I^TZFV>$NHU/7))\P$CVX&<GG ST!KKJJ33;:\OR ****D HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ I&. 3Z G\A2TU@65E'!*D ^A(Q0 Q)-^_P"7
M&PXZYSP#GI[TL4GF*&QMR <9SUS_ (5!]GD_O*/7!<9^N#S^- )M\[\-O' 7
M@#9U^\>^X<#TH 3[*?[R_DW_ ,54L<)C;.X'Y2H !'4@YZG/2IZ* (4B*NSY
M&&8MCGONX]_O?I4U%,D4LA53@G&#R.A!/3GD#'% #6E"R"/;UQSD=\]OP_SQ
M3V&Y67IN4C/U&*;''M4;L,P)^;J<=AD\\4]@2K '!*D ^A(P#0!0>+80IP2W
M0C<,<@<\GUS5N*,Q[LD'(4# QC;GW/K4/D29!+*<$'DL>ASCG..E6Z "HY)/
M+4-C.3CJ!V)ZGZ4DJ,^W:P7!.>6&?;BH(69G*,0RJK8!YY5E )S[9Y]Z )VE
M"QK)C.X*<9 ^\,]3Z5 CAYP^ ,KM R"1@,V>/7./K]:L2,J)DKE00,<8'8=>
M.*C21&90(]I.<'"^A/;GD T .,P$GE[>X&<CN >G7O4C_<;_ '6_D:7:N<X&
M?7 S^?6D?[C?[K?R- $-%%% %BBBB@",2JSE!NR"PY''RG!Y^M-:=%8J0V0<
M'"Y%0M','+(,?.Y!#+DJVXC@GN=OO].:4F $B09?)W<,>YQR..F.E #@S!FF
M!)B;&02<J%&T[5S@<@D],YSUI&4S$.@P-KJ=W!+<;3CG.TY&3R.U+YT&W9SM
M],'')S_.HQ(%?Y"1%A<  X!R2YQC=C'X9SB@"5(@$?>BEB21P&.-H  ) /4'
M\ZJ!AED)!*#YP#DC.>#TP3@XZ_6KGVB(\9//'0]^*BN%5<'&$(;=L&') SD$
M\<#(YY].F" 1;FR09)1@D?*Q)SA2>G8 K@X[FFLVPEEWA<8^7(;DH.@]6!R?
M4^_(3\Q7*[R.55@6R1UV]>0!]  >F30.<^_48X3'&P9ZYP&XR,C!ZXHL^S^X
M"=8[@\B0KD9^9BW![8QP??)QR.]3.)!"0-KR!<C=PK,#GG@\?@?0YH29-J[F
MP=JY)X!.!G\?_KT]FRA*D<XP2"0<D#M@X/J/K0!R7AHL9M55N7^V1LV#D#;O
MW8)Y/+<<=,GCI785R/AK/VK5\D$_:.=H(')(Z'Z'_)KKJ "BBB@ HIB2))G:
M2<8SD$=<XZ_0T^@ HHHH **8^[8VW.['&,=<^_'U]JA43AEW$[<C/S*>/H #
MC.,X[4-I;@6:**:S!<9SSGH,],?XT)WU0#J*C,J#KN'U!I5D5C@9SUZ'^E)M
M)7;LEU ?11WQ]?IQC_'^=(S!1DYQP. 3U.!THNDK]-[^7]>0"T4P2*2!ALGU
M!^M/H33U3O\ ?^J073VU"BBBF 445%YR>_Y4#LWLKDM% .0#ZC-% @HIN\;M
MO.<XZ'&2 >OXBG Y]?Q^I']/Q!% DT]G>VGS04444#"BBB@ HHH)QZ]<<?U]
MJ "BF[ANV\Y^AQZXS]!FG4"33O9IVT?J%%%% PHHJ)9D89!;&,\JP)^@(S_D
M^AI.25KNUW9;ZOMHG^-A76UULW\EN_1=>Q+10#D9]>:B\Y/FX?Y25.489(S]
MW(&X<<%<@]LY%/K;KKIZ;CZ7Z::^NWW]"6BH1.A!/SX'7*,#QUX(!X[\<4@N
M(B< MGW1@!WZD8[CCKR..:-[6ZJZWU7?\5V?EV=G9NSLMWT7J[Z$]%1><F[:
M-Q.,\*3WQZ>O%#31J<$D].@)^]G'3/7!_*IYXZ^\M-7Z+1O;5:K57%V6EV[+
M5;ZZ;[Z/1V>FQ+135=7SM.<=?;/^3^1I2P7J<9Z>_P"5-M+5]';KO>UMK[^7
M^8DTTFFFGLTTT]^J;71]>C%HJO)=0Q &0LH+;02CG)Y/8'CCKT]^10MU _W'
MW<9P%))]<#&3COQV-%URQG]B7PRL^5]-&HOJGO;U!-2;2U<?BLI:>KY>7_R9
M^=BQ14*3QO\ =W=<?,CKS@GHP!QQUZ9XZT_>N[;R2<= <<C/\N3Z4*2;LFKV
MO;K:]KV:3M?38?5KJM&NVE]?DTQ]%%%, HHIJL&&1G'T]/3U_P :&[*[V0#J
M*A$\9SRW&<@JP/!QW'KQ[]J43(0" ^#C'R-SGICCG/J*2:>SZM;/>*O):I;)
MW?2VS8+75:KNK-?>FU^)+12*P8!AG!]00?3D'D4M"::NM4P"BBBF 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% #7#%&"G#$
M<'.,?CVID2NJD.23N)&6+<8'&3COGBFRRJH902'QE>#R>HP<$<]/THC9VC?D
ME@6"DXSG:"/;J: )Z:RJWWE#8SC(!QGKC/3I4"R&,'SB02?E'#< <_=&.I[_
M (>M3)(DF=I)QC.01USCK]#0 DDBQ@%@3DX&!GDD#^M2 Y /J,TUD5\;E#8.
M1GUJ.8E57:2OS <8Z;6..<^@H FHJ&*56"KDE]HSD$<@#=U]\_TXJ:@")I55
MMF&+<<*,YSZ<CW_(TNX2(^P\X9>X*MCH?0C(SCI]:B>-GE!*YC.T-\V.!G\>
MI'3^IP\R10X0_+QD  GCD?TH 8K&+B4LQ8_+SOP.!U.,9)I\R2-M\MBN-V<,
M5ZXQTZXP:!Y4WS8W%>.001WJ:@ J)C'%\VW!)QE5&3G+'/KTS4M1DQ2?(2K$
M<[<\C'&<=>,X_&@!WRNH) *D!@",]1QD'ZU54 3X P [8 Z#]V3P.W)J>0,$
M CR"" ,$# 'J3VQ^N*(XP,.R_O.<DGG/(/0XQC@>U $M-?[C?[K?R-.IK_<;
M_=;^1H AHHHH L5'*9 H\O.=W/ /&#V)'?'^>#)5=)'W$2?(N#@LNP$Y&!DG
M!)&3CV]J )ESM7=][:-WUQSTXZ^E5I1%EBO,N0<9/8@MU('W<YS^%6BR@;BP
M /0D@ YZ<].:SYC^].T!D8!F<RQ@*W0X&=[# 'RC .2,XS@ 5=K%03\I8ANW
M #9_44DP1,&,&0<?NP6SUP6SGZ]#^'K 9MK/@\ !T?:JIM ",""^X_,2 V,'
M''7(D60L3NY;.T*!@D#GA2<DY;''MQ3::2>Z?X/7\/,!VWYBRF,J#E<L0R@
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MX;S_ #'+LYXV6:X^I++Z&3<*8O#YC2=&O4E*I*,83_%?$'Q"XEX4XAPF!P>
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M>9!BZ5.GF[PT,NQF6TOK59UL;'$X"C5Y\?"A+#XF$/VM^V6W),H 4-D,KJ>
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M$/A+P5K-S-+ NE^*/$NF:?+#97-G*C1:DEC#J!TMTDBU$V\UO<K'[?\ &O\
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M12 AAE2"/4$$?F*6@ HII95X9E![ D GZ#J?PIU !1110 UF5!EC@=,TJL&
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M%  / )J1+_\ X+2)N9]'_P"">\>8\11!_C8P9P"5'F?VA'E=P12P1S@LP&
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M"XCSK%U88'P\]K4S7,\WP&'QN*QU3%5%"LJD,#A,NPM1X./?EV$R/+(9=&'
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MU;6;N]OY4N)OJAOAU_P613/_ !D=^Q:Z[E50WPT\9($0LF]VV^'6#&-?,"Q
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M'T_6/V2_A%JUBQ+A@\MG>VD]L[HJNB%E*D,VY6!*FQ9?L@_\%*=*LX;'2?\
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M%5\P_<9@GB15$*'EH@A\P @E<DTYOV%OVU3EV_X*L_&DG*MM3X,^#8UW\J,
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M7/S$_OI_WT/7'KZ\?7CK4<LNQ0RE6YYYR ,$YXY[8STK\E!_P3U_:,F#;/\
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M,4(## )"\H>6P#D<],K]UEW+]T*2H16SC_:#8&<=P3ZT.SMIJE;RLO+^O/9
M50VZ882+.SJ5W-P6Y))(9AD\$%?4$<TZ7:"-\BID'&XL2V#V;#,G/.4*E/NQ
M%5+59D9'.XJ40 *2%4-O)X''S8P03T'KD9Q!'_KY!P_. A^F206^4 $G()'M
M6B:44[:JR_%_*Z]/S 8RQ(I D(W?N]Q=W92_ 90YVY'/W@>0!C&<QO&CJBR
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M*** #_/^?SJG(WES@D$AR  N3U4*=W]WUSR3P!UXN4FU<D[5R>IP,GZG\!0
MU&#@G&,$KUS]TFG_ -:  .@ ^G%% "-R#]#_ "JA$DK-UV*$*NK?-OWC (.3
MC;M/&.=W&.^A1@#H * (9(V*JL;!!T;())7&, @C!]3UP2,C)IDXVPKD_<QW
MQNPI&,^YYJS4<KJBY9=P)QC /8GOQVH K21R+$K*R94@_,&(()(((S_M#!SQ
MCG(XIH4LH/RC+$D8X. 4]CURPZ<FI#E/WK8=&Y"G.5#<JH7[I XR3R .,\8L
M1LKH&"X!S@8'8E>W';\JI2:5EH[[Z;=K?J9RI\TN:ZM9*UNJZ_=H9SQ*95)"
MAPNT84CD\@CO@'.>3SG/7 F>,DLV1@G=CG.  ,?+@]OKZ'(!J[@'D@9]<"C
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M-3Q5?/<HA0G7K5L1&/[X27)D5T!F5E*]'E#D<<D1O&Z $X;D <;A@@ERW1W
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MD8'^N0JS!\\1B-L!<@_?)P1P.34OS$A3(2K$*H"X*MD?.R$ MR0<YVM@X).
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M481C"*6B2C&$81BDDDE&,4DDDDD@HHHH&%%%% !1110 4444 %%%% !1110
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M^I _K2 Y'P^[B^U53S^^09(P2#)(.V!P,=O<UV%<AX>N!+?ZLH'SQRHCKG(
M9Y&R#QVY_,<UUK,$4L>@&3_G\#^1IN]]=P%R!P2,GH,]:6JN5EQ,I'[K=A3C
MYB%)QNY('S#L<=<&OSL^,7_!6/\ 87^ 7Q$U/X4_%OXI^-O"?CK2_&5E\/#I
MO_#.'[4&NZ9J_C?4]-;6--\,>$O%'ACX,ZWX5\<:QJ.F0WEW867@_6];FNTL
M-02%6DT[45M$!^CM5_LXY^=N23T7N<GM7D_P)^.OPV_:1^&NA_%WX1ZMJ^N>
M ?$<^L6VCZIKO@OQU\/M3N+C0-8OM!U9)O"GQ'\->$?%UC'!JFG7<-M<:CH-
MG!J=O''J.FM=:;=6MU-[!0!!$[;C%@;4! /.3M(49[<CGBIZ** "BFN2JL0,
MD=!ZGTXYR>U(C%ERPVG)R.>@[\@'_P"M@]Z 'T5X!^TC^TY\&_V2_APWQ6^.
M7B6_\-^#W\2^%/!6F+H7A'QG\0?%GB;QKXYUB/0/!_@[P=X"^'GA_P 4^-O&
M'BGQ)K$\-EI.A^&]!U/4+EO/E\A(8)95]=\/>([;Q/H&C>)-,MM1BTW7M(TS
M7-/35](U?0-52PU>PM]1LTU/0M<L=/UG1-22WN8UO]'U>QL]4TRZ$MEJ-K;7
M<,T* '1445Y]X%^*7@+XDW_Q!TSP1XJT7Q/>?"OQW>_##X@PZ-<271\)_$+3
M/#_AKQ3J?A'5I#%'%'K%AH/C#PWJ-S!$\RPQ:K!%(Z74=S;P 'H-%%% !144
MT@BB>0E0(U+G<6 PO+?=5V)VYP%1F)P ,D5^57AG_@M7_P $\/%>E>$/$]G\
M4_B=HOP^\<ZCI&E^'?C%XW_93_:Q\ _ >YN/$&M1^'-#NKSX[^,?@GHOP@TC
M1M4U^5-&M/$>K>-;+PXVHG[-)J\<H", ?JU14,+R2*S21F([V"J3DE!]UCC@
M$CD@$XZ'# J)J "BO)O$_P ;?AWX1^+OPP^!6M:V]M\4/C'X5^*/C;X>^'%T
MS5KA=<\-?!J;P!;_ !%U!M5M;&;2--;0I?B?X*5+75;ZRN-4.KD:8ET;.\\C
MU@'(&>#@9'H<=."1^IH 6DR,XR,^F>:Q/$OB+1O"/A_6O%/B+4K/1O#_ (<T
MG4]>U[6-1F^SZ?I.BZ+8W&IZMJ=]/M80VEAI]I<75Q*5(CAB>0@A2*Q_ WC3
MPO\ $?P5X-^)G@;6+;Q'X,^(7A?P]XT\'Z[9I<166N>%_%FD6>N^']9M$NX+
M:]2UU/2;ZTOK=+FU@NEBG1;BWAE\Q$ .THKBOAQX]T?XH>!?"_Q!\/Z=XLTG
M1?%NDV^LZ;IOCKP5XM^'/C"SM;G=Y<'B'P-X[T;P]XP\,:DNT^=I7B'1--U&
M %3+;*KJ6[6@ HHHH **\Y\2_%GX?^$OB!\-_A7KWB?3].^(?Q=B\97/PY\*
MSK>/J/BFT^'FF:?K/C:[LOL]K-;PVOAO3=5TR?4+F_GM(0^HV%K \UW=P0/?
M^'WCO3?B1X9MO%FC:5XMT;3+O4/$.FPV/CGP5XL^'OB5)_#7B35_"]]-=^%/
M&VCZ#XAL["]OM&N;_P /ZC<:;'9>(_#UUI7B71)[[0M7TS4+L [>BBB@ HKQ
M^/XZ?#B3X]W/[-*ZW-_PM^U^$=I\<I?#9T;7!;_\*TOO&-[X"MM>3Q"VG#PW
M).WBK3KS3I-$CU9M<@CCBOYM/33[JVN9=FT^+'@/4/BQXA^"%CXAMKGXG^$O
M /@WXH^)?"J6NI?:='\!?$+Q%XV\)^"]?NK\V0T@1^(?$/PW\=:=864>H/J)
M;PU?3RV<=L8IG /1Z**S=:U:RT#1]6UW4I'BT[1=,O\ 5M0ECBDGDCLM-M9;
MRZDC@A5I9G2"&1EBB5I)& 1%+, 0#2HKR_X)?%_P5^T%\'OA9\=OAM=WVH?#
MKXR_#SP;\4O 6HZGI5_H>HZAX.\>>'[#Q/X;O;[1M4@M]0TNZNM'U*SGFL;R
M*.YMGD,4J*RG/J% !17!0>/[6?XDW/PS_P"$;\;I?6W@JW\<GQ:?"&MCX;26
MESX@O?#J>&XOB ;8>')?'4,MBVJWG@Q+LZY::!<V.M36RV-W#*W>T %%</\
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M7.G27\$ O8)8I;82K(H(!Z#17B=U\>?A_?Z1\5)_AYXI\"_%/Q5\(M$UZ_\
M%7@7P=\2? $FNZ9K>CZ7J&H6OACQ'=7_ (BM-(\"W^K7&G2:=%?>.+W0-*TZ
M61KK5KRSL;2[N(JUK^T/\,].\)>"/$7Q*\8^ /A%JOC+3O 9/A3QU\3_ (<V
M^H:3XJ^(.C+JVB>!_P"U]-\37_ASQ!K]TT6I66D2>%M6UG2_%+:1?7WAB^U;
M3!'>. >ZT5\X67[1^B7O[6'BO]DQ/#.M)XI\)?L[> ?VC+OQ:\U@/#-SH'Q
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M?$F@W,5V^B>+/#.O:'=:;XD\):=)<:>]X ?KLI+*K'@E02/0D9IU?DS\5?\
M@K9\*OAG_P $S/#G_!2:'X7_ ! \3:5XNT;P;!X=_9^M&LK'XM7GQ1\1>,AX
M"\3?!Z:.2.ZL[;QC\-/$>G>,H?'"F"2+3+7P'XGNEC<63(,+4?\ @J#\4_%_
MQ%^!?PK_ &:OV)_%'QT\8_&3]A[X4_MU7]KJOQV^&7PAL_ OP_\ BSX@G\,Z
M1X5O[WQ9:7R:[XGTO58D74VTM%LOL\AEMWDD5()0#]?C$#()-QR,<<8XR/KW
M/YU+7QK^Q[^UZG[5?A_XI0ZU\)?&7P(^+GP"^+NI? SXZ_!SQWJWA7Q#JG@G
MXA6/A+P=\0+(Z)XN\$:MK?A3QMX1\1^!OB!X2\3^'/$^DWEO]KL]3>UOM,TW
M4;2ZM(OLD');V./T!_K0 M%%% !1110 4444 %-?[C?[K?R-.IK_ '&_W6_D
M: (:*** +%5FN N[Y/NHS]<9VA6QT[[NM3.ZIC<<9Z54D=9!@1X()RQ&.,8X
M (W9Z8;Y<<GD 4 1NTA9MC-]YC@Q2* N3T9E"MCC&#SU'%1F5 2OF(Y!SM!P
M2_\ $<%!CY>#^\YQDY^[3QD@A3T#,Q;[Q(&">,X))SMZ C QCEC(&D63<1&K
M\QA5&<?+@8ZC(SU!/J,XJER]7WVOY:/3U2_'H I/FHPVG&.1U)QM(QC(ZL#G
MG !XJI]I"JZR%D?<H4JN\C?C:2?X0ISR>@P1C.!;=UB0OA@NX@;0-X#-C.,D
M8R0A'/J>!Q')$Q(;>PW *RC8&SN *LRJP_B49&<8.,X&;327]WIO\UMKO^@
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MX8^%?A1^T3XZ_9>N/CE\9[[XN^/O!GQ7U+Q#\2OAMXK\!^._$UK^SIX'\/\
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MQS\0/'&M^"O''QE^Q7AUB'0[SP_IFI2^#-/U32O#.DW5K?7-V>%OVX-3\5?
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MPQ87FK:A<ZKJUY8^'_#NG:=H]I<ZEJ-Y<WU_-!9)+>W<TL]S)(TCY /Y7_\
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M&=(M='\-:;-=RQ:EXBOK'PYHEG%90SSK;6VL:Y>PZ99R2^7;ZGJ4JMY%Y+&
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M+SP9J.E:5X]\2)^U-J,!_;ONM-U?P/XI^&5KXA.J-^P[;_L.L][IEGKNAQ?
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M?!3Q_P"$/&PT&]U-/V--&_8\_P"$!T+3;-=?3X0Z-?Z(GA"X6T^)]LBGB/\
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MSXNZC^U=H>I_!R;4?#VL>"(O&=WX_P#&GQ9T#3_$>G^/O"VD>(=7BE\._O\
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MYO\ 6;SQ-X*M+.VMKE!KNL_VA8OI%Q>"WM+:XLS<-?65Q%:SJ ?D;\;?B?\
MM?? WXA?%C]B/P-^W!\8?%45I\=O^"3<?@K]H_QSH?P0\3_M!?#/PS^W#\?/
MB=\&_C-\'_%$]C\+=)^''BJ]LO#'PJ;XE?#?5-=^&UMXAT2'QR+;5[S5].TG
M19KF3XZ^-OVSKK]JKQY^QG\+_&7_  4X^*?A']D?X!_L[^([;X@_LO\ C?\
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M'BB97I;5K7IZ=]-/)?CV#^?+X.0>!/VD_BG_ ,$5O%OA7PUKO[+S^&/VKO\
M@I[X'\3_  ^_95^,_B2P_9U\0_$_X0Q?&O6/BKX\^&FHIIVDCQW\+/C/\3?"
M/B76+.]N-&T^ZU#P+XX\2^$;V*6S^V7$G'_%7]H?XX)K-E^V%\'/B!_P4&U3
MP'K7[?\ \,?A7X8_:-^+_P"U)\"?AA^R/XT\*:G^W)X:_9[\<? _X4?L$:#X
MQU[7O&G@_1_"</C3P;H_B3QC\*O!GQ<U\:-JOQ7O_'"36"1Q_P!*OC#]D_\
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M9V>E:+:&&*RTNQ2VM;>TM8[:WCA6.'8 ?R__ +#'BWQQX>^#/_!$W]IKPO\
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MG^/7BNV_9?\ @M\++WXFZSK/_!3[5_\ @F3^S!^RS<^/]*\3>-]*^)^BS_"
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MW#&-IQQUZX_SS0!/37^XW^ZW\C3J:_W&_P!UOY&@"&BBB@!FZY]#_P!\I_\
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MROX!]WIQU4ANG3)YZTUX55?W:DG/ )+#&<GACCZ9I[7-NIPT\*G('S2(.22
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ME>"20&.<\\L0> !TR*MT4 ,>-7(+9R!@8)''X&A(U3.W/.,Y)/3..OU-/HH
M8Z*^-V>.1@D?RI2BE0I&5 Q@\@@ K@^O![YYYZ\TZB@"G'"%DQY2K&-P7"J,
M 9"\@YY'J.OYTK+(LC-&I'0 @*1MQG&"1_$6.>OX5;HH CC+E?WGWLGL!QVZ
M9J2BB@""5Y5(V(6&,D\8'XDYZ>WTS3$'G9\P[MH&W'R\/G.<=<[1UJT1D$>H
MQ4:1K'G;GG&<G/3.,?F: )*A01>8VTY?YMPR>,L-W!X'S8Z5-55L*Q:(EI"S
M!E^]@$DM\O&/F '6@":4N%_=_>R.P/'?KBG)N*+O^]CG@#G/MQ0I)52PP2H)
M&,8)'(QVY[4;TW;=PW>F>>.30 ZD) !)X !)/L.M+2$!@5/0@@_0C% %:2;+
M#8P*X^?CIR >2,C@G\JDB$0W>6<],\DXZXZ_C5>54C95#$!AD[F&<;@.,^V[
MI_/%*\B0@F)P2W7<=WW02,<CN<?B,4 7::Z*X ;. <\$CG!'4>Q-*#D#G)P,
MU5:642,BX.,GA<GC9[_[7Z4 6@ H '0  ?0<"EIJDE5+#!*@D8Q@D<C';GM3
MJ "FO]QO]UOY&G4U_N-_NM_(T 0T444 6*@N/NK_ +__ +(]3U2DE+\$ ;6S
MD$G.&V'L/[V1]* (]P]<#U/ _,\5&R-(K#>/+)SMC_UH)X)R&YXZC[N,\$]9
MUE+(B%< J!D$Y.%X'*XYZ$>],,;1;U&PQE@<[AYF 1@%0H''?D87).3G(!$7
M"D1F.;("KYK(0" O\+,[;V &".,<CJ,4JQEFWJS8^4-N<YV@_,I3[H&,X.,G
M.2?2-Y2C,HCDDQ@KM("KG!8@DX. 6)R,=J220!<\%&Z,)$! ('+8)+8/6, C
M'&3D8U2?*K7U7JMMTO+^K@3 YPP.&9!G'.,[UR,9QC.1GV!H154GYMS-C)XR
M<?3Z_K5-Y-LA2-\;0&9P!DJ2=RXX'3DG)QQUJ&1V*>8GR$*?+<9)8#[PQGCD
MXSSD9J_Z_/\ S ^;/VJ-&_:M\0^$/"]M^R3XU^%O@/QO#XPB?Q5JOQ4TF]UG
M2[OP6VF7T4]CH]M::7JY76#K<FCW:R2V@22SM;JV$T1N&=?B?]@GXS?MF_%[
MXV_&G3_BW\3/A!\2_@C\$KG4?A?J/BCX9^!DT#2/$WQO@;P]J6HZ1X3UVX6W
MO]3TSP)92ZGI_BBZ>QM])DU6\TZWL;G4PEQ-;?=/[5'BCQIX%_9U^-'BKX>:
M!KGB/Q]I/PV\6-X*T3PYIFI>(-?O?%%YIYT[1FTG2-+M[C4KRYL[R[CU#R[2
M%Y%2T:3'R CPW]C/P'/^R]^P?\*-*B\(>)M4\4^'O@Q=?$[Q/X*BL2GCW7_B
M#XFTJ]^(WBKPY/:SVUK--XLU#7M1;PO:VEU;F_@O;:QT^ZA#!57]+RS'8##>
M%^?PQ&2<(8W-<QXAP?#/#M6MD^2OB?#SQU"CG_$.>8C.:V8X;,:>%PN$PN1Y
M'D7M8X?"4*^99S*>(Y:44ORO.<#C*WB7DE;#YQQ5A,!@<DQ/$6>8:EF>:1X:
MQ5/+J_\ 863Y0\LI82M@W7Q>)S'-,YQGLW5JXVCE-%U806%A)=1^UQXL_:]M
M/^%2^!OV3/"GAQ]8^(7BN]L/'WQ>\765GXA\)_!KPE96EJT>KW?AEM>TF]U_
M4=7FNIA81VEOJ]M NF/:W5DD^I65W!Y7^P!^T1\<_B3XX_::^!_Q\U;P+X[\
M7_LV?$#1/";?%KX;Z0V@>%_%Z^(;'5[R71)]&$DMG9:[X8.E(=1-C]F7_B91
MV%Y:)>Z?+=7WB'[6O[7?[2/B3]EGX37WP&_9[_:$\ _$S]HJV\4IK]I%\/O$
M'B7XB_ ;P=X;O$TK5);W3=#TN>TT?Q_XSL;F!_!#ZK)9065I=WFJ1^9>65I+
M'F?L@_&_2?@/^S'\5],^&W[!O[7'A6U^"&G^&_%UYI'C?PF9?B]^TIXP\<:O
M<Z/X@UK2K@Z?;R^*O&L"Z99ZOXAGD5;:STNYL[*W6WM[:.*/ZFEP7F-#PKS&
MECN$.#*N<//H9'D^+P6(X6GQ9EF/PO%<,#FF<YIG=;C"5?#X#%5Z%?@W*,DP
M.&K93F.6U,=Q9B,;A\%2RS/JWRM7C#!XGQ3R^6!XFX@P^4PR9Y[FN&Q&#SNI
MPSC<%C.''BLMRK*,NH<+NE7S"GA<5A^)\WSO%YEAL5@*LLHR+ 4*M7,:^$C^
MPVER?Z3K@(#*'B9@H+MCSVS\JG)&#DKQE<CIFOQN_;/_ &_?C+\(_P!IRYT/
MX0-I&I_!7]FC2_A#K_[5\<OA[2-1NI(_BKXSL;"#28M:U"9+W0;NQ\+7EA=6
M,^D)<,-1U:X%^H&FD#]3O#/C>1O U]\2=4\,^)-(6;P+IOC;4?!4NGW-[XQL
M?M&@IK]UX2ETBQ@>]NO%=F9'T1](LK>:ZFUE&L;9)9GC)_$/X&_L4?M@_M!_
M#'XU_$GQ%\8=.^ 5I^V+XK\8:[\6?@A\3_@#;^(?%^H>'E\0:[;>%[#Q!X@\
M07^B^*/#"Z=9S3+X<M=/L-/FT?2X=+GM8YRL35YGA-EO!^&QO$?$'B#5X>IY
M3E>'P?#E##9\Z^)IRS7B3%U<)F&+P.%REYGC*N:9'PK@N)LUR3$TZ6(RJ.>Q
MRFIB<PHJGRU/7\5,RXFQ-+AW(>"HYV\TS2MBL_Q&)R&&'P^,CE?#^'I8C+Z5
M>IFTL'A:67YKQ#B\GRS-,)5QE+,)975Q\J.&J^TBX_N'\7_VB_A#\"/AC??&
M;XI>--+\+?#>UCT@Q^()%O-1?4;G7RHT33]%TW3(+O4-8U/5=X:RL-,M;JYF
M4NX0013SQ?-=C_P4F_9@\5_"[XO_ !-\$^+]4U:7X)Z!:ZMXS\":QX&^(GAC
MXBZ3<:Y,-/\ "/V_P3J/A8>+8-'\0ZQ/8V@\06NAW^EZ=:W0U&]FBM4W-^8E
M[X0_:2\>_L2?LIZMKWP/^)FN^._V!OVHM&@^(?PAU'2M=L_$_P 4_AU\,9&T
MVQ\1>"=-UJTL/^$\@M?#E]IFFV,L2:K%KSV&NW6DO,TL)/W#\._BMXY_:8\4
M?M/^*?#O[&^J_"#P)XC^!]YX*\+?&7XL>#[GX6?'WXJ>+[S0;G3+?PGJ^BRZ
M:-3?P1I$S7$&GZO=^(XK?3KBUTLPVK27ZOIW9C?#GAK(,GQN,QV+J<08C*.)
M\\P6;YCE/&_"N6Y7EF$R7BS(,NRS+Y8.M3QF99TN*N',XAG>&QN24,35AA*R
MGA:=:&59ZL)Y>'\0>(LZS'!8?#4:>14,RX:R;$X' YGP3Q'F&-S''YKPQG68
M9ICJ>-I5,-@\HEPOG^6QRG%9?G>*P5.GC(3HXNK2>-R:IB_"-'_X*)^(/BW^
MRQ\/_B)+\9?"7[.?Q:MOV@O O@/XLN/@+\2/BMX*-EXSU+QM+X?^%7A=&T'5
M?[0OO$?AS2-&:^^(-C=3:/HVLV5[!?OI-SJ,&G1?JEX=_:8^#OBCQ]\:OAAI
M/BJXB\:?L\6^E7GQ4T;6/#?B'PX= TK5]'FUO3-:L+W6=+L;+Q1H-WIMO-<I
MJOAB?5M.C$36\DZ7)BA?^>RST_XH^,O^"<'[-7P$L_@#^TAI'Q$_9W_:>^$L
MOC.#6_@[XVTR.;3M6\6_%/7[S5/"X@TR2[UC1O"EAJ5A;>,?$,VGP:/X>NKZ
MV-Q?7+217#?7?_!3+X+?'6W^+VF_%;]FCPQKVO:C^TW\(/$'['WQC?PUH^MZ
MD^@6>O:YHFH>%?'&K2:2T]OHEM#I)US2;SQ;J-O!!I]C86ULE_&-2M8S]IQ)
MX;>'V)XDP_#6'QN5<&0Q_%7BSA\FKT,RX=Q&59?#(N*.#,=EL\VS?"UL;FV)
MR'.>%<=QEF/"^'S?'5HX+_A%P&62JK&9E6Q/S65<?<;8'AN7$"P68\78C+N'
M?#?$YOAYY;GM+,,QQ.>Y)Q+2S+#X++<8L!EN7YEE?%2X?H8Z6482,ZV65,76
MQR4:.!ITOHGQ]^V;X=^(<'[%7Q$^!WQ^MOA]\/OCG^T!#X %OXO^ ?C?Q'J'
MQOTJSU:+1M5\'>'YKW08KKX<&\N8-0AL/'VH10:)<-<P75OJDMG:S%^9^&/_
M  4FT'XM_'C]I3X2F^LO!FA^#O#^JP? G77^'_Q+U75M3U'P-X9\;ZU\2_&/
MQ"M[S1(;+0[+1KG1=/\ ^$<\-ZO8Z:_B.VTZZ.C:EK][K8L[#EOVK/@->^ ]
M7_X)4?#;X4>!/$WBGP-\%/VA_ VE:I>^&O#>LZW;^%O#>A67A>S/B?Q??:)8
MSQ:'INHZA9WNK:GKNKBVL&O))I9I8$\QHN<\)WGCCX9_MD_\%'/!>L_!OXT:
MI8_M*^'[/4OAOXY\,?#_ %G6?AM);>#O@IXQFO;G7O'-DUOI>F2ZEJ6J67A;
M1-,M&O=8O/%L[Z3-;P7L2R/X6!X;\.\?PMC,3@<OCF-3_5KB7-^'J>/S3AS"
MYUE^'R_QLR_*,'C<TG&G@GGV98?@[$O,)T\YABJL<HA6PF#HTL#.5>CZN,XD
MX]P7%.787%9C/!8-<49!E6=8O#97GF+RG-O[3\)J^;/"X%<^->49=6XHPN)P
M-*MDWU*-/&5Z.*KUZF)A"%?Z:^#O[;WPU^'/[$OP<^/?[0W[0NA_$>/QM+KF
MBZ=\2_#?PL\1^![[XL^)!XN\266G:=X%^"-IH_\ PEPU*&SL!IQTRUT)+F==
M-FU:ZCMX;IYU]:\%?M]?LN^.OA'\0?CCHWQ1T^S\ _".Z%G\47\2:%XC\+^*
MO VJ3/'%8:)K_@C7=-M?%EIK&L7$L5EH%E%I%S+KU])]CT@7DRE1^(L?[/7Q
M]T?]CG_@FC\3=-\ ?M$Z;J7[.&M_%U?B3X+^&_@NS@_:!\$:9XV\<:M<Z1X]
M\(_#3X@:#K-GJ.JZ7#I-J(X-9\+7>HRZ=K.G:DALXY;O6K#TKP;\#?$WQ$^&
M_P"VS\6?$/[-/[7?QK/Q6T7X6>%K/P_^T9X_\!?"7XP?''3_ (;Z_;ZE_P )
MGX:\$^!?@UH,G@OQ9\,DT^VU7P?=ZH^N?\)BD2:78PB[OM;M[GV,[\+?#J4,
MXS*7$%7GJ>(>9Y*_[!S/@_ 8/"TEXF3X9PV34\MJYQE.2X:IF/#L89U@,QI5
ML+E5%UG2PZH9)"KF6&\;)_$_C^-3*\#4X>C2I0X)RS-(+-<LXCS7%8NKB/#K
M$<15,Q>-I8'&9[B'@>)(TLHQN65Z.)S"4(>WK_6<UE1RZM^MWP'_ &]_V;_V
MC/'%[\,_ ?BGQ)I/Q'MM"_X22+P)\1_A]XU^%_BO5?#JK$SZ]X>TSQQHNBR^
M(=-2.:.6:72_M4MM;R1W$T*VKB<_:MKT?YF;E2"S$\$' '  ^@S]>:_GM_8;
ML_VA?^&JO USX.M/VR]=_9\L/!GB+3_B1J'[>OPVT;1O%_@HIIFI'PQX4^%O
MCJ]>;Q9?S6_B&33H+G2-,M]%\/C1/[8:ZTV<3VES#_0E:EB9<Y'*8RI!(QU.
M0.OMT[\U^/\ BGPGDG!G%4,IR#&U,5E];*L'F,L-7S.&9XO+L5B9XN%3#8OD
M3KY;/V=&C-99CL1CZN'5>,HXZO2K85GZWX8\39MQ5D%3,<\H0IYAA\TQ66SJ
MTLOEE^&Q$<-1PTYU,,E5^J8U*O4Q%.6/P=&C"M&G:6&P]2%>G3MT445^=GZ2
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%&0>A!HH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHJ"24HX4*""%.<
MGNQ'8'T_PH GHHHH **** (%E9I2A4  L,\Y^4X'MS4]%0^:?-\O:,9QG//W
M-W3I^M $U%%(Q(5B!D@$@>I Z?C0 M%5/M#CAHP#Z98\>O"U+%*9-V0!MV^O
M.<^H'I0!-4:Q!79\DD[N#C W,&/OU%244 1R/L1V&"5!(![D=L#FJFXARXQN
MR#CG&2@!'KQD_E4S6X+%M^-S$_=7J23C)YH^S_\ 30_]\B@"2.3>N6V@Y(P#
MZ''>GLV%9A@X4D>Y SCBJ31XD$9(.<?,5&1D'\#T_6K*J(HWP0V-S]AT4<<?
M2@"LSF0Y9$) P,[AQ^(]_P"5,X'4!\ <'=V^G<]\D=J=+(6^;'*_+M4Y8YP<
M@'''KQP,FE20QEB &R!GJ/NY] ?7N>F/J0"S'&(B3YA;/'S$<8], ?C^%*J*
MLADWY)!&,C R5/U_A J(VP/\0'/93^1#.P_(#_"OA1D$ X)'3K@D9P!^?:@#
M2HJ#>8X48#/RH,<]P/0'_/Y4B3L[JI4#.>?F[ GNH]* +%-?[C?[K?R-#ML1
MFX.!G!XJ-7,D;DC&-PQS_=![@'O0 VBBB@"Q5*2(I@D@Y8XP,8)RW7//3@8]
M\Y S9DD$8!()!..,<?F155T90&+ JS?*,L2,@D=>.@QQZ]3W &RS,L2JJJ&4
MJN6E6,' (."V%R>H4D9Y]*JN\CA-T04*^YG.QF[C'5TY.!D%AC!)STM5&P+;
M!O90!\P+",<$G[X5VV]!G'S?=)&<AIV=[7^=@*K#?N4\ $L20H#@[V*J$XW
M-@D[<XR/=KXP?)4;HU=$0*KF-.=[%F .UNORG(/9L\VC(BR.J)$C *&9F WC
M:N"JJ22",<D+R-Q7!X#&?,!4L HW/&0HR#T8\=\'@$L,<#IG5.]NBMWO_72S
MW[VZAFKA7!8(A88", QD.X!\$H=HVD< D<'A<AJF),#,JDD3#RU1$+.O7)ZA
M2#W&Y<9)]ZLRX+,H12WE;E+,RA<%LGY><GC)'.!C-5I2LJE1(%5@N]20@4J#
MCR]Q!/?)(]!CGB@$#2QJ6+/*9@CCYB#&!&$QD#G<1DD8Z8Z4],QDKE2S MN\
MN/<C$EL@G)WC:?F]3QCNVW7ST++/(T1P,A0IZ'A0=I7'&0/8#/:XZ@*, G;\
MJ':6;85YWA0<$GOD^F>32^0%<1RQDLDK,22K;R\);DG)?<-_0_=PO.0,8%-8
M7<ZLJR/&<@;EE;) ;G;(3N08R"%/(!'.<5<VJ0@8[CM#!?X@0!R0QP,;B"N.
MI^AI=K-\H;RRV<[ "&(R<MG[IQ_=&. .^0N=+1J[[OL[Z6:OI_7GG.#D[\UE
M9*UGHUUO?]-#C?#L;1ZGJX5FC96B9P7,@8F1UZDAN<AB22=V??'8S$B-0K.N
M\Y<A6<D$#.&'W21C@Y[G&,&N;\.,1JNIPL%;Y4+,5&6Q+*#GKT8'&<Y !.#P
M.LD(24'!VJ%)4=.C#.,@>GY5-1WFG;9+SO;_ (/0(P<8N+=[WV5K737ZF8C.
M&1G:9=X&!NWED!.P[@N8R')_VA@'-7<YYR3T )9G8_[S'/\ @,_0U.5,X+1L
M8P!MVX&,XSD\'@A@.".!2?9Y,#]X&(!R6R.2<\;0,CU)R:;J)V?+KWNEZ:)?
MU^6;HRM;G5NUG_G_ %MM<@99'>-TF*>2>0V75U;AD(SP<)P>?H:,X/5E!SP6
MX/0<'>WY87MUQ6EM7^Z/R%)M4=%4?@/\*E25V[::66BM^!I4@YI).V^NM];>
M?YI_(H%2%5MP&_&X@;2>"5W$'D 9S[GC%0NK-D"7:I;=@,1S^! YQUZCL>U:
MV!Z#\A1@>@_(4U-=5=W;NK+?;IT6A'LI)W4TM$MK[>ID^4N=REMS$;F:1F+8
MZ'S&)?(' W$C@*, "@J220QS_M95B1Z;N3S]UCQUX(J^829=_P NW(R.<X"@
M$8Z=1G]<]JGP/0?D*?M%V?3JNFW0%2EK[ZUO]GH]]^KO_D9^YG(#9!)51N.>
M2V-P'IGMUXY[&KD49C#9(.XYX!&.,=R?\_I)M7.=HR.AP,TM9O5MVM<VBK)+
M>W7[_P#,**AAC=-VY@<A0,$G&,YZ_4=/R%34AA1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 (QVJS8S@
M$X]<#./QJ-'\U6XVX^7D@]1[>G<4Z1!+')&20)$9"5)! 8%201@@C/!J$LMN
M.03G8/E],%1P?H23W)SUS0 ^&(Q;LD'=MZ CIGU)ZYJ:BB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "H9)O+;;MSE0<[@.I(QS]*FI"JGJH/U /\Z (XI!("<8P0.H/7Z5+3<!02
M !@$\ #.*9%*)=V 1MQUQWSZ?2@"6BH4657;<T9C(^4*I5PV3G<<D$8_'.>U
M34 %0^4?-\S<,9SC'/W-O7I^E34R12Z%5."<8)R.C ]N>@[4 1O-L8KL)P <
MY Z_7Z4^-_,!.-N#C&<]@?3W]_Z"LT+J"S%2%PQ^\20I!QDY_P *B0[2"6_B
M4[06.0 HXQ\N25(Y_''6@#2HJC)+O92-R@<$$X)^8=!G!XSU[G%*DSQL_F*V
MPD>6"K*1UW9WA<\D8VYQWQQD NT54:"0DD2;2 -A!/&,;@5QC#XP2#D D]:M
M#.!G .!D Y ..<$@$CT) ^E $-P%,1#*K9( ##(!/0X]O;^6:B6XVJJLN2
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M6?Q;T3Q=X&TSQ&EKK-_X)TW7M4UB/2KO2&M9_O#]F7]HSPE^U5\ ?AG^T?X
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M\(Z)J/C;6O"W@SP]8V?A[PSXH\7^*_%OBSQ!HGA[PMX0\+>(-;O[U?L4=O.
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M>M7X^8T/^PO\A2 KF&3'5RQ^]NF9D.>HV8P!GH,<4WR)..% SS\W3=D$CCJ
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M0#G.!SR1G(/0TI2332O_ %\P+"K*N&12." 0%(P<'@;L <#&.@XI?,<DK(V
M >-H!W#!49&>I(-20%^%V[8P@"87:,#:% .3QMZ#C@4YHDW;SG)9203\O)"G
MCZ'\*S^_]0.'T,G^TM08L"79P!E0R$-SE<Y))'3!(SD<<C\6_P#@LY_P1.\-
M_P#!7:3X"ZG<_'G5_@5XH^"%K\1?#MOJ!^&^E?%?PUKO@_XIOX0F\36S>&]3
M\5>$WT7Q797'@S2WT/Q-:7]U%%%=7,&H:/JD443V/[5Z/&KZS?@IE5R48*"5
M9I'5]KX)'  (SQSSC@=>\*(I8#YE'RLYS@YXR3V'IP/SK2;5]M;*S^_3?OY
M>._!3X6:3\#?@U\*?@MX;O=9U3P[\'OAEX#^%^AZKXANI-1U_4-#^'WA+2?"
M>DW^MWIC0WNM7MAH]O<ZM*%96O)IS!N4*6_+B3_@G1XN_:@_:P_:Z_:4_:@\
M:?M#_!NTUZ_\*?LT_LY^#/@'^TOX@^&D.L?LA?#GPQ;ZI>:YX[N/A'K5D=1F
M^+WQF\<_%CQ<?"_B.Y37/#OAB+PSI]U!9WZS*W[.MPLC2%65OF89^3Y1GLP
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M6M+J]EK$7CC3++Q=\.?#7Q"T6*VTE?V$^%'[6_[)_P ??#7Q%\:?!#]H_P"
MWQ@\+?"BXU"/XH>)?AO\7/ GC#P]\/7L;74-1N;CQKK>CZ]=Z9X8L8]/TO4=
M274M4GLM,GTVPO+^UOKFTM9IA\Z>+/\ @JK^P+8? #]H_P#:$^&?[5/[.GQZ
MT7]F#X9:Y\1_'WA[X4?'CX6^(M82&RMI;?POHLT]OXDFLM+O/'_BMK#P/X+O
M[[;IFL^)M6L-)TR>_P!2GALY'>/G]R_S _-7XR_L2?MFQ?&/X>_M*>-O@?\
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M[C-Y/:^'?%<2:YX<LO%.A7$5KK-@^H6"W5Q9S7"$ _#;]FO]EK_@H/X<LO\
M@DK\"OBG\!/A!X#^&'_!,OX@7&G^,?B]HW[1%CXUU+XSZ)X;_9!_:$_9M\"_
M$'X>_#F#P/HVIZ-X=OY/'OA[6_&/AWQAXATKQ?IVIZW_ &)HFD:SI&E7OBE?
M!-)_82_X*7^/O&7[->I?'7X>^-/'?Q1^"W[8O[.7QQ^.O[1'Q(_X*4?$#Q1\
M%_B1X7^%OQ[TSQ9XEF_91_8F\*66@_!OP1;:EX=+>(+'1OBMX)\#:O\ #_0]
M!M_"OAN_\>>,9[;Q2OZ0?$/_ (*M_"N7]L3]CW]DSX _$+]ECXA1_M(?#H_'
M75_'_C/]H%_"4:_".ZU_PYI'A.S^"&A^%_!GC:3XI?%#XAZ7?^+O&/@[1=5U
MCPGX=_X1?X?Z[J%_KZ1-#(?K#X)?\%#?V&/VE_B+=_"'X$?M9? 'XO?$JTM-
M5U2#P3X$^)WA[Q#KVKZ5H4IMM:U7PW;VMT\/B_2='G66+5]7\*3:OI^G20S)
M<7*F*4(U;K_7X@?D+XR_8 _:K\3_  /M_!=_\$4U3Q+^R7_P4Q_:D_:R^%.A
MZ?\ M;:[\%]*_; ^#/[4/C']J;4M4TWPK\7?@WJ>C?$_]GGXB>#_  7^TE!#
M8?\ "8)I^GZGXL\(:GX8U&YU+P#XNU+5XOT!_P"";G[,OBGX+:I\>OBCXV_9
MU7]G/6_B]<?#;PQI'A[Q-^UW\;/VR_C)JW@+X3Z?XQ;P_=?%CXF_$[QYXT\&
M:.\/B#XA>+9?!O@CX5RS:=H6CW]S<^(?$NO:GJ<5EH'I^I?\%./V#/L_Q[M_
M"G[6'P#\>^)_V;?AW\0_B;\4/!'A/XI>#[WQ)H7ACX607"^,KQUCU%X);/P]
MJT4/AWQ#J-M)=V'AW6KVSL-<GL+N:.%^O_9)_;D^ G[8/PN^ GCOX9_$#P)=
M^*/CK\"X?CKIOPNT?QQH?BOQ1HN@Z3=^%/#7Q+LI9M->VCU(?"CXC^,-+^''
MC35(;6UMK+Q5+#ITL5K=R_90.W16 _+W]I;]@7]J;XQ^,/\ @H)X5\/> =!'
MAGXC_MA_LC_M_P#[//Q"N?C_ *_\.-!^*.O_  (^$7[,WPP\8?LR>-;CX9R6
M/QJ^#&KZROP-\77.C?%WPT=3TG1Y/%7@_6+#=?Z'J&FKQ&C?\$[/C-XW^&O[
M2OB74/\ @GK\#/"VO>,OA5\*_A+X1^!_[5O[?O[5_P"U9XT^+GA/P[\7]#^,
MGQ7\/:S\;%\>^)?"G[.D+7GAW2;C]G;Q;X!TCQ;XK\+_ !ITK3_BGXQN=(TN
M%?#+_KKXV_X*(?L-_#K0O!WB3QM^U?\ !#PWHWQ'U/QGH_P\O-2\=:2O_";:
MA\-_B'%\*?B'9^%+6!I[[7[CP)\0Y1X2\9+I]K<'PQJD=VVM"TM+&XNESF_;
MX^ /PZ\'>)_&?[1'QY_9H^%.@Z;^T%\=?@9X:UFR^,"ZOHFK:W\'-8\4?:/!
MVKWOB#P_X1FTWXVV'A[PMJT_CKX6Z5;:\^A^)[&Y\.>'-;\7,;6ZNT!^27AK
M]AS_ (*":;^S?\:[2R\$>)X-'\._M2_\$_/VC/V4OV)OC5^W#K7[27BKPTG[
M)O[1'@OXT?'+PW#^U3\0/"^I3>$=$^-&F>%-&TOX<>"O$6O?$;P_X&UKPQ+K
MUSK.C#QK=Z/H7T1\2?V'?VFOB7\1OVG?B6OA3P=H$7QX_;@_X)#_ +2&C>'-
M2\;V%[J&B>!/V0]3_9PUWX[Z1KES9Z7+I<^NZ!=_#CQA9>&;:SN;S3_%;6UE
M>V-W8"_A9?T%C_X*#_L8/^S^O[52_M0_!>3]GB3Q%_PA</Q1_P"$ML5T*3QU
M_:!TC_A DA#G6)?'S:J#8IX$324\6EU)72)5D5X_5/V>OVH?V>?VK_"6K^.?
MV;_C7\-/CEX/T'74\+:YXD^%WBW2O&&CZ+XF.@Z+XDE\-ZM?Z1-+%I_B&TT;
MQ%HU[J.B7:P:GI7]H0VVHVUK>+-;0@'XT_\ !1SX%>)O!WQ;_:(_;)\4?$3X
M-_"'P5I=W_P2+U_X$>-/C=XCU?2OA5JWQO\ V2_VGOVFO%E[X ^..O:#H&O7
M_P (_AQX]_X7UX3\(0?&#5+.[T7P1KFN0>,-222T\,SV5UV'_!*_XJ_$C]HC
M]NG_ (*8_'OQQ8? >TT[5/AW^P3\)-+M_P!FOXQS_M#_  R\+:]\,--_:B\1
M>)OAUK/QPC\#?#W0O'GQ8\.67Q2\+^)O&Z>%O#_]C>%-"\=^!?"4U_>:YHVL
M.OZ[_'OXC?!#X0?##Q%XW_:*\8_#SP%\&X!IGA_QGXG^+6IZ'I'PZMX/&>LZ
M;X.TG2_%-_XF9- 2Q\0:]KNEZ'#;:NXL;R^U"T@F&""OQI9?\%#O^"7O[._P
MU^#\VE?M'?LS_!?X5_%GPYJ'C+X0Z-HLFC> _"]_X+M=>ET#6/&L/A31](TL
M>#_!5GXFM[S1M7\9>)=+T+P_::U!=V%YJ<5U:SH #YQ_:/\ V>?V[O!'Q1_;
MXL_V6?@G\#_CM\/O^"CG@S2)+GQC\4OC7<?"&Y_9I^+FD_L\:?\ LSZQ<^.?
M#,/PV^(&H_&'X2:UX0\*^"/&&@6?@^[TWQ58^(H?&7A74M/MM#UK1_$ND?)>
MO?L!_P#!1C3X_A'\+=;\'W?[0/PJ\,?LB?LL? WX7Z!HO_!1_P"/G['GP+_9
MV\=_#7X)Z=\/_C9JGQP^&_[/OAO0/&?[35CXF\<P3^+?#OB 7_B'4+_P];V/
M@2TT;X;V9U'7M1_;+X^_M_\ [&G[+E[X*T[]H+]IKX.?":_^(>DQ^)/"%GXL
M\7V$,VK>$GN;2Q_X3AQ9M>#2OA_'?WL%I<>/M7-EX-@F=8I=>@8L5A^/'_!0
MC]BS]E_6O!GAS]H+]I_X-?"G7O'_ (?'B_POI'B;Q?8+=W?@M[C[)'X]ODL7
MO1H?P\:[#6J_$#7GTKP:US'+;+KC3P3I& ?EK^SQ^QA_P4#^ &F?!WPKX'T'
MX:>$O%5Q_P $6O@]^PG??'./XB:;X@TS]G']JO\ 9ITOXT7?P]\>M\--2\*2
MS_%GX=>*_%'Q'T"\M+K3KM+_ $-="N8_$'AK4+:\<5Y]^S%_P3^_;1T_]KS]
MB#]H/XH?!-/!%I^SIXR^*5Q\<_B#\8_^"E?[0O[:WQC^*VH^/_V7/BC\)V\6
M?#GPOXY\-:?\(OAU\/1XW\2:5J%QH>B:=X1\6WZ:G;1:9X8\"^&/#5[HGB']
M[/#W[0/P@\6:Q\3-!\.?%'P%K&L?!K3?"NM_%2QT[Q%I]Q_P@&A>.?")\>^#
M==\37(D^RZ?H7B?P8C^)M(UHSOIM[H\5S=VMQ.MO($^<OB/_ ,%._P!@WX0:
M'\)O$?Q,_:J^$/A'1?CGX!TSXL?"O4-1UJYE7Q/\)=:AMI],^+$UM865[>>&
M_A?=Q7EJ(OB'XLM]#\&K/*+>37!.)(8P#1^.G[/OQ#^('[<'[!_[0/AX:&?A
M]^SIH'[6NG_$9;[4I+;7FN?C1X"\ >'/!0\/::NGSQZK'_:7AO4_[8:74-.&
MGV_V:<+=F0)%^9G@+]AW]O&S^ WP&_X)H>)/A_\ L^Z1^R5^SI\:?@%XG_X:
M]L/C)X@U3XD?%#X"_LT?M%>&OC]\-/!6E_LX_P#"HK;_ (1#XW^(8O O@GP1
M\1?&^K?%O4/"UE>0^+?'GAUM>N]8T[PY9_JWXO\ V\OV1_ ?Q<^&'P%\3_M
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M^'7Q._X*#?&/]J/QS^S#>_M*_'O]EOP_\:OA;X^_9M^$/P>^&^F>/_CA\%?
M6L>-=,U[X5?$'X>:EX]NOA:-"\0?#?QI8W^ERZSKDVM>'=(@'E'@?_@DK^VA
M\-OA9XHM/AG)^Q!\,/B0?^"F'P$_X*$?#_P3X5UOXZZE\#?#>G_"_P" _A?X
M8^*/A-K=]K_@Z7XA:_J?B/6/!T']I?$=88;_ ,4S^*_$7Q#ET'PAK5OI_@P?
MT$>.OC/\,_AQX\^$7PV\9>+;;0/&/Q[\0^)/"7PATF\TW6YX?&7BCPAX+UKX
MB>(- M=:L],N="TW6(?!7AW7=>L-/UW4]*FUFUT;4$T4:E=6ES:Q_/?BO]L#
MX=W'Q>\!_"CX>_%CX8?\)!9_M4G]F7XO:#XL\)_$_4=2N/'!_9K\4_M''X7_
M  V\2^';"V\(6OQ+T_P1!X8\=:YJ>OW^J^#M#\)1:]H>IRVOC:]T;3Z /@[7
MOV ?VN?CK+\8_C1\==;_ &?_  5\>?C)\>/^":>K6GPW^&OBKQ[XS^$?PL_9
MQ_X)\_M0:/\ M#1>&;7XD:]\-O!/C#Q_\5_B!J>O_%?5+G5+WX;^'/"UC<:C
MX.\(0/;:;I>I>*=1[?X5_P#!.WXR>"_B[^SI\0?$'BGX9W&D?"#_ (*0?\%,
M_P!LK7K:PO?$EUJM_P##C]M+0/VGM(^&GAG1H[GPE:H?&WAI_CEX='CJVGOM
M,T6UM](U@:+KOB!OL<5U] ?"[_@JE^PO\8OB/X'^&7@'XU:GKFI?%3Q/J_@W
MX3>,[KX,?';PU\%/B_XIT./6[G4/#_P@_:#\3_#;2O@7\4M1>R\-:]=:7#X&
M^(6N_P!O6^E7UUX?FU:VA+#U3]A+]HGQ9^U7^SM8?&+QYHGA[PUK]W\7_P!I
MWX>#2?"RZFFCKI'P2_:=^+WP0\.7BMJ][J%X^IZMX>^'FDZGKF;A8#K=[?M9
MV>GV36UC" ?@%^TG^S?\9?A1_P $]?\ @G[_ ,$_O$OQ'^#7@3_@H;\/?B7X
M;_9P_9 U'X):_P")_B1KOQ,^ GC'P1J'[)_[1OQKE\*^)_!/@_Q%X%T_P9^S
M%\:/B)\5/B/"W_"3>$?AYXF\">"[Y_'>IWEYH]DW]/OA3X<^'/A[\+/#'PC^
M&*KX.\,^ _A_H_PV\ IIL%O<IX/\/^%_#-OX7\+?V=:3*MI,-!T^QTY;:W:,
MP3"UCAD00LVWY"\,_P#!3']B#QI\8=$^#OAWXSRZEXL\0>/?$/P@\(^+O^%4
M_&&U^"7C+XL:&^J6^N_"[P)^TEJ'P^M?@#XQ\?VM[X;U;2Y?!OA3XF:MKE]K
MVFR^'[:QO-;M%TV'R3_@FS^W5\0OVYO%/[6OBRX;PII7P?\ A?\ '?QW\(/@
M[X.A^ '[1/PP^(-MH/P]^(7C;P'#XS^(/Q)^,::%X/\ '6L^/X_"@UZ\\ >
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M4]S:S:+=1GQSXY?\%9? H_9T_:B\;?LX:7XKL/CW^SG:?!G7+SX6?M0?L_\
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MT]I>Z7XOTWQ&\=FMCJVDW$MQ8_0?[5G[!%O^U?\ %CQ1K?C/QA%HOPK\>_\
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M0[*_N=8T>\TE-?TRXLKO3+[2HM3MY+-6N5_+R5GI\_ZZ@?#?['/_  3CU?\
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MQ\_\6,?<'S=OO=/3I2B65C@#<,@,0AX!Z]SS@YZ&ITC6/.W/.,Y.>F<8_,T
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M+Q7X'\(RZ5^SI\2/ .KVC?#;XM_$2Z^-7PB^'UWI5K9_&;P9=>($?5;O5?[
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MNK7X'U'P!^UA^T%X_P#VA?%MUX;_ &Y?C]IOB3_@CW_P44_9T^'_ (^^/'[
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MCYB22P&<?+P  .<&J3BGU^[_ #;_ *MZ@?S:>)/V4?VV&_9)^+O_  2ET_\
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MP;KWQM^#_P"V;KGC7X!?M0? /XF?M*^+_C!^UQ^S#8_LNV \,V'BKPIXXO\
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MZT ?FE_P4X^#7QV^,GPK^ 4G[.?@+P;\2?B'\'/VV?V7?VCI?"?CKQ?8> M
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M8W_;G^.OQ1_: ^.7Q+^%OPB^%&I?&']HS_@C]\2?!WPYT7XU3_$'4O"GPO\
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M2WR_,0W.15X]WKO9/S7Y ?SD_LS_ /!-']I'1].^-_PW?X8>%_V"OV?/B?\
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M7D5=[@A^"3GH3U&%!STZY.>N!@S>3Y;A-Y;<%&2 ,!BR=,\XSG/X4FH]'\K
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ML*D"Q;8(9@ ,A./P)S_X]C\*B2/>[ ,R??.5X/#@8YR,<_H*5Y%<*R J,,2
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MJ3_&UO!L*7,7QB\<6VFZK-XR@OH[#2IH/ZE;#XO?!_4_BMK?P:TSXH?#B_\
MCCX8\*6OC#Q)\*K#Q?X2O/BMX>\#ZE>VEM9>)]:\#6^IR>,=*\*7]_=V,%KK
M6H:5!I%Y=W%K''<O++"'[/3-'TK18+B'1=.L-)MKR]N-1F@TO3K3389+ZZ</
M<W\]OI]M$L]Y<. \]W+OGD;#2R,135NKM_7DF!_(W\;-(_X)@I^RA^VA8?\
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MYM;:_;]'/^"Y7AKX6:WH?[(VK_%OXG_!GX:Z!X1^+7Q UC1E_;.^ 6I_'_\
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M\\-S!IO@_P !> +CPU:>&[.YNK*RA\,C2+70X39);6T7[!X&2<#) !..2!G
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M?( )SMY)^4;<9! YQGI^=6B 1@@$>AY%   P  /0<"@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH BD<QA=L>_.1@$# [GIC'KTY
MQUIZG<JMC&5!QZ9&<?ATIU% !1@=,<>E%% !@>@J"2$NZL"!@ =#GAB<\$=<
MU*[!%+'H!GBFQR"12P! !QS] >WUH DHHHH **** # ]/?\ 'UHHIKN$4L02
M!C@=>2!_6@!U(PW*5/<$?F"/ZTV-Q(NX @9(Y]OI3F.U2QZ $G\!F@"NL&P$
M+@ ]>N?3V%0VT3 /R/O;>2S?=+ ]2>OL?K5I)!*K;01CCGU(/H<_YXI(8VCW
M;B#D+C&>HW9SD=\]>]'?SW\P(VMRQ)W+SCC![ #L1Z?J:LJ-JJO]U0/R&*6B
M@"JR>4S2G# EL+C!^=L]3D<?3UIR3AV"[<;LC.X'H">0/I^M3D \$ CT(S0%
M4'(50?4  T +43QEV4@@ ,A/&<[&+8_'IGMZ4]VV*6(R ,X__738Y!(I8 @
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M  (_:O7P!-\5=*\9VWB?X4:WJWB#X7?%'X5?%7XE? [XP?#+5/$=A#H_B5?
MOQ9^$/BOP5XYT'2?%.CP0Z=XKT&VUTZ-K]O:Z<=6T^XGTW3+BTXWX4?\$_?V
M5_@?>_!?5/AI\+Y-$UWX"ZG\9M>\!>(K[QW\0?$OBFX\5?M$6.E6/QH\<_$/
MQ%XB\3:QK'Q<\;^/8M)LAK/BWXGW?BC7X?LL+:3>V"I;06S=M+ ?A#X"N?VD
M?V7O$O\ P41\<>"/VE8_%7QK_:#_ ."NOP+_ &!?#WQ0^(O[/GP#2'X7Z_\
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M0[_1_AU;ZQ\2? ?A'.AZUJ:V6F^"O$^@:,+R_P!2_4SQ3_P2Q_8L\;Q>!O\
MA,OAYX_\0ZAX%^&NB?!]=;N_VC?VD8?$/Q!^%GAO6]3UW0?AW\==>T_XM6FJ
M?M"^#M)U'6-8N-.T'XW77CS3[6+5]7T^""#3=5O;.?W;X$?L<_LY_LV-I?\
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MC#^Q5\*?V<--\!V?PCO?AAX8\/66I>+OV+OAE^TOXK_:E_:1TSQK\.?$]O\
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M&>O3I0 C.F[RF!); QC(YY'\OT]JD55484 #.<#U_P BFE$+!RHW#H?ITI]
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MXR.<D]QTH .SG RK!4R2!\VUF&5YZY;UZ <<5&T*/M=G.6P%#1J03VP<'C/
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MQ8VI_#3XB_#3Q;X2U_P!+_PBVKW^F>)?#'B+QCID']HGUC1O^"77Q=UWX?\
MBW2O&WB_]COX4Z_XD^-?[$WQ0T'P;^R'^QOHOP7^%GA'1OV2OVEO!'[0NO6V
MI:U+XBU7XM_$/Q?\5KCPM'H1O/$?BVP\%^!H+/3)=#\"?;V\1:OK7M/[8?\
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M'O[6G@WXB^"-=\"?\$IOB1^UO\6]#\ _&FV^+'P[O+;P'\6OAGH:6.D>#(_
M7@"Q\>_&SQ[97UA?>&/&4=SX:M/#_P#PD6J?#Z;3+BWU&'Q)'U.N_P#!33]H
M'X'3/%^V?^Q5IOP!NO'7[/\ ^T%\</@!'X3_ &C])^,5GXG\1?LY?"C5?C3X
MS^ 'QBU.P^%?A*U^$_Q8N/AYH^K>*-.O_#3_ !6^']_9>&?&5OIWBB[NO#<$
M?B+2UK_@F'XI^-VEV]K^U%\8_#_B;4-:_P""<GQ7_P""?7CR3X+_  Y\0?#2
MQN4\:_$?P?XN\+_&?P,/%/C_ .(%]X4\1^%=#\$:&&T34-0\06-YXUA.MVMW
M!HB0>'8\[QI_P3C_ &FOVAS)<_MB?M<>!OBC>^!/V=/VC/@=\"_^%4?LX:E\
M)M-TCQO^T?\ "K5O@OXK_:(^,6FZE\:_B$?B%X\TWX>:OJ6AZ1X7\'S_  V\
M&V7_  DGC*XM-.$VK:2^B@'8?LZ_\%$?CU\3/C'^SE\/OCM^Q]#^S]X2_;&^
M!GC'XU_LX^)]+^.^B?%KQ21\//#W@'Q;XG\$_&GP7IWP_P#"NG_#WQ#>^&O'
MUAK'ARY\+^,?B'I<Z6MUI>L7&D:PCVL7ZW#ISU[_ .<#^0^E?GU-^QCK\?CC
M]A3X@:/\2K"QUK]BGX'_ !<^$=C:ZCX'N=1T[Q]JGQ,^%GPU^'EEXHO([;Q7
MI\^@6?AS4?AXFNW&AI<:K+K5EJ+:3#KFE21C4C]L^![?QC9>$O#%A\0=9T7Q
M)XXL?#NB6OC'Q%X:\.WOA/P[K_BB#3K:'7M9T'PU?Z[XHN_#VCZGJD=W?:=H
M5UXE\076DV<\%C<:SJ,L#74P!U*QHA+*#DYZDGJ03U/J*?110 4444 %%%%
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M)/Q#9M>U5?%WBVV\2>+[B#3[^^U.U^<OV6?V=_C7K?[3'[&?Q:^*?[,/Q"\
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M>?%J[\36WA3P#^S]\*OA/\%O'_B8?!FX\0:MK4_Q*^(.J6_AW3=)\9^-M,\
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M[='YY!W;LCKG.:GHH 11M&.O7]23_6EHHH **** (I8A+C+,I7.TJ<%205W
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M PHR>>_T%*K;E#8*Y[-U'U_G0 ZD8!E93P"""?0$8I:1AN5ESC<I&>N,C&:
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MA^(8_".C^.K;4?$5POB"2QM;O5KC1GTNRU[1#:R+J3:Y7;RN!_2,T# ,=RG
M)QAL' S@X)X/0\$XZ \"OA_]H+_@HI^R)^RYXU3X<_&/XL7.D^/T\(?\+"UG
MP=X*^''Q<^,FM^#/A])/-:P>.OB'I7P:^'_CVY^&_@^^GM;^#2_$GCQ?#FD:
MK+INI#3;RZ@TS4;BT^C?@UKGQ!\3?![X8>(_BOX9MO!GQ5USX:^!M<^)W@ZP
MF>ZL/"7Q#U?PEI%_XU\,6ET;J]2:VT#Q)<:GI4#?;+HM;VD1$TP99)/QN\0:
M#XZ\1?\ !0;]MKQ;^P%^UAX0^ _[3GAGP[^SFO[5O[//[67P.L/B)\$?CCH.
MB_"B\O/@M\8OA_XG\+?$+P)\9/!_@N/PUXBOO ?B#Q;X6UW4O"]KXN\(Z];:
MIX).LVMQ>:N@/VG^'WCWP9\5_!7A7XF_"WQ=X<\>> /'?A_3O$W@OQKX2UJU
MU_PSXG\/:Q:Q7NFZUH6KZ?+<VNHZ==V\RO%/%( 6#*P!7CL=A4AG*AEP#M1\
MASA=K8+LPQD\;#P!N -?RO:!\=;7]HC]G[]@[X5_ /X1?'WP!K?B[2OVUOB!
MKG['7_!/']ISPC^R1\ ?%^G? W]HD?"CXC?'FY_:VO-9^%?Q5L_@%JGQ0U^_
M\=?"WP9\'KFSUSX@6WQ5'B#QEH6IZ-X8^U3\;^R5X^^._P"U#K?[#O[/7C?]
MJW]I'0O %]^U#_P5J^&'C/4?A5^UMK/C/QQ\0?AE\ T\(2_"[P%K_P"U;X/M
M_"_C7XE1^")M?:TTSXSZ.WA_XA36^FM%9^(H+C4I]<NFG8#^M&2"7<K>9AT,
M.6,,CJ4C,99"GFC!;JK-DHZ*2">GAOP>_9J^#'P!UWXM>*_A;X+.@^)_COX\
MN?B/\6O%FK^)/%_C#Q-XT\4S1W$.GI?>(O&^O>)-8T_POX;M+FXLO"'@C2;N
MQ\&>"["YO;7PGX>T:VO+BWN/YT_ ,?QM^%_@']G+]H^;]M#]L'XC>-?"G_!:
M!_\ @GOINA?$+XX:YXC^&>O_ +*^G_MV?$;]D9/ _P 1_AO#;Z;X0^)WC:\\
M!6=IXEU'XX?$#1_$/QJN?'6FZ3JX\=QZ=8P:77/^"_&GQ.TG]G[Q5^VCH/[<
MW[2GCO\ :O\ !'_!6[X@?LS^"O@)KG[0VL:_\(-<\(:C_P %)M8^!-M^R?J_
M[/;W7_"-Z^_B#X#ZW>^.="\8:YX?N?BOX L(M"\3^'_%NA_#3P18^'[4;O;3
M7OW^0']/7PV^+_PU^,">.9OAEXFT[Q>OPU^)OC+X-^.YK"'4K4^'/B;\/[J*
MQ\8^$[K[?86CW%YH5U<6UO<W5C]IL)FF!MKJ>-)&7T:0*N6>2/<!_JC$79@O
MWEPJ@L>HP$9F/8DC/\D'B_XH?'O23KWP&^#3^)(?#?[2O_!;;_@I%X/^(3^$
M?VE)_P!C[Q-XMO? FCW_ ,0O OP1T?\ :8MO!?B_Q)\-)?BGKFAW]Q.OP^M=
M%\>^*;3PQ<>#_#/C#0UU34YI/U__ ."5]_\ '[2=._:D^%WQO\8Z!XCTSX3?
M'+2=#^'/A.[_ &P3^V]\9_@OIVN?#KPQK_BWX.?&CXU:IX0\'^,]4O=%\776
MH^)O MM\3X-6^(FG>"/&UAHVM:U?Z=HNC7!:?^?X;:WM?RM_F'VS\-OVJO@A
M\5_C%\7O@'\-?$^J^*?B#\ ;RSTCXL1:;X!^(</@GPKXEN[;2;Y_!H^*E[X2
ML_A7KGC72K+7M$O/$7A#PYXRU7Q1X:M-6L+G7-'L89'>+Z- V[$++NXC*EI#
M@\DGYUR<CG'< <],?R2?#OPY/\+=4^+/P[TC]HW]I[X,?"O]J'_@N[\:?V7_
M (Z_%N?]I+XG7_B'PMX"\(?"'XB?%?P;X9^'GC3Q'X@NO^%*>,/VA_C+IG@O
MX4>(OC#X;N-)\?:AHFIZ/X,M/%=OK$_AF]TWU#XP^(/B5\.1^VC^Q]\&/VP?
MVD;[X0^#/VL/^"/OA#P9\6I/COXN\?\ QV^!>M?M@_M,:;X&_:4_9XTS]H/Q
M1JWB3X@ZY'I/PZT[P-XSTO2O'.O>)=<\'VGQJ%I?7EUH;:7ID))ZV]-?E?MY
M@?U%JV%**JLL;.H5T<%<8/&0N2V<G QD=LXJY%&R#YF!X]",<*,<DXQMZ>_M
M7P)^T'X(;]G+_@GS\>O!7PY_:*\1_!27P%\ /BS:^"/VG/C[\0O'GQBUOX2:
MK>Z1KM[H_P 1?B!\1O'U_P",?'FO67@[5M3BN$U?5+O7K_P_H6EV,=G!<PZ1
M;6S?SQ>*_C/\</V=/V;?^"@GPNN_$7[5?P6^,L'[!&D?M)> M;TC_@HAKW[?
MWP1U#P=\//B1X9\(^-OVE?@W\=_&C0_M)_"#Q5XHT_QGIE]XB\$Z_IOAWX?>
M(?#5A<^)_!NCPW6C>)KRYD#^M/XI?%#P5\$?AM\1OC+\3=7'AGX;?"CP1XO^
M(_C_ ,2RVE]?P^'O!?@C0M0\4>)]:DLM*M;[4KR/3-%TJ]NS:Z?9W5[<^6(K
M6WFF>.-NUT'6]-\3:'HWB/1KC[7H_B#2M/UO2;ORIX/M6F:K:17VGW/D7,4%
MS!]HM)X9O)N(8IXM_ES1I(K*/YT?^"F7[0VF^*?B+^WK\,O OQ@L_&7@WP__
M ,&^W[<7Q/\ %'PNT#QZ?$/@:'7M;US2[7P/XXUSPUI6J7?AV/Q!K7A,>(+7
MPYK-S"FK7?AN]NH()'TB[57\*NO$'_"AO#W[,UU^S!_P45^*6NZA^T__ ,$Y
M?VNO'_[07Q<^+_Q[\:_M"^ _AOI'P_\ V9-/\9?#?]NR#X?ZSJ?C+P_\#]+^
M$_QKOO#7@)]&^&/AWP9X6UCP]XI;P>WA36=2\)Z?)I8!_5S17\A/@3]H7]H7
M]DSX1_MJ:/X2L_C3:?M%VO\ P31^('[4/P?ET_\ ;YU/_@I?^R7\4!\*=1T+
M0M?_ &IO 7BKXPZ;??'3X0_$:ZE\>Z7XC3P%KFE6/PB^).@VQNM$T'5]:\(Z
MI"*R>//VM/V;-!\6?$KX!_&/P4^K^)_V _VQ/BKIOA+5_P#@JK\7?^"EWCW]
MI+Q)X+^$L7C'X4_M)_"GX1_$GX&:/H/AWQ%X'\90V%QX@N_AEJ7A/X;^*?#?
MBYO"@\$:G+I_A:PL@#^OMY"K!=A(.W+#H-S%0.G)XZ5)7\QMKI_A7X3?M1_L
MC^$?V3OVX/VC?COI/QU_8%_;B^,'C;PQXF_:\^)'QY@^(/C+2/AQ\'#\*OVD
M!I?B/QGXA_X1#6/%&K^*?$UKHFG^%[?PWX"AU>$7'@/PEX>OM'UF2ZN_#C]K
MKXCZS\(O^"+5]\*/C7JGQ>^,GB/_ ()=?'[XR>,? UK\1;SQ7J_QB^)W@7]C
M+X1/H.I?%3PY:Z[<7_B_5U^,]U?64C>(Q<:I;^-[O6XXYX-9AU1H@#^F"23R
M\?*6SGIVQCKQWYQ]#2O(5"?+EG( 4D@ D9.2%)XQT"D]20%#,O\ (U^PGXU^
M/]]XF_X)U?'>W^.OPR36_P!IS5=/G^-OBCQ?_P %;OC5^T?K/[7FF>(/@_XL
M\1_%+P=X6_8Q\0? KP_\*_A1\2_A?XM%MK_A_0_A++\-8/@8O@W5?AEKMU>:
M5>W<%SVO[)7@;QIX.^!W_!"_]J"]_:9_:^^(/Q;_ &U/B%X9^$/[2%_\2?VH
M?C/XG\*_$'X9_%S]B/\ :<^*DGA>V^'^H>-KOP5X2O\ X?>+OA=X.U7X?^-_
M!.C^&O'EG=V&HZWJ/B2_UW6KJY0 _IU^&GQ1\ _&/PAIGQ!^%_BO1/'/@;6Y
M];M='\5>'+T:AHVIW'AO7]4\+:['9W:QI'<#3O$.BZII4TD)DB:XLIBCM'Y;
MOW<LGE)NV[LLJ@9"Y9SM49/=F*HHYRS*.]?C5_P0C\!>$_ ?_!-[X/P>%-?\
M:Z^=?\6_%W5/$B^,OBCXT^*,NA^(++XM^,/#=UHNF-XT\0Z^?!]E]AT"PO+_
M ,,:&NDZ6VOZAJ_B6\TPZ[KVH:A>?FC^S-X\\6^$OVN?@=XI^*7Q@^)'QX\+
M_M/?M,_M)_!'P_\ M3?LS_\ !0SXC^+O"'Q;N/%"_&JX\+_!?X_?L"?%./1;
MC]FYO@;X=\*KI-GXR_97-CK/PQ\;_#6UU74?$6G>'_$FM1Z@ ?U%_#/XG^ /
MC)X*TCXC_"[Q9HWCCP+K\NL0Z)XJ\/W)O=%U9M!US4O#FJOI]YLC2[@M=:TC
M4;'[3"&MIWM7EM99[=XII.[8D D M@=!U/\ GVR?0$X%?RD_L%ZOX:^ '[+O
M_!$6Y\/_ !A^(/A/P!\1/V\OVD_"OQHNO%?[0/Q+\6^$M4\0S?LY_MR^'?"?
MPW\27/CWQGJ^D:%H.J_$+P=X&OM%^&BKHOA^?XGP67B.V\,-X[U2]U6?H_'7
M[2?_  MCQQ^T%X:E_:H\<:1^Q_\ $G_@NKX+_9@^,GQ>\"?&'7/#UKX*^#-K
M_P $U_A/XDM_@QX-^+/A_7;&]^#O@3XF_M@Z)X;^%OBGQ#\//$WA>_6\\?:[
MI=CK.EZWXTN+@@'] <G[6'P77XC>.OA/;:MXIUCQ]\,O'OP<^&OC_0?#7PT^
M)GBEO"?B?X]:+'XA^&;ZW?\ AWP?J>FV/AG4]&E34=<\;3WB>#O!%JR/XXUS
MPXSJE?2-?R ^#K[PO\(?VI_VKO!_[.?[0?Q%\6?#[1O^"O7_  1E^%EKKTOQ
MV\6_%358/"FL^#O#-CXQ^ VI?%'7/$_B'Q1XW\':#<ZAJWAJ[\/>*/$GB"YL
M;*$^#M:GN;C09TB\[NOBE^U1X^O/B_\ M-7/Q>^"OPG_ &E?AY^W!\1OA1:>
M/OBQ_P %6/VAOAW;?".[\"_M8:GX)^&_[+VO_P#!/+PO\#=<^"6K?#_XB_"+
M2_"_A^W\+W=KKWCSXMVGC:S^,Y\=V/B+6=+U7PZ ?VA45_)[I_Q \3_##]N6
MZ^-?BCXI^-_CQX-\3?\ !3?6?@)I?QJ_9L_X*!?$*/QI\.W\=?&34?A5X4_8
MN_:2_P""9WQDLH_A1=_#;X8:QJVD^#->UWX%Z>_Q%_X1CPSI_P"T1I<UF+_Q
M#XDD_JOTO6-+UF!KG2-0LM4M([F_L6O-.O+>_M!>Z3J%UI.J61N;666,7FF:
MI97FG:A;NPFM+^UNK.=4NK6YBB -.BOXJ?\ @H)^T%+::3^V7^U5\*?&GQ(\
M->,?A-^U%XK^&GPS^/\ \:O^"KGCSX/>./"WCWX4_%WPUX&\1_!K]GK_ ()W
M_"+1+[X;Z]\-4O\ 1M<T;P]X,^-=AI?BCXM^$[F\^)'Q!DOM"\2Z9K3_ $7\
M3OB9>_"3]NKQW\>/%GQ;UWXZ>$-*_P""BOPT^$%MX\_9^_;[^*'PZ^/OP#?Q
MAXU^'GPRT/\ 9"^)7_!-SXJV"? 7XM_")=:\406.MZO\+XIO'OBOX?\ BBX^
M-_AB*3Q1!+XHMP#^LNBORN_X*Q_$_1?AS^S1X6T'6+[XQ+=_&3]H7X/_  6\
M.:%\&?CEHO[,%UXZ\0^*=9U76K;X>?$3]I35T%]\#_A#XPL/"^I:)X[\7^";
MS3/B-J5K<67@GP3>QZ[XJTZRO/YP_$GQPU7X?>"/^"C7PGT3X^W'[-OPH^%O
MQ6_X(GZEXBB_9Y_X**?&W]KB']EV]^,G[;?C+P=^TOJ>E?M$_$ZS\,:[X,\3
MZS\/?#WAB_\ '_P^TE[[X?:/:66E7M^1K&O^)]/0 _N,8[58X)P"< $DX&<
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M3?:#LL-(GO0#^O<RE>#&V=N0%5VR1G(X3@<#!."<@%0Q56<[LH&U"Y/89'H
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M:'_A:T)$7Q+?3[/P3-\2&>Z72)*\D^+\'A!_B+\)HOVV/'__  3^\$_"*/\
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M3_P4P\*>)?@1^QOJWC?]DVW_ &C/CC\0_C]>Z7^UEIGPN\>ZW\-K7]F'X"^
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MOOVY_P!G#X5:Y^Q]_P *"^$<WA#X=_ GXR?M.6WPLB\$>#/B=_8X^,%[\9=
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MD2_O@)?OJ&&W10!GQV827S1# DA5(WE1$65XDEDF"-($#L@DFFD",VU9999
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M'^'_ ,68_P!GS4/#<WQQ^!'B#Q'^WQ)^QA\4?@W\2_@EX=E^(6G?%+2?V?\
MXG?&.[^$WQ'1_%NH:+X'\-:OX-T_PK\3M&^+?PV\1>/+.]LI_"NG:2UUI_C+
M7;G2U>/;\.GGY^F@'&>!_P#@CY\%O!K? #2I?VA_VSO&GPR_9-^(_P ,?B;^
MS#\&/%WQLT$?"KX+WGPHUF:_\'>'--\/^&?AYH&J?$'P]8:+/=> ;9_BWK'Q
M%\0:'X)G;3?#&NZ3>RRZS+](_#S]@CX+_#;0?V4_#F@WWQ$EL?V/?BY\8/C;
M\)WU;Q-I<][?>+_C?H?QO\.^,[7QR]KH$,.N:#'I_P ?O' T:PTY-+EL9+?0
MGGNKXZ>?[4\'^!__  5T_9_^-_B3X%6.@?!_]J_PE\./VC?&_B#X2_![]H?X
M@_!FT\-? _Q;\7O#T?C)[SX7)KD?B_4?%EOK5R_@'Q=#H/B2X\%P?#W7[[1+
MW3-(\:7VIP36R[_PL_X*G_#?XV6NK:O\,_V?OVKM6\':O\./C'\0_P!G_P"*
M]_\ ";1F^%_[3]K\%QJ"Z_HWPCUK2O'>H:KINN^(&L7O? 6F?&/2/A'+X\TA
M;F\\-/>?9;M8G>/:_P M_P"F!XO^U/\ \$R8O'VM_L\:9\);SXL:=X=U?_@J
M)XT_;G_:!\=^%/BCH?@OX@?"K6_%/[+/QO\  5IX[^%^N3VNGRK9^&_BE?\
MPL73O!4.G^./MVGWFJ0>)-/\1>'7U:UB^C?#W_!-'X$:7H.G6OB/Q9\:?B9X
M^;]JOX/?MG^-?C7\1/'&E:S\6/BM\;/@7'H$'PVD\<ZU8>$]'\+V_@3POH'A
M[P_X6TKX<> O"G@WPMHWAO36M]!L],N+S5KN\WO^"?\ ^U5XY_:I_8(^ O[5
M'Q*^$_CGPM\0O&WP0\+_ !%\6>#(/"%EX?O?&OB";P/IGB/4-5^$WAEO&_B9
M9_!7CN[N9I?AA_;GB:WU?4],N=/?6DTR9Y&C_,[X2_\ !6KX^^/_ -GW_@E5
M\?\ Q;\$?BKIU]^U5\7/BY\/OBQ\(/!7P9TK4_&GQ@ETK]FGXM?$[X>R_ O1
M[OX@ZXWA[P=_PG&@^'DG\9>-/%_A.VM--\+>++WQO/X<\*VUSJ8'9=/P7]/K
M;Y ?>WAO_@F'\+O!OCS3M4\+?M _MB>%O@MI/QDG^/ND_LA>'/C;_87[-FG_
M !&N_%=QX]G2RTK1O"UC\4[?X:R?$&ZN?'$OP/\ ^%K'X.S:_<2^=X(DT4MI
M)T_"?_!,CX/^&OBIX6\;W/QD_:B\7_#WX>_&S7/VC/AG^S/X\^+%IXJ_9_\
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M5>)? FMZ3>Z'J&CZW?YU&YU+3DM[!,3QQ_P4!^!?PVC^ .H>/+GQ'X2\+?M
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M_P!G[XR_%[4]-\.Z;\?OB3HOCW6UNK.]\?WOA]=:N?%\EE!]2W'_  4W\<>
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M%O<^)/BM\4?!4USX_P#MWPGUW_A&_ 6BZ3K&L>,?/:333;:=I&NZGI: ^^?
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ML>#2TTNH(4L 3C )Y.3@?F>* (_(C_VN.?O'M^-344U75L[6#8ZX.<9Z?RH
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M4M->MY-3T6YLM4L+R'6=.CAAEFU#19+>XECU2RA2>"26ZLWD@CBGAD=_F"E
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MH^M_$7P5:>,/%?Q"T;XA7NF2W6JZ\UC8^-H#JOC.VD\+17%GX,LOVNMOC?\
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M%+9W"Z.MZ$+"96OIM;\0/F'_ ()M_"OXU?L_?L5?LX_L^_'_ ,+>"/#/C_\
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M'QK\$?#O@OX90?L\?#O6_'_B7X7>/Y?'/]I_#[XB:#X6D\'V6I:GY-D?,_\
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M^-Y/AG\=M5^-,VI^*=<\/W<GA3QAX_MO&7@"XTRZU#_A#9O[$\3^''@/X4?
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M+%OI!U#P[\5/.MI?%*6NG6]M'=,UI)\>_#_6OA%X4_8!_P""1OA>']G3X,^
M-.^%?A3XH>%?V@?C=\=_V#?VC_COX$_9J_:Z\&?#+X8^#O%_@WQ7^RC\*;3X
M<+XG^.WQCNM?UZUT7XV?% 77AFV3P/K]MX6UK7O%GC'2(YO[-?));SB9 KX4
MH3NW$$L%8L>5!#$'.X'!&"QQY-K7[0WP6\*>(?'7AOQ3\1_#GAK5OANOPI'C
M=/$EZ^@V'AYOCEXEN_"'P@M;C6]9CLM%NK_X@^*[27PUX;T[3M1O+Z\UQ[32
MWMXK[4+""Y0'\DW[-'P\\%^#+C]FGXD_M _L^:K%\&?AU_P7%_:2OX;OQM_P
M3_\ &GP<TKP;\._CQ_P3\U'_ (4]XO\ "_[,FH^%?&OB+X'?"'Q]^T1J?PYU
M[19A!_9N@>/6\.>(_'^I>'OB#IFL_P!D?0O@SX>^'/A?XP_9B^+G[9G[//Q"
M\=_LI_#W]HC_ (+?6NL:?>_L\_$7XV>&_A)^T-\7_P!OVX\8_ 'XZ_$;X.^'
MO WC'Q5>^'?%?P7T?XK^%?A[\7O^$/USPUX8O/'%C=V^LZ-8>/K76=1_IT\.
M?%CX=^+?B-\0OA?X<\5Z7JWQ#^$\?@V7XE^$K25WUCP7;_$'2-2UOP1)K<3(
ML<,7B;2])U#4=+$4LSM# [3QP2';7I;E8U>3:.%&XC:"0N<98D *N2<L0J@D
MD@9H _D[^ _[)7A7XJ?M#?LAR>)/V1_$$/[%.M_\%!/^"B?[0W[+_P )/BS\
M#]9T7P5\(/@EJ?[*WP_T?PGK.O\ P>\6^%K&U^#7A7XF_M(VWQ8^,?P;^&OQ
M \->%+JPMO%OA[6++PSI^L1:=:Z9^H?_  3:MO#O[-__  TW\%G^'?BWX9>&
M?'7_  4^_:O\/? 'P9I'PH\;Z3\/]*\+S^"=$^+(NO#@TKPR?!_@'X6:L-)\
M;ZGX?\0W,_A_P#K/BV_?P[X9O+SQ!K=CIMU[WX,_X*F_\$^/B1\6]$^"O@C]
MJ;X;Z_X\\5>*KGP)X1^S?\)!#X%\>^.]-F:&Z\#?#_XMWFAVWPE^('C1)DEM
MHO"G@[QOKFOW-S;SVMIIT\\$T<?T]\;?VB?@C^SAX8T;QE\>?B1X4^%/A3Q#
MXT\)_#C1=>\9ZBFEZ;J7CCQSJ8TCPIX9MIW1P^HZS?"7R%(6""SM+W5+R:VT
MVQN[N$ ]KHJ-) [.H!S&5#9'\1!.WTR!@D GAE/1@2J/OS@$ =R#C/H"0 ?<
MJ2.G- #Z**\U^+/Q?^&_P*^'GBGXL?%SQ7IO@3X<>";6WOO%?B_6C.-*T2RN
MK^STNWNKPVD%S<"*34;^SL\Q02,DLZ%U6(/(H!Z517B*?M'?!+^V[_PW<_$3
M0=+US3_C-9?L\-IFNO=>'[G4?C9J7@33_B=I_P ./#PURUTZ/Q3XAO? &IV_
MBFW3PS)J]G)ID6HN+SS-'U:.R]FAN5F *HX!"\G&!NR<$@D9 V,,$[DD1D+
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M!'."J@G=MRVT9;HF/,94(!8P/045X]\"/CO\-?VD_@U\-/C[\(=9NO$7PO\
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M00#0 P_OP7&%V @@\Y'7J"!CKP3BHXX_-W;2JX SQG[V?0C!&.>/3Z"]@#.
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M-_\ !1']@AOV9T_8A^$&F^*="^)=SXZF\<_$#7/@_P"./C58W7C/PW<^%X_
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MK)KWPZ^*M]:R2'3E\?>%M:F.L6/B2SM;?5)M49;^]N+JY6.5>P\9?LV?L_\
MQ A^,$/C_P"#'PR\:)^T%X<\)^#OC5:^+O!^F:_8?%/PMX#AU:'P5H?CBRU.
M"\M==T_PH->U=_#\5[$R:5<7\UU:&*[V3*.V]_Q_KM^0'YE?\$V=;_:\\*?'
MCXZ? SX]GXEZ=\.]'^$WPK^)/A7P-^TS^UY^SO\ M0?M.?#_ ,<>(?%_C?P[
MKTTNJ?!LV?C6W^"'CSP]HFA:AX5N/B;9ZC+:^.O#'CVP\*^([G2+X:#HG7?
M[^Q]+_X+,?MUCXIW6C2?$[Q!^RC^QE=_LIQZR]@OB%OV;],F^,MM\:=*^'$-
MPL<\UK8?'F.YUKXJ1>'GF &M_"^36X@BZ #]T_LX_LD_LQ_LC^'M=\-?LU_
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MB_QI\0_#R?&WX9Q:GXSO/AAXF\9:E_8P\%CQ7X4M-#TKQO<IJ'](_@#]E/\
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M=MKJ-?L^LZ<UE?P7,"+%<K-& B<.5VE)>J>GR=K: ?D1^P9XK^+/AK_@WT^
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MV%I]NL[:>SLKWR(?M=K9WDD$EY9V]RJB>*TN7LK"2>V1U@EFLK.9T:6U@>,
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M+.*QN[.&R73HK.YM%A\BXM8M,2+3XH)89(8[&.*T1!;QI$K:MUOIT=_\@/Y
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MX$S%%<%%8Y*,F12:5E9WOY_GH!_&3_P32O/V2;KX>?\ !'#5OV-O'FI>+/\
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M+DJQVG.!O(QR,<8(]>W?'85+*)#M\O/4YY X[=0:>N=J[OO;1N^N.>G'7TH
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M^'VH^-O&7Q#N;_\ 8&O?@=I=K:Z%9?%MM8U&]\!CP#9^(+4"778X4/\ 7/\
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MHT[7]?\  ?CKPE>S:!K^J>"_$NEZEX>T>"?1]0N_K?Q+^P9\)_'EG^WUX?\
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M>([3P_XM@M=+M]*M-&NKGXE74<]QH5GI][&=+T][>2-FO54 _-#]H/\ ;/\
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M%O!MEX?^_/VA?V=- _:)N_V?;WQ)KWB#P[_PS[^T?X"_:3T ^'TTZ1=?\2>
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M^?'>_P#^&.?A5X0_:_\ VA/"WCG0/AGX9\3?M%F\N/!7C/\ X)_?M._%BT\
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MXAF\47OC-?!-C\0?#/PTTS]HQO@3;^);^2_M/@;)\8CX#2Q4>%KVQO? R_\
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M[.FM^$U_9F^'=T^FZ;I/@K5+JR\<ZSXFL3K7C*YN],TVWLM)N*O@[]M#]O\
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MV^*OPF^&^NR17&H:?\&_$ES);6O@/Q!-J=EI&MWGCZWTJ]^(&L:OH.AWNO\
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M@+W.1G@564S)PJL 3D@H"><9YSZ<#CL!5@K&902QW\87=CH../IG\S22O(I
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M.>,=@1WX[_G2JNU0N<X&,FG?THH B\H>9YF3G.<<8SMV^F>G/UI'A#L6W$9
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M/+7;G/).< =?I3Z (I(A(022,#&  >OU!J(@P?<&_?UR.FWI]T=]QZ^E62<
MGT!//3BHH93+NR -NWH2>N?4#IB@!T<8CW8).YMQR!UP <8[<#\:DJ"*8R$C
M &!G@D]_<#I4] !1110 4U_N-_NM_(TZFO\ <;_=;^1H AHHHH 6*(QDDL#D
M =^Q]R?\_C1<?=7_ '__ &1ZGJ"X^ZO^_P#^R/0! TN45  &3;M8L,!E&,XZ
MX(SQP>>HZU"",_*"WJ%*LRD\\IO5CG[V2HQGVXNC8L2,4!)1>RY)VYZG [=2
M:@#[9"71@'(.P /@;6&"%)!Y7=QGJ,X(H BSP201ST*?,#P/N@]^,?-TYST
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MBL17C?+<SJXS%<(\4<499G^6\.UZM"A5RRKA\HR2K/+L+A,SS-8[B"I33H+
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M]P.F/7KUJ6D(!Z@'Z@'^=+0 4444 %%%% !1110 8 Z "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*JM#(68AP 6) RXP"2>Q J>-2B!2<D9YY[DD=>> <4 ,:4"01[<YP,Y'<>G^
M?U&9"H*LO0,"#CW&*7 SG SZX&?SH)P"?0$_E0!5^2W^4+NW?-R5&,<=_P#/
MI4L<BR;OD VX[J>N?3Z?K4$UY;PQRRSE(XH%9Y9I6C2*)%1W:261V58XE5'9
MG8@#:>X-0PW,=S;QW-NR20S1)+$\;!EDC8;E9&4G<"N&4C*L""#C($.:4E&\
M+\LIN+FE/D@TI2C#>2BVE)K1-I-W:':7+S):<RAS/2//)-QBY6LG))VOT3=C
M3HH'0?2BK$5BIB9I20P);"C@_.V>IXX^E.CFWL5VXP0.H/52WI^%/E0NNU2
M<@\Y[<]O?%1QLJLL6WYAE2XQ@G;N/OT&* '-$3*),@ 8XP<G (ZY]_3V]:FH
MHH *, = !110 8 Z "BBB@ HHHH *:_W&_W6_D:=37^XW^ZW\C0!#1110!*\
MBQC+9Q@G@9X&,_SJ*8ADC8=&8$?0HQ%3,BN,, 1Z'\/\!5$LQ(&3L48 Z ,
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M''ZU6=6\]'"N5W*&/&!QP1SG: 3NXX-6B0 23@#DD] /4T 11&0AO,SG(QD
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M9TNW\8ZSI-E'!;Q66F:IXDCU*]T^U6!5M[2:*W$4:Q")/PP\*_!O]I[XI_\
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MI^H>&]*^)/@GX:?$.:632+^WMM0\)^.)_$,>G16^K: ;]/Z4/BK\6_AI\#/
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M+\)0/!7Q:T"R\?:3X4\.^)?#WQ+T;QM9/KOC^"W\3_VLS+(LDI260!\#;@N
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M2%ZJ#]7WL PDC0INRQ?)X)!W8QT))(/.3A0B#/RH.<@$E%%% !1110 4444
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M/0@_0@_RJDDFPE, [R >N1D!?0@\<\D4_ M_E5D9Y!\JN=@.S/< ]V&2?_U
M%NH4D9I&0@ #?@C.?E8+SV[T1REW92 , '(SSG!_K3&'DL9 =VYF&#P!N)<\
MC/=<?C0 R6-%+,'!8L21W&22?NQR-QTZ?4BG0R/E4V_+R-V'Z $@Y95ZGCD
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M=(L/V@+KXVW6K?!WXJW?PP\(_#[P-XAUOP//\,(/&'A[Q+9^"](UZ;PE\4=
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M=^)7["'ACXO_ !Y_:=\$>*?V=?\ @LI^U/\ L_Z!J?BRW_9(U'X\2>#O#/\
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MK]HG]C'_ (* _M)>)_VP_&WA+P_\,?VSO$_[+=K^R'HVA?!R7X':5\)O@_\
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M77+W6H32:I\,+[PDXGUC6KH*UUJFH3W@!^4?Q7^'_P 0/'_[0G_!-?X#Q_\
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MLZ@[0Q*@["5W %@1P"&4 $U%%0).'E:((^4+!FQ\HP2HSZ;BK%1U( ;&U@2
M3T45%YN9&C$;D*4!<#Y?G4MU]L $=1N!("X) ):*** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"*6)9=A;
MDQDLN>@;ID^H]OQZ@5*,X&>N.?K110 4QWV*6QG&.,XZD#K^-/H(!&" 1Z'D
M4 ,C?S%W8QR1C(/3Z4^D  X  'H!BEH **** "BBB@ HHHH B,67#[V &/D'
MW>/Q[]3Q3V&Y67IN4C/U&*;*<1N?0?7^H_F*9;DE&SQ\YZ#'93ZM_/\ *@!4
MC**^X@YY!QC&!CN3Z"J0Q\K==HR1GG.5/7G'W2*O22A"%*D[O3&.H'.3ZFFR
M1;F0KM 7.1TSED(X P?NGKTS[F@">J]T0L1)SPR] ">N.X(_'%,MR23DD_(I
MY)/4G/4^PJW0!4 \H"8G<".%QM/SX/.>,]SP._0<!Z(6<39&&);;CD94KC.<
M<?2IR >" 1Z$9IKJQ0JA"GC'4 <@GIR.,]* (I(6=BP8 $ 8()Z>X([FI(D,
M:D$YRV<\^@'<D]O6EC#A0'(+9/(R>,\<GGI3'C9I%8-A1MR,D9PQ/0<<\=?3
MM0!+@'J ?PICOLQ\K-G/W<<8QUR>^>/H:220)\I4G<IY!'T/4CU%5D8+GS%\
MS@8SAL$9W$;NF>.GI]* +*2K*2 I^7!^92.OID>W.,X[]LO9=P !*X/5>/P^
ME-DD$8!()!R.,<8&>_MFAY BJQ!.X@8&,\@GOQVH 8DH+^7@Y7<-Q(.=O&2.
MO.,U/35VD!PH!8!LX&>1GD_SH=MBEB"<8X'7D@=_K0!"\@9S 5/S84G(Z$ G
M@^W!_P#U4X1K'&ZKT(8_FN/Z4$>;&2GR.W ; W*5;&<C/IQ2A62)E9RY"M\Q
MX/3I_G\J &4444 6*CE*!1O7<-V ,9YP>WTS4E-9%<88 @'//K0!4EFC\L !
MA@@ ;>^U@N!GL<?3CZB$<X(/!)/7<&Y_A8\I@8RHP#CW.5<J&92@5=S+G@Y
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M,J!A3QP?3 QG$HC9E4G!B)R5)R,,<9VXQG)R,DX-(I0,5ER5"@@$$@$D;<8
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M+X(_\(Q/>/JVFC0([>V^+MUXB768+;6)#-HL-@EAB[:XBS ^4-;_ &L/ W[
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ML&D-'>>%M6L_%<VBZY?7/A_<\4?\%+OVBO@%X<_;=TW]IO\ 9/\ !VG?%O\
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M&WXQ^&?B+H>L:D;V#Q ^LZY\8GT/Q5X*UO1TT'7_  IHEQHNI7-S;^(;R.R
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M+HL\7QLV^#?VT/#RZ9;36OQ!\<_ _0_AWH7A>Y,'B#0D\4>#9)[NR^LO@O\
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M'P?H7ACPK%KNMRQ-?:FGA[P[HNDK=S2K9:=:VXCB7O* "BBB@ HHHH ****
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MQP,4ZBB@!KN$&XYQD#@9/-,69&8* V3TR,#@$^OH#3V57&&&1UQ35BC4AE4
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M_&+XU>-_!7A+Q+\:8[@Z7JVEZY?GP;X7USP9IBV%GH=KXN?4-2O;+TSX^_\
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M>V,6L_:=/B^7/VL_^"5'[0_[0GQU^*/B[4O#O[%WQZ\!_$GX>_#SP;\--?\
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M/0@@_0\&EHH K&."-@22K8.,DGCGMR.YI\0B&[RCGINY)]<=?QISQ+(026!
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MJQJHVE1U#'&[@\\$XY/)!P<#&!BE)O,NX22@[@@F##8PZ; BY^89X9\_[77
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MZ+J/CKXF> /'/BBX\1>)]"\:^(K<IH&E7GAOX;:MX@\.Z9X.EU, _0'X-?\
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MX1#P58Q7=[XGU35[V_LM%Y/XG_L0?M$^*_VCOC?\0=)\+^&[GP?XY_X*S?\
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M0 4444 %%%% !1110 4444 %%%% !14*RDRF/ P,\YYX /3'O^AJ:@ HHHH
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M?ZT11,C9)4C:1@9]0>_IC@=L\5+)]P_5?_0A2 Y*R0GQ3?/D<0,,;%SC<O\
M'][MZ]#BNPKD-/"GQ)?-\V[RG[\9#@=B.,#IC\^2>OIM6T\D_O *B>78RKC.
MY6;.<8VX[=\YJ6D(!Y(!(Z$@&D M%0RQN^W:VW&<\D9SC'3TP>OK4H& !Z #
M\J (Y8]X !"G=DG!YX(QP0>^>O:@?NXU!^;;U[>ISCDGZ $D_=!.!4M>0_M
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MD8<!HVV@Y7=DL I" (O<KM" ;E('\(OAO1OV6]>^&VJ+\68/V:KW]DCX._\
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M:M86=O-=WEQ%9VELC2W-W=R16MK;1(J,TMS<3O'%;QJLB,3,Z<,.,Y _)_\
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MB#:>,/#%UX"DTEO$$7CBW\0:/-X-ET!(VF;78O%,=ZV@R:.L*M*^I+J!M$C
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M+!KG0O!&D_%#5)=.XB\_9V\+>#_@S^S9\3(]?_;<^'EO#^T)^W+XJ^#OQ_\
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MW?\ :FF6OV>XGBAEVRR*I;H?[1W[/VN_$WQ%\#]$^.OP=USXU^#K&XU3Q?\
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M4_\ >(^DA'YX49I[,\F#"3@ AN0N#V^\/3TXI\0E&[S,_P .W)!]<] /;K0
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M$OPOU'Q'^U;\8=3^*7PV/[3/CGX=:3\2=!C^._B+QAJWQ0U/PMIVH:DWQ \
MV_BSQ9?77@'XBR6'B[PW<Z=<Z+HTZ@'];DT%K<2PRS0PW,UA,TMM.\ FDLYI
M(S&\L$K(SVK/$6B=XVC#1F1&8QNRGQWQA^T'\%/ !^+,WB+Q_HL>J_ SP9X3
M\<_%[1]'AU3Q3XM\$>#/&,GB9O!6JZ_X7\*:=KOBI[;Q(WA;Q8_AVVMM(OKV
M_CTO59;&UD3S7D_FJ_X*._%#5Y_%_P"WQXG^%GQ"_;&N/^&-?!6G^ C\6-9_
MX*9:?^Q/\"/V8?BGX:_9N\/?$W1M-\&_"GPMK&H?$O\ :>\5^-;CQ;X4\1>)
M/%?Q[^&WC[1?B5XVU]?AKX0U=M#T'7O(\W^(/B#Q-X<T?_@LK^U]X:^-WQO\
M,?M!WG_!)K]@'XMVFM>'_CQX]T/1;;Q/\2_A!\2;S7_'/ACX;Z;XCB\&Z%>:
M-K'@:RE\%7^D:-Y/@?4/%?CNT\&S:-!XXUJTNP#^P2.9I@)@7. K96.6-=NS
MC>C $-^]+;' =6.2@,?RQ3PP7HDBN!'<PRH8YX)U%Q;31J0&CF@8/;LB^:"Z
MR(5 <2,/D5E_G/\ C7<Z;\9/BA_P5C\??M!?MW?M ?LF^)_V&]9T70OV=/"W
MPP_:2\4?!;P5\'?A+:?LO_"SXQ^#OVDO$WPP\-:WH7A;]H&X^+GQ9\4_$G0[
M^'XO:+\1/#&KZ5X+G^%6D:5:W5AJ4+>+:S+\?_VL]._:K^)GQK_:(_:L^ OQ
M!^!W_!&;]@C]JG3/A=\"OC=\0/@3X7^'7[67Q.^%O[7'CSQ[XUU7PMX.UC3[
M?6;W0?$OPLTS0[CP+XPM]8\!:K8I+!XN\+>(+S1_#=UH0!_4M/9VEY'-:W=M
M;W-I)&L4EK<1"XMIH1G;'+;7"-$\ X:.)HVA#C>J^8FY7K% \Z3*BM<PQS11
M3$9GBBD,$D\2.WSK"V(6=,B(-Y0^4D _/O[*?Q,OOBO^SK^S_P",/$FO:5JG
MQ%\7?L^_ [XB>.[>VETR'4$U3XA_#[2=?N=9O-&L'5M*M-;UEM=DL-UM;64S
MVE['8[TM90GY7_M/:;H?QG_X*P7'[.WQ:_;&^/?P!^#^G_\ !-_P=\;-%^%7
MP@_:1\6?LVV_C7Q[I7[1/QA\->(/B?<^-O!7B'PMXF\[X:^&SHESJFC:=K5M
MHVOQ7NA7WC.QUK1_"5G9( ?NLZ6K1"(*&.Y)9$;<V'$DDXD)D. XN8VEC8MD
M2IYB?.@(=YK 1HC-A0F4"%2,Y949F&0A12&"J61/FVK@8_G8_P""?W[6?Q7\
M;?&#]@/5/V@_CMJ=WX.^)7_!./\ ;RUBUUKQEXGL_"WA'X]K\#?VT?V?O"7P
M;_:'U'2F_L;PKJWCOQK^S*8?BAJ6L:?:1M#X8\>>)-1M;>V\.W=XZ^'_ +)&
MN^./VZ_%O_!/SP;X]_:N_:7NOA9X[^'7_!:+XW:GJ/P=_:,^)/PWO?C GP;_
M ."F?PP^'G[.\OB'QY\/?$.A>)M7\(>!?AWXY/\ PA=EINN16)T?3M+T*9K_
M ,)3:AI>I '[O_$3]N']F'X0^&+?Q=XZ^(>HZ-I^H?''5OV:-$LK+X7_ !4U
M[Q9XE^,WAC^VVUCP'X,\"^&? NJ>-_&4>CVGASQ)JUQKWA;P_JOA-=#T?5M?
MCUC^Q[>YO4^AOAK\0/!?Q3\*0>+_  -J%UJ'A^XUSQ=H<-Q<Z#XC\*3MK'@W
MQ=K7A#Q0@T7Q+I.@ZPD=MXGT/6+:+47TX6.MVT2ZQI5YJ6BZC:7]U_,5I?AK
M6/VF_P!J#]CB7XK_ !H_:+O+[PO_ ,%P?^"O/PM\,W/A']HCXL_#R;1_AY\-
M/AG^U9XF\%^#K$^#O%VAO'HOA:W^'^D>"M-MK 1-!\-=6\6_#JX>;PIXHUO3
M+O:^!_Q'\8_M,W7[#OP+_:5_:E^.7@?X)_%;Q-_P66\?:KXE\,?M"^-_@=XT
M^/'Q:_9V_P""A%W\-/@3\ KKXX^$O$WAGXGVOA;X=_ [Q)\0/&'A_P"'?@[Q
MSH#Z_HOPRTA[R&]\)^ ;G3(6TT!_4<T4!E41 J$<92(M$%=F=I2$CV$-*CL[
ML!^]&'^;8K+RVJ>.O .B^,_"'PUU3Q;HNF^/?'FC^*M:\$>#+K58[?7_ !+H
MG@%=!3QCJVAZ/YJ7-WIOA5O%?AF'7KZVA^SZ;-K^CV]W+'-J-I'+_,O\3?BM
MX \?GX"?L[_!?]HK]M+]OW1OAY\*OVB_'\^O0?MVV?[!/PSUCX>^#/VCO$'P
M?LOB3\:/VN?"][\./C3^T+J/P=UGPOK'PE\.:KX(U+XB>$O$GA[P]/\ %WXD
M0:[XF\2>&?%NO\)^P/,?VD?CK_P2!^,'Q8^/GQ8\9^)]&\#?\%@?!'A7Q!HG
M[7_C_P :^%/'&B_LW_ML?"KPM\)=#OO'6@WO@G3/VEM,O?AY>6^C^+?&?B7P
MM'=?M#^&_!'@[Q5\1-%UA/#^EBR0']1_PS^(W@+XP>#=/\?>!-5N=;\*:[<Z
M[8V%_=Z/XB\.S74_AKQ%K7A76X_[$\2Z5HFM6\=MKFDZK:B>XTN"'4H8TU.R
MFOM,O;6^NO0T%J J*<@$.BMO(0X&UEW#"YR"C<;F+;26+9_D[_8Y\8>+_P!K
MKQ!^RO\  K]JW]KK]HSPI\*KS]FS]KWXW>%;CPM^U!\2O@7XX_:.^+GAW_@H
M!\:OAGK-IXF^-W@+QGX1^)GB?1?V9/A!I7PZN?#_ ,-;#Q@FBVVG^.M+U?6M
M+O--\&V,-MZ;^S[9^+_VROBW^Q1\$_&G[7_[57BOX#P? O\ X*XW$'C'X5_M
M)^/OAAKW[5/P[_9F_P""@?[.WP&_9J^('Q(^)'P>USP?XF\27<OPN\0?VBWQ
M$\-Z_H^N^/?+O+Z?6+CPMX^\6Z1XC /Z=DBM&D8(6\W8 Q,DHDV@R;02S DH
M\CN,Y=)&$APQ5J&M[-G56C#/%)YT9*NSPR+&T>^%\%HG:%VCW1LKR0EXP6C#
MJ/S8_P""4_C[Q+KW[(?@_0_B;\4_$?Q,\:^$OC/^V3\&M"\7_$SQ';:W\4?&
M_@G]G7]K/XP?!_PAJ'BW6+ADU;QGXHT'P'X4\)Z7XI\678N=5U6[B36?$MU/
MK&J7-U/YQ_P56^(EG9V7[,WP/T^__:;U;QS\>_C!XHM/!WPG_9I^/WAO]DN7
MXR6OPV^&WB+QGXE\,_%7]J#5]?\ "/B?X9?#32K%;?Q!?:9\*/&&E_$SQYJ-
MI9:#IFB^(O#:>*[:( _6O%DCE%8HTC/*R1&1%E=ER[.L>$=Y P8[@6E.T_,2
M<CK:HDI0!7;<[JJ,K3.PVEF14S,\ZQ% ^QVF"@+O 4#^/3X-_$3XS?%E?#'[
M-,?[4OQS^'OP_G_X+@> ?@#))\'_ -O7QY^TSXY\)_!S6?\ @E[\0?CWX_\
MV>+3]M&\30?B'XY\.2_%K2=1MKN*\N+W7?A3XABG\.^%O%$WB'P+I'B&T]^\
M>>*O&?P83]HG]DL_M0?M!>"_V6- _P""PW[,?[.?C+XU>+OCUX\\2?&#X$_L
MS?&_]BWX5_'75OA]I7[3OC7Q#J_Q4\&>&?''[2'B/PO\'=,\;ZQXW7Q7X&\+
M_%Z[TS0_%FFW8TV_@ /Z/?#_ ,9/AIXM^*/Q,^"GA[Q;;ZG\3O@UI'PW\0?$
MWPG%#JD=[X2TGXLVOBJ[^'EY>WD]K#I]TOB.#P3XEDM4L+N[N+9=+=]0M[-I
M[.:7PCQQ^W7^S+\.?C%XK^ NM^,/&NH_%#P!X.\,^/O'VB^"?@I\</B7I/@?
MPYXWU"#3O!K>,O%OPZ^'7B?PCX9UCQ,\IN]"\+ZSK$'B34-!AO\ 5K32IM&M
M+B]C_/3_ ()D^&/AMX$_X*$_\%9OA[\*?C%XO^,_@SP9H_[!6E6-_P"/OBWK
MWQW\1_#V[G\!_'?4K[X2_P#"U?%VN>)_&GB/2/!KW?V[2K/QCXE\0^(O#HUZ
MYT6ZU62WL[6UM/AK]J?PW/\ "/XW_P#!<CXW?#'XJ_'7P5\2-*\6_P#!+?2[
M+5=*_:)^,T?A_2;3XP^,_A /%R6O@MO'+^#[5I-,BN- \-S2Z))/X,\(Z[XB
M\)^#9- \*>(M6TF\ /ZN6,K $E]Z!U8HLB8/R\CG#@X)RH()&.2  2)&?GCW
MOG<K_-+(H5B792A)4!BR[TP-Z!0P**N/Y8OVP?"7C'7O W_!>_\ :JM_VE_V
ML_"_Q*_8@^)<OB#]EK2/ 7[37QA\&_#'X0:Y\-/V$/V8/C8IM?A1X:\6:=\.
MO%^F^-?&/B+48?&WAKX@>&_%/AV[TF]U*TT[2M)O=8UO4]3P?^"EOQBTGQ;\
M8?VY=5T'Q9\<$O?V6_AIX2\,ZYX^\>_\%4]9_P"">GP*_9<^)U[\"M.^+GAZ
M\^ 7P7^!MG>_$?XZ^,O%*>,_"OB#5/%'Q?\ "7BG1/&?C!H?A;X!UX>'=%UG
M2HP#^E_PQ\9_AOXN^+'Q3^"GA_Q6NI_$[X,:+\./$7Q*\+I9:W#=>%=%^+T7
MBFZ^'-S-J,]C;Z3?Q>)+;P1XGE@BTC4=2GLDTIO[9CTZ>XMENG^#/C/\//B%
MX_\ C'\-O!OBNWUSQQ\ ?%7ACPA\7M!AL]8M9/!VO^,O /AKXJ>&=*N+F\LH
M+'4I]3\">+/#FOH^AW6H6D-OJ(LKZXBOXYK"#\:O^"1?C[Q-\5_VAOVF?BAX
MUUL^)_'/Q'_X)^?\$7/'OC7Q T5K;S^(/%7C#X ?'+Q'X@UR:VT](;6V_M?4
MM2NK[R+2*"SC:61;6)(Q@_$OQNM_V<Y/VOO^"^?C/XO?MG?$S]GSXA_ 6+X
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M1&3D@D\GEFY)QR1G#'Y5 9@6 5<$8%,EA!4E?,8EAE3+(5P""1L+[ "!@@*
M5)4Y5F!LT4 5A;HZJ9 Q<J@8EVSE"2K<'AE))5A@J3D$&HGB?<0HDV !5578
M)MPORA-X3 (Q@J1MROW20;U% %2&W4*A8/NB9C&&=FV9# ; 6(4!'*!5PH3Y
M,;!BI'@1@<[SU.-[\DJR\_,-W#<!LJ,+@#:FV>B@"G#;C<7<2!P"H_>/@JP.
M5*AMK*&+, P.&);J:A6VDC4+^](5\1_OB?+B8X*J5V$;5R QRV#@' (K2HH
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MH6L:_HUE?REIK;3=:U+PMX;O=5MHV"7]UH6D27(D-A;^7T !  "N !Q\I)Z
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MVXJ#N3!W97D[P!@*P! ! (OB!1C#.,$D\@[NWS94Y '3_P"N:1)&WLK\(NX
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M6G(NQ0N<X&,]* /EC6_V'_V-?%OC3PW\3O%/[*'[-_B3XD^$/#=CX-\*^/\
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MH S]!BEH A$C&)G*C<,\8/8^_/\ GMS3HG9U)88(;&,$<8![\]ZDHH ****
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MX2"[*X++;,QVE2Q\UH0N.0&8 ?=!SD@#/;^>O]I;]J#XYK^U=\3_ -IGX?\
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M@,/F>;UE#$Y=AVZ.#R[%8?'.I&+CB,-5C6P4L?!VC^B_FC^[TY^\O^-+YO\
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MP\J3QF!P2KT<1A*U/$X>O0=>C6HSC.%:7,HEFBBBO#/?"BBB@ HHHH ****
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M&T\\\9(QTY.(<;MZ[^2^7;1]-+ 69=OE1@$, 5Y'.0$89P,\'BH3(QC\O P
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M:MJ6C:T?%6A?"._;1KY] BDT8 W=;_;J^*C>,?V;=-^&7Q,NO%GA?XA_%/\
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MPOX1U?5=.T/Q;X:T3QQ=Z!')#?V,>IZWI^E^/)94\/F46]Z+_;;-\._M*?\
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M>/\ ]IS_ (*_W_QW^*>OZ#\*?&?@GPS\ M.C@MM&LKZ'Q(OC7XG>#?!O[/\
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M-/=6=UK?K9+LW9]4!6;*$JLA$P&$C&6B4D  H2<AF'S.23\Q;';-E(V2-0Q
MP,EMP!!SG<%Y)QU_#%-PF-VQHF!.<@\\CKN.5R,$$ DYR/6GQLKOM54DD'(9
MG.5!.!E2?F"]< 'KC'<N2O%7[]?G:S6ENN[UZ@5[G+1EE<2G[I+R%%"\\! 1
M\V"2&YSTQP"*<8#[$;<UNI"M 8GN ^[D,S%7V;0,8^IYQ6L;5<@-@M@,>,J2
M68]#CC@?J.E5!$V-N\*KN3A0"Q9@"JC(&-HR<DJON,&JBU:U]5OIWO:W<"95
M:,ODOA<*"" =@)PH&YBS Y)QMZXP<TQ900& )&67+G$I8*2<C &S"\8[X!P0
M:<Q1'0+YBR[=B-\KE0,@,V0%+')#<MTR3]VE,;2 '<6=3G:RHAS@C<2IY'.<
M9(R1]:%T;^]JWSTOOWO;\V$N[(5<?=QSD<X!'3J.3GGI4L2NB[MP*,,A0,$;
ML*!GG..N>"3GUJNN2!O^<C"LI 4!AN!(9,,0"K8SU!!//2=$8*7.-K%65<D[
M0>,<\<$Y_#UP1G)6;MZV^]]0.-MU4^*)1L;>L&W=P5(2*,%OO9 ^8+C;G.<
M\$]E]E/]Y?R;_P"*KCX4+^+7(1 !:2J7,F',A6$CY 22@08(XR>=I^]7;!&6
M)E+X;DA@3QZ<L1]!DX]>]5/XODOS8%*6$K(6+L?W1!08"<EQNPV?F(XR<C
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M /?O%_\ P55\._!+XF?LP>'OVI? .I_LT^&_C]^R#\1/CQJW@OQ=IWC'Q_\
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M@;X;_&K5?"-E\&/B3XV\,P:7JSZWX1\">/O$/B&Q71=<#Z<TFBZG':\UH_\
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M^B>(+G5=>\,_#OQ!I]VOPZTV]\,.VG^*KSPN ?;\_P#P5H_9Z^)G[2G[(OP
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M_C )I%OX<L[_ %/Q)X>L-4_+C]EGP1^UW^U/^R/:?LJZ#\ _AYX?_9E\5_\
M!1/X]_%77?VMG^->C(]A\+_A)_P59^)?QV\5>$;#X,6.@_\ "P)OV@-4\7_#
MR_\  ^BWZ,OPZLM&U71/'D_CB;6+6\\*0?;NA_L8_M#67[/'P@^'\WA30K;Q
M7X8_X+->/OVT/%5FOB[P]);Q? 3Q'_P4#^-'[0UAXBM[VUN)(+_7%^&GB_PS
M?OX6CDEUI+R8Z3L%Y;/:P"W4O/YV74#['\+?\%*_V2/$?P6^)GQRN/''B_P!
MX1^"OCG3OA;\5?!_Q5^#_P 8/AI\;O!OQ.\00>'+SP?\.[KX!>*? ^G?&74O
M&_C^S\8^$;KX=>%]!\%ZMK'CQ?$VDV_A.RU>_FELX<ZU_P""HG[%D7PH^+OQ
MI\5_$?Q9\*/!_P"S[KOP[T#XYZ5\;O@M\;_@O\2_A-=_%WQ#I'A7X8ZAXW^$
M/Q*^'?ASXGZ3X8\;ZQK=M!H'C.3PH_A6^BM=7NDUDVV@Z[+IOYP?M>_\$[_V
MC_B]X\_;5^*WA#PU<:E=WO[>7[$G[7GP.\&>&/VB/$'P \2?';PI\ ?V1_ G
MP(^*7@K3/C9\-M6TGQI\!?%]_+<>/+?P#XEO+W1X)/%GAOPY<:C=67A35[S5
M8/,)?V!OCCX[^&G[0/B;0?V1?CY\,O'_ (O\<?\ !/3PGX7LOVM_^"CFI?M@
M?'GQA\+?V?\ ]MWX:_M$?%.+7AXJ^.'QC^"OPS^&OP\T6W\6ZU\.M#T#XO>)
M?''BG5-0\9K/X>\/W?B/3M%U=/?^NNOYL#[K^/?_  65_9N\ ?LW?&+XW_"V
MS^(OC;Q)\&/B;^SM\//&'PP\>_ K]ICX2>.M%MOVA_B#H.A^%O'.K^ _$WP6
M3XF0> -;\%S^+?%/@'QC!X)N_"GQ&UKPL_@/1-4N/$6HP:=)^MO@[7]*\9^%
M_#7C/0)-1DT'Q7HFE>)M%?6M#UOPUK$FD:[8PZGI[ZKX=\2Z?I'B/0-1DL[J
M%KW1/$&DZ7K>EW)DL=7TZQU""YM8OQ;_ ."@?[+7[27Q4\7?MH_$#X-_#)_'
MB^-?V??^"8=I\+='L/&_@CPGK?Q'\;_LD_MT?&S]HKXH^!],NO$VO:1;>'M4
ME^'GB+PPGAW6?%]QHOA;5M6UV#3?[73['JOV3],_@[^T/+\5OB7\2OAKJ'PD
M^(GPPUSX9>#/@1XQUU?'5_\ #_4$^W?'#PMXD\2MX)9OA_XU\;:?9^,?AI<>
M&Y_#_CJT.I2Z5+?ZAI.J^%-8\3^&-2TK7;U >2_M!_\ !2;]CS]F?XHZK\&?
MBQ\1/%T?Q7T+P'H'Q2USX?\ P\^!WQY^-'BC0_A?X@O?%&GP?$O6=,^#OPS\
M=2:7\/\ 2[OP?KEOXG\8WIAT+PG.NE6_B6]TJX\1^'8M5GU#_@HM^R#;?%OX
M2_ [1_B;J_C_ .)7QP\$?"KXI?#C2_A+\+?BY\7=$U7X2_&KQ!J7A?X<_%W5
MO&OPT\"^*?!/A+X5:WK>ESV5U\0_%OB'1?"6AM<:9/KVK:=9ZIIUS<?!/C[X
MM?M"_";_ (*U?MBZQ\!/V1]7_:PFU+]AG]AW1=5TWPA\7?@S\*O%'@SQ.GQ.
M_;:U'P5<>(;SXR^)?"5G-\)_$<O]I67B_6/"6H^)O%WA2]L=.O-(^&/C,:O>
M2Z5O_P#!.S]@OXN?LH^/CH'Q'@T6?PQIW_!+W]C/]F"3XD^!M:TF/3+OXM?#
MKXI?MA>.?B_H/@70[BX'C#0O!O@BV^,_A&#P-J>MZ+8:5=^'UT.RTH?:M)O-
M*T\ ^L? '_!4+]B[XG_%;0OA%X-^)'B>]U3Q?XZ\1_#/X;_$'5/@W\:/#G[/
MOQ<^)7@Y=67Q'X ^$'[2GB#X?Z;\!OB7XOTZYT/7K*+0_"7Q"U.^U:\T'5X-
M"BU1M/G*6O '_!3;]C/XF_&C1?@;X-^)FOW_ (H\4>,_&OPV\!^,K[X2_&'0
M?@3\4?B1\.#J3>/OAU\)?VC->\!:;\#?BCXY\++H.O?VEX:\#>/M;U&630==
M@L(KR;2-16V_-'X2_LW_ +<>L? /]@K_ ()U?$#]ESPW\.? G[$?QA_9*UKQ
MS^V3:?&3X6>(?AG\2?AY^POXY\'^-/ &N? WX>:'KM]\<]'^+'QZO?A]X>TW
MQSI/Q"\ ^ ]$^'VF^(O&Z+XS\8M+IUOJ/K7['W@+]O;X,?#G]E3]@_7/V3/
M.A?#/]F_4+_P1X[_ &SO$7Q1^&GB_P $^.O@GX.\-^*_#OA'QI^SU\./"_BF
M#XY>&?VF/B+%K^C-XBU#XE_#CP[X+\!3KX^N#KGCU-6TRVO;:OUUZ_A_5O\
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MW\&M7\:?$_6O!7C*]TZT\'_ 30_A]X'C\>^#;O1_&T.IZ/I4TIV _4CX*_\
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M57X6Z#::9::#^T;X"\*W7@V32]5NK'QEX[\7QZ1J&K?;?CG]B#]I'5?V)_\
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MRT\/RZO>^(KZU^'6B^ [FS\"Z%X2UGQQXM\5_%_P#8>'EN))TTS4?S8_:/\
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M'@K1]?G\2Z-)IMZZV]T+_3K46=Z8[>[,$C '\;/V/_V7K_P)\<_VI/B#X_\
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M7^U9X;\+2Z-XE\-^"/BIXJD^*MQ!\ O$_CWP1=_&BV\-?"?XQ>//@UJWC)_
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M;BUDF^FY/BA\+XO#VH>*YO'_ (%@\*:3XKD\ ZKXEN/%GAVW\/:5XXB\71^
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MX?T6\U?0/A]]NT_Z._:LLM;_ &1/VL/VR_C7\%?V%_$GQRT;QG^PG^Q!\-O
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MT30/&%M?: _QRLAX^\237GB[4/"EPW@?3;21;3Z66W9=-%KNWU_,#]8_B_\
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M5GJ^B:[XH?4;'X<?%#P]<:EH/B[4;5KWP_J\M]82?8O'?C1^RO\ M!>'4O\
MQ]HG@;]HGX>_"+X1_P#!:+]LWXXZUIWP+_9Q^'_QS^)'A_P)\6?@Q-H/PR_:
M6^%7[.7Q0^'GQ%\._%WPCH'Q9\0:KJNIW?A#X>^*_'&E2>,_$_Q \"6-SK?A
MRZ<2]P/Z?OAA\7OA/\<O!>E?$?X,?$?X>_&#X<Z\U[%HWC_X8^,O#'Q"\&:X
M=/NY;.^BTGQ3X2U35M#O3:7L,EO>0QWTKVLZO;W2P7"-&GY\^+/V]OC9XM^)
MGQB\(_L0?L1:U^U9X:^ /C;6/AA\7_BOK?QY^'W[.?A&\^,GA6'3D\:?";X.
MP^,O#_B?6/BIXT\"Q:C::/XIU?4[#P-\-+#Q*E]X3A^(%UKFCZC:V&!_P2>^
M&=WX-\._M2?$:>[_ &H-</QP_:%LO'MUXQ_:E_9T^%_[)OB/XI:QHGPG^'O@
M#4?B=X._9[^'_@;X3ZUX)\/^(8?#.FZ3<W_Q.^&G@CQQXNUOPW>^*;S3KRPU
M.TUB_P#$O@%\9-;_ .":]S^TY^SA\;OV;OVO?'.D7O[4_P"TI^T'^S3\3/V<
M/V8_BA^T7X8^.?@#]IGXE:M\<]/\"W?BGX3:%XDM? GQF\&>,O&OBSP%K]C\
M;3\._#=YIWAC1/%.G>*[G0;[S=,0'Z._LY_'[]G_ ./7A;X8_'CP[X:B^%?Q
M0_:=\ 7,MOX+^+_@_3/A=^TSK&A_!;5[_3_%/@CQAX5U;[%XUU^#X(^*?%VM
M66IQZ<WB'PIH,OBHZYH.HS:+XPT[4]7ZWXA?M<_LE_"?P;J'CWXM?M,?L]?#
M?P)IGC[7OA=J'B_XA_&+X<^$O"UI\3O"M]>:=XG^'=QK>O\ B&PTU?''AS4-
M.O[77/"4ER?$&F3V5U%=Z?&]O*J?E1\1/B'^T]X;^+7_  2^_;8_:N_99^(N
MFZAX<^'G[='P[^//P]_97\!?$#]I_P 1?L^WO[15W\&=8^ MMXL\)?"^T\9^
M.-<N&\'_  @_X1;XG>)O!>D^*/"?AOXG:A/86=Q)X5O-/\10_!H^&/Q2TCPM
MX)^.^N?"C_@HE^RI\4]0_;T_X*U^./A_\6?@I^R3X?\ VI_$OP.\$_M.?'72
MO%6D>'OV@OV3;CP%\:_$OCSP/\?O!_AW2;[2/B/\+?#]_#X.UOPW-HD/CS2_
M#_BV&]UIIVO_ ))@?O9XS_X*"_LM>#_VC?V7OV9;WXJ_#JZ\7?M<_#;QM\5_
MA!K^E_%#X=CPWXBT#P]J/@72?!5IHOG^*H=2\9:E\:+[QA>Q_"*'P?8ZS%XP
M3P'XY;2[J5=#NJ]E\&_M9_LH_$;XL^*?@'\//VD_V??'/QS\&-JR^-/@UX.^
M+WP[\4?%;PPV@3BUU]->^'^C>(;WQ3ILFC74R6NLI>:9'+I%S-';7Z6]Q*(J
M_!WX0> OC_H6J_\ !+SQ#XZ_9GU+X#ZMJ7[._P#P4S_9PL=?^!O[)GB'PCX/
M^"?Q!^,_QH^"NL_LL?%KXL_![X=S?$.;]E,?%7PSX(U3XQ^*;/5_$$/AGX3^
M/_$GB+POX@\0^&YI+E(<KX)?#KQ5XL^$O_!);]C[P9^PS\>_@)^T/^PY\</V
M<_%WQY^+/BSX':I\//@]\*='^!GAG4]&_:8\2>#/VE+FSC\"_M!+^UEN\0^%
M;"U^&OB;QKX@\;V'Q;N/&_Q)M/#^I:'JKV0W=WU_KY@?NTO[<G[#L?BS4_ D
MG[7O[,/_  F>D>%/%OC;6/"DWQ\^%DFN:7X,\ W&LV7CKQ1J6E'Q2;NQT+P7
M<>&O$-KXKU.[BBM?#S:!K::O):+I6H&WUM-_;#_9)UWX':C^T[H_[2_P"U3]
MF_2I;N+4_CS9?%OP%/\ ![3)K/4H](N[;4?B&NNGPI9WEKJ[V^E3V-SJB7R:
MI-;6(MS=7%M%+^$'@7]A_6;W]E/_ ()I^&O%O[)+7GBC1O\ @L_\7OC[\<=%
M\0?"*TN/$&B^"]2^,G[<.NZ%\6_B'!J&D27T>A7&E7WP9FL_$VN&2VDT&Z\#
M6D<W]GIHT$7+?M,?LN_M#:;\4_CG\6?!GP]_:&\)_"GP'_P69N?VD-8MO@#\
M#/AM\6?B5K?@/QC_ ,$P?@A\$M&_:.^$'P1^+_@/Q]X%^,Z_#;]HI]:O/$2Z
M/X(\5^-+.<^,O&/@73;OQ_X7M&A0'[_1_MF_L<W'P:M?VAXOVJ/V<)_V?]3O
MM1T>S^-2?&SX;GX4WVLZ9I^IZIJNAP>/SXC_ .$8?6M,TW0M6O\ 4=)74SJ%
MG;Z3?RSVR_8KCRO</ ?C+P5\4/!OACXC_#?Q3X7\>^ O&VBV7B3P?XU\(:SI
MOB+PMXJ\.ZQ +S3=<\/Z]I$]YINKZ3J5O,EW9ZC974UO=QNMPC9?C^7;P)^R
M7X_\>^-OAE\7O^$%_;>^,.D?$'_@K=^QK\6OB;KW[7O[.GP:^ \^MZ1\!_V>
MOC5H=]^T=:_L[?"WX9_"C5_A[H<&MZA\-_"WB3QY\8/A[H7BWQ/XC\&^$=0C
MM19Z9I]ZW]/?AKQK8ZEXV\<?#W3?"OC30X_AO%X02;6-6\%ZIH'@+Q!'XMTJ
M[U.UA^'GBBYMX]%\8)H,=HUGXICT*1QX8U26UTS4 EQ=(D8!S7Q3_9I_9V^/
M$OANY^.WP#^"OQIO/!S7C^$KOXL_"SP-\1KGPP]_):S7\GAZ?QAH6LRZ+)?3
M65E+>-IKVQN9;.UDF+O;PE/:%MX(HTBBACCCBC$<4:(JQQHB[8XT0 *B(H"H
MB@*B@*H"@ 3T4 5H8%3)=(RW0-@$X)W-SC/+Y8^K')YYJ);5L$9"="=I/S'!
M7<>.H' ] ?IB]10!%Y$6!F.,D #.T=B2.2,X!)(]"21@TCQ(5*K&N">0#L!&
M,') .00 ",<X'I4U% % 6N"-L48"D;,'E=N"N#MZJ0"IXP0",'FIUMXRH$D4
M;$=<J&'!)7[P.=HQCL#R!D#%BB@"G-:13,A*8:-PZL&P P(8,1W(89!QG(ZU
M$8!&VP $R8'/? (PV000JCY000,G'6M&FE%+*Q&67H>>.O\ B: *;6\C*RD*
M2>FXY'(.<\="VUB,8)&3VH^SN0N51G"@,[,V&;))P%Z<G))R3[$'=>HH SVA
M2,L71 FT;0 2 Z* I"A3C!5 O<!>G6JL**IP%"Y0;B%QDJ8]IS@9^ZI4G)PJ
MCHH U)E=@ N>X.&V]2ON.VZE6,&-%=02%7/^\%P>1UYSWYH H) LDF"B!BPD
M,@W"1BIY5^2) !PN> >1CFGM:1K\\B"4(V4' *DLRALX.6Q(_P V ?F()QTO
M+%&IRJ@'UY_QJ,K(TI# F$]1E<8V^@^;[W/],4 4]D>3MC"KV'4Y(P22/4 #
MZ#'U8T4?ER*D:JSDDD*%R2""2P&2<NYZY^=NY-:/D1?W!^O^-'D1?W!^O^--
M.S3=VOO_ #8&4\$?F1E(8UCC&6"K'&%/S OL^42##L GW06+9!J<0"=3F.-E
M!*[7Y5E4_(Y!W!BW.3R3@<\5>\F+GY%.1@Y&>.N.>V?2GJBIPHQP!U)X7@=2
M>@[]3WZ"FVFK*_\ 6O\ 7D!3^R!0 BG&<E6?*@Y!RH X((!SUXJ*:US& WDC
MG]V?)60H^"-V#QD*6&0 <G(]*TZKA'=V$HS'EBN2,9W?+@#D?*3U_G23U5[_
M ->H&?Y"%=KKN.Q%S@,=RYR<GID'DY[X/<5&8D6)8<!L@D?<ROEL7&U=P8<#
MLHQD^IVZ_D1?W!^O^-.$:   $ 9P-S8YSGC..<G\ZKF71/?9V2V\O/4#(9%,
M2CRHP,ALE5!.X@;F!4\G:"2OS9 '& 03V\+8&U(<!BXP%:1MZR _+@NI?S"2
M3DEFXRQ-:4L<8C9MHRJX!Y..P]?U_&F)'NCE! +Y8<G/.Q<<\#J?H#FCF6FC
M6[>V[]=U;IWV JPVJIEL@@J5V9<QG[P^969LD9(] "W&6)J#R6RSJX.]@2 O
MEJ!&H4@ '<05('S!?E4 9' O".8$?*P7.2 ZGC.3QG///0_2K/DQ<_(#DY))
M))/J23D_B3C)QU-)2U;:NGLK+S_3J!7='CQ^\8[CCJ<C )X^O?\ #'O9C5=J
MO@;F12S8Y)(!)/U/)]342)(V1,,@ $9(//.<;?;UJ9F2-1D[5X4<$XX.!QD]
M!4@1JD@D+,V4RQ W$XR>.,=AQU..W%!65I#N"F$D\9.< <<8Q][!Z^_'2B9S
MY6Y"03@J1CG=TSGCN,TL<R,$7=ER!D8(Y"Y;)P!V- $H4*,* !Z"F/(@81L"
M2V!TR/F.T ^F?Y4&6-692V"H!/![XZ>IY!P,G\:8WER*TB]4! ?!^4J-P(!Z
MX)ST/XT (\;97RL*H^\ =N[D=<#G@8S[XZ<5,R*V-RAL=,C.,]?Y57BE"@AY
M=Y)&WY3GZ<*!R?Q]>U22B4[?+SWW8*CTQ][\>E $U(RJPPP!&<X/K_DU7@=F
M9LL2-H(SCN3Z >E6: ($202$D_N_FPN[C!/R@+C  '&,\=N."GER&0ECF,DG
M:6R,;< ;<8X.#[$9Z\U8HH 0 *    .@'3UI'^XW^ZW\C3J:_P!QO]UOY&@"
M&BBB@"Q4%Q]U?]__ -D>IZKW&=BX&?F_V_0_W%8_F,>] %<!"P$A(3!/!(YX
MQR.>YX_PIK;-W[L[D1@I);<4;#94;CN7)(Z#!!/8FE&[^XY^BL?Y@' ]2 3W
M&:5 I<(X=<KR2H4?+EMQ)4$' Y.3T/N2 1N0 >HWG:2.002JMZXX4CMTXY(R
M[ C"JN<E/F4_-\N<L1G., N<CGOG.,N?"N53D+@G&&W H"-YSR/F^7H>  33
M N#P'W8(VD9.'&WIUP0,*?7UJFK1CM?Y7=T]^NG]6 <,;QN.$XR>G][/(Y_N
M_P"2:)I+>(J#YC9&X[=S#''7/&#^/O2-G:P*L#M/RL""<Y &.I#'CCGTYH,;
MRJI7!PN"N"0I&< 9.5/]X$GGD^\@("6X"%-H"CD9(YXRS9(/\7=N-Q/%/R\.
M&/R9&T%@I!S@X&#QTX]AQWS7\Q1(J2@,KJ&3(.2HY8JP*[ATRPC4#U(Z6#+Y
MF -FT?=0CY@,<' 8$+CCGKQ@G/#L[7Z=_G8">)HLAMW[QURP^;JV&; Q@<C/
M%/E.Z/*G*L1D_P"SGYCD].._:J*F0N0%;@L1M0D=<<=<C#'TQQR:N'BW 8$?
M* 00>N0,$ $X/TZ'D=J0')P.J^*9.!M-LZLY;'(6$H,9R3R>@] 177F:(8!;
MJ0!PW.>A''0Y !Z;B%SN.*XZ':_B=EE95Q:R,H.SY2$MB"KLBL<[B2.H/RG@
M5_-A_P %V_\ @H3_ ,%9?V./VA/V8/!'[ /P$G^(?PT\=>&/[8U;6;/X!>+O
MC=_PL_XLCQ=>Z5_PHO4=4\-3K'\.K:/PK;:+XB@U)6T;6=7MM?UB^T[6UM?"
M>HPI4DDTDK:(#^G]I(V#1[P2P*8![L,8ST!Y_K7YH>,O^"O'_!,_X>>,/$?P
M_P#&O[8WPD\,^-?#/B7Q+X.U[PSJESXB@U2W\3^$=1OM+\4:/#;#0V_M*YT*
M]L[[^T/[-^VPVUO ^H-)]B"W1_171);V]TC3[G6;5-*U>YL+*;4M*BO([R/2
MM2GLH)+[3(;I41+J.PO7GMXKA8U2=4$BH%?;7Y5_MI2W*?\ !2O_ ((LPK(Z
MPR_%K]N-[J-MPWB+]B'XE&-F"@+\LLA.Y@""YV\L:D#Z6_9B\5_LB^*/$'Q<
M\4_LR^-]!\4>(/VB+KX=?M>_%-]'\3>)M7N?$5E\3?"%M\#_ (=_$=-%\0.D
M7AO0O%GAC]FL^%=(T_2K'2;2ZE\ ZG?S:=]ON;R^O?L&/8@4EW1-SH8VN'1>
M79RSY?8Y)!#.X+N3L=VSMK\)OBO^SEXF_:)_X*E?MIV6F_M/?M$_LYZ9X1_X
M)Y_L*:I,/V=/&NF?#S7/$'CF]^*G_!0-O!?B+Q+XJ?0M5US4=*^'BZ7K=U;>
M VO(?!OBZ?Q+(_CC2/$%CIMC9K\!^%/VF?V\_P!N'4_V=?"]E<?M#:Q/IG_!
M+7]@#]JWQ!;?LN_M7_ K]B?7/%WQ*_:9\%_$*Z^*?QS\2?\ "9>$=7UGXC>%
M?"?B?PCHWA_PUX)T:.P^"_A7Q)%XHLO'_ACQ&NO>&;2, _K7G$2KCRYF208W
M1L2A90"%(Y4LRHHRJ"20*H0L,!>%\6?$?P#X+U_X=^&/&7BW2?#?B/XO>*]0
M\!?#'1]3OY!=>-/&%CX/\2?$&^\.: K;HYM3M_!O@[Q-XCDMW*A=-T2_>-AY
M1CKXE_9A^./Q^U?_ ()I^%OV@/B=%\/OC+^T9H/[/OQ#\4WQ^#OCKP-\0O!'
MQ?\ &GPT@\:)X7N=!\;?#2XG^'>L:A\1XO#>AW&O_P#"(30^'M*\4:UJVD:;
M::;!IR65M^1'PIT'Q)?_ !?_ ." G[0/B[]N_P"+7[2_BG]KKQSX[^-/CGP'
MX]\2>#]<\ :MXXU?_@G=^T5XIUCXB_ 'P;IGA/1-0^"W@SX9:IXWO/AM>>!O
M#\L/AV+2?$/A.W\9V-QX^THZWJH!_41&S!0LT[F-BK 2,S;O,^<$KM\X'=G9
M\RE6V=]JL_=!)([+OW^<Q\S[1(2#@JK_ 'PNU 2R*ZE8B RX^2OY[_@#^U1\
M9/%7[+'_  ;S:UJGQPUW6_B)^U#\9- TGX\7MYX@T^Y\1?&'PYH7[%?[57B_
MQW9>+(;9!<:O9:-\2?#'@B\\0^3!';Z3XEL=#M]4-I<210R?/_P0\=_&C2O^
M"7_[+_QT^)'[:?[?WQ%_:+_X*&^.O@K\/M.\-_"2Y^$GBOXD^(=3@G^,?B;_
M (4Y^S1:_$]_A[\(?V==4\2?"GPKJ,WQ0^//C#7TOH='^'=UXI:^@\=ZC;7$
MX!_13^T'X>^&'B_X5ZY\//BQ\2=?^%7@_P")&J>%/A\OB;PE\9/$WP'\:7'B
M;Q?XIT31_!_AKP9\3/!_B7PIXNTCQ1XO\2-I'A/1]+\-ZW;:GXG.K2>%XX-0
M@UN2PN'_  $'P#\">'+W]G'X#GPQH6@?LNVG@SX17_PY\,B\$/PQMT\">'?$
MO@_PO>&\5YYKNX\$ZYH.LB[ENK^\U ZBUUJ%W-JLE]C^2#QC=_&WXQ67Q*_9
M>^+7QB_:U\"Z)^S_ /\ !6;_ ((]1_#K2?''[37PC^-_[2WPHO/VB/B?IFF>
M*O"?Q#^-_P -=/\ '/AN^U;P1JTMG\2/ /A#6=>\:ZM\-O%D&A7LGB_7M$GT
MO2H_T9^-/QP^/NI_M7?%O]DRU_:H^)7PD^%WQ)_X*:?LR?LK7GQ0TC6/"]MX
M^^%?PNO_ /@E7H_[1-WX"^&/BW7M#O+/P7XY_:+^-_AJQ\/0^,);.[U:#6?%
M_B:T\&);>,-:T 6H!_1K++%NC:.0!#D,59@A *!20/D8;!]X@@1E6W!&4E;9
M(V+#)(!9B"Q8"0OF3') 99!EE7!20DL YY_F0^,'Q*_:4^"UQ^U_^R!\+_VS
MOC7K^C?"W]J?_@D)X:^&/[0?B[5/"_Q&^//P:_X;6_:.T_P?\<?@/XD\<Z_X
M=ETGXD2^&/!^BZ!XX\/Q?$+0M>URQ\(_&K2-"\3WOB"PM]-8_H_^Q-HWQ'^"
M_P"VG^V[^RSK?[0GQS_: ^%W@CX*_L6_'OX=77[0_BS3_B#X^\$^)OCQKO[6
MO@KXE:!IWC>+1-&U:_\ !NJ2?L]>$?$FD^']3$]IX9UC5/$-KH":?H]Y;Z?:
M@'Z,:-\1O &O^//'/PPTKQ1IU_XY^&^F^#M;\<^%X'NDO_#6G>/X]<F\%7NH
M%X8[8Q:]%X:UI[+R;B=T.FL)5@)MQ+W3"TD W2%E4[@?,D*#!V[E.=F%+X9E
M_P!6#@E4XK^=3]N#XW?M)V7[0/[9GPO^'/[1?Q*^$EA!\8O^"%G@/X<ZQX2.
MA7L_PNB_:?\ VI_'?PV^-FI^%=*\0Z-JNAW4GC;PS%8QZY8>(;/5-(U*32[6
M*_M9+,SVT_V9^Q7I?CWX._MM?MP?LHZU^T+\<_CY\,O GP;_ &,?C_\ #RX_
M:"\5V_Q%\=^!_$OQUUG]JOP;\2_#MEX_.BZ7J=UX.U)_@3X*\2Z#X9U22YM_
M#FJZKXEA\.K9:-='3[< _0;QS\=?@C\.=!^+FO\ C/XI^"_#6E_ GP=!\0_C
M+<W7B&RDN/A?X+O--UC6[#Q5XTTZUFN-0T+2M0TKP_KNIZ7=:A:1)JEII5_<
M60N8[:1E]0@GL[VUAO;>Y\^.ZMH9[::*258Y[>>-+F"2-<KF*6,JX&-K)N4@
MJ) ?Y<?VO?AE+HWBK_@Y;^(-K\4OB_J=RO[ _@BSA\!ZWXSL]3^&-JWCC]F/
MXC7EI?67@T:-9S1W'A-_"C6?A)SJ\J6EGXA\6V82[GU:1X>]_:7\?_M/_P#!
M."^^*GB'X6_M'_'C]HK6/$W_  2(_;*_:ENO"OQVUGP_XW\->'/V@OV:_B#^
MR?X?\+?%7X>^&_\ A'])TKX:>%+#P_\ M#>-]3\5?"[PPUE\.+G2/".@!]#6
MZTQ]4N@#^E-8!O60,R%@@.V1E=TR< M&=Q3+G:,XW<]:L21VZD[V<,W)S)+@
MEMJ MAL $#:<X!7=NRH8C^>?]B74OVS_ (>?M>_ 70O&OB7XHW?P8^/GPT^*
MFL>,+/\ :F_X* ?LW?M,^(?B>WAW0-"\8>!/CM^S'X'^'6C>'O$NC1)J-Z^A
M_$+P_P##*W'P6M? OCS0-7C\-Z1=Z)I-[)]4_MF:7XY^,'_!0C]D+]EVU_:A
M^.G[.WPN^(G[)W[:/Q,\5:/\"?'>D_#KQ3\4O&?PN^)?['6D^"]&M/%4^C:E
MXATB[\.:-\0_&WB=[GPG<66LW&D:?JVFS3CP]?>(8+H _6:'[.<EI9 P147]
M].C@?+E=H96&W*+RH*,2#B0-AJK$@RO3&%,A,BD#!&]Y69DW*R,6)W.2A;)*
MD_S,?LQ^._VB/VR_C=^RK\%?%W[:7QZB^&7A[X3?\%,M2U7XL_ ?Q7X4\ :I
M^U78?L:_\%"?@_\ LV?L[_%GQ+XE\,>%[C39&\4?#_6+V]\;7?@4:1X>\?ZE
M;WMQ';MX-\1/I<V+XF^,7[0;?L>?&_\ X*BK^V-\:M&_:*^&W[8OQ6^&GAW]
ME2W\6Z+-^S'96?PM_;9U3]F;PI^QGKOP&MO#+7>M^./BKX!TK2;=_&\]Y9_%
MF3XD^/-*\:Z#XJL_"<6GZ5. ?TB?$OXE_#CX/>#M1^(_Q4\8:'X%\$Z3?>&]
M.U+Q3XCOVL=%T[4?%GB?2?!GAJUEN=W[F36_%'B/2-!L5;$<UYJ5M"<)(6'H
MRI; 99L,N2=LDH",&!( W'RW9P&9!AW?E@QP!_)=^V6WQ%^,W['_ .TK^U5X
M_P#VP/BQI_B#1/\ @IQI/[+UQ^RA%XE\&_\ "@M&^&_P@_X*:_#SX.^"?@_)
M\.%\.7&J/\5_$7P_\(^&?CS-\4+#6X_B5>2^)G?3[^W^'MZVF1?77[2G[6/Q
M8^'7[)G_  <'^,G^/.M>#/&G[-_QPUOPI\ -<O/$.DZ?J_PELO$O[$'['_B;
MX?:1X+6_A*Z='XC^*7CKQ1>>%+=[6=]8\3Z[J4>F_:M2N)P0#^A$"V691N^1
M694&]RH.W<2HW$;E>3&X#*^8R$A9"I\K\2_'?X(>#M"\7>(-?^)OA6RT3P%\
M1?!_PF\<WEMK2ZDOA'XG?$'4_ .D>$/ OB6#26O;K1?$FMW?Q0^':V^D:A#;
MS6]CXPT/4+N.UTR\2['XG:YK_CKXO^*_^"AW[0OQ5_X**_&/]C*V_8/_ &EX
M?A9X'\.^&]5\,P_ OX4?"KX=?#?X0?$32_&_Q\^#M_HT,GQY;]I)_'>I^(+^
M;Q#XA)D\(:SX;\*?"R[\'>(-'U>XN?G_ $RU\;_L]>!O^"N_Q;^&GQ[^-^F>
M)?$'_!<']CWX9SMKOCBSU+0_#?A_XB_&[_@FMHOCN30=*A\.PSZ+/XE\ ?&+
MQ!\+=7GEEU"?4/AAHGA/37CFN+$:A> ']1@-HNZ+S0 P8,F\J.&6-\XQ@EF"
MG)!!)(P 2&;++<LOF'(#!6,DG"@([8W'A<B-V88W.(V9BRQX_E^^*'Q7^.\/
M[*7[9O\ P4ZC_;7^./A+X]?LV_M:?M'^ O '[+MOXK\.0?LU:1IWP(_:>USX
M(?#+]DOQW\"%\/P)XV\6_M'>"-.\)7,_C+4]1A^+$WB[XM>&_$GPX\1Z#8)H
M]E>Z'[5VN_M+R^"_^"T_[5'AC]M;]IGX=ZU_P3Z^-US??LT?"7P-XG\)6OPA
MT0^"OV-/V2OCMJNC?$CPA/X2U&Y^)_@[QYXE\9Z[HVJ>#_%NN:AH7A[2KW7M
M2\*Z9H'B/6+G5I@#]]/VKM-_9NU7]F_XT:7^UP_A0_LTZIX#UG3_ (TR>.]1
MO-/\)KX&ODCM=2?5]6LKFUO])CA>6"2TU/2[RRU/3+Y;:^TR[M;^&*X3PWX:
M_LW_ +(O_!/W0?BI\>+K7/'EK+J7AKPOI_Q(^._[0_QS^-?[1'C^T^'WA35[
MQO!?@N#XA?&?QC\0?&.A_#SPYK'BR]ET7P?X>NM/T6/5M5N]5N["XU:>2^/E
MO_!9B_FC_P""3_[>&JI<0V%S#^S#XVU&._\ L\=U#I-R+&WO$U:6SN$>*ZMM
M(E5-0FMIEF^TV]JT+V]PSM&_Y2_MI?$W]H3]BC2?VB?AW\*/V_/C=\=9/'/_
M  38\8?M=W_C/XD:UX3\3^-/@]\8?"?[2'[-WPU\%?$7X8^(_"/A;1=*\ ?#
M7]I'PU\5/BE#HOPJLK"X\%:7<_"&]O/AY8:18CQ+;W0!_4Z%LX>?-V9<?,9G
MW,[(H4LQ;,C-&J*K.79E50"<"HO,@>=E:4%D!(V,XDQN*J%,9$CC!RP0G&\,
MV Z$_P W_P 8_&?QC^*?AS_@K9^U;JO[=OQQ_9J\;?\ !//XE_%[PE\$?A'X
M!\3^&/#GP4^''AOX(?!#P;\5O /B7XZ?"K6?"^J-\=8_VCM8URYU[5G\87M]
M:W_@3Q#I?A+X6/X3\2Z1+JIQK7XZ_M8^*-:_X*:?MEZI\2?C?HGB/]BK]D_X
M,_&_X(?L5:7KO]D_!&P^-/C_ /X)P1?&'Q]X:^*?@VPTVW\9?$G0;;XAZQI%
M[9>%-5\31/H?B3PYJ6I:%;MK>LWL=P ?TNEK1<$RN6#,BDO*905"AT4C]Z<[
M 9 ,EF&6R3R@:R(1Q<;PP7:_G,Y=20T?SY)="S!HLDJ78&/+,*_EA^#?QK_;
M-_9_\2?"CXW?%7XO?%WPW^S[\5/@I\??BA\:OBE^TO\ MG_L??M,^#O&O@WP
M1^S5XX^-UI\>OV3_ ($?":R\.^)HM5^&^O:'HOB/4?AO\%(+CX:WWP8U763K
MNC7%SIVC^)]*Y_X(_'/]KSX1_M6?L$W\NJ_M^:QX7_:HT#]HBY\2Z'^V]^T1
M^RYXN;]J6Q\*?L9?%_\ :#\)^,/A3^R9\#?$7Q'UG]GF)?B'X+\&N1H^J^!+
M3P;H_B6U^&WB#PEKFH:[IUWI8!_5O<SVEM!<3R7,<-E% ;B>YEG7R(H8XWEF
MEGFN'^SQ6D5NC22/(Z0QQ NVU26KYD^ WP8_9XT7Q-\0?VH/A!J5SX\UW]JB
MT\(>,-7^+E]\4_%WQ:L?$O@*U75]?^'^A?##5?$GB7Q)I/A'X,:?-XP\2^)_
M!O@KX=_V1X$M;[Q9K.K:;IH:]\VOQ<^ &G>(O'W[,7[)'[2_Q&_X*C?'[4_B
M/_P4(_9A^)K^-?@Y>>)?"FJ^!OBQX[^)O[+'CGXG^(/!O[,W@G3-!M;/]F3Q
M+^RMK.AZEJNA^-/"EEJ!AT?P;J7@OXJ1Z_XA\3V>JVWD?["_A#QSX[\!_P#!
M*?\ 89U7]JO]J;X5_!3Q7_P29\$?M@:;J?@CXQR>"OB[\9/BM?1_!KPM-\)?
M#?Q<TO0[77=$^#O[,O@KQ"NNZ=\*?!FH:?J-]I_Q!\(R^);W7?#W@J6UNP#^
MIV5K8.I21=ZJ6R7.X#<JCDD$JQ<*ZC^^%;Y7YLW+K&J98@,0O.X@EB%7(' 8
MNRJN<?.RA?FVBOY>/@[XQ_:&_:O^+7[*'[-_BG]M/]HJT^$V@>-_^"OWPUU'
MXR_!OQMH?PY\>_M9^ /V.?CA^SKX ^!GC?Q-XW\(>%[2WE\1^$;KQ3XB\*>+
M?&/P_M/#MC\1-:\&^)KFX@NO#_C/7["__7C_ (*/_$[QC^SMX"_9_P#VH='\
M>7GA#X9? +]J/X/7?[3>GW6JW5EX4\1?LT?&'4+W]G;XEZSXVAMX9HKC1O@U
M<?%OP]^T+-?7*+#I,7PENKUI(T\Q@ ?H"0K-& [D&58VW22[7W8#))N60RJR
M.J@MP?DS)B/Y?E:W_;?_ &1IO#MSXI3XX>$ET*Q^!7Q9_:4O=1G7Q!;O#\ _
M@?XAB\(?%KXFWEE=Z1%>C0_!'B.2WT76_,MAJ)NG1K.VN8RI'\_W[)W[9G[9
M/Q2^*_P<_9L\<?%OQE+\1/VV_P!IC]G'_@I?\,)WC.F7_P -/^"9?Q#\/?$S
MX[^*_@9IVH6]DX7P9X&\0_L]>"OV?/%?VI8+W5D_:4TS1<B/5KW5K3YD'Q'^
M('QB_9Y\?_$+XJ>-M;^(OCS7?^#<_P#X+;1ZYXS\2W2WNOZK%I_[6&AZ#I$>
MH7!CC&W2]#T33='M(/LZK;6VG1VSF3R%H _L"\:?%OX;?#[X1>*/CUXR\7:?
MH?P@\$_#O6?BUXE\=W2W]SI&D?#G0?#LWC+5_%<\-E:W.I2V%EX;MI]7:.TL
M)KS[.K0VUN\K+&>VTZ^T[6]/TW6;":*[L=5TZUU73[U#/"+K3]2M(I[:ZB61
M8) LUH\942QQS1HP62.)BRG\R?VZ#'%_P1/_ &R5PCK!_P $K?V@ J.04<Q_
MLD^*F17C!4LIPNXY"LIV' 4D_DE\5_B[\7?V'O OPD^)'[(G[7WQB_:U\;_'
M+_@F'^VS^T9X_P! ^(WQ)?X[?#UM:^!'[-_ACQ_\(?VI/ACX!;[1X6^#/AO2
MOBQ?Z3\,H/AS\.-%T'X;?$#0_%]MX8/AJY\3>'%U5;T23LNG3RO_ %^0']5T
MV!NP)2QW$H$RC!F)=MKE=N3E"X90-J ."$ 8S?N0!'(>26 +?-NRQ.1(^QD9
M?,$I=/*8@JRDJ3_-G^PMJO[3'@S]KS]EO?\ %W0;CX2?M$_#SXH^)?&^D_%'
M_@K+K?[>WB?]J#0;#X>R^+_"_P =/@#\*-5^"G@G2/AMJWA/Q?%X8B\:7OP@
MU3P/\$(OAQXROM#A\'WFK6W@B&T_2']H+XP2_#K_ (*>?L)>%?%'Q1E\!_"K
MXA?LN_MZR7OAW6?&;>&? 7C7XC^"?%'[(^L^%'U'3;V_LM!UWQ;X6\&7?Q$U
MCP^UR)M5TK0Y/%NH:?Y5FFJ3(-I*_*GK^?1_=IV _258(I%4JI<JNPB/Y"49
M!LB>-E)<(L@(!4K&6!&.*N>5$&081IC$(AB/$F5(9F8* RH-J8# *K!0,;PK
M_P F7A+XR)^TA\1O^">W@_Q]^W%\7_"7[/7[2?[7'_!>JVFUOX=_M*>+?AM#
M\>O!7PR_:[U ?LZ_".R^+?AKQCIGB"P\*V'A*VANOAS<^"?$>@ZG9>!]'_X0
M+P9<V&@>(ITN_P!D/^"5_C;7O&?PK_:*\*S?%+Q;\<OA1\%OVSOCA\#?V;_C
M/XR\57OCKQ3X]^"'@ZP\%7,<=]\4[FZN]4^)[_#7XEZW\3?@Y9_$>_U34]=U
MNS^'4/\ ;6N:QK-IJ&J7:NNRWVM^M_PMW _0KP-X_P# ?Q+TB\\1_#_QAH?C
M;0=/\4>-/ U[J_A_4;35-,M_%_PY\5ZQX$\=>&_M5L[QOJ?A/QCH.N^%];M(
MRQL=6TR^T]RLML\:]ELB+$1X;Y66;<Q9@2/NH"2!&6# %,+D'8=P)K^3#]G_
M $9_A-^RU^SI\&]"_:=_: ^$'PI_:H_X+0_MN?L__M%?%Q_VC?&&J>._ OA#
MP%\:/V[=7^''PT\$?$#Q)K=YK'P,U[]I?XB_";X8>$_'7C;PI?>&O&GB?Q/X
MYUO6[75(O''CVSU9?UU_8'UG7?!/[5?[>7[)FA_&OXD?'[X%?L[6_P"S/KO@
M#Q)\6OB'KOQE^('PH^(OQA\-?$N^^*O[/6M_&3Q9>ZOXN\;Q^#].\&_#CXD:
M;:>./$/B'QAX,T[XL0Z)J6I'1KGP[:P)N[ _6+]WN^<DQ*R\_O&(9@ GS<DN
MS,.<EF).<@L*E80D-+&SECT*/*49@JX(1#L;Y0IWA2< 8; 7'\D__!4K]HCX
MLV\G_!2'X^_L^?$[]MR%_P!BXW?@_3_BII_[9?PH_9*_9-_9]^,_@+X%>"/B
M-;_"+0OV>KF_U3Q1^V#K?BC7_%^E>(?$K?%;X4:DOQ*U7Q?;_!KX4>.=(M]&
M@U:Q_8S_ (*C_$GXI^%?^":GQ \>_";XF^(_@[\5=8?]F#3-#^)G@?['#K_A
M'4?B7^T1\#_".L:IH]I?13Z=<'^S/$NHV<FD:C$^GZA8W=QI=^CV=Y*0@/T^
M M_G9"OFR,LKF.0Y:,(J/("I8*VW9N=?F8A2^XC-3)%:+&8I257:R^69&"F,
M@@IA-H(P)%,>"=H?*[0<?S7_ !-_9\^)NG_'G_@H1^SWH_[?7_!0>Q^'_P !
M/V(?A'^V%\.+=/VE]<B\9:5^T'\17_:J\/ZAXGN?BC9Z9!X]N_AU;/\  GPS
MK-I^SS?:M<? @Z[J_B2ZG^'+:)+HFB6'AGQ0_:(^)W[36BV7BFQ\<_MI>*O$
M/P7_ &'/V0OB5^T7XG^%_P"W-\-O^"9W[)W[,?Q#^-_P-7XRR_$;Q9XRM-:C
M^(OQA\4>-;/5++Q#>V'BCX6?$[X)^!='LM/T2*TEURXUS1(0#^L7;ISEQN0A
M-J./,<* A*I_$%(!!B5QG/,08Y*G@-*^(W@G6_'7B[X;:;K,L_C7P#HO@WQ!
MXITC^R]=M;?3M*^(7_"0KX2NH]7GT^'P]J[:O_PBFN^9::/J>I7.GM9QG5[:
MQ>\TUKK^7+XO_MR?M1_##]E+_@FS^TQ\-OVD_$'B/X]?M5_\$W?A;K'[7/@G
M5_".O?%3P3\!_@Y-\-O!/BSXE_\ !6M?A1X3TVX@\+ZS^R]XJ\<7EMX]T=;/
M2_"O[0%GXETGPG%I\MW\.M->T]5_:%\=_&CP)?\ [3OP2^#G[9G[0,N@>%-(
M_P"#>#X=_"OXWGXH#X@>+K>S_:+_ &U/&?PQ^*OQATWQ!K8U?PSXF\2?&GP>
MUA=^/-0N+&_\*^.;.#3]-O\ 2+CPM#;:4@!_3Z%MAF/>0S1EV!DD,@1&4EV9
MB70*=H5BPVC:$(55 A9+4 ^2V6Q&A DD*[-YV'&[!#,K1J1PY\V$$_O$K^6K
MXW?!KXH^"M2_X+#>#/#O[>7[?]OX3_8-_92^'/[5'[-FG7'[3WC[4]?\'?&[
MQ;\$?C;\0-;U'QMX^O+F?Q]\9?A[)X@^"'AG4=,^"WQ5\3^)OA)H\?B7QIIN
MF^#;6QU/08M"^VOA_P#M8:SI?QO_ &\=1^,WQQ3P9X:\*?\ !,+]AS]HK1-+
MUKQ7:^'O"_@:^\6>'/VLC\6OBCX'TF[N+:#1;>\\0Z1X+LM?UO3D,?\ :.G>
M&=.NY%N?[+B< _;^-;? ;):0<-@NYR<9RHR,M\K;@HW%E<$EP6=&EJ)!Y;?.
MQ=E4.Q!VB/<5!)7 4QGC .Y6Y)#5_)I\(Y/CG^U1\)Y-8^(/[8W[7?A1?A1_
MP;\_\$UOVHK*W^$OQ\\8_#2XUO\ ::^)7P\_:N\0^(/C;XKU[0+JQUKQ+XAN
M-1^%GA^[UO1=:U*X\%^.Y95D^(>A>)H])TJWL?J_]C+4_C%X%_:;_P""6WB[
MQ-^TK\??C+JW_!0__@GE\<?C9^TUH7Q5^)%_XC^&E]\5_ 7AC]C/QUX5\8_"
M+X46]M8?#[X)1Z/+\9?&WAB/0_AAH/AC0]1\+7FG+KMMJVOV4FM:B ?T2/+&
MA"LV&;@* S$G!.,*">V!ZDJH^9E!^<_CQ^UE\!/V;=5^%&@_&#Q[)X:\0_'#
MQ>? WPH\-:-X/\<>/_%/C;Q#;1P7.K)IGACX>^&O%6O0Z)X=LKJUOO%?BW4-
M/L_"GA&PN(+WQ+K.F6TT<U?GG^U9#=_'C_@H[X'_ &2OBM^T1\9/@%\ +3]C
M'6?V@?!OAOX(_&KQA^S;XG^.WQ?L_BY>^#?';:K\7OA[K7A;QW?:'\ ? =OX
M)\2'X>^'O%6EZ;J%W\44\3>+K'6=*\/VT5M^8W[/%GK_ .TO^V5_P2Y\8>/_
M (^?'SXC6'PZ\>?\%>_A%\(/C/H/QM\5^&H?C_\ !+]DKX[^ ="^#/Q&\7Q>
M![W1?"/CV\\<Z#''X3^*OBZQTN#3OCWI'@[1[_Q2FL:,]I;  _I+_:._:H^!
M_P"RGX=\)>*/C?XUN_"MAX\\;Z?\-O ^FZ)X*\=_$GQ9XS\<ZGIFM:Y;>'/"
MW@3X9>&/&'C77[R#0O#>OZ]J9TG0KN'2M$T;4M3U.6QLK62Y7S;Q1^WU^R_X
M0?X)P:Y\2-:@U3]HSXC^.OA7\&/#-C\)OB_K?C'QGXO^&'BZ;P1\1F3P;HWP
M_O?%VA>#_ WB& 0>+/B)XFT+1O .AZ?=Z=K]WXH'A_5])U6[^,?^"EOP>\/?
M$C]L7_@CO<:CXY^,?A68_M@?%[0(H/AA\9/''PQLIK:+]BW]I;QY)>W5KX0U
M734NM9>Y\$V?AB75%:+4KCP%XD\;^"IKF31/%VJP/^:/[.G@K6/VJ?VIO^":
M7CGXM_'?]J&Z\3>(/!?_  7JT.\UGPE^TC\5? UT^A_ K_@I)\/?#/@/1(I_
M"'B33)8=)@\*>(;#POJUGI\MM'KOAOX>?"K1=46YTSX=^'+2S /ZF/A_\2/
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M\+/VD/\ @HI^S /BE\8OB5\)/@9\2/V>-<^$<7QS^*?C/XV^.? MC\8_V?\
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M#\1_#K3_ !5_PD5G>>!]>L/$7BR'PXNJ7.JW>C6-[;W$M_<7NG6-S:@'[O\
MP\_8P_9,^&/PPTWX*?#G]GOX1>"_A9HOQ!\-_%BR\#Z!X,T>RT9OBMX3\3:/
MXT\.?$?4XTA-QK7CO1O%/A[0-=M/%&LSW^N+?Z/IDLM[(MG;)'VVJW'P(^&7
MC[QG\3?$5_\ "[P)\1_$_P ,;6]\=^,_$&L>&_#/B?5_@W\#[S6=1BU;Q'J6
MIWEE<OX ^%>H_%'7;FZU:[;_ (1[PI>^-[MKR_L)->7S_P J/^"@?[>OQO\
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M]F']D76M/\7?L\_'?XV^"/%/[(FLW^B:!^U0MM:GX6Z//X2E^)<_Q*\-^/O
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MVS/AKKDNL?M"^'_@1H?P_P##/@B70+_]G7PCHNHZTM_\0;^;XA:;J&@:;IE
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MCP#K=EX#L_C3IOQP^&VJ?#[1KGXK>)_$7Q-\36VO:CIOQ'\-W/A/3;"+2?\
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MF\%1ZQ'X.^%\BZ?I-NA^'/A-?$/B%O#_ (*8'PUI#:WJQLM,A%_>";@OAS\
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MQ-H'P(^)?PNUC]FSQ#X0T4ZI\+/V:?'?P[U3X7ZEX3TK_A*-/AT_6? /P/\
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M\/I[CX=:#)K'@#0QX=GUBYN)(;'Q)X=L+*.VOP#],[?]ES]@G7]!^*/[*P^
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M]7&W)S^\/.?X1WJ1H@R(A/"8P<>BE>GT)JI<NEOGO^H'PG\+_P!D_P 1:/\
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M=9O6T);2WBEGJ732WNK3MY ?K<KB2-C@ #<,'##[H/08R,'& 1Z9KX3\;?\
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M?"^S\21?M6:E\,-8^.C7'B'Q=9S^*==^#&A^'=$^%?B+1KW3-?LK_P !>)/
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MI^@S3Z78/X\T'P7\8_%%_P##^/Q#:F[U?7-2LKS2GZWP1_P4]_:$\3? >?\
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MA]HMQX>\(V6C>&[S4[GPWX4LM)TF[N+46?A32=%@OF?[5J@OKLB=/P1^./\
MP7ATCX,>+_C%H>H:#^Q7;VG[*<]KX7_:*\(?$#_@HW\./A1^T+XN^*.A>"]
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MXE:UX7$=KJ>@:=^M_P"V'^U#XK^ 47P/^'WP@^%5C\:/VB?VE_BE>?"CX+>
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M$N->U#5]&T8 Y;Q5_P $M?CO\8]6_:$\>?'[]K;PGXK^)?[0UM_P3VMM0E\
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M$^(.B3>&_$WC;P5XP\"^)M4\(^,M!L]>\)>,M<33?$?A37]!\0PZ/JMDEFP
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MQ4^'G[27P&\>?"6[^%%CK/[/?Q2^$%P?C_XPN_C[XGN_ 7P(A^$7@KX?ZO\
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M_ =_\=O"/@#X=7WQIU>[\%_M(?M0_LZ>(O 7@SX5_#_7])_:#^*'P'_8TO\
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M%]3\2^)-4\6Q?)_P._X*R?M/_$#P[_P2C^('B']GKXN^*=<_;)_9,_:<\?\
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M\7>)?$^E>&]/\0ZY:-VZ ?<'[9?[-:_M>_LO_&']FZX\73>!;;XL^&K70/\
MA+;?1X?$,NA"UUW1]<2Y31+B^TN'4 YTH6S6[ZA:C9,6$RL@SB:C^RD-0_:N
M^*O[4!\<7,4GQ0_9%\$?LIR^!O[$@DMM#@\%_$GXS_$5/'D.NMJ8DO[O4G^+
M\FCR>'WTNUM[:+0(+H:K.;MH(/F_7O\ @JW\(/!7@#XG>*?B=\$_VK?A=X^^
M$'B_X!^#O&7[.OBSX7>&KGXWW'_#3WQ'B^$_P*\7>"]/\(^/O$O@/X@>"OB!
M\0%U/PI8:]X,^(NLI9Z[H.N:#J=CIVO:>^EO3\>_\%4M!\ ^(K+X<7O['?[<
M6N?&]/V<K/\ :F\7?!'PG\.OA)KGC3X=_"23Q[\0/A[J%_XSUU?C7#\,[;7K
M'5/AMJVH6?AC1/'.O:]XNTS6=%'@.S\2ZC'KMAH2 \!B_P""/?C[P7=?LR:M
M\'OVD/A%9^+O@#^Q!^SC^P_=>)?CW^QOX1_:+N=.\/\ [.-KJT&D_%S]GZV\
M1_$_PZOP'^(OC-O$&H-XVT^>Y^(O@[Q*=(\"3ZWHFH7/@VU-W[M^Q+_P3''[
M&GC3X)^*F^.6K_%:X^$'[-'QI_9J4Z]X$TCP[J?C"R^+/[4X_:9M?'NL:EI.
MMSV5IX@T +_PA^I:/I>D6^CZ]>33>*+0Z!%Y7AN&/X<_\%?OV;_'FKZ'?:CX
M$_:0^&7PB^(7P$^)G[3/P1_:&^*/PE3PM\*?CQ\(/@WX4T/QS\2-?^'EI#X@
MU?XJ6,FC>"-<LO%VE:=\1?AMX%O_ !GX=6[UKP:FM6*V4]U[;^RQ^WGHW[5'
MB+3M#M?V=OVI_@?#XK^%6E?'/X7>*OCA\./"VG^ /BO\*=9O](T^SUWPAX\^
M'/CWXF>%=-\1*/$7AS4Y_AKXZU7P7\3HM$UVSUI/"=QIL&IR:: ?,WA;_@EW
M\5_@IX6_8RN/V;_VM;#X<_%K]D?X*_%K]G34O'7COX!Z?\4O"'Q8^$'QF\7>
M!_'/B.WO_AY#\2_!-]X4\:>&/%'PZ\+:SX*\0Z=XVU'3(I;;4=/\2>'O$&EZ
MLUM9==\!?^"7Z_!A_P!D"2X_:!\8>/;C]E+5_P!OG6+KQ#JOA31O#OBOXIZC
M^W=\0-?^(.O:SJE_X=U.VTOPMXA\$:GXANY$U/0]%:S\0WKRWUIHWA.%HM+M
M[?Q _P""@^O?"G_@H3\5OV>/B3\/O%GAO]EWX2?L+Z9^U3XX_:"FT+PZ?!W@
MM[/Q%\5[KQ=XL\5Z_P#\+ ?Q-_P@$'A/X<IX:T/3-#^'>I^)+CX@P:]]NM4\
M."PU=N[^!G_!2#P7\9?BC\,_A-XG_9^_:H_9KUGX\>$/$'C?]G35OVC/AYX1
M\':'\=-&\*:/;>)O$>G>%V\*_$+QYK/A/QMI/@Z[3QI-\//BKH_PY\<R>%+;
M5M5A\.R3:!KUKI8!\4?!7_@BS\1/A$G[,'A*/]JOX:)\)_V2/C3\)?BSX#\.
M_#S]BSX;?#3XA_&%_A=-JEBEW^U+\7++Q]K>O?%+XBZOX5\0:]977C[PKIGP
MXBU7QO?2_$?QAX:\5ZE<2:5%]"? S_@G3\:_@?XA^#_P]\/_ +<'CN+]B;]G
MSXA:G\0?A+^S?X9^'-EX'^([:>;O7K_P;\%/BK^T3I'C66]^)?P ^'5WK]P=
M \"CX<>&]8\2:;I7AG0?B%XK\5:;HLRZGT'[;'[:'Q1_9A_;!_8?^&/A/P+\
M2OC%X4_:"^&_[8O]K?!7X.^"/"OB?XE>//B+\+E_9UU#X;7>F>)?&'B'P5X4
M^'_AOPQHGB_XDZCXK\0^,/'/A3PB\,NFVVHZC)JQT.QO-6+_ (*C_!C7OAEX
M$\7>!OAA^T%\0?B]X]^*'Q+^".D_LA>&_ 7AZT_:6TKXO_!V)KCXM^"O'&C^
M(_&V@_#7P#;?"[35LM;\4^.O%'Q*T[X=3Z1XA\(7?A[Q3KDWC7P;;ZZ >#>!
M?^"6'QR^%GPQ_98\,_"W]LCP]HWQ/_8=\?\ QA7]F[XA^(/V;+?7?#4W[/7Q
MGT)O#OB#X.?'#X?VGQ?T.3XC>*=-MS9ZCIWQ4\(>+/AA<7.J^']'NK_PM,T^
ML-J'L'P:_P""9=Y\*]1^#>NZ_P#M#>)?B=XE^&'[=G[0G[=.O>(];\!>&O#^
MH^/_ !;^T1\*OBS\.?$/@Z]M/#>H6.C:!I.@WOQ9U#7](OM*T^6-;/1-*\.1
MZ-!;*+V'Z^_9A_:<\*_M,^&_%^HZ7X0^(GPN\;_##QQ>_##XO?!KXOZ)H^@_
M%'X4_$"ST/P_XLAT#Q1:>&M;\4^%-2L]<\&^+/"OC/PGXH\'^*O$GA3Q1X5\
M1:5JVCZS=[[M+7Y5^('_  5"\*?#?Q3K$_B;]E3]L_3/@#X;^-FD_ +Q)^UI
MJ/PP\$:%\$M*\=:Q\1=*^$MKJEOX:\3?$W1?V@?$/PQ'Q&UJQ\+?\+7\-?!7
M5? >HRO)K.@:YK'AI(];< X7X@_\$V_C*OQ4^._B+]F_]K_3OV>OAE^T]\0(
M_BK\6O!UW^S!\-/C#\2O!?Q&U7P]X8\+_$/Q;^SC\7O%NNV%M\-+[XBZ7X5T
M_4M5L_B%\/OC/H_AOQI>ZWXP\):=I=SJT]@OZ6^ _"OCSP]KOC"3Q#X^TWQ7
MX(NY/"4'PR\.0^#(- UOP-I6B>$].T7Q):^)/%=KKMW;_$"_\3^);2^\30ZA
M%X9\'P^'[>_70+?3]0AM5U%_S:_:#_X*\?"#X!W'QLUN?]GW]K3XK_!O]G/Q
MQ%\+/C5^T3\'OAUX%\0?"/P7\6FET&WO/AZSZ]\3/"WC_P 07/AW4O$6C^'O
M&_B[PEX%UWX>^"?$U\^A>)/%5CJ6E:U!IOIUW_P4L^&.G_&#]I3X=7OPK^.V
ME?#;]CNX\2V7[3?[46J>'O =E^SW\*+WPU\%O#GQZ:TN+]_B,_Q-\5WNM^!_
M$^EP6-EX'^&GBB\TS7+O3+37+;3X]:TNXU  [KXJ?L56?Q)_:7^)G[13?$:_
MT>]^(W["OB?]B4^$H_#%IJ%GH]GXE\?:SXZ/Q(CU236;.>_OK.75SIO_  C$
MEI;6EQ%:+<G6;=I6C'KGPF_9^LOAU^RE\.OV7;[Q#?Z]HW@#]GOPA^S_ "^+
M8K2#1]4U[2_"WPSTSX;7'B4:6+C4;32;_4[;3Y-5BT];N_M[&XF$'VFY2,RO
M\G^#_P#@J%\-I_$$^E?M!_ 3]J#]BO3K[X4?$[XX^ _%/[4_@3P7H'A[XA_#
M3X,Z$OB_XH:AI@^&GQ'^)VM^%/%?@OP6X\9ZQ\,/B?I'@;XC?\(O!J>I:=X8
MNCHNMVVFVOAI_P %*/"/B?7/L7QB_9^_:B_8^\(:W\,_'WQ>^'7Q&_:=\%_#
MCPQX-^(W@'X8Z*GBOQS?62^!_B;\0?%7@/Q-HO@=IO'\GPZ^+_A?X?\ CE_!
MNE:[J4.BR2^'_$&FZ6 97[,__!/?QS\$I_V#=1^('[0.F?%75/V#/V>?CK^S
M%X.F\/\ P?7X:67Q ^&GQ-M?V?= \!W7BFTF^)7CB73_ !9\.O"?[/FC:;K6
MHZ9.^F>.]3UR[U=-*\+&SALY\OP5_P $Q['P=\3_  /\1X?CGXM%UX1^)_\
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M&74K@@ +\S8&<>WK@>D1CP6"J60G.2<*_3#%R-I.>F"!P !3;O;RZ=-K?IW
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MG\5?%JQ077A+P?KUKJ&ERWWJVG?\%'_V.-4_9[\2?M/P?&O3])^#_@SQW/\
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M\+/@='\$_CY\9/!O[!__  4*\<_'*U^)?B3QM\#/AQ\2?$W[07[:7[-/Q?\
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M9H?ZS_9TVJN6PH('/.#Z\>U1)"[,PD&%)W J-I+<#DY/;/XDG- '\_O[:O\
MP3E_:9^.W[2'Q.^*GPD^&G[,O@GXA^,[GX?)\%?V^_AO\<OCQ^S-^U+^SWHO
MAW3=!L=;L/B[\,_AGX0\2>#_ -LR/0KO3]6O? ^F>.?'GA?PQKV@:M:_#_Q9
MH.FZ/HMIJL[OVH?V#OV^O&7@_P#X*6?LX? C3/V7)_@U^W_\4V^-VG_&?XF?
M%3XD>&OB!\.+O6_A+\#/AI\0OA;J/PC\,?!#Q1I'B*XUN?X,RW'A#XBV_P 3
M-.MM$TSQ0]YJ_AK5]0T.VT[5_P"@A(E0[@6)P1R<\$@_T%24 ?AO\8?V6/\
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MC'3FB3ZV\K-K7U6NV_W 29XXY7'RYZDCL0/;&.AX;(&*:65OD!<&/Y%(QR,
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M R6-/')+.B20K/;I&;J-9HC) KH63[0@?,*.@=XI)"H=5+*" ") _FY^$G[
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M30_[4;P[KT^O:7X;O+/Q)IFI6MO97FFQVNJW8!Z)UIB1K&,+PO&%[#'^/?\
M+H*HVFI6^H00W5A/;7MI=)YEI>VMQ%<6=S&RL4>"YA=XIU8JV3"TF%!;L13M
M.U&TU2V2\L;JTOK24R"*[L;F&\M96AFEMYECN+=Y(7:":)X)E60M'-&\;A64
M@ %I(@C,P8G=USCU)[>Y-.D02  DC!SD8]"._P!:\2U+X^>"[#X[:!^SK!;Z
MWJWQ%UGX8^(/C#JJ:79VTVA^!?A[HVOV?A72]<\>:K<7EM_83>.O$<VJ:1X
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M4MK);=KNYLK-;N[M]/MFO+N*U6XOKMQ%:V=N9BHFNKAR%M[:,F>X;*0QL>:
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M3< "04DZ9[1NV,9/7&<\=*:D)&'\QF!R-K= 67(([\ @<YZGVJ;@G[YSCJH
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M@/Q=H'C ^ /&_B#X;^.?^$?U&WU0>%OB!X933YO$G@W6/LK/]B\1Z&NKZ?\
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M&K7NC,O[L*,2,2B[Y/++E!&LLVP-L21@=S *'"AV. K@'' \<\:_ ;P=X_\
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M\6#]EJU_:4NIKNPTNU^ PUK_ (3%;&#QE<+\+9_B9#\,8/$B3I/I-VN7X/\
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MBYH/P_N/BGK'@3PO:ZS%IT_B_7=.^&]EJ/C2Y7PVNK6JZ!H^LWBW3KHVIK:
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MPQ)X@\8Z'?>%?#VI7KV>BZ[XAETO2M*U"\O-<T6+4/H8N&B):,A%W,8AL7@
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M$%LF@:+J<%M-)!\6>//!GP*O/V0O^"3NL?&GXD?LL>%=6_X=CZ#X?\*?"?\
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MX=U/R;4=U)5_*:%@A .8Y,MD,"I (.:<;O=?CNW?[OZT _(K_@F9X*LO'?\
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M;3PE!XOUKP-XU\>VMAJ,'QWM_A5X.\=^)M4\2R^#K748.3_97\3>)?VPK/\
MX)^?"']JG]KC]H;X?^!M1_X)(_ O]I_0+OP)^TC\0O@!XX_::^/GBOQ'XE\,
M_&_QIXY^-7@CQ'X5^('CNY_9^\*:-\*/$Z^#K?Q8FCQZE\86\3>--,UZS@TI
MK/\ HBO/V8OV<-5M_@U!J7P!^#5Q#^SM?)J7P"MG^&G@T6WP2OHK.+38[CX3
MVZ:.L/P^9=.M[6R"^%4TI#:VMK RF.V@6/%^(7['7[)/Q;^'_@KX3_%3]F#]
MGSXD_"[X;):Q_#KX<^._@Y\/?%O@;P#%8V<.GV</@KPIKWAZ_P!#\*P6VGV\
M-A%!H5C81)8Q):!/LX\N@#\ O@EXA^,O[9&O_P#!.3X+^./VO/VC[OX0>);'
M_@KSI&K_ !-^#OQ3UWX/>,?VP?@Q^RQ^T;\&OA'^S;X^\:^/?AX/#^LRW6O>
M!=6L_$-S\1?A[J'A74_&$MWJ6N:%KEOH'CG5(M0_5'_@F9>>,?%?[*?CWX>>
M._BC\3_B3)\,/VH/VW?V<?#_ ,2?''C+4=9^+M_\.?A/^TK\5?AG\/Y_$GQ&
M3[-K>O\ C+P[X+TK2=*3QM<S/X@OKG2[35[^]FU=)[A_OJS^&/POTK5?!.JZ
M;\/?!6GZQ\-O"VJ^"?AS?Z=X3T:UO? '@O7H_#\.M^%/!=S:V"2>%?#.K1^$
M?"T.IZ)HCV&EW:>'M"CN;9UTZQ$6KX;\&^"O =EJ&F^#/"OASPC8:GK_ (C\
M8:EI_AC1-/T2SU'Q5XMUB]\1^*_$M[9Z3;6T5YK_ (FU^_U'7->U6:*74=9U
M2ZO-0OIKFZEEE(!_*O\ L#6WBCX(>!_^"9'@[P/\8_CSJ?@OXW_'O_@L3<?$
MWPOX^^-'C;X@:'XD@^$T'[26B^$=,EL_$FIW5I#I-GK'ANQ\<SZ=81P6=]\0
M+C5_'%RMUKNIWVHS>1_LJ^'7\+^'_A=\=/#_ ,2?B[X8^(GP[_X-</@I\1?!
MNF>&?C%XIT'P:FNZ3X)^,WAZTN)OA_IU]%I&NKH\QL?%NE2RK-;^'O'=M:^+
MX;>/Q!/;7\?]9FA_ 3X'Z)!X.M-&^#_PRTJV^&UUXWOOA]!IO@CPY:1>!KWX
MG'6#\2+GPD+?3U'AZ;Q\==UEO%[Z4;1O$8U:^.K?:Q=R[^1UC]D#]E+5[KX9
MZAJG[-GP)U"[^#/P_P#$OPF^$T]]\*_!D_\ PK7X6^,O"D_@3Q5\-_!*'1BO
MAOP)XB\%W=WX3UCPGI2VV@W_ (=N[O1[BP>PN[B"1MWZ6W_.Z _";Q5HGBKP
M'^S-^P-\'K'XZ?\ !2/]HKX[_MN:?:?'CQ7X2\%?M<Z?\+O&?Q?U#PA^SIX(
M\2?%"SO?VC/B#XT\(WG[,?P0\/7OB+2?%/\ PK7]G35-#U[Q-XBO;73-(TI_
M#G_"7W4?QM\,?^$N_:$U[]E_X??$_P"/_P >WTC]GS_@OGXF^ GP_P!0\+?M
ML^(OC1XG\#>%M5_X)B^+/B_<?#S7_P!IVQL?#^L?&/7/"_Q4E\0^"['6/$%G
MJ?BOPUH'B[XB_!6;Q)KFF7%[J]]_5;\6OV4/V7/V@?AWX;^$'QP_9Y^"WQ<^
M&'@YM(N/"'P^^(GPT\)>+O!_A*70M/&DZ/+X7T+7=(O=.\/OI>D.='LFTB"S
M:WT>232H\:?++;-SNH_L2_L7ZOX&U#X6WW[*7[/$WPYO_$_A/QK?^!(_@QX!
MMO!]QXS\!Z-I_ASP3XK;0;3P]#I(\3>$O#VDZ7H/AS6DMUU31M%L+'2M/N;>
MP@@@5 ?A?I_Q2^+OQK\>?!_]G#XF?M2?&[X8?"#X\?\ !2[_ (+">!_&/C[P
M/\2]:^&GQ*U^/]FSXS^,[']F[]DOP-\;M-O;3Q#\+?#6J>'8O$NN6.C>#M6T
M;Q=J^A_"2?PEX=U.RTR76DGYO6O'/QMNM27]D#P+^VA^T9JOPA\&?\%K?@S^
MRGX1_:6T;XKVWB/XX:K\)O&'[#NJ_'CXQ?LZ>(/C-=Z??WGCN;X<_$O4]6\%
MCQIXF&M^.]$=M&TS4M6G\<^ 8-4B_H7\<_LI?LS?$_P!XH^$?Q%_9Y^#'CCX
M4^-O&FM_$?Q?\//%?PT\'ZYX,\2?$/Q'K5UXD\0>/M9\-ZEI%QI=]XUUGQ+>
MWNNZCXKN+5]=O-7O+K4IK][NZFGDW/#'[.7[/7@3P;\./A]X-^!WPB\(^ /@
MWXA@\7_";P5X:^'/A'0_"?PS\6V]OK=G!XI\!>'=,TBVTGPIXD2V\2^(H%US
M0K2QU4IK^M*;H_VK?>> ? O_  3SC\9?#GXV_P#!1G]F>[^+/Q?^+7PX_9Y^
M/_P9MOA!<_';XF>*?C'\1O">@?%C]EGX/?%?Q+X.O?BAXVNM4\>>*/#UIXT\
M1ZS=>&_^$JUK7-3TFSU&33$U&Z@A2,_F;\5/BE\<_AI^V9\1_P!H[QC\;?C]
M\4/V>O!W[>WPV^$LGQ6_9*_;/\-:M\/?V?\ 1?$/BWX7_"BT_8S_ &F?^":?
MQ*L/#G@O4GO_ !+XE-IXQ^+GPOO?B+^T)=0>.]+^*'A:?3+72;/PO#_3'H_@
M?P%X>U_QEXKT'P=X<T+Q/\0+S1]4\?\ B32O#MEI6M>-+_P_H-MX9T'4/%>L
M6MG;WOB*\T3PUIEEX?TRYU6XO)]-T6SL]+MWALHX(!XIK'[&G['GB+XY:;^T
M[K_[+G[/NM?M&:3<:?=:7\=]5^#G@+4/BS8W^BV2:=I&HVWQ#NO#\OB>/5='
MTZWCTW2M475/[1TRPACL+.YM[5$A !^*GC+]JKXFZ%^P)^UIX@O_ -HSQ+H_
MQ>TO_@M9XG_9V\#ZI)XXEM?&^@>$KO\ X*K^ _"WAOX*Z '8:E;Z-/\ LYW<
MUM8^&K2%@?A'J5SJ7[CP])=7<'%?%#0]?_:#_;E_9<L/B#\;/C[HMO\ #O\
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MOB]\5-+N/A__ ,% -2_MU?VW[W]A?XR_M->*_P!DW]NOQ#^S=X.TKQ#^T?\
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M@;??L\_$#0/#U[IX^%'A7X:V'PR6.+X,ZQ8-;Z_::(_W=_P18\"^(=1_9#\
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MI6K>)?&%KJ'PJ\/R7EGKLVI>%_%TWV4^/] \41Z/X<M[#]^O'O[('[*'Q/\
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M7?=??_P/78#\WOCAX.\;?%[_ (*HZMX7'QA_:(TSP)\ _P!@3X/_ +1O@OX
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M75PA'E2(,[1M 0J&!92K,#T=SM;84Q_+!\;OV7-#\1_%K]LWXT_&']BK1_\
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MKF@^)_#FF:%XUT'4+F\DL_$BI)%:)Y'X&_X)-_LU?#_1OAIH^D>)OCUK-O\
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MXX>/OA/X_:3XA?M%ZS\8O WQ$_:2^$W[.N@_!S3/$/@3X>?%":#Q1<>+=?\
M#?Q%L?'NK>!I]/\ "5AJ%_\ N'^UY^R7X6_:\\&_#CPQXA^(?Q6^%.K_  E^
M,W@SX\?#SX@_!K4O!FF^-/#/Q$\!V'B+3M OXAX_\$?$+PKJ&G+;^)M36]TW
M4_#%W'<EH3YD8C99/F&?_@E#\%/%VD_&B/\ :"^,G[4/[5'BWXU? CQ+^S1>
M?$?XY?$;PNWB_P"'?P;\7ZGI_B'Q%X9^$VG_  L^'OPJ\ >#-1UWQ7X?\(>*
MM;\4/X*U3Q+K^M>#/"EOK>JZAHVDVVCT ?EA+_P52_:8^*6C_''X,>%OVA/V
M3/C5J?CW]@S]K_XN>!/C=^SO^SC^UU\&O!OP9^)_P+\'>#[ZXTO3O'/Q.^(F
MN^&_CMH6K:9XZNY_#_B[X7^-?"WBOP=KNBZ+KNN^%VTK6[&UKZL^!?[1G[>/
MB3P=^Q)^QU\*O'7[,R_M!ZE^P!X._:P^-G[07Q5^&WQD\;^!+/X?ZI?Z#\._
M@MX2\*_#>'XW:'XY\9?$OQS?#5[GXE_$'Q+\7O[/TF3PAJFMP>%+J\\>Z#H^
MB?4VF?\ !,;P3K'CZP^*'QM_:@_:]_:8\8V?PE^-?P)MY/B[X^^&]IX9A^%/
MQ\\,:%X9\?>'M.\"_"GX4_#CPAI&IW]MX;T'5_\ A,](T:S\;:KJ5A9RZ]XB
MUO2++3=*TYO_  ['\.VGA#]GJT\-_M6?M:^"OC)^S5\,?$OP'\#?M+>#]=^#
MFE_&'Q'\!/$]]H=U<?"3XD:3<_!6^^#OC7P]H\'A;P@WA;6M4^%J>,_#^M^%
M=.\4V?BA/$E]XCO-: /BB37_ /@H[XV_X**>%=)\+R_LS? S]I+4?^"67A'5
M/C=IOC>Y^*_Q\^ O@_Q1H7[5/Q0TC2IOAKX,\)^+_@_?>)$^)VH(]T/$^O\
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MWQ#\1?%WQ?>7N@_\)-JGQ6O?$O\ PE;G6;3Q!IGAZ2W\=>*XY?#0FN=)DTD
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MP#\-](M? _Q0^&EK\-_!VMXUJ7QK\2&3Q;X@T20Z')H_@_78)+N*T\P\2_\
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M?%[Z#X5O=?\ B9\1=,\=^/=7O?"6@MJ.LO9KJ=EJ3::W ^1_'W[8_P"WE/\
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MKVXO[NYC-\]U]JBL=/@NELXOS]_:._X)_>,_@GI/[)OA/]D;X$_M"?$/PI\
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MCJ I_P!=M (R, \YSG) Z8 Z<4C%(4D2-O/+[0?GSM4#G<V#M!!(48Y/3N1
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M3M.EU7ZFT+]N+]NOX;_'3PK\#/VLOV8?V<_!]QX]_97_ &G?VG?"_C#X)_M
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M_90\,^+OB%^TQ\?_ -F36/C!\2?VTDT3_@G?X?U_X ^%-(\</XHTK]L_P_\
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M<GHV"$4*,!O+?!8<XV@A1@<\@"D<2NL:R[%8EE#;BY&T9PP*!264A0<$@GU
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MQJMMKT]G%I%\B^(-,1M.N+Z-;B)Y(G7X@^)7_!*_XP?M3>#?VAO%W[77QA^
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M#Q#I\UG#K5I'I^J:)J<D"^8+348](UW0=8DTNYO4TC7=&U(VFI6WY6_L@_\
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MA;3XV'QK8"\U.\M[#1+/3;4Z##I4L4E\;V5[Q;N.UVP+XQ'_ ,$A?B.G[/\
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MV7O&?[+OB[QQ\9?"WQ/U'X&?"W_@H]X+\::OIGA+5/"=WX[\5?MT?MJ?#?\
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M*/B1^RW\>5\/Z5XP_L[3]'N?'?P.^,?@[0_C/\"?$>JZ;H]A8Z3;:UX>\/\
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MOPA\'M=A\/7'B'5OA?\ '7]AK]ISXV_M3?#OXB:[I4UUIMAXC\(S>/\ QUX
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M\']*^.6C^+/BAHEQJOVC2A9ZA%\6]/U+PGIE_:7-Q!J.@+'K"263F*4 ]=^
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MZ[?4M1TFZL=)GAFY#X]?M3?M&>%?VF_VF_ OAOXM>)=)\(> ?V]O^"&?P?\
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M:;W4X[6UU[XN^!_#<A\ >)/%^F-<0>.+#PSHGC/5)!XBUK7K.-KFUW _(_\
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M>A3;G&<$D\4E%17-Y+T>NFE_ZW DC=G W)M5F*1[CGY1DC/XCI^ Z<.*[AD
M#"EN_08XXQUSC/H/IB9)$0!"I+$G! !QNSC&3D=2#C\,YICQF/:&8C(('ED+
MP,9#%ASUXQCOQ6>G3;IZ?,!)(O+4$D'=D#J"#C([D?AZU8G \M >FY?;^!JB
MB4NQ&0<+SDDCD]AVQCMC&?;%6'811IO&[&U3T/(4\\_0^] #'_U"?[JC_OI-
MO\S59"(V5N&(+9Y /S;O4GIN/O4_F"8>6@VG@C=C&%(...>G08_*G(R!EA*
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MJIUA_#*J^HC0&731JJJT0U;3G59A[M\3OBW\,?@=\/O$_P 4_C+\0/"7PO\
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M-+?6#BZ'XX_&KX%_';]L'XP?$[]I;1_V0_BC\-/A+\2_CK_P1L\"S_#+XO\
MASPCX=^)OQ@T']DO]M+Q9\6OCG^T3\3_ (9Q>)=5?PUX+\'_  T\>:/X(T.'
MQG.OCKQ+X:\&ZVVH>'+7P]IWA*VU#ZF_:#G_ &J_V</VG/\ @HY^T?\ LY_L
MK>*?C;XL^,?[.G_!.KX:_!,Z!I/AZ[T/5_B/X*\7_MLV_P 0OB#XLTVX\6>%
M=4\6:-\#/#?COX>Z_P"(M!MM3TKQ#XLCF\'^!=#U?1%U%?$WAX ^Z_!__!2/
M]@'XA^ _BO\ $WP=^V'^SKXA^'/P-L?#%_\ &CQE:_%3PBOAOX86/CE]3@\&
M2^.M2N]2M[7P\OC"XT?4K/PO#J3PS>(;VUELM)BO+DK$WH_[._[7_P"R[^UE
MH7B'Q'^S/\<OAM\:]+\)ZE::/XO?X?\ B6PUG4/">IW]O)<Z99^*M&CD36_#
MTNI64$]YI(UC3K0:G8VUQ=:<;FWMY'7\,K[2?C)HO['VO^'?@7^R'^V'??&]
M?VCO@3\8/VH/VCOVK?V:_P!GWXC_ +2/Q2O-0UW4KSQO^TU^S[\,?$?Q+\7?
M#7Q=\9O@]+X3\*V/PH^&FIV-KH'P'^'DGAS3_A;\/_$ \&:+X6G]V_X)E^ O
MVB;?]M;]K[XY_&/PG^V6W@CXO_LY_LI^$?AU\6OVT] _9N\%_$KQ[J?PD^(/
M[3LWBNP3X;_LT^'/"&C?#?1]$@^(^AOH7ASXA^&K7X@:E87%UXBN7@T/4]-T
MRP /O7X8?\%#_P!G;XD?M7?M5?LBV/CKP=8?$7]E#PUX-\4>-EO_ (A^"GN=
M0TG5]"DUSQYJD&A1:J=3T71/A%]N\*:-\0=9ULV]GI&O>)[*QNOLJ"">]]:_
M9\_;2_9,_:R'BP_LR?M%_!WX\OX#N;&V\9P?"WQ_X:\7W?AD:L;L:'>ZO9:5
MJ,]W::/XB^P7S>&]>: Z)XABLKR?1M0O8+6>2/\ &S]K']G3]H'XJ?$?_@LA
M\#_!WP7\?7TW[7W[/_[,GCWX'>.[^RM[;X'?%@? OP;I_ASXC?LZ^)_B0NMI
M9^"?%WQ$EL;KP/\ V/XNM]*TR^\->*M2\02W]YH]IJB1?2_P-?Q_^TS^WY\(
M_P!I?1OV1?C?^R5\,?V?_P!CWX[? 3QC?_'[P;X$^&OC3XH>*/B_\2?V>?$O
M@/X2^%O"_A'Q;XLN-<^'/P-LOA#XXUVX\9->#P;#XB\:Z58_#6ZUZQU?Q-J%
MJ ?>G[07[;O['_[)][X5TW]IG]ICX)_ ;4O&ZW,WA33_ (J_$7PQX+OM;LK&
MY@LK_5;.UUO4;2?^P].N[JUM=1UZ5(]%L+BY@AO+^&25%:AXZ_;Q_8O^&/Q
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M^&W@O7_&'A;3O$>DR^#O Z>$/$&D:1XA7QKIG@SXM)?:=X7NK.Q\26P^[_\
M@DY\-OBE\.OAU^USJOQ6^ OB/]FS4/C#_P %!OVH/CSX2^$OB6^\'W^JZ=\/
M/B=J'A'6/#>KW$_@'Q#XI\)"Z\0&*_U36[31=9N=.L?$\NO:3!=:G!;+J^H
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M)5MK7BS7/B_J?[1OC"[M+29_#T>@:FWP[\8>*?$'Q;UG1O$=I<^'M1 /O?\
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M,?[8?['7PPU7X?\ [8WPWUCX3_L->'/V3?B%^TO\(=>^,/[1WA#XK^$OCO\
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MKQ?XOU#XFZ?\<?BO\0=!\=_$"_L;5#H6@>#]3U/X@O:_$);#0V+ ?LK\//\
M@HE^PO\ %WXP_P#"@/A?^UM\!_'/QCEOO$FEZ?\ #GPS\1O#VIZ_K.I^#5NV
M\7:7X;BM[M[;Q1J?AA-.U*77]/\ #ESJMWI4.G:A->PPQ6-V\,/PS_X**_L)
M?&SXG^&O@K\(?VO_ -GSXE_%'QAI6HZWX:\#^"?B=X;\0:_X@L=&@NKO6X=#
M32M1FAO]:T33K*[U/6_#\$LGB'1]+MYM3O=-M;%5N:_GW^"?PV_;D\?>/?\
M@F+%\0?@W^VOI%M^S5^U)\,_&_QQ^$M_^SC^QI^S/^PU^RI;S?!+XQ?#K5=
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MX4_LH? 7QS\;-:_9"MOVJ/BG)XV_:Q\9?#SX?^";B#XE6/PNUSP)X,\1:/\
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M_2=+\,W^LZ;!JTER/PY\5_LO?MP_M<^*_P!IZ"ST7]N3Q5%\3?\ @DA^T?\
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MHOX(_;-$\ ?$/2/VP_V<_!GA'PUXE\%^.-'U7P_X3\5Z%X(L/$>F>$O"U_\
M:&TO0K*];PQ->:?I4.I"E\,?A]\+_A'\/_\ @GMK7[:'P"\2>(/V#/@O\1/^
M"P7PTMO ?BGX'^-?B]\,O@;\6-;_ &Y/$FG_ +'GC#XA?!?3_"OBO43X#C_9
MTT#XG_#/X+>,-0\'ZMX1\"#Q7H%AI%YH\7C/P]JS@']+G[/'Q]\)?M'^%/'?
MB_PCHOB#0;;P'\=OC_\  "^A\1#21<:EXF_9X^,'B_X0>)-<TPZ1J6K6L_AW
M6?$7A#4-5\-37DT.IOI-W:OJNG:??-<6D65\$OVJ_@Q^T+H_Q@\1> _$MM)H
MGP*^+OQ/^"?Q(U/7+G3=)M=+\3?"35IM&\8ZDLRZE.L?A 7]K>G2O$.HG3;?
M5;*PFU..(:?Y5Q)\0_\ !%'PAI?@7]B#5-*T'X;^,_A!X*F_:Y_;K\0?#?X?
M?$'PEK_@3Q7X=^%>O_M>?&+6OAK;ZEX8\3Z9I.MZ8DG@:ZT">QCO-/@?[#+;
M%1*F)'_#/Q_\&O#&A_"S]HKX?>"?A;HGPTT'X4?\%LOC5\2_VXO#5M^PKXP^
M-6A:I^R]XUNOVB;_ /9/\>?$O]G_ ,'0_#F^_:K^ '@_Q9X@^'7C*#0/".O^
M--#\$Z);V_C2_P##=U9>%;W3)@#^Q"#Q]\.;OP?_ ,+ M?'7@^Y\ +9R7I\<
M6_BC1IO!PT^&4V\UVWB:*^;0Q9QS@P2S->B!)LQNPDXKP?XO?M8_ KX,1_L]
M77BGQA87MA^T]\8M%^"?PEUGP]J&A:MX=UKQ5K?A#QEX^BU:ZUQ]8M=(M_"E
MGH'P_P!<FO/$5M<:@!J4FCZ1;6M]J>K:?9R?RP6_P%^%.M_LU?M$>/(_B?\
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M\5OAGX._:VUSX>_$[XN^$? GA;Q);/K/A+4_%.JZ!J5QX0UBWC=]]%K_ %W
M_J)T/Q%X2\4Z=;ZEX7\1Z#XFLIK:SOH-2\/:Q8ZQ9366HP)-8W<-WIMS<6[V
MM_;%;BRE60P7,/[^W+QKO6AJWC#P/H'B#PYX7U_Q?X6T+Q3XNDNH/!_AO5_$
MNDZ7X@\3R6<8GOXO#NBWM[!J&NRV<1>6Y2PM;MK9,R2*@+,?Q)_X(_V7P'F_
M:+_X*O:Y^S3\&]8^ WP3\3_M!_LZZKX(\$:M\&?$7P!^U)<_LJ^ 9M4\<Z)\
M(/%GAGPCXA\(>$O'6MW6H>*/#UGJ7AC0SJ]A?GQ5%IEG#KZ+7S'\>/#O[(WA
MWX^?\%&O"W[?/[(7Q+_:7_:2^.GQT\%:[^QJ?"GP*^)GC+XB?%3X"V?P6^".
ME?!KX>_LO?M$>%M$31_V?]2^&7QOTKXDCQ;<P_$[X7-\//%]_J7Q9\5ZE9:/
MXILM;F$[*VG<#^D/5/B-\-M'\5Z5X&U;Q_X&TGQUXB1+K0/!6J^+=!T_Q7KE
MN9@D,^D^&KO4(=:U&%Y=ZQO964RF3<J?.Q!Y'XBZ7\"O'$'A[P3\5=1\!:I)
M/\1/!.H>%/#?B3Q%I=CJ3?%;P)JFD?%#P%-X8@_M.RU=/&N@WVG:-XPT./1V
M76/L*07T<<NE7;^?_&E_P4NL;/XC6?\ P4XT7P_^S;\.OAW^TN?'WQ6UCP=X
M#\/?\$U/VG_VK_VZ_B*_@2ST>'X>_M+Z-^VOK7B:S^'/P,^'.MZ/X?MO&7@/
M7/AAIVK^%OA'X<8Z5X6.I_$F6[T%_NO]M3]D;X4?%[2/^#BW]H#Q%^SAI7Q)
M^-5CX/\ @[-^S7\3;OX87VM_$C2=6\%?\$^O@?XH\$ZO\ O$DVD2>(]*UC2O
MBC=/<-JGPWN;74[GQ%I,6CZQ<7-SH4-A9%W:VR[_ /#Z?D!_1+^U+^T)X9_9
M5^"OBSXZ>,M \4>+/#?A35_A[H^H^'O!=KI%QXCOKWXB_$KPC\,='DL(-=U+
M1=-F^R:QXRT_4-1674891I=E=FV2YO&M+2Z]>\-^*/!GC&+4;GP?XH\,^+;/
M2-;O_#VIW/AO7M+\0Q:7XET>9AJ>B7SZ9=WD=EK>ERC_ (F.F71BOK&;)N($
ME))_,+_@M'H&H^,_^"5_[3'AJ'PCXT^(\^NZ-\%=-O\ P5X"TC4];\?^,-/N
M_CI\)(_$FA^%=+T.+^U9/$>IZ>NJ6MN]HL$]GJ#QW;7-@EF]Q#^1?Q>\"^$_
MC/;?MO:]_P $;?@IXN^$7@73/^";7B?X-_%]/A5^SUXZ_9JT3XF_'C3_ (X>
M _$O@+X8^$OAUXCT'X*:I\2/V@/A]^S]H'[2O@[Q+>:$;37=);XJ>"_AWJGC
MO1-6U/3K?21.5M7?U6WW;7_3[@_JN\.>./ OC8ZI_P (=XO\*^+#H6IRZ'KC
M>&?$FC^(/['UBV#&?1]7_L>^O!I^J6X1VDL+[RKJ+RY':(>6Q6OXO\:_#WP'
M9V5[X^\:>$_!&G:I>KI.EWOBWQ7I/A6WO]3N8G$.FZ5>ZMJ-@)=0FC9C#:64
MWVD_ZR- R@U_-7_P2\\ _#6[_;?\*>.OV>?B!X'O_"W@/]G_ .*'ACXJ>'?V
M8?\ @D)\0_\ @G9\(H=-\3:SX';P/\._VB/&WQ$^,.I)XL^*O@?Q)X=O]4^&
M/@RV\ ^)_'7A*W?XH3>(=8\-Z9KURVK]A_P5 \1?#:;]N_PQH?Q>^"_[.NB:
M>G[,?@O1_A[\=_VH/V'/VE/^"B4?QAO?&7Q1\<'QI\"?V<O@=\,-?T_X4^#_
M !_X.&A>'M3\=:EK$EQ\5/B!!\0O"&DP:9+X.T!-31W=K6^=G?\ K[M /W]\
M':3\%OV??AMX*\#>$HO!'PK^&7@_0]/T#P9H@UC2_#WAW3=$%S9:9IL5C/JE
MZB7S:AJ.H6*OJ<MQ=WFMZSJR7=W=7NIZNT]SV*>+?"4^M:CH$/BSPU+K>DZ=
M)KNLZ"GB'29M9TC2(+R[TN35M0TV.Z-U9:3'J=A>V4NHWD$-O#?V=W9M.LMM
M+&G\L'_!-C]F/P?\8-1_X(_^'_VE?V>I_'WA_P"#G[ /_!1Z"#PU\?\ X)36
MNF?#OXBZ5^VU^S)X.\$Z-K_P\\=6&M:5X%\5:'X-M_%>G>#O!M_<7?\ PBVD
M:7/!X5N+ZRT>RU**WI_P&^$WPJ_X)7?M4_&G5?V*/!'C[XJ_'7]N_P#:ET'X
MW:WXF^&?Q+T[5Y/@YXC_ ."I7CFUL?''QP3X&:9I_P"T%\3?V;/A?X+T#PK\
M3/%WP:\'37.@>/? VAG3[[2E\+:WK6HT7?;UW_K^NH']1.@^./A_XLTF;7O"
MWC3P=XGT6"^?2IM;\/\ B+1M<TRWU2>XAM1IDFJ:7>W5C!?RW4MI:1V$DPNI
M)WM[98GD>.-K&A:YX9\1QW\WA?Q#HGB'^R=4N-#U@>'=<T_6%TS6;$JUWI.H
M#3;FX2QU:T1D%Q:7,D=];*5,D"]_X;O&/@S0OB3I/[?^@_"WP9\._%'PB^-O
M[&/[('AYM8_9$_X)[?&G]AC]GGXJ:WX6_P""AOA[0O%TO@;1-?UKQ5=?&?Q;
MX!\(^.+6TU_XL:!JEE<Z%I>HPZ+I1N[7PW?7VF?J+^V/^R#J7PT^-O[?/PS_
M &!/V?H?A=;?%+_@DAX';5? _P"SEX*@^%6D_%7Q'X9_:C^(&E^+/#FAWGA"
MQT'PO<_''Q#\#9?%G@?PW?-=P>-YAKVDQQW\5N+:XMSF?9=]G_7]?>'](VA>
M+?!GBMF?PWXJ\+>)56[U73I&\/:_I6N21ZCHTEM9:Y8LNF75ZIO-(DN[.TUF
M(JEQIYN+6'4%B\R+,V@^)?"WBM=3'ACQ+X?\32Z)J=SH>NCPYKFFZV^C:Q$S
M)/IVL?V7=71T[4+657-Q87?DW$4H=IH0Y8G^/SXK^'?@+\2?V@?C'9?\$@_V
M:?%_[/7Q0UO_ ((??MR^!]"N_#'[+/Q%_9&G\9?$'2OCI^QG_9OP^\#:)XP\
M%_"?4/$GQP\">%;WQ!X<U[Q3HMO]LTK6/&W@'0KKQW)J%G NA5/@3\(=0\>6
M_P"T)/\ \$]_B'X>L/BMIO\ P35_:]^%5MX6_98_X)7_ !2_X)SZ%9^.O&7A
M7PC8?!'X>_M!?%[XB_&SQ%#JG[2?@;QWI%Y>_"2SLO#OB7QYX6U"^^)>L:SX
MO\/:)KPN]>.9]E]S_K_A@/ZD_$_[5'PMT#X]_ W]GJTGG\7^*/CA+\;['3]6
M\(ZCX;UOP]X%UCX#>%/"_C/Q3X=\>W%OK?V_1-;U'1_%FE?V9ID5A>RK(J-J
M":?;R6<\WO7B3Q9X7\(Z5-KGC'Q'X?\ #&C:>]K%+JWB36]+\/:59S7+LL ?
M5-8GLK*.666.2.W'FK(\B.D>)(W"_P R_P"R;8?L&^)?^"C/_!.;6OV"OV8?
M$7P7@^&7[,O[6'@3]H+5K3]EGXC_  "TCPCXC7P%\%X?"_PE^->J^*? WA72
MO$WQZT+4V\77VLW-W>:WXGBMY]0GU77-2@UO3KJ\^D?^"Q?B[X>Z#\:OV1[/
MXP_"S]GJ+P);>%OCWXETG]I']K3]GKX]_M>_ KX>^-Q/\,]$M/A5H7[-_P '
M=7T;POK7QU^(WAZ^U'6O"'COXG7FFW&C>&_"/BGPW\-6U;7/$NJZ<S772[[:
M^>R_.W3Y@?NI>>+/!]II4>O3^*_#%GH%UI5UKT.KW7B+1X=(GT:R2*>]UN/4
MI[U;"XTRWCF@EN]3BE:TA$D,MS.&,;BM<^*_"UOX9D\87/B'0(_"<>DIKC^*
MYM=TI?#(T4[98]7;Q%<7\>B#3V0;XKZ74H[63<";E"PE3^/C]A+]ESPS\9?B
M[^P]\//CU^SJWBGX/> _VY?^"S7C?1_AK\3?V1O$GP-^$'AKPWKGA7X2>(OA
M+<VG[-/Q&A\1Z?\ !_X;^(;?QE+XT^'/PU\07=SI^G7U]%Y)G\1:'/Y/K$'P
MI\"_"3PYX#B^/'P5U2\_X)D?L]_\%A_^"DC?$?X/?\*?\2>//A#\,_"^JZ;X
MTM?V7O'GB'X*Z+X7UV/4?V;O!'Q0UCQ-<Z4-,\+ZG\/?!WBCQMX)\7R6=GIV
MAIJ&DM2:]WE6NFSO^=_^#]Q#BG)2N]+:*S3L?TH?!?\ :%\&_&_Q=^T+X.\)
MZ=X@L[O]G'XNZ#\%O$^MZ@-#;1O%>J^(_@E\)_CSHOB/P'?:)JVI27OA/4/"
MGQA\-VD4]U;Z;=S:G!J3)9?9Q!>S>TQ:OI=U8:7>:=K.DWUIK<R0Z-?V6K6-
MU;:TYBEECATJ^%X8M1N3%I]U.(+%KEE6SFN%C/D,R?C3_P $6-(^$^CQ?\%)
MM6_9]^%GBCX/_L^>,?\ @H9J?B[X&>%O$OPT\4_"&RU'P7J/[*G[+4,OBOP)
MX&\8Z%X=U+1_A9XG\7V_B#5?A_!9Z+IVF0>%[K3K32]/T^TCAT^W_*CXV_ ;
MX[^#OBE\<O@]X0^'?Q*M/A%_P1Q^)?Q@_P""J'[*]SX,T;48O#7Q4/QJ^,'P
MC_:.^''P.\!6.F6?F^)V\">"E_X* _ :]\'P2F&WL_&7PTCM'5;55ME=K1*_
MJO3[O0L_JD\9?%(^#_%OA_0(O!GB7Q7I=UX:^*&N^)_%_A?5OAY%I/PWO?AY
MH'A_Q':^'/%NCZWXRT;QE=:YX[L?$1?PY'X5\*Z_8:?)9&[\9ZAX6LM3T&[U
M3P;]FC]NOX;?M:Z]X3\/>!/"GQ$T"^\9_L8_LR_MOZ?)XML/#]I9P?"S]JC4
MOBEHW@CPS<-HWB#598_B#H4_PNUV?Q/;+'+X?BBN]+;2];U'S;Z&S_'+X&?!
MSQ=HWQ@_8-^/'BWP%XGTGXC_ +6OPL_X+&?MO_&&'4] U.34_ WBC]IS2/V7
M=8^%OPW\4O\ 99$T#Q7X!^!=K\-_@XFC7LJW-S+\,M3L[**864T<'LO_  2#
M\,^)O#_Q%^#,^M>'?$&CC3_^""?_  1Y\(7,VK>']4TL0^(M+\8_M@S>(?#L
MR7EC:O!XB\/PZGIHU?192-1TYKVT>\M+?[2@=<SWM^# _7/3/VG/AQ)^T/\
M%3]FG53?>%_&7PI\ ?L_?$*^\2^*Y_#&C>"/$4?[1WB'XT>&?A[X;\):C<Z^
M^JZGXS6\^ WC#[?HUUI%B'MY=.70YM3<WL.GR_&CX)_LT?$7QY\!/'_Q]T7P
MA?\ BSX/>/Y]=^ DWC;QIJFBZ=IGQ+O8[$V=UI'@V?Q)I7A/QMXNTF?1+#5?
M"W]OZ%XCO_"^L6::]X572]71[UOP5_;?M/V$-'_X*>_M<>+?V_/V:]>^-?A+
MQ+_P3J_9D^''P/U"^_9S\?\ QO\ #^N?$*Z\;?M87?C#X9?#N]\/^"?%FB^&
M_P!H3QA8:GX&A^'%W$^G>*[>.WUM-!UW25N]22Y^ ?'GPS^(G@3Q=X*T3_@J
M'XG^$>C>*M4_X)[?L-^"OAQJ/[7W_!-GXO?\%)X?%VN>&/@5=:#^TQ\)O@SX
MV\!?&7PSH_@+]H*3XX_;]5^)/AO2=.C^)_Q0N]8\">+-+\2Z_INGZ8FC',^R
M^Y@?VWI#*K-,ZR2J&V"-EE#L(SL6.*$QC>L;$ @M)M<*3EE!&5H?BOPCXCU7
M7](T'Q5X8UW6_"5\NG^)]%T;7],U;4_#&I2?,ECXBL=,N[B^T>_$:G9;ZG%;
MS[4XCV+Q^;O@?X<_M(:)_P $>+?X4> O''Q6U[]JRW_X)_>(_!/PN\:_%#PO
M#\+_ (RM\6+CX):WIGPEOO'_ (4O/&OCN?P9\1]-UB\\.6&L6NN^._$&IZ?X
MELGNO$.L7.HK>3#\L_V4M+_8G\3?'[_@F!8?\$Z?V<O$/PA^-OP6N/$\?[=&
MOP_LU?$/X)>*/ WP#E_9<^*7ASXC?"?]L;QOXJ\#>%D^)OQ5\8_M-W/PLN-
MT3Q%KGCCQ/J'Q#\.:S\3].O9-+L]1\47 Y-]%]S_ *_K<#^G/3_&G@O4-;_X
M173/%WA?4O$QT.W\3#PYI^OZ1=>(4\-WLJQ67B%='CNY=0_X1^ZD9(K+6/LS
M:;<;XQ;W#AUW=4>A(.1@$[P1R,@Y[@?WBO!!PHX&?Y-/V%/V,?A5\%_V4?\
M@W@^+?@7]FO0OA_^T;J7Q_\ #DGQH^*&B?"[^P/C#/X>^(O['?[7FJ_$G3?B
MWXLM=&MO&,OA?4?$EEX.TZ[TWQG?-H.G7VG>$=(LX[>&RT>T']9:Y.W^\1&2
M/1BW0\$CH,\''7!Z%-M^GSM_E^0"90#YO-D+#.47"C/&.@+ D9SSZ<]WAW0,
M5.&89)QG) <G&>  Q'IUYJ M,S!R0%PS,00ZO@E?+1VV&,C;N)P^1W!Z6H8U
MD7YRP8!=R X"DCD9_BSCKTI ,,<@'"-G*XZ="3N[D=, 9Z=JMQQJF& (8K@Y
M)/7!(P2<<BB5I% \L$DDY&TMQCVZ<_GGBI!G SUP,\8Y^G;Z4 (Z!QALXR#P
M<=/I3%A16##.1G&6)Z@CH?8U+10 4U_N-_NM_(TZFO\ <;_=;^1H AHHHH L
M5FCACP.IYQCN3P?XQV+84*1MVG((N32F(*0 <DC!.*K(F]B,[<AG) !SR..>
MWS=?:@!@."2H56*A2X0;F ^[EL8X[<D,>33&C5E:-V4AV#,7 (!4Y'RKCT !
M'(.&Y.:L2.0%A(&% PWKY;!<8]3QSGC..:@?:@C?8"SR%-V<8^;&<8P20<$<
M<<@]< $;H &^;>!M49+%3]T*"Q/F8!/3/&,# P*E#E@S.RJZ;(V3:?O \A2,
M CGY3TZEB1@B!2[3.P>)2APJ.6.Z->'9AD+O# E3@G;A?>IP>I&X#(93)@!P
M>?D'?.#A/0]<$8T;:4;;I+\?EY?\-8 5V$N%D4 QGY"Z %N><%2Q.,=&[ 8[
MTHY*KG VG)[C&,#V)S_A39 S$,"H8#JL8R0.=H/8G)P>N3WQ5="%EF09(\M9
M,.^YAC/RE2/E_7@9ZGA*/-[U[7UV^7?R M#!P=J\C[F2%7A2<#D@G..>@4 <
M4OT55SC)&<\$'^8%(I) /'(X]N%."?\ @1QT.!GG- 8'A7 /<2*R,.W<8(ST
M(/(YZ<TG&RNG?Y=FD];@-4!0%&2!SG!.<;B.@QU;] >_$ID8QB,@(O !96)D
M 8'*XX&3V()Z^HS=C&$0<'"*,CH>!T]J;,=L;'TV]\9^8=ZE;JV]]/4#BV'_
M !5=FVT@K!(A! Z&!&!..!G)('H/8X["29D8J%   (+9.XG^$ '(/N>/KVY9
MF_XJ>V;'#P [?1A$ZAL]\!L 8&.?6NIEC&6EW<J!QC/W2",X!;TS@$_I5SO=
M7WLOU K2/O.Y]H. HR#C ))ZX)&"=P'4#'>H9&;*H!YSE=P0/&)/L[ (TB 8
MF$9;AI 0,N4#8(PLIWM'NP 9(T1BI(5R_(V.HW;E(!)POKG&#_"=XW^*'P:\
M5?&;PQ\:?"O@S]F?X&_M&6O_  4B^#>K^)M"U"7]J;XZ_P#!6'PAX3L/V[_
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MO\L'[5GA?X!ZQ\7/'_CO]JG3_"#_  =^'G_!QYX1L?&7C'XIZKJ6D^!OA_\
M#CQA_P $I_A#I<]UK.MR:KIFD>&O#.K_ !*LO!%C'J-_=1:,/%=SIR3O'>W<
MB'MOB]<^%5UWX^P?M*:WXITS]@B^_P""ZWQ:L/VU+@:WXWT[P9%\.O\ A@3X
M=7'P?L?C%K'ABXM+W1/V;[G]HFW^'(^(,5Y,GP\DUFZ\.1>/+B'PM=^(48YN
MM@/ZI0EQG8Q=Y5VMN<$LJJ6*B-0SY4MDEI&5MP(23"QJJK$P$8E\QYBY,>],
MN%5@Q/F-ESL!4*=Q( 7=ELD_Q[7/A+X%_$?Q,OPC_98UCQC=?\$Q/&W_  57
M_P""??@[X/)\-?'OQ T?X.:AXPO_ (._&_4?VL/"'[,GC70?$6G:Q8_ ?4)=
M/^&FGZ_8?#S7(/AS:^-+WXFZ;X1^R++J:6_IGQMMO@W^QWX5_P""I7[.?A;X
M>7FA_LK6O[6W[ /AOP_\+H_C_P#$?]FO]FKX0_\ "_/@W\.]9^(7B7XP_%[P
M1IGC/Q7\(/V5=?\ $FFV]S\;+#P9H=QH_B5]6NO#%Q!I=EXPUG4[0YO)?C]W
MH!_2M^T'\>OA]^S!\+[_ .+WQ9O]9L/ ^D>)_AEX,NK[2-(O_$6J#7?B]\4?
M!OP@\%QIIUDWVIHI_&WCKP];W]ZA,6GZ;/=WMT%M[=B=_P"*/Q8\#_!G0M&\
M3_$G7SH6C:[\0?AE\+M'N8]/U;6IK[Q_\7_'F@?"[X?Z%:6.EVM]>E_$'C3Q
M5H^D?;&B2SL8;N:ZU*XLK"UN[I/XL_!^M^%+'X)?\%+_  )\+]:_9YN/A2/B
MY_P0K\>>#O"G[']G\:+?]E*#7O%'_!1ZW\)?$KQ5\$[_ .*^L:E8_$6&['@G
MPEHWC/XN_"2ST'X:>+M5\-Z;:'0H/$6@:X9_Z#/^"Y'@?X*^+?V1/AKK7[0>
MB>&]0^$WP^_;B_89\5>/M=\7:GKFA^&O WP_O_VHOAWX.^)7BS7M>T34](;P
M]H5M\._$_BC3M>U^_O[73M*T;4;Z\FN[*XAM+RWGK^B_JX'[!M%.X.SS@T,K
MX!'RL=VXXVI.H.X[@X0,I"",HH(KSKP[\%/A_H'QA^(GQ]TC2KRQ^*'Q7\ _
M"KX:^.=<75]7FL]9\(?!C5_B=KGP[L%T*ZN'T2PN-&O_ (P>/FFU/3;"VU#4
MH=6BAO[J:*QLEB_C0_:M?1?$W[0G[:K?&C]H_P#8J^#WQ1\.>/4T+]B77/C-
M;?M?>)OVK?"?[.^I_#'X?3_LH^/_ /@G':_ SXPZ'IOQ#LKG7KB_UE[/X ^
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M\=2>+]2_X1;P?XA\/75I8:U?_";6;;P[;^,)?%FFVLB:C87MK:M*_P#7G;R
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M9764%@^&*%KQ2*K2>9*0 VT[V0KG*J L7ED(A)"H"/E)&[&U5TXX!$>&) Z
M]<?-P3W^]UQSC-2.N]2N<9QSC.,$'I^%/F_NKM_6PHQ<4TW>[;O:V_3=[=SG
M=LLL8<M(9(WV+DR!G7*$[MA4G<4WMT(FQ,A29583SI)'AV>XRK[D$3%CN.#A
M(A^[&<LBA%4D.ZAU)R+TD;H2,HR 9)W[9".XQ@\^A!Z<YS3X8PX#JQ7:PR#E
M\[2#]XX.".PX'XFCG\E^.W]7*,O"MYH_>D.49E*RCRW 0^:ZF0-N)11D2,VX
MLX*M))O<MN9,EVG5 XDC\R4%LAMS%D*L%8@!6D;=,5=PLBX &G<[-R[E#97
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M8R0R129VR1RQLKJ".HK^3WX)_'WX[?L1_L1_\$Y_%'@?XI>,OB]H=U_P3_\
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M#WA:^O\ P!X&\&:Q:> /A;X:\<^)?!]IHMA=IK&M^$88KKQGJ&O^*["S\0
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MM^S?:_M<^ / '@KQG\+?A1^S)^T=^P!;?!7Q'?\ @#P-<_!/]HQ_ SP_MA_
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M0V?4'C'T[X_P8,6V<EWW].^-OKD\9W#IF@!\4)C)R0P( Q@]OJ3_ "J; '0
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M/M+\0V'PZ^+NI>$HK2SA\.W_ ,3O"?BNYT>WLK*UTV:TM[2VBATOB)_P3O\
MV-OBQ\=M/_:8^(?[/W@[Q1\:;"[\(:E<^)KR_P#$UKI'B?6/AU*9_AUK_P 0
M/ .FZY9_#KXF>(O %PEM<>!/$7Q"\*>)-<\%366DS>&]0T^;1M->V^-?"?\
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M$;X5>%?&:^-+[QEXEM]8T?4]3^&WA[PCXHL-<;]:?VOOVH(/V5?AKH/BK3_
M'B+XN?$7XD?%/P+\#?@A\'_"VJ:1X?U/XG?&#XD7\UGX:\-3^*->!\/^#?#=
MAIUAKWBWQIXQUIFL_#'@WPUKVLQV.J7UI::7?@$G[.O[%/[.W[*-_P",=7^!
M_@&]T/Q!X\@T;3O%'B[Q;\0?B3\5?&VI^'/"\VJ2>$/!:>-?BOXO\;^*]+\!
M>"EUO5T\&^ -(UBQ\%>&O[2OWT?0[">^N+BMOQ'^R1\!_%GQUN/VD-?\!'4O
MBUJGPCN_@/XGU.7Q=XT3PCX[^$5Q<^(KN'P/\2/A=!K\/PP^)&E:==>+O%4V
MC/XW\'Z[?Z$/$FM1Z3>6R:E=+)\$_%3_ (*B?$?]G+X;7]U^T]^RA#\$?CEJ
MWQKT'X(_"/PCXH_:9^%6C_LX_%_4M>^&_BCXM/X[TK]K3QUI'P^T7PM\._!W
M@KP+XQE^)%YXI^&EAXMT/Q/I.G^"?"7@[QSXC\7^$M.U;S?1/^"U&EZQ\(_C
M#K6D?!#PU\3OV@/@W\<OV3_@AJ?P<_9Y_:@^%GQK^'WC:^_;0^(&G?#CX$^*
M_A]^T+I6EZ)X:GT;7?$L^L:3J^D>-_"'@7Q'X<U7PKK":QIBZ%>Z)XBU8 ^Z
MOV?_ /@G)^Q[^ROXYMOB5\%?A)-X>\9:9X0NOAWX4U;Q+\3?BY\4T^''P\O[
MBQO;_P"'_P (])^*_COQKH_P?\$WMYIVGO>^%?A;8^$M%NH=-TNTFM'L--L[
M.#V#XI_LQ_!SXN_$WX*_&?QWX:U>[^)_[/\ =^+)OA7XJT#QY\0/!M[H^G>/
M(_#\7CCPSKMMX*\3>'].\<^#?%C>%_"]UX@\$>.;7Q)X4U2\\.Z1=W.ES7%A
M;$?FE\//VPOV]6_;?_:!\!_%W]E>.U\"_"_]@?X-_&U_@S\&_P!H'P3\6O%%
MM\3?$/C[]IJQAM/A\=8^%WPHN_'/B'XQ3?#BR\"V,?BCQ)X,\.>"T\&Z;KET
M8T\8W?\ 95'PO_P54\4>+?B#XP_9Z^-7P6^'?PQ\?ZK^RW\?_CMX:M_V=/VV
M_AK^T=XJ\-K\%-&\//XU^'_Q1_X1+P1X4U#X+?$J.S\;Z3=>#O$MA:_$'P5>
MZQ8:Q'INOZA)H(&I@'Z0^'OV0/V>/#7@/]G'X7Z!\,[*P\"?LCWUCJG[.F@K
MK_B]H?AG>Z9\+_&GP9LIK&ZN-?DU?7!#\-?B+XS\-1P^+-1UR,V^NS7K-+J=
ME87EGG>,/V'OV6_&_P"S5X$_9'\5?"'1=5_9]^%^B_#?0/AMX%;6O%EE??#V
MW^$=OI]I\--6\#?$#3=>L_B3X1\7^";?3+2/P_XWT#Q=8>,++;.XUYGO+MY_
MRH\+?\%9OBOI?PFOI?@O^QM\0?CIX9_9R_8$_9._;%^-GC_XH?M0^#?#7BBT
M^%_QK^"OB?XG2:(^LZE\/+Z_^*?Q\TWP]\//$ES(%T[PUX/\9:I!>:CKWC#X
M?SZEHUEJ7ZP?&_\ :3N?A]^QSXX_:Q^&OPV\0_&:/PM\$'^/.A?#*QU*V\*^
M+_&?A2V\+Q>-[O2]+N9]-UVVM_%8\)_;;S3=(_L^]_M36;6#0HWADO4O(0#S
M/P[_ ,$VOV*O#GP1^*_[/"_ ;1/$OPP^/&KVOB+XTV_Q"\5?$#XG^-/BIXGT
M[^S6T/Q3XW^+GQ'\5^)OB[KOBCPK-HFCS^"O$%YXVDU7P'/IFF7'@NXT6;3;
M9X_0OV<OV+/V<?V39/'&K? OX<S>'/$7Q)FT*7XA>.O%/CGXB_%OXF^-(/"T
M-S9^&M-\3?$WXM^*_'7Q"UK0/"MI>:C%X9\-W/B1]!T+^T]2DTG2+6;4+QI_
ME;X\_P#!5+X4_![5U;PGX+\3?&[P=!^R'X._:SO/%/P[O[&2;48?C[\7/!'P
M3_8V^%'A72K^T2VU+QA^U5X\\2^*+7PAJ.K>(- T;POI/@#5M4U^YNK34+::
MT\*_:)_;Q_:>\+_!3]KCX/\ [0W[.\?[(?QTUG_@G3^V%^TK^S3XZ^#_ .T3
M9?'3PQJUQ\$/AM%#X[T.;QG%\-/A%K_P_P#C'\)]>^(GPWU^VAM_#FM>$M:L
M;^;5?"_CJ\N=!U&R(!^A*_LT-8?M;_$?X\Z(_A&[^''[0_P"\.?"7]H?X>^(
M-+GO9O%GBSX4:YK7_"I/&.GV\D-UH6K:?J?@+XD_$WX=?$S2]=AB;5M%TSX9
M?V?-);Z)J5M/SWP#_P"">G[)7['NL>+/''[+7[/O@3X??$G7/"FH>%=(UN_U
MSQGKZ:-X>DO!KEG\./"^I>+-6\87OPK^$=QXCMM*O+_X??#"QT'PE =-TVZM
M?#$T^BZ1';>>_ 7]L;4-<O\ XL?"'5O"=]J^N?LQ?L3?LE_M$:YX_P!4\7M/
M>_$W4?CGX'^,=]-I.H6$FBO<>'M1T^]^"%Y=:AKT]]K<FJMXF\\Z;:M9-]L^
M6&_X*K?M(^/_  _8ZW\ OV+/!/CI=-_X)Q?LT_\ !1OX@WGQ#_:F'PRT3PWX
M:^/OA[XI>)IO@KH-SI_P0\<ZGXD^(]E;?"_4K?PCK6IZ1X8\!ZZOVVX\8:]X
M AM].M]; /TJ_8__ &=I?V7?@-X6^&.LZ[:>-/'M_K'C;XG?&?X@V5C+I$/Q
M&^.WQC\9ZY\4/C1X^M]-EGNKK3K#Q%\1/%6NW/AW2;J^O[C0O#0T?0_MMPNG
M*]<%;_\ !.C]B6U_:(N?VK8?V<? "?'&;Q@/B1/XM8Z[)I1^*#:8^C'XNVWP
MZEUAOAC;?&!]-)M9_BQ!X+B^(LJO,7\23-(TK_%OAG_@K?XGT*U\+_%+]J#]
MFRS^!G[-GQ@_8D^-O[>'P-\:>&?C-:?%;XJR_"3X >'OA=XU\8^'_C+\,[;P
M)X5\+>!?'_B/P3\6_"GB#P=I'@?XH?%+19KS[7X6UCQ#::P5$>!^R9_P6:\+
M_M _M#_!OX ^-+7]CZPU;]I+3/'$WP?L?V7O^"@OPF_; ^(W@WQ)X'\$:K\3
M;SP!^TO\/?!?A+PFOPTU[4?A_P"&O$NIV/BOX>>)/B]\-[?Q3HESX(O?&-KJ
M6K^%+_Q, ?IVG[)_[/,?P\TOX4I\+-&@^'ND?&VW_:0T_P (Q:AX@2RM?C=;
M_&UOVCHOB+'<)K":@=57XW22>/TLGO#HLNHSO:76G/I3G38;$G[*7[/NH?"3
MXH_ +4_A-X5UGX-?&SQ)\6?&/Q6^'6OQWFN^'?&WB;XX>,=<^(?Q.UK48-6O
M;Z>WO/$OC?Q)J_B5_L$]I#H^K7,5UX;AT8V5B;?Z*D"K%%L<(9&4%R%8MYB[
M1T)/WV1QY9P"H 95.1^):?\ !6[QYX5^/_P:^%WQF_9A^'WPF\,?'?X_Z3^S
MYX0T27]M/X*^+OVO?">L^,M;U30OA_XR^*/[)>@Z'MT+POXAN;.SU#7K3PA\
M8?'GB?P%H.IV6J^(M#>6VURRT8 ^LO"'_!+K]B#P7X)^)OPYTWX-:CK>@_&$
M?#"'XB7?Q$^,/QT^+'B_Q)I_P4\50>./A/X<E^(7Q/\ B5XN^(&E^#? 7BJU
M37O#W@W0O%>E^&;6^N=3DDTF5]4U*2^^EM6_9Z^$.K^,_BY\1-6\'Q7GC+XY
M_"CPO\#_ (K:J^M>($'BGX7^#9OB)<>&O",EC!K$.G:9%82_%GQ](NH:#:Z3
MKMS)XBD:[U-XK;3%LOS(\+?\%7OB5KGCC0-1U?\ 8J\7^'/V8]:_;R\9?\$]
MI/VB3\<_AWK&MK\7]$^/WC+]G/PGXRTCX.VN@PZMJOP@\4?$7P[I'AC6O$=Q
MXLT?Q9X8UW6[M;'P7XI\.Z(WC/5/"/VD?^"EG[2'Q'\$?"7QM\"/V<_B/X$_
M9A^(_P#P4,_9,_9[\ ?MA:;\7OARNM^-]"A_;J^&7PA^)NL^)O@8--E\2^%?
MV?OC+INC_$7X=>!O%Y\6ZAXP\2+JWA/5]8\!^%_#7BNWUE0#[X\;?\$G?V#_
M !Y>Z%=:S\$]6BT_2OA[\-OA/JWA/P]\:_CWX*^'GQ,^'WPBT"S\+_#+PK\<
M_AMX-^)>C>#/CQI_@SPU:6V@:2?C)H7C:\GT*"+1=2N+_3 EH?3?!?\ P3\_
M9,^&_C'X,^/O GPNNO"VN_ KX"P?LN^ %L?B+\5&T$_L^6EOJ\&D?"'QYX1N
M/&]YX7^*_A3PT=?UFZ\+V?Q5T;QA-X4U._FU'0+BRNL2GQ+_ (*F?M#_ +3'
M[.W@?]F"_P#V7O!-EXV\2_$O]MO]G+X3^*=(OOB!X1^'4&J^$O%'BO-]X%?6
MO%OA'QC':6OQ(ETV/P??ZSH>F#7?#.G:A/K%E)Y:2JGQ9^TO^VU^TQ\._BMX
MD\,_LR>%?&?C;Q);?\%>/V9OV8?B?X3^(_QW\":7X2E\+>,?V-_A-\;;[P#\
M()-:^%&J7'@#P%XKN/$]K:ZY!#_;?B:/Q+I7BKQ)8ZS::7XN.A>'@#]"/A1_
MP3#_ &2OV>]8U/QW^SI\+M/\ _%/3OA_XW\!?";Q)XU\7_%GXV^$?@3IGC:T
M;[9I/PA^&'Q0^).N^#/A?X*FU..T&M>"?A-8?#[2];\.V2>$WEL=&,<$/Y[?
ML:_\$DOB5\+OVL?V>_VB/B;\#?V*_@&O[,6E_%J\TB[_ &5/BA^T9\0YOBGX
MX^*/@;7_ (;2V/A'X<?&KPUX=\%?LA?L^6.A^//&_C&;X"_"W5/'>ES?$1O#
M4\.L0Z?X>^VZQ]&WW_!5?5_#</[:7Q2\;_LUZOX3_9,_8B\?_&#X/>/?CS<?
M&3P:GB_X@?&'X;ZMX+TO0?!_PX^#E[X?TNTET+Q[?>.M%\/:;XU\7_$OPM8Z
M!XI+Z5JR7.FP7OB./?\ V1?^"IVE_M#?'S3?V;/B-X-^#7P]^(_CCX;^,OBI
M\*W^!?[8_P '?VO?#NNZ/\.-0\(:=\0O!'C^^^'6G^&]5^&7Q6\+V_CKPUJZ
M:%)HWB?P'XGTP>*KOP?\2_$$_A+5;:( ^GO%7_!/;]E+Q=\"?A3^S?=_"^YT
M3X7? G4K77/@I%X*^)7Q8^'WCGX3Z]9Z=KNEQZUX!^+G@7QQX>^+OAG4YM+\
M3>(=$U*]TSQS;W.LZ)KFKZ1JTEWIE[+92?(/QT_X(Z_LZ:K\%M5^$'[/OPN\
M#^#=)^*_[3/[&?Q7_:8M?B)XS^*GC&'XX_#W]G'XX^'?B#XQT_Q?K?B37/&_
MB'Q'\1?%'@FW\2:%'XKU6ZAUKQ1JMUI \7^)I;?3+"\T_P"BOBC^V1\6- _;
M2\(?L:?![]FJ[^+VKW?PC^&_Q]^)GQ.U3XO>%_ACX/\ A?\ "/QI\7_$WPGU
MC4)-+U'PWXH\2>,/&NE?\(KJ?BCP]X2TO3K&R\4V%EJVF7/B3PS?Z=:S:S\-
M> ?^"Z7PP\>_$+X8SKX(^&>G?LT?&;XP^%?@O\-/BG;_ +8?P*UWX]W>I?$7
MQ5I_@/X5?$/QA^QWITL7Q%\+?#+X@>,]7T:PMYE\9:O\2O"'AW5[+QI\1OA=
MX0T"T\17.@@'W[X/_P"";7[''@;X=>//AOI/PEOM3T'XH^._A;\2?B/KGC7X
MI?&#XC_$GQ[XN^"'BK0/&?P<O?%OQ;\?>/?$7Q3UK3?AIKWA709O!OAJ\\8R
M^&M"L;6YTC3-(L]+U&_L;ON_C;\(_$6G7WQ0^/\ ^SG\+?A#XU_:Y\8_"+P9
M\#K&^^-WC[QWX+^&VO\ PX\+>-?%?BC2/#?B^\\*^%_B(UEI7AR_^)?C_P 2
MQQ:)\/[C5O$M[J \.:CK6GV#VM_8_#W[+G_!5#QK^U5\7-9\%?#K]F31=4^'
M]CXT^.7P\77]%_:E^%?B#XV?"[Q;\&=8\8Z#I1_:R_9D30])\??LZ^'?BGK?
M@>^TOPSJEMJ/Q+U'P]>^(?!J>,-"T2V\2(=/^7_V2O\ @J!^V?K'[)_[$-QX
M[_9=M?CU^U'^V-\0?VG_  Q\.X-/_:(^&O@WPCKNC_!Q/%/Q!/C+QEXRTCX9
M#1?!GA:PT'3]>\"6EEHG@[7-;BN? ^B7;VFLS>-8H;0 _97]C#]FWPW^Q_\
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MZ*RT Y*[F<^*8%#G8(< 8[&$ Y!'?S'R",'.<'BOF3XF_P#!/;]BCXR_M%>
M/VN_B?\ LW_#7QK^T?\ "E='_P"$$^*VLZ9<R:YI4WAJYGO_  IJ%[907D&@
M^(M5\)7EW->>$=7\2Z3J^I^%;DI/X?N]-EAB9/IV:.(^*8-OW1""2&R%_<MG
M).<<JG7IG'&1CK2%\E@AW C QR2<!0./H*0%1?D)<*&^?>Y(!=FX).2=Q.T
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M  1$^(G@N7X7>'U_:"_9QLO"/PC_ &EOA9^T2/B/H7[#NB67[6O[0>H_#?\
M:&TCX_6^E?M1_M(:W\8M>U/QIJ>HZA9W-CJOBCP1X<\#:EK>MMI^N:@D&C6V
MI>#=3H_LF_L#_M1_%CX%ZK\+_C7\9SX"_9(\0?\ !03]IW]H#QE^S3XL_9MU
M#PU\<-<T[P=_P4'^*?QD\!^ ;'XP:I\2?[)TW]G[XKZYX<\%?%C4+O\ X5%=
M>-_$?A;Q)J?A_P .^.+?PMXBLY+;^C>2,2H4+,H)!RC%6!4Y&"/0@''0XP00
M2#$+6, J#)M.?EWG !(.%[HN1G:A50><9 ( /YQ/A3^P+^UA\=M'_P""@_P?
M\8_&R7X+?L@?M-?\%#?VJ-8^+OPB\1_LYZQ%\8_'/P>UCQEX=M=5L_@9\:[_
M .)F@:'H7PO_ &B/".DSV'B3Q-JWPK\<WMK9ZKXGN/A_K-A>ZE;3:+W_ .WS
M^R7XY\(_ O\ ;3L_@]J7Q+\7_M*?MR?MH? SXY_LCWGPF^$7BO4[G]G'X^_#
MWX9?LW_#/P)XF\:>-;'^W_!O@GP'X.7X ZOX]\9?%+XC3> ?"4/A'6-5\&6M
MIK.OMI>F:]^_+VL*Q-D%R%8DN=Q/S>80<\ ,X#'8%.<D$9-(D*R@,_\  =@
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M&R<D\[1W/MBI64,I4YP1@XX-1[ D;A<X(8G)R<[<?R H 91110 ^5%< ,VT
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M3N+98$$:E75&;85V+\V @W!\;>=V".<D9S^-7=**O==;Z];WVVZNRL LL;3
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M$I /4 _49Z]: %HP/0444 %%%1"4&3R]ISDC/&,A=WUH EHHHH *AEB,FW#
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M1?OHQ8L50LXD)W#(4%F'8G(''OR*"LCJ6 +,K %B5!V#:Q';U/\ C41Q]['
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M\/K:U\>>^_LA_$/]DC]J7]J;]E#4_P!E_P 6?LZ_!_\ 9(_8@T[X[^%/V._
MNA?$KX<_\+M_:A^(7C?0_$WPO\?>+O"7PYM?$>H_$+PU^S7X1T"R^(&MZ>OB
ME8O&WQV\=/;_ !1U70-,\'>"?#/B#QJ ?T9JP90PZ$9'3I^!(YI:@M=OV>+9
MP@7" '("*2$ /4@*  3\Q'+ -D5/0 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MQ%--%'*SHJ1/(B2LCNH/XH?\$9?!J_!K_@GIX^^).I^,O"&K>*_&?QT_;?\
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M95#%#NSA0>N=WS$\=_I4<NY)O+$>Z,CB10@*MP2)<,A*GL CGH>,9IQF,49
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M#D'H151S*<IL8J&X(4YPI^7DGG.!DXY[>M6(N(T!!!"@$$8((X/!H 8S2^:
M ?+XR=HQWSSU]/\ #UGJ%FD$@4#Y"0"2IQR.BE<\Y!SN  SWI[.J_+N 8CY0
M>IZXP.^2, =SQ0 XYP<=<''U[5%"TAW>8",;<94#US]>U.B9F3+C#!F!&".A
M..#GJ,>U24 -5T8X5@2.>#FG5&D2QDE=W(QR<\"I* &AT+;0P+<C&>>.OY4Z
MHQ$JN7&[)+'D\?,<GCZU)0 4U_N-_NM_(TZFO]QO]UOY&@"&BBB@"!Y6<#(
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MD?SJJ9/L_P"[ #?Q$].IZ8&>@]_P% %RBHHI#(I8C&&(QG/0 _UJ6@ HHHH
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MB@!UL1(S!U4@%@/E'8G'/4GW))/4Y/-6)D5$)0;"2J[E^4X9@#@CD<'J***
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M22>Y/I@4454_A7^+_P"2 LF23[N]ADGY@?F& #@9RO.><J3Z$4@<OG=CAY0
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)/H<4444 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>ex10-69_003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex10-69_003.jpg
M_]C_X  02D9)1@ ! 0$       #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" 21 X0# 2(  A$! Q$!_\0
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M/.,C:>.H[XZ\>M %BBH(I0^$P<A<DY!SC [$^M.$H,GEX.<D9R,<#/3.<8H
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MX%^,'Q#\2_%@WW@;Q7H?PU\:?#[QE;>#8K_Q!';Z7?)\)O!VJ>)=3\$#1[<
M_J1U75K#1-+U37+Z"_DL-&TR\U>\CTG2]6US4S96-K+>3-8:#HEKJ>MZM>21
M0R+9:;I5A>:IJ5PJ6NG65S<,B--9ZG;WUI:WL"70BO;.WOX4N;:\TZ[2VNHH
MY(6NM/NUM;ZTF)?RWM+VV@NXKA);62!)XI(U_EP^+/[(?QVG_:&_;>N_A/\
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M=]9U+P%X!\0:/#+XCTO1-4O+2W34);B-+-TO([:9X8Y/R=_8#_8+U_\ 9O\
M$?\ P3R^)%G^SM8?"CQ_9?!C]L_P[^V!XIL?^$9M_%U_K/Q.\;^!/'/PWT/X
MJZOIFLW>I^/X/[?TK5+KP+%J%UXILO T(NK#2Y="M]0GBNLWX^_"KXN^%/V]
M_P!L'XMZA^S-_P %*OB?\,_BYX!_92T[X<^+OV"_C]X ^$NGW]W\-/"'Q!T?
MQK:>-](U[]J;X ^(KK5K#4_%&FQ:5<R:+K=LMDEU+!J%L(WBD /W\TSQ'IE^
MEA-#)<0/JMI'=VFFZC;S:5K")+:6]_\ 9KG0]36TU6QU"TM+B%]0TR[LX;_2
MQ(@U"VM0R[K\FJ6<T$(CE5C?QG[%M>)_M;_9_M9BM3'(XN9%MLW!$'F+Y"2R
MJS)%(R_@'KG[#NO_ !'^(W[4W[4<W[*U_8?'/QI^VE_P2V^,/[/_ (N\?S^
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M5^$7B^_U+2=/@;PM:Z[-=V5FWVQ^Q#\ +;]F3P;\.O@7<?"JUE\1_!7]D/\
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MVA/%OB;X2:_>?"WQ9I/AFQ\#>%M&\17>E7GC76]:\$^6ZA^Q/^WEX1^!5O\
M!?X4_"_]GW2/A-\>OVAOC[\?OVHOV?/ _P"T[X\_9XL/!_@/Q]>:(_@;]E'X
M-?%[P5^SOXZU#1_ 'BN2UO\ Q-^T7XN\&^!OAOK7B'5]3\7^'/AY+X=TKQG?
MZ\@!]T_"?_@HSX4_:#O?#-E^S_\  KXZ?%!O%'[*W[/G[7UO<O-\(? ,.G?#
M3]IJ]^)6G_#G1]1C^(/Q1\/7'_";6\_PI\7'Q-IMA9WNBZ0D6G26VO7T6HVF
M[IKO]N9-1U/]I>P^&?[.G[0/QIC_ &3[O3/#OQ2O/AP/A1-_;/Q+;P9X<^(O
MB[X/_"O3?$'Q-T/5_B1\1/A_X0\8^&KKQ19Z38V>@SZ]JUMX)\(Z_KOC2"_T
M.T^>O W_  3FT'XF_M,:Y^T!^U1^R_\ LMQ^&IOV./V/_@C\,_A!H]S'\6]'
M^!OCKX$_$C]I3Q3XLT;P1JFM_"[X;:>O@BRT7XB_"N'PEK.D^'/#=]=3^';S
M3I/#VB6>BZ;<:ALZ[\$/V\_@!XX_:GTK]COPQ^S;XS\!?M5_$K6/CGX5\>_&
M;XJ>// 7B?\ 9B^,WC?P#X5\%^/+[5OAWH/PA^)VD?'_ ,!KXD\'V'Q:\*Z1
M;>,OA5K(UC6O$/PZU:YAT!=(\6V@!Z=K_P#P4>^&FA?$B^\ +\,OC1=0Z!\1
MOV0/A7XFUZ[T/PWX;NM'\5_MM&RB^$X3X=^+_%V@?%C4].\.7.L^'8_BI+IW
M@NYOO!"7?B"1=*U9/AY\3)?"74V7[?GP4G^,7[2WPFU'3?BYX;MOV4O@M+\<
MOB3\3_%OPT\1^$_A;JOA/2->^(/AOQ>OPXUW7EL=6^),O@;4_AGXBB\1ZWX;
MT*_\%S7)BL=$\3:_J,&HVFD_!7Q9_P"";O[1WC/X_P"L>-);'X#_ !.\5>*O
MBU^R%\2O"_[?GCOQ-J?A3]JW]F3PY^S_ *)\(]*^+/PQ^#_PZ\-_"/5]$M/"
M_P 7M0\!_%3Q'9>&_!'Q?^%_@.ZO/VGOBSHOCSPMJFA6]U;^.OL_XT?L7^)_
MC9\>_P!I[Q1K7B'2-&^$_P"T1_P3J3]C$O97-Y=^-O#_ (EU7QO\=-3\1>(5
MT2?3XM!FT>'PS\5-'_LJ5M>>ZGU;2[RQGT^RL1'>W0!R2?\ !3?P8WP[3XAI
M\#_C%<0ZC?\ [-GA#PSX=TKQ-\!_$6LZE\8?VH_BAX8^$_@7X">*G\._&'4M
M.^%WQ>\*ZUXU\)^(/B=HWCN[T?1/#'@W59-:L?$.NW&F:G86NIK?_!2WX4^%
MO%VN?#7Q?X2\4>!_B+X1_:"\4_ 3QKI7CWQG\+O"7A#P?!X6^!_@W]HB3XP>
M(_B7>>-O^$0L?A9J_P ,_B7\,I-+FCGD\;'QCX^T?P??>"M/N;/5[C3OB[P[
M_P $S/CS>^&?&5_XH^"O[$'A/Q#H_P"R+\!/V4O#OPI\#^+OBQ%\*OCO-\'/
MC/X?^*FK?%CQ]XP\+?#KX7?$+X)>+;73_#8T_P#9GUSPG'\4?''[-OCSQ-K?
MQ(_X2KQ[<V-GHMY<\(?\$P/B_P"!-<\(?M):=\.?V<?&'QTTC]JCXF?'_4OV
M>OB-\7_B[XZ^&*>%?B/^S)\.?V8(-)_X:?\ B1\./B/\4O$_QJT32/A'X0^(
M^M?%OQ1\(;R'Q1X@U[QQX172-+L;G1?%]B ?<?Q._P""A/@;X/?"[]G?Q_X[
M^&'Q4L/%_P"T7XU^'OA'1/@YILG@GQ-XU\':1XS^)/@_X7:S\4/%&L>%_&>L
M^!&^$O@K6?B!X)N=3\?Z1XJU'0]6A\:>";/1)+O6_%VD:>+6F?\ !0#P-XB_
M:!U_]G_P5X4;Q9K_ (6^.=C\#[^*/XL?!S0_&VKR6'A73_$7Q,^)W@SX3>)O
M&NF>/_&?PI^"FJZSIG@SXC:[H^FR>(XM>M/%UQH?AC7M'\*7NJS_  '-_P $
M4_%LWP \%^'-+_:C^*'PU^-EOH_P1T;QEIGPCUSPAX>_9YT;0OA[^USK'[4^
MI>$?A/X?\8_"+X@^-_"7AWP3J'CGQ9H7PI@LM4T?3KY?"7PM;QEX?BT_P[%I
MUIZKJ/\ P39^*]O\:_%5GX;7X$I\#/B+_P %!?@Q_P %$/$GQBU@ZS'^U-H'
MC#X4+\,]?UKX3Z9H6F>!1X0URT^('C3X9KI;?$X_$KPW-X:^#WC[Q[\./^%=
MZT);35;T _;!6#9QG@D$$8((_P#K8(]B*=3$# '>0268C'92?E!]P.#V/:GT
M %%%% !1110 FU=V[:-V,;L#./KUI:** "BBB@ HHHH **** "BBB@ HHHH
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M!0W?ODGJ<5$"22,/\I&"4ZXY'W2P/(YZ>U*LS(_E*%DWC+C$BLA;Y2"2ACP
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M3P>:GHH *"0.2<#U-0^:?-\O QG[V>?N;OIP>#[$<<YJ1AN5ESC(()] 1@T
M*"#T(/T(/\J6HHT\M& 8-R6Z <X QQ]!4/VEO[J] >"W?Z*<4 2RNZ,@5<AL
MY.UC@@J!T/H2<'KC@TJ1!&9@Q);KG&.N>WO_ %J 7+%Q&%7>RLX!)^ZF Q/
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M[GXK_P"A"@"JYC! <X(!Q^\VY!9CG&T]R1U[44CDYP /EX.3ZDMZ'LP_'-%
M%ZBBB@ HIKN$&6SC(' SU^E*K!@&'0C(XQ_.@"K,D@+R Y7C"ARK= ,#)5!S
MD\GGUYI(W9D:,HX9@P!9D(PV1G(=CA?X@,XX[FGN&$A9\F'(R,Y'0 ?+USOP
M?UJO)AI T8.[&R,J#&R%B <L<;E8XR/;!XZ "R(R$!@CL<;57))Y[Y X.",@
M^O!IA;(;*JFTX9$9FP<$Y(.!N"J=O)'(.:ED5@P+'YO+ /SIN(^;(Y8$@Y[#
MGD#O4> 1CJI[=N01Z9Z$]?7UH 7=(V0V%PS[=I(&T[=A;&,OP=QY[9[59C,<
MG'EC*@9W(N/3@\YY'MFJK' )Z#@9YZMG&  2>A^E65DA168*1M4;L*<X^G4\
MCMF@"R      !@ <  = !V J.7_5O_NFF+<1LH8%L'& 5(/()Z8SV.?I49\Q
MM[Y)B*.5!88QM./E_P XX]* ,/P[P+X>M_(1CT\K&/S!..G?K73UR/AIRQO!
MDDB]<'/3)B+<?F*ZZG))/1W0!12$X!/H"?RKX[^+/_!0S]A+X#>-M9^&OQM_
M;!_9N^$OQ%\/6VC7FO> OB)\8_ ?A'QEHUIXAL(-4T&XU/PSK>N6>LV46L:;
M=07^G//9H+NTD%Q#OC#,J ^Q:*\V^%GQB^%GQQ\!Z!\4?@U\0/"7Q3^&_BE=
M3;PWX[\ Z[IWBGPGKBZ-JM]H>JG2]=TBXNM.O?L&LZ9J&EW0M[B0Q7UG<6[
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MKMU'J7CGQIH/P]\+64&DZ'9:CJES-JOB_P 3Z)I$?D6DB0/>&YNFAM+>YGA
M/7**\$\(?M"> ?%GQS^,O[.^GR:ZOQ#^!?A7X.^+_&XOM*%MH#Z9\<_^%AOX
M'AT+63=2C6-3<?#3Q*-7L4@@.G;+$Q>>EX/)]MEU.Q@:!9[J"#[5,MO;&>:&
M 7-PYVK!;F:1/M$K,518X?,9F8!0Q#8 +U%9%_K^C:5!-=:KJ5EI5M;M"L]Q
MJ=S!800FYF-O:^9+=21(HNKA3;VI+8N9PT4'F.CA=)IE6/S6#A>!@HP8$L%
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MX=\3Z5HWBC3]3T>T /?:*^4/&/[6?P_\.?&#]DGX7Z(L_CRR_;!N_BI!\/\
MQ]X)U;0=;\#Z?:?"CX8:E\4K_5K[5+6_N!J^G>(-*T\Z9H<WA\7B/?N9KB3[
M* ZX7Q(_;?\ @AX,^+'P:^#'AWQ=X8^)GC[XH?M$VG[./B?PS\/_ !YX*UOQ
M'\%_%-[\&OC7\9;/5OBGX:M=8FUWP[87.G_!/6?#RV%]9VVIR:MJVG/!;206
MUZ* /LRBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH @E1W92IP!U&
MYAGG. !QT&,GU]JGHHH **** "BH5682L693$1\J@8(/'6I&8("QZ#'09ZD
M<?4T .HJ(3(Q &[).!E2/Z5+0 4444 %12HSJ A (;)R2.,$8RO/4BI:BE#E
M1Y9(.[G!V\8/?IUQVH >H(503DA0">N2!@GGFG4U00JAOO;1GG/..>?K3J *
MDT3;F?*[>&&3AL@!?X@5'3C.?IFGQJ6B8<;CN .4."0,?-& .#Z#(I\DL:_*
M_<[<;2P)P#CH?4=:198AA5!7)  "%1DG'H!0 1HZ*X8@D],,QQQCJ>1SZ?\
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M#8>!@@D ]">1GU^@H :'5T4*XW8!D^?9\PY4]1T))PO&>M6H &9F(P<#$?H
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MC\8/V-M5\,Z#X"UK4_#>GP^$?$'AZYT?P?XA\!?$+QEXI\2747C&/S'X=_\
M!0;]J/\ 9G_97_99_:O^*?Q#\6_''1OVK_V'/C'\(_ 'A'Q;]ANH-5_X*/\
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MV*OCK\;/^"L'P[OI]*L8_"%U%^USI=[HG[//PTL8+>\N+FWN_A_^TO\ $O\
MX* >.M+M[FQTZSTZ'X6?#2YTQ+J>UG-E\=^/OA)\5/#_ ,/OV-O&/C#3O&/P
MW^ 7PW_:T_X+0'QSKVM_L+^(OVUM&^%GQ8^*_P"W#XN\0?LX?&7QM^S9;A/$
M-OX=UCX?6/Q<\/\ @?X\Z=X4\3P>#?\ A9.GV(M].\/?$VY\6Z/_ $]? ?\
M9:^%O[/WBWXS_$+PQJ7CKQ9\0_V@/&%EXJ^)GQ!^*?C_ %_XA>+]1M- &J0>
M!/ >CZIKLY7P_P##3X;6>O:WIWP_\":':6>B>'H];UN[*3ZQK&J7M[]*.]H
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MK*!'ODRO4G*L HR1UVC"\9#''!!)Y!+C*B@EB44 $LZLB $$Y+L H''.3P<
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M_&7X$? OPAXD_9]U#P'IGQ2\>?M,?LD_ ;0]6^)7A35_&W@G1[']H?\ :(\
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M3/B3X8_#_P <^)?A]XR\6^%-$U[Q7\(O$>J>+OAEKNI64-UJG@3Q-KO@_7_
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M\1:[I.I>$_#NDV N+^QM+2X?^M$^ / +>#O^%;+X)\''X<C25T#_ (0$>&-
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MH:L[ 7O)B'65O^^U_P *FCC$8(!8Y.3N.?;L!5!58,68G80)?-<#R_7:#VR
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MA_5M>\6\)_\ !#S3/"?[)=_\"?\ A=_A_P :_%SPY^U7X/\ VFOA'\4OBO\
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MX7/PJ\!Z$)[3P_H6M1?$.\TR^T7Q#KGBS5;;5AJWBA_%.H7&LQ:;I.E\9?\
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MX+2ZC^/MMXW\&PZ=X:&M7"_ J;5M:TV/0\CX)?MK?MO_ /!04?#&S_92U?\
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MKFO3>&D;QKXCM/%!N;Y9+/Z[T_\ X)"_LI7%Q\6-6\;Z[^T=\9/&7QR_9O\
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M=\7>))SX,^'_ (G\-?#::&"\MK;7_'?A?53HHTW6;I3J<=WX%^RK_P %%O\
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M  L:]_9X\6:5+X4L==LO"W@KPV_CK2[F"_\ Z$_V>_V7O@5^R?X-U'P!\!_
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MGK'C[PE\$O"MWX)^'-AXJ:\FFL[T:'X=U35; &.UB%]!JE\+P3-*CQ@'X/\
M[-OQS_X*2?#_ .('P.^(OCFP_:Z^+_PK^,?PV^(_BWXG6W[4'C/_ ()3Z;\*
MO%M_I/[.7BGXQ> ?%'[$WA+]D;XO:Y\?-&DO/&_A;3/"UI\-[NT^-EG>?"7Q
MO=^,O$NJ:5KO@]M;ON?_ &(_VCO^"DWCGQ5^Q5\>?%B_M.>*/A'^V''I&L_&
M67XU_$+_ ()7Z%^RQIOA;X@_!'Q9\0- U7]BOPM\&?BKK'[5MAK?PZ\3:7X?
MM]%\$>,U^*'B+QK\-K;QMK_Q&T31/&=A)<VO['? 3_@FC^PO^RS\1XOBI\"/
MV;O /@#Q_9:?X@TGPSK=E)XIUJU^'FC>)[EKKQ)HWPGT'Q3XBU_PU\']'\0.
MS#7-&^&&E^#]/U>)VMKR![8F,N^%?_!-']A?X+_&2\^//PK_ &9?AEX*^*-V
M_C1['Q'I-KK3VGA.?XC37=QX_E^'/A6_UB\\&_"R\\;"ZGB\5:A\-_#WA>]U
MZSNKFRU"::TD,#M*Z;[?\.!^(O[/.M?MX_%'PC_P1Z\0^+/^"EO[2)U/_@I]
M\!O$=U\?'T?X<?LQZ9I/@"W\,_LTP?'[P]??L[6T?P1*?#7XE7L.DW'A3Q=X
MT\4GXG6GB"'5?$^O:1X=\+ZI;>&4\.VO$7[5_P"W'-X%_9U_9-\,_$CXZ_$[
MQ9XM_;=_X*3?LV>(_CO\,]5_95^&?[5'Q*^'O[$_C#Q=8?"7P38^./CE9^%O
M@%H'Q+\?:%';7/CGQ7X>\#R^,==\/_#GQ-J_A#PWHEW?:]K6C_T2^&_V6O@+
MX,T_]GO3O"_PN\*:/:?LGZ!=^&/V<H[>WO'_ .%1Z%?^!7^&5_8>$Y;F[GF@
MCO/ 3-X:N9+Z2_N9=.FG1[AII&G;@_B!^PW^R/\ %7X:^(OA!\0?V?\ X;>*
M_AKXJ^+7B+XZ:QX7U;1&D@/QJ\7:_?>*=>^*NDZA%<Q:SX;\>ZAK^KZGJDOB
M;PSJ.D:K%<ZGJ7V:YABO+B*9 ?B!X:^('_!0OQ3J/[/?[+WCW]H_XQ_ FZ\4
M_P#!2CQ)\!#\0[CQM^Q=\6?VMG_9L3_@G=\8/VB-=^&7QOO?@II'Q$^#/A7X
MLZ1X^\'O;>!_&\GA?1O',G@F[\#>/=5\/RZW;?VQXB\A^*_ASXT?$CQO\+_V
M;O'O[77[2.M1?LF?\%\/AS\"/A5\7X]0^%$'QDO?A_\ $+]@FT^/FA3>._$>
MI_"76?#WB_QA\-M7^(GB[PMX4\4WGAF"YOO"6KSV?B&RU76$TC5=/_HN^&/[
M$/[*WP7T'X;^&/A7\!OA=X'T/X0?$'Q'\6OAS;:%X:%M=^'OBKXO\*^(O OB
MCXDOJ\EW/JNM>./$?@OQ9XA\-:]XF\07>JZSJ^FZD\-W?LD,"1Y_Q._8B_94
M^,_ACXA>$?BG\"?A[XQT'XJ_%3P_\</B%8ZEI=U:OXG^,7@_P]X9\)>&/B9-
MJ.G7]KJVF^,M$\,>#O#&@6.N:5>VEY'I>E):EI([BXW 'R!_P6RO;RS_ &"K
MR[TOX@Z?\*-7L_VM?^">LVF_%S5M/T74]*^%FJG]N[]G2"T^).H:=XBMKKP[
M>6_@FX(\2W%IKUA<Z'+]@\G5+22P>9*_.[]JWX]?M4_L#^*?VC_V9_A1^U)\
M9_VA=)U'X9?L.>-;3XH?'/Q?\ ]4^-/[,OBO]IS]LZ;]FGQU)I_Q.\3^"?!O
MPLT#3/B!X $GBSX81_&7PSJ?@GX7>.]&U#6Q#+X!O(O"MI_1;\6/@O\ "KXY
M^"KGX9?&7X>^#?BC\-[W4?#FIZGX$\>Z!8^)_"6JW_@WQ#H_B[PK/J/A_54N
M-,O_ .Q/$FB:-K%K'>PSQO=:="LZR1/*&\+^%W_!/_\ 8L^"_P ,?B5\%?AA
M^RY\#?!_PG^,\,T/Q;^'^G?#W1KSPS\2;*?3CI!T[QU9:M%?KXHTBRTH_P!F
MZ/H^IE]/T2T:2#2[.UMY7BJVF[??^5_Z\P/YG_VN[/\ ;)T3]E?]N/\ 9\^/
M?Q _:%\'_"V+]GWX-_'?3= ^-_[9/[)GQR_:P\+>/]._:F\ >%9SH-_\)_#$
M'BV']FWXEZ-<W-SK=Q\0O"U[HOAOQOX,DT?P1XI\.Z9J]UX?L?MG]L;XG?M=
M?!'XS?$O_@G+\)_VH_B);_&/]N;0_P!DF?\ 8)^-?C]=-\3^-_AJ?"-MXH\)
M?MNW1N+'2=%TS69/!O@+X*^&_C'J3QZ;86P\3?M!:O+"-.MTL[5/UU^&?_!.
M7]A?X-_#?XI_!WX8?LI? [PK\,_C=H\F@_&+PM:>"+"Z@^*&@RV5WIMKHGCG
M4]3&H:QXETG2[2]N(=$T[4[^>RT"&>6+1+>Q*I(OL/AK]F?X">#W^"$WA[X2
M> ;*^_9H\*ZUX)_9\U:X\/VVI:]\(/"OB'0-/\*^(=#\!>(M3^UZWH-GK_AO
M2=/T77##J$D^K6-K%%?2SQ*8WE*[M_6]OZ[?(#^9GQ!_P42_:O\ VC_@9XQ_
M:O\ A!XG\>>$?A]XK\1_\$XO^">^HZ/X;\:^&?AA:_#+XS?%#5=.\8?MX_%'
M2O%/Q$\.:SX,\!_%#1?$OQ7\ _LA^#/B7K6D:QI_P_\ &N@ZWJEK82WAL[RV
MC\>_'W_@H-^S1\-OCM\()?'?B_PGIWB#XK?L(> X+#XJ_M\_L]_'[]K#]F72
M/VCOB?X_\!?%'Q!+\>-6\ :I'\*/ 'Q7T#P]X"\-_!CQU\>/#/C&Z\'?$KQ%
MXOUGPK<:C:QZ7I.@?TT0_LV_ "S^%OB_X(6WP.^$]O\ !SXA7GC#5?'OPH3P
M%X8/@'QGJ7Q#U>X\0>.+WQ-X4.E+H>M7/BS6KR[U?7KG4+&>ZU#4IQ>SS&:%
M">#^&W[#'[&_P=^$WC'X#_"[]E/]G[P3\%?B0TTGQ%^%NB_"CP=!X(^(;7$:
M6[M\0-"ETR:Q\9LL$4=O _B.#4C;6T4%M;>5%!$JOD?]6_S _G;\<_$_]O;]
MG;]GC_@H%\/+OXP^-_A%<>%/A!^S+XV^&NG^/OVZ/!'[<W[77[/WQ*^(?[2F
MF?#G7/%EIKJ>"]!\;I\&OB5X$GTZ]T'0OBE<^)8K?Q1X;\9:;X8NH=!\37.D
M:?\ J7^S=X9^(?[-_P#P4K^*'[+*?M'_ +2'QZ^$_C7]B7P=^TM+9?M,?$C_
M (6UKGAWXN#X_P#BWX9Z_JO@?7[K3]-F\(>&?$OAL6$FI?#CP_8:9\/M&U&Q
ML[KPQX?T>"6;3HOM;X:?L'_L9_!WX8>*?@I\,/V5?V?O 'PE\=:EIFM>-_AY
MX5^%7@[3/"_C;5]%U.WUC1-4\8:5_94T'BJ]T+4+&QN="NM=^W2:3+:0-IXM
M(X(8X_H(^ O!J>.F^)A\(^'9/B/-X3C\"2^/ET2P/C%/!$.L3^(XO"/_  D"
MV<FJ2^&(?$5P^O1Z/)>)9C6&?4! 9V78.+2OT _,#0_%'AWP_P#\%K/VB9O$
M7B'0?#\=U_P2_P#V-3'_ &]K>F:0MW)'^U5^V89WM3?SV_G)9>:([@AB5EN(
M(PN94%>4?&[[-^U9_P %!_C5\!/BO^U[\;_V9O@=\"_V/O@5\=/@QI/[.G[2
MM[^S=+\5-4^*/CKX^:)\9/CKXF\?^#+O2M=\<Z#\&)/AOX!\+V'A?5-;U/X:
M^'-0U.ZUCQ?X=U&7Q/8;/TU^,W[%7['W[0OB2Q\:?M!?LL?L[?'/Q?8:);^&
M=/\ %/Q>^#/P]^(OB&P\.6E_J.K6N@V>K^+M U2^MM(MM2U;4[^#3X9TM8KS
M4+V=(EDN9">9\:?L$_L1_$#P-\-/AMX[_8^_9D\;?#SX+FX'PD\"^+?@C\.M
M;\,_#"TN9Q<7%GX T#4/#T^F^&=,NKA8GO--TB&RL;]DB-U!*T*$)*[2[O\
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M*N=!N-(^+6A06LWB6_\ #=[]KTS6C/8V\"6-W??!_P"V;_P2V_:$_:8_:/\
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M/Q)T";Q1)KGA[QZ\GCC5]-UC5?"_B+POI^BWVBV.J>&=174K/7+B:'@?$?\
MP3@^/?QC^%GQB^'O[27[;:^.)/B?I_PCTG0M,^$'[,_@CX&?"OP)%\,/C)X0
M^,>I>*V^'@\;_$+Q%XO^)?Q U/PC!H_B#Q1K7Q130-%TZ]NE\+^"M/\ ,G^T
M 'QG^WG^WK^W9\/_ -FK_@HU\'/$WPJ^$/[.W[2?PR_8[\._M._"+XF_!?\
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M\!S?#[7M%\%>+;[QG>:;X;_4WX[?L1>+/'OQUU']I3]GW]JCXL_L?_&3Q?\
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MJ /8@T]9'#;I#B,@[20 "205Z$GE<GT^O%*R*?WJ9+-DYR3P5(Z'IS@?3VH
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M\3-/U:;P3_P1\^&OC#_@GK^SMKVNSPZC!XJL_C)X_L/C5H?C'29+>:[2UO\
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M2KJXI>"O@+)^T/!^U]XD\0Z;_P %*OVK/#6K?\$Z_BO^SWXIT[Q1^Q)\"O\
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MM>#H;[4M:OXH?G7]E3_@F[^U]^RE?_L*:YI7AO\ 9DUN/]G?XX?\%!K?XF>
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MV'Q"N?!^K^%O&7A*^\.^*?"GC_P3XZ\4^$=;T#Q7H^L6^LG3;;7GT/9\*_\
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M_P"T)\(KBX_9C\6_MA? *U>\\ ?$SQG\?O@CX'UOP_H.NV6E> ?AYXAU35?
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M=/I"]_X<_P""C>E>+O@C_P $Z_C-H'PC\2SR?\%%KW2M+\ >"[SQ9X>T^_\
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MARUT1M/^&?QZL-4UGPU/I,MWXB\3>%=>\,Q?$;Q2FLZ;IWPP\1P0>B_M#?\
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M^PY^P=\,?'_QAUC]D"+X@_"#XY>,=*US]KN7Q[XH^%&DZO\ %#PS;>"/B?\
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MZ^&7PZDT7XOZ%J/A6RT;3/'MB ?U):1I'[,?_!-/X7?#[PAIO_"P[?0/C/\
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M;ZNNA:=;:OK9TSPI)J*Z]?C1])O+35-5-I82C3].NK:]N_)MIXI6RO OQO\
M@I\5=9\6>&_AC\8/A?\ $;Q#X!O_ .S?'.@^ OB#X3\7:UX+U-+JYM#I_BS2
M_#VKZC?>'+X7EE>6C6>L06<_VBUNK<Q^9!*B?AAXM_9-\6^.9/\ @X,\;?!_
MX56VB?M@?$KQ'XA\%_LR?&>]\+)X=^(5Q=W_ /P31^ ?A'PW9_"?XG:II>FW
MGA^RN?%NL>*_#$'B;PGK\-E9>)M0U;^TM3AO[*YCM_@CX'_#[1KGQAX>\<_
M7PA\?OC)XO\ @7^QO^UQ#>?LK>&/^"3=G_P3J\+7&G:E\ O$&AZ)^QO^TI\:
M)[#PA>:EJOC7XEW7ARU\$>"?A%=?%*X7XC>%U\>6MU9^$8AXMU$ _H!_9_\
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MUWXTQ^)=?\$VWA&TOKX6>L>/?"XNF\3_  \\.>,[BQ@\ ^)_B)X;^P:@NO\
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MM8_LB>]UR.P?1=#\07^G<1KO_!2[]C;P]\*/AA\:(/BW<>,?!?QPU3Q'X?\
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M^)?[8OQ^_;QT+Q/KGQ$_:1^+WB3PSH?AOX6?M+?M _#OP;I?['G@#0+;X4?
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MB1\'_@1\._V5OC#8V?P<^ =MXA\1?L^_"OXE?"3Q#XM^*/C'X\ZG<^*_#Z7
MT_7= U>\/A+PW+XG^(>G6'A[Q)+H7@W6='T>^NX_??B%_P %#?A)\'?B)\9?
M$VN^/?'7Q!^'?AW]G?\ 8G^(_@?X7?#KX.Z;JNH>*-9_:Z^,7Q/^$?P=G^&7
MCIO$6F:SX\\6_'+Q=I?AOPE!X-\4:-X5\-> (M,TOQ%=>*H;'Q!KCZ+S\/[)
MOQ[\8ZY_P5(\:^)K#P!X6U+]N_\ 9K^"W@+X?>%8/&VJ^)[?P9\0_#W[,GC_
M .&'C70O%FOP^#]*C/AW2O'/BZRM]*\2:-IMRVOZ##<^(ETG3I;@:2OSCK/_
M  3C_:0?P/\ $#2$\/?LD_%8^)?^"<?_  3:_92N_AG^T!#XM\8?"#XF^,OV
M3_B'\8/%/QL\'^,([/PK'J?ACPWXPT7Q[HUK\,?BO9Z1KWB'PEXI2#Q=-X!C
MF\/P17![R[^6O_ \P/U._9M_:=T[]H^S\<A?A)\>O@3XO^&7B:U\*^//AA^T
M+\.X/!/C'2[G5]#MO$.BZII.I^'M>\:?#OQKX;UG2K@36&O?#_QYXIT^.YBN
M]*U:?2M4L9K5OS;\1?\ !1SX@MXW_P""D'@_Q3X4^,7P(\%_LD?M5?LK?!;X
M>?&G1O@7X!\86>J:;\5-2_93T._\-W]EXL^)[)XMUKXF^+/C3J.L:?KEMX?\
M/6?A#X!^(O#OC*VD;QQ:)H=W[+_P3)_9"^+O[+3?'U/&>A>&/@;\(?B#J'PW
ME^"?[(7@/]I'XP_M7^!O@3-X5TGQ#;?$;Q/H/Q2^,GA'P1JVA3_%S6-:T667
MX9^#M M/ 7A2T\%VFH:<TVL^)-<AL?(OCO\ L)?M/^/?'W_!13PIX5@^#/\
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M/$\_BB#2]0\3:JFAVUUI.EOK"]Y=_O\ ^ !]P_LW_M>Z;^T#XO\ '7PQ\3?
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M"J/11W)[>IY/U/)[U %62,(B$!B0<$=3A@2<X']X"HX5/FJ=K@9.=V=HRK=
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M;RV$2C&2$.> O9>3R3D$D!O6*UV?KTMO\OZZA*3U Y/&![G@ _4T@(W;<!B
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MZ1%KUS<<AI_C;_@I9\$)_B_I@^)7QB^#OAGX@?L?_M0^)_#/Q9_X*<_M??\
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MBNYT2WD$M?Q4_M4?#V'7/CO^WYX(_:.^*?P!^&G[4OC7]J3QO?? &_\ %/\
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M;\H,9!&1C)W9)"EE/&.N3QR,8S\F_$O]B+]E7XQ_$;QK\5/B+\%/"?B[Q_\
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MT7PK+:QS_+OPF_:3_:V_9Y\-?\%$/BGXA\>_";XJ:+>?\%I?A%^SMX T'5O
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M/QIKWP)U;X3:UHG@?XH>(=(M_ /B'Q3;SPZC>HD[ ?TR[G'R9(QQ@$J  F[
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M?XCO=(EDEAT7X@?#'Q-J7@WQ]X4OC+%"R:MX7\4Z/J>AZI$@>..^LY5CDEC
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M0 <GUQ80H2J1\.%D.,$';D<C/' ]^<?4U CQ#YF?'S80N=LA.#@-CI\Q&?\
MEG@@'YBXJPS'#;OF4*<HJMEG!RN %,;8Z9+'!].M5*Z7=JUW;>]U9KKH!&R_
MO$<;1R=S.P5B.,?*Q*#ZHQ/8X&VK";$SYB'9C(^0L ><DD9 R,<D@5'VP6"D
M$[B4);:?N[0^Y>S?H#TS3@"O0!<Y _=A0P]^ &!&#@<>QQ6;DVK=/3[K 6 ]
MN.0O;J$)!'Y8/U_*F,)"=P)\HLI7)& IP,;<9'4C'''6HLXQZDG&!CGDX Z
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MOKGQ:_:'^)/BGX@_M6_LX?ME^._B!\0_&GA#5O%_BKXT?LRO\,CX)FNY-*\
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M_%;6OB#QAXR\(Z=KOA>VN= \-Z-;WVHV%QX$G[?7BWXA>(_@GX#^,/P8\<?
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MQZ_Q8_X)<_L4?%[4-$O_ !!\*_%'A&+3?A+X:_9\U31/@U\9OCS^S_X3\;?
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MM;\,&PTRW;0]9\=/J.HGQCJ.E"VO/$[7]\VM37OVJ?S/YM_'7BC]KCX%P?\
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M"<;?O8]&Z9]Q3B(YL*3N*\D#(P>A_6@"4$, 1T(!'T/(ILGW#]5_]"%. "@
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M7PPU#X3-\-OC/_P3W^,O[$7Q8MO'GB#QCH7C3P+J>MZMXO\ &GPQ^(/@#3]
M\%>)=*\;65_XI\4/H7CW1M>UKPI<Z1H4<7B#0KW5-0@ET/4?U:EA*;=K2'(;
MISR,8!P#D')RIRC?Q*<"IOLR_P!]_P Q_A0!^6F@_L.?%'1]9_X)7:K-XK\%
M7T/["'P(^(GPM^)L:2>(K8^-->\7_LS>#?@IINJ^!HGTNY TNW\2>'K[5+P:
M^MC>0:#=K);VMWJ>^S?\X?B'_P $=OVC?$'[-_[)7P!U?P/_ ,$]OVA(/@1^
MQ-\(_P!FZW\3?&G2/B]\//BA^SM\;?AUH5[I.M?&_P#9Q_:$^#?A.+XPZ[X/
M\5M=:+?ZG\+]6U+X8W0\0>!M%UC1_&7AZ77=<AM/Z<0, #K@ 56DA(RR$EF8
MG!Y4 DD\#!Z]#G^= 'R;XA_9H\4>+/V(#^R?K7[0GQ=L_'=U^SIHWP2O_P!J
M;PGK=_X7^-3^--*\#6'A5_CA8ZO8:JE]8>-[[Q#8#QI=JFM%[F^N+FRGU&1+
MB2=_@N\_8_\ ^"@'[2'Q&_9!?]L[QE^QY;^!OV.OCGX2_:%L?B3^S]I7Q9N/
MCE\<O'_P[T'Q+H7ABSGTKX@:;I_AC]GOP=XL?Q FK?%;P]X:\2_%>[\36MK<
M^#]*U;1M!OY[B7]JEC)A"-\I/)QV._=QG-(MN%8-O<[3G!(H _GJ\:?\$O?V
MMM>_9ZTS]GJX\4?LQ>._ GPC_;T^/?[2O@/X3^/=7^-^F?"#]J;X&_''Q?\
M'#XBV?PP_:WL/!VE6>L:#XJ^&7Q$^-4'BSPO;>%3\2OA?XAU7X<>%+KQ9X,U
M-Y)DT_Y<\:_L/>/?^"<WA'7/VF]=\8_LY? SQ$G[8O[/?[0'PAM?V3/V+/B5
M<_LF?LW>)]#_ &6?B]^S#\0O"'QX^&O@#Q OQ$NOV>_'_@#QMJ_AGQ%^T9HO
MV#Q5HOQ'\<V'CSQ-X<T'1;.#08/ZN6B4N)"Q&W:2,C;\ISS[>OXFD>%)'\Q7
M='V"/?$^TE0P=0W!#;3DJ&!7#L"I#$$ _E1^#/[&_P 3O^"EOP]_;W^)?Q2\
M:_"?QKJOQ)_;%_91^.?[./Q-\6_LJ^.;#]E'XA^)OV9O@+X T'4/"4O[/'QN
M\0?\)O\ %G]FIKB]\7? W7?&NL7^B:EXYU1?%GQ&\%36MQI7AN&V_5K_ ()^
M?L1^-?V;O%/Q/^(_CKX6_P#!/KX,:GXY\.>#O!VA_"_]@+]EG1?@QX4T/2O#
M>I:KK&O:]XP^+>JZ-IOQ*^*&N>+;_4+&"V\.7.F>%/ OA#3/#>GFPTC4_$&I
MZOX@N?U4$"AB^YR25)W'=]TNV!NSM&9&^4?*!A5  Q4B1I'D(-H..!T&/0>_
M>@#\&?VL_P#@E1\5?C_^U5\6/C7IL_[$WQ-\/_&7PGX \-Z!XA_;)_9R\4?M
M&_$O]C5?!_@R+P7K"?LK^&;[QQI?PK6Q\37:WOQ-@L]4M_!4VD_%C6M8U[7[
MWQSHL]GHEC[;^QQ^PK\>OV1_B9\!-9@^(GP?\9_#WPY_P3F_9._8<^-EHWA;
MQMI'C2Y\3?L9P_&'_A6?Q!^%4J:C=:#:>'O&DGQDU:/QYX>\76[7FEIH&F2Z
M#J$KWEQ:P_KND0C9F#$[NQQZY_J:8UN"2=[C))P,8&3FG?2V@'Y>_M$?LI?M
M9ZW^VCX%_;._95^*'[/'A+Q-H'[+7C#]E[7_  M^T/\ "[XF^/\ 1K_1/%?Q
M>\)?%8^)=&;X:_%#X:W5I?V]SX.L-,%K?W-S%Y-S=.Z;VA9.:\4_LJ?MZ1_$
MSP+^U?\ #[XY?LF:;^UU<?!/4?V<OC[HGB/X#?&&]_9C^)/PRT?XI>*OB5\'
MM=\&^&K'XYK\5O OCSX77/C#Q#;7\M]X_P#%GA[Q[%XN\4V]SIWADP>'+S1/
MUM10BA020!C)ZTWRQYGF9.=NW'&.<9[>U(#\J/V7/^"=GB']G;XQ? WXN:O\
M9U^)7B/P-\+_ -MG2_C)J=WX(E\,7WQ8^-O[<'[2WPJ_:6^('Q)T.P@\2:QI
MO@CP=H7B/P%K'ASPOX&EE\0ZG8^&+KPQ87'BG4+K1[R_UGYIU?\ X)??M6Z#
M8_LW:!\.?VA?V<=3\&_LZ_'/]KG]I+3_ (=?'KX!?%WXB?#OQ'\</VB_VK/B
MK^T%\,OB;K6@?#[]H7X1S^(-=_9S\/\ Q'N/#/P^L?$E]J.@67C74-<^*D.G
M0>*-*\ WO@[][/*7S#)DY(7(XQ\I!!Z>V*'A#L&)(P "!T(!)Y^N<4 ?A;\>
M_P#@FS^TQ^T1\6/A3^T#\4_&/_!/;XQ?%G0/@Q!\&?%7A_\ : _8J^(7QE^!
M/PTU;3OBSXW\=V/QU_9:^%OBO]HN[N/ 'Q0\0>&_%?A[PC\2&\6>(_$,OBN3
MX;^"[ZR\3>'M TZ;P_>_77[ _P"R3\8OV(_@M\(_V=[WXL_#KXF?#/X?6O[1
M^H>)=7T_X/:A\.O&?BGQA\5?V@M;^,/P^U7P_I^D^.]0\#^!O#'A3P[XU\:>
M&/%?A&Q\-ZFFM:Q)X9U#PK>^$]#T>XT74?T7^SQ9#;<D=,_@>GU YI9(A)C)
M(QGIWSC.?RIIM;?U_5P/S\^-_P"PSX1_:8_:D^$OQC^/UC\.OBM\"?@K\%/B
MEX-\&?LX?$7X7Z/XTT&X^-/Q;\2^#3K?QH\17'B>ZU;PSK$OA[X;>"D\ ^#M
M'E\)27VBIXO\:ZH-:$>K"P@^7OC#_P $C?#WB.W_ &OO!_[._BGX>_LS?!;]
MK_X*? WP?XJ^$'@GX*:?;>$/"WQL^!/Q)N=>T_XW^'-*\+>)?!^B6_\ PFGP
MODTWX;^*_#5CH^G7&H3^$?!GB*;6+Q]-N=+F_:1X@X5=S#;W&,GC')^E2*-J
MJHZ* /R&*0'Y/_'G_@F]J'Q^^+/[;=UXH^)'AZ']GG]O#]F'X<?!?XH^!&^'
MFIW?Q:\%?$OX-?\ "=6?PT^)GPV^(;^-8_!4>BZ;!X[EUW4?"7BWX8^(Y[[Q
M1X:T&:/7+71)]5TN?R$_\$P_VC/'/PW^/'PV^-7[2'[,YM/BA^R-\<?V7=(U
M+]FW]@'P5\ KS7_$'QH^'5[\/[CXZ?&W5]4^*?Q2\3^(O$GARWU74[[3_A_\
M'=>^"OP^O+S5M9FU+3[^WETC2O#G[?T4 <7\/O#+>!?A]X*\&/=OJ;>#/"'A
MSPLVH"W:W;4O^$<T:RTG[<MIYER\'VT6?VC[,)KEXC*8EEG90[_ES\$/^";'
MCWX6>'?V8_A_KWQU\-^)O O[(?[>OQK_ &O/A&NC_"+5?#?BS5_ 7QD\"_M9
M:$_PC^(NM7/Q.\0Z)JGBCPYXN_:MUS58_B7X<\/>'M+U+PKX1TS0)_ 5OK.J
M7GBR+]>J* /RVUO_ ()S2ZS\>M7^-Y^+TML=3_X*(_"_]OH^&T\!"<H/AM^Q
M1;?L?-\*_P"UG\4Q%AK26J>.QXK73%ET^5G\/KH%VLAU6V\Q\#_\$P/B0O[5
M/P0_:,^.7[07PQ^+UQ^S1X\^(?C3X4^,M#_9-\.?"_\ :W\9Z9XU\&^//A_H
M7P]_:,_:DTGXCZT/BEX!\$>$_'<UO)H/A?X7_#>'X@Z[X7\&^)O'7V_4]'*W
M?[+T4 ?$/[2O[+OC;XL?'_\ 8T_:(^&OQ3T3X>>*_P!ECQS\1+K6-$\5_#.\
M^)7A[XE?"[XP^%=,\(_$SP=#_9?COP!J?@;QC/I6BV%QX)\?1W?B73?#NKH\
MFM^!_%>FSS::W@_['_\ P33B_92^(_P'^(J_&'4/'4GP4_9K_:<_9W71)O -
MIX<C\1)^TG^U=X-_:>D\727T7BG5SI=QX-?PBO@E=%2#4(=;CO3X@?5-,DA7
M3;C]5J* /S ^#?\ P3FMOA'\*/\ @G+\,$^*UYX@C_X)^?%/QG\28-:G\$16
M,WQ6B\9? K]I#X*76@W>GKXDO(O",5M%^T1)KK7T<_B5[Q?"9TW[%;-K+7FF
M>?? 7_@FQ\;OV?+_ .$GPY\'?MGO!^R%\#/&>GZW\.?@S8_LT_#JS^-TWPX\
M,R&X\"_L^>._VG;_ %[79O$GPE\'S1:9IXU'1_A+X8^+/B7PUI%CH>N_$N]+
M:EJ&J?L!10!X?\!4^-B_#B^3X_7&CWWQ!7XF_&]+"XT'2['1K6Y^%Z?&KQ]'
M\#9+O3M,U;6[*#6IO@JO@!_$134I'EUM]0FO8K*ZDN;.W_/ZU_X)DZUYOQ5\
M/ZE^T)?7OPJ\:?\ !1?X-?\ !1WP'X(@^$^DV7B+X>?$+X?_ +0.@?M%?$;X
M>:CXY3Q;L\=>#_B7XS\-:7;:-J=WX9\.ZUX"TZ2]4GQ7YT:VOZXT4 ?E]\?_
M /@F]X8^._Q%^/WQ5F^+/CSX??$/XL1?L;:Y\+O&/A'0/#5QK?[/OQ9_8@\8
M?%KQQ\+?B?X;7Q/!K.@^,SKNL?%34-*\9^#?%?AZ3P]KW@Y=4\*SB2+Q#<75
MOGVW[#?[66L_#[XIV7Q'_P""E_QWO/C!XN'PH/PL^(?P8^%OPY^!WP_^!=S\
M'_%4OC>QN]!^!FGS>+]!^("_%#69[K2OCGIWQ1\3>)M+^(G@:9? ]E8^%-(L
M].C@_4UX@Y!)(P5/&.=I) Z>IYJ2@#\4],_X)#R-HWQB\9^)_P!I[Q78_M9_
M%7XO_ GXZ:7^TO\ !CX,?"+X+V/PS^(W[.%AXJT3X;WWA#X(6VF>*O!OB2TU
M'PMX^\?^#_BA+\5=6^(.L_$OPIXQU#PSJVLPZ+IOA>RT/[F_9A^ GQP^%$_C
M_P 1?M _M:?$+]JCX@^/I?#L"7.I^"?"'PB^%/P]T'PD-5_LW2?AC\(O!)OK
M'0+[69=:N[OQIXKU_P 3^+_%'BRZMM'MY-1TO1-!T?2(_L*2(28R2-N>GOC_
M  I(XA&20S'(QSCM_DT ?DG^TQ_P3)UG]I_Q%\6/#/C?]L;]H9OV4OCSXN\)
M^,_BS^RAK&A?"?XA>&?[1\.0^&+:^T+X/_%'XB^$/$7Q0^!/@KQ;)X2TK5=>
M\,_#_6+8:!XAO/$_B7X;ZAX%\0>(]0U!O/OBU_P1\M_B?I_[6_PUTG]L[]IW
MX1?LU_MK^,_BC\3?CE\#/ACH7[/]A>:WX_\ B_HMKHWC:>#XVZ]\)M=^+2^!
MM6DL-/U*X^'TWB":QN;""Z\"W&KS?#J_F\(R?M/+%M)<%B6<Y&,@ [FZ 9ZX
MQ]3ZTJVZ.BD[E8X).2""#D\'W'I]* /S?^(?_!.7X6_$7X:?MX?"[Q3X\^*A
MTO\ X*&Q>#4^+VKZ9<^#;#7?"=YX-_9[^%'[.EOJ/P[G7P=+IFGW.H^&/A'X
M?\07_P#;NFZ_90>)KW5I=-L[?2&M],MO%?\ @J%^P=KG[1'P7_;;^(GP=TSQ
M'XR_:-^.'[!E_P#L>^%?AM)K7A31_!6N:/8?$;Q%\2M-:"[UNVTF32_%.IZI
MXPUC39M<U+Q;:Z-!I]M9R0Z9'J$1O;C]BYH5V,<,Q!&WKE<L,E2H!'!/0]SZ
MG,:6ZO&0S/@E@0Q)R,_[7/(QW]<8YIWT _*+6_\ @D[\./'OA?X[Z#\9OVD/
MVJ_CYJGQ?_9L\=?L>^&/&GQ2\3_"R?Q)\"OV?/B%=66H^+O"7PHD\'_"/PGI
M5[KOB6\T;PC/XM^)GQ5TSXD_$;QD/ OA&#Q'XAU6#2FAO>Y^+'_!.Z+QU\4O
MB-\4?A)^UW^UM^R;JOQQ\.>$O#'[0>D_L]>)/A19Z-\77\$^&K+P-X?\<[_B
M7\)OB1JGPP^,%OX TO0? T_Q:^#VH>!O&-YX4\.>$;%[]KGPAH$VC_I*%^S?
MNXUW(Y#L6#-R?E;IQC:HX/N><XJ0VZ;BP)7)!(&,9!R.W0>E(#\I_CI_P2WT
M3XR0>.?"5E^UW^V7\-?@I\:?A/X4^"/[07P*TOXB>"OBCX,^,7P^\'^##\.D
M-QXE_:(^'7QE^)OPW\6^+?!#1Z!\2O'7PG\<>$/%7Q$DC'BWQ#=2>/)KSQ;/
M^B7C'X3^ _&OPE\0_!#7_#]O?_"_Q9\.M:^%&N^%)#++97O@#7_"USX.U/P_
M++*;B9K>X\.W<VFF65Y)3%(SRO+\ZR>DR1"3&21C/3OG&<_E4@& !Z #GKQ0
M!^0_PF_X(X?LT?";6O\ @G_XEL?%7QK\5^(/^">UI\;/^$%U;QKXLTC6;WXS
MZY\=-3U;Q3X@\5_'Z=/#=K-XT\0>%_B!XG\2_$;P+<:<V@IH?C+6=0U.6*Y,
MGE)[%\/_ /@G1\*?AQX_^#'Q&TKQC\5]1U;X(?M*_ME?M1>&+'4=2\+-IFJ>
M-_VX+GXDW/Q,\.Z];6OA.VN)?"'A:;XGZZ? 5K876GZMIQM-*;Q!KOB!5U"2
M;]%Z* /E/X&_LG>!?@%^Q]X$_8X\+ZYXOUGX??#WX,CX(Z1XA\0RZ%=>-+OP
MNN@W?AM-0U"6QT"P\.S:TNGWCR!D\.)I[3(GG:=/'YD<ORA^S9_P2L\ ?L\Z
M]\ I]3_:&_:C^/\ \/OV2O!-_P""?V6O@Q\=?$_PYU7X<_!1=;^'+_"?7?$U
MDG@KX8>"O%/Q#\32?#C4_%G@7PK<_%/Q3XVTGX=^#?&WBGPMX'TC1M-OK;[%
M^K=% 'Y@_!3_ ()F>&O@=XH^&,?AW]JS]MK6O@)\"]:DUSX(?LF>(?B[X;@^
M!WPZ6VM)['PKX6?4_"7P^\,_'#XC?#CX<64ZV7P\^&'Q>^,GQ#\!^';2TT6V
M_P"$>OH?#^DIIOO'[5'['OA/]J.^^%?BV?X@_%SX(?%_X$^(/$'B+X-?'3X$
MZWX6T+XF>!V\8Z ?#GCKPY&OCSP9\1? 'B7P;X\T:*RM/%7A3QOX&\1:%?W&
MC>']32UM]7T;3+ZU^QJ* /RZ^%7_  2K^ /PET_P5I^E^+OCQXLE\%?MJ^+/
MV^_[<^(OQ!L/%WB/Q5\?_'WP2\5? [QM<^+M9E\+P7FK>$_%&D>-O$OB[4M"
MMFL+NW\9:G-/IFJV/AR*Q\+VU7X6_P#!*7X._#WQ%\.[SQ9\:/VK?V@OAO\
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M"7O[&GA_XM:=\7M+\%_$3&@_%;4?CSX5^#MU\=?C9J'[,7A#X[ZIK=]XGO\
MXP^$OV8[WQY/\#O#_C\^*=3U#Q99:KI_@:*WT7Q?>W/B_0;+2_%$TFKM]"_M
M)?LR?"O]J;P'H7@;XM6/C(Z;X5\?>%OBEX*U_P"'WQ%\<_"?Q]X&^(7@YKT^
M'?%W@_X@?#GQ#X=\6:#K%C!J6I67FV&IQ1W.FZC?6EU'+!/(E?1YMP0 TCL1
MG#':#CC ^50,# QQGWI91MC50NX#"\@G@*1G"]^![<_C33L!\EZ_^QG^SEXK
M^'O[3GPN\0> KF]\"_ME^+=6\9_M$:.GC+QO ?'OB76/AY\/_A3JNH?VG%XC
M34_#7]H>!?A;X(T>>U\'W.A6$DNE3ZE]G&HZMJUU>^9?'W_@FE^QW^TMX]\1
M_$?XG^!O'T7B7Q[X5T'P/\6H?AK\>OCU\&?"WQU\$>%(=0M?#?A/X]^"OA'\
M2O!/A'XT:'I%CJ>H:+:V_P 1]&\0S?V!=S^&I)Y/#[?V8/O8+MVX4D*=P!1L
M9XYXQR<#)Y^@'%*$<!V*@*6W1A ZMM/#*Q!R &)8 #)ZYVY!&[Z:=P.-3P)X
M/M?!MK\/;+PIX;M_A[:^%HO T'@2#0],B\(0>"XM'70(O!\7AOR#HR>&4T)%
MT:+0A:_V:NEJ+ 6WV7]S7P_\'_\ @E3^P[\#_'?@#XB> /A=XS&H?"*>YO/@
MMX4\=_'[]H?XK?"CX&:A?:7-HDNJ?!CX-?%+XG>,?A1\*]6@TBYN=*T?5/!O
MA'2+SPSI5S<Z9X9N-(TVXFM7_1%HI)0,@;%SM#!G"G()=@QW,1C(!XQQ@TH4
MLRJ"X&8U8K'Y:Y5LGY2I'0YS]>3W&[I*RTZ@?G?\5/\ @E+^P3\:OB%X_P#B
MA\3_ (&3^(?$/Q1\1>&_&?Q"TNW^+GQOT#X;^+OB!X0L]'T[PS\3]9^$'A?X
MBZ/\*)_BMHMAH.DV-C\3_P#A#$\>1VEJ86U]DN;OS]K6?^"9O[%GB+XU:G\?
M[_X+7:^/]=^)/A[XU^*=%T?XL?&G0?@YXR^,WA.6PF\.?%?QQ^SIHWQ!T_\
M9[\:_$O2[W1]'U>'QSXJ^&>J^*)M<TG2]=NM4N=6TZSNX/O\6ZKDEF; /!QC
M..#P <CL23QVX!#;?"KECM+*I.[CD;@0 <=._N::E;HOQ_S ^$?$'_!-W]BS
MQ3;_ +0%IXE^#4NK:1^T[\1_"WQF^+6A7/Q,^+']A-\9/!UW/J&B_&#X<:);
M^.8=-^!?Q4_M&=-1U;XB?!&W^'OB[Q#J5IINH:[J^H7FF6,]O;\%_P#!/7]C
M[X;_  ZU/X5^$O@ND?A+Q!\8OA]^T#XHO?$?CWXH>-O'?C7XR_"CQ?X3\=?#
MCX@^.OBSXT\;Z[\5?'6M^#_$_@?PG>:,OBWQIK5A#8Z):Z&]E+H?G:<_W$8E
M3Y>75P<[AG&"H &,8X9OY]C54Q*0H:)20"%WJY7<QSR"K@=^0/;(S@BEKJE;
MY_Y_B!\\>(_V7_@)XVN?VC'\4?#72M8E_:W^'FE_"G]I"6;4?$,#_$WX>:-X
M0\5> =,\+ZF+;6(1I=C:>$?&WBK14N_#1T?4)(-9N9Y;V2\2VN8?$OC1_P $
MROV&OC_XCT_Q7\6?V?-'U_6K+P)H'POU";1O&?Q.\"0>./AKX7+Q^&OA_P#%
MC1? 'C+PQHWQD\$Z%%)+!IOASXKV/C31K:UGNK6*S6&ZGCE^\_*R/+7Y67)P
MI8(NX@_NP20"<#<"#MQ\H0'%*3*9%5XSA?\ EHK;,Y4X&_TR>F?O<<]#=UTM
MUZV].H'B7AC]G#X'^#=:^)/B/P?\-]!\*:O\7O!?P_\ AW\0Y_#HO="MM?\
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MD9XSN7C/&>#FGPQM&&#$')'3/8>]2%4 )VKP,_=';GTJ(W"9  9L\9 &,DX
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M=H\NJ^'?&W@W6/!OQ3\#:G<:+I-YJG@'Q[X6U&]T^UGNC;Q?A#\$_@W^U/\
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MBB@ HHI"0 2>  23[#DT +361&(+*"1T)[4*ZN"5.0#C//7 /?ZBG4 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !42&,NP5</\ -N.,9PV#SWYQTJ6JZ(PG=MI"$-SD8))4CC.?[QZ<9YH
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M?RIL1E)/F XQQE0.<]\=\=OKZ4LSNFW8,Y#9^4MR,8''3.34HY )[@>W;TH
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MR*MXKNV* ,UH03G."ABQ@8[AR.V, ^M=:8LR"3/(QQCT]\]>?Y<'% $M%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %1>4/,\S)SZ8&/N[>N,].>O6I:9(VQ"V,XQUX') Y_.@!]%0B4F)I
M,#(SQG@X..N._P"O'K3HI#(I) &&QP<CH#UX]: )**** "BBB@ HJ.5S&NX
M'D#DXZ_Y_+-+&V] V ,YX!R."1U_"@!])D=,C/IFEJ%H0T@DW8P5.,#^$YZ]
M>: )2,@CU!'YTR.(1@@$G..H';CM_G\ZDHH **** &21B0 $D8.>,'L1WR.]
M*B[%"@Y &,__ *J=10 45#YI\WR\#&<9SS]S=TQT[=:FH **** "BBB@ IDG
MW#]5_P#0A3Z9)]P_5?\ T(4 14444 6*, ]1FBL_S)]Q"_-@D$YQM&< L3@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M4_,,D-QVQR0#FE5G &&*^PQQ[<@GCI2TLWL[Z)[VZ:=^KZ6 MR&-5 =<KD
M#." <<>P!I&'F1 1C ., Y7Y>A'&>H_QZXJ*/,C;9"77:6P<<$%0#P!V)_.I
MV^11MX56!; Z)GGU/UQSUI <9#$P\7R9QM^QG<N<@LRQ8)! SPI!./05VP4*
M,* !Z"N/M1(WB>5V:,C[.XR<^80JPA0,$#Y><8'0D'M78T6:WT **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M;C/\^QQ($ZNCYVL#C&>O&<XZ_0TZHTC6/.TDYQG)STSC^9J2@ HHHH ****
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MDG '4TBNKC*G(SC/O_DU!*SY=<?N_+8D[>_&!NS]?RHA95!4L 2_ )Y.54#
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M,4/,KDG8\4Y4OM*AF55;R\D#!)8#IG.T\#O3C\A!522-C!=I4LP). &/);
M.>1CTQ0 --'(0WF;B1A3%&60X)QDY89R2#SZ4T2*K G)8#[J?,V3URO0CZNI
M!&<$ 9!@YV%< \)'GY,G.W[A&\'Y@21R0"!U+(D='7YVE;#;FE/SKN((4@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M8Y0D<8WL><C(PIQT]A5I/*)"E<R8.\X/+#AOF[\YYZ'\J@88=E4 98[02 .
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHID@8H0GWN,8..XSS],__7H ?14<0<+A
MR2V3U.>.W-24 %%%% !1110 5"TZHQ4JY(ZE0".0".X[$9XI9B0F02#N49!P
M>3C^M5E4_P"LD&Y,DEC\S,2?+"D=U&%8>_( (Y +0D!C\S!QR<<9P"0>^,\9
MQFHQ,C,,)EB0!DH&'N06W8'8@'VYXJ5-C( JC8<C!&.YSQ]<F@1QJ<JB@^H
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M8VY! !()8\X&.O<^N0#U<7W/^!2?^C&H DHHHH **** "BBB@ HHHH ****
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MT- $/[WSN_E?AC[OY_>J>BB@ HI#G!QUP<=^<<5'$9"&\P8/&. /KT]_Z>M
M$M%%% !3)/N'ZK_Z$*?3)/N'ZK_Z$* (J*** +%4#*9% 8KO20AE'!7AL!AD
MD$@9YQ5^JY@3KG:Q.YFXRYY )SU(!Q0 I9EAC*]=J#H3P5&>!^=1X 7S0?WO
M!*]<%N#\G7A2?_U594!549X  !/? Q548^T9X^\W/MY9'7TSQ]: $,C-A'("
ML>>"AXRPY)[E?3UQ4*LP8DCA0&4EU7+#G&PKN;!&>" >G'=]R)"[,J@@;=IZ
M@C&TYP?5F'4<@?C$"Q7Y\ Y).!@#D;5())W/SM(RO9@>A ))#(X+AD# A.1@
M'C(ZMVR>X]_9%.0O7.#OSTW9XV^V,]/QJ.5RH  9OG5MJH&;C:"V6EC&,=L$
MY!P<D8DS@D$$  'DKGGU"_<^A)SV/6@!U30<,Y.0-J\D$#J>Y '>J[$ ')P,
M')/ '!ZGH/Q(J>?:R1G ;!R"&;C*]<*>0?<$4 6P01D'(/((Z$>M5Y$529,X
M)89R>.>#@'OCWZ>U2QG*)SSL7/KT&>*)$$B[2<#(/ !Z?6@#D]0;;KVE$!6#
MXP1\V,,V<D'"D[<+QU('>NL087 [,_7_ 'VKDM239KNE*,D#;S@#J['M@=ZZ
MY>A_WG_]#:FW>WDK .HHHI %%%% !1110 4444 %%%% !1110 4444 %%%%
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MSM&OWDSD<8&TA3W]33I/N'ZK_P"A"@#EM5;_ (GFEIC^)6S^)&,?A75+T/\
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M\;L_-G&!GIC/\Z$E5R0 PP,G(Q_7_.* )**** "BBB@ HHHH **** "BBB@
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M^;;RI_B&W@<CY<]<^^#3Y/N'ZK_Z$*<,X&[ ; SCIG'./;--D^X?JO\ Z$*
M(J*** *ZLT>%7@HF K+DX]^>I(_^M5L2QX&77.!GD=<?YX[57CC+Y#%@1R'(
M(+ ]CD8X[8 ZD]2:8!EMO/5@2.H R 3Q@9( Z<\X]@":2)=K,FYB_7'(*N<D
M@8X]<C^6:KLAP0ZL%.!DJHZX &[&[GIR23G!XJS!(Q*H0 NP!>"&!0 .'!/'
M)&.!WZCHV24EFC*!@"1P2&X ((." 1D'- $" 1 *(@ "2%5"&^8DY!!;(SDG
MU&:>+9=AE<?O55BK \A=OW/=3CYAWY((SFF F,[B =__ #U(PG# 895P =JD
M9!Z@<4Z-F53&6+*[8+/PRB3 (&"1A<Y&<''4"@!,_4_0?Y _&CZJYX_A[=>I
M&>OZ?C2R*ROM29PN 64!"&))!!!4\D # ZC'&>L9&.C;<'YMJA1V^\ !@XSU
MP3T%-6OK_7W-?F _/.W^/'0<GTW8] >OIWQ31(@PVR0-M(#Y?:I8!<L>RG/4
MXZ<$$5-%$6=I'#QE"R@,5PRL<[Q@' 8C@$Y&,'J*)HEC3!WL'PIP!D;3D8PI
MX]212=KZ;=NVBNEY7N MN,/C&,(PQZ ,@'KQCIR>.YZTNS=,VY"4))R0=I.%
MP<CZ''Y=<BHT=D(8#D@CYPPX)!'.!S@#('N>@J>.5W<*0H!!/&<\?7W(H YC
M6H@FJ:60$"F>,KQ\^0P4X.>>.OMVYKK(_N#ZM_Z$:Y?78P-2TJ0,03<(K* A
M# -QDE=X.<$88 XYZD5T:NP94 !4GEL$XRS$C(XXZ<^N<4 6**** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M7\S:=V_.T DG *C"DJ<E0#R1QD].*"Y:0,T:B0$';N9F '*D@#CW&"!CJ2:
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M#YN@SU*H2A8HSEN.)&RHS@84 ?.%[XQCGG*'<*&Y+E222?E7:,=N,GGU/?\
M0 #0K ;57**I!)8Y RS'YB.3AL[C@#(S@"EW(,!R0@Z(-C%NI^8J22>H&>O/
M7%#;N@<*#]X'J>Q(Y]..G:ID3S"T@(&UU.,9R%1@>0>IW>^,4 0%5!#8<%,_
M*S."I..'4@@YQP,D#G/49TP<@'U /'3FJ,<?FJRAV7 3E3CGYNO7FK4C^4%P
MN[/'7;T'T- $9)F8QGY0I8AAR3M.SD' YW9IZ0[&#;R< C& .O\ ^JDB0[O-
MW9#J3MQ]W>0V,YYQTS@?2E$VZ4Q;<;><[ASUX 'T]>F<XXR <[K?_']IG_7Q
M'_Z&M=+']P?5O_0C7+:VC#4=-DQ\HE1?_(H;]<X/8$?05U2#"@?4_F2?ZT .
MJ&24HRJ%!R/?CG'8'Z_@?:IJ* "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **CD3S%VYQR#G&>GM_G\J6--B!<
MYQGG&.I)Z=NM $4CEG,) VL,%N>,C/ICCZ]Q3DB"QN@;(;=R !C*A>@XXQFI
M'7<K+G&X8SUQGKQQ38H_+4KG.6SG&.P'3)]* (OLP^7YS\K;ONCK@#'MTJSD
M'H0:0C((]01^=111&+=\P;<%[8QC/N<]>O6@":BBB@ HHHH A,69/,W'J#MP
M.H&.O7I^7:G&-?,\T</@ GCE0<X/M[_6I*:PW*R]-RD9^HQ0 [(/0YHJ**+R
MPPW;LD'H%Z#TY_S^-2T !('4@?6BH98O-V_-MV[OX<YSCW&.G6I0, #T ''3
MB@!DKF-00,Y;&.?0GL">WI3D8LJL1@D9QZ?G3JA$V9?+VCJ1N#>@)Z8SVQUQ
MG/TH FHHHH 0C((]01^=1Q1"($ YR0>@'08[5+10 4444 %,D^X?JO\ Z$*?
M3)/N'ZK_ .A"@"*BBB@!\<PD) !&!GD@]_8FG2*77 QGGKG'0@=.>I!_"G!5
M'10/H /Y4M %59A&H0J24 0G*X)7Y21D@\D$\\TDDP9,;6&2G.5Q]Y?0T1@-
M,^=O#2?*W4Y<\@8/' ZD<'--DC92S879N&!W&2 "!C YY^OO0!&/\#^8!_ X
M.#CJ>:6@HQ0O\NS/N6R&V@8X&"0!C. O'M30"<YP&<CCL&;C _V1P!P.AXZ4
M -9F4%EP5S@G>PVG:,' 4@@]!SDG@C S3_G#C>P;!"A1\J98,P9L<Y 7 XQS
MR#4K0.Q(X"$C(SU& .G3(.2OH3FGK'(.&"M@C#9^;'J<CKZ<DX.,T?C_ %_P
MP%8GC)9VX)^8@>F,;?7OGVQWJ86[\'<OKSN/\R:DBA*[O,5#PH'&>F[/4=\_
MC2Q)(KNSG(/0;B<<]/0#''Y8INUW;;I_7J XL(8TR,X"IQ@<A3SSCCBGH0RA
MP,;A[9_$BJ\8S,X;+#,A ;D AP 0#P" 2/H2.]6@ !@  #H!P!^%(#E]<.+W
M320P!NHU4[202"&.3T&,$#/4_49Z9!A1WZG\R2/RSBN9UT 76G$  F[CR0,$
M\'J>_P"-=.O0?0?RH 6BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MU:?<7_=7^0H =1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MQGN,\=^,TD1<KEP0V3U&..W%.#*> RD^@(_QIU !1110 4444 %,D^X?JO\
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M!)1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !3'8(I8C(&...Y [\=Z?00",$ CT/(H JF99 8P-I<%025P
M"?7!)J:)"BD,026SQG'0#O\ 2G;5'15_(?X4Z@!",@CU!'YU#%$4W;B&SC'4
MXQG/7UR.GI4]% $<DHC )!.<]".W/?\ S^=/!R ?4 _G00#U /U /\Z7ITH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M<!D<9ZXSCG'J*IJLZC"JPZ9P5Y(&,\@]J +]%00^;\WF9_AVY(/KGH![5/0
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M'/\ NJ>WUH EHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBFNX12Q!(&.!UY(']: '44R-Q(NX @9(P?;Z4^@ HHHH **** "BBB@
MHHHH **** "BBB@ J+S1YOE;?QR/[N[IU]JEI-JYS@9]<#/Y]: (C$3+YFX8
MW XP<\*%/.?Z5%<$"2-NNW!QG_;4?U//^%3&4"3R]ISD#/&.0#^@IKR)Y@1D
MW$E1D@$#<>.OO^M #DD\U6P-N..H/4>U0?93_>7\F_\ BJM@ = !] !_*EH
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M>YZX[XS4U%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M44 %%%% !102 "3P ,D^@%(K*PRI!&<9'K_DT +1110 4444 %%%% !1110
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MMD"+:%2=VV.,9/4_NU/]: +5%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 C ,I4]""#Z\^GO340(" 2<G.3C.< =@!T [4^B@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% $)F(E\O;W W;O4 GY<9]LYQFAIML@CVYR5&=P&-
MQQTP2<?7_&I<#.<#/KCG\Z1B%!8C.T$^_ SQ0 ZBHXY!("0",'')!Z_0FI*
M(8I?-W?+MVX_BW9SGV&,8J:C '0 44 %1++N;;M_C9,Y_N@G.,=\8ZT2H9%
M4@$,#SGI@CMSWIR+M50<$@8)'?\ /F@!]%%% !1110 4444 %,D^X?JO_H0I
M],D^X?JO_H0H BHHHH L4444 0F= 2,/D$@X7(R#@]_:I%8,H89P1D9ZU$/)
M9RNP%LMDE3U!Y.?K2^;&F4 (VG& IP._]: &S2##1C<&RO(X'56/.?3]:A2-
MW*MD,H8 [R2<*>1CICK@?CQQ3F5Y&9T7*L1@D[3P IX//532K((AY;[@YR>
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH ***C:5$(5B<D ]#CDD#)Z#D=Z )**** "BBB@ H
MHHH **** "BBB@ HHHH KI'()68M\A+$#<3P2<<=../I5BBB@ H(!!!&0>"#
MT(]#110!7DB8LIC 51RP!V[N?0>PQG_"K%0R+(64IC;QGYV7'// &#QZ_3I4
MU !1110 4444 %%%% !1110 4444 %,D^X?JO_H0I],D^X?JO_H0H BHHHH
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M=-N6)*Y9$) W$#8V !ZEFQG'?VK1TT@V%H5)8&V@&2,?=A1#Q[;<'WS@D<T
M7J*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *C:
M)'8,PR1@#D]B3TSCOWJ2B@ HHHH **** "BBB@ HHHH **** "BBB@ IDF_8
M=GWN,8 /<9X/'3/6GT4 54-QN7=NVY&?E0<?4<]>OM5JD)"@DG '4FD#J06#
M J,Y/88Y/Y4 .HIJNK9VL#CKBG4 %%%% !1110 4444 %%%% !1110 4R3[A
M^J_^A"GTR3[A^J_^A"@"*BBB@!MO]YO0JN#V/)Y'J.1R*DE=T"[!U)S\I;
M]![U%:_<B'?RO_B:MT 1E?-C4-D9"L0.#G&<=.Q_E3681QD(02FT<G<1E@.1
MGW]J=))L7*[2<@8)]3CMS5-_F96W*NX&25?F)V %EP<?>! XQCH,&@"SO<P[
MQR^3T!/1]I.!SPO-5F9BVX_?!7&5*@$'Y<@\XR<DY^G(IR7 "H(\.K;MK'()
MYD.2/J!^?TIKLSL20-Q 4 9([X)] 2>?0>M %N)F929"N0QY7@ 8!YY//)/7
MIBHI\-M9"6(!!V_, ,$Y. <'(]>WL:JM%+@G" =QC=D=\<CG';U^M3+(R @
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MM\]06 .8\#'/!SP21UY!P#Z=: )98@Y#DX"#.,=<'/))Z<>G'/7.*(9#*"2
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 R0N%)1=S<8&0.
M_/7 X&:$+E07&UN<C(..3CD9'(P>#3Z* "BBB@ HHHH 8LB.2%.2.HP1CG'.
M0._:GTQ8U0DKG)ZY)/?/?WS^9I] !1110 4A( )/  ))]AR:6D(# @]""#]#
MP: $5U?.TYQP>#_4<_A3J8B*F=N>3DY)/\Z?0 4444 %%%% !523_7K]8O\
MT.K=1F-&8.0=PP>IQ\IR..E "M(B$!C@GH,$YYQV![]J?4;QJQW$$E1Q@GJ.
M1QT/(%)$9"&\P8/&. /KT]_Z>M $M%%% #!(C,5!RPSD8/&#@]L=?S[4^F+&
MJL6&<G.223U()XZ<D4^@ HIN]-VS<-WISGIGZ=.:=0 QHT8AF4$C@$Y['/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHJ&:1H]NT YSU![8]/7/?TZT 34444 %
M%%% !32R@@%@">@)Y/;^=#L51F&,@9YZ<5"J^=MD8X*MP%''RMGDG)ZCVX_&
M@"Q1110 4444 -#J25# D9R >1@X/Y'BG5$L05V<$DMNXP/XF#'H,GIQFI:
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M( HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH 8[A%+$$@8Z>Y
M[_6E1PZA@" <\'KP2/Z4I4,,, 1Z&@ *    .@'3UH 6BBB@ J&:-I-NT@8W
M9R3WQCI]#U_(U-10 @& !Z #\J6BB@ H(!ZC/UHHH   .@ ^G%%-<,48*<,1
MP<XP?KV_STZTV)752'.26R.<\8 QG [@\8H DHHHH **** "DP/0?D*6B@"
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M82KR3T.3C@;>GTXJ6@ HHHH **** "F2?</U7_T(4^F2?</U7_T(4 14444
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M]X8 (QB=P.#Z@ ^^<CC%5HHWLGK:[] .@J-XU<ACG*],''?/\ZDHJ0"BBB@
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MYHW=W*8+L7+*Q4; YW*<D,CDCH&!7@XS@4_#C[R!?O D'*C(*C!QDC)'TZ<
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M8CALC')^[CU!'7W]N:FHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MN<8.'&<8^AX]B>E-$BB-T9>N_:QQ@L>@'^T"<?R.>*0_O'^0 98A0W &T'/
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M#T INQ=V_:-W]['/3'\N*=10 56DCD:0LH P%P=V#D9YZ'U_P]K-,:6-3AF
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110!$T0:02;CD8XP,<9[]>
M_P#GC"/(RR*@ (;;D\YY8@XQQP!GFIJA>4I(B;0=VWG/3<Q7I^% $U%%% "
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M(&X* Q Y)P,G.,G)YYZT[:N<X&?7 S^?6@"+RCYOF9&,YQCG[FSK^O2IJ**
M"BBB@ HHJ.201@$J3DXX_.@"2F2?</U7_P!"%.4[E#>H!_,9ILGW#]5_]"%
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M** "BBB@ HHHH **** "HWE5&"G=D@'@9')('ZBI*8T:,0S*"1P"<]CG^9H
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M@YR1G&%ZG(_GFG-(9'>/(*'&W:.3@(QP1G."6S@9 ![BH=K;F4AE()V$@DR
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M6"YC&FV/FWLJRHR+%^8MC^PE^TI:_M-:9J3?L]> ;/XD6O\ P42UG]K+5O\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M7!J'A.!]4O(=&E75VU18@#U3X>?\%-_V7;[X*0?%_P#:#^('@W]CZZL_B_\
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MWE_9.'[+>JKJ,G_!7:#_ (* 7/[><GBKX/Q_#>;X0V_[8,/[5">*5B7QM/\
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M>/7J/Y_RH EIDGW#]5_]"%.4DJI/4J">,<XYX/(Y[&FR?</U7_T(4 14444
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M8%,-NIC$9D8A6++(5W-U'10 =I^G'?(P:F81F0HO^LB&UST^\& X.&.X?,6
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%1RHTB;5<QG(.X
M'@=OQ_IZ4 2457CA='W%@P^;NV3GH3VSW..,DX[&K% !1378(I8@D 9P.M5V
MN%967:ZY5AG'3(//'/'MSZ GB@"227RV5=N=WN!CG'<?U]>F,U-56#&USD.
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M_K>O:D29'("[LD$\J1TZYSZ=/K0!( %    '0#IZTM1F5 VPDY^AP. >3TP
M1GTJN\A64,6;RRP  Y!^7G@#NW?OU'8T 7**:K!QD=/\0#_(BG4 %%%% !11
M10 4455>39/AGX(R$!R2 H!^4<_>(/TR>U %JBJAD+2*59@I9!@\ Y8 \$9_
MR:G:54(4YR0", GJ2!T]2* )***AF60[?+)&-V<,%],=>O>@":BJT#,68,S'
M '#'H<D'\L8JS0 452)D9V56;.Y\#<  %8CN#[5:C#! '.6YSSGN<<]\# H
M?1110 4444 %%%% !1110 4444 %%%% !1110 4444 %(Q"@L>@!)QZ#DTM(
M0""#R#P1ZCTH :CB0$@$ ''(QS@'I]"*?3555&%  /.!TSZU#,7#QX9@"0O!
M')SG_P!!!_3WH L45#*LAV^62.N[# >F.O7O1"LH!\TY;U!^7'; Z@COZ\T
M3445&)59B@SN!(Z''R\'GIUH <S!%+'.!CIR>2 /U-".'&X9QDCD8/%5Y$E9
MVQDH<8&X < =O]X9J6)65,,,')/7/4YH EHHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BHY0Y7"$ALCH<<=^:6,,$ <Y;G/
M.>YQSWP,"@!]0NLAD4JQ"#;N&XCHQ)XQSD8'49Z'BIJC>5$.&SG&> 3P21V^
MAH >W0_0_P JKV[,=VYF;A#R<XSNSC\A3'E)D!4MY84AA@C+9/8\D8/;^AI(
M75"0V<LJ 8!/()!Y'3EAS[T /MRS$[F9OD7&23C).?Y#GK[U:JB\D8.V' /\
M;*,;1P1Z;L\],CU([7 0%7<>H R>.<9R<],X_/B@!U1^8N_R^=WTX^[NZ_2J
M[3^5*N3(Z.&R I8H0>!M )"CG+'@<9([R%XL>8,;^"#@AB<XP<\C/W2#T'!H
M DE_U3_[IJECG&W+$@*^[ !)PORX['\Z%D<B0._56.TL,C< 0 ,\A22 ><\>
MU-=PH)W*I! !+ '>?N8'7EL 'IGB@"RK&+*R9)<@J!\WH#Z=3CMBK"JJC"@
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$* /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>ex10-69_004.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex10-69_004.jpg
M_]C_X  02D9)1@ ! 0$       #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" 2/ X0# 2(  A$! Q$!_\0
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M"3X?>(?B5\6?@QILWP[_ &I?@U^UOXRO?CI\1O$GP\^&'BGQ#8?&KQA^S_\
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M0V/A+5?VK#J_ANR_:I^&+?'_ $[P!^S.?&FA1?%W5?V?KNQM_$$?@7XH^/\
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M^&;SQ/\ LG_#KQ6=<^!7C_QOKFE?"W]H>V34O OQY\.:+8:WX#^!>HW'Q/\
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M'^T%^T7\1_V;_P!CA_C1XR\ ^$=4^.EMHWP;\)-\--$\9ZNWP]F^/7QF\<^
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MP%^QKK^A_#']H+Q9XCU7XJ>)_&W[5'PQD\9ZQ\-[/P];:U\/9(=9^'OBUH/
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MR!\&_$GC/QCH?[17P,MO@W#\=]'\>ZGXT^)7Q0^&'QU\.?#_ %N[^&'BG5?
M,7A']E#QWH'CM/"WQL\5>,['1;_4O#]SX7O8M;X.P_X*[ZYKGBG2?AM9?\*X
MO=6TSXB_MY>$_$WQ2^%_PV_:#_:0\->*--_9(\2?!CPSX3U+X8_![X%IKOQ$
MU>'63^T1X.U_XO:A<>*=2\+?#:S^&/Q+TB#4M=DUOPMJ]G]3W7_!/;XJ>)D^
M,7C?XA_M777C/]H/XL^'OV?_ (=WGQ$NOV??A9!\*I/@_P#L[>(O'_B?P_\
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MOE/#,3P#[=ZM*"R*'!)X)SZ@Y&<<8R!@=/6I** (O)CR3M^\23R0#G'8'&.
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MA@?Y"JFVXP5"D*<Y7Y>_)YZ_3T_/,_G8BW?><;=RC@Y8@8([<'/;-,2:1W
MPN1N7;RH]2<]SZ9P,=^" -6*0D%HTVY&[<3NQGD#'!&.@Z'D$'G-CR8\YV\\
M8^9N,=,<\?0<>W)S+4$C2AP$!*X&3MSR6.><CH!T]^W!H_3S=ON 8Z/'@0*0
MIR6P0?F)./O<X_3'TJ<_?3Z/_P"RU'*TJD>6"1M.<+NY[=_\?H:D/WT^C_\
MLM #Z*** "J]QG"8!.&.< GL?058HH @9GC@4HF]@J#:3@]!GKZ>G7\JA +2
MY8%,L2<C('R$8R05.3CCWQUI)I&?*'Y0KG!4,2<$@=L<CFF&+]V&\UMQVG;\
MN1E@/KP?;VH <X(E("Y *G<6506"J=NQ07Z?-O"[1C!SR1'(?E+  D$L1DN,
M@QG!^53@XZ8X&<<4IYYW?-Q\V 3P , $$'(!&,'G..1PU@-BA H9MRL!\@(W
M!<$)LP,<_+M.!Q51W7S]-NOX@1%W98@$!+-'N101L+%BS=<J5*K@OE1QD$U.
M-P#DJ0-I(W%7R>1@%1T/XD<^U-0*@VKD,&W/]X87@,/F=V.0I"X)&2>AR:0+
M$5V1EB <DEVXYR!QP><\8[<\FJ=WHE_5WUOUW6FH#]R+C<%;+ ??=L#G)_U?
M';D\>N.X!N'0L.>0"P]L'!SQWZ^N#4D:B0L-^T #ICG.[/)],#I_A231A -D
MA )/R@C P"2>YYQ^':LVFM'N!/%([-M9< +UPP)(( Z\<@DX&:=/_JS_ ,"_
M] >AW,<:$ ,?E7G/]T\\?3]:;(Q:$,1@D,2.>/D?UYH_X'Y@8?AXG%[\@53<
MO@J1MXSP >1C'//?( %=)7->'AD7A_NW4GXY)_QKI:<G=MKR\N@!1112 ***
M* $) ZD#ZD#^=+UZ5')&), DC!)X /7Z@T]1M55'10!^0Q0 M%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MM^G/I4\'^K' ')Z9YYZY/7/7/?ZYH FHHHH *8?OI]'_ /9:?3#]]/H__LM
M#Z*** "BBB@!COL&=I;G&%Y/?G]*I,=S%ONY.?G**![$A=P)' !8 DA2<'%6
MDC99&<L"&W<<\98$=3C@#'&/QJ!ANF901DN>O.,*#G'X8^M #6C)B1]SIL8G
M&T*^?,VC&<@9ZY(.5.< D8@9U\S82V]P64,(22!P<':'PO'09P#M/2K>3_Q[
M]\_?SQU\S[N<XQ\O6JTD&)AN9>J=G!P2 0")  .,D;",=0U.-D]=OUTL .JN
M^Y@H;Y3EL; .G4@;V!&=G&1@9%(B!<[UB,8;Y9,M'G))&$4X;![ECR">,XI>
MS*HVMT <C(<\#/ &!\IS@X&>>U2QQB08& R !\@L"QR<J<]/IZX/(P*;5K1;
MZ66JM;S]/4"/!"N2>GS$;5!*/G>GR@=<#EL].W-* ,$#&<$=L_CC&<?09J<V
MV[AF'M@?GG)^F"#ZTMP%"H"/ER>@ .57*G/3 /)'&?S%0 ^*;>=FW&%SG<#T
M('8>_?'T]'3#*8]21_XXU/4?*I(&[:,D#'..?PS39#@ ^Y_] :@#E_#>&DU
M@R@K=R9R?W9!&./T(SW!Q765ROAYPSWPP1MN\'IC)68_^RGUSG\^JH ****
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M[Y<?+@[.I)C.<!AP,]N*L1R"1<CL<$=P>N#^= #Z8?OI]'_]EI],/WT^C_\
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MC!7U;7+G3+&XO8='TN*22**34=3DB2PL8Y9%CDNKF(2$*N:_D@_8C_X+1_\
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M_KXJDOH <\_NRYDDZD]<?,,?,.1M4X(XJS#(A4QGDY8''*_,<$9]06 (H 0
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MG]AGQ#^Q?X<U>U_80T[]A/\ :&^'GC+PG\5/ ?P=\*K#\2]:^,K?'?\ 9_\
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MG=^/?M+3:O;_ -4L5N$B.,F7# 2."''4#!.2%'\.23C')IHBDW*'RX#*=QZ
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M0X[4Z1U:1'!!7,8SVR'R1SST8=J628DCRVRN#NXS].HS^&>0#CF@"P)$) #
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MITYS['$PN%<@*OW\!6W+_$2N>YX.<CJ.X%(,VZ["-Y8$YX&.W/'0 CGD]2:
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M0#  ] !^5+0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M1L6W9R",;0.I![?2IJCD?RP#C=DXQG'8GO\ 2G(V]0V,9&<4 .HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M>J3_  .\+?$?7[[6O$&K6FFZ#J>M>,]6O(M*O_K+_@D-^V1^T1\6OCK^T/\
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MOK5;R.&:&62!I5ECCGA=U42+G^<#_@XFT*PU?Q#_ ,$@M#'[/7AW]I^RN_\
M@HIX>TFU_9O\0S^ M+\-?%R*;X4>,8;7X<W]Q\2Q'\.;'3];>.WM OBUTT!!
M&B7<;PKA?#O@3\&/CW_P3_D_X*B_\%%-3^!'[-__  1>^!_B+]G'X8>"/A3\
M"-?\::;\;/A-H7Q.\*Z]=V+?M'_$SP%^S-!>>&8-=NWU[3?"7A'P'\/M.O\
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M=4\07MO/J=]8>&]%TC1;6YN)(-.TRRM(X81W-( HHHH **** "BBB@ HHHH
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M1@\1:!?V^HP:Q8V>L:=/I^J0+>MYW^S-_P $E/V2_P!EOXW>%OVD_!,WQ_\
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M+6BP^+]6U_4K[Q#IMGXZAT[5Y4LEO[>:+3-)BLOTN50H"J, 9P/J<GK[FEH
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M&=4QN(&>F: '457B\W>V\DK@XR !G<,8QSTS5B@ HHHH **** "F'[Z?1_\
MV6GTP_?3Z/\ ^RT /HHHH BE:10OEC).<_+GZ=QCG^OI21-(20P.W;D,R[#N
MR.-N3QC/.1G' [U-4$LI4+Y94DD@\YQ@'C /U_*@"*0(,[&W-YA9@6!(X;=@
MGD $],XS@ =Z@(R"" <!\!@#M)C;IVQTXY')ILC,1D('8L6*D#&&))8!P> 2
M,'K@]>2*C\QP/F4*0"V&4LO"G:BA",L",D*?EP#C )JE&6_Z@2&&,L7V$Y &
M<#;]P(<J>,\8QMZ]LTC1JJJ41"R!@$)98^H'S[0[ ,I)+ $\9 .*B1G.<,9
M@!W!2%)R-RXQQLR5Q@$;,G)SBP-[KD$JP*G=M&S')W*S'/ QD@-@] 3Q523Y
M4KJ]UY=.M]_N^0"1.2IP(U(?&$5R W& "ZQDD<<E"ISU(R!/&8W+%MFYL$
M#>,'D9SD9R!CCZU6&P!EWRN6)!+%2H) &T%4 VCJ<<C)^8C&%1!'&D:LQ6,!
M4;(+@#.%! Y!W<Y!/3FHLTK[:VW[^CV 4,&!PK*0<?,>&89X+_P 9P1T.>>E
M))$9 2TBY=!@]#@'(*CHYSQV&3[XIV"&VNZ!O+R(U'S28ZDG=\I;(R3PW;&#
MA\0#EA)*[@#(8LBA3T*A=H91C'WB<_6C7XM?7K_7S 09P."QQZ8) [D=L\<=
MLX[4X(6^\K*NTC)']["]?<$X]^:81GHQ&"<$8R1DXYP>",'/?%2J[8",1M
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M.<]L8Z>N>]344 (#D ^H!_.EHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M2Q<# &,@KCD< 9]*AC=XBP9C*%9E7<54HH;"@G!)(4 9S\V22,\F227>NTJ
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M_)7\#/V2_P!J#]I7_@HY_P %T]#^$/[<_P 9/V*_A[K'[1GP5\/?$+3?AO\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M)SR>BXS_ $_2KH(=0<9# $9'8CT^AJN^UBT4:A7 !!P%! )!&5Y'*D8X^OH
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MD*%SG( /!(LT*+E2 @8 ,JG.!A@2<98D\F1"8ST5B< *]DVD][*[O=::]_U
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M2,XP&QM)&1D Y&1D=<?RS?MK>+OC-_P3S\9?MM> OV8?C?\ 'G4]*UG]A+X
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M([?$+X@^!?"/B_Q=^SA=ZSH?[2'@3X$^*8_']M\*-"D\9^.=(6^MAK^I#T;
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MEXNTSX@>$];^!7[>/@S3_A?X:T_X;_&_3O@O\9/A9XS^$GQF\:Z##97OP?\
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M??PTT?XL?#'X6?\ !/+PEX_^"OB7X)W'A+_@FW\*/AO;_&S7_P#@EO\ '/\
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M/B;Q_P""]'T=_M]T8M*U#\.M:^!GQ]_:$^(W[4'C[XL? [_@I=^UC\.O%7[
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MNA]NM $R.'&X9QDCD8/%.JH1)G]P#Y8 Q@JO)&3P_/<5-%O"MYN<@DC)!^7
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M_&'QV^+:V/@KXB>,/B''XHD^$WA;P]X#\0^"[OQ!?R:MIFC]+^W/^UQ^V_\
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M_@K3]1U;5[#PAJFM/;'4;_PO8ZIKVN:A9Z!=7,NE6UYK&J7$-HDE_=-+UU%
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M)XSC JSC 0JZ[0H+QA0"YQD!  -I/&-I SSZFG,CD;FQLX*E>&Y'&3)A.AY
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M=C..<?3.,T )+$5($:L05(/< ]NO3O5D_?3Z/_[+3Z8?OI]'_P#9: 'T444
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MC./QQG^5/J&64Q[<*#D,><_PX] ?7Z4 3 8 'H,44@.0#Z@'UZ^]+0 4444
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MGN1U5&"L6*[@=X X[L"#SVP/UJPR^;&"H"EL'GTSZKZT +_J8A@;MN!Z9+,
M?U.?YGO4:IYKK,/EP<%3R?ER#R*5U*0;21D;,GM]]>>?UJO'_K$Y !;CD@'V
M'.&)/8#J,'.>0"Q++C?'MSE<;LC W ]O;\_;IE;< (P'3>?_ $%:BG 9RFU,
MNJJ&;)(+94';D A>#COT-2V\31*RL<Y;(PQ( P!@ @;>G0$YZ]2: )Z8?OI]
M'_\ 9:?3#]]/H_\ [+0 ^BBB@!&56X8 CW&:ISR(\94'801@L" "#R 0"0<
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_2IXY=FY9"Q((QU; QGJ!0!#G@G@  $Y..#G & ?2EC,:XWH&1E4I\N]<\]
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M$P=.-^W/5SRC"_DYIMZ)-Z$+Q>\+V[?Z^<-WLV_]MK:)=_\ A-/UVHK\C/\
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MJ.NRA6A_X)X?\%#G5VVJ6^!-L@/4C_F/LP)"M]X #&,YQ5@?\%0/'$I(M?\
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MEO\ MX_\%#-@,O[)O[*D*C@B;]MSX2 $J0.''B$' ..JY.<$ XS%_P -Z?\
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MFI+_ &3<)9:*^I:E)+;K;)(/UKB+,Q611MYX#F3.WC+*2<$C[P_A.!Z5^?\
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MV&O^"=?\2:/_ &EH-Y<)9ZSH]Q>P:OIMP\<<MBT8EEC\GBF,4)22))-D15@
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M.X!C\KKC!))J<[C;/+* 9!,!M  $@$8*Q+D?>; VXX$AR?EY'I+P]\/H)/\
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M'+$;6"CPV7?,\8F;<\8ED4I'N4AT+JWD*JL\KL4'EHZD<B/!HMI7CC(;)MY
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MCXP"R2.H53*$0(%*LNYR1P2SI+*V;E6+,?-F9?):-<#]T@^R&5@P'S>9(ZY
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M&5F?#A5*JSM(5 &"H4!B!D_K+X]_9D_9K^+/C_XM>-O#_P 7_AM\#?"OP$^
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MD[6]-\)^!=5O/V0-/^(FG> )=0&NVH\26_Q3NM6E\1-XR@LM6L+??;S:M/\
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MIIILNN][KULF9^RAY_?_ ,#S,IT5V0J@51(0(G=5=CM^;8KD[QNRX(W%0>%
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MQC:_O0C&G+7>TH03L^JZ[;"^K4[6B^7S:BU;YG]+C6(+M(&4%T3=EIFR #M
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MBGP9XQT.9ICHOBOPIK.C:[IL=Q>V\-^;6_NK6;Y&\/?\$?/^">7AWX)_M$_
M-/@7=>(?!_[65EH=G^T7XC\>?%;XM_$;XM?%?_A%KJWO_"+^(_C1XY\;:_\
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MOXBU+M]$X\*4H-KJGRVV;NT?JV)X$  ==HX !_IU]/KGV-)]KM_^>@K\H/\
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M]3_WRW^%?DB?&_\ P6F*AD^"?["Z,9"&BF\8_$XE(P5 (>/Q:X<L-Q.0I3
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M,@,,@D'CALC\^,9K\B3X._X+8,Y(^-?[ J!T4".+P#\50L;D$D+YFFRM)M+
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MBBE9?U?_ #&%%%%%E_3?^8$"O(92K*0@+@':0, _+\V<'([X^G6IL=^?S/\
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M];*ZO_7XE,_*% &#T&5CYX/ *G><D9R1SP6 SFIW$(3!VM(<<,<L?FY^4'G
M!.!T ]J;)'TY8F/Y0,=5SM)Z<G'(QT]^M*@+. 4"[R2S;7R< D<G&,8 XQD<
M=,@DI7BO5W]?\M=RXP47>]W:UVE>VG^7XC "!G80O)R%(4 9_+.,\]S^32P)
M&& 8 [<CCYL G!^\!CH.N"!5UUVQ.HR>#CJ3D]NYZU4QD@%>6< $@@@$HN0#
MCH6)!QC(H4VDE9:*V[U^1FZ"<G+FDKMO1+J[O7<B8.I4*T9'?=&S$<Y(R0W4
M<\G@YXQS39"D*NZ1KNQN<I&O1<Y9R%.0H/L!SGVLR1^60!DC;G)0$#D\$AE
M'&<$=3UIFV0G,8!&-KJR!E8'D*<J3CUQCMFFJC[*_5W:O]V@_9:KWG97TLM?
M5[O\ ()"L/+5LG.> 00/<'(R?7^0J O,"9%4,!U8@KD$@,%CY9AQP0<$<CK5
MMT2,*JD2'/W206'R@#A1GD <G_$U)Y*8!+E<\C.T8SS@9&:%4:Z1_'_/_AOR
M?LEW?W+3^O\ @][U,*=H!F7JRG+(<'!.>A'484@ =",U'*).BAUBQYAE4EW,
MAY.5'S.> 2@.3QG ZVE0/)L)X0.H(P>%90"0<C)Q].XISPQHH*G+A\GD9RY
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M*O&$7@_X@_$?35U#7O$'A_0];T;P'%H>DZ*[VQN;/1K/37O/EGX!_P#!+?\
M;4\%?L:_\$>_A7X@^!6D>'OB/^RS_P %B-0_:Z_:,TRV^(7PKE7PY\%Y/BG\
M8M=@\?/JUAXMN-/\4WO_  C'B?PE;P>'/#]_K/BY+*VL[.;1XS9F*U_K5%F6
M+F2-@K2-F)8I($&"/NY=-WUYQSG;NY\S^+_Q;^%'P!\ >(/BU\<?B1X-^%'P
MN\(QZ2/$_P 0?B)XCT_PMX0T#^V]9L/#^CC4];U26&SM7U37=4T[1["*20/=
MZC?6UM$"\HHY%]J5H]7:]OE?TZ@?R1>*_P!A/_@L5\6/VD/V??&WQO\ @]\3
MO'MK^S5_P59^%?[2^_PI^TU^RY\/?V-KS]G+PC\5]9U'3]3^ /[+OA>'PYXH
MO/BE8^$_$EUXC\7^/_C/K=A\19[);_0[&'Q=J_B:\@L?TA\#?L'?M&:'X+_X
M.)QJ/P>TZV\:?MX^+OCO-^RM<_\ "7_#B>\^*.A^)_V8]?\ AYX(+WUOXB9/
M D5SXMU_5-/\GQY<^&;^R36-0O;JSCLVENKK]9/V>_VY/V,?VJ]9U[PO^S)^
MU9\ /C[XG\,Z7_;FN^&/A7\5_"'B_P 0Z5H)NX; :S>:%I.I2:A#HZWEQ;63
MZN;5[&.]NK2TENHY+J+S/H#7_B-X#\'^(?A_X7\4>,/#?A_Q#\6/$6I^#_AI
MHVJZM;6>I_$#Q1HOA/7/'6J:#X3LGD6XUB_TSP?X7\2>(KJ*S#M%I>BWMU,L
M:1.4'&*?NSYDM;N-OENP/Y:?V,O^"4?[4/[&_P %/BG^S7:?"/P3\<?AE^WG
M_P $\/!1_:#\"_M#?%+0I/#WPH_;Q\"?#V'PAXE^$GBKQG\-]:TOXJW_ , ?
MB9X<U";P=X \2?"_5/$MW\'=1\%Z?=Z1(MHXUB7T[_@F-^R9_P %*O@W^U=X
M)\7^)_ ?[0_P3_98\ ? CX@>#_&WP._:\_:^^#'[:5CJ/Q(FLX[+X=^"?V+O
MB#H.G>(/BU\)_@UH%Y91S7MQ\1O%VD2:GX=M=+T6_P!&N[R%67^D'Q5K>A>$
MKV?QCXDUJR\/^&/#GA[6/$?B/6]7NH[+2=&T+0M,N=3U?6-3O;MEBL--TS3[
M>XOKV\EECMK>UMY;B61859CUW@_Q9X:\>>$_"_CGP7KNE^*?!OC3P[HGBSPC
MXGT.\BU'1/$GA?Q'IEKK.@:_H]_ 6@O=+UC2KVTU"PNX6>*XM;B*:-V1P:4E
M?6_V6_NN_P#@?B!X]^ROXF^,_C+X _#[Q)^T/\!="_9C^,>J6>L2^-?@7X7\
M>^'_ (GZ!\/[VU\2:S:Z7;V'CCPM9V'A_6EUG0H-+\1W']F6PBL;K5I].E>>
M[M;B>7Z" Y4@#_6*O3GL2?Y#\>>U&!Z#CIQ4BR[%9=N[<21@@=0% Q]1].14
M 7,CU'YBER#T(-9H5AM!11DJH+,%)SGD#!S@CGO^7-@$6V=Q!W],#;]W.<\G
MKN_2@"UD#J<45#)&90F,#'/(SU'3@_YXJ11M55Z[5 S]!B@!U%%-9MJEL9P,
MXZ<=^OH.: '44R-_,0.!@-RO(.1V/'K3+FX@M+>XN[F6."VM89;BXGF=8H88
M($:66661R$CCCC5GD=B%15+,0 : )J*X/X7_ !.\"?&?X>^#OBM\+_$^D^-O
MAS\0?#VE^+/!'C#0;AKK1/$_AG6K9+S2=<TFX>*%Y]/U"UD2>UF:)!+$RR(#
M&R.W>4 %%%% !15=YW4[5B+,6VJ"P4-@X)!(.. 6]..M><?"+XQ_#CX\>!],
M^)?PD\4Z=XX\ ZUJ'B?2M(\5Z.M\-)U.]\&^*M<\%>)$L);^RL9+J#3?$_AW
M5]*^VPQ/8WDEHUSI]Q=V,D%U, >GT45Q/Q ^(O@GX5^%]2\;?$7Q1X?\$^#]
M'DTJ'4_$WBG5K71-%LY]<U>P\/:+:RW]XR0F]UCQ!JNEZ'I5DC/=:CJVI6&G
M6D4UY>VL$P!VU%11RB178 C8Q4@GD,H&Y2.V&RN>^,C@@F,7!/2)CWX([=>,
M9XH LT45Y;\'OC1\,_C]X(MOB3\(?%5EXV\"7NN^-O#-EXETZWU.ULKS7/AU
MXX\1?#?QG:6L>K6&G74\.C>-O"7B/0O[0B@;3]0ETN6[TNZO=.FMKN8 ]2HH
MKS'XS_&3X;_L^?"WQM\:?B_XGM?!GPS^'6B3>(O&7B>\M=2OX=(TB"6*%[@6
M&CV6I:MJ%Q)//#;6FGZ987E_?7<T%K:6\L\R(0#TZBO$?V@?VB_@Y^RM\&O'
M7[0?[0/C6Q^&OP>^&NF66L>-O&FJ6.MZE;:%8:EJ^G:!IS2:7H.E:KKMY<W^
MMZOINE66GZ=I=Y?W5]>10Q6Q)KSGXW?MR_LL_LX_LZZ=^UG\:?BYH?@?]GK6
MK#P%J6A?$:ZT[Q+JL&O6GQ/CL9O O]B>'=!T+5/%NJW7B"WU*TOH+&PT&XO+
M/3/MFJ:G#8V.F:E/:@'UI14%M.MS#'.@8)*B2)N5U8I(BR(2KJCH2KC<CJK(
MV58!@0)Z "BBOFKQ5^UI\%_"'[0W@K]E?4=2\7ZE\;O'/A&+Q_9^&O"GPP^)
MGC+1?"W@B\O/$VEZ-XK^)OCSPKX1U?P'\*M"\2ZUX-\5:)X6U#XA^)/#</B/
M5] U.PT@W=S;/'0!]*T4@S@9ZX&?K7&_$;X@^#_A-X \;?%'XAZ_IOA/P!\.
M?"?B/QWXY\5ZU.UKHWA?P=X0T:]\0^)O$6KW*1S/!INBZ+IU[J%Y*D,KK#;M
MLC9B!0!V=%9NC:M9Z]I&E:YIS3/I^LZ=9:K8/<6E[I]P]EJ-M%=VCSV&I6]G
MJ-E,\$T;2VE_:6M[;.6ANK:"=)(DT'8JC,%+$#A1GD]N@)QW. S8SA6. 0!U
M%<#X$^(NC_$(>+CHVD^,M+'@KQYXC^'>J_\ "8>"?%7@K^T-:\+O:QZCJGA<
M^*-)TK_A+/!MTUT!H?C?P]_:'A;Q 8;G^QM5O1;3E.^H **AEF\L@;<Y!.<@
M#C\"?R'T!K\X/''_  51_9K\#>-_BIX%'@;]K_XA7/P4\6ZIX&^)WBSX*?L0
M?M7_ !M^&OA;Q5H.B:-X@\0Z/=?$GX6_"3Q5X-GO/#NEZ[83:]!::O/-I+F6
M*]CB=%#@'Z2T5Y_\-?B=X*^,7P_\#_%7X8:_IOC7X<_$KPEX>\=^!/&&C332
MZ-XF\(^*]+@UKP_KEA-+;Q.+;4M,NK6Z2*:..[A6=8KFVAG#Q+W4<K28)C95
M(R"QZ\ C  /!!ZDCD$8H FIDC;$+ 9QCCZD#MGUJ%KD*TBE&Q%M+'D85B1N(
M8*-I"L592R':RE@XVTTW6&*[,[?+WD-_J]ZELR*0&C&T9!E6,L>-HX) )XW+
MKN(QR1CGM]0*DJBUZ%SF,DHRI*JN'>-GV^4&15++YA9=@D$;,K*55MV X788
ML$57$;[)&65"$? )B91N99P2,Q,!A""7WD1D N454-U@\Q-CY><X&7)5%#$!
M"SOM14#;RSKA2,D>*_!']H?X>_M!6_Q2OOAR==N=-^$7QP^)O[/?BC4M8T:Y
MTBSO?B)\(-6B\/>/H_#<MP3_ &WH.B^)_P"T?#+:Y$(K6;7-!URS1=M@99 #
MW6BJQN-JLSIL";C(22%C10279]NP;1M+@L"%W.NX+R@N2VPB,X="ZL&#H1A2
M"&0-N7:V=_"$E0C-DE0"U17S.W[5?PZU#PW^T5X@\"Z)\1/BQ<_LP^.=0^&/
MQ&\*?##P1J_B7Q?J?Q%TGP?X)\;ZGX-^'^CR)IT?CC5].T;X@>'8-0?1[QM/
MLM9_M71KB^34-&U*&W^C%NR?E:-5DPSA!,C%H0VU9E^ZQ0Y7<Y41(21YIP"0
M"Y15-;L$X951BVQ%,@W.P!+JJ;0S/&%9GC4&0( VW#+E%O09E@V#SRJR&'S8
MO-6$R+&9S$7$K0!]ZB54*,T9VL596(!=HJO-<+"&+# 5&D+,P1 JC+,SM\J(
M@_UDA.R/*[RH9<U(]3BFACG@,-Q%, 898+F*6"<,VQ/(N$S%)O?]TGS*&F*Q
MY#&@#3HK.34H9%:2-H)85>2/SHKF*2(RPSO;RP^8A9%EBE3RY$=U,<A\N38P
M8#ROXU?'+P7\"?@G\7_CUXO-YJ'@GX*?#CQ[\3/%]OX:-CJNNW&E?#GP_J'B
M+7=%T.SDO;2SOO%%Q#IL^FZ3I%QJ-C]LUF:TL)+BV-QYB 'LM%<WIGB2WU+1
M[+66M9]-@NK"&]N+;59+:UNM)DD@BEN-.U?9//:6>HZ=-(;/48%NYH[>[CDA
M$TC(X7HD;>H;!7(Z'J#W!]P>#0 ZBOBC]M']O/X+_L+>&_AYXA^+ECXTUV7X
MF_$C0OA]X=\/?#S1+?Q)XAM=/O+NP3QC\4/$-G/J.F6WA_X3?"C2K^+7?B9X
MWU.\AL/#UG<:18HE[K?B/P[I>J?7.L^)=$\/6$FJ:]JNE:)IL5Q':2ZEK&J6
M6EZ;%<SW*VEO!)?WTL%JDUS<R1000&3SY9I%A2-I?DH WJ*^8/A7^UC\-/BO
M>_M%K8)J'A3P_P#LT_'C6/V>?&'C3QQ>>'O#WA3Q!XX\.>"/ ?C'Q%=>$=3D
MUJ<W>@Z+=>/;7P=>7VL0Z).?%NA>(M.@M)8]/6XFY'P[^VAX:\;>+OC%X2\!
M_#+XA>,3\#?VJ_"7[)_CO7=/U'X::9H=OXDUCX7_  ^^+/C3Q[IMQXD^(&BS
MZEX'^$GAOXAV$/C^UM;=_'B:CHWB"#PWX*\01V"2S@'V;17R+\)_VQ/ _P >
M_A-\%?C7\%/"GBWQ]X"^./Q G\(>'+N*]\#^'M5TOPQ:W_B^VF^*>K:1XE\7
MZ7=7'@Z;2_"MOXKL-(T ZU\1+OPIXGT'57\$6SKK-II/T/H_Q!\&>(=<U_PS
MH'BOPKKGB/PI+;P>*?#^C>)=&U77?#5Q<LR0V_B'2+"[GO\ 1I92K^4FH00-
M+Y;B)7D41L =G17$6WQ'\#7OB&S\)V7C'PA>>)]0TBXU^R\.VOBK0[C7[S0K
M2]?3[K6K31(+V34[G2+:\BFM+C4X+:2R@O(I+6699$?:RV^)/@B]\8ZC\/++
MQ=X1O/'VD6,.JZIX'M/%6A7/C'3M)N&A2'5+[PO!>R:Y9:?*;B'R[V\L8+1A
M+&?/ =<@'=45\Y_LX_M)>&OVE_"GCOQMX/\ #/B;0O#7@SX[_'GX#V&I^)?[
M'B@\;:C^SW\3_$GP?\9>-/"C:3JFJB?P9?\ CKP=XHT[0;S4#8:A=P:-/=7&
MGVJ36JS<A^T9^V=\*?V>/"VHZK<SP_$;QIIWQ1_9Y^$4OPD\!>)/"5[\2(?%
MO[2_Q@\&_!WX=IJN@WVMV<F@64NK>,HM>GN=;:R%SH&C:S/I:WUQ;PV\X!]=
MT5YS9?%OX8ZEX[U/X6Z=\1?A_J'Q.T:R_M/5OAO8>-?#M[X]TS2R8MFIZCX/
MM[]_$%AI[K/"WVNZT^*%5FC.XAUSJ-X_\')HJ>)'\4>&E\.2ZG'HD/B$^(M'
M_L*769-;/AE-(35A>&P.J/XE \.)IXG-R^OD:,D;:@1;D [(D#J0/K17ENE?
M%_X6>)_'/B'X:>'?B-X U[XD>#+2.^\7?#[1?&OAC5?''A:SEEC2&Z\1^$+#
M5+CQ)H=K,TD2Q3ZII=HKO/!&!OE*K7^)GQ.O/ %S\-K'3?"3>+[_ .(?Q+T'
MP&UC#XT\!>$;O1-&O['5]6\1^-XH/'/B+P]+XNL_!FBZ/=:SJWA3P4FO>.+W
M3([B\TCP_>V]A?RVP!ZC<_=7C)RW;/\ "?ZD587[JXZ8'\J\G\+_ !T^#_C/
MQ5-X$\*_%/X8^)?'4'AC3O&\O@KPW\1/!_B#Q8O@K6&"Z1XO/A[2M8N=73PQ
MJK'&FZ]+9QZ3?' MKR0GC>\?_$WX??"CPIJ/CKXH^./!OPW\%Z,L#:QXP\?>
M*M#\&^%-*%U*L%O_ &AXD\27NF:-9_:+AU@MS<WD0FF=(P0[!: .[HKXL\)_
MMT_!K7O%O[5=CXCU;1/AK\,/V3O%7PJ\%^+_ (]_$/QQX*\,?"/Q+KOQ0^#W
M@CXUQCP[XIU/6;:QCTOP]X6^)/@:WOM6U6XLK34M1U^&/16O88FF;Z0T+XK_
M  Y\5#PD?"GCOP/XH7Q_X>U'Q;X"?P_XQ\/:NGC;PMI#:9'JOB/PFVGZA<CQ
M)H6ESZWHL.I:QH9U#3;)]7TT7%TC7MLLH!Z"[%59@,D#./7\J@4&9A(3MVLH
MV@9!VD..3@C[V.E>>6/QC^%VIZ-X8\1Z=\1OA[?^'O&VH:MI/@O7K'QSX9O-
M&\7:IH5EKM_K6F^&-3MM0DL?$&H:/:>%_$UWJUEI%Q>76F6/A[7+R]BAATF_
M-O@>"?VC?@3\2?%VH_#[X??&7X2>._'^D>%M&\=:IX%\%?$[P1XM\8Z=X'\1
M16$_A[QG?>&O#^MZAK%KX4U^#4]-N-%U^:T33=2M]3TR:VN'2_MRP![+-")1
M@MMZ=L]"3ZCUI4CV!ANW;N>F,<8]_P"M?-=I^V=^R7J2_%<Z/^TQ\ =?E^!&
MD:UKWQJLO#OQA^'_ (@U+X3Z1X>DNK?6K[XB:=H^OWEYX.@TR\LKS3[Q]?AL
M4M]2MIM-E=+]1;-Y)\(/^"DG[)7Q2_9H^#?[5.L_&CX1_"+X;_&OX=6?Q-T!
M/BE\9OA1X?U'1=!N;O1-.O--\0W$7B^\T*W\3>%]9\3^&_"_CG0K#6-0N/!W
MC36+7P=J\D>OR06=P ?;RQM&#G9W*$-N=2 222>64\#L 1[FKDV-D>?F(ZX&
M3]WTYQD^M>'1_M'_ +/<OQBD_9XA^.WP7E^/L-D^H2_!*+XH^"9/BZEE'IB:
MT]T_PWCUE_&"0+H[IJ\DC:/A-+==1 :S*RFK-^U-^S/IGQBA_9YO/VAO@9;_
M +0%W';O;? V?XL^!+?XO7 N+$ZI"MO\.)=<7QC<2RZ6'U.&&+1GGGTY1>QQ
MM;DRJ >ZHZH0RH-V,%BR8.>3A5&X9(R PXZ'G%*!YDF20I;+9 !QC P"<=>I
MKY^US]J?]FC1/'^B?"K7/VAO@5HWQ-\2Z]X@\-^'_AUJGQA\ V7CK6O$WA.S
M75/$WAO2_"-UXACUF^US0-*EAU'6=,MK)KW2[2:.:^M[>%DD;I_A#\=_@K^T
M#X=O/%_P*^+GPO\ C1X3TS7K[PMJGB;X4>/O"WQ%\/Z;XETVVMKS4/#]]K/A
M+4]6TZUUJSM+_3KN?3;B>*[CM+^UN3$;>YMI9P#V%(@KJWF;L9P, =01V/O3
MFE*R!-H()09R<_,<=,=OK59/E="JY.3P.,_*W?'XTLA)D.X;25 VDYR.>?<4
M 3R3%&"A0V5!SSGDD8& 1V[D4^.3?G*E,' #=_IT/M44)"QR''"LQP..B*:0
M@W!W !=N5(8;LYP<\8H +;^/_=C_ /9ZGD3S%VYV\J<XS]T@_P!*@MCDN?9/
M_9^*M4 (!@ =< "ER!U.*CDD\M0V,Y..H'8GJ?I3'7SXUQ\N2&YYZ9X/]>GI
M0 Z?/ED D$M&,CJ,R*"?RJ@LA$Q08=D^89#Y8CC!."HX/!SVQ6@4)C*9 W9!
M.,C#$DC'&<J2.WX56:$HA)92$4  CLHP!G.,XXSCVZ8% %A9&,;.RA2H8[<D
M]!GK@=?I2Q.9%)(QAL8Y] >X![^E-M\>7Q_>;I]34U !3#]]/H__ ++3Z8?O
MI]'_ /9: 'T444 12HSC:, %6!SU!( !4X.".>?YU25"B1J1C:&4C((#9.,_
MQ;B 3D\8R!G-6;DD*""1MW,2#@X _P 2*;*JJ$P "QR2  6(0\D]2?<YH IB
M$98O\P\TRJ%.,$9QNS@8YYZ_B#0[X+%8V()"[5S&I*,68[P.GH!RS<'OB<JR
MA'8*4++P"<@,I(8\<[>XZ'/?%0+&0S;R&!+8=,9 ;:"5'&&QNY'?US6D7S;I
MW4;;Z=.BMKI^@%=@[)F5'()<QA9MY4DL<%' WL3C8#G+;15=(Y5"ER^=PW9"
MI(%R,F8%@D;E.6^4[1RO(&+DB*692@<< ;MA)7:  <MO!*Y#'!QDD<9)8(RB
M#8HVLZJL<<<:[54\J7!#[5P?GQDDYQVJ^RVO_7]>:OW _EP_X+.?\%@_^"A?
M[!O[</[,/[//[+O[*GA?XK_#?XC^'?!GB*>?Q)X.^(GB[Q1\?/%'B+Q[JOA7
MQ#\)/AAK7A:^LM%\":SX/TC3K+4+^^UBV\1ZP]]XHT#6KW2/^$4M+B+4_P"H
M-U\MBI5E50J8'SE&7("%5S^]0#$CAF25\S1[8Y #88SM&4MQ)&0^#M=UR5$?
M1ERX^5=HVCIMVC(J2-&0$'$:DL5Y59%48VJ&!#$8)!$FS!).",FDDT_O[@5Q
M&I5U :1^/DN'+.N2>@ )7=CY@>N!TQFOQ]_X*KZE\0?&?BG_ ()Z?LZ?!SP;
MX-^)?Q+^(W[:/A_X\O\ #GXB^/M3^%_@?Q1\/OV+? ?B+XYZG)XG\;:3\/OB
MIJ&D:7I_Q;MO@FJM'\/_ !'%>:E=6.F20V;WL>H6G[&JA)41[8W4'8,(RGNP
M.TG:!@8!ZYS@[:\[U7X6>!M<^(?@[XL:UX.T?5/B+\._#OCCPCX)\97EL]SJ
M_A?PS\2KGPC=^/\ 1]';S%CM;/Q7<> _"CZOA)9+HZ-9CS8X?M=O=DM5;TO_
M %Y[ ?@7^W?HO[>>D>!?'_[=WQ@\.?LT_L_?%G]GW]GKXK_L]_L6>#_V;?B5
MXV^-?C>]_:9_;M\6?"K]G[P;X]^('Q7^('P:^#VF1>'_  =XKO?#4W@_X9Z)
M\/-:@UGQ?J[^*_$VJWDWAG1='N<']J3XM?M8_L7?%2^^&W@;]J+XJ_'+QUX0
M_9;\#>.OB5\0OCV/ D_PS7]IS]N_]J_]FO\ 8'_9B\2IX#\+^#O#'AWP)\*?
MA7+H'[1_QB'PS\.2Z=9WES+,WB'5M<%Y?7TW]#/CKX9>!?BIH^B:!\1?"ND>
M--'\.^-?!'Q)T72M<BEGL-.\=?#+Q5I?C;P!XFBMUEA4ZCX4\7Z+H_B31O.1
MX8-4TVRNS");>)DX'QC^S+\!/B1<?&>3X@_"7P'XVE^/_@#PS\*?C4_B/0TU
M0?$KX<^"CXM?PKX.\21WDDUO<Z1X=N/'/BJ]TF.WM[:73K_7+V_M9/MYANX<
M^1_\,@/QD_:4F^-'[)'@K]ISP#\)_P#@I'\6/CS\:_%G@/\ 92^!^@^ /C%+
M\._%_P 9/@S^TY^VE^T1I_P!^&WQ^\*ZOX4\&^%]%\!^&/%VC:UXBUK2_@]-
MX;N/"]M=_#Q_$?AW3M*L(KZ#4?.OVJ/B]^U)XI^%W_!6[]HKX?\ [6GQS\ ^
M$/V;/CAX!_94_84^%_PIC^'&A:=>_M(^$/!7P@^&DFM>.M8O_A]K_B#Q_P"&
MO%O[6OQ=/@O7_A]/>6WAN]LO"VN6.J6.J^;H\/A[]=? ?["W['WP9TWPU\/_
M (;? /X?>%O"VF?%KPW\>H;7[#J&M:SJ/QG\&"0>#/B=XA\5Z_J.I^*O%OB_
MP@GV=/#.H>+M8UZ/08M,TR/3;>WAT[3XK3VA/V8OV?F\&#X?)\(O!Q\$W'QF
MB_:,N/#*:=(-)N_CDGQ17XU/\3[R)9%?4/%TGQ72+QX;K49KF'_A(H+:^9&-
MK'#1R/[_ ,/74#\*?VK?CY^TQXN^!7_!1S]KWP=^US\1/@#XV_9E_:)\>_L8
M?L8? GX<OX!'@37?BEX>N/"GPAT.Y^-7A#Q5X+\2:G\2?B+^T1\6?B%)J?A#
M3+^[BTKX>_#:7X5^+?!%A9ZT/$7BS7_V"_:M^+-Y^R9^QKXP\5:KX^\82>+_
M  QX&\#?"KPK\1=-\"Z+\5OB+XA^-?Q(U?PM\%/AEK=C\.M5U_P#X/\ &_C'
MQ1\5?%GAJ==)\0^)_"7A*YU34_\ BH-1T?0AJ+CX:\5?\$HO%'Q>_;!TKX]_
M'C4OV1?$WAGPS^T;X7_:(L_B!X0_97E\)?M;?$&R^%/BBZ\6_ 'X.?$[XB_\
M)SJ'PXN-%^%&H1^%M&U7XGZ+X!C^('Q)\"> ?#/@O5_[#@FUW5]5_7+XM_"G
MX<?'3X=>+OA-\7?!/AGXC?#+Q[HL^B^+_ _BS28]1T#Q#IDMRE\(M0@<L(9[
M2_M+74+'48)%O],O[:WU:PFL]0M;>^A.5Z ?SR_"WX]_M)_ W]HCX\_"/XA_
M'OXZ?!C2=&_X)^WGQ&\6^*O^"A7Q?_9J^.%IX#_:P^,/QK\)? _]D;XE?8_V
M?X-;\-?"7P[XK\3KX^C\0_"O2_$$7@?Q4G_",?V!\/O#USIU[?ZR?"+X@_M>
M?#7PK^U9\$_'W[7/Q8_9X_;:@_9Y^%?@'PAX _;3\9?"?X__  2U+]K']IOQ
MEXT^'7[-/[3?[/'[1/A3PI:WUOX#^+7Q!\ ^,O $'P"\1?"K0(O"OB;3K:^'
MPETVSTI+/Q/^R'@W_@G;^Q)X$\*^/O"'A;]EWX,6VA?%CP%_PK/XL0:KX2B\
M2W_Q5\$C4]5UR+P_\4=;\43ZSKWQ&@M]6UJ_N[/4/&.J:MK%CYX@LM1M;>UL
MXH*WA?\ X)U?L/\ A/X3?$OX$Z)^R_\ "3_A57QEET:?XJ^%?$&E7/BY_B%/
MX:$!\*2^)]<\47>N>)-3E\%S6T-UX&:;6]W@B]5+[PM)I5TKRR'(_P"OZ_K\
M0/Q$;]H7]HWX=? #]K_X0:7\>/VNOA?^U7K7QH_8+_9%TCX)?M,>*OA9\>/&
M7[.GQH_:_P#B[HG@>7XW_ ?]JKP3ILEI\4?A=\1_A9XEOO'?A+PWXT\,Z3>_
M#OQ1\,-;E;PGX$L_$D?AFQ^@/V^?VO/CQ:_&/]NSP3^S1\9=0\/7_P '_P!G
MO]BS]CKX::5I-YI^H6NE?MW?\%$?VE+WP)H'C>:SO;9X-0\8?!CX8GX<>)XH
M+S4I!:Z?XJU5;G3))9<+^IMC_P $]?V+M'^"'C#]G'3OV<?AO'\'/B'X@L_&
M/COPF^FW]]<>*_&VF7VG:IHWC?7_ !9>:G+XXU/QMX=U'1=#N?#/C&?Q.?$W
MAE]$T8:!JNF)I=G'%M^#OV(OV1_ MC%I'@W]G#X1>%+"T^)'PX^,,-IH7A'3
M-,BD^+'PBT33O#OPO^(=VMK$WV_QCX+T?1M,@T+7=2-U>I<6L>J327.K)<7L
MS<&E?3R_JY$9J3:6ZU_&WZ>I^%W[3%W\=/AC-_P6*U-OV\_VR)/A%^Q?^Q[\
M*/'"I9^//"/AGQ1XE_;@\3?"SXM_$Q++P1XTT7X>VMY\+? 3^&M0_9W+_!GP
M';V_A+5_$OC.SN+V&;23J'AO6>E^,OQ:_;;\<?&#XB_"?XBZI^T>OPK_ &)O
MV3_V8KOX]>,OV8_VCOV:OV.]0USX_P#Q.^&6N^.?B]^T+\3O'?Q<\5^&-9LO
MA9X#TK1H9/ WAOP[JMG\+9_%&D_$>'Q_:>+=/T6WT[2/WLUW]F;X#^*]*^+6
M@>*?A)X U_1?CQXN\.>/?C/I6K:#:W]G\4/&7@_3/!6C^&/$'C.UF>1-8O=$
MTOX;^ ]/TY;D20VUEX5TNV$;Q1L'X/XX_L*_L>_M+>.?#_Q*_: _9J^#'Q@\
M?^%;+3]*T;Q1X^\#:3XAU$:)I.JW'B#1_#NLM>0F'Q1X8T;7;Z_UG2?#/B:'
M6-$TW5+V[U"TLH[RZN9I8^=RS\"_CK\>OVI?%?P,^&7Q>\??M%?$3QIX+_9>
M_80\!>)O^"A&G?L!?M#^!OAO\<?V=_CO\0/AGI/QAT3]L^\T:TM_#_P[_:C^
M&5_\*H&\6:=\'-.\=Z1X(N;*/6]:\._#KXFPZM8>'] _8#]NGXJ>-?@G_P $
MM_CYX\L/'5QX[^+/_#+!\#^"_B$WAZ#PI<^._CA\5/"VD_"GX:^+4\)Z?,EI
MX:NO%WQ2\:>'=4'ANQGM[?2+C53IMLT<<8E7W'XM?L)?L;_'KXA:'\6/C1^R
M]\$_B7\1/#VGZ5HMAXN\7>!-$U35KO1= OCJ7AW0/$#RVAM_%.@>']1>34M
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M[CXXM]2O_A/^S]X*^!MS/\>K+PE_P3+_ ."?7P0UK]L&TLOV]_$G_!.CX/\
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M\.:0Y_M1U+PEX6U;Q+X=\4:GX6\/ZKXG\'#61X0\2ZCH>FWVM^$AXBL(;'Q
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M /YS/CE^UIXK;X _\%>?$NE?';Q-X9^,7[2O[=DW_!-[]BKP-9_%;5;3Q/\
M#OQ+H^B? O\ 8QCUWX1>'8]:%]\/M>B^+_BOXH?''7-5\*V.C7PL)=#\72W4
M]Q=:+=S9NJZCX.^$'BC_ (+$_MGZ'XR_:,A\4>(_VFOV?O\ @F!\%O$/@O\
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M7P$^*/B#P;XOU7P/K?C;P1>R1'1+3P]>:5H6EZ]H%AJT8!YQ_P $<9=5T?\
MX)N?!WXL?$?QY\1?%]S\:6^+'[4$GCCXV>/_ !#X[\:_\*N^+_Q(\:_$?X0R
M^)_$WBS4M0N8I/#WP$OOAWINHV]G-#I5M=Z==W<-O%]KFGE^)_V /@;_ ,%#
M?C-^Q9H?Q.^'?[9_P,_9X\!_MM^(?B_^V#<W>C_L7:]XV_:2\+V'[7?Q.\5_
M&2PFTSXH^*?VHXOA._B?3_ _BS0O#_AC6+[]GB[TSPWI-EI5G)H&ORZ/%JFH
M?OKX-\ ^$? OP]\,_"[PKX;TW1O '@SPCHWP]\+>$UB>[TO2_!/AK0K/PUH_
MAWR[XW376FVNBV5MIOE7AF\^TB5+DS,7>3J=-TZTTO3[+2-)L;'2=*TJSM-.
MTW3--L[:TT_3]/LH$M;*PL;*W2&UL[.SMH8[>UM;>*.&""-(HD2-%6JY7J]+
M)]=/Z_ #^7"T_9WT+P=X2_X*H_&CX(6/C;XL:9_P3"^%_P -/V7_ /@GA\']
M4\2^.?%G@_PC\9?V#_V/_#_Q7_X6A/\ "NPUVV\(?%3XL6GQE^+7]A7.L:UX
M8N]5U34O!OB#PYI4$4GB?7FU=/"0_9E\#_%[]B3Q;_P3*^(^K?M<?M7:7\,/
MCO\ '7]KGXJ^!OC9XI^,GB'X\?!FR_9#^*AL;7]K2_E\9ZWHW_"8?&O]L/5/
M@+_PJ/PMXHL=.U/P3K&G^*;;X9>'?#?A?PQK^DVG]1EAI&DZ4;I=+TS2]._M
M'4KK5[X:=8VMD;[6+YQ+?:M>_9HHA<ZE>R(LEW?S>9=7+JK332,H-8/A_P )
M^$O"3ZN/"/A;PYX836]3NM6UO_A&O#NDZ(NKZU.Q>ZU75/[+M;4ZIJ,O[]I[
MZ\6:YFQ*SRMG+G+MJOQ].W?3_,#^4GX7^)_V76_9O\&?'W]CWQ_X\_:*_P""
MNGA+_@GG^T)^V!\5/C#\(?%L_CSQ%XF^,GB#]FS4=(\1?#_]MS2+75=9DTS3
M[SXZ^-X=7^ ?[(^HZ/9WWA3Q_P#!;2/#_@KPKX<\/_#S6]/GPOV)!\+_ (7?
M'/X0?%_X(_&/X!?M$:E^S/\ LV_&S]HG]JGQM^P3\/\ ]HGX_P#[1/[5W@&]
M^#^HZ/%X'_:K^,?C#XEWFB^)_C]XY^+&J:/\6?A=\)/B+8W/Q,@U_P"'.LZ)
MX0\.> - CNM.NOZX=+T?1-(^WMI&G:7ITFIZE+JFIC2]*LM*;5-5N"!/J%^]
ME#"]UJ$S*/-OKCS+EBOSR,<5<M-/LM-AN;?2M-L=-:>\GU&\CM+.UL5N+ZZP
M]Q>L+*.(37LPP9[R8-.Y7S'D+ 8.5]U^/W^GZZ ?QZ?L7:]^RM^SCXP^)OC#
MPAXDT/\ :W\.?"3]A?XQ_&:\_;\_8 3Q?:_M@7O@3XC^,O!&B:YX%_X*.?#G
MPYXCU_PC\6/VK].B\77'Q0^&WCWQ5XBC\=Z='\%OBKK\GPF\#WFA:DU[]>?\
M$8_ GP-\$_M)?$?P%\'KW]F;X\O\'/V6OA7IB_MT?L2ZKK7ASX>_M&>&?'7B
MF2/3]!_;E^&.G>*_&/P_UG]NW2;KX>77CL_%0^,?&/B_Q'X/\<>(;W48/ 46
MJ)X=N?Z4+&QM+*.=;>WL].%U>2ZC-]@MXK:2>^N0OVB^O&AC3SKRX 7S[RXW
M37 P9)#4=IIEI81FVL]*T^QLVEGG6/3K*"W#7-W)YEQ/LM8H(/-N7"O/)Y8F
MDD&Z21F"D'(]KK\?Z?G;8#^??]J_QY^R'K/_  4/_:-\.?\ !33Q9X6MO@S\
M#/V2_@5XS_9 ^ _Q,\07MCX8^)NK^,=1^-%]^T3\8_A7\/(KBRN?C)^T%X6U
M+PA\._ASX1N/"EOK/C[X616D<_A.ST'4O'4FJ77Q/_P3Z^-WPF_8^U3]FOQ]
M^U1\7Y?!&E?"?_@D1X@_;$\.>%OB5XONK_XJ_&OXN?\ !2#]I7XD_M)?'#6=
M"T[5[J3Q1\;?BCX'\*_!WP5X7\276F0:_K^GZG\0-1;58[8ZNEX_];MZFD0M
M;ZSJUOIR3:$EW<6NJZC#8K-HD-U;FUO[B/4+U,Z8L]L/)O)(KB$3VN(I&E16
M"SR:1H]S<V5]<:5I=Q>:99W%EIUU/IED]WIMI>1BVO[.RG>!I+2UO(X%M[NV
MMWC@GCA1)%DC"X.76UU^('\L7[%_[+MO^U%XR_8C^'/[3EIXA^(7@;X1_P#!
M-3Q?^VW\=?AG<^)?%#>$_B;^T!_P54_: UCXHVG@GXDZ':ZY8:?\1?#WPZTS
MX6_$:TTSP1XDM[WPV-3N/"-Q;6\5IH]G;#Y1^%7Q \!_&[]I#_@G7\5?AA??
MLM?#_P".7[3?[?'@3XCZUI7@KX\?&GX[_M[_  =^$7A_PM\3OBGXZ^!/[1?Q
M#O[GPSX4^#GA6/P7\/)OV=]6_9.F\%V7@3P[97,W@GP;8:S<_#G5/%T?]K4-
ME!'(QM[:U@E^SP6SO'#'$S6L'F"UM]\:*Q@M_-F\B$GRX?-D\I%\QLYFF^&_
M#.E76I7ECX=T+3KK5M5.NZK=66CZ9:3ZGKH@%D=9U">VM(9KW5?L@%J-0NGF
MN_LP$/G>4-M)Z=GZ>:O^H'\GO[+7A3X">/\ ]G7]BK1_@G8?#O2?&_\ P4D_
MX+&?%#X\_M&OX%N8Y-8/@?\ 9P^.'[2W[=>B?##QTNCZA?ZAX?U#X=>$?AO\
M%?A7?^$=<GTR[T&SUVWTS5[2&6_%G=\;\+KK]FSXR_"3]D3Q9HFOVGQ#_P""
MY_QL_:Z^"'Q'^-?B73-7UR^_:K_9GUGPS^T9X<UW]KWP3\3=/@OCXI^!?[(G
MP-^!%AX[^"UE\+-<T_PU\%O%7AE/!EIHV@>)O$7C+2M;U/\ KZM=&T:PDF?3
MM(TO3C-?:AJ4AL=-L[?S]2U1F.I:E*888]U_J)9FOKUBUQ=EV,\DF33X].TZ
MWN[O48M.L8+_ %%;=-2OH[6V2]U!;:,PVRWUZ(TN+Q;:$(D/VF1UBBCV(%"A
M:0'\G?A3X(?#GXK?!/\ 8_\ VHV\%3^(_P!J+_@HQ_P67T_X^_"7XH^(9=5U
MKQA\"O@-I_[2GC3]H../X1:AJ88_"_PYKG[$_P"S3H_ACQ>/"\&A6?C^Y\7#
M3O%,WB"RO].MQ5^%6H_LT_%7_@I+\,/B;X5M? W[0'C;]H_]MKQCXTU3PSXF
MM_$WP<_X*Z_\$X_'WPA\ :S;Z_X:^*.H>%O%>NWVM_L"0R_!N+PEJ7PB\=1_
M#7PQ;Z5\:_#%C;K\6;;Q)8VDW]9UK=Z7-<RVEJ]C--I$L=K=6UL;6632IGL8
M;B&TN(8F9].F;3+RUN(K>9())-.NX984:UEW&\+33XY+S4H;"".]NH5BNKN"
MTB6_NX[?>8(I9XT$]PL1=A!')(P0NVP*6- 'XU_\%D?B-X/T;P1^S?\ !/XF
MZ-\&[+X7?'WXU74'C3XK?M1^/?B%X#_8_P# K_"GP7KGQ&\-^$_VA+'X?:WX
M47XKZ?\ $O6-,_L_P5\%O'_B_P )?#+Q_P"(-!?_ (2>_P!4N](TGPMXD_"]
M?$/P=T[]F?XF_#OQ5)X.\#?LE_M/?\%Q?@G\/?%'@GX$?"#XG_LU? WPM^RW
M^R]\$/@S\<_C;\4O"GP?D\6:_P")O@7\(_&^N_!F?Q1\3O'.EZYH^@KX5\2-
M\6WOM&TC63JEK_;(MO87L4T$T5M>HDT:S1W$<-R%DC^SWD"R(_F!60_9KR$.
M RY@N$"DHU>,>.OV>/ WC_XZ_ _]H379]?E\;?L^>'_C#H/P^TJ&_LHO"*3_
M !LT[P9HOBKQ)K6EOILU_?\ B33- \'?V%X9O;?5K&VT[2O$_BVWNK._;5+>
M6P /Y-_VA)_V:8O"?[2MG\'/"UMX!_X)D_MP_P#!0C_@GE\%+5_@=X>U;PM\
M+/'/@S]G;3]=^/?[?O[2?PCT3X=:5:1:=\)]6\*?#C3/ ?Q+^.'@S3[70?$4
MGPO\=^/8_$6JP6;>(;SV+Q3X=^#_ (DA_:YL?V&O OA'P=^Q7^W1^U=_P2N_
M8]^%_P#PJ#PJF@? ?XT?$GP[\8=>\;?MT_'?X6>'?"]K8^%=9\&ZM^SO-8?"
MKQA\4O#%C!X:^(GBCX->)6N=?\02>%9;Z[_I4\?_ +/W@WXB?&7]GGXXZW=^
M)%\4_LTM\5+OX>:%I^KP6/@QM7^+7@RV^'^LZWX@T3^R[BYU;4M$\(G6M(\*
MRV^I:7!I,/B;Q 9[:_:[MQ9^U7NG_;].O-.CN;K36N]/FL1>:7*EI>V"S6\M
MLDVFRM#-%!-9"4361:"2*&=4=XI4+Q27R.S;:2777O;^NY$IJ+2>M[V^1_-3
MX*^%7BSXZ_MS?M??\$V7T76(_P!F+X8_\% H_P#@HG^TUK%U%CPU\0? 'Q=^
M%7P%^-WP!_9OM[Z:[NDU&#XH_M?#XS?$GXEZ-_9]I91?#_X)0^&[Z>6W^(KV
M]S_1;\-_BKX#^,'@'PS\2_AGXGTWQAX#\7V4FI>'?%FE^>ND:M80W5U937=H
M]Y%;3BW2\L[J',L"%X[:>1$,(5SY+^R[^R?\/_V5_#/BW1O"^L^/_B'XL^)7
MC&Y^(OQ<^,GQE\6GQ]\7_BYXZGT;1?"]GXA\=^*/[+T:PG_L'P?X:\.>#?"V
MAZ#HN@^&/"_A;0-,TC0="TZ!)Q/]$7>N:#::KIFBW^H:9:ZQK7VYM%TV\O;"
M'4M9.D0QW.I'2;":X6]U'^S+>6&YO39V\PLH)(Y9S&KJ3!9_+O\ M"_"?]N3
M_@H9X-_;B_:T^$OA;]GF?X'?&S]E/XZ_LI?LG:/\=9/CGH_QK\,? 30D\2CQ
M5\7?AUX2\*:!9Z#I_B']JCXN^&/"WQ0\,R^*[5-8NOA_\./@/;WL8LUO;&O3
MO'WQG_9J^-G[47[/7Q:_X*,^$%UCX$>/O^";/P"^)_[(/P/^+/P:U_XH_#CQ
MO^T=\:=:\?ZO^TYI.B_#23PCXLL/'?[3WACX?67P3\(>&O MWI6I_$#1O!_B
MOQ9+X,T7R=?\97C?T:ZCXD\-:7J6BZ7JFKZ/8:OXBFO(/#FG7^H:=:ZEKT^E
MV$VK:E%H=I<W$=UJLNF:5;W6J7\>GQW#V6G6UQ?3K';1F6L[1O&GA#Q-IUCK
MOACQ7X>US1]6TF/Q!IVJZ'K^DZOI>I:#(61-=L[W3KVYM+G1GDB>+^UK66:R
M+HX,X$;E0#^0#]C/P?\ LO> KW]D.U_X* _#"?1OV<?BG^S=\6?VD/V5_@A\
M<OA9XK^+7@3Q/^U%^UI^V+\</'_BWP;K_@N\\.^.(/B'^U;\+OV8=1_9V^'G
MPP\+:OI>O?$63PSXD^)$G@*RU"XN/$4UISOPL\('PW^SM\#?$_A/X#>-(=$\
M"_LK_P#!;+_@KRWP>\7^!==\60W/B?XL3>)/@+^Q[\(/&&CWEEJ<.K>(H/V=
M_C!XD\*0^ ]2CO+R73?"3A+1X=(>=?[*/#GB70?%NA:7XJ\)ZWI/B3PUK]C;
MZMHOB+P[J5AK>AZYIEW$)K34])UG2;F[TW4["[A99;:]L[J>":,ADE92:W-D
MDB[QM;:VX"3#*&08$@!S\ZD?*PP0 ,,*=M+W^7W_ .0'\C_Q'^$=QX9^ _[+
M'PX_X)\> WU5?V3O^"._[0?[2'P[^)W[/_P^M]'N?&O[1_Q@\%_"#]D_0_BE
MX";2-)TR#Q7\?]2^$=A^U%XMT.:>2_\ %WB7Q'>^'VNH-7GU&SD;T6'5?V,_
M 7Q4^!/QQ_X)9_ 6W/@3_@GW^RW^V3\7/VA?BO\ #KX+>.O $GC?0'_9ZU/0
MOAA^R[\0O%WB#P-X>\2?&OXV?$GXPW.D_%[Q#X3\43^*?B!X7\2?"^^\1^,E
MTCQ'XEA@U?\ J>21!&QDW2; KL6#')5@58*[,%(8!A@@ C<,8&.:N_%'AJT\
M0Z/X9O\ 7M+L_$^OVNL:EX=\-W^K:=:Z]K5IX>&FGQ#?:+HL]XNI:C8Z$-9T
M<:S=V-M/!I)U2P^W20"\@,@E=VV%)V3=KVZ=S^;'X'_L2:%^R[XP_P"",/P^
M^&?[/%C/\9O@=^SK^TE^V5^TE\4-*\&Z=8_%+XD?%'2OV;K/X3ZE\*O%?Q>N
M[!M1C;XO?'/]J_Q!X@L?"&J:]<Z396GPVTZQL])ATKPYI\VG_"7P%\2Z,?C+
M^P9^T'HWP]^&EKK7@'Q%^V/^V_\ M*^&/V?/V$OVD/ _Q0^$?Q'T3]CSXX:]
MXM_9Y^/'[8WQG\:?$+XM_'+XR>*O'7CM= USP3JEEH$WCA_AJTL7@S1=&\._
M#?PRO]JC1>8%$A4)(&D)8!U+@[D=T(*N5SN!.0" 1GC#428E2]W)(K_=R=@+
M*05;&X!=V-R#GL<Y -5R6>Z[[/\ R%&7,KI6U?X==#\L_P!E;X5_'+]G?_@C
MI\._!'P^TJZG_:OT7]B;Q#XWTW2=3:1]0U#]K;XC_#GQ!\4M7M]1&MD/)?ZK
M\>?%^HK>?VJXDFN[DB]*D.M?C7\-/!'[*OC2V_X))^&_V7/V5/B1\0_C1^S]
MXD\;?M2_M)_%+5/V?O'WPR^)?B#XT_ 7]E#XB^(->^&/[1GQF^(?P_TB;Q#\
M?/C;^USXR^'WB#6M+\0Z[X@U"#Q+X>N?%15+:W\/R77];[1,4"Y8 2$L0QWX
M8AB1M)RV27R&ZY.<FH8]8TNXO[K0%O[:;5K&TLKZ]TU;NVFU&UL-0ENHM-OK
MVQ2=[NUM-0FL+Z&RN;J"&&\FL+U+=Y3:S;'))+17O_P=?3K]S*/X^/V/_!UK
M\6OVE?\ @E/?^%?!?@O3KFU^/_QB_:9^/R_!+_@GW\>O@M_PS]\3+S]E_P",
MGB7Q1\)?CQ^V9\??'7CSXD_%'XH>(_B?X\AT'Q=I^O7]A-\0&T"?4O$VA>&8
MK;P'I-S]2_LS_#KQ_P#%+]H?X^_ :\^%_B36/V7O^"5?[<?[8'[4UKX(TO\
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M ,+W_@*Q\5:KXG\;Z/IOA#Q-#]2_\%5M=^*5K\=?"7CCX<>!/'_BC4?V-?\
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M;!M.[8&*)'-MR3R0/D1"6/'SG'KQQ6MM$F_NO^>OSV E62*4D\EU#B16'EA
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M/\:^#M"\6^'O#R_"";PG\,/V=/\ A OA?\5_B?\ $3XJ^-/'EWXN\(:/\/\
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M>'_ G@[Q#^UWXL\5^//!.L> H?"^C_"_3/"OC'1?AQX3\*:3\1]1U/P'%?\
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M /AOQS_P5K^*?[/7A[]J+0?VC?AS\ V^,GPF_:R_9[_9)^$-YX&^+GBSPU\
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M:I?B;^UQ\</B'XL^%VJ:1X)\'7MQKGA>WT74/VWOCOHVJ>)]6T0WM_IXU+P
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MAK]SXD\<:]JGB6\\2)IWA#5;P>,?$]T=9O)'@\0:C 8+P^U?LT_LY^$_V9O
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MO\!?A%\*/AC\-M(_:M^-'Q0_:;\)WGQ'\<>%_C':_LSZ%\%?V2M5\+V/C?\
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M?V^?VZ/VI--_88^$_P *?$GPE\&_$?X_>/O^"D"_%;XX>)?@-XCM)+']F_\
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M?IY/C!^WOX@^+7Q_^!.@?M(?LZZ&W[&W@[PC\5?CG\>O&G[+OB!?#/CWQ/\
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MKOQA=+HVGQ6P!YS_ ,$6?#WQ9N_V.KGX[_$[XI_\+)U+]KWXQ?&/]J?2)V\
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MM]]M6U^V6UG<6YRO[W;=_C_7J!_/3\?OCO\ MB^)?AM_P4*_:@^%W[6GQ/\
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M,0R,,QV,W(W<[5  ;&,X YJTZ6Z<, ,C/\7Z8_IS2 K":1P>67:"#U'[Q?\
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M&']W P=O.,4UB%/[L QD\--(8V7H%*[BQ='&?F<?*.@/(J>3(0Y<H?E^=!G
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M$UUI6CI=:A/;V,#ZGJ$5M9+<7UW:65L\JS75S%&A-?SR?LH?LK_MF:]\(O\
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M1_P_S 8(4!!^;(((RQ/(.1QGUI)!$6!<X; QR1D G' ZX.?I4U1/$'8,688
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M@]F[9S_^OBM5'31W^^[?7;1NW?34")%,!*HR[7Y=G?8SN<@@*!C>5"@9(7.
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M$]>H]*D)P"?0$\].*@!:*ABE,F[( P%/!SUSUX'(Q4U !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 )D'H0?QI:ACB\MF;=G<.1M [Y[?YZ>E34 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M3'3>I7.,XYQGH0>GX4(FQ0N<XSSC'4D]/QH ?1110 4444 %%%% !1110!$8
M09/,R<Y!Q@8X 'IGH/7K3V)568<D*2!ZD#-.IK':K-UVJ3CZ#- #(G:126 &
M&QQGT![\]ZEJ.*0R*20!AL<'(Z ]>/6F2RF,@!0<@G))'0XQT_K_ /7 "*5I
M"05  &1@$=^ASQ^OYU/44LAC ( ;.>^.@S[^E2 Y /J : %J%9&,IC(&!GGG
M/ !^G<4Z5S&NX 'D#DXZ_P"?RS5>)MTV[C+!C@'..%'],]/Y4 22*$8S Y<8
M^4XQR G;YNAS4?VA^N$&.N=P_GBG<?:>V=WXX\K^5+-%NWOOV_+W VC .,D@
MXYYY!H $'G$2,<%6 PO*G;AQR>>K8.*?)*R, L8<$9)+A<<XZ$<^O!_ID@^Y
MC*M@XRI!'0==JJ,\\\$]\\X$U !4,LI0+MVL22,$^@SVJ:J,D0B .[);@9 '
M3#=N3RH'XT 3QR[CAGCZ9VC<&!R.#NX.,X..<U-D=,C/IFJWV8':V\Y"\<=#
MA1D<]@IQ[G.>.7I#L<.7W'G.5 SGOG).?_K@8'% $]0M*PE"8&TXR3GN"3ST
MXQ_GG$U-==ZE<XR,9QGZT 593^]R,' 0CTR"3@X^E+]H?(&U>H'&X]?P_&G?
M9L=)"/\ @*TFXP,(QA]Q#9)VGYCMP  >FW/XT 6J8?OI]'_]EJ.64QD  '()
MY..G8<5(?OI]'_\ 9: 'T444 & >HS69(I=R0S  D!"04&,#*XPP;C&> 1U%
M:=47C*'+JKAF.!N9<$Y;/ Y]/\F@"LCC.PD J""0'<_+@?=4H1TR?FP#V)P1
M(#S@9()[HR_JQ/X9))Z ]*<&(.050@D ,3]T\@J0#D<* 202.2.02UR2K9<K
MN!R^3M!(X.#@8SP"0.V >*J+L^WW_I<"-I0KJF5WMD9+JNTXSRH.]P><;@1R
M-O %(XD.W<8\+S\RMYA'!&,94'CY<GN,XIJ1R, JR^8=HRVXD 9 XP%"]P<>
M83SD@\!D<3KN5O-WAB'(E'E$<<A2>21R<XSUS6FC=TU_P-?FE_5@'*H"A#O/
M4;E*[1N/=6!)QD$]B,5(JQQ J-H+ 8P@#$@$9;;D$^A^HY J%0FX[3,"I7)#
M[=Q+!0FQL@J6(RX(&"<'@9=(P<C" E>"&0. <Y (+)]00^!W' I]WK_78"S!
M"QW#S&; 4_/T_B^ZBD(@]0N0>,] !"(BH93(\A#MM=^2J#C:Y4@XWY((!]Q1
M'(4W$RLC-M4[ &5FYV@;B,9R<G"C/![$OWL)%C\L[FR59G4+W.X, [<\]5&>
M,9YJ&Y<UM;;]%?2[_P"#^(#E&(T0_,KEV;'4J". 3_M%6!)&0/4U*9-T80K\
MPVY;(Y*GD\<_UYYJ,9+$L%#Y;=M)(P"5&,@<G +D*.0,9R31@Y''91]-H8$_
M\"W CN<'/2LY];^3^]K_ ('^0'+:P"=:T7 )'F)EAR$Q(2I)Z_,>!CN03P:[
MB-=J*,YZG(_VB6_K7$ZNSKK6C[,$F1!@\JQ,C C'(+!>1D<8!!! ([7=MCWE
M3P,D< ^Y'.,'J/;TZ5K5_P"7?_7J/YR 1Y0CJFW.[;SD#&YBO3J<8SQ4M1HR
MRC=MP0<?,!D8 /\ 7BG/RC '!*M@^G!YXYK(!V .@Q15*.<(N6#-DLO7/*L<
M\D],,,=^.G2KM !14<D@C )!.20,>W-/4[E5AT8 _F,T +13)'$:[B"1D#CW
MI4<.H8 @'/!Z\$C^E #J*:[!%+') &>.M-CD$BE@" #CGZ ]OK0!)1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 44UV"*6() &<#K4*W"L5 1OF(&>,<G'\Z +%%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %5Y(6=V8, "JJ!SP5;=G@CKT]?>K%% #(U*(%)R1GD>[$]^
M>]/IKJ65E!P2.#SQ^7--B1D4ACDEL@Y)XP!CGGJ#0!)@#H,5$\99U<$ *K#!
MSSNQ^6,5+10!4^SML==PRR@9P>,9]3SU]OI4D,+1G)8-\H7C/;OR3_GZFF_:
M5_N/^0JN6.Y^6VR$MC)R$(0@#G /(&!VS@@@4 6&G )!3(#$9+* 2"1W^E->
M3<@PH4$@@A\-ST!"?,,]Z6.([E<E60@D @EB&Y&<CKT).<Y[G.:C*;Y64 #A
MNP Z-Z>S+^7M1Z[ ,C<+(=QW'(VH#N<'!!R63))SD?O.%P,]14C,&F4X(RT8
MVMU^]SP"1C'Y=>.M'V9\=4^]GOTW[L9QZ<8QU[XJ;8$B/"AE0_,H!.0,[AD#
MGO\ 7O3=D]'= )+'\WF@@! &*\Y.PENV!STY!I\4@D!.,8('4'K]*ABFQ\C[
MW+,!N90  V%Q@'&,\_C1,71E$>U05)...0>N ". >/QSVI .^T\9\LX_WA3&
MN RD%/3^)3T(./QQ3$C,@8+A2"S!SG*ARVT!<$' SD-P" !G)(NA$P/E4_\
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MCYY6Y?CY\>01YB&+_A?'Q4FVLF&R[/XLA0/,W[J*++;\G8'QFJE]"/B!-?\
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M$0[\?,RHB,/[;_\ @G@!%^P[^R=:>6T,B? OX>[()#"'2%M'B:$8@Q%GRBA
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ME 1&!@JHR:(D$CR\%XN!'(8V1E>2-2QB6-MH:-U8(NYBN3(R8!QHU=-:J_\
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M;DC*47&$*#GB'&E*E[RG*+4HPE:S3E&4HQ24DWS23BFKM*UWL\;( ';;\H7
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M>V,<2Q^9E-V]0$ ;#*5X)P RJ')QU)W9ZCG-,1I(V;;N"(?NL-Q<G(P#%O'
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MQ=V=Y9SE2BM9ZA;BVN[9V5FBD>"2-WA>6"5I()IHVE$LL4*/$L4P8))(A=0
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MDR@.$RDA?8=H499MP#* ,#:Q+9(V+1;IY85VNJ^3=I)=,%4S-+$ZS"?Y<K"
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M1N23&Q&&-DR6X:)N<N4B56_=#A&>123)OFV-L9"RQ?,^,$*"S@O>7E):?/\
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MMOWZ7[+YFG/'VE2%2I*<W)<M)I*G4M?56;5.SLK134KW=FD4Y%$HW%&0RRJ
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MZ\:7?/I&K)<SVU]%])3_ /!1&9?B3^T5\2K;X,:Y8:]\?_BA\+_BGIM_\/\
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M\\Z:6WD0M++L1#+Y:B)XI&1K<,9$!C"GA)6D8[#N1@P5S\MAI! T;8:,M'<
MF9GDV)';3J&1DC"QM.2R'+_/&K(=N[<O^A4VG0[PWEQ$!A@&*(G8%VMDN'R2
M.7&"'.>"2=SI-/2=0(Q&BG.US'$QD#=S&56,JIR2KQDGGAAC _IL5K+_ (UU
M3[._%N-:ZZ?\BU75NCW5^FIJ_H?5):U/$"G)VT:X6HII>3^NNS6Z?332Z/\
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M4RX1'4E1C>1$=I&,H%7.#D9)//&22P! (9 03G8NTYB*KG'10!$H"Y[;B,#
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M $&I%N549N+F,-A1N>7+.03\K&8 @CD%"VT L>%I/L5Z\8/V^X3/)/VB; &
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M_P"%[-G9/R_LF+?HFWV6YUR^AWDLIPG'CC.;04%RPR'*E"7([M.+S=_%UO\
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MXBS;$:4IAICX?B1)5BVRG!=F5F7:&'/]WKVSH53][MY^:.24F/:"5!#'!9L
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M$OC/!\MIY@R(VF.$9]_ERL0A(6,1EE&3_=5/93*A"-)*N<JI0N8\#HH+9"Y
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MA)%7S/!%]A#LW9B$TP,*.WRE(D9B5XQN"U9M_P!AO]M(13 _LH?&]LJK$?\
M"'7"!I3(K2O\\\4C"2)!$50$@_,KD@*/[AXM,6$DM;QJ[[@LA523NX&W'W3T
MY9A@$YZ\H=-$DFU8D"JJ)O<%G 4<Y:-9 ?FW, S*>3D8.3,OIF\;2?\ R2O!
MB26CYN)M>K=O[9OKM;7]'D_H>\#TZD9?ZW<82O!JRI\,I:W3N_[)EKKT:[,_
MAZE_8;_;.\V<I^R?\<T260F7R_!EU(P)02"2W<S;@%.86_UDF[^''2!_V&_V
MS+;>P_94^.TXE3>Z#X?W32H69(\;DO?GE0MN5HG&U!(S A17]QK:<EM$6( S
MG;&6 (/(+ $='Z'&"<X;L!5ATI?,W"*0'DK$ Q5"N0P60*PRP..3C /#<XG_
M (G+XVU?^JW!EE_>XF_#_A9^7;LQT_H=\"_%2XLXPIU(_#+V?#3LWV7]EKLM
MKZ'\0,'["W[:3A&/[+GQU ,+-AO!%Y;O&^>(R&N'#EO[Q!]2AZT+^PE^VI.D
MB1_LH_'&+<J!V7PFL 9@,2,_VB[MW=G;))CB*Y;<H K^X7^S(FD8G?$JIL*,
MI\MB.1DX!(+?*.V0<G%-DT[8Z!ED8DH,*GF>6APJ["H+-M8JFW@@>X"EQ^F;
MQM'_ )I/@576MZ?$JO\ ^ YUOU=WU+?T.>!Y0C"/%?&+Y)-_NH\/4WJK7DZN
M&QET]TE&G9W?-)-17\1/_#!7[:DENBQ_LJ?&X2HS+([^'K&,E65C(\23:O%N
M,DOS ,\9*.R$YI?^& _VWE15'[*WQA/[N(';HFF*N3&N453K&X(A)C*,% 5=
MH;;M>O[2=-\9_#W5_$^M> ](\<>#=7\=>'4>XUWP?IWBGP[JGBW1[?$'G/J/
MAJRU*;6=,BC:YMT:34;.V7=+$"5,L&^L/&WPY;Q%'X,7XB>"AXM6]:T/A1?%
MOAW_ (25[Q%,KV"^'O[2_MG[4 N'M&LENE7=N@&*7_$Z''%W?AC@EKHI+B:4
M>]XK^V=.ROK;1:%/Z'/ [LO]9.,;))<J?#48-I)<[2R?6I))\SV?-)VNS^,R
M/_@G_P#MLEOM1_94^,:R%WX;2_#VQ=Q)1O*;Q%YVV-SM5/*SA5DY4@ E_P""
M?O[;0#(?V6/C#,J J672O#D;/\A=OWW_  D'F.K/D [=H+;=I*Y;^R76/B?\
M*O#>O+X=\1?%#X<>&O%%R+>%/#&O>-_"FCZ_F_$?]F(NCZGJUKJN;]9[9[-1
M:%[@3Q- KB1"W<36161UD@A997*LKQHQVB-%D4D1LP4_. 4;)4EUQNS4Q^F9
MQTY.4>%^"9MW?(UQ,X*^KM%YQ9<OV6F]+VT-E]#[@6T8RXCXO48I+?AQZK1?
M\R?FUUTO8_B:?_@GS^VX0LB_LI_%\R9D1HIM-\/R1NGE@Q.S+XC!7YR0R;#C
MRP=WS@+?D_8 _;9M_-2/]E3XN7$$ZX9FTSPUE7!C02;#XDDN#*P;<TB0$1QQ
MA&R4%?VI12:?<W%[8VU[93RZ/<+::I$D]G))IMY)IUOJGV/48DF,MC<KI-[:
M:@L%U%%(MC<VE\<6MU#.^/I'B;POXAT9=>\-^*/#NO\ AN&:\AFUW0-<T76-
M#ADTI)%U.&YU&QOKC2UFTD0RKJ:RWJ-91QN\X1$D*2_IF<<N5WPQP0F]73<>
M)N1*VRBLYZ6NNEV2OH>\#QE>GQ)Q>K7M+_C&W=.W263]KI:^JV1_&3'_ ,$^
M_P!MUF2-_P!E/XL'>"ZL;'PL$0R[5'F-)XP 5UP6*\#H'D04H_X)Z_MPQQH!
M^RC\4-RIA0D7@S9OD.Z7*R^+T5"[;6+!FP5(VD$L/[.?"VL>&?&&BV?B3P=X
MC\.^*_#VIF1=-\0^%]:TKQ'HE\8)GMYUL=7T>ZO=/N'BGC>"X6.=A%/&\3,2
MA:N?F\>?#&WUD>'YOB)\/$\0?VE'I T"Y\:^%X=9;5I)3:_V4-(FU2.^34A<
M$6@L'MUN_M)\@0;Q4_\ $X_''/[3_5K@E1NK0Y>)?9NRMM_;6U]?7M8T_P")
M2.#DO9KB3C#MS?\ &-=?>V_L9)]K7M^*/XV&_8"_;@M)623]EGXQ1^6\DK2V
MVFZ#=2$,Q9HXIK#Q%<PN$^Y#'YJ%E  .#Q5D_8,_;825''[*7QCDE+2*K?\
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M_)Q[D @5;) 19"Q^1AE7?A6X&S=C&1NSD#G& .,TD4&2#,QD*KC!V[%Z<*
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MQC;:5%\(;KPE\4/B''XR9)H6U:YMXI;36/TG_P""UOQF^,/@']I#_@ES\,/
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M0_#4&A7'C^'Q_P")[".]\0Z=I6GZ>OE)].:)_P $6?V5=*^'Q\&ZMXN_:/\
MB!XOU;]K'X+_ +9OQ"^/?Q+^,K^./CU\6_C)\ +^&?X71?$;QOKGAZXL;SP'
MX8TNUM?#NF>#?#7A_P -:?INA1O'HS:3JDL^IW'1:]_P2#_92US]HG4_C[>7
MGQMM=$\2_'C1?VK?&7[,6F_%K4++]D_QO^U+X?CTM-*_: \6_".+3A+J_P 0
M$O-$T#7+VV;Q-%X)UKQ+H.FZ[KOA34=4@-_<%_O[_G^ -)[I/U2?YIGREXP_
MX+&?$?P_\&/VM_B=8? 3P7>:G^S9_P %=-(_X)H:/HL_Q"UMK'QGX5U3Q_\
M"GP@GQ3U#4$\/17&A>)FM?B2)Y?#%M#J.EV=[8$-J=W&95KR/XX_\%JOVJ?
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MPCXI\(>&]:D\1>+K;QOKVH:SK_A;PY?370B30M>U@S7=K^L'[.?QE\:^'_\
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M0-1TO1;.^T/13I/A'4M!\/\ A_P_+H,>B:>M@B?,[:N_FW^&K_X N6/\L?\
MP&/_ ,B8_P"WQ^T?\1?@)+\%/"?PP^)7PE^'/B;XQ^)_&NF"X\5? 7X__M9_
M%W5-.\)>'[76#:?!#]EC]G5=*\6?$:]^WZK81>.O%OB3QYX3\%?#31I]+O\
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MQ.^/FB_&*T\=65Q\9;K4O&NK+\8_!'B?Q79>)?[:OKXWH^%_VE?V;?%OC;X
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M ,$^OV+?VT=%\=^-_P!CR2V\=_MG^-O#?@S7/!=IX@_X)V_L\7^DZ?K&@/\
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MS4;W3?#FF>'O#NEZ?IMAA?MZ?!CPI\*OVG_C%^S)^RY\//@K\+?V??C=KO\
MP1;T']H'X4P^'5\#?LVMXE^(7[5G[6?@I[/XC^!OAV_A[2Y-'^+G@WX<?"#X
M>?$'PM91:&WQ6\,:=X'^'6OZI_9?B>VDM?Z;)O@A\'6T7XN:#<_"SP#>>'_V
M@-3UC6/C;X=O_"NDZEH/Q=U?7O".B?#_ %V[^).C:C:W%EXN.L>!_#6@>%-1
M75[:ZBO-"TJRTV='MHE2O(/ 7[!_[&'PR^$7Q!^ G@O]EWX+Z+\'?BJ(I/B;
M\.9? VCZMH/Q'6WMK6SL#XYAURWU*;Q1_85GI^GV'AH:U>WZ>&]/T[3+'0$T
MNVTVS@A33O??UONE;^NBTZ ?&'_!-3PMI'P2^/O_  4)_9ROOAY\!_"WC/X>
M^/OV=/'?C/QY^S'X+\2_!+X&_$>_^,?PKNY/#!A_9NUGXF?$[P[\&?C'H&B^
M$K"V^(T/@?Q++:?$G3]:^'GC[4K0^(-;O2?,/&O['7['_P :/^"HGA?POX5_
M9&_99T!_V8_#'AO]NG]I'XJ:#^SM\(].^*GQ-_:%^,7C[QKIO[->@ZQ\3-,\
M)VWBWS-,U3X??%3X]_$:Y&M?VKXL\26'PN@U2[N]$O\ Q/I]]^AD/["/[+/A
MKX6^$O@Y\-OA%X/^%'@#PG\>OA9^TI:Z3\.=!TW06UCXL?"3Q_X7^(OASQ1X
MAU!K6[U+Q!JMUK/@[0-/UW6-3U&7Q!J?ARSB\.G5;73!$L'TIH?P]\!Z#XS\
M:?$31O!7A;1?'?Q*MO"EK\0_&6G:596GB3QI:>!;'4-.\%VWB36(8(;[6H/"
MMCJ^JV>@Q7KNFFV^HWB6D4(N9@:L];WM_E9?CVZ.P'Y#> O@_HGPW_X+I>(O
M&,7BCXB>.?%?Q=_X)N?%'Q;K.L?$CQMJ/B,:#IJ?MA_#6+1?AY\/M"CCL/#/
M@7X<^";&[CT_1M$\,Z%I][J(8:UXTU3Q1XLU#4/$-YJ?L]_!O2/@]_P6*_:N
M:V\8?$SQYKOQ*_8&_9\^)GBWQC\5O'5]XSUU=1\0_M:_M=VFF>$O"]K);:?X
M<\%_#[P?H&FZ;X8\+^#_  9H.@:/8Z7IMIJ.J6VK>+=5\0>)]:_6@_#OP&OQ
M @^*LO@[P\WQ*M?!MW\.;+X@MI%B?%D7@'4M=L?%5YX/BUT)_:$7ARZ\1Z=8
M:S/I7FK:3:E8VMZ\9FB1J+?X?^"+?Q]JGQ1M_"GA>'XEZSX1T+P#J_CVWTC3
M5\9ZIX'\,ZUK_B3P[X-OM?$7]I7/AK0_$'BOQ+K>EZ5).UE8:GK^KWMM#%/?
M7,DA;JN_Z[_UKO<#\B_VB?AK\"OCC_P5$\/>#/VK_!7PX^)?P2\-_P#!+_XP
M^,?AKX=^+^C^&O$_P\L==U3X\>'_  Y^T?XOT>P\66.IZ'%XGT?X;I\*])UK
MQ(7CU'PYX5\07EI:30Z7K^NY_)C]DWP%\&OC=^S9^T'XH_;=\.^#_B%J'P__
M .""'[ VK?#GQ)\8;+2O%7B+P1\#?$'PC_:LU_Q!\1? VJ^*X;K5-"UG7/&W
MA'1=5\2>.="O(/$-QXJ\'>"+B^OK?4-&T&X/]+_CG]A#]BKXE_#?X=_"7XC?
MLG?L[^-/A=\)KG4KGX7_  ]\4_"+P9KGA/X?R:S,\NN0>$M$O=*N+#0[+Q$[
MLGB'3-/CAT_Q!"_V76+:]M_W0U/BS^Q;^R-\?=1\!:[\<OV8O@-\6-:^%=G%
MIGPYO_B#\*_!WB6;P7HUI>6.HVF@Z*-5TBZ6S\.VFHZ7INHP>'@CZ-#>Z?97
MD=@+FV@D1--N^FF^O9N_]:ZAMMIZ$/[$=Y\1-:_8N_9#U;XL7%]-\6]4_9<_
M9\U+XI7&KO=-J<_Q O\ X2^$9_&<E^;J>:Y?49?$,FHM>2W<TURUVTK32NV2
M/J#9*N%.,,=H3=@N!SEG7)_#GG@Y!J&!&D96!"L<JZ(<1EE!*!?DC^4 *!QA
M5 4$ ;1<963[PP<%E^;=@@8)]CS0Y..G=7M:UM[:Z7UUVV5M!679?<O\AN64
MX3!(*J<^K,R@KUP,@YZ<8XZXO2QF0 !F7!/0D9SZX/;M^-,DB^[Y:C)=6<YP
M<*P;OUZG\ZL5F.R6R2]$E^212\B0<8!'NQYYSDC!!/<DYYYJV@*HH8Y(')R3
MS]33JA59?-))/E\X&X8Z<<8_S_, FIDBED91U(P,\=:5F" L>@QT&>I ''U-
M,$T9(&2-QPNX$!CZ GJ>O'7@T )%'M7YE7=N)R,'J<CG&>/Z5-110 4P_?3Z
M/_[+3Z8?OI]'_P#9: 'T444 %5Y(V7!A&&8_,0><>^[/?J:L52,LN3\PX)'W
M1V)% $,IF9=I8DAN1DJ1MW [60@[NN.=I[@G%0+YB D2YW,0BR!79!SN5@F"
MQ"YY/3()).,6B>Y.222?<DY. /<]NE(A^]_>  5'.%QN(SR,YV@<\YZ'IFJB
M[7?2VOI=?Y@1KP@9PA.3GY0BG)( P3QU'4\GIU ICA4C+!1%\RR@,0 60[E9
M<')/<*^8SQD$5,=Q.2$!)'W7R1QC(4KCIU]LFH72-V"G(9"#P_+<\  Y R,
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M=-\5WNO^#T'P=;PMK^I:G+XT\?3Z_P#$2U\6ZGK>D0V5[I%KX3T^7[$_9O\
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M,GH1CUR....G:G44@&JBIG:,9Y/7^M#(KC##(Y[D=>#T([=Z=10!"+: '(C
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MB@"=I$0X8XR,C@\_D#S[4'[Z?1__ &6H40RY\X-D<#C;D'KT//(J8_?3Z/\
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M7U(122.>,L#W).>M)9UX777_ !KSBM+;WO$UV]6X<!\WKRKMYL7]C>*%DO\
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M-=Z0&"EBI'_"5^:,XVAVC6(,0#)Z-'_!7'X:L59?V4?V]I$W^673]FB\8!E
M9L_\5;N&%964LFUCD*Q8$#]7OLH_Y[3_ /?QO\:/LHX_>S<'/^L8]/4$U7^L
MWAFO^;38F6G7Q3XN7_ON7UWOLK;&G^KOB1K_ ,;.P6S_ .;:\+W3?KQ#9VWU
M6KWW9^4!_P""NWPYP"G[(?\ P4$9M^V2/_AF25C&!_'YB^-%B=3@E=CLQ!&5
M4@BH&_X*\> F\S[/^QM_P4,N_*V[F@_9ILMOSAMIS+\0XRJ_*V78!1T8CO\
MK!+'Y94 N>"3R?P!X;^?U]UEC:/;B68[LYR[L!CMC/0YY^@]Z/\ 6?PRMKX1
M8F7_ 'EKC2&G_;G#6OSUT\V9_P"K?B6]?^(K8:%NB\+>#YW[W<^(4XVZ<M[W
MUV1^4_\ P]?TN<A;#]A+_@HA=, K.LO[/.G6WE*[HJ>:4\=7**Q60N\;LC(J
ML6&,E;"?\%2KV;:+/_@G[_P4+NF*"0A/@+;85&90"SKXHE4/APSQEMR9(;!'
M'ZDXDQ_KISQCB20'OWQR<GJ<>F!5E;4X!\^;D#J['J!UR<Y]_P Z;XI\-?L^
M#_+_ (O%CCF5_/W>'H_UV"/#?B.F^?Q4<UT5/PPX'IM:]>?B"=U;32SOJV]C
M\L5_X*=>+ID>2T_X)S_\%"940A2\WP3LK90V3\NT^(Y)F.!P8X77) 8J,-3F
M_P""D_Q0D"-:_P#!-G]NR6-V*;YOAQ86Q5E8CE!J$SJ"%!#L%B*D9<,<']2)
M;8H"_FSMDC(0Y.<XSM'&,=\\=>F135MUD 5]XW-M)=0'.U=X8DYY.T 'GY<8
MJ%Q5X>7?+X0X6*Z.KXG^(-96T^S3RO#._6_.UNN5MJ2T?#7B"UIXHU[V>C\.
M^!Z*O_CCF>+;:>G+[-1MKS:<LORQE_X*/_%U)&8_\$TOVY-RD!-O@*PE0]LD
MV]Q,54Y)!4$]"0.2JC_@I)\85E@BG_X)J_MN1F:2'?(G@:VECBCN)5CC=GRB
MXBC<2WB,4-J=RDNJ.Z_J4UDHF)"97 &X@\#&3C ]>/3U(J46D1BWX.=I;;TY
MP>/7G&*QEQ3P#K;PBP3UWCXC^(<;KNKTFTO)Z^@UPSQ_?WO%"O:VT>!."'K;
MNY]/+1^A^60_X*5?%")6-U_P39_;KCD5)79+?X<:=>J!&\,6T/!J+!VD:;,6
MT,SQH[ 8CD"2#_@IIXX5@MS_ ,$X_P!OZ/<I96M_@Y!=*1A_XO[8@"$%1\K8
M8[ACL#^HBH%&!P/3;D=NA*Y'3Z#CC-2QP+(6P63I]T8SNW9R"!D   >F:UAQ
M7X>\BY_"#!MVU4?$WQ#IS;N_MO 5Z:Z-^Y.ZT33]Y$^&N/[IP\4:\5K=?\0_
MX(JM=O<EB\.I>OM865G[S7*_RT/_  4Z\8$*5_X)R?\ !0S.]%(?X'V2G:SE
M2ZY\3*N% !;<P&&!!P<A'_X*=>,4V@_\$X_^"AWS-M!_X45:OD\]?*\42;<X
M^\Y1.V_<5!_540;?^6LIX Y8]N_!'-.\D_\ /63_ +Z;_&G_ *U^':V\'<.^
M]_%7C[7_ ,P:M;YA_JUQ^UKXHU;_ /9N>#%^$<ZY?N?J?E(?^"F_CTNZK_P3
M=_X*!LBX(<_!FU1R&B,BYC77I2#QM8*65)#LW%MH:/\ X>;?$>9@EM_P37_;
M[8DJ"+OX216(+2#=&!(U_-%M"9\QWD01NHC8"0@5^KDEOO4J99!R/XCU_$G_
M !J);%5ZRR-QT8AAS_O YQVR*I<5^'5M?!["*73F\3_$2I;S;IY=0BUY<E^[
M=U9KAKC_ /Z.C5Z:+PXX)U[_ +R6<SE&_=4I\N\8RV/RP;_@I3\4DW^9_P $
MV/VZT50%$A^'%A(K2,%.%\J]=C&"0IFQ\K@Y&T;J<O\ P4E^*3D*?^";G[<N
M\@Y7_A7FGX_A  D-^%8L'/N-K9[X_5'[*F>O_CJC]0 ?\^G% M4!!#-P0>22
M./4$GK64^*^ +KE\(<#YN/B3XA\N_53PREHM[.S6UF'^K/'SU_XBEB(]DO#_
M ('GTU?-+$1:;=KI*RZ/H?EO_P /&_BR0"G_  39_;A)+>6JOX%T>-F?*!P0
M=1(5%WY\URL;A6*,Q4XK/_P4?^,AB9[;_@F=^W#,55R8Y/!6D6KY3CC=>L&!
M("J%+2/]Y(F49'ZJ&!2""3@C!_KW[_\ ZJB^Q0^G\_\ &IEQ9P&K<OA!E\KI
MZ_\ $1?$-J.O52IPOI\NK[#CPUQXOB\3\34U3_Y(/@>G9+I[M:=[O6^C6R/R
MKG_X*,_'>-08_P#@F3^V?(Q4NR/X?TA1@#(16B>X0RG&"C% "1M=N=M!/^"D
M/[0,@9D_X)>?MEX#JG[S3O#T+ N8P7VRR(2B@S%V4-_J0 "9H@?UA_L^#G.X
MY_O,Q_F:L>3C&';C'^>34_ZT\#I*WA/D\K]^/?$A)>EJW7UTTW"7"O&TI-+Q
M3S:$5MR\&<":[Z.^%V6GGT/RC_X>)_M#>66;_@F%^V%N"NICCL_#\F)0"(5#
M$QB2%W&&GCWK&I$A5E)(#_P4/_:,+,%_X)@?M<LH61@SKX?3.PL5&/*8 N,9
M0%GWDA%D7]X?U5-C$23E\DDG#'J3D]Z3[!#ZM^9_QIKBG@>-VO"?))7MI+CO
MQ(:7I;$+[_Z=?ZL<:62?B=G#:W?^J' B;T2V^J6Z?B_(_*;_ (>'?M,.N8?^
M"6_[6#NK.)1+?^%K1 %D15,)N8DEE)CD21LQ1J,2)&\IAD*N/_!0;]J4F5U_
MX)9?M1^1%(JEW\2>"%E89PYCME2263&"8]FY'7:7DBR=OZO+;JBJJG 7...N
M3DY/?/\ 4BE\G_:(^G'^<]Z'Q=P;:T?"/AV*3^+_ %T\1JLFNS53,*<?GNGT
M:NC-\)<:2O\ \;6S^%[OW>$N 5;R2>7RT71.^BWZGY,G_@H5^U8SO'%_P2N_
M:A9D$9S)XF\(PQMY@@?:LKV!C,D<4^90K&))TFMQ*S1NZ/B_X*"?M9S[_(_X
M)6_M, JT2K'>>,?!EG(2X9R[,]BUL(XU!!,5S+*)-J&$;@Q_6(P ]6)Z=0#T
M^OZ^M @4#'!^JCV]/H*G_6WA#_HU'#J_Q<6^(373>V:I]--5:[U&N$>,;)/Q
M8XB?=KA/@!-[]?[,MU5W;IINS\GU_;\_; ?;L_X)5?M$_,[*3-\1/ \/E[1R
M\H_LUCY;$D(81-(P!)C!PK1G]O[]LC?L'_!*7]H09+!7/Q-\"",D<C<PTT[0
M1GD!B3T!Z5^LWDK[?E[8]?\ /7K3&MD;OCZ#&?YTUQ?PA&S?A)PO4LU[LN*O
M$7WO+W<]I>NDX_/9O_5'B^__ "=?B5;_ /-*^'WZ95]W3N?DR_[?7[9;%%/_
M  2G^/I4J)-__"T?!"J/E0;,C1F;S,R,""JC:C'<2"M0C]OK]L^-V/\ PZB^
M/6"'5'7XK^!WR0I<Y5="9T7<H56*X(.>ORG]:39QGJS?H/Y?6J\5KAF63"@%
M@A'\2@C:3N_B(Y.!R<^E6N-N#U_S9KA)^O%'B4W\FN*U;_(/]4.+O^CL\3W\
MN%/#ZWK_ ,BJ_P METZGY/+^WW^VC(Q:/_@E!\>1)O; F^+/@:W3:J,<EI-"
M4+G:-N1R2H!)P#;7]O']MV17$?\ P2C^- =4+JLWQK^'D2OCRP$5FT;/FDM(
M=K*JA(BV\EU2OU6-H))-I+*@)P=IR^ <$,#M SG((YXY!(IS6,**6RS8&<,
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M_P""4'Q"!8PEVE_:*\!PJ%9HS,1_Q2!;=&&;8F/GVX+)@FI$_;:_X* \L/\
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M"H5$;[,QMHY8YEV9 D&%W D9##]:DCW)O &XYP.<9!(&22#S_G&:IDA9461
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M::Q=ZGI^D7%I\/O#$3:E92^./$FG^'M(O9--D6%UN'6 >Q?L\?\ !1/]AO\
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M:]X;^(VHZK\4-'^)'Q.\7K/!XPT[XK2?$#PO9WL'P^\,#PW* ?TY(P=58=&
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M/#NL6R7FE:SI-_ S175A?VDD=Q;S(<-&XR%;*C^9'XL^+OB3_P %"OBA\(/
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MM_C?\3?BS??MP:+\64_:U^,<W[,_BS]L/X'_ +(OP2^(?[-_Q-T^3X<_L_\
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MB!J7P-_9X_9^^)-W+\7&USQ)^T#\0/V7?"W[0/C_ /9*^*G[4O[-'P\T"_\
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MQMU3X7Z=\$/%?PY_X0^6RT:6Z\*^*?$OQ#U7Q1>WFI^[6OBCPK\(/V>OA/\
MM6_$+_@HI^TEX]_:@\=_\$[/VD?VY_CS\,O#GQP^)GBSX2?M _"=OV:7\4>*
M9?AG\.O#&KV7PP_9+\%?"+XI>./ 1_9P^)_PKT7X<^-KYM'/A$Z[X\\2^(_%
M>M6X!_1[X!^)7@CXI^%-'\=_#GQ'I?C3P9XBCNY] \4>';J+4M"URUL=1N]*
MN;S2-3@+6NH60O["[BAO+622VNHXTN;:66VG@FD[;S,*K%3EN O!.<$X]. #
MGG [D#)K^2S3/A_^T+\'=*_8=_X)[^']:^(&N?";X ?\$T/!/[4?QV\/R_\
M!1#XC_LG>(_C%\6?$GB&S\%>*(5_:*>V\6_%^Q_9T_9_C\->+=:O/AE\-O$_
MP[\&^&Y/B?\ "K3]=G3P?I6D: ?4/V6?B'\4?VE_$'[,_P"S!^TA^U;XDM_V
M>[#]E;]H+]LK3O&GPW_:@^(GA;QY^TE\.;O]JGQ)\.OV<O#_ (N_:PT'1O@?
M\6?'/AK]G/X$V^EZQ\6O&7A9?!,WQ5\4^*?AKXR\9ZOXCT-[N?7@#^C3P=\:
M?AM\0/'/Q9^&_@_Q)'K?C/X%^(?#7A+XKZ1!8:K G@[Q-XO\#:%\2O#VB76I
MWEC;:3J5_?\ @;Q/X=\12QZ'?:HFFVFL646JO8W<HMZ]*-RH/W)",$A@ORDA
M0V,G&/E+-\V.$)^Z5)_'7_@BKI>F:M^S!\7/CUIOQ#\4_%W2OVHOVS/VH_BQ
MX8^*_C>[AU#Q9X\^$?@/XA2?LT? O7]<UI5MVUG[1\#_ ("_#Q[+79H4FUS3
MLZY<&XO-4N+^\_)W6O$'[1?BK]DWX%?M=>$OVB/C=K'Q2_X*5_\ !0;X@_#K
MX7ZWXK_:R\??!WX8?LZ?L9_&[XD_&GQYX)^'7PCG2S\5_#CX>^.?C+\)O@KX
M'^#WPM^+7B3X9>,_''@7XB?&_1++X3ZGX>UJ+PU+; ']>/F?(S[6^4$E3@'(
M&< DA>_!R >H.,&F"<$9\N08Z[EVD$YV@AB""V!@$ _.OJ<?R?:9\:/C]\*/
M!'[4/@+X?_&S2_@W\)_&?[5/[!7[%NJZMHO[;GQ<_;O\1_L9?%;XT?$N70_V
MI_%VB?M#?M _#KPW'X2U76_@[XQ^&5CX>\'IXJ\?:;\,?CUK?_"4WJ^#];U+
M6-%DYW]HGQ;K_P ,?'G_  4A^&O[)'[67[1:_"WX3_ G]C?]A;P@OB_]J'XH
M_$[1_A+^VE_P4B_:.T;X=_$/XEZ#\7?'OCKQ)XYC\8_"+X7O\*/&CZUXF\=W
MR_"WQ;XH\;1^$;GPS>^(_$NGL ?UPBY4KN,<@ &6X5L'N%\MG\Q@W[O;%O9I
M/D4$UQ?PX^)/A?XK^!_"WQ%\%'7KCPKXSTFVUO0)_$/A+Q5X&UN33;MG6"74
M_"/CK1O#?B[0)VV%VL->T/3=1CB9)9+18W5C_/K^VK^V3K=I\5O^"CVN? 'X
MR>(-4\+_ +#G_!-CP]^S_H.E^#_'^K7/A@?MX_MN_$O6/"_PK.L3V.H7>GZQ
M\2_AE;^ /A+;1ZO=2ZCXG\,?\+4UJP L]2U6Y2YYO2KO4_!6C?\ !4?]LWXF
M?M _'7XF_#;_ ()F:+X:^#7[.O@34_CI\5-"\#ZK\6?V%_V.O#7BCXB_%CQ[
MHNA>,+2Q^)?C;XD_'?XF^(O!6MZ7XZ;7]%UZ^\-+=>)=#US7$L+O3 #^BSX>
M?$KPU\4O#$/C#P@GB%]#N-8\4Z'$WB/PEXI\#ZJ;_P '>)]6\(ZRS^'/&VC^
M'_$<5BVLZ)J!TC4Y=*33O$&DBRU_0[K4-#U/3]1N>V^TIM+[9" "6 7+!00-
MVT9++SG<N5(5BI8"OY/M4\,^-](^$/[?GBC]I_\ :(_:FUCX>_\ !,;_ ()H
M?LU?L^^)-!\.?M2_&7P3#\3_ -L?PK^S+X@_:B^,7Q5\7>)? _BK0/%'B/XD
MW&H_&'X*>&-(NI_$DNFZA>/]B\2:9JJ:'X?L])U?BU\9?^$/TSX[:9_P4'_:
MV^+7PMU__@GQ_P $TOV2_&_PS\->#?V@O$?P.\>?&+]HSQE\*/%FH?$G]J![
M+P[KOAZ^^/?Q U#XS>$/#GP1\ ^#?%47C3X=:1XJ'B:RUSP-J&H_$:-K@ _J
MF\TJ_FD.%+?ZMB4;#?*3M<J JC<Y+;<;2#@BN&^%_P 7/AW\:OA]X6^*WPJ\
M3V/C;X<^-["35?"7B_2%N1H^OZ5'=W5DNJ:;+>P6DMQIES-9SO8:@L(L]1M?
M*OK">XL;BVN)OR^\87'CK]DW_@AOXQUKXU^+_B!K_P 6OA#_ ,$W?%GB7XI^
M,M8\?>,[;XA:]\;D^ ^H:YXMO#\0=/UVV\::;K>H_$V]O;?2M7TG6[#6- 8V
M4&BWMI':6R1_!GB?PEXC_P""?GB+_@GQ^QM\ ?B)\0M-N/VCO^"?OQ<_9*^$
M]JGQ7\>>/_#>G?M(3?%G]C6W\1?'/0+?Q3XF\6V4=W\&_A-XS^.7QMT*#2)%
MT/1_!O@+6/"OA6STW0IH+!"S8'].37:KU208VYR -I;. <G&>@(R?F8 9 8A
MYN%!VLK*2 5WX7=D*?E!.YL;B& 4E=I+!05+?QS^$OV@_P!H+Q'^R%H_C;P_
M^T=\6_!7@#]BJ/X9_P#!-?Q;^T5XH\8:I<:YI'QQ^/O[:7A'X!?M+_M-?%35
M?$-W'H_BGQK^RY^RM8> ;[P9XN\6Z?J_A3PE\5?CSX_URZBEE\#++#^J/[+&
MA?#CX7?\%+]8^"_[(_Q=^+/Q)^!_A3]C+Q!XC_:[T[Q9^T/\3?VEO!/AW]H7
M7?BY\-[3]G#57\4_$3QQ\0F\%_'#QQ\/++X]^(/'OAS1]7T?^W?!5MX)\1ZY
MX4B-UH&H70!^OOQ5^,GP[^"^F>&=3^(>O'1U\;^.?"_PR\$Z;::?J6MZ_P",
M?B!XSO'M/#WA/POX>T2TO]:UO5;B*WU#6+];"REM]"\,:+X@\6Z_<:7X8\/:
MUJ]A\KV7_!3/]B>?X]K^S7'\9W?XFS_$MO@E;WA^'GQ4'PDN/CE#83:C-\#[
M7]H-O!/_  H2Z^,L4$,T$GPPM?B3+XR&JP3Z$ND/KEO/IT7C5I]G^*O_  5H
M^)>L>-M5B;PK^P5^Q7\&=8^'&DZI/##H?ASXG_MH>.OV@K;XK?%>X,OEK#J>
MD_";]G/PIX!T/6[R>0:#X<\5_$BSM+B&V\3^(,_%/PB^(7[.G_!0'QY\&/A/
M^S[XI_9L^!?[ /PJ_:.C_:(^&GP^\+>-/AI;?'_]N;XY?"GXH^)OB]:>)O G
MPETG7YM3^$?[.%C\;-*U7XQ>(/$'B/0W^,OQTU'PRUS'HGPX^%5U>^(O'CL^
MP'[L_"7XY?#3XXZ3XKUKX::_+KMCX'^)GQ'^#WBX7&DZQH=[H/Q(^$WBS4/!
M?COPS?Z9KUCIFHI-I.N:;-]FOTM7TK6]*GT_7-#OM2T?4K&^G]1^U _=BE;Y
MMI(7*CC))<$H . ?FX)YP00/RQ_X)C7A\3W'_!0KXIZ?"Z^ ?C#_ ,%+_P!H
MG5_A9<IB33=2\._"[P5\'/V:_%OB+2I558I])\1?&?X&_%+5;:\MS+:WTDD]
MU%+*TDLA_"K_ (*-_M!7'Q'7]LKXZ?#O65\,_$WP#^TA;_L7_LU^)/B!_P %
M(?BE\-/C9\+OCUX/^)'@CX()K?[-O[#_ ,#?AC!X/M/"UQ\0M6F^(NJ7/QO^
M(.J>,?BGX-GEU[QF]M\'-1\.: C:[)_UVMY[W _LC$T;LNR)G#,5+>7@ CJ6
M)'RJ1\RL<!AC9N+*#Y)\ ?CW\,OVF_@[X ^//P9UB[\2_"[XH:+_ ,)'X'\0
M7.BZMH+ZWH$E]>V-KK$6EZW9V&IV]AJ+6,EWIL]S:0B^TZ:UU"W#VMS%(W\S
M_P"V+\</A+JG@'_@K_\ M%_M&_M-^.O /[1W[*_Q ^)7[/7[$7P;\*?M%^+?
MA1XB^$.MZ%\"O!K? ?Q#X&^$G@WQ5H5IX]\??M2?%3QM-XXU7QAXS\(>--,U
M?P#JNF>"VBM_ G@_Q-:S\)\5U^ O[-?[+_[>%A\>OVH?%_@KXO\ _!-SX-_"
MO]D;]AGX2>%/VC/%7PI\1> =<\ ?L'?!'4_A1\0/AI\(?!_BWPO'X_\ B#^T
M=\<_&GB"8>*O&7AOQG9:YX.\/V'@JXE7PQX:\9Z>%9]G]P']$FD?\%"OV6]9
M^"_A[]I"'Q5XMM/@!XB^$'Q<^/$7QHU#X5_$NU^&^C_##X)ZK::5XPUWQ/XK
M/A1]-\-WVI?:QJ7@#PWK$UKXF^)>C6NH:IX"TCQ!:Z?>/#]'6OQ6T2[^(-C\
M-XO#OQ%75M1^'$/Q/@U^X^''C.U\ )HT^OVWAV/P_=?$&YT:+PA:?$(75TE_
M-\.;G5XO&=MH4<^NW&C1Z5"UU7\B/[0'PT\,6G@_QE^Q)XZ\4:OH/P3^$FB?
M\$+?^"0D>D7'Q3U_P/\ #*#Q_JOCS1_VHOVL_&&HQZ!K7A[13XEU']G_ %;P
M-H=UJJ/Y^KWL2Z5?S36I;35^COBWXXU&+XJ?M!:/I/[0GQ%^"7[(?B+_ (*)
M_L;?\$G?$WQ$M_BWXQTP_"+X _L[_LI>(?C+\44T3XM:YXKGUSX?^,/CQ^T?
M\1K/]E?Q;\9O[<C\<+=3Z?!)XMM_%\>G:CIA9]F!_5&;A=Q#02Y";QNCY8;@
M,+GJP!#;"0W(109"46*68EHW$<JJ04!( !9E#<88@[0&PQPC$?NW;*%OY)/B
MIK/A;PA8?\%!/V?_ /@GK\8O&NG?LS?&I?\ @G9^P]\/?%7AGXR?$OXO^$O"
M/[=G[4_[0OC;X=_M":Y\ /BAXC\:^,_L7B+X;?LT^+_AWXP^,MOX/\5_8M&\
M=:):3:P+#Q?:>)S7HWQUUWPA^R'\<O\ @H_IGP=\9?'G3/ FA_L__P#!//\
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M$#..PR.!].IHCR)BI).-_<D=B.#Z!L=*M+T'T'\JA6-Q,7(&T[N_/( '&/\
M9_6@">BBH'#A]^XB-<$@-Z#GC'<X[^OK0!/134<.-PSC)'(P>*=0 4P_?3Z/
M_P"RT^FD$LI[ -G\<8_E0 ZBBB@!CNJ8W9YX& 3_ "J%$MW)"ISC)R&'!/O[
M_P JDE$1 \T\9..2.?P_SS4)V@?Z-UR-^/FXYQPYQU]* (W$L1RN0I<J,,"
MG)X4YZ!0 .:8R',C1X9GYR2Q+$ X)4*Q!!R>% R!D 9I^Z63*MEBK$[<*" "
MZGI@<94'FHF0 _,&!.2VXD$;<D[ I(( &3NYVC(.>*J._3;KMN@&["=J2RA)
M74YC5AD$$_,H(4\<.20">2,C&:I'EN%WK.V[*I,-K/CDN2K*"AR,_NS@8#*>
M]T @*5#84':<@':S;F^5D+Y.3Z=<@JN"(63YF"3 [F#*A^S!P<#:H8H1E,;4
M:0,1R3D=;3U?5?<OO7E:W5]] .?U;PWX=U._T/4];\/:#JFJ>&KB6\\.:CJ.
MFV6I7_AJZE@6%[O0KN]L+FZTF[N(T2*>YTZ>VEE1$660A0:UI5"1J/+!1(@S
MGS6C51& 0H9?E&U>B@\=,<8$V9RLK/,!)M(95(91E< ?)&593QEB$YR#A0#3
MX8G:'#.KJF2HVJPWL#D/@$;2"3R<AB,$=W>RN[=$WK;7MIW_ ,WJ!G03[S+Y
MHDV$QLD8\UV4C?D$IN!(R.5)SSV KS#6/@[\._%GQ5\ ?&K7?#@U'XE_";PK
M\3/ WP^\0/J>K*GA?P]\7KCP/<_$.&WT@:BFB2WOB)OA_P"%;9]1N=-;5M/T
M_3;NUT^\M$U:^CF]:5%AF@*Q@AY$16+/N =E4.X3,> S8&>[8X!Y_&;X:?\
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M:P_"S7=*UCQA\#+;Q_;6=_IWCWX@>#?#OC&]TN;P]X=\17'B$ZG!HO<?%?\
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MC2=,EMUBEL;0Q?.7_!/[X0_"SX4_!W58OAI^R?\ %[]CJU\8^.-3UK7OA/\
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M":_-']K#]O/X@_LU_$GX]>&(_#G@'7O"7[+O_!+OXL?MM?&/6KK3_$?VV_\
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MKIUA\,_CEHM[I'A/5/A?XMU&U\*_":Z3XIZWX.N?">E2Z#?WFG0O^"7[:?\
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M"0.F*C?;$H53&#P68DDL1N./ER<9QMP!DX!ZD4TKNP"L@92KNCR%L>8/E)4
M$996'( V$@\].<YJ!E9#G?(0"#N$C;1R"?E5"A .<Y//\7>G>:0"& ^^%4;1
M$SY4$[5D8CACCJ<@9P"< \X]EP 03N*?+@C.2KC SZ#(SZUJE;2[:MU_SOIZ
M>8"-,Y5E78=RE?-PI?C)V[=RY !!+;3P3PV-M+Y9" 2SA"<'E(V/L1E?7/'/
M'7U+78R-DM&GEJ#EF+_?.'4H7\S(0 @_*H.2<X-%T@GA .XD(&1HWVEL'&5'
MF*<'(R""0#C=R<K:R6EWK;IV_KHNP&%XHL];O?#_ (@M_"NI66D^++WP]K5M
MX<UG5+:;4K#3-=ETVX@T74K^PLIH)+NSL-4GL[RZM8IK:6>WMY4AECD"R1_E
MM^R#_P $ZO%G[)K^']6TKXC^$M>\4_#3_@G'\!?V(_A1J)\*:]%;:-X_\#:S
M\4?'WQH^,>NV=SKT\UW9_&?XI>*/A_XBO=!TVYAUD:=X"M8-4U*[U-HKQ/UD
M E/"RK%(6&Y48>:&7.%9LG?GYB 02 ,@\G'Y!_M*?\%7_A_^SY9_M >-D\(V
M&N?";X%_%OX7_LI1^.]4\3ZEHH^*?[8/Q,\7^&=,\3?"?P1;Z9X7\3N_@GX
M^#=?3Q!\9?B"\5TT7BBT\0_#[PSI-YX@\#^)TCF26KO?;]%Y?*UP/J[]G_\
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MP'J-Z^GZ;\0O&]QX8TS7+/X??#J]O+>[MK?X@>.KOP[X/GGLKY(-8=;*ZDB
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MGX1?$+6?#NG?#GXS0^#ILMXCF^$_BOQF-#VR2:B]I:P2W@ -;0?V,_AAX?\
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MXD^*.M?##PO^S19>#=6^/.G_ !I^#WQH^"OCWX9:%\0[PV/PZ\1^(/A?\4?
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M?$;P_P""? -@OAK7/C_=>+_"/@?Q-??%/Q7I^J&*3P7I>@^&O"OAKPW>^(]
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MCH?A-8#5H-034)K&S73+S5=/X(_\%8/V>?VB/$?[-.E> _A_^T18^%OVMO\
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M9_\ @J5X]^)'A']F33?V;O@K\?\ X6Z7^V=^U-^SA\*?V8?VHOB5\//AE?\
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MI\31AGB+-N *95G0,P R63?Y9/3)8$'JPP22OEQ6X>0@,N<DH,#YV!^4#=D
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M- ^)OVI?A]\<OCRGBVW^(/\ P30^-MI_P5%\&)\3O"'[,'_!0?\ 9-USX?\
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MH;QG\5_#7B#5_BEI;_#G6O$D5I;V%EX4\,_#K1=#\->(M8\:2?U(O S,S!P
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MTH _GU_:=^#O_!1K]KC4?C-X[LOV;O!/P#:'_@F?^U-^RS^SUX)\0_'?X?\
MBSXCZ/\ M#_M:>+?A'H7BWQOXHUSP<MWX*\+>%/!/@7X8V>J>#QH7B;Q)<ZO
M9QWTFIV>DZ_J-KX6TW*^+'[ G[0^M^'/^"GGP ^'7PQLM#^'W[4.@?L!_LW_
M  -^)/\ PL;P79: O[%GPX\&?"SX/_&KX<W&B)J$7C3P]XJ\ >%]<_:B\7K;
M7/ANST?Q+:>-_#^E>$=5O];FNX+;^AK[,_'[P<=/EJ6.(HQ.1R,<%^>0<G<Y
M4?\  5'7C XH _ SQ1^SW^WM\-M,_P""B7[.7P0^"WPV\6:3^WA\;_BK\2?
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M+.&.>\&M67P_T[54:"TGTZPB_5N-"B!2<D9Y]<DG^M/H _&7QS\*OV]?@_\
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MY8?"36H[WXB>#_A]JWCOX??#WQG_ ,+/MO#=[X.TKP29;;2M5L!IYYSX]_\
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M2Z&B6SQ/<_JQ):12QB*0*-N?*(+'/ PARD??H1D^N,<P>2L>412HCVJ4\L3
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M9 -[^9GS&'RA=OW>/EQG_P"MP!2/"(\%F!W$CTQ@9SU/T/IQS2 ?:C82@QM
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M@V=_XGBO;RYNKZ[@U6:XCN+Z[N[N<S7=U/.\RBV[K9@?AY\-OV@M>\"^!_\
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M:7XNU'1]7\4:5;2^&]!TRX72O$VJ^'?#M_KVFB46NI7&@Z)+=1R'1M/$/*^
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MDKZQJ!N #^6WXY>+?CO\%O&?[?'PT_98^,?Q-T+X7_$#]OK_ ()W_L)/X_\
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M  SG.>^WICN,5-10!!##Y8(;:Q..0.>  <D^I&?K1'$RNS,000>.>I((X/'
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M<\]/Q].PJ>@ HHHH K*SQ%C*3M/"C.[N3V''']?PL@Y /J,TUD5\;@#CIFG
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MCG^9H ?1110 4444 %,6-4)*YR>N23WSW]\_F:?4<C.JDHN\CMG'^?\ .>*
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M!05CXY'S')XQSU]<GZC\6EP8_P!XRKY@.W:H'R9!!/J2".#TYP3FF @*%)&
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 A. 3Z G\JBAD:3=N
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MN?IBFK7UV]6OR3_KJ Z)6F"-)P3TQ)M=4Y)'R\Y)YR.JX' SF,PK%,=LRAR
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M1J*WQM;']_KG/\*]ZL=>M( !T 'T&/Y4 +1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 53<@9^3H2/O+VJ2*,KEV
M(9G)((SPK'(').<  9XSCI4FQ/[J_P#?(_PIU !1110 444U@2K '!*D ],$
MC /'- "DX!/H"?RJ.*7S02!C&.X/7G_/_P!:EB1D4AB&RQ/4GC &/FYZ@T\
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M,/KUX_\ UT@,'Q(1_9UQSC;)$23GC<N!TZYZ'L,\UK:60=.L\$$?9X\$=.%
MXK(\1?\ 'A>?[T%:VFN/L-DO<V\7;C[F?IT% &A03@$^@S101D$'H>#0!&DB
MR9VYXQG(QUSC'Y&I*:J(F=J@9QGKSC..OU-(\BQXW9YSC )Z8ST^HH ?10#D
M ^HS10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !4<JNR@(<$-D\XXP1C.
M#W(XQ4E% #4#!5#<L!R<YR?7/^<=*=110 4444 (<D$ X)!P?0^M11+(N[S&
MSG;CYL],Y[#&<C_&I3G!QUP<?7M44(E&[S,]%QD@^N>GX?XF@":BHI1(=OEY
MSDYP0.,>X.?\_40[;GU/_?2?_$T 67<(-QSC(' R>:;YB[/,YV_3G[VWI]:
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MH22.6KDXPOF,6<$ D;%PR@'D#UYY.1CO3XH2S-O#J.<?PC[YP ,8'&,  <9
MXXI"&B<E 0 W#-M(Y)'0'=U8XXZXSQ0 ["1+SS,-QV MU<DCCIPK>W3/7-0
M ,,$[A@[EW 'N 6. X&,;,LV!@]2*D+%F)()+'L, D#!VY/8+SSV-.VJ(R69
MU;+'8"!O'4*00W4<97#'G!S0!%@C..>5)X['A<Y/?;M..,#GD\H&+,57RRR@
MY7!C.<]=V"I &#M*MGDJ1W4'()P54@ [@Q)V$MDD@8 W<\8QGFAV!C()V[<
M%4#-C:3DD$X.,DGN.GI36ZZ>?]?Y@1,I(!1W?)8DJS ;C@\].#D8 X ' &:!
MY3G(+2,!OS(IRHYPN2!NP3R#GCOTI8U95;<1M(!1.%(P,8D?.%S\NW."0&X]
M'@$Y^9E;&0H!E7CKRHP3Z*60]/F[G2336[TZI*SU7]=O4!X!4 8 7=D88, <
M$X&%! QGC<<=,=")5QM!C),V!D<G'(W<'C\*K X "JZYY((.W[IP<<[6SVW'
M&2.<YJU"K"0':VW# -U!!/RG/T'7N:R>G6_W?HV!B:Z"VG71<<MY?H/F1<'I
MZ.5'X^F:T-+<&RL,D9-O$?SCP,<#U%4O$! TVX!.,2*3TX#21XS]1DCZ&K.C
MKNL-/9L[OL\0(Y !6,@\?48/XU6G+U^+IWMI\NX&U2-G!QP<'!]\4M!&01ZC
M%2!! [ONW$' 4C@#&[=GI]!4CQK)C=GC.,$CKC/3Z"D2-8\[<\XSDYZ9QC\S
M3F=5QN8+GIDXSCK_ #H 1G2,#<0HZ#\*<"" 1R",@^HICHL@&2<#D$''4?X4
M\ * HZ  #Z 8H 6BBB@ HHHH **** "FLZH,L<#.,^_^13J8Z!P V>#G@X.<
M$?R)H <"" 1R" 0?8]*6D "@*.@  ^@&*6@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH 0D*"2< =32*ZN,J
M<C.,^_\ DTK*&4J<X(P<<&FH@0$+GDYY.3G '\@* 'T444 %%%% !1110! 3
M-YN /W>1S@'C:,\YS][/X<^U3T44 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !54&XWJ"#MW_,=JXV\]^O/&.A_6K#.JXW,!GIF
MH8I'=RI((PQ&!CHP .<G((.: %=W6(,3A@?FX!XR1T^G/%$2;MLK9WG.3G [
MJ#CI]W%2.@D4JV<'K@XIRJ% 49P/4Y- "U6E1O,5PK./D'# !<$G=@@EL9R1
MD \8&:LT4 55C=P[2@[QPG.T$!0?X<<;B>3SSCM@/A1T#;@!DC&"3GKG.2?;
MO1(TJL BDK@9.W/.3GN.@YI)I'0@+CE2<$9Y!'N.N: +%%-5U;A6#$=<&G4
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MU-("#R""/4'-(Z[U*YQD8SUIL<?EJ5SG)ST [ =!]* )**** "BBB@ HHHH
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M+&A0%2VY<Y7C! [CJ>_/&!["I**0!1110 4444 %%%% !1110 4444 %%%%
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M@#MWZ5;J*)&0$,026SQGT [_ $J&YZCK]QCU/8C'\Z +=5KG&$SC[QZ_0_\
MUJLT$ ]0#]: (-GF0QKD#Y4.2,]%';(__5FH_+\C]YD/CY=NT)]XCG.3T^E$
ML@8%,$;6QNR /E)!Q@YYP142,$8'[PP01NSZ8."<<8H M>;^Z\W;_P !W?[6
MW[V/QZ?XU%]JQDF,< GAP3QZ +DGT'K3_/&,>6V/3Y<?SIZNK(S[,!=W!QGY
M>O3CUQ0!&+@%D 0X8@?,=I&6Q]TC)]?S'!!JS4*D3(^T;3RH)QP=HP<C/3(_
M*EBC:,,&(.2",9XX]Z ):*** "BHDE#L5 ((!/)'8@=B?6I: "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@=+LGR055L# P0'<>F>15+EY7??II_P0-^BBBI **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M% !114'VB,9R2N"1DC R.V2>O^!H A,GES,Q)(!(V[O4#D G'K^?M5M'#J&
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M7#EATSP21G.?Y  Z.BBD.<''7!QCKG\>* %HJ&(RG=Y@_NXX ]<]/P]/I4U
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 0,)?-!7/E
MY7/(QC^+CKT]._KSB>J\AF#G8#MP,<*>>_4@_P"?Q,D1D*GS,YW<9 '&!V!/
M?/\ G@ $E%%% !48BC!)"#)Z]_T.14E01F7>P<?+@XX4<[ACD$YXS_B: )P
M. ,#T%56D*3'<Q" \C&1S'GTS]XCOC\*FE+A?W>=V1T /'?KQT_&HUA#@-*#
MO.=W..A(' .!\H'3\><F@!['S(F*<[@0,\9YQW^E,CA!'[Q!D,Q7G. RJIZ'
MOCO_ /7J95"*%7@#.._4D_S-.H JO"1(&1 R!<%"<#=G[W)Z@8^HST[VJ"<
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M36=4&6.!G&??_(I00P!!R#T- ",P12S< 8SWZG'\S59O-EYC*M$=P(Z-C8H
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M@!L@YQS@CK]":<@4*H4Y4#@YSQ]:BGSM7 )^?L"?X6':D#,D*$+DX P0?QX
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M$9^ZV[KGC.2.AXJ:D 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MQSSM&QLGC.<>@/)[@<TD,H)6-1D '#Y SCG.WG&?3.>_K0 .GEL9LY(.=I
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MBYVG9/,3MY&"23C..>3U^N3FJ7POU7Y,#JF.U68]%!/Y#-,1Q*C$#'5>3GG
M.<@^_K2HZR*2 <9P0P&>@/(Y'>E*@ A0!D'IQDX]OYU $<,;1[MQ!SMQC/;.
M>OKGM4U0PQNF[>P.=N,%CTSG[W3.1TJ:@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@".5"Z;5.#D'G/0=N*6-2B!2<D9YY[DD=>> <4^B@ HHHH ****
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M%(8D@'( (&21SSGMZ<T -EB:0@JP& 1SGUZ\5/4$L<CD%&  !!RS#GUXR/\
M/?M/0 4444 5[CHG?YCQZ_*:IR(3Y8$TA:0DK\V ",YW# R 01CUQVS6DR*^
M-PSCD<GKZ\&J!C*E24*X+*ASR <MTR?U[]/8 BE<JD4;?.YXPR_? (P_&X*H
MP#\Q&T$$KQ2S%%#%DC4#Y0V7+*2/E  ^7J0, <#CJ*>'V_-C=D,"&.&+$<%
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MS2LVF^BZ?UH!TT90J?+&!GD8QS@=C[8J2FJBH"%& 3G'/7 '?Z"G4@"BBB@
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M2 N,Y!R"=W& 1SW]* *;+NW*_P Q)&[)SG@$<\=L>G2G D%<LQ564XZ@ '/
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M!!'J#D>G\Z %HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M&!QZY/7TJ:B@!JL".HSCD YP?\^M.J*.((S-NSN]@.^>W^?TJ6@!DB"1=I)
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M&!@8>S'8IC60@J,Q1E0#DD$E6&TYY!R<$8SCNC$F(G)CP<[0(3@A2>0JJ!@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HIKNJ#<V<9QP,]:4$,,CIS^AQ_2@!:*@(E\W(/
M[O(XR.F!GC&>N>]3T %0R/&I ==Q(./E#<=^OZTDHF+#RS\NT9Y4<Y/J#VQ2
M)&6SYR[B#\I)!X/4?+CN* +%(0#U ..F0#C\Z:[JF-V>>!@$_P JBAD=W8,!
MM R"."<G@D8XX'3/!SG/&  ,L2L1L.5)7(0>N#@^E!0-'^Y4)N(/R@)D9YS@
M=Z2:- NX90EN65=Q.<\8) Y/ZXXJ .Z@ .VT$ <*.I '&#CDXQGWZ4 78U94
M4,<D9R<YZDD<]^,4K@E6 ZE2!VY(..?K53=*2J!FW@G=R,'Y68#)&.!C/ _/
M%2!V52CD^:<[>X!;A.0,#G% #XU,:,9.2"6SG<0H [D#N#Q3TD60$C(P<$$8
M/3/T_6JA:1&Q*QV;06&0?E^?=T ZX ]>O'2IEDA0?*" >3A6[$CGKCD&@"1Y
M%CQNSSG&!GIC.?S%1PQLC,6P <X .<#Y=H_##?G[U,R(^-R@XSC.>,XST^@J
MO+,"!Y<@)!.X*03C'<<]QC\<=Z )$>-F(5<, <G:!GD \]>N,_K4U4A%*#&R
MC!.XR$,N2"00/?\ #'X5960$A#G>!@\'&0!GGI_^L4 24R0%D8+U(XYQSZY]
MJ) Q0[/O<8Z#N,]>.F:C&]8F+D[@<DY!.W(],=LT .C5D3#Y)!)ZEB1V_3C'
MM49+R$O"Q^7]V03A#W++U!89'/MCIUB223,8+'J@;I@DM@]O0CICG-6T1(QM
M10HR6P/4\D\^M #(4= V\YR1CYBW&.G('^34U,>1$P&8 G)5?XFQUP.IQGG%
M/H **** &/&KX##('09(Y_ BA(T0DJ,9&#R3G\R:>2!U('UJGYLI)"X;!/1,
M\ D9/S=\?X4 /D,ZO@99#D@@*-O)PN,$L .3G!(7[P)P8C-,1D,A 902HPV"
MV#P<CU'#$^GLYC.R[6CRI[X)+=<AE!&W' &6(;D^F5C@B2$ @QK@97.T+\Q(
M SD@9/ )SSB@"$EG.>2S%>G!)"#/H ,@[O0 XYQ419R0HQY8)$@,6Y4<\CRM
MWS$^A9&'."3C(LLL0!*2 N/N[FRO/!R/H359B44MYK3.%8*(PK'=V^8D#CHN
M2H7/)QDEQW^3_KR]0'+M.55M^WYF&U1M_P!K:H50P"@AL%^G&-M2K)#&&,KJ
MAW90DE3G:!P1R1DXQTSU]J<9(<;2B(^6=61Q(7(Q]X,R'< !][:3D_WC4TB[
MQMWB//S LTB@XQD81E!XXRW(/?I5\BWN^[T_X'Y?,"10Q .&;(ZDC\<9(/U^
MGM0JD@*@+ 8.!C/W=H.20>@_.JA>1E48.%?"A000A[G!QVZG@8-7$=D9@""P
MX9L$CCH ,C!Y.>>WO2>D6FT[/3OOI?7S[??N (L>\&0 8!"G;A@P(XRO.<!N
M1COSTH*EG94)X9F!.<MMQD$GDY)//7BA/+9L.V  S9SCYB0./P9N!GCGMFG'
M>CED!(R=K8!4AL$]QGG)!_I4 /EW"SD&TJPB8;>">X]2.>O7C/;MS7A-9EAO
M1*, 7[[1\O3R1_=YZYZUU$A9K9R?OF-N .=V#P!SD^GK7.>&&S!=;R0WVX\;
M<#F($<_[2D\YZB@#JZ1LX.,YP<8ZYQV]Z4D $G@ 9)] *;N#*2A!QGD<@'&?
M\* (X3*=WFY_AQD*/7/W?PZU-4$$C2!MV,@\8&/E).#^('^3FIZ "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BFLZ*<,P!//
M)Q3J "BBB@!KHKC:PR,@XR1G'3H0::&13Y8;YAG@Y)Y^;K].:DJ/RUW^9SN^
MO'W=O3Z4 2444UR0K%?O!21QGG!QQWY[4 .HJ*)G8'>"#NP,C;Q@=LGOGG_]
M0>SHOWF STR: $>-7P&&0.@R1S^!%,C$(8^7UQ\P!8]_<GI[5(KHV=K XZX-
M1;/+8% QWD[B?FP "1],G_.: '3 LF%!)W*<#V.>^/2JICD/'E^^&("G'(R0
M<]N.Q/!XZ21S/E1(RJ,'=D8(88!'7KD\\=JDDF4+\CJ6R..O!.#QD?6@"#9,
M&W;2'SG*[2O3;QN//R^HZTC)._."K@9#D+@E3E1M&1Q]!SW(X*^?*3@;,9Y)
MY)Q_=4=.>#O(X!*DD@4]9)F*\94L 2$XQN ;G)Z<Y./\: )!&)1F5#N *9)P
M2,=<*0!G)[4CI;J0'&#CC)?H23V/J2?7GTQ4Q=00I8 G& 3R<G _,\5'*L9(
MWL5(!QAL<=_Y4 2*Z/G:P.,9Z\9SCK]#5<FU/7;Z\;@?S&#4T<:H"5)(8 Y)
MSP,XQ^=,^SQ^K_\ ?7_UJ %D+[%\K.<CG )V[3V;WQ[TBJJ 2R?*Y'S$D\D]
ML D?@!Q[5*2J ;B . "3[>OKQ2,JRKC.5.""I]/>@")6E:4$',1SCA<8V\'/
MWNO^<<5,X4J0WW3UY(XSZCGGI3&!CCQ&"2N !C<<;AGCOQGTQ[4S<YA9G&&&
M2 1C[I!''/I_AZT ,,9$B[%.S,9R#D<-DGDYZ?R],5:;.#C.<'&.N<=O>HX2
M60$XX)48&.%X'KZ4YG5>"P#$< ]><@<?6@")$9P?.7+ _*2%! (Y *\C)Z\\
MC%6*BB:1@?,&#D8&W'&.>YSS_GFI: "BBB@!CQI)@.,XSCG'7@_I38XA&20S
M'(Q@X]<CWXY[]Z)9&0+M .21SGTSVJ'[4#P%^;L#D#.,GJ ,<'H?YT 6ZJ3.
MS;T"X0<$D$%B,%0I^Z,L ,D'@]!@U95LJ"Q4,0"0#P#W'/I5664DLA"[<CGD
MY (/7[O)&#0! K*"#\A89RI8Y]-I4+C.#C=N SA\8.VJTR@'>J OD9QO;8>>
M,J"I*],[L'., 5HHF$+@C#'  &",/MX=2KX[X!'ITJN6."V?FP#_ !.0/HSE
MC@'^\ >,8IIV=T D8&U\@9R,'HW+%=N1@E0 K;#E3DD@AJ5F5?O%.>F]MN/I
MV]\_X4$$+N<D+][.W&"-I^8;FX^4<@G.3TQFE)&W.8V5@6# !@BJ#\S[NBGM
MCN<XZYT3TN]VUI=Z6[/Y7>V_7J#%V ';N *X^<]>N-O &.3G\/QD'EN6"R-D
MDLP,3XYP./EY'%11O'*H9D#,1C]YE<CLR*#@(_.,<G;\W.,SQHKDJ2,  \YX
M.2,###I[DGIGUK.7Q/\ KH@$15<[68J,$@[V.2"!T<D#()X !'3@9!GD"B)4
M&'QC R22!W^7G SG/0=/2HI8Q&FY=TA! V@*0!_>;/(4=SDGD4T,48,,$JI0
M<'!''/ SD8QZ YYI 3G(MFP-I$;8&#P><#!YX/YUROA4,L5XK;ODOA@L/F.Y
M ,'@# !P,#@ 5U4K;K61B=F8V)*\X]AGOVYZ=ZYKPLHD@NWWLW^FLV3UR@
M^G/M]!R* .M8;E93T8$?F,4Q(Q&I4$G))R<9&0!_2I** (HXA'G!)SCKVQG&
M/SJ6BB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@"K.KLZ$8"J,ER-P&"#C:"&YQUZ?K5D$'H0?H0?Y4$9!'3((J..(1YP2<X
MZ@=L^@'K0!+1110 5#YC^;LVC;G[V&SC9NZ_=^]Q^F.]34R1Q&A<C(&..>Y
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M'8@]^.U0_9TZ[S]<)_/% #(Y'4A% *EQDX;C<1NY''&2>3QWZ4LW^M7Z1_\
MH;5/&JHNT-GDGG&>?I[TCQ!V#;B" !@8Q\I)'4>IH EHHHH **** (I8S(
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MG)Z=!R>E %N.3?GY67&/O#&<YZ?3'-25#%&T>[<0<XQC/&,YZ_6G22%,'8S
M@Y(Z#&.OIG/Z=Z )**0'(!Z9 -+0 4444 %%%% !1110 44?UHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M((5*DG>>AVM@].>:64%( #\Q!7IGG!SW_K_]:@"3S"8O,"YZG:3V#88Y /0
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MA#X?^#U:"UFN-.B'H_PW_P""H?QN_9[_ ."?/[ ^N6WBW]FWQ7XV\6?\$^?
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M*! X. H'S87[IP.A(Q\QQV--63U_3]?N >NX )(<2.!V ^\2H("EAQUSD'U
MP*=LV C=OR">O((&.N,\AOI[4K()3D.%"J%<<;AMR3C.!D Y'4$CT%-79C*B
M0+T+/QN(/#+DD#'/H#QUII^]S-=6[ ,1(B656:0Y (C!PN<]> !GL!@';[5"
MT4GS,ID.9&4 ;$ 4#.-K[1U!Y )]2>M6F^9BS??3KN'3(![>HP?XNQZTXJP<
MN6DVOCY'7 5@#DJ>3@\X'8'KR<M3[W_KML@*)B(3$J%A,V"49DD;;RH? =%
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M\BXDD8^7C.<@Y)QC( S_ $SU-.P[N4<-Y>YB,#:."=OS#D^OUITJA8@HZ!E
MSS_$* $:8."L1.\XV\8Z$$\D8'R@]?PYP*<!)Y3A\ER& &0>HP.1@?YR<=!
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M 6 Z'&&4YZ8(.>,]O;D^Q'J*4LH )8 'H20 >_!/'2JZVZ[-I9BK*01P"05
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M_9U(1\%_NAE+X;^\Q!!"XXZ=>^.*<@,Q$C?*58# '!"D,/O#/4D?A3;GJ/\
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M1GG]/?K4R-O4-C&<\=<8)']* ();<2%B6QNQ_"#C  ZYSV_6ID38,9ST[8Z
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A)P">N 3CUQ0 M%1Q2>8"=I7! Y(.<C/\JDH **** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>ex10-69_005.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex10-69_005.jpg
M_]C_X  02D9)1@ ! 0$       #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" 2/ X0# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M2,"_!VXS\F5'S$'+JZNO'"YW;65@(+IT-E+&V[(418  +2O\L<:ABIWR,55
M0,LRC@@[?YZ/!OP&^,NJ_$'2_BMKFN?MG3>*_'__  5S_;*^$/C6RO\ XT?M
M$P>#M&_8D\5^'_VH/"?AS3-&^&DOBR/X>^%/A DME\/?&G@#QOHOA2PO/#_C
M.7PSX@\+^*K*5+%1XOJ_AG_@H-XH_9P^->L>,+[]HO0O$?[,E_\ LI_\$_\
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M/>,/!'AGPQX3L;M+&YUR_P!<\6^'M%TUK-+N2*!!:W-Q/.TT3P0R1R*YFO\
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MVFO@CX?^%/C;XX>*O&H\$_"KX<QWLOC?QAX_\/\ BGP!:>'DL(]/DN&O-/\
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M7--^)OB[Q3:W#:GXT^+.@>,-4\10V&AZ]8WWZ#Z[^V'^UUXMTOXO?$?X<?\
M!-;XSMX6^%OP0O;OP=X#^.+?"OP/\>?C-^TIXB\8^$QX1^'/PZT?2?BCXO\
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M-8L?#\=E;?$;4X?CCI7AD_!'Q%X?M/AE\&$\4>!M:U#6X #^@BBBB@ HHHH
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MR<9J6B@!  !@>_ZG-)L7=NQ\W&2"1G (&1W_ !]!3J* "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** (C-$"07
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M<8QR<9R<],X'/%1RQ[0"N\E\DC!.,@GH!Q\Q[\_K2_:'_NK^3_X5+%*TA(8
M8&<@-Z^XI 3+T'T'\J@NAF"5>?F1P<=1\C'CWR!5BJ]US"_ /#'D9'",>GX=
M>W6@##\.$FS.1C_2'/XE&+#\"<>W0\UTE<UX<_X]&' "W4P '3G>>/0<=*Z6
MF[7=MN@!1112 **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@K"NFH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M9)BN!GY1>2;1Z H6 'I]XY]S744 %%%% !1110 4444 %%%% !1110 4444
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M>I/4\8_D *<JRE24<A<M\GR\X)R,D9&[Z\9J-L[0P0LN1UX4\X.6!Z#KP>H
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M."VY#QG )SV&!Z5<I"0#@D GH"1D_A2T@"BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M7).><]*L4 %%%% !1110 4444 %0NLAD4J3L&W<-P X8ELCOQBIJ* "BBB@
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MDE@-H!)/7'!'.>HA$RQJ XCW#:,LI9"5RYP0&4@\97G/0T.0?D,A'((3:H&
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M F+S$WME2 5!4L,9(+AN,@\*3C@=JD/3YL')'88SD!3C &> 3Z')I, @\9W
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MVEZ-8Z5I/PGMIM N9];\.V$MIIFGM=&\FU#3XKAA)=69ETLSVQ5KF=IOA/\
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M&O[+34\,0RZO)#9ZAIT_V5\$?V2OCYX:O?C!XS_:!_:S\5?&[QY\6O U_P"
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MFF9<78K"XE9MAZL\?_JKF>)P]/-,16Q6.J4L;7P$*ZI<R7P?^S'X9NOV8O\
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M65?L_P  /B], TCJJR;9/A@[ HI)A7[J$JDYNAF6LN3]O3]H^4JB_P#!5/\
M9 1PX5H[']F+XH7:EAD!6=O@U<A=Q&6(1 .=N!BOPTGF5RA62/S6DD8AI2_D
MR0EFEN&WM'YB%U/^LD2!BX?[X13#'=2"-P[PJZ2IEXY$7Y6RLJ[)KB21@LA
M)A(^<E%STKKH_1_X&@W?+N'Y+E5K^&WA-5L[[\M;(:O+OVO]F^AYS^D)QG=V
MEG44YRC"4_$'Q/:DTW:,8PSF%I\J4FELM+)+3]U(_P!O#]HYD63_ (>J_LC
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MS'#$JDAC1=Q"LOW3) UP9+I'(.Z.*5BLK11DER1D'A64;\ LX4-\CMN;%4_
MW@I7O&*VVX8\,HM[]9>&]2W1>[:^E[[I+QIXU=2:C%3A%JW-Q1XC23NKZNOQ
MQA[WM]B_FUI?];3^U_=M'+YW_!77]LIF5E<&']C?P[:G[-%)"S@*/&9)=%DV
M2R+(C,GF&2!WC)%.7]L.T0()_P#@J-^WU=R&.-S]C_9M\%:;YN47;MBN_B7
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MBA=)%=3!\US\2MJN3O <H5E&T9VJ,_F;).D,$L8EE9,LVUQ,&\QD"LTX#R,
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M5J%_JG"ZIM3Y;\(91*<FE))<T\5.4FY+E:;;M[JL?8@^,/[(;R&1O@U^V9<
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M\NW#M&0'8[=H5P^+'[),*C;_ ,$R/A @F6-B!^U7^TH,(-RHY\J)&#J,JO/
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M_AK3_#NMZEXEMKJ"*X%S!/X9TZRN=:MYH4E@:X:>PC,*S6\EPR"5&;/"</\
M".886ACJ&89KC<%B,!3S/#XRIQYQC4PM7+ZD'4>-I/&<=+$4<'3:<*N)QM/
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MOOU  Y''+9]/H*G)P"?3F@ IA^^GT?\ ]EH219,E<\8SD$=>>_M0?OI]'_\
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M+' DL?GPMY.V&/9&IPJ.Y+,THVC:YVJ=@7%^W7=$4CCCP&D!:9F@EC7Y0,$
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M8#,98]I(Z8U8Q5N:#N_YX^G\QI*C"K3A>E%/V;CI%I)^]:]U?JK];:^9EQR
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M*%(4>80V%.6&&R 3GKQR<C-2*Z?,^0JE'8D#D D$9'J <8Y_&JHWJX:.,,W
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MN6-O/.8[-KO;^)/_  6U\(?#GQ!^UP+?]AS]MCXB_"3]AGXJ:]\+OVDOCO\
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MF'3X_$7C/PA\5O$'@W0_"6I:!!XJO- LXQ>6_CC1M:E@U6YTZ6*P\Y'1;M1
M?"_A+_P5 N?%?[4GP?\ V2?V@/V*/VI_V0/B?^T+X9^)WB;X"W_QDD^"/BKP
MC\28_@UH5GXH^(NA0:U\&/BW\1SX;UW0O#>H6>KBV\1VEC;7*2QVGVR.]N;"
M"\I?2)\;;<K\1<Y2Z\F$R.%K:].';IKNM5]Y5/Z/WA'&,Y0X"R>THN*3JYN_
MAM?WO[??D^ROTN?/;_\ !"KX(QM^\^/'QWVMYD@$5M\*T3# J\0=_!$S+@LI
M4%B2@*AMQW*MK_P0R^ 4$T;'XZ_'TLFZ1)$A^%T&PG#1A$?P1)$9E8L1,\<A
M"JJ_+P:_2/6OV[/V/M/^&?QM^+5C^TG\"_&G@W]G#PKKWB_XUS_#KXL> ?'M
M[X"TKP]'J$UW9Z]8>&?$&H3Z=K=_+ID^D:-H^HBRO-6UXIHMHKZ@P@/"_"S_
M (*,?L;?$S]F/X+?M;:C^T#\&?A'\(OCMH7AC4O#%Y\8?B[\)_!L^D>(?$GA
M_3O$,GPP\0W]QXVNO#MC\5/"\&H)9^+_  39ZW?ZIH%_#<6=\D<L$@2U](OQ
MJ4''_B(V?Q4KJ5J>2J/O*SNGPU*]UKNE;33<G_B 'A(VG+P\R&HXM-2G4S=S
M5FFDG'/XK1ZJZEUO=:'Q&_\ P0V_9\3&/C?^T$ZR,9F(E^%SRF;]Z?-#Q_#D
M$2LTI+E3F;9&)=X7;5B'_@AG^SA&@;_A</[0X*NIV-J/PWAMPJ/NDC6'_A7T
M:;9"'15+NJ@[HT\PF1_J/XC_ /!3#]GCX+?MF1_LE?%W6?"OPM\//^Q]8?MA
MK^TE\0OB=\._ OP4D\.:M\83\(-*\#1:IXEU[3VE\4:IJ"G6].N4N/[-U#33
M&MH\DKDI][W'C+PA;^#[GXAR^)-$7P%:>%Y?&LOC"TU&VOO#C^$(-*DU]_$T
M&K6CS6=YHK:(IU2'4;.:XM+G3]MU;RRPNI.#^D'XRSV\1<^:2=VH913T_P"W
M,@LW9^MMC=> WA''XN ,BB[IQM_:;]/^9XMFDNJ_$_&G_AR/^S0DK._Q4_:(
M?S"J*D6N_#2-"P)=6=)?AM=)(0P!R55> I!7I(O_  1!_9A5@\GQ*_:)E,:[
M!"?$/PWMW6(MO"YC^%:AU,G[S<Q+!AM#;"5#]<_X+$3ZQ\*/V#/$/P6_9!^(
M7Q/^.?\ P4:TKXK^._V=/@%X@^+?PJ^#@N?@W\*YK34Y?B!XK^*GC>Y7PEI>
MJ^+_  'XE^'OC'PG\/M-M=9\17A\:+HMP]O+HM[?2=/H'_!6&&\\.?L6-XX_
M8\^/OP8\<_M5_MD:O^Q/XP^&'QLMX_!'BGX(?$30O"WB#Q1>>)H[J\T2\TKX
MN> =3L=#@N/"7BGP7=6NA^)-/U%[B'5;?4M.O]'@S_XC[XMVL_$+B'?7WLL_
M!K(E;Y6\GWT?@;X7R2OP)D#LFO@S'9]?^1Z_7I_EB6__  1(_92R%/CS]HJ4
M)&TH+>-?A^(Y6,4D'G,%^&.U)!OW#R]JAD7*LH937;_@B=^R6TRNWB_]H21X
MTDRR^//!PX?&\OY?P[C0\L#E2H!QL0)D#]$+#]L?]DK4_CG=?LL:7^TQ\!-1
M_:6L_M9OO@/8_%CP9=_%>UGL+$ZG?65SX(37'U]-6LM*635+K1C81:M;:8/M
M]S80V DNXF_\-8?LJ+H>G^+$_:*^#LOAO5OCLG[,-CKT/Q$\/3Z+>?M&3:K+
MHJ? ZWOX+R2&;XF/K,$VG+X25O[5^T1.AMO,"H>=^-_BM4;YO$3B>'56Q.#D
MG?REDC4>ZY4NBV6FDO!/PQE92\/^&)I/3VV%QM:UU;W54SFLEV;2C=:-O9?!
M$?\ P1;_ &.HXUE.M?'N>1E=US\1=*M4"N2S1%;/P-%"RF3]XC$M(&^[)C(J
MVO\ P1J_8V>-%;_A>-P555>5_BM*KJA;<5=X?"R9# D':"^PB,,. /J+XA?\
M%*?^"?OP@^*/B+X)_$_]LC]G;P)\6?!\V@6GB;X<:_\ $WP]8>+M#O\ Q7?Z
M;I_AK1KO1FG>Y3Q!JDVL:;-_PC*!M=M-/O8-5NK&+2C)>K\O?#'_ (+(?LO:
MS^T9^TO^S1\?O'7PF_9L\>_!C]K^/]E?X8:5XI^*O]HZ[\;+B\\*>%M>T'QC
M=Z;_ ,(SHL'P[MO$FI^)3X9T.WU;4]0TO4=9TC4M.M-?FU"WFLX<H>-OBM2F
MY0\3N-XMJWN9Y7P\4KWLEA</AFHJR2BOW:LK05H\JAX'^%5--0\-N"XIMR:_
MU?P,N:3;;DY3E*<FVY-RG*4G>\FY-MV(O^"-'[%SK*K67QIG9Y6E+R?%J\<J
MOES1+''G0T_=K',P1&B+Y"Y9V7E3_P $:_V+Q;&-+/XVIOD$A<?%W5&D$A9L
M$)+H[QR$[L/OA9]@4,2 HKZN_9E_:TM/CW\8_P!M/X >(O!MO\._BK^QG\==
M*^'/B;1(O$S^*+;Q9\+_ (D^ M#^*?P(^+MK=OI.D'1E^(?@S5KRUU+PRQU&
M3P[XE\+:_8KJNH6JVTS\[!^W1X ?]K7]JG]GG5;7PUX6^&?[%/[/?PJ^,O[1
MW[0/BWQWI_AOPW\/O%7QAN?%^O>&/ .K6&I:?#IFGZ?I/PD\%7_Q+\4^,-1\
M46D>G6FKZ#8)I,D=S+J$=+QP\6.;F?B=QUS7NW'B;-$[O=MJIMIJNOWFW_$%
M_"]*R\.."U9))QR# QV\XM2[:)I/1:Z'SL__  1G_8T<QS+:?&R.7_51.WQ=
MU&1V(8R9\NYT.ZA5PK-&TB('="RR$@EA73_@BO\ L; )&#\;##$KDVP^*%H\
M<F0,"4GPB)@$D!GC(D4K,?,4?NTV_17A;_@IY_P3P\:?!;QG^T/X5_; ^"FJ
M?!+X9Z]X;\-?$GXB?\)4MEH_P_UGQO>P:;X+@\;IJ%O;ZKX.M?%][=0Q^&-:
MU[3;+1_$"2))I5]=1%9:]*\0?MS?L<>#M+^/FM^*?VEOA#HFA_LMZGH&A_M"
MZUJOC'3+;2/A%X@\4*Y\.^'O&6KL_P!@LO$NMN%M]-\-PW-YKMS>S06,=B+J
M>*%J_P"(Y^+BTCXH\=6Z)\29FW][FW^/:QG+P3\*YIJ?AIP2V]Y/AW .;MJK
MSE+F;]=UILCX@E_X(H_L:3Q!6N_CLBC<B@?%"SC)5T>,L9/^$0\QQ\QD4N65
M90"I7Y@;4/\ P18_8VA^47?QR=8'W11O\5+3RT?)8&,)X30/M!$>YBYV@(<Y
M.[N?B+_P5/\ @G8WW[ &H?L[S^!_VFOAA^WC^U'=_LTV/Q0\#?$NTL](^'][
MIWA/Q1XAU77GL8O#VMW/B'6M)U#PV^C:GX/U"3PA>VDDXEN+VW?[+;WGU'IO
M[;/[(&J^&_A]XQTW]H;X6:EX8^*WQX/[,/PWU>V\1)<:=XQ_:#_M+5=(/PCT
M.:.(F[\9C5=%U6V;3/+4JUC<.T@C57I_\1V\7FFEXH<=>2_UDS+79])>3ZW>
M]Q4_ _PFIRE./ACP3[22TD\@P"<6M+Z/M_6Q\8I_P1?_ &+70)-9?&;_ %95
M9'^*U^S(K8^1(X]#6*->@98XUCQ]Y3A<6?\ AS!^Q/#$SC0_B_>%5VH)_BYX
MB50@_AC1+&**(9^8!(U.[D8/%9O[9_\ P6?_ &6?V8?%6F_"#X=^.?@_\=?V
MD8OVDOV?OV?_ !G\!-/^*]KX;\6^$A\:OB!I_@C5M7^T0^'O$EIK?B;X?Q:A
M%J_B'X?Z9YVMZ5;[7\2S>';:2.X;ZY_X>$_L33?M,R_L>67[37PGG_:5359O
M#_\ PJ;^WG357\46VEG6[OP1%K2V<GAF3Q_::./[3N? 4>M2>,;:T/FW&AQ)
MACA/QM\7IM\WB=QVKJVG$V9V:]).47_V]%Q=M5WT?@MX5WY_^(8\#.HE[LY<
M.Y=*46OA=YJ<7;5I.,HK6ZUU^8E_X(Z_L4X)_P"$/^* #( ^?C7XX&T[1AA&
MDNT,!P-B@8R=N2PI?^'-W[$#J&_X1#XG*&55=4^,_C5]\:MNV8FN P)<9)B$
M;YZ2 '%>_P#PF_X*8?L%_'#XX1_LZ?"K]IOX;>-_C'>3^,K30O"^ER^((++Q
MK>_#UIT\<V'PW\8:CHMCX'^)FH^#UM+V3Q1IWP_\2>)+W0[:PN[S4((;:VN9
M(/1OVJ?VTOV6OV*_#GA?Q3^T_P#%WP]\*M*\9:K?:+X/M[[3?%'B7Q'XJU'1
M]-?5];B\->#_  3H7B;Q;KEOH&E*FJ^(;W3M#GT_P_IC_;]8N[2VVR5E_P 1
MF\6M'_Q$[CJZV?\ K%C6T]7>SI:ZZIVMY%?\0:\,6M?#;@IZ).W#V6TT]M'"
MC3A3DK_S0E=>[+F@W%_'Y_X(X?L*1Q(S>"/B60%E(#?&/X@8B\P[C@IJ13E@
MH!8<=@<#,R_\$>_V&E5?,^'_ ,0[D%8!YI^+_C]YA]G:+!417\63*L21SN2'
MDC!C8[2 /5?BW_P5<_X)Y?!3PK\,?&/Q _:E^&UKX<^,?@*7XK?#G5?"=OXL
M^*,&N?"JVN4L[OXI7MM\,/#7C&\\,_#:QOW_ ++OO'?BZ'0_"]AK,%WHU]J=
MKJ=G<V\-WX\_\%0/V!_V:=0\-:5\:/VC?!GAG6/&7P<L?V@?!>F:1HOC?QQJ
MGC'X-:A?26-O\0/!^G> ?#'B>;Q+H+?9[W4YFT87E]:>'=/U/Q/=V47AW3+_
M %6"'XQ^+-3^)XG<=U'JH\W$F/3BK:V4*<%KOK?8I^#?A@K<OAMP-'_NU\F>
MNFO^ZK7=66QYA'_P1_\ V%#\[_"_QNVTRGRV^,OQ01&^82 MY&OHYPP^3D!2
M.,DFD'_!(7]A.V.U/A-XI0C<7$OQK^+0($C!G*F'Q=$D9E VNZIN968,<FN<
M\2?\%E?V6K/]LW]C7]DKP9JL?Q$TK]LGX-:O\:_!OQI\+1^+M:\&0Z!?WEIH
M_P +-.T:+P_X'UNW\03_ ! U<:\FLZM=ZUH.D_#2U\-W/_"9S65YJ%M:P_3W
MP[_X*&_L;?%30/V;O%_P]^.&B^*O#W[8&H_%C1OV;]6LO#7CB"/XI:A\"M-\
M7ZS\68-,MM0\,6ESHX\&:=X$\5S7L_B:'1+:\DTEK32)]1N;NRCN,UXM^)^\
MO$'C*7\J?$69M=G:[[?H=,O"GP^M:/ 7",>]L@RQWZ_\^T[WUW_R/#1_P2+_
M &$F;'_"E_$4HE0%Y1\;_CB)9(V ^1I%^(4:F,J3D*BYW$IMP -1?^"2'[!\
M0B/_  I;7)2Q4-$WQJ^.3MN0 ,R^9\1#$))O^6S["K]?E)KD_"?_  7$_P""
M6GCSP7X]^(?@K]K;PKXL\(?#B+X6+XCO_#O@7XN:I?SZU\:]9\5:#\,?!7A;
MP[;^ 3XD\<?$?Q9JW@OQ+:67PW\&:1KGC6T&F/<:CHEI;2K)']Q_LU_M/_ S
M]KSX9V7Q@_9\\?V/Q"\!W6LZYX9GU"'3->\/:UX<\6^&;H67B;P7XQ\(^+-*
MT/Q9X,\8>';LK#K'AGQ3HFD:W8B:VEGL4@N;>6>*OBYXGRY?^-@\963^SQ'F
MD.FEVI:_(TCX5>'23]IP#PCRM?\ 0ARYW?7:FM'ZGR2W_!)?]@>-2D'P%ORD
M;%HA+\6?C2PB+-^\5&;XB;%#L9-Q*MDLX7 933S_ ,$I?V#4,3']GKS'1PX=
M_BC\97*C<7 ./B(-ZCC X.,#)'-?IQL&PH>000<XYSG\.]-$"8'."  .O;C)
M&#SWYKG_ .(M>*DM)>)''+@MH_ZTYNDNR5JZT2TM9>272)>$WAE-6_XAWP-5
M=[VK<)Y%47JW4P6(;DOYG'F=VW.[?-^9A_X)2?L%,ZRI^SI"[JJJ''Q,^,19
M @()5I/B*Q"XQY@7F0 ;]U(__!*C]@@J'/[.ELV&<JDWQ%^+TJEF787:/_A8
M01N00NX$C@C%?IE%:A4V^86 //'4<'!Y&./3'!I7BB4X*YR,],]>,<G/;_)Q
MB'XJ>)\])>(O&TEII/B?.IQ=M=8QQE-M]FI*WF;Q\*_#JG"/L^ N"X\J25&'
M"7#<:<$[W4;Y3=)7;2:6[T/S3A_X)9?L%DIG]G'39(8PL<;/XY^*;H551@JD
MOC]UD4$G#,&Z=2>18'_!+;]@V,-_QCCH.YIS<LLWC3XHSGSRI0,6;QL^\!68
M%#^[4G(4'YJ_2".WA"A$^144* !@8RQ]&]?;\NCGMD< ;P!R3P23TZ' *^Y'
MMZ40\4?$F%2,GXA\;12;NX<6<24OLM:1AG,(QWUY>6[;;U;NUX9<!Q?,N!.#
M5;:"X4X;T^?]DKUON?FI'_P2\_813="/V;O#WEF57V/XR^*#KA5()"2>." H
MP0.-O.W!!&7?\.O_ -A"65(D_9H\-NBEB#_PE?Q%")U.TQ-XV5!( PYV[@"<
M8!Q7Z/RV,>_S/ED.T($8, BX&2&!!)9@"?3/7-?FM^W=^T;\<O@U\5OV,/@[
M\#O%O[.OPQO_ -IOX@_&3PGXD^)_[27@3QC\1/!_@[3/A;\#/%/Q;TV/2?#G
MA+XU? KS-4\1ZGX<_L9KK4/&0AMK:[EN8]-OKJ(QR75\3O$&M+GGX@\;5&U9
MM\7\3<VB:5FL\D_+5M>2V-5X:^'\XN$^ ^#N:2:_Y)/AMJVEKVREWT6W38O1
M?\$Q_P!A:,31Q_LR^$2AW-(&\2_$";EU(^8-XTE4!QD= HY(Z#&B/^"9G["Q
M6,']F+P,\,:.I;^T_&:LB2+E\RGQ&XD <DH9'<QEG12FYA7S5\'O^"FDOA*?
M]J#PK^U!XA^&/QBU;X!_&'X+?![X<?$K]ASX=?$?Q/H/[2/Q#^.?@&^\::7\
M$_A]\'?^$R^-/B2T^//@$:%JEU\0?"ND_%'Q?X=T/P7J6A>._$6I>$-.3Q!%
MH7O]_P#\%3/V9]-\"^#/$MMX:_:$UKQ5XZ^+OCK]GS2/@1H7[/?Q(OOV@--^
M._P]^'E]\6O%'PG\5?"Q],M]4\,>)H?AO92>.].O]6N;?PCKO@VZTSQ=I'B>
MZ\-:QIFJ7,KQ+\04DJ?'_'25V[+C/BQ*[2N_=XAIIOSMTU;M8TEX<\#+W'P-
MP9."C;WN$^&K<C^RX/)Y)JU]+-.]N7OKI_P3._80#N8_V7_A[Y;EBWG3^*+A
M9S*R,T?[SQ(Z8=Q%M'3@84!W#WO^':_["DD7[G]EKX9 J'B5C;:X"J,A$@25
M=<67:59@^QAGG/(-<U_P4=_:E\=_LR?"'X#>,/A_XX^"GP8/Q>_:?^"WP4\4
M_$_]I3PKJ.N?#GX4>!OB)8>,;S5O$_B7P[%\2O@Z8=4TZZT?3].M5U;Q]H6G
MV]_?SP7=QM="GSW^S[_P4>U:VU#]K63XT_%OX$?M;?!W]G#PG\!?$6B?M/\
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M?7[$V&"?LG_ 1DR,2?\ "O['G9D .'=V]ASU!).<93_AW]^Q$K$G]DSX"KL
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ML[R.S:2Y+.XE?_GFIWJH"HH7[->PB,2QR!8XHLOYDC[C&@)=V8MC*H Q^8@
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M6XXYX]ZB250FTD1C,8! & 2., <GLH]L4U'3=:@?R"?MBZIX)O/C5^SW>_\
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MO#FC^%]/U36M5N_#>EZ9JFI"[TO2Y)[?^S7U&.!O)$9_,[Q=X;^%'QL_9?\
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MI?MM_%WQ1X=6.[DGDT7P=I^N>#+/5M4N7TJQMM'L=+TTJMIX>DCM?U0^#/\
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M<2)D1@-ID^8H>0 2N!\Q#$<YR<-U)P<D$3L!_*/K/PR_X; _X)@?\$@/M?\
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M2OB'\,_ F@^+?@UX'U;6;OPWJ'B6_P!32+3_ -Y/LS$ %E'S9)&0<97H>N<
M\YZL??,4D:Q#RP>?E<-P,8;[H].A(QP":&[[_P!7 _G#\*?\$F?VG/!NB?M&
M^(/"E_\ LG>"_'OQ+^-'_!.?]H#X5_##3O&'[17C'X?>'?%7[#_QBO?'FM>!
M/BE\9_B)IGB'XI>/K;Q]X=M]"M[+XN6_A72M4@U>YNK3_A6=AIVB6&HZK]I?
M#C]ES]NCX,?%+QAX/^#?QE_9^\(_LL_$_P#:_P#$7[7?C?Q5J/AKQ1XB_:3\
M/:=\4?'X^*_QQ_9M\.>'-0\/GX5Z_P"'?B+X[FUO1=$^.&L:KH7C+P'\._%E
MYH]A\-M1\8:+H/C"W_68I&2Q8=<;0I4!0,\<GW/3@9)'WB*?D<9/0 <ON/4G
M'1<#GIR#Z#'(G8#\D/V>/^"?7Q&^#WP__P""5'@_6OB)X)U6^_8 U;XO:C\0
MKC2-.\016?C^#XB? ;XR_"?24\%B\B2;3)M+U/XEZ7JMZ_B")/,TW3-5AM4D
MN'B!_7B&(H0Y/5,;<8P3M/8X[8P !C' Z54. /D4'K]S QDD]L=22?KG/6KL
M4V\A=C+A<Y.,<8&!@^_MTI 22/Y:[L9Y QG'7_/Y54!\V4$<$D$]]NU>A(X.
MX*O';=T.*O8!ZC-5G@+.QR IQP"5;@ <$ @<CT.1D=Z &/ 0CDL""YD(QVP!
MM]^!U]<'MRQ)-L;1Q*N\[CAF90 5P&#!74D$?=RO3\:E2!D8G=E<@X+%CU4G
M)( /W3CCC-/DB9V!4@ *ZD<C)88!XX./?_\ 4 4?/" 2,V1D%2059AD@KM)P
M"6# ?-R.3CI7XD7W_!/']J_P;\*-;_9"^"/QX_9)U#]CV[;QOIWPJN?VD/V6
M_%/QK^.W[,W@CQW<:]+<>!/!5[:_&/PW\,/B?IW@JW\2:EI/PEU_QWH'AW4O
M"?AO^R="\;1?$^VTIWO_ -NIH0=L<B[R6W$J 5"L-G1NXP3Z8/49J.2T\OY0
MY=0F[#CA#'C#HHR-ZC 4'@8!!X %J6RVZ7_+_@ ?D)X;_89_:I_9M^(FF^(/
MV,?V@OV=/#/@^V_9%_9%_9,O],_:<_9X^)WQE\2R:5^R+!\5],\*^*K+4?@[
M^T=^S_X?MKWQ-I7Q2G?7=,N-$N E]H\!TN;2[&ZEMEZG]F'_ ()JVG[.?Q"^
M!/C/4/B;I'Q*L/A'\!?VKOASXAT74_A=I/AZU\2_$[]KG]JGPC^U7XV\?>#]
M'M=;U/1/AMX,\.>*M'U_PSX/^'=K:^(9M(\*:EH>DOXHNFT">\UC]2UW%]CK
M(C+@J)"9%;(8$ A0R8&1E<$@XSGBI8D(EW,K<L>K%HP@4@?*P&">W!P,9(P:
M;C9M[I:VUUMTN!CW=A'?65UI5Q"SVEQ9SZ8\<+RVO^@31-;26\,EF\$EF&@=
MHXYK9XWM]P>W:*9(98OQQTG_ ((9_L4^!/C;\!/'?PR\+^)? WPD^#7P@_:.
M^%-[\#$^-7[3_B30]>3X[KX!LK*\\-ZAJ_Q\N+#P'HGAW2/#_P 0+77?#&CZ
M ^F>-;_QXNN:L(-=\*>'-0M?VI>))"" P&.2&QN/][N>?<#CKSUB>!0 RGYD
MRREOGP5!? )P44X^X 0<D$\BJ[/5=_Z3 _%6T_X(=_L<:#XY^)-WX(T_Q=X"
M^&/Q"_8E\7?L6VOP_P!,^*7QQ\3#P9HOC>/Q9HNL^(/"MQX^^+?B_P /V^G:
M9X&\16>D^&/!;^#I= \-:UHUGXETM[?4!'Y'<^'OV3/VU_!,OQ!_:.\=_M#_
M  B_:'_:T^%7[&?Q*_9G_8VM?#G[/>K?"'X:6VK^(KOP[XUU#QO\9-&\0_'/
MQO-XM^(WQA\=?##X0V'C>X\,>)_A9X \/Z%X7NK;P[H-E_;E_=0_KB\)<,JR
M# 7!7RQM1I "WSJRR ,QSQCKM)P#3!%*BA58L<%229MH&,93]\WS#GAP1D=A
M4N/-JGMIK_6G_# ?DK^T%_P3K^-/QDU_]I*Z^&W[3GAOX'^!OV\_@YX#^$W[
M:_A*?X*:C\2_%.H3>%? E_\ "WQ)XQ_9O\?GXM>#=.^$_B[QA\)M6?X::GJ7
MCCP5\8-+T^#PYX6\7Z)H]KK5C>-JV;\6?^"67B#QY??'OX:?#W]HO2_AA^QE
M^UCXM^$?B[]I/]GI/@L_B?QUJW_"K_ OPI^%?B3PS\)?C4WQ0T+3OASX5^,_
MPR^"?@#P;\1;/7_A5\1=3@MHO$VJ>%-6T+5_$1N]._8-01&Z[2GS*S,H&2"_
M(( P1MSD\GDY!&,(R#($+2(I^4[2JKGKD@H2< ]>!ZG-3R[Z[7UMIHK[WTOT
M7DP/R3^*?_!,GQ#\2O&OQU\,Z9^TC'X4_9!_:J^//P[_ &COVC/V<9_@W9Z_
MXS\4>//!</PNB\5^&?A_\;[GX@:?%X$^%_QJ?X/>#+CXI^%]3^&'C/6I))O&
M"^#_ !7X53Q?<G3_ -=949#N+ [V/3<F._WE8'VP2>W7LB1^: R,C81068-N
M8@'EARH/7&#W^89JQ%$R$EBI! XY/([_ #5($5M\KN,L=X+\MN P0,#/)Z]3
MS[DDFI&GVLR["=IQG</8]Q]*8;=\GYDZDC[PZG../Y4?9Y!_$G_CU $Q!FB&
M/E+ 'GG&"#[>G_UJ6-"B[2=QR3G&.M1QR!2L)&67Y=PQC(!/3.?;IUISSI&2
M&ZY&T C+ @9..P&<$GTH D8;E9>FY2,_48ID<9164MDL2<XQU '3\*=&XD7<
M 0,D<X[?2GT 52WV<XRTFX9RS 8QQ@<=^O\ +/:<_?3Z/_[+3L ]0#^%-/WT
M^C_^RT /HHHH IF&8]3NZX+.3C/<<5$Z$-\RD(P( .,'A>P)[*W7U]Z>#*Q(
M5V) SRP'7CTY]ZC( RJJQ&3F1VW$$$YVKG.?3\>>@H 3IWPJ*3LVCD#@,'Z\
M XV=.<Y&T JVX E5+.,X4-M)89XSD<9&2.Z@@CT<C1[F5SO4+C&&)(8@J2,#
ML.>>M*S1C<V".3@[3W.![]P#33:V3>C5EJM;:M7V[]0*6R5,R.W[YV!7=%O9
M5'+(67)V]0 &P5 ) Y%(@ :8^9,V\AGC,7"AA@CY45?+/&T*&.,ALGFG/L.T
MR())'R$=88U!)RJ?.S;E( 5<MC<1A>#2-$OEB.4G>05\M4(&YLX!&"-Q[D@A
MN>O;5;*^_DM/N[+\.K 1;8.K*TBL1&V=H4*2=Q#")2-LH!"X9L':N5&:JM"$
MP"X4X!!G5G=CC;@;7Q&F,C:"!D X':X8E504=B%4@JSE@=JEBC'H@VG.T#@,
M2!N."L07<ZA0^T;VC3>2N0.%=U&U<=AC].2]KN_Z6LWW[Z;V SUCD@C!=(9&
M7?A2TVP0LK!3N^9&D!Q]TL%P"&)Y/X6?\%O;WXJ:F?\ @E_\(/A?^T%\<?V:
MK/\ :)_X*7?"GX)?$SQO^S_\1=?^&7CG4/AMXO\ A?\ %!O$GAZ#6]%,EI++
MJ"VD,FD)KNG:OIVG^((=+UQ=-FN-,BDB_>"?R<'<KQJB$D$$Y7T1$D0G:,DA
M5;@@\9&:>RVE4/);I*(&26$W$4<SPW<2ND=Q"[J0D\<<CJDL+>;&K,%90Q%#
M7,NVSU7]?J%VM5OY_P!,_AI_:8^(O[47PF_:^_:-_9S3]N#QK\%_BU^SOXS_
M &&?A-_P3BU3]HG]L_\ :QT[6_B!\.;GP_X3L;CQD?V8O@G^S1\6]%_X*#:E
M^T'XK/B7PM\?O&OBG5&U3X?ZI=*;R#PCH&@(+KU+QK^T/X]^%O\ P5HU==9_
M:I^*/[0_B76?^"E_@_X:Z'\&?@_^V!\>OV?OVB_@U\//&LVGZ9;?!7Q-_P $
M[OCG\*->^ O[2G['_A2RNY/$NI_'3X)6UGJ/B'P\+GQF?BMX?:,S6W]H;0V$
MES9W$ME;7-_9)<?V==SP0RWVGF^C6.Y6SN#YEU8K=0@+,(9(O-C #Y&!0-/L
MWOH[Z2RTX7]K:M81Z@UM9-?6EC(1(]E'>;#=P6DFX_N4<0%B24SS4.+2>M^R
MN]?3<-7O:_EVZ=$?Q;6GQC_:,^*WQ5^'WPI\2?M7_M,^&M&\6?\ !SQ^VM^S
MIK6H?#_XV_$?PGKTO[/.A?"Z76-!^"ND:]I.K6U_I?PTA4G3M'TC3KF*#PPV
MHW.K>&9-(\06,&JV.;/XF^)D?["/QO\ A]=_$OXF?%;QS^R7_P '.WP_^!'[
M$6M?&7QOXE\>?$/2=(\%_M)_"?1_AUX)M/B%XTN=0\9^(8[3PAXK^(.G27NI
MW>I7DFD:KKUF))=%?[%;_P!GMO%$/$E['*J&$I->0P"&%B+@R 2:DFR,A;J5
M))4ENP!/-$6B>1EV@>9_%S]FSX7?'+Q9\ _%OQ*T_4-<;]G3XQK\?/AQH-OJ
M L_#$OQ4MO!OB?P;X>\7>*=%2W/_  D&H^#K3QAKVL>%&N;F)-)\2RV.NA+B
MYT^T6&6IK5QDOQV5^GEJ![X(=TTHCDW*7D"H""B,9F9@0C$@B;<Q)8X(VF%0
M@4W&BE/)PW'.7/8L<'CG@@#/ Z544-&[/$60LR[@[[@4+DNRX)PQ+$Y))]O6
M999 Y5BS)M&YSN !RV0,@$X '0=3C-3S+^\^WN3_ /D0&L 1NQ\P 9&P,AAG
M@GJ%.><>@R#@"IS ^% "X"*"-Q W 8/;GMSC/ J(JO\ "Q(QTS@8[?>QVSGD
M=NF>9/.QW)S_ +8X[>WUXS^=3*:5M_\ MYRI[=N:+O\ +;Y@[+9I_-+_ -*:
MO\@-NS9WJLFX $EBH(&"%* %2 1G/KSBCR9!V7V^8G [#)'0# IK2.1\KG)/
M]X\<$X'/^/'T)IV]L#+Y..?F8'\L@8^E/F\X_P#@?^4$'_@/_@<+_=S?\.6$
MB4(JLJDC!/&1N'.>1USR#V/3H#3C&A.2BDGN5!]NXJIYC?[?XO\ X$4OG,.K
M8 ZCJ>3ZG)[CD' ]1@X.=+5RC'SYKZ_*(D[]5_X%#_Y(>\+%R450N  ,[>F<
M\ >]/CB !WJI;=D'@D !<<X!Z@FJK3KNVF<*W'RAQDYX  ]>">O/N:7SP!Q*
M7Z<C+#/<94=N,CKSG@4E43=E)/\ [>EMWMR;#L^D9OM:%T_27,DU^>MMB\$0
M9PJC/7  S[GW]^M)Y<?_ #S3_OE?\*I^>3T9N3CA7ZXSW![=^GIT-'G9_P"6
MC#IT##Z]<?U[]L55UW7WR_\ D ][_GW47FXJW_IPO  = !]!055N& 8 YP0"
M,].A^M9TDQ4 B1QG/4D?PD]\^GKSG''6FB=_[[]<=2!] <8R.IYZ=L<UE*O"
M$N5IMZ?#*EUUT4Z].7_DB\KK4I1=KNZ6NZ6EN[YS3 48  ''&!V&/_K4FU<[
MMHW>N!GICKUZ5E-.YX$KJ0><DGC\ !S]<X].,QF68?\ +P^/7C_XK/Z4+$4;
M>].--_RSE34K=[1K25GTUOH]$1*Z=H^\NZ4O_;:=5?\ DU_)&W2%5;&Y5.#D
M9 .#ZC/0^XK$\Z?C$[DGIQG)], DGC.<<^GK2^?<9_UK_*-QQ&_3.#G< O/;
M. .I(&:I5:4E>-6G+TG#?M_$>NWWAKU5GV:JW:]%ANNR7>RZFR40G)5<XQG
MSCGC/7')XI0JJ"%4 'J   ?KBL874O9WP.,A$8<=\J6 ],$YSVH^UR\?O&XY
MZ1C_ -F]*/:1[Q_\&4__ )8._E4_\$8F_P#Z8-A55?NJ%SC. !TZ9QUZF@(H
M.5 !.<D 9.>>3]>:ROMN>DV?7 /'7K\OL:/MA_YZX^HQ_-:/:Q[Q_P# X?\
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M2:OI=:V7MH?:<(OSKX1];7TQ3Z]KOR;LGU5%<TWB/10I;_A(-(P,\G4K!0>
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M _\ #2G[/IQC]H/X)#)P,_%?P)R3G"C_ (GW).#@#)X-0#]IW]G1E+?\-%_
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MO(G_ %[X)_Z+'A).U[2XIX<B[/9O_A<DDFE=-NS6S/NYX!&H9B.<#&&8#C.
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M2!D@,%/4EL?>)4!6P.3@\<FI5.?,8NV\@DC:J#:N>%+9!'S=>I'/K503/G:
M(_X4^8NXXP"X4 *0OWMN >_&:J%[Z=G^@#!ND#C9"R@$/OC89P#E@6 8GC<"
MA)4XQC'#_+<(NT3.% 9&:8-(NP<*I9BQW9^4LX; Y9<<K*[R1F-D+D#Y6",
M65BP(R.C$<@GD$CTJL)G0JK(Y<A6.0P )&< <# /K]*U^Y/[_P"K_P!("TTD
MN,[2"B\H3O)#%E,C2*4VEN5(!8J%+Y.:C+.NZ1W<M)A72$EX^ -H"R;F+$#Y
MF((!Z,!FDC9IR7V[63"ABJX96/SKDJ<D*21@Y!((&2*:)$+AM[!H^0%3<6&
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M.^I%_8$_:T(43_\ !43]I&3 7<P\&>#8LG<A.S_3R$)"NC;A+]\, H3F-_\
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M^TL[$/\ \%/OVKA$=LFR+3_"2MYS-F4K*)2PC*$(L+ I'MW+ER6/Y@_M%_\
M!93XY_#+]NG]N;]F[7OVUO\ @FS^QYX#_9I\=?"#P[\,;;]J+X"_'CXA>/\
MXC:)\0_@CX5^(VLZPNI_#[]H#P!I;P:!XAUFYTJ66#PSM,4MHC;#;^;J/Z4:
MC_P5X^!'PV\>0? KQ5H_QR_:#^)OPQ\$?L_ZC^T_\4?V2OV8/B5\1/@=\)=:
M^.OA'2/$GA'Q#XA@T?4/%OC;P_X5\9Z;J$'C#1-(T:S^(NL>'_"VI:='K>I7
M%^KDR_$[C-?#B.'X=;0X#\.XI75]/^,-=M[[;OST/^(8<)[.EQ!*.JM+COCY
MWO;?_C*%?9*SVLMNNFG_  3M_:)W8E_X*??M=M$29'POAV*7S2[,=DL$ZE(R
MK!3"R/ NU2B(!@3/_P $Y_CFS8;_ (*<_MH")CND0:QH2Y)=6*Q2)&)(PH0X
M#&107Y+(-E?(OQ>_X++>.M$^-/\ P5L^"$7PM\5?!#0/^">_P>\">,O!W[1/
MC3]G_P"(/Q3\$7>LWF@7GB7QGK_Q'\/Z1XR\!JGAWQ':S:5#\!_#^C:U:7/Q
M&T*Q\3^.!XF6QLHM#@]W^+__  6W_96_9WU'XE>#?B5X8_:3\:>)?V>/AO\
ML[_$C]HKQC\(_P!G+Q+XD\ _#SP1\?\ PQINNZ)\3]?G@\07Q\,>#K%;T3:Y
MI%[>ZCXITI3=P:1IOBR/0==O;/6'BKQW!*,,PR6/:W!G ,$F[:M0X#J)VLM>
M:^FR:5YEX6\'MM_5,X;:^WQAQO5?73FGQE2=O)026OO2N[>@K_P3C^-3$!_^
M"G7[;)4XWB+Q%H<:DG:S%"]M+(@W*^W+/M5]GS!5-#?\$W?C"^X/_P %-/VW
MF4@!?+\7:/"R/DAI"ZP*7S&^S8P*!E$@7@@S> ?^"OW[,/Q!NOCYIEKX"_:K
M\/>)O@-\*/ _QY/@/Q'^S1\1E^(GQC^"OQ,U)M"^'7Q*^!7@'0K/7_%_C;1/
M&/B)[/1;&RU;1_"_B/3+RZSXCT'0K72]?NM*^0?VL?\ @NWH7PN_9@_:&^(G
MP1_9M^//_#1O[._QR_9J^!OQ+^ OQ\^%S>'M<^%L_P"TQJ-G>^!/B)X[TSP1
MXVU>VO/!WB;PO'K%AX,.C>-89]3^(5QX5\*:R=#;6H[F:UXL^(4;N.:Y3'OR
M\(\"I?=_Q#YI67;;87_$+>#)*T\NS*71<W%7&3]VVS?^NEVOS[[GUHG_  37
M^+S)_I'_  4U_;AED\PDR0^,M.MOW8;"(8H8C"&5,!Y%0"1R9-B@[%%_X)J?
M%A<F3_@IK^W5)@G&WQWIZ *3\JX%J3D#Y<D\^@QQC?$W_@M!^RU\)?$VKZ#X
MT^&_[4VGZ+\-]%^"NJ?M._$.U^"1O_A_^QA??'ZRTK5? 'A7]J#6XO%+77A/
MQ;%I>OZ%?^+]&\&Z1X^_X0FRU.TN?%$^FQS%H_:O^"G/[5WCG]D7]EB^\:_!
MS3?#^L?'?XH?%3X*?LW? "P\365SJ7A<_%_]H/XEZ!\./"^L:Y8V][ITFJ:7
MX4L=6U?QG-I8U&PCUY=$MM)>\T^/4C<QM>+?B(_^9QE?_B)\#)+_ ,Y[_GM=
MD?\ $*.!M?\ A)Q^O_53\9?/_FMU;T5O(\R'_!-CXJ&(J_\ P4O_ &\&F+,R
MR+\1-+B"J<;4:-; (Q7GYB_.3P!P9O\ AVU\3&V9_P""D7[>AQ][;\2[,*W'
M3']GL5).#N!/<# Q7R]_P43_ &QO^"F'[(?Q.M/'?@_3/V4;S]GNX^-?[+'P
M ^ 'P.UO1_%?BS]IC]N7QS\9M=TS0_B[;^'=9T/QIX>T7X)ZG\-X+K4==\*:
M<?!WC>SU;1-$U7Q!XAO;/3E@L#Y'XD_X*L_M@6'[27B?XF:;;? R']AGX?\
M_!7CPA_P2(\0_"F_\#>)I/COJNMZYI7ASP_K_P"T39_%>+QZ/#EM'HOQ7\6Z
M7::?X 'PZ:WOO UM?R7.IPZW;I=74S\6?$*5O^%W":7:Y>%/#VGNK;P\-8W\
MKWM\V1_Q"+@%_P#,FQ?7XN)^.'VVY./H6^?R2>K^^Y/^";?C9XW23_@HM^WT
MUQO?;,OQ>@C1 8BFWR(["(/M<F0,Q1]V >!BJ[?\$P_%$W[V3_@HE_P4)=F^
M8#_A>,T2J68LVQ+>RAC52I"@$/M4<,:[C]@/]I[XI?M#?%__ (*4>#/BA?\
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M9?$&K7<.JOX9T[5X],?/B/A;_@O!^SU>^%/&OC'XH? #]I7X):%IW['?B?\
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M7XM\=Z]IMWXP\":#X7^%MJ]CX57X?:EX=U/_ (3(?VEJNJ7.G2/!99O[1O\
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MP^\3^'K?QU\1+J>Z\2:QKFJ77AC3&N_#&F_;-'U[4=?MK.P_3;X$?M)^+O\
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M^6&#;2)M2<$[@#O/S'D$X-?>M%8R\1_$25U+C[C>2>]^+N)7?U_X7"_^(>\
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M2.-V[CMD8';ZY% %BF'[Z?1__9:CE:4$>6"1@YPH/.>/\_SJ0_?3Z/\ ^RT
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ME>'KRW;1]-TB;PD]]-:6\WC**.6:Z@_8V#]JG]F"'Q/)=']I/X!FV^ROA_\
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M_9R".V5:3XW?#;RW!"8=&'B9LK+')!+'&@)"3(#\S#-";]L?]D%7>.7]J?\
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M'B[5K'Q#?> _"_[1NLZU)\-;#4M/T^SO/$%K:W27O[!-_P %#OV'6 V_M:_
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M'U'P'+XB^+'AVQ\-_$SXLZDFK0^._&*>#K+Q3<^%9-.\#//9Z3ILEF+/B/\
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MG3--&IZ5I7@7X0?#=K;6KO5]0\0QVWW7+@11#/ *@$XYQ&WI@=.>!BOR,/\
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M,6E^ME;KIJ_;_BG_ ,$UOV./C+XPTCQWX@^'WQ%\*>)='^&/@OX.:?<_ O\
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M$C3]4^(;-/JFM>HO]5^%_P#HF.&O_$<X>_\ G"?.0_9!_96&T#]FWX"?(I5
M?A#X#(564J1@Z(0058KTZ$TJ_LA?LLC /[-OP *A@P4?!KX? 8$?E#.="/S>
M43'NQ]T@8P,'Z*==Z,N<9&,_Y(_SZTV-#&NTG/).>>_U)_S^=1_K)Q)_T4G$
M?_B1<0__ #_&N&.&HZ1X<X>@KW:AP_D,4WW:CD23>G5;'S\/V2OV6U8./V;O
M@$LB!521?@Y\/595C $:@_\ "/DX0  <C@<8IR?LG?LQ0IY4/[.OP'BBR&\M
M?@]\/@N\; &PN@(.$7;R"1PRLK*#7ODD1=PP8  *,8/9B>Q'K_A4]/\ UEXE
M_P"BEXD_\2/B'_Z("_\ 5OAS_HGN'_\ PP9#_P#.(\#3]E?]F>,ED_9X^!88
MJJ;C\)? A.U-@51G0B-JB- HQ\NQ<=L7E_9J_9[162/X$_!= Z+&P7X5^!PK
M)&I2-60:*%*QH2JK@ +\H 7BO;J*F7$7$4TE/B+B*:3;2EQ%Q!*U]':^?OIH
M'^KG#NO_ !CO#[OO?(,A?_O"/#D_9H_9ZC5TB^!'P5B60LSK'\*? JK(SY+,
MX&A@$L22Q(8L2<YS4C?LW? %Y%E?X'?!EY$&U)&^%?@@R(!_"KG1BP7A,!2N
M"@ZY&WVVBI_M_/\ _H?Y_P#^'_/G^+SUL?\ J[P__P!"'(__  R9)^'_  BZ
M:::=-#QE?V=_@1&"(_@K\($!+$A?AEX+0$N%#,0NC<LRJ%8\94 '. :LK\ _
M@G&J)%\'_A3$L1+1+'\./""K&Q5T+(HTG"G;(Z\ $J[*3ACGUVBI>>9Y+XL]
MSV5]7S9[GLD[]T\\:\MMKKJ[BX>R!;9%DBZ762Y*G]ZR5,\C'P&^#(Z?";X7
M#Y=F!\.O!X!3G*?\@C.T@D$ @<GCDYL#X(_"13E?AC\-U(P1M\ ^%5P0R-N&
MW2QSNC1O8HI'*J5]4HK*6;9O-6GF^<37:><9S)?=+.6OP*_L'(UK_8N3?^&?
M)_\ YS'E_P#PICX5\8^&WPZ&#D?\4+X9ZX*Y'_$O&#L9U^CD="04C^"_PLB!
M6/X<?#N-2 "(_ ?A= 5Z%2/[-(*D9& !U[]*]1HK/Z_F%FO[1S-)[VS3-HO1
MW6L<WB_N:[;-WU639-%)1R?)U;:V494K>G+ED4ODEYW/,X_@[\,48L?A[\/V
M)!!/_"#>%U))(8DD:9S\PSCUYSGFK2?"GX<1[0G@'P*JJVY5'@SPXH5@0P9=
MFG+A@RA@1R" <D@$>A44OK^86M_:.9M?WLTS6;^^IFM5^E[I;)):#6492FI+
M*LKBUMRY9EL;-=5RY:FGYJ2?F<0GPX\"1*RP^"_!T*L%#+'X4T)%8*NP!@MD
M <1DQC(PJ$J!BK*^ _!R'*^%/"RGY\LGAO1U8^8NU\,+3C<N%;@[@,'(XKKJ
M*S>)Q4M98O%S=[MSQ>*FWZN6(=_G?KW-/[/R];9?@/\ PAP=UZ/ZI=?(Y)?
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MSVF_[^R__'*:++!S]HN#[&63'7/0.,^G.>*O45DZ--[I_)V\OY"/94_Y(_\
MDR_]R%;[.PP!,_XX/ZG)/MDD^I/6G^7)@#S>G'1L_CAU!^H ^@J:BB-&E%MJ
MG%-[OE5^^]E^IK=V2Z+;RTM^7J5_(?<K&9_EW<#(4[L=06.=N.,\\GGFG>6_
M_/5OR/\ \54U%5[*G_S[AKKK%/\ -B_7U_S(O+<?\M6_$9_FU)Y;=Y&/XL/T
M#@?3T/2IJ*/9TT[J$$^ZBD_ON']=?\V5F@9L8E88]"_/_C_M_D8 06S#_EL_
M_CW]7/YU:HI.G%WUEKT4K+[N5_F5S2M:[MZE,6K;B3,Y&, '<1V)S\_/(X]
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M ***:P)QCWSSC^%A_,C^?:@!U%4X"X*H[,S*TI8EB01G &3R<$=#TSQQ5R@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ IDBED*J0"2,$DC&"">G/3(XQUZT^B@".)61<,<G).<D\=NO/^?QJ2BB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBF2!BN%)!SV..QQS]<>OT- #Z*B#&*)#)DD!0Q'S$M]
M>_/>F_:$]'_[Y_\ KT 3T5"LZ,P4!LDX&5P*FH **"< GT&:@%Q&2!\PST)&
M!^//&>WKSZ4 3$ ]0#]0#_.DV)_=7_OD?X57MV9B=S,WRJ>3GDD_X5.[H@!8
MXSP."?Y T 1I(AD*!-I&X;L  [3@\BFO#(Q)#KM)R%(;^>2/PV\CCCK1&C>9
MYG&QMY!R<X<[@<$ CC&1U%2B12YC&=PSU''&,\_C^HH A2!E9<E2@S\HSCD'
MHI^7[QR>!SD]>MC8G]U?^^1_A5=G*S$DL5!&5!R.8QV_WB#^M6$<.-PSC)'(
MP>* (9)(XV"F,'Y01A5P!DC'Z4^)U<$JNW!P> ,_E3V1&.64$XQDCM_DU#)&
MX!$.$R.QVC.&]._W<'VH 6*)ESYA5\A<9RV",Y^]TSD=.N.@IT<HD^Z#MQD,
M<8//89STYY _&F0,S%\LQX0C)SC.[I^E02RQC#(3&2<%MK L,<?<#< \\CGL
M>M $UP%55/RKA^IPO56SSC\3ZXHAE1PD8 <;<AN"K ="O)R#V/X].:C:=)%5
M8W;<,%N''R[2#DLH!Y(XY)ZXXR)4\N.-)"HS@#*J,\_2@ $3"7?E=NXG R#@
MJ5';'^<^U6*16#*&&<$9&>N*6@!K@LK =2" 3Q@D<'(R>.M,CC*@[]K'=D'D
MX&!QEN1SD]>]2T4 %,/WT^C_ /LM/IA^^GT?_P!EH ?1110!3:.=OO#<!G +
MKW&.P':B.79O,C-M11VW8.2#C:,G[O'^)Q4T1E)/F XQQP!SGV)J,?9E8G=S
MSG)8CKGIWY]<B@"NSJKC #^<&E3=E"4/S$8*X( 8?*Q )Y)'6G)C<-Z\9;<N
M.F%;(P"V,$9X9AQG-*!&S L"D>^7Y?G&XDY5P<$8*[C@$#!)^JO&6+?(2C-E
M>F#G&",D'EN1ZYR.M $,ZYD7RBABVG<I;Y=PZ?*N7Z]<<9Y88SEL<3@LLBQ[
ML$Y4.5((X ?"H1VVG(P"I&,FD <R8S(4'"C<S D<,'5L@8(.-O=5QU)I7&$*
MYDVJ')&),[R?E&,;CE1T&1],\US.R7IT_P"" .RQ@ E8V8D@ @$A=I8C'!PH
M8GN!CMBB(L5^9B75MQPP.,]#E3MR!G SQQNQQ@9(NB1;\J2KMDD%@5.TL00"
M!@D8!&0<U L@+'9(J*!\VR/YLJ<<*5*X (ST)]\Y%I<T=;K6_P"-_-VZ68%C
M?#'(0?,W[3AG)=WR0,A5S@*2,D*%^9<G=C*H5*@J,ME22JXR'1>#@9SDY(.-
MN<MMK^?_ /X.'OC-X_\ @Y^SU^Q5JG@CXV?M%? G0/'7_!2#]GOX6?&;Q5^R
MQJ_B'2/C+JWP3\8>%/BK%\0=!\(6_A31]>\1>(-<GM+.UU7PSX;TO0]9NM3\
M4Z9H@@TB]GAB1/S]_8'_ &L=7L_VVO&'C7]F']K#_@IC^U#_ ,$\/V=_V;OC
MWXK_ ."A.M_\%#+/4M9'P:^(G@KPS!XN^&NC_!Y_&O@/P!X^7XH30:=J\_B?
MP1_8_D+X7:\O#-=07%O%IF;5F]'_ %YVL!_8%NWA61HRI/.[+Y7!)VJO(;IM
M8_*.<]:T8\;%VC P,#^?7WK^;[]C'_@O]IW[37QX_9T^$'Q#^ 7P]^$>@_MG
M^$_B7XG_ &7=9\&_M>_"SX^?$F"^^'7AZX\;6GA+]IKX1>$-%TK5OV?/$_CG
MP'''K?A^VO=8\4Q6NO7">"=1,>NPZE_9OCWPE_X.(OVCOB?X _8M^+]O_P $
MN]8MOA7^W7\2O&_[/?P)U#3?VLOA]>^*/$/[0'A_5?$VA:!IUQX?U?X>>'DT
M+X0ZEK/ANZL?$7Q(UZ^T_6M M[#Q/K&G^!?$%GI7AJ#QN@/Z=9./%49?)3R)
M@1R0<6RD# /8ECTQDY)KJDDB&U%R,G !4@9.3U/K7\^O@#_@KG^T5\2O@7\;
M_'VE?L(:9I/[2W[-_P"VAXM_8P^-7PM\4?M7_#CPG^SU\+[GPAH.D^)]=^.O
MC?\ :>\4^$=#BL_A7:>'-4MK:"UTCX:ZSXKU7Q)+;Z9I^EFVOX=3MO)S_P '
M"E_;?\$]OB[^VL/V2],\3>-_@-^W'H_[$WCKX1?#G]HWPWX[\"^,-:U+4_"\
M$'Q$^"_QVT3P%<:'\0/#.MZ9XPTFX\,[?#&F6>KW3-MU>#2VBU2< _IB:>)9
M%A+?O& 8+@\@L%SG&W@D9&<@$-C'-.:54(5LY(!P 3U.!DCCD@CK7\@?[1O_
M  5M^/?[(/\ P4)^#'Q7_;7\#?$/X!W_ (C_ ."9?QA?2_\ @G5X3_: C^*?
M@KQK^TU?_MGZC\/?V<X!XC\)V*_"*Y^(?Q0\#Z2NIS^/[O2YH_A_X1_MFUFU
M&ZGT>;0M1^W/VN/^"TGQM_9,^*7[.?[-WQ"_9C_9Y\ ?M&?&#]F;4_VB_&TG
M[0W[;.C? /\ 9N\+ZS8^)[WP[;?L\_#7]H;Q!\'=5\.?%7XTK=6NS6(;G3O!
M/A/23>:/>#7K[2=8AU"  _HDHK\[/AQ^U=^U-\4/#_[#GC/P[^Q1JEEX._:,
MA\97O[3>IZS\??A)<77[(FG:#H8NO"FKV1\+2^(-'_:$T/XB^(([FR\-ZC\/
M=4L9X?#TNDZYK%AIEU>WFEZ=^ALIE&WRQGKG@'TQUQ[]/RH FJ%!+YC%B=GS
M[>01RPV\=1QG'ITXZ5(K X&06P"1^6?UIU !1110 4444 ,9$8@LH)'0FGT4
M4 %%%% #!&@8L% 8Y)//?K^=/HHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@!BR*Y(7.1UR".^._OG\C3Z8L:H25!RW7)
M)[Y[GU-/H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH ***A0RF1@P^3YMO '\0V\@Y/RYZXH ?)N*$)G=D8P0.XSR
M>.F?7Z41[@@#YW9.<D'N<<CCICT^E/HH **@8R^8 H^3*YX'3/S<DYZ>U3T
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M>/?&_A_P]KVGZQK^H:FUAH,OPQ\&ZOJOQ8\<V&H*NJV7@+PQJ6IQ6#+=6#3
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MTZWU*\\)WM\NE6GC/4(X99D\-^"+K5F72[?QQXF;1_!\VJ,-,BUJ2\'EFO\
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MXS.JZ/\ V!X=^)_CSPGJMZ=8T<^1''K&ERW?O_Q__:*^#_[+7PC\6?'7X_\
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M\.KXRMM3TG6_!7C6;Q1/J6@V5EX4\.^$/$WB[7I['PSH>HZE  ?8--#J25#
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M[X>EU#5$;1O&/@/Q=H7B+0+Z*^><PWCV&J6&FZO8:CIUKXO\8?\ @I_^S?\
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M$U [M( 6 &%/W0Q^]CD]<=./QYXJ49G^5P8R!D* 2PSP<L?E(YQ@ $'G)Z
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M?5OV6/@Q\ /BOX@^&UU^VE^R5KOP4^.'_!/KXP?$7QAX/M]=_94^$/QY\5^
M/AG??M&?#OQSH^L_$1/%=Q;:-\2+WPJGPW\)W.K?&[Q78>*?#EJ?V=\6?M<?
ML_\ @?\ :"\!_LHZ]\0!_P +_P#B3H'_  E?AKX;Z1X4\=^*;U/"\W_"1Q:=
MX@\6ZWX9\,:QX6^'6B:[=^#?%-CX=U?XBZ[X6L?$6I:!JFFZ!/JE]:RVX^D
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MTGT_4Y=/T"Z6X^Q:K>6>E3W$T7VW+&RL6!+;UQ@*?E*CM@G)8DXZ'COV\_\
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MK<Z=9?LOV_[6O@KQ5!X:T75VTM9-9\43_LD?!?X8_"^;0(;6PTEM6OM6TXW
ML[6>6?YJ^)7_  2U^.NM?&?]K#PWI/P<\ _$SP7^UW^TMXF^,NH_M)>-OVW?
MVLOA]X/\&_"_XHZ'X+\._$+X=?%']BKX.>*?!&@?&/QGX5\*>&]<^&_P\-MX
MUT'PKXQ\'W'@]/'?B708_#VK:%K/]$NI_$KP)HECJ&I:OXS\'Z5IND:RGAG5
MM1U/Q7H%A8Z3XE>&"9/#NJ75W?PV]AK;I=6K)I5Q*NH.EQ%(+;RY(W>;Q-XP
M\*^$-(N?$GC#Q'X?\*>';=HO.U[Q/K>EZ!HD/V@E;8R:OJUS:Z>GGD(80TZB
M9G"QL^V3: ?DK_P5N\-:G-^QU\&_V-/@5;>%O#7BC]IG]I+]F3]F;X2Z#XA_
MM:V\&Z;X;^'_ (BA^.GB71?$*Z+:ZOJH\%#X.?L]^*_#^M/;V&H31^'KF1)(
M+J6Z\B?Q7X_?L'_M;?MO2?&OXJ_'/PI\'O@UXU^,?@#]FW]D;0/@MX<^+&J?
M%+0/!G[(FD_M5>#?C5^V'KWC'XDR?"_PI;>+OB3\<O"^D77@WPSX$T;POI_A
MC0O#7A3P['J/BR?6?%>NCPW^J?CS]IOX*^&/VB/V<?V=]:N++7?BQ\=O#?Q5
M^*'PO^QMX=OM/T7P?\+-$T"RU_QG/JEW?)<:>=?N/B+X>\(^$WT.*[U3Q1_;
M6N_9(YM$\/>(9[3W#1?B/X#\1>)_$/@WP[XT\':_XP\'20+XN\):)XJT'5O$
M_A9[@C[(/$F@Z=?76J:$+IU:*(ZI:VI=E B$A(4@'P%^T!\(_P!J;P+^V1H_
M[8?[,/PP^#WQYEUO]F%?V7/%/PL^*7Q@UGX"WG@A-'^*]]\3O#/Q'\(>-]+^
M%/Q?LM5\/ZU)KE]HGQ+\'7&@Z/K$EKX=\$ZWX;O=6GTJ^T&Z_(#PK^Q^G[1_
MQA^+G[%TGQU^&_Q#^*WA']D?_@IWX^_;*^-?PABAUGX<?"3]O3_@JAXQTSX9
M^'?!":(FJ7&MZ2WP@^$OASXO>'=&\%^(-4T7X@3^ ;31-3\2_P!CW/B*WMX_
MZ;+[XV?".R_X2.&]^*'PUM)?"GAS3O%WBJ*Z\?>%+>3PQX1UFXN;+2_%?B1)
M]6@.B>&=2NK*^MM.US4&M]-U">SN(+.ZEEBD$>_X$U?P1XDT,>+/A[J/A77O
M#?BN5M=MO$_@R[T75="\4S2J+.76H-<T&2>PUV>4626D^HK>7;NUHMNTV( J
M@'X2?L]_\$P/B!?>,8=;^*G[/W[,_P"S!IG@'X'?$3X9>#-4^$W[0O[2?[57
MCV;XJ^._AIJ_P5'Q@^'$OQ9M_AOX)^!'@?PS\-/$OB[3/#O@FV\*>.O%VMP>
M*/[.OO%GA>UT-#K79^&?V8/^"E.N?L@ZQ^QUXE;]E7X*?#?X<?\ !._XD?L?
M^ [7X8^.?%WQ$F^/?Q?N?@E!\&/A;\4-;OO$?P=\%7G[.'PH\)65B^M_\(+X
M;/Q+\82ZUXAET[4M?OM#\(02>*OVFLO'?A">V\/W=IXI\,WUMXOFN;;PI<67
MB+2+F#Q1<6%K?7]Y!X9EANW3Q!<6UCIVH7ES;Z4;J>"VL;J>6-8H)GC\1^-W
M[5?@_P"#'A^+Q7]CTSQOX>TB7XL7?Q&N?#_Q"^'MAJ?@#PS\%_A5XX^)'C[7
M9/#VO^(M,UOQ;?:!J'A;1?!.M>$/"-EJOBSP]JGC/3-<\0:5IGA?2];U>Q /
MFG]K+XE>*/V:/^"4/QB\4:AX2T/X;?$/X?\ [(E]X)\-^!?"?BR]\<:'X3^*
MFN>"+;X7?#;P=X>\9#PSX+O/%EO:>.M=\.:)IVJ6_A7P]/JLAA^R:;9O+%7R
M/X%_8C_;LB\!?LT_#GQK)^S3X(L?^"<'[-?CWP'^R3J'@+QOXY\2P?'O]IJ7
M]E[Q+^RW\*?C5\5]*U[X8Z./@A\./"GP^\7>+3J'PXT:]^+_ (BO/&?B^?4[
M?Q1=Z;X+TNV\4_H+^SQ^V;H/[2WQ&MOA-%\*/&'A'Q#!^QY^R_\ M<>/8O%%
MUX>O[;X;R_M1:A\1D\%?!?Q1;Z?>S3_\+&T&'X4^)=7U::UB;14MX+.XL+QY
M)(\[FL_MP_![PC^UAXE_9.\9:UX8\$:QX:^%OP4\<1>.O''Q%\!^$=!\2^-O
MC[XU^+_A3X>?!?PII'B#7;#Q#XC^(^I:;\%?%OBZ33=)L[PIHDVC_(;G5+1)
M0#Y.UO\ 80^*_P *_@E_P3 T_P#9O/PO\3?$O_@FC:Z!8:7\//BAKGB+P)\-
MOC!HU]^RSXQ_9J\?P'QSX9\%>-=6\!^+I8_&-YXU\*^-F^'/B*#[<FJ>'=7T
M&WL?%%]=6GQG^U!\'_'?P0N-$_;=_:L^.O[-WPH_:J^(?[:W[.?CKX<:=XKN
MOB1-^Q!\-O"G[.?P6^.O@[X?_LW_ !-_:%N_!=IXB\'VOB7P;\7?VAO&L?[1
MGC/P1X;T.'X]>-_"NEZ-\/[JSLM*T/Q#^^'COX__  4^%VO>#_"WQ+^+?PN^
M'7B?XA:C_8_@#PWX^^(O@_P9X@\=:M]HBM/[*\&Z+XDUC3=1\3:E]JG@MS9:
M/;W<XGFBM]IN'6$^E:IJFG:;H^IZOK%W8Z;I&FV5Y>ZM?:I<V]IINGZ=91/-
MJ-YJ5W=O#:6MC9VT<\][<74L5M;VT<LEQ)'&DC* ?S>_LW_L^_';]O73OB;^
MU'XX\0_#)O#WQR_X*?\ [,GQ/O[S0K7QU:?#WQ[^Q9_P3SLM%U?X2:-\(F\2
MZ);Z[XQT/Q7^TYX7U;Q-H?BOQ3I_AOPY\2?"^JZOX_T>RT[2=?T'19?6?VNO
M^"6WQ"^*W[5W[07QU\ _"']B?XS)^TSX7^#UC!XX_:R?XH7'BO\ 9B\8_";P
MM<> YM;\)>!O!?AC6='^-G@+5/#$=AXHTWX;:QXZ^#)L/B&OB&;4_%%[I/BN
M?[#^RGP_^//P4^+>M>*_#_PK^+_PK^)_B#P.FB2^-M$^'7Q&\&^-];\(IXCL
MCJ&@/XDTCPWK.I7VA+KU@OV[1&U6&U35+(_:+)Y($8IG?#7]I']GGXR>)?%O
MA+X._'3X,?%WQ;\/V,'CGPM\,OBKX#\=^(_!<Z7L^GM;^+="\+Z[JFJ>')EU
M*VGT]DU2UMMM]#-:'$\,R1@'Y(?M1?\ !-_XU>.? _A;]GSX7>!_V+OBU^S;
MX/\ @!X)\ ?!KPI\7-#\1_LX^-?V-OVAO",.N6<W[3?[.?C/X ?"_P 2>*[8
M>*;34]'OM5\ ^'/%?PJU'POJGA*QL/"?CO3]$\2:W;+@_M1_\$X_VTOCOX>M
M/A7K?Q$_9M^/VDZ-\(_@]X=^ O[7'QAB\?\ PC_;#_8D^./@_P"&^G>!/BK^
MT'\(_$'PA\)ZCXG^*FM_$CQ/HUA\:;'1-8^-7PN^P>/;F^\%>*M3\3^!(K6Q
MA_9?P!^TO^S[\6?&/C'X>?"KXX_!GXF^/_AVTR?$'P1\/OBIX&\9>+? LUO?
MOI4\/B_PYX=UO4=9\.20ZI%+IL_]M65@D%_%)8RNMVA@JK\)_P!I#]GSX\7?
MBO3_ ((_'7X,?&*^\!7R:;XYM/A9\4?!/Q"NO!=]++>0PVGBRV\):SJTWAVZ
MF;3M0CBCU=+,336-W#"\CP2A #\8?VD_^"3OQ+^(G[0G[1GQ)\#^ /V$/C)/
M^U)+\)=:OOCG^V#\/O%/C?XO_LU^)OA[\%O!'P&UW4O!?PST_P /:CX#^.OA
MS5]"^'^F^/\ PCX)\2>,_A'H'AKXB:YXL7Q _BSPAK5MIMGO?M4?\$P?C[\6
M9]&^&/PN/[*&B_"3P-X=^#>D_LC_ !NF\+ZK\%/VE_\ @FOJ?@/P[X?\-^/;
M_P#9HL_@I\/;2U\?:3XZG\,Z?XVTGP5K'Q-^&7@[3?$$UYX0\4:3XO\ AW%I
MVAVWZ^?"?]I3]GCX^:CXMTGX&?'GX,_&74_A_?1:;XXT[X4?%+P7\0+_ ,'Z
MC,TT45CXGM/"6L:O<:)/+<VM[;1+J,5OYEQ9W$$9>ZM[J"#YRU#_ (*,_L\Z
MW\<?V;_@5\#?'/PU_:*\1_'CXR?%3X3^*+[X3?%KP=XLMO@JWP?^"GC?XP>,
M]9\<Q>&)/$>+VSG\-^&_!:>';FXT6Z;6/&VG7#WR"T-G> 'U[X#E^*-Q<^-H
M?B=9^ [6*'Q_KL7PV?P)J?B'59KKX81V.F?\([?^/?[=T;2(-,^(5U?MKC:Y
MI/A]+SPW96ATL6&K7T\UTD?HOF&',8 8+W.1G=\W0 @8W8ZU\<^-_P!N?X&_
M#[]L+X%?L0:YXG\-0?&CXY_#?XD_$[1=,N_'?@?2KG2-"\ 7GA/3-(TVZ\.Z
MIKEMXKU;Q)\2K[Q)J\W@#2- T34?[7T7X=?$G6I+F"V\*7,<W(?LG?\ !1CX
M ?M5?9O#^E^-OACX0^+GB#Q-\;1X'^!-Y\7_  7K?Q?\4_"GX3?%OQM\,]#^
M, \"VLMEXCL-!^(6D>#&^(.G6"Z7?C1_#FKV9N-5OEBFNP ??D;EUW$8.2,<
M]OJ!4E?*]A^W%^QSJD?C>?3OVJ?V<-0M?AGX.C^(7Q'O]/\ C?\ #F^TSP%X
M'FUN\\-1>*_&.JVOB"33O#6@OXBL+O0DU+6KJPMVU:WGL58SQ%#J^"_VPOV6
MOB-\,!\;/ 7[1?P+\9_!X^+]'^'_ /PM#PM\6/!6N^ T\=^(==T7PQH/@J?Q
M1I^K3:/;>+]:\1^)O#6A:7X9N;N+6KW5O$.BV4%D\NIV0G /I,D#J0/K1D>M
M>2Z]\:/A1X?U/Q]I/B+XE?#W0-4^$W@O1_B-\4;'6_&F@:5/\-_A_P"(9?$J
M>'_''CU=0N[;_A$O"6MGP7XP.F:]KOV&PO4\+^(#:RSG2-2%I\H_$S_@I7^R
M?X?_ &:OCM^T=\)?C3\&?VBK+X)?L_\ Q0_:!'@_X2?&+P7XEU3Q?X=^'%KK
M%F;2QO/#]WKK:7::UXYTE/A\->N[";3=-\07?DW(EEMI+20 _0.60Q@$ ')(
MY..@SZ'T-#J)54;@#D-QANQ'0]N:^:/V??VK?@A^TQ8:U9_#'XJ_!_QOX]^'
MEIX;MOC3X#^%WQ9\(?%6]^$'C'7M,>XE\(^*;_PM<MY<MKJ=EKVCV&J36%C;
MZS<>'M5,$%O<6=Y96OGL'[='P6D_;KOOV!K/6_#DWQ>T7X Q?'+7EE\;^%K2
M]LGU3Q))IV@^ ++PE)>-XAU+Q1<>%-*\0_$;7-L-M%X<\'6WA_4[B*[M/$\%
MU8@'VND(C;=NS@$?= Z^XJ;(]1^8KY7^#/[;'[(O[2?B_P 5?#WX!?M+? SX
MR>-?!%O/?^*O#'PT^)WA3QEKFD:;::G)HEUJ\FFZ+J%U/=Z);:W$^C7.N6 N
M]'MM4 T^XO8KUXK>3(_:7_:<A_9Z\3_LN>$;7PG:>,-9_:6_:&MO@U$EUXGM
M_"UKX)\&Z-\*/BC\:_BC\7-5N)M,U6.]T;X>> ?A3K-Q<:=.NF6MUJ%_I5M<
MZSI<-U]IH ^N3$#+YF[!RIQ@=<  9Z\XX_2G/$&=7+8V[>,#^%BW4].M?GI\
M"/VZ=&_: U#XH?%[PSX1TCPE^P5\,O#FJ7.D?MG?$GQG!X)\.?&/Q!X>N9)?
M&7BCX4^$]6T*V@O/V;/"6E65Z&_:)\5>*?#FA>.]=M9V^'.A>)O!%E#X[O>O
M\-_\%#OV/_BI\'/C=\8?@?\ M+?L\_$OPU\"O"6K>(O'^NP_%K1M.\'>!Q%X
M=O\ 7_#][\2?$$5KJ5YX(\'^(;>S:YLO&-QH=_IUWI45]J.B1ZTUHMK, ?<&
M1ZC\Q2U\6:?^VW^SCH/B;P3\'/BO\=?@-X-_:<U[1_"#>*/@3H_Q7TCQ-XA\
M/>+?$7P_'Q%O--LH9+/1O$%QX3BT"VU76M%\;>(/#/AC3]7\*V2>(;J+3HYI
M8X][X$?MV_L?_M1:QXJ\/?LZ?M'_  ;^,^N^"M)@\0>)=*\ >/=%UR[L/#=S
M<RV5MXLBCMY<ZGX+N[V&6RL_&NE"^\*W-VAMH]7\]HXW /JK[2VUFV#@9"Y.
MYO9>.2/3ISU]98YMYP8WCXSE\#GTZ]:^4?@/^W7^R!^T]XK\4>!OV??VCO@_
M\7_&'@[2TU_7?#?@3QMIFN:O#X8?4SHR^+K*TB9'UKP>VK+_ &9'XMT$ZKX:
M?46CLUU4SRQJWU7/RL>0.2??^$GN!_(?2@!DDC/N3  #GG))^5O3&.<>M0Y7
MJ!^(4_S I3NX"H7/]U<9P._.!QQ5I7$<*,P(P "#C@].<9'ZT 5$<QN7#9!Q
ME""!]W'/?'0].M75;S8V#84MN7 .>O&><?4?A5?(EE1D.W*DD]=R+QLZ#'SX
M.<MQD$<C#O(\L;]^=F7QM&3AB^-V>,].G'H: )XT$8*[LY.>@'4 =!]*DJB7
M\R1'V@8:-<9#='SU [YJ]0!%%%Y>?F+9"CD 8"Y_QHED,84@ YSU)'09]#1%
M*9-WR[<!3USD-GV&.E1W08JH5%?YLG<6XQR,;2IR<=<\>GH 6 > 3@9 ^F:7
M(ZYX]:K3<QQY&"67(]#L;CGT-1@F14A"X7:"9/E90P&=NW.<G//3'N#0!=IK
ML51F S@9P:83Y,0_BV@#^[G) Z\XZ_XU7:XWJ5*8W C*L'//HH )_/WH LQN
M77<0!R1@'/0X]JDJO$V(68 G:6.&&TG'S'U]P#T]JDBD,@+8"X.,9W=@<YP!
MW'ZT 24P_?3Z/_[+3Z8?OI]'_P#9: 'T444 %4%0R,X4@8+$DD]V; X].O/K
M5^LX[MS",L$P223ABRMST['G&>YY' P (QYVL')!*%8G8JRCC<5QN#_+G(XY
MZG(-1OL1=B.T>XY$;',[E>?E5LD^A).,#=P,D*'!*IOWL[[@-N"H8,?F8'=Q
MD;L9SUY-*R>8I7='DCA@W((.=RLRN,CJIQG.,$'!IIV?]?JF!5=6=4C=I!N+
MN'.(W3ACY4N=ZN /WFU/*) "Y;.6$4B'<\BSQ("RJ8_)C)'\;KU+ >N Q&6P
M>:F5HP!'(87 (&UL%PRY <_NR'8D Y89&?4;JD$;8</&X5V'ER*XW G );"@
M!>F,*>/O D"M+Z7:_%=>VVRZ+SW 9" $3 C7+# B VQDE  A);D!@VX\Y/3
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M]EC2M*\!_!2Q^(?PO@@FB_:6^)O[3/Q(LM#UK3_!_P =+?XD:%K_ ,+OB-X
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MU[3YK--26QTBV\4ZWI&DQV<ES:I>^7'K&I:;I9DL7N(4DGM;$O9><L/G6OF
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M/B]IGCKQ?XNCFUJZT<^(?VC_ ."H-QXM^"7_  2,^//PR\*:AXO^*OQ0\4?
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M\:_%SQ_\(_AIX7^$]M\8_A1/%XNO/"/@76OB%\>_BEXD\=Z]//>ZCH%CX?\
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M_L7>%/B+X'_9WE^('Q(UKQ;+X+\*_$S0="\):AI,PO&@AUJW\)^!?#FF^ _
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M._ 3P!^T-^R5^PIX@3QOX:E\1W/P#^'7@/X1?\$U?@[\0_%5E^SUX5O?B_\
M'GP'X'\2?M*?MZ?&S6=+^&'AOX:_LUR6?@KQ'K>I:S\0+7XCZ-_1M^SK^QK\
M(?V8A\0-8\%:K\4O%GQ,^*UOH5K\1/CI\:OBGXN^-GQO\46/A:QN].\':+<_
M$/XD7NMWUOX:\"VVH:C<>$_"5A;67A73=8U36=<.AS:OK>MZAJ7#:Y_P3A^
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M/%=IHT^E^,]-\006&D6NF]=\:/C9\?OV(?B9_P %+?%EQ^U/\8/C?I/[-_\
MP21\,_'7XFQ_$CQ#X<G\*Z7^VE\5O%GQFTKX*7_PJ\#:?X6L?#'P:T2?2?A%
MK"W_ (/\.1SZ#<Z=KWA'4=9TW6]?LKO7-9_=N[_9U^ =[H_B7P_??!SX<W&A
M^.?B_HWQ^\;:/=>$]-DLO%/QN\/ZWX6\1Z+\5-<M/(>'4_'&EZ]X&\&ZM8^(
M+OS;N"]\,:+,D@.GVOE^&?M4?L4^#/VB/#.N>&]#TKP)X,E^,'QM_97^(7[3
M_B"Y\$PZOK/QQ^&?[-'Q'\*>.[?X8^)+Z"\T^6[37M)\&6'@2TN=9.JZ7I?A
M;5O$-D^E746J31N.+2OZ;/U _'KXW_%SX]?\$]KZZDG_ &S_ (R_M3>)4_X)
M!_M2_M!_M%Z5\5?$/@O7_"FE?%[X9Z9\#O O[+'Q0^%>B^%_"?ANW^&=U\:?
MBSXI^)'P[T/PSIE_>:3\3;+3+WQ%JG]M>+?!7B#Q??\ EJ3_ +4GPVN_&7[(
M'A35?VHOAG^RQ_P2J_94_94^!^L>//V3OC7^Q-\"/(^+W_#-&A?%;XG?'[XX
M^*/VKO&WAO5-7^'/@_P]J_A./P?H]IIUK\)_$&LV?Q/OO',_B!],^Q:3_0'X
M-_8)_8M^'W@7Q_\ #3P7^S%\'O#O@+XJ>)?"OBSXB>%K3P?IS:9XRU7P-K6F
M>(O!"Z]%<">6[TKP+J^CZ9=>#?#GG#PYX3:U%OX>TK3[.6:"0^,7["/[''[1
M/Q)TCXN?'/\ 9J^%/Q0^(VAV6D:9%XC\8>&[;56U;2?#NJ2ZYX6TOQEI+2#1
M?'>F^&=8GN=4\+:=XVTW7[7PUJ%W>7>B06%Q>73S"BVM/Z] /E+XS_M6?'KX
M#_\ !%SQQ^UA\;=3\(>'/VH/!W[!5YX^\1ZSX.UOPIJO@D?M%:M\*HK/PSJ/
MAK5M/FU7P;>:1K/Q.UGP]?Z6=&GU3PY(NHQ6NESZG8?9UN_CKXF_%OX^?\$Z
M/B1\1H/%?[9OQI_:L/@S_@D/^TC^U9^T9IOQ<B^&K:'X+^+GP+E^&/A7X#_$
M7X:V'@GP!X6B^&EO\<O$$_QE\,V7@68ZWIWC-O ]UXAN/[6\3^%?$^OZI^MO
M[:7[,VI_M8?#3X>_"&+6O#.E> [;]I+]FSXJ_&#0_%/A]_$FE_$/X3_ ;XM^
M%?C'JOPK72F8Z<\7CW7? WASP_JR:U;W>C3>&;C7;2]LYC<PJ6>"_P!@']BS
MP!\-?B3\'O"/[-OPRTCX;?&2[T*^^*/A(Z/-J%AX['A>:RG\*Z;XBN=4N[Z^
MU'P]X3^QP1^%O#/VW_A&O#EH9K+1-+LK*]N8)TU;3^N_Z@?AWXNTG_@H5\-?
MB1^R9^R!JGQP_;B_:*^+/Q@_9"D_:/\ VT=<^$OQ=_9B^%GC^[UKX0+\./A/
M:?#']G6_^*O_  JSP-\'? TOC[XG7WB#XR^,/ R:G\:_%L'A_P"'QN?$^FW&
MN^)M;O=KX>?';]JWXG:%_P $\?V7?$O[4_C;X=77[1_[=G[8 \)_&?PI\7_V
M=_BG\>_B-^Q1^RI\+?B7XA_X5GXV^(?PMTWQ?\&M;^*I^(NH>'_A;XQ\3>!V
MOM:TS1O!:>);S5KCQZU_JM?O#^T)^R/^S-^UAIOAC3?VDO@GX"^+L7@K4-2U
M/P?<>+-'^T:KX8NM<MX['Q!'H>N6,EIK.E:=XEL(+;3O%&E6FH0Z5XETZ&+3
M]>M-0LXU@7Y<^('_  34^!OQ;^/_ ((\1_$CP+\)]?\ V9?A#^R7/^SI\'?V
M8X/AYIFF^'_AUXDU_P"+'A+XAZ[\0O"D^DS6%MX/DT_P]\*_A9X6\$1>$;30
M]9\.KI'B.YMM2^QZE#$$!^6VE?M ?&34?!GB7]B_X<?';]LCXY7_ (L_X*'_
M +1_PR_9C\6_#CQK\+-+^/WQ;_93_99^&/PGUW]H/PQXD_:]^,>M>%+'PGX3
M^&7[2'CKQE\)+KXT>&O^$[_:!UW0O"]IX)\'))JD'B#Q]X8X[X7?M!?M9?$3
MX'ZK\ ?AM\?OBUX*UKXN_P#!:_0?V,_@C\2M2^+_ (:_:(^+7P@^!'P3^$7A
M7]H']JBVTSX\>)?"S67QCM;/5?@]^T1X3\,:CXYTKQO<Z?%XATWP#KVJ>(+?
M2$BM_P"@7Q[^Q!^R'\4?A9X!^"/CW]FKX.>)/A%\)Y;1_A;\/+KP+HEGX7^'
MCV6G3Z1&G@K2[""UC\+Q7&D7U_I6HP:0;2#6-+O;NPU2.\M+N>"3J?!O[*/[
M,?PV?P=-\/?@!\(? $_PZ\7^-/B%\/X?!G@'PWX8M?!7CGXB>&;OP7XY\6^%
MK+1=/L[+0]?\7>$[^^\/:_J>G0VUSJ6DWMY9W,CPW4ZR '\UO[:GQ/\ B+\*
MO _[<VO_  >^+O\ P4&\7?![_@GAX'\7?#V3XN>(_P!N#P9\!/"7@O\ :D/@
MS3OCSK;:CXFU_4?''QZ_:V\?79^+7PL\-^$?!GQ,^'!^ =C%%I_PF^'WA+7O
M[1US5+OT?Q+XK\<?"GXE?\%6/^"BGQ*^)'Q+D^-?[$O_  3<_9Q^!PTZQ\=Z
MAH?PBU?]IC4OV7/%GQU\=Z38_#.RMSI-II^J>-OB[\"]2\,Z%-:SP:%XTUS6
M]:L;6:_U-8+?]T?B#^P-^P]\6_B3XC^,GQ5_90^ 'Q%^*/B[0/\ A&?%?C3Q
MO\+?"GB?6?$NBQ:2-!MX->DU?2[R'5KBUT!$T.TU.\@GU2TT:--*M;R*Q1;<
M=AJG[)'[,/B7Q-\3?&NM_L__  BUSQ1\9]/\ :7\7-=U?P/H5_>?$VP^%EWI
M.H?#>#QN;JTEC\2KX*NM!T*7P[+J\=S+IPT72([>18=-LDA /QA\+:;XL^(%
M_P#M6^$/VPOV[_V@_@[\./\ @F!\$OV;?A/X@U[X9?'S7/@CXKU[QSJG[(OP
MZ^./Q?\ VS?C=XWT.XMO$OQ*OM>\2^,I?"OP_P##'B>XE^$C:C\./&TEYX0\
M5ZKK=W!I?@/P_P#BU^T;^TA\,/BE\9/VF?VCOVAOA3X<_9)_X(O?LT?$;]H;
MP!\&/'^N? 36/$O[7GQ:^'OQ5_:.\4^,O%#>"#X:\3>"/'7A7X9>%?A5>ZAX
M4\,ZCX2$NJ_$BZ\+ZS9W_A:W.BS?T)_$_P#8Y_9 ^-_Q"\/_ !=^,7[-'P+^
M*/Q.\*1Z9!H'Q ^('PK\(^*O%6F0:+?RZGH=K'KNNZ->7TEOH>J7$^H:):7$
M\T.C:E-/=:;%:W;RR'T#5?@I\'M?T_XI:7K?PM\ :MIOQRN;:]^,UAJ/A/1;
MNU^*MW9^&-#\%VD_Q!@GLW3Q;):^$/#7A[PQ;-K:WA@T'1-,TJ/;9V<,* ''
M_LLR_$B#]G+X!:-\:/$L7BGXY:'\#/@W9?&W68Y[1KS4OBFWPV\,OXXU?4;2
MT6.*QGUSQ,-5U2.!;>VA,,ZSV\*PSC;^?'QF\->.OVHO^"DWCCX.+\:?CGX)
M_9Y_9>_8A\ >-_BE\/?@-\8O%OPCU/XG_&K]I/XQ_$"Y^'FD^(O$'@:\TGQ;
M8-X-\"_LT:MJ5N_A;6]!UR[3X@6&BZEK#>$=<UK0?$_Z/_#OX*^$?AW\1OC=
M\3=&L;F?QG^T#XP\->*?'VN74&CP2W"^"? ^A?#OP;I$::3:Z>9=&\.^&O#\
M-O9W.I-J>ORW-_>/>7\UBVGV.E>A:3\/O 6@>)?%OCG1_!WAO1/&?Q ?P\_C
MOQ9IFC6&G^)/&,GA+3)-$\+-XHUNR@AU'7F\.:/++I>AG4[BZ_LNPEEM;+R8
M9'1@#^43]E[XN_MK?%;5/V!_VD_%WQ,N= ^,7[9'QY\&?$G2[C6/^"CUYJWP
MA\9?L]:EJ^I^-/C1^S;\.OV!?"GPXU+P),/A-^SCI_B/2/[>N;>W^*/A;XP>
M&K'Q1X^^*ZZN;[1;OW_X$?$GQ%XJ_;>_9[^,&M_M*_&?XG?!O]M#]H#XX?$G
M]CG]I#X#_M2>-]4^"7Q ^$.B_#+XB?$%/V-OVD?V ?B=86'A'X3:1\-?ASX-
M\0K;_'#X:^%M8\6:AXY\&:!J/CCQ)\.?%GB74-*NOWC\ ?LG_LK_  G^)'C#
MXQ?"G]G;X(_#OXN?$&2^/C+XE>!_AAX.\+>.?$\NJ7AU76DU;Q5HVC66KW;:
MSJ$;ZMKD;7N=7U-1JFJ+=7NVX)X"_9-_9?\ A5\2O%'QE^&W[-_P.^'?Q7\:
M/JLOC#XG>"?A9X)\,>/?$+Z[<I?:_-JOBO1-%L]<NYM?U".&_P!>E:\\S6KZ
M""]U0W5S;PRQ@'X.?"#]J'QY\8/V7?\ @F#X/L/V@O$Q^/W_  4G_P""@&I?
MM/3Z-I7Q9UJX\?>'OV.=(^+WQD_;+UWP';S6FI3:SX>^%^B? ;X<>!?V>]>\
M*0-IN@P1>);SP7Y BEU&$>-_LZ^"?A_^U/\ M$_L<?$SQCXJ\<1:?\6OVE/^
M"M7_  5<G7P7\5/BAX OM4^'_P //B'X _9'_9:G>U^&WB?0M6\7I)\&;WX?
M76EO"+TW/A/3?$WA"WL9?"7CSQ/H.K?TG> ?V4_V7_A1KLGBCX6?LV_ 7X<Z
M_+KNO^*9?$?@7X1?#_PIKA\1^++6XL?%FOG5M"T"QU$:QXCT^[N['7-0%P+O
M5;*XGM+V2>"9XVU8?V<_V>;/4?@_JNG? SX-V6I?L^:=J.D? ?4+3X<>$+*]
M^"^E:QI4>AZMI/PJN;;2(9? &EZIHT-OIE_I_A9M+LKNRM[>WN(9(K>%8P#^
M?K]EGQMJFL_MT_L\>-]:_:$^+OQ>\,_MC^-/VEOV@_V3_P!I/X'?M:?$KQC\
M'/CC\ I_#/C7Q_H_[,_[4?[!OQ3^R>$?V<[?X)^ ]>\-:+X.^(/P@\)F]O?'
M/P_T'2_&>N?#WXD>)]9T'7_M/]NCQIX?^(?[>/["G[)'C#]HKQG\$?A_JWPB
M_; _:3^+N@^!/CEXD^!6K?%S0? >C?#[X8^#/ASK/C#P?XG\)^(8O#=Z_P 3
M?B!\0IETCQ!I6LVD7PON-1TS4M,?1KS4;3](?A_^R]^S9\(?&GC#XB_"K]GK
MX)?"[X@_$!KJ7QSX[^'GPL\#^"_&/C)K_4EUG4F\3^)?#6B:=K.M'4-85=6U
M$:C>3C4-3S?W8GNR9CXSXI_83^$/Q/\ V@_C-\;_ (]^'/ ?QYT#XI?"']GW
MX/:'\(OBM\+_  EXR\$>!=)^!7C#XS^/VUJVA\1C6[77M<\6>+?C'=ZG=7ES
MHVF3:3%X9T6"UDO3NDA /Q(^#VM_%G]HOPA_P3J_95\.?M"_M#Z;\&?BC^VY
M_P % ?C=X/\ BQI/QD^(6E_&WXF?\$T?V5=9^)OA3X.Z)K'Q<AU9_B%XJ\"?
M$S5OC!\#M(\.^/M3\5-XE\1?"N7P=XLL?$$GB"33M5MO+_&>J6"?LL?M2_%;
MP]^T]\>O!G[:/P=_:V^(_P"Q9_P3E_9R\-_M:_&J35?A3XR^#?QFM?@K^S=\
M*/$OP8U/XAZS+^TGXC_:#L-,TKXW?'GQ7\?/#_QAUOQ3\'OB/?ZS#KVB>!/#
M6E:OI/\ 5K#X#\%VFL:#KT'A#P[:ZWX9\/7W@[PSK,&C:5#JVA^$=3ETBYU+
MPGH>H);?:=&\*7\_A[0)KSP[ILMKI=U/H6B23VCOIED\7&#X!? G_A:LOQ\@
M^"/PA7XYOI@T>3XT?\*W\'+\6Y-(6UEL4TK_ (6/'HJ^,3IRV<T]HMJ=7$0M
M9'A\L1NR4UNO5 ?@AI^H_"3X\>)_$WQI^.7[=WQZ^#W[5WB__@IW\2_V6/V5
M_!'PD^,WQ5M9?@U!\ _VE[SX8^"?@L_[(O@SQ$WPM\9:7\4?A;\/KGXE_'KQ
ME\8_A?XHL4^&GQ:O/&GB#Q1HG@_3/#5Y:?$MM\4_VI_CKXF@^-[_ !>^$W@3
M]J3XL_MZ^+_A3^S=?:S_ ,%/OVFM \3_  53X9_M+:CX%L?V4]1_X)I_"+]E
MKQC\'O$NDV7PG\"ZC%\;[SQ[K6M/XELM>U[XN>+_ (C>#=.;PS<^%_ZRK'X$
M? O3_BAJGQYMO@I\*-.^.6N:/%X>UKXRV'PW\(P?%S6-!BB2UBT+4_B+;Z,O
MC34])CMH(8%TVZUB>T$$:Q"$H@406'P*^!>A_$[6/CAX?^#'PHT;XS>);"/2
M?$WQBTSX;^$=.^*WB'20L, T[6?B'9Z+#XRU6Q$,,,9M]0UB>+9'&H0JB57*
MW+3ROV^]?=U\P/YS?BG\1O"GC/\ ;RT3XQ0?M#>./BA\-_C#^WQ\,/V8?A)X
MA^!7[4GQ5^#/[37[%7QC^$6KV?PM\;_L^>,/V)/%\3_!GXS_ +,?CKQ_\,?&
M?BCXJ^,+_P *V/CS_A7/Q:\2^-Y]"\3>%]#\&>/--I:1\2O OBW]O/X9?'B/
M]H/QO\7_ (7?M0?ML3^&?@/\3?@Y^U?\7/A?\>/V:-7^#/AW5[3XC?LC_M _
ML%?$=)?A;XA_9/O-2^#7Q$MOB!XWT_PYH?C?0;#QD?%?B'POIVH/X;^)5I_2
M+!\!/@E:_$^^^.%C\%_A-8_&C4;(Z??_ !EM?ASX-M_BI?Z:UE_9IL;OXAPZ
M.GC">U_LXBQ,,VKM&+,M;X$0""'3O@+\!-(^(GB3XK:;\&?A'IWQ7\564FG^
M)OB/IOPV\':?\2?$EE?1-;W%GX@\:VFB0>*=7M+^.![2X@U75;B"Z2,P3+(I
MV%2LK6?K9^?EU]?F!_.A^RS<?$+]M3QC_P $\O /B[XX?'K0_"_QU\._\%%_
M^"JOQO\ "_A+XY?$[P+K6N_ 7XR?&JS^&W['GP;F\0^%?%NF^+_#_P ,D\ _
M'""ZT+PKH&K:%H]M:?#&_30W@N(I9D\P_9K\:_#OQ_HW[*'PA_:-_:3\?_"'
M_@GO\7+W_@J/^TU\*X?'?[3'CKX96OQ=\,_#_P#;)T;X?_LL? S5?VCY_B!I
M/Q*UKP/\/?@=XFU_XZ:;\/D^++WGCBPUCPS>ZU;:QX4^'NHZ;;_U4Z3X#\'>
M&KBQNO#?A#P=X;NM+\+:;X(TJ;2O#NCZ1/IG@C1IFGTCP983:?96\UIX3TNX
M>2?3_#EB\>BV<TDLEM9QR2NQ^*?VE/V(O&OQEU?P+)\(/VE_$_[-G@WPEX2L
MO!K?"_0O@O\  OXI?"^P72]9O=1T/XD?#7P=\3_!^H:;\)_C=X9L]6U70_#_
M (_T"'4M,M="NH;.\\':H^G:<T#:;=[KKM?]%_5@/'?^",YNO$7[)&O_ !?A
M^*'Q5^*W@[X__M,?M(?$?X,>(_C#XW\3>/O%</[.NE_%35?A+^SOIL.N>+]7
MU35CX>/P=^&?A'7;&*ZE75=0_MR75-6DE\0:QJ^H7OX>_$/X[VGQN^)'P6^/
M7PY\:VO@;XJ?M-_\%0O@K\+/@AXC\;?\%'/BYXF_:T^'/@CPK^U=IG@GXG^"
MK3]B'X8?#;PG^S[\*_@[_P *G\#^._#>O_"KQKXI\3W\FD^+A<?%3Q/XC^*N
MIZ#9C^L_X%_!GP1^SO\ "#X7? CX8:?-I?P]^#O@#PG\-? ^GWEU<:CJ$7AW
MP;I%KI&FSZMJ;(LFK:Q=QVHO-4U2X2.74=1DGU&:)+BZE5+&F_!OX/Z1XE\0
M^+K'X3?"_3_&7C#6M(\0^*?%VE^ ?"EAXH\3^(]!N#=:!K?B#Q#;Z,FIZUK>
MAW3/=Z3JNHWESJ6EW):XL[F"0,Y;BWL_Z8'\TO[0'A6;X^?!O_@H+^U;>_$K
MXTR?$#XO_P#!3#P+^QK^P+8:3\=/BUX8\ _!_P 5> OC+\$OV&=%^)7PU\!^
M$?&&D>$[_7;GXP:#\5_B1XCO[^RO=/U?P_X>&F/;V=I>^*9]6\8_:Z\4? ?X
M[_LR?MP>,_BW^U'XFE_X*)_&C]LOX]_L'_ 'X2:#^T;XX\&>,O@3H6L?M-WG
M[(_PG^!OAKX!>&/&UKH-EX$\:_!>?3?BI\9_$6N^ +H?$W3OB1J'C'5-2O _
M@$:3_7-'X2\%QVMCI-OX5\+0V6G:W)XPTS2QHNEI;:=XCEU.\UF7Q3I^GI8Q
MQV>OS:WJ&H:JVN6D<>I3:Q?7UZ;E[^ZN)),R3X8?"QO%6K>-Q\/_  !_PG6O
M#18/$/C2#PGX9?QAK'_"+75KJ'AM=4\2BQ_X2#43X;O["QO-$:[OYCHVH65K
M<:>;>XMH2J2:>K7W]M>O]7 _-O\ X*IZ?>VO[)'PG_9*^%OB[Q/\']:_:@_:
M7_9,_8[\!>+_ (<Z_J?ASQUX&\%7'Q)\/^+/B3K?@[5](FM]5MM9T'X"_"KX
MA26-S!/&=/%N]W>3?88I]_Y&_M=^%/AC\&_VO_C!\#/&&H?LY>!OV/\ ]G7]
MG;X?_&CP9\'_ -K_ /X*"_M/?L[67Q?^(GQU\6_$?4?C5^T[9WW@SP=\6/B'
M^TIX\T.X\"^'?A7H.DZQXCU>\^&OBKS-1\,>&H_%7Q)T*[']7)T_0M9N-.GE
MM-/U=_#^JR76G75S;66J3Z+KRVEU9S7%I)/#--I.K066I7ME/-%]GU&""^N[
M1I!#=31R\OJ?@_X8?$:Y\,>)M:\-^"?B!/X8OI]9\%^)M4T+PQXQ'A^_$Z?:
MM0\):WJ-IJ3:-?FXM%2XO-(N[603VL:/*)+55C7*WU7I=@?S/VWQ2_:Q_8TU
MC]@"]N/'NM?'C]I/]KS_ ()K?&+]F3X#>'_%$WQ>.@>+/VEM$^/_ ,#_ !U^
MRYXA^)FD_%#1_#OCJU;X7? KXT^-_$G[0?CSXA>"O#OC_4/"/PD\77?B0Q:R
M;335YG]I?3?C'^REI?[57@?]G?X^^.KS7_\ @GQ_P3+_ &<?@EXB^.7CKQMX
MUO[C3?C-_P %"OVL+CQ'^TU^USX[N(K?QG-H_B3X8_"+X<W'QUF\3VNC^)[C
MX<:)XDO#H.C1>'=)LM-N/ZOI-,TN[GMM1N[&SO+W36N)M+U":"&?4M-DNXEM
M[U["\8S36375LBP7)M)X6N(%6*4/'M4U6TS38YM2EATVS235XHEU21+"))M7
M2&U%E;)JLPA,VI1PV2BTC2]6ZC2U5;<!8@L=-1>NMK>J\P/XY7^'$>I_"[_@
MI9IW[+/Q8^ >A^%OAY_P2^_:%U3XN)^QS^UI^UG^U=H/C7XZ_P!GZ7\1/V;_
M (G^/OCU\0O ?A_X:VW[1?A>'X=?$-O%EYHGCC5/C/XQ\(?$'3;SQKI0\.6G
MA2^'NWB?XP_&+]HK]HJYO_AK\3OB1H4G_!:KX >)OAK^S/HUM=^)K?0OA)^R
M3\)?C-X,\(>)?VA_!^GW+#3?!?CW6_V3O%7Q3_:,T;6]2;2[V^\<?$_X4>%=
M,2>]TR\B7^HWPUX(\'>#M%'A;PAX.\)>$_#7FW,Q\,^&O#ND^']">:]4Q7DO
M]D:19VFEF6[0>5=R2VCFXBS'*63<#OQZ+H]J^F?9M)TVV?3K)])TMK>RMH6T
MO3&BMD.F::T4 -AISI8V<;V=H(+1DM+8-%M@B"-Q:3O9^>[W0'%_"O7?A1K7
M@VST?X.^)O"_B?P3\.K[4?A-;MX4\2V_BVP\-:Y\)[Z?P%XB\":KJT&HZI/%
MXF\#ZOHEQX8\3Z7J]Z^N:5K.G75EK*+J4%RH]''F*TC,H*A>(590BJH!+ C
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M0_!O]FN\^''A#4+_ /:-\4^,+BPOO!WP[\3:=HMUI_C1_$]Q?RI>Z=.%:/\
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MW3OA;KGB"\\26/Q4TZ3XC+\2;CX>R)\2M4CG;4_"/@"UUK^S/#J _0+X@_\
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MA[Q'\.O!'A_2O"USIOA3PGIG_"3ZTTH!\F?LY_\ !5OQ[X"^ /[*_@/Q1/\
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M:Q>H=;M-8V/AG_P2_P#!WPZU/PUKFN?'CXX_&+7=(_;Y\0?\%$/$GB+XIQ>
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M&\-?&/XM?M$?M6:3\0?V;=>_9"L;;]H;QUX6OQ\-OV;?$CVR^(/AS\/1\,O
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M #)Q^'- #J*CD8A"R8)XQ@;A]X \#K@9I@D8Q$G DYP,8)P>/E//(_QH F)
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MVCO!+_%*#QGX@\*>,O%/ANP^)_C#XQ^'/ &J>*])TZ*'SAO@E^UKJ.I?M/\
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M?'[P+/\ "SXTWIT[X/Z]X9;6?&NJ?%35U2]DN]!^'O@OP7I/B+QWXQ\0Z/\
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MAN5E/1@1^8Q3(XQ'D DY(/( Z?0"GL=JLW]U2?R&:CBD,@8D 8..#G/&?04
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M/X@0^.M?D_9XT/\ X)1/\09?#GPE_9K_ ."E/_!1/X/^'/VA(]8@U[X;:/\
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M1?P%\6_$CQ'\&_"7QK^#_BGXP>#X[F7Q;\*/#OQ0\$:W\2O"T5G.EM>3>(O
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M8KN&:V>Y$L3+7\??P:DUKX=?$/\ 9Y^.?P(\%IXS3]CS]@?_ (*._M'R:?\
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M=L=1\4>%;SQCJ-V\MKX4EU+R3X,>%O''QH^*/_!/*>7X<>)_!/B+7OV^+?\
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MS7M1!\8Z#8W?U!X#_:O_ &9_BK:>/]0^%O[0OP(^)FG_  ICN9OBC?\ P_\
MC)\.O&5G\-K>SAU"YN[CX@7/AWQ#J4'@N&UMM*U.>XE\22:9%!%IU^\SQK:3
M%?PF_:$^ WQ0^)G@+_@LE\:])^"?Q3OK[XN_M=_LW? Z_P#!/@?P1JVA?&GX
MK?L$?LZ6O[,N@?M5:;\(C!:Z+XH\:K\:O#FJ_M366G6?A6]FN/B/X>D@T+PE
MJ%SXAOM'%MY)^V7X8O/VIU^*?B?]A+]EWXF>!?A#I'_!/KQS_P $TM \:V_[
M+?Q*_9]O_'FM_MZ_M#?LR?#&+P]X(^%'C3X>_#GQUJ?P7_8L^$?A'XA_$CQ5
MXNN/"FF?#OP5=>+=7L-!UE+O1/& T< _IB^&GQR^#?QEN_&%C\)_BI\./B7>
M?#W5K#0?'=M\/_'7A;QI-X-UW5-*M]=T[1O$Z>&M5U,Z'JE]HEY9:Q9V6I"V
MN+C3+RVNXXRCG;^>NK_M^?'[XE^*/B.G[$'[#6L_M3?"OX2^+O%GPZUSXU>*
M_P!H;X=?LZ>$/B5\2/A_KC>&/B-X-_9NL_%&A>,M4^+!\!>);?5/!GB'QSXK
M7X7?"R]\>:!XB\,:%XYUMM$U"[M?T(^%?P9^'WP.^&_ACX2?!_PEX?\ AUX
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MC3M/%NNA_8%B^PV?E!1:Q;/Q2^,_[5_QVLOCG^UEK?[/6@_L]V_Q<UO]NO\
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MXS_X)P>#?''[:%GHOC_]M#]COXN?M'?M$^"-*_9\^"D6F?L^_#SPOI7P4O\
MP;KWPJM+[PS+XF7XX)XQ^.'AKX=ZYK7Q.U/QO\&M1AM_%&J6GP>M]2T#3[34
M@#^B'PYX7\)^#=*M?#?A'PYX?\*Z'9&4V6A>&]'T_0M)M&N)3<3FUTW2[:UL
M[<SSLT\QBA3S)299,N2U>!S_ ++_ ("O?VE_'_[2OB&:[\6>(/'?P.^$_P
M3X-\266BZEX'\/\ A#X8_$;XE?$^*^TC2Y]/::XUWQ-XJ^(-O=:]?:G<7:0Q
M^"_"7]EPVTMC,\G\_O@O_@H3^VY\5/AU^R%\(/!WB7]HKQIKOQ%\#?M0_M _
M%?\ :(_9]_9\^ ?C3]I'Q)^S9X2_:F\4? S]DEO#_@OXCIX1_9U\)^+_ (N>
M"!9>.OB9\0H/AQXBTC1[;PM:P^%OA_IP\>#6]"^C+G]I;_@H/XC_ &,O 4MK
M=_$M?C9IG[3'Q=L/'Q^&N@_LBS?MW?%+]A3X3^*/%GAF[^+_ ,&/@5JNM_$?
M]G2^^-NC>(]9^$?ACXN^&['3+FTL8X_&UMX4\%^&?B!KWA#PE9@'[Y:OX9T;
MQ MK'KNB:-K<>G:K8Z[I<>LZ=8ZFFG:UIDPGT_6+)+ZTN5M-4L)E$UEJ%OY=
MU:RA7@FC90PIZKX3\-ZS8MI&O>'=!UK2I+U-6?3=6TC3M4TYM3AO?[0BU)]/
MO+:6U?44U%FU!+]H_M27I>Z$OGN\A^,OV-/V@+?7/V&_"G[17Q6_:5\._'/P
M;9>#_B/\1=3_ &C9?AM-\%&U#X5>$=>\67,&K_%#X=);6L'@KXD^!O"NB/H/
MQATK2=#\/:?9>.?#?B4:;X4T"%5TBV_*GX#_ +9O[8OB+]J']@X:W\3?VF_%
MO@C]LWXE?%,:OH/Q;_97_9N_9\_9BU?X(^'_ -GKXH?&33O$G[.?A.'Q7KW[
M=7A/5/"U]H?P^M]-U[XZZWXCTWQ;I?B:[?Q98>&]1U;PEHMJ ?T<26EO;W1O
M_L=H+Z:WCLY+T00F\>TBN'GBM&N%C$[VT=S=37"6V]HTEEEDBC$LC;^2@F^&
MNMVE[:;?!.KZ;\.]6\F_M0/#M_8^ _$.BV-MJCV][ &EM_"FMZ3I&IV&JO!<
M)IU]8:9J-I>LD4%RCGGOCEX-?XB?"_Q9X4D^*_Q"^"FGW^FI/KOQ)^%VM:+X
M:\<^'O#^F7EKJOB Z#XDUS0O$5OX<?4]'L;W1[_Q%8:=#K^BZ5J%]?\ AG5M
M#\0Q:;JUG_-U\!/A/;>*_P#@G;_P2F_9JU"WUW2_AM_P4_\ VS?'W[0WQ]L?
M$WB;Q!XJ\0?$'X ^.=-_:2_X*#:;\)/'_C3Q+=7'BWQE)\3_  9X.^$/PG^(
ME_XEU:_UCQMX%3Q7I6NWVI'6+ZYE /Z.]/\ CE^SAX]^'&K_ !:TKXL_!;QK
M\(/"=Y>WVN?%#3_'O@+Q)\,_#E_X6\J;4KW5?&]MK%[X6T6\\-M)&]_/?:G:
M7&C,8VG:W\V R:$OQT^!-M\+K?XVM\5OA@/@M?6NF:E8_%F#QMX4F^&>I6VO
MZU;Z)HUUIOC>#57\,ZDFN^)=2M=$TJ2RU&<:MX@O[;2[(W.IWL$$WX >)?V/
MX?VD/VE?^"BOA;]D;PK\"_"'PY^#?QN_X)5Z?XA^%7B#19/"?[,_QP^/'[)3
M>.OV@?B]\._B#;_#3PYJR69D^'7Q:_9K\.>(=7M?!?BN6QUWX8^#]!\5^&]:
MT/P\^C6ORY\.OBW/\(-)^$VIZC\.=5_:P^&/PV\6?MR_MY_#CX?_  ;N/#/P
M>^$?QF^(_@#XG:A\:/VJOVV\_$?Q GA[0OV4_P!F[QS\<?#_ ,#O^">W@R]N
M+Z_^,'Q+O;S]H'7/+T_3?AI\3/"X!_7E9V&EQRWFH6FG6=M=:J\3ZE<QV4%O
M=WTEH&A@;4)4C6:XEMEWQQ?:6=X 61=G(J6'3=/MI+V:WL+.WFU&9;G498+:
M&*2_N$BC@2>]>-%:ZF6"**%99S(XBCCC#;$4#\__ -K/]L;5?A5^P#?_ +5O
MP.T6TU7Q-\0O#/P)M?@;I_Q%LKS3M&T_QA^U1X_^&OPO^$^N?$NQL;F*ZM/#
M?A;Q#\7/#?B+Q]IUOJ5G,NDZ3K.G0ZO:3O'?Q?&_B^Z_;7^ OQTMOV8/#G[;
M_P 2/VE_B1\=OV ?VR_BO<ZI\1/A;^SMH&J? KXU?",_"/PU\'OC'\.-'^&_
MPQ\':-H/P_\ %?CGXHZOX=MOAI\5#\2+'4+WP[I<MGK]['H/C*35@#]R7T[3
MY!9![&S<:=(DVGA[:%A82QPR6T<MD&0BUD2WEDMT>#RV6"1XE(C8J9EMX%(*
MPQ*0$4%8U4A8L"-00!A8P!L4<+@8 K^8KQC_ ,%6/VJ?'G[-VB_M/_L\6)UG
M2/@C^Q]^RW)\1?#R^'_"NJ:#\;/^"C7_  4$TSX+^#O@[\$;^_OSHR:3X+_9
MB/Q<T?XL_&;2_#_C'X=2ZIX@^(7PX\):AXO\.:-HOBBWEZ*/]K?]NC]F3PM^
MV9XE^(>I_M1>+/#/PH_X)\_%+XWKJO[9>D_\$_\ PE\0M&_:UL=<C\,_ R/X
M2_#W]D_QMK&HVGP6^.6I#QKIVGZ-\3?#NKZ7H?B/X76VD:#XNUO4-:\0V4X!
M_2HL$"*B)#$B1JJQHL:A8U545510,(JJB*JJ %5%  "C ((5"A8HU"9V (H"
M97:=@ &S*_*=N,KP>*_GN\:7_P"U_P##O7/@3^RYXD_;(_;D_: _:L\>_"?P
MW\<?VH_#/[*/P4_8LT;7/#7AS3M$_P"%9:+<?#OX@_'"#X9?!7]G?X1^*?BW
M%XENM<36;'XM_&7XCZQX1,GAG6_AYX4TOQ7'J7'?LJ?M4?M?_MA>"/V'OV?+
MKX[>/_A%?_'?1?\ @H3\;_&W[1<7AKX'-^T9XF_9T_9&_:A\-_ 7X*>!]&NM
M,\+>,?V;K7XN_$;3OBIX$\4_%3XB> ?!/B3PI/X5\):CJ?P\L;5?'MEXGT,
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M[/Q5X[NM5O?@M\0?%T^FW%SXAN]-TC1_%B:];Z6^F0>*?M)7GBGP;\:OVY/
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MH'Q=T7Q/\3/AII$GPFU 7&I:SJ/Q!\.Z;X7UK7]3AUVRT67P3_P4TU.?XO\
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M,-!?2&T;4?\ A.?$/BFXO]4\77^MV,MQ#KE_K4T]SJIN;HW/[N8(/C/X4?\
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M?!+]IO\ :E^(WQ8^./PQ\/ZOX7T;QGX%\??$#Q;X'\6>,[CPU8'QU^T!X?\
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M%$GQ*\(^*_'.O_LS_!'X7_$GX_?$7X>_''P=I>D6DGP4\>_$.P\(_#C1M6\
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MQ+\;^+/B?XET+P+JGA[3+CPKX7U7QA=^%]&B_M*RL='ALM;UNVU#\P_VBO\
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M(>.=*;P_92>+M*TK2HM/CROVE?\ @IW\?_V6M)F'Q2_9R_9<\%>)/!/P9O\
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MUC]FC]G_ ,2>'_B9X4\1_!WX>ZWX<^,_Q'T'XN?%K0]3\/6=]IOQ$^)WA5O
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MXE^(O$FK>+[_ ,0^,IKS06\+2^'?#;:=]!_&#]I7]I+7OVDO$/[,7['7P_\
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M_'#QEJWPV_9!\4:1^RM^W[\*_P!BSQ[K?A.;XQ6O_#2NM?%;XC?L\> V\*_
MSPMJ.N7EW\)_%_PZO?CQ)H7B3Q?X^\1_$SPUK_C#PC?:;IGA;2-/;4[_ $0
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M@^&M.T.WXSXL?\%:?VB?V:7_ &DOAE\</!'[/?BSXV^"?VG?V;/V9?@GXK\
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MD/X3_P#!.7Q3\//A!_P2A^"^J>._"6J>%_V#/&5Y\:/CS+#9:PU]\:OCC<?
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M5U'QA:0^%?V;OA7^T/X7T+X=+HMX]_J7Q(^.US\*M,M_'LOB#^UH+%+/PGX
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M7QB^"_Q_^)_[1-]\5OB?X0^/G[0?[4WQEGA^'EKX1\*?$KXX?&7]GS0OV7/
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M<6O[//B;4O%-C9?&N[N?A#X&\9:?:?#:SB\&^(M4USQ3<W4.F:#I%G!J>H7
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M2Z=I'B'P_KFDZI8WVD:_X?UW2M-UG0M:L+_2=4L;6_L[B%/7HX_+4C.<G.<
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MUGP;J_Q#L['Q7;?I_P#9DR#ESZ@L2I^H/;/H0?>JCAF.57+('PN=HP3CJP[
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M  3\+;G7_$5L-*6]UCQAI/@'P2GAK0M9@U#3H+#3_$_BY)-/N7U>-[/Z]HH
M^7/B=^R[X1^(W[0/[._[2C^.OB1X-^(O[.>C_%OPGX?M_!FH>$$\->-_ _QI
MC\"3>./!/Q!T?Q1X.\42W.C3ZK\,/ FN:?J/A"]\'^*["^\/QVJ^(9-%O]3T
MJ\\\^&/[!GP+^$W@;]B[X?\ A6X\;GPW^PCJ>NZ[\&8M5U[2[RXUKQ1XD^%/
MQ(^$&L>*?B/<)X?MT\3ZY<Z!\5?'&M>=I\&@6W_"5ZR=::T86UO:)]N_9\$L
MK@-SM8H#M)/)'(YQE1[$U''&&9HFR0&D?(&W+;@O3&,8R0!ZX[4 ?FI\/_\
M@F'\%?AOX_\ !7B+2?BS^TGK/PH^%?Q,\1?%[X,?LGZ]\3M*F_9E^$GQ)\0Z
MKJVO)XA\+^%M)\':-XYUW3?"VNZ]J^M?#OP5\1_B+XX^'_PTU.]CN? GA7P^
M=(T$:5]/_M3?LR_#3]L7]G[Q_P#LW?%YO$\'P_\ B-#X?36;WP3KTOA7Q?I5
M]X1\6Z!XW\-ZSX7\16]O<RZ'K&B^)_#.C:GIFHV]LTUI-:(\&UV5Q]'O"B(6
M!=@,?(6^7D@= ,\9SQWI@MUF1"24 )*JN01\QSEN"0>2 0,9Z9R2[ZW ^&_B
M=^P'\(/'6C_LVZ=X#\6_%K]FK6?V3/#>L> ?@+XS_9Y\3:#X9\2>#?AMXF\+
M^'/!_B?X;SV?C;PG\0/".N^#_$.B>#?!ZWL.N>%;_5;/5/"VBZ[HNJZ3K-HM
M^W)?"'_@F9^S=\"?%OPU\8>";OXO7FN?"CXI_M-?&OPSJ7C/XF:IXXO[KXH_
MM::-9>'?BSXU\5:YXHM=3\2>+=>&DV^HP>'-3U_6[^]TP>(]?^V7&J"ZMELO
MT5, 4AE).W!"GDDJ<@%CR < <=/3-0%FFD*R*%!PG&3E3OYY ZDX[CFAN_2P
M'Y?Z7_P2B_9^\$Z)^SUIOP@^(_[2WP*UC]G3X)O^SIIGB_X/?%FV\+^-OBE\
M#I]<C\43_#_XN:]?>%]8&M0OXM.I>+=*\5^%+7P9X_\ "6O^(/$5]X*\5^'/
M[9O8Y&Z'_P $L/V>O"'A']G7PC\'?'W[17[/NH?LN>#?BE\-/ /Q ^$OQ8_L
M_P"(WB#X:?&_QAI'Q"^+G@/XC>(/%?AKQ;9^,-(\:>/O#7AGQK=Z]-I5IXXT
MCQ1H=GK?ASQ9HU]<:E+??J28%V_-M<JN-S+S@9P %9< >G/M5>" ,#G:S *&
M:2,,64[MRXR,9XW')S@4^;R_%@?G5\,_^":GP ^"^J?LSZI\+?$?QQ\,7?[*
MWBG]I/Q+X'F?XG7_ (DN/&%C^UGX[LOB;\:_"'Q6U3Q?HGB36?'/ASQ'XZTC
M0/$-O=3ZG8^,;*XT.UME\6RZ??:W::M4\/?\$O/V??#_ ,2?#_C>V\4?'O4?
M '@SXU:W^T?X _9>U;XR:S<?LP?#[X[Z_P"*-1\>W?Q*\-_#>*RM=3\ZP\>Z
MQK/CKPUX'USQ1K/PQ\'>,]7NO$OA+P/H>L+:7=M^E<<8C).[.1@ @   \8Y)
M.,^OUJHXD\XJ5&V1]S,& .Q5(X!Y;)&=JG/?IFCF\E^('YDW7_!*K]F76?%E
MUJFH^*?VA[GP /VD](_:Y\/_ +/?_"[?%%M^S]X-_:#TKXLV?QQU?QOX9\!V
MD5M/-8>+/BI:WGC'7? OB/6_$'P]M-:UWQ#J7A3PIX:O]7NKH_8'QC^ /P^^
M/T?PI?XC1>(+Z/X/_'+P#^T'X,T_1]:NM&L#\1?AA-J]QX.N->AM"&UG0=.U
M;5#K<NC79%K=:OIND74S-]ACC;W QI*'VERH;_5C*8&3N*M@.&;C(ZY& <<4
MK11@H\6T*JA-@R)&&2.6SG(+%B=IS@G/S$U>CMO_ ):?D[[VZ/4#PSXF_L^_
M#;XM>//@3\2O&&FZF?'7[.7C?7_'GPNUW2]6N=*NM.OO%G@'Q+\-/&6@ZLUL
MLP\0>#_%_A/Q1=V?B#PQJ,36&H76GZ%J9":AH]I<Q_*WP=_X)@_LS_!7XB?#
MOQKX?NOC7XLT3X(7?BB__9Q^#WQ+^,OC?Q[\"?V:Y?%^FZQH.JCX,?#75[@:
M/HD]EX:\1ZUX/\(7'BEO%<_PY\%:M?>%/A]-X9\/2G3D_2([4;A>0<[F9N20
M.IP>!TY/:F8PK #<Q!P.1D[0H&1G;D #(Y .:CF\E][^_P#IZ=P/S<^#W_!+
MS]FGX(>(_!&H>#-9^/L_A3X1+XY/[.OPF\1_'?QQXG^$7[,U]\1/#'BGP5XD
MU;X*>#=2NWCT;5H?!_C;Q?X3\)77BB]\7GX=>&?$FL>'OA['X8T;4;BPE]>^
M"?[$O[/7[.WB/X6^)_A3X8\0:1JWP:_92\%_L9?#P7OB?5M4L?#OP+\$>(;;
MQ+8Z5]GU RK-XDUK6--TBZ\3^*[A9M6\0#1]+%],191Y^Q%B9"(_+,J,Y570
MX9%*[B\F2<J&+*"/FR,9])ID$?RH/O1LK'!W'/&20.3Z9Z<^M-.[6B^]H#YN
M^%'[-'PK^!W[-_AK]EGX:Z7K?A[X4>%/ >L?#?18O^$HU6[\5Q:-KUOJ4>M:
MQ)XNG,FLW/B[4[O6=3UB]\3W$LFI7&MWDNJS2R73,[?/.M_\$P?V1-?\"'X:
MZAX,\4+X/'[$GA;_ ()XP:=9?$3Q-I;VO[*OA>]@OSX(TZ\TVXM[JQU+Q(]C
MIEEXR\3VLD6L>)-,TK3=/O[DQ6<&W]%#@,00K8 ()) Y+9Z?0?YSF*-#&50J
M#&6(3<3N4$LQPW4C'8X /X56F_SW6MU?37=>:[@?%W[0_P"Q%\&_VC/%_AKX
M@^(]:^-GPU^(GA[P=K'PS7Q]^SO\;OB1\"?%VN?"SQ!J<.M:O\,/%6K_  ZU
MK19->\$_VQ;QZIH=O>QG5O"FH/=:EX/U?0;Z^OKFYY6P_P""<?[*?A37_A/J
M_P .O!?BKX2P_!S]G3XA_LH^#O"OPN\=^+?!GA6Z^!/Q+5+GQ#X2\3:38W=P
M/$]]!XAC'CG3?&&J7,OBV#QX%\87>M7NM@W1^^RI29V4A@X50B\L HP_7CY"
M  <D]>.::8(@6 ! 8Y8&5@688P6ZD<@$A2 >_4TUR6^"[M=.[3Z6TNDK?._<
M#X0M/^"<G[)6G?#;XI?"RT\ :[8>#/B]^R9\(OV&?%^E6/CSQA!<2?LS?!'P
MOX[\(?#[X>>']535QJ/AU+#0?B7XQMM8UO19+#6==EU)+G5KR[N;"TGC]MD_
M9A^"5]\5[KXRW_@6VO\ QO<?L\G]EF<ZK?ZKJ7A9?@1)XDE\5:CX$A\)W<\_
MALP:[JSVQ\07[:<=5UFPTS2-+OKR:PTRTAC]^^S()2ZH!(T>U.9,, PR'C,@
M1B,$AQ&#@#C()J]! 0A+$*3N& N  <#/7@\9_K42=KJVZW[=-/NU\P/S]_9^
M_P"";/[+?[./Q!\(?$GP/I/Q3\2^*/AGX,U?X:_!$_&3X[?%_P".&C?L[_#;
M7/L$>L^ _@1H?Q/\7>)=)^&6BZMIND:-X>O[S0+:/Q'=>$-'TSP=)KO_  C%
ME#I*_?4CE2&A1'.#T8QL,<,"7#*5R<] 3R.V3<-NF"Q=B0,@@X QR,@<'!Y.
M>HX/%1QQ^:K'=MPS*1@=!W.>1_GCC)E.W^5W;\ 'VV%!+/DL%X8@8(W9P."/
M?/T[4Z<A@FWYL,2=OS8X(YQDU5X))ZDC.,$@'+,/_0L5=CB$1)W=0!C  XYZ
MC&?R%("KS_=;_OEO\*F6'?&N68#@[2J$ CMAU/3MG/''2K5% $;DQQDJ 2N
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MZ2)YG1-,A&\0^8-RX90&7*G(8M@[/+(!W-@+][(Q0!_)SI?_  3[_:I\9?\
M!-#P[XP^+WPS^+NE?'O6?$'_  3S\'?%_P#9\^'^K?#34_CEIW[$7_!/B_\
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MK6[?7M%;2O"?P?\ V>M.;6]8M;.#55U&[M=":^@L?$&/O59E .R!\*IXC$1
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MOT %%%% !1110 4444 %1>;^]\K;^.[_ &=WW<=.V<U+1@9S@9]>] !1110
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MCM^+MU\59O\ ALBWTSQ3X(^%7A3]E;XS-^P-^P4FM_\ !4?]J#]EO7?V-O\
MA57PY^'WPQ_9XO?#G[(OP/\ V>OB2?VC/B)\7_%]_I?Q<L+SXDZI\1]8^+/P
MWUW0/ EMI>G> ;2\L]>]]_;'\7S^*OCSXI^-7CG]H?QC\4? OPV\9?LP?L5?
M$>R_9>_:9^,/[-'[37[ '[:,_BS1/#WB#XB_ ?\ 9XUFPT_X2_M8^"/B_P"+
MOBAX(U37[3QEX9O=:UKP7I\UMX3T_P"(?A/1]0T!?Z4]1_9T_9_UKXK:1\?]
M8^!/P<U;X^Z+IT>FZ/\ &W5/A-X'O_B[I&E012P0Z;I?Q)N=$/C'3].MX)98
MHK.RUZVMXH9&A@"+*JLS5?V;?V=-?^+>D_'[6/@%\$-9^/VA6\%OHOQNU3X1
M^!M2^+^C6\%HNGVT&E_$F[T*Z\9Z?#;V06R5+37%C@M0MN=D)5 @/Y]?C)X[
M^+'QX^+O[1/@OP%\>?C-X&B_:K_X+*_LP_L)?#75O OQ$\0^'M:^&WP7_8/^
M!'ASX^_M3^(OA.MI<V^F>%]9\5^//AU^T)X'\9ZQH>GI;:A<S:;IWBBSURQT
M9--GP_&%MI_AD?\ !3W]GSX6?M8>,/V;_!OQ=_;0_9B_9%_9F\1_&;XX_M'^
M-/!&N?M1^$?@!X0_:?\ VE/ &L_&Z?QKJWQ5^#GA[]H[1=0NO@/XR\4>%_'O
MAG4K7Q1IFI3>!)KOQ_K-IHFK?TIV_P -/AII5WHU[I_PV\$:3?Z'XD\8^--%
MU&Q\%Z#97>B^-_B"FL#Q]XNT:[MM-CETWQ1XU?Q#KS^,-?LYH=5\2IK&M3ZM
M=WT=[?22Y?B?X*?!WQ9X4\6?#_Q9\(OA?XL\ ?$'5KOQ)\0_!?B+X=^%=>\)
M>//$.H7%I<W^O>,?#NJ:3=:)XDUJ^N=.LKB\U;7+.]OKF:TM;BXN2;2.2-I7
MT _-O_@CYJ/A>_\ AA^TE9^&;/XH>";OP+^TYKWPN\??!OQ/^TK??M<?!'X3
M_$[P9\./AG<^*+3]DWXVZ^;GQEKOP3\90>(-*\8:CX9\5:M%?>!?BAJ/CWP>
M/!W@>ZTG4- @_(KXJ_M(^/\ PCKWQ@M?$_[0?Q-\ _"3_@F5_P %:S^T?^U!
MXGA\=>,B&^&/[0G[>_P@TGX)?!OQIJ0NIKS7O@YI_P"SC\9?VA?&FK?#>&:\
MT71[/P-\)([C3H=.CTZQN/ZO? GP]\!?"[PAHG@#X7^"/!WPV\">&[:2T\.>
M"_ /A?0_"/@[P_9S7,EW+:Z)X7\/V6FZ-I<$UU<37#II]G;QO<3RW#J7ED+9
MFJ_"/X5:Q8>-++5OAG\.-4T_XEZCIFL_$BRU/P1X<U&U^(.J:1!I=KI&J>.;
M2ZTR6W\5ZII5MHFB6^FZAKR:C=:?#I&FP6DL45E;+$--;_UI<#^=O5_C1\7/
M@QXE_9M^,/QQ\:?$K1O$?_"LO^"DW_!;3]I_X6:OXQ\110?#[X6^!_@UX?\
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M[-/[7'Q%\ >/(-5\.R>./#FD_%K6_&%WXB\,6L]CXJLM*U1-<\1>%]<_9?\
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M"[@W"G+!QC!) )%6-SKR)#M#%=BK@C:.0N]<@@<C<<$\'/2H\*?WC@+PTN2
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M8:YM;_1M5L[G^C#]J[X*^'_VDO@;X_\ @/XWU7Q9I/@3XNZ*/!'CR;P)K?\
MPC/B;5? VI:GI#^,/!]OK7V*]GL-(^('AJ#5? _BE[>&.]D\+>(=:M["]L+N
M6WO;9/C+^S9\-_C5X8^$'AS78]6\'Z+\#/C7\$_CKX B\!2:+X>CTO7_ (#>
M)K#7/"/AXQW.BWMBO@J_TZTN?"?B#1K"RL;VX\*:C?Z9IFIZ+.;6ZC-;7Z?U
M^@'X*-<:A^T!^TF4CO=4EL/VQ?\ @NS-#:)#K&HRZ:_[.'_!'KX%+8ZPD$*7
M%E#9^']5_:F_9COK:]CL([K2=;D\<HM_->OJPBD^P?\ @LUXL\):S>_L(_LW
M>._A+\5_CMX#^,_[3FM_$CXO_!CX*^$=3^(7CCQ]\%OV;_A%XW\::EIS>$-$
MU70[[5?"\WQC\1? S3O%9DU.VL(=-U!$U!KF&==-OOKSX%_\$]/@K\ M:_9R
M\1^&_$WQ,\3:C^S%X$_:6\$^ )?'&N^&=435-2_:V^)WAKXN_&7XC>*Q8>%-
M(N]2^(>N>(?#1ALM5TV^T?2K#0]=\06K:#>SW_GP^_:Y^S_X.U_]I/X??M1:
MAJWB>[\<?#+X+_$_X(>#_#QU#3H_!.FZ#\7_ !E\-/&'C?Q(=._LG^UI_&5Z
M_P )/"6C65^^O)IUIHL.HVL6DR7.H37]N@/YRE.N_L8/\:?VU?V$OV ?BI^Q
MS\+_  U^SA8_ OP[\'/VBYM1\#Z9^V/^V%^T+^T9\#_ '[-LES^SQHOQ@\4Z
M[X:TCX.SW7B/0=4^)'BH> O&OB&#XO3^'M$M[KPSH-]?Q_67[4/[67[0'[._
MQB\!Z/\ '7X?_LY?M+_%_P"#_P (_B;^TSX L?AK\/?B7\-SX#^*?QY^+WP/
M_88_8P^"?A/Q=XD^*'CEYKKX@^.?C+\;]%^)WQCUKPC&WB'P1HCZAX8^%?@V
MYL+NSU#]@/C]^SWX'_:+L/A-H_CG5/$UCI7PF^/?PB_:)TC3_#EYI=K:^(O&
M/P4\2CQ?X%TKQ;'J>C:NU]X6MO%EKI?B*YL]/.D:I/JWAW1FM]<M1 ]M=^)_
M&3]@+X+_ !Z\6?M ^-/'NN?$Q/$O[07PW_9W^&-YK7AWQ9I^AZC\++7]EKXF
M^-OC1\'/%GP=U&TT%[KPMXV\/_&#QU<?$.?4-;N?$NFZCXCT#0%O-#ATN*ZT
MR\ /DSX[?M<_M[_L$?"OXR_%K]JSPS^SI^T1X1L_AY\,Q\&-7_9T\'?$KX/W
MS_M1_%CXO>'_ (,^%/V;]?\ A]XC^(O[0WQ!\?>"[O5?&7AOQ?;?&GP;IVE^
M(9="T;QAIR_":ZUU="TV^X3X"?\ !0+]L?Q=K_QU\$6W@[P=^UMXB\._L?\
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M5T;X3> /AU\&?A/;_#7XD0/X^L;;PU\+HE\7>([B[N/B=_PFT-PNEAV;[O\
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MM\-[Z[L/"WA_P5X7^#_ACQYI"ZR_PU^'O@?P+H6L7NI>(-1U.*?6-:U+5KH
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M/A1\0/!GQQ\>>!K3X:_$?Q5\.O&_@+QAH?B'P1IWQ)\)6L^G?$3P?X<OM/\
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M:9H?@WQYXSL'8_#GXD-?>+=(U+1M.NO#FHOIVLSL_K/C;Q=^TI^S5\5?AO\
M!WX<?M->.O@A^Q;\,KO]D_\ 9$_94^+?P6^&'[-'[1G[''AWXA^!)?!7P/\
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M5O?'GB;PE\5_!/B*?4['Q+I^HRZ;I.C7^EW=C#=6-Q^\7@CX8?#OX9R>,'\
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MIEP<?3Z]_I58G/RJRY).-Q'S*"1QR"<Y'(_/-6OLR_WC_P!\K_A58EL!=Q(
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MI0@?"[/,0;F+%B<$@$?,V5YR ,#@8.>33),?*^ 2 V&.=JY"]/X3G&1NR.,
MXS4A91NB;!!56/S!3D@ ]73&!@@?AP"!2>B2W\];[ZO3M==?R ,$%78%#@!<
MON4$J1C;G&0,X(QT[YQ2A6(VH-Q/."Q7(R23N!!XW'C//'H:15*@8X)_NEP,
M8R,MO=2<=A[D< T]'V,3P2%7 +!>7SD%CGD%>IY)//-9O?3R Y+Q=>0:790:
MCJD]O9Z7IDS:IJMU*TI6STO3(_MNIW<C+@K'::?;3W,KJS/&D;.BNP5#_.3\
M)O\ @O+^S[8?\$P/$/QQ^)_[5?PP\3?MEZA\#?CQ\9_"'PQ.BFQUBV\6^)[W
MQ_XS_9U^"A\/Z%X=M](N=6T+1-4^&?PS87-S-=:[J5H;_5M1NIM0GO)/VZ_;
M?^'GQ!^,O[)W[1?P>^%/B+0/"'Q*^,/P2^*GPJ\$>+?%$FI+H/A/7_B-X-O?
M!MOXCO6T;3M6U.0:'::U=ZM9PV6FW<MSJ5G:6QB*2NP\X_:>_9'O/B[^RK\-
MOV2/AG?^&O#7PNT'X@?LFZ/XWL?$1U<'4OV<?@+\5OAKXT\>^ -"CT6SNG?7
M?'G@?X>+\/K2.]^S:*VF^(;^XO+B"(QO(*^Z _,/QE^TI\9I/VBKG]F?XR?\
M%9O!?[#5[^RY^Q)^R-J'QU\57.D?L4Z1KGQL_:I^,2?$C4_B;XC4?M%^"M;T
MS1O#/A_PQX&\,ZO;Z;X$TG2M!BN_B ?,N=]C%9I<_9A_;G_:@^*6J?L;?">+
MXVZ9\5['XP?\%#/VF_"/A+]J*R^$O@OPA_PU5_P3]_98^!7B7QUK?Q1A\,65
ME)X+LE\3?'#5_"'P2A^)7PMT7PSH?B_2=.M/'?@BTT?2O$\3S?H5\"_V$/!^
MC_%3]KCXU?M(>!/@3\8OB/\ M _M5:Q\7_!FNZCX T/Q?JG@'X2^'_A/\*_@
MO\)/!)UCQGX;;4;#6M(\*_#(:WKT6B3-HT.O^)-472]0O+222YN.,_:4_9__
M &T+O]M#X,_M._LQ6'[)_B+PK\(_V6_BC\#-"\&_'SQ9\7/!-]X>\4_%_P")
M?PT\6^-/%7A\?#'X8>-[&ZTX^%O@WX"\*Z7;23:5=V<=SXA?;):+#%=#5OZ^
M0'JG[</Q\^+OP]G_ &?_ -GS]FR'PG;?M*?M=?$C7OAS\/?&?Q TB^U_P+\%
M_!'@7P-K_P 2/C#\=O$OA>RO=)E\:R^ _"6C1:7X/\#-KN@VOB[XC>+/!FE:
MOJUGH#ZS,G,_!_X)_MX?!?XY>!+KQ3^V-?\ [8/[._B_PMXKT_XSZ7\<_A_\
M'_AO\4/AEX^T[3(M1\!^-?@:_P"S]\*? NB^)?"/BG4HK_PKXX^''Q!:ZO="
ML;G2/%/AOQA>FRU?2=0Y#XT_L]?MH_&3PW^S%^T!::W^S5\.OV\?V5?B%\2?
M$?A[0=-O_BUXR_98^(GP[^)FA:Y\//&WPK\7^(+GPQX6^*6BCQ-X*?POXIM?
M%VE^$M4N/"'Q)\):0UKX>\5Z +F*[]9_9Z^%W[9.K_&75OV@OVO_ (A_#/P[
M+IGP\O\ X8_"O]F+]F;Q1\2?$?P1\-6GB+7]%\3>,/BE\1O&?Q$\._#_ %?X
MO_%G5KGP[H?AGPC=O\-/!>@?#3P=::];Z)9:IJ7Q#\0:C&6L!-^T!^VQ'\(_
MBE8_ 'X5?L^?&W]K+X[I\,_^%T^*/A=\#G^&.AR?#OX2SZWJ?AO1/&'CKQK\
M:/B-\+O!%A=^.O$&@^(M!^&_@O2]?U?QOXTU+PUXDN;/P[:Z!H6J:]9^8W?_
M  4S\/\ BR'X9:!^S3^S'^TC^T]\4/B)\!_"G[2^O_"/PQHWPZ^$OBGX*?"/
MQO<ZA8>#9_C9K?Q_^(OPR\'^$/'_ (OUS0?%/ASPA\,[+6]<\7>)=3\)^)M7
MM[*U\%Z+<^+:POC1^S;^VOH'[2W[0_QM_8]\=?L^:))^UE\#_@G\)/%GB7XZ
M_P#"P[WQ1^SKXC^!M]\5K?1/B?\ "KPEX2\+ZWX=^,NFW^@?%W4-2B^&'C3Q
M/\*=/L?'.APZU=>,M9TGQ!JWAZVY?7?V5?VZ/@Q\=?C5\7?V4_B3^SYXZO\
M]IWX2_L\>!OB?X^_:HM_'NG>-_AU\3_V>/"7B+P!:?&;P_X4^#G@N;PI\6['
MQIX?UVVUS5?A#J&M?!+1--\;6FI:CHOC :+X@NM&MB[[L#@/$G_!4KPQXF^)
M'PF^.GPU\3^,-/\ V1OAO_P39_:]_;^_:5\*W_@"QT_XAZE!X \5>!/AQ\-?
MAGJUCXBCAO/"7C_PGXE\*?M(V.I>&[?7[.'4?&'@N329+^]TFU%X?LCXI?\
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M^S7XHTWP/\;/#VI?$/XC?%/0/AGXB\7:+XQU:RT7P?X8\!^(/%6H>-K6._\
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M<OCWQMHVH1?!C4/A;X$M?"^N^!8S\0O&OB7P.MUX:\->*OJ7X^?L4_$GQO\
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M]\1>%M+^(_A74_"FK:QH-OJ0%F^L6NEZI>_V<\I#07313QL'B##@/B]^QWX
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MH?V8/@9^TE\0K;]J&X^./CKXQZ_\2O$G[-'P?T?]DC]IGQ7^R3XH\1>$=/\
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MOVM?V@O"WP#^-/CO_@HI_P %(I/V'OA3K6F:C\?_  Q:Z%^R=\'_ (U:_P"
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M?](\6C]ES]FVZ^(?[*7P.\9+\2_CI\!?C]XL_9L^,7[:_CXZQ;>/_P!E2_\
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MR-4\,R>"?%7U!\;_ /@F[\&OC!XQU[Q'IWQ9_:2^".E?$7X8>#/@I\?/A_\
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MPW4[<D=L888)J1X0[!B2" !T!Z$GN/?F@"6F'[Z?1_\ V6GTP_?3Z/\ ^RT
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MHA\))_ -WI<7Q#3XLR)-%<6WPQ'A0^.KJVGMKR'03I\PO1[]\$/CW\(OVE/
M-E\3/@AX\T+XA>![S4=8T4ZUHQO(Y-.\0^&]0ETCQ'X9U_1=4M=.UWPQXH\/
M:I#-I^O>&?$NFZ3XAT6\C^SZEI=L[IG\%OV@/@7^U%\2/B+^R[^VGXK_ &5/
MCW\$KS2/$O[8VN^-_A=^PEXF_9OO?VM?!GB_XJ^'O@]\*/V;OC?\7YOB7/JG
MPG^)GQ)E_9Z^&OBWX7?$Y/"7BCQ-=?#1/'OAC0]"\0ZYX1T;Q9<Q?IE_P3<^
M _C+X+?!OQGXD^*GA7XB>#_C!^T3\7_$WQS^*WA_XJ_&/PM\;_B!!K-[X=\*
M?#GPG-XO\5> ? _@#X=6/BZ3X8?#KP%;^,_#7P]T?5?"&C^(EU&STKQ?XN2*
M;6[L [_X@_\ !1#]BOX3?&K_ (4!\0/VBOA[X<^+$6L^$/#6J^&KJ?5[FS\)
M>)?B(]NG@/PY\0/%>FZ3>^"OAMK_ (U-]I?_  B.A^/O$OAS5/$2:MICZ7:3
M)J&GM>>"?"K]O/Q3^T+_ ,%%?C)^RO\ !BS^$5U\&_V6=$T>R^/_ (D\4M\4
M[?XN:M\5==TO79[WPS\+M/B\(V7PYCTWX;7C?#RU\7W?BGQ#-JNLV_CC[9X:
M@AT^TLKG4_SU'[/?[6.K?LF?M _\$QKC]DCQ[!XV_:9_:7_:&UOXX?MS:KK/
MP-3]GSQ+\'_C_P#M.^)/B#KW[0_]I6OQ*G^+^O\ QMM?@1J>C>!? WPXF^%\
M&M>%/'OASPKIM[JFE?#[PMI.N5^L'["?PK^)_@33OVKO'GQ@T/4] \>?M%_M
MP?M%?%Y=(US4M-U6[M_A?H^L:+\"OV>YMVD:EJ5E:6NK_L]?!KX9Z['H8NGN
M],;5Y;:^MK>^CN8% -OXR?\ !1G]B/\ 9^^(6M_"SXS_ +1G@/P%X^\,7'P_
MB\9>'M3'B"[/@.U^*8G7P+K/Q"U;2M$U#1O 7AC7Y;=H(/%_C#4-$\*V]S<:
M=;ZEK-C<:OID5S[?K'[0?P<\/>)/BGX/UGX@^&]-\1_!'X8:+\:?BUIEQ=W
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M*/"'PGO_ !?H6I?$#XF^+M'UF_U35O"=OX-\"216>L:Y9 'ZK_M!_M=?L_\
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M@#]&=<_X*F?L:Z5X9^&GB?1_%_Q)^(4?Q=^$[?'[P7X;^$'[/7[0?Q@^(3_
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MOC[^TS\1?B/\!_V,OC+:?&BS^"'Q]_:/^-/CGXT>"-"\1^-_&NJ_$'QMX/\
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M=7L-7M?"][%#>7.K7TT !PW[6?\ P5GL;'X6Z_IG[*G@KXM7/CSXB?'CX?\
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MX/\ BGXJ>&/B[-\9O'.E:[\-O 6D_#WQ7KVO3_$G0M4\%Z]I6@ZO;^6<M?\
M@J!\&/#'A7]HGQ!\=OA-^T/^R[K?[,WP)M_VF?'/P\^-W@SPC)XV\0_ N\?Q
M#:6?COX?I\+/B'\4/"WB;_B?>&;_ ,*ZMX<;Q1IWBKPIXEGTNR\8:+H=MJVF
M7MW\!7'_  1[\2^(OV;?B/I<GP:_8I^&_P 7_&'[1G[.GQSTWX#>#+GXHZQ\
M%-=^&O[-WB$ZGX3_ &>OC7^T+JVCQ_%?XC3:P=<\?^(Q\3-,^%F@:/X(\:^)
M--&D_#C7]%T&\/B'O_A=_P $Y/C_ /##P-\??'GPF^#W_!/3X"_'#XE:I\-?
M"/ACX,:)X=\8?&'X;:[^S?X8\2C7?C-^SW\=_P!H;X@>"(O&7BFW_:*BO]8M
MM5U;PQ\#=-T?X8F/2WTWPWXPU%]5URX0'Z>_LZ?M2K\?M=\>^$=7^ '[0W[/
M'C/X>Z9X)\276A?'+POX-AT[Q7X/^(<6N2>%?%?@+XA?"GX@_%7X5>,M/N)?
M#FL6.NZ-I/CE_%GA'4+:"#Q5X?TB/4='GU+ZJ+*0/,*D#J0N#O'_  (XSR2*
M_(_]A3]D_P#:0_9&M_B%:Z%X+^ GPU^%GQ:^/G@_Q#I'[)7@CX[_ !9\=?"7
M]E'X-Z9\.-0T[X@:G\"_$7B7X3Z ^J>-OB5\2X])\377P=TOP7\*_@WX:LM1
MU"[T36XM4CU&37/UOA?:J.J!P5P?,(61 0.!M#CRP 1D#:0!S3NULP)#$@A9
MT"_/@Y(8\,P7G#@=/3'Y]%1 D9E7 '0(.@Y5,Y)SSMW<YQGJ:F28.P0(,'/(
M((X&[I@''U Y]ZL8&,8&/3M1=OKOO^'^0&6R^9(IW(-Q5>%#,,\9SN'KD<9'
M'IFK;08RX<A@FW=C&5 /OQR<U8P/0?E2T7>FNVB6EOR HQIO!8.5",&VJ%(/
MRYP<@GN0,8YSQDFHE95(8LHPC-RN[)4 D#D;3ZGGWX%:> .@Q28'H/R%%WWW
MWVU_ #-CM(I#+PJY?)PB!N54Y! 7&,_[7./08$MU=F0NX 5]IR,J58*IR "2
M >YYJ['$49F)!R.@&,<D^O3G]!1'$4<MN!!# <8/+ \\XXQC@4<TN[_KY 4H
MK<+(8R^]EW!9"#OQP2""Y4DYY.!TXQS2RHN2C'.T$!MY7[ZY)9.4;&X@9'&.
M,'FK33A&8;,D'&=P&> >X],4WSP3@H!G)RS#L">P)[8''6CFEW?X 4_+;RMJ
M ;59%#,0-PZG9@#<P(Z<?4X)*&W&^0&)0K.OF$L2#MP58G' 4'/?(YXJ\EPK
ME5"C!; (88SSR 0#^.![59I\TN[_ *^0&7$B+B&.-XPH_P!: #$PR=P#<=1U
M!R!D>E2R1+$0%[JS<CN,8_F:L20EV5@0 H P03T)/8@<YQTJ.X"EE#*6X)'(
M'<9Z_A2YGW?]?+_ANE@*3%+974'RE9P&F=<*3)PBIS\Q&#GI@'H2339$"E2J
MI)(RY\W V 9 (4+A-S#@G&[!//:K4<>\D KD $DY;D^G(QT_E4FPP*HY;)/1
MF]/1B0.!VQZ=*:DT[^=WTO\ @!G-$JLLTJA8=NUDQA55L$;2I7D$ +D$8YQD
M5'Y6Y]WW07R)%.)%R?E+#*@HV<!HUVDC!P*TGB.P29!#$, 0<C>"!SD@8W=@
M.E2YVJLN 5XPO?YAC!)XQG';L/K3<W96W:UWLODUJ^C] ,^6S@8N6"L3@$L<
MR X R -O4G>=Q;@DC'&!8%5IFWN%EX.PN@08 R&52F>,AB>.^.US?F3S-N><
ME<C/W-O7I[_2D8^9(I V@JR-U(5GX0'&!\W./J/4$+F?=V^7^0&<+<QRJ2_S
M DE2CO@O@ %@,,,8/)'!VG %.X:1V4MYI*?)YC*F HP=@4C/5<9&.F3R3IF!
ME4G<N ">A'3GJ2<?4]*J1O'*ID"OC+#YAL(V\'*DY(ZD'N,$#&*OFCWN_3^M
M (V$<08LR'<2P+J"BGODY^7(QS@YQ[<RI&1'YC1HN=H 4;<[F !R.HP<\#TY
MYJW]G./O#KTR_.1_>+,RGU*D9[YP,5B07WYQE0"A(*G'9\\D8Z8&<]>,@S*7
M9V_I (RDC8C>6-Q(#*"ZGGYDZ84]FSGD#;@FFH/)R#*6+G!8C<Q)XP0H)R>Y
MQ@8YX)J9$663( 60)C=U78"/E !R!D@C/88ZY)NHFU5!P2HQG'ITJ>9]_P %
MKZZ>0%2$!)$08&&; !/0HQSS@\D]P*)@/,;D]%)P^T#C'3:W/'MU%2NXD8P@
M8).-^1_#\QX'."!CK_A0L# @[E."3T.3D$=23ZT)M:IZ@+$=D#MR=N]L$Y^Z
M#QG X)'IQGI4D3F1=Q ')'!ST_S^6*A6W96!W@@,IQ@C@;>.N.<=QW-6J0$$
MLIC(  .03R<'@_3OV_&I#]]/H_\ [+3R >H!^M,/WT^C_P#LM #Z*** (Y)!
M& 2"<G'! ]^Y%-BD1V.U-I R3\O<]./I4I53C(!QTR <9^M 50<A0#C&0 ./
MPH IA_+D=CDC=(,9XR7X."<=C^=#KB/S$ V.Q=UQDX/"A>PP>6!.,YP,XI-Z
M)+(9$"A<DLS*P)=CC"A <\'N<#KGK4C2"1?+A)5CC:VT;<#YB.H'0&@#-G56
MP,(,D-_"DR,IP-C;2"&0<[C_ !$=,4P330,1(OR/DHBKEW0@9 9(PBL!T+%>
M1QG JR8@H/VA5E96PS%02<Y=#NSG"@HN<#Y@!C@$@8H-JJ4D(+)&SL X  &7
M )"D8 (Q@=!TK1-6MY:WZ^F_]6Z@0Y<2IA)0XC"MO975,N_WCT9@&SQD9 R>
MPD9"S!=B$E3\P0#)SU89;&.<8XQ[Y-*&9%Y1ASRL;NZ8/)R6)8*03G:I&,D*
M22*0/*Y)2*2,(K-N3.UP&P<$@;CQD)CYADY[4[JZVO;1WZ]GWU>EK_>!(-H(
M$:<D$DH -JKCD].!D849)YP, THD2&3RWB8J4# ;59%Y ):1CP<<G)/7CH<P
MO(24",ZMO7#-&8U!Y^\!M9\]@&&WGKN%3 -(" IE:+*KF'8JEL E5=E7@#((
M8D\Y[$P_BNT[/?IY=?/R G=_- 5!C!W DC:0 5XVY_O#';%-2.4[ER@R2P(R
M"%!'&0 ><\_X\UX=^TG'\;IOV>/CE!^S-<Z#;_M&R?"#XD1? >X\4BW;PY!\
M8&\':ROP[E\0+?!M/&F+XL_LHW)U..XTU#M?4(9K594;\2_^#?;2_P#@L!I?
M@3]H]?\ @J?J7Q0NM-E\6^#1\$(?CG<^#[OXK1:['#XL'Q@DMY_!][?Q#X6R
MW#>!O^$'74;F2(7B:X/#PBT5E-RG:^FVG_!';3=>A^^7CZ5+/0GN9UN98[1+
MB[FCL;2ZU"]F2VC>=H;.QLXYKR^O)40PVMG;12W-U.\=M#&[RA3^9L?_  6#
M^"'_  D]Q\-;;]EW_@I#>?$G3O ^G?$.\\ 6_P"P1^T ?&=OX'U?6M3\-Z5X
MJN-'E\-QO!I.J:[HNL:797$TR?:;S3-0@0,]I.$_3SQ8<:9"[ $K<%HO,Y$L
MFQC"H&UB29%4#<NU6VN<@5^:7[).JVGC+]N'_@JI^T#JVJ6T7A'X?^-?V=?V
M.]"U2[O8WTVQT+]FCX%)\;?B/<%C*8;2"T^(G[4/B[2]7ED=KA9_#*K?LHM!
M;0-)6;Z_\-;R$?</PD_:"^&WQSU#XQ:;\.;C6-1NO@5\6[[X'_$.XU+0+S2+
M.T^(>D^#?!WCC7]!TJZOU2+6U\/Z9XZT6PUN\L&EL[#Q#'K.ARR_;M$U-+;V
MYL&(XA8 KN+A1L.\-A@_0J258LH.TG<PX9A_)=^SK\&] U_P)_P1V_:#DMO$
M.G_M;?\ !03_ (*%_$C]N&Z\6_\ "9>++C4?!GP,^)&@_M&_MJ^._!'A;1H]
M:@\->%O!'BOX7Q?"_P"&?C?18;&;3]?D\7LNJ2ZC=1Z%+;>!?L?:K\0/CO\
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M)_AG?>"?!?B'Q!9_"F]LM<^'OB;2?B!IWA_7/$OBSQ;\2;:WN0#^QCPM\4_
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M+77QBAU;XP?"CPWX'\:S^&=:\2>!+G1]2DT*.1M3N;28 _H1^TQ*7+6S1E5
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M6D^+OB#\4?$%EXST3X0_$;PA>^.="\<_#JR?P)\._A[H'AJXAL/J;X0_L5^
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M\*^%/ WQN^+?_!0_]EC0M#\?>+/&'CGX<_M(?M@>-OB99W/P!M-5\%?"N_\
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M_P#A#_"WY)_\%.]=B^-.O_\ !4&WNOA-\$-*_:0,W_#.'PW^%GB7]B7]H/\
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M)Y_$W]I;X1?M4^)OV<9_'W[?W[47B?X;:K^SQI_Q-U;]G[]L7]H/Q;\,[_\
M9TO_ (@_LW_LA^'OB+HG@;24\!ZQ^T9JGP_T_1/#/B.S^$?Q7^*,]CXG\1V7
MC*XL-1L_TF_X)*?"Z;PQX3_;0^-ES\!=>_9PM/VI_P!O?XY_%?PU\)O%'@F?
MX<^*?#?PY\&:1X$^!/@[4/$/@^:&S_L:[\>M\)==^+<EE;Q26R77Q$E-E=ZC
M:""^N4Y-]ON_K\P/T.\2?'[X!>#_ (D>&?@[XO\ C5\(O"WQ@\:I#-X,^%7B
M+XF>"-#^)/B];J66*V?POX%U+7;/Q1KHNI+>5;<Z5I5T+AX)$0F2)E4\3?M
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MPC^,7QV\ ?"KX?'X-^#=<\*Z*F@_\)3;^%XD\4&_^$^@W-CJ !_1OXP_;?\
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M_ 3PE\7+_7O#QU3PAX:U#P#\%OV</A3:^&O$+:)8-)\2?$6E6T#W?B/5EUH
M_H^^%7QT^"?QWTC5O$?P0^+/PN^,N@>'M>O/"VMZ[\*O'WA'XAZ1HGB6QAMY
M[_P]JNI^$]6U:TTW6[6&ZMYKG2KR6"^CM[BWN'A\FXA=_E;XB?\ !07X ?!O
M]J/Q3^SG\9/&?PV^#^B>#_@C\*/BSK7QD^+7Q:^'_P .?!0\1_&WXD_$_P
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MSXS_ ."KWC+X@>-_VE[;]BOQS\(O'_[1OA'X6?L8>-?A-^RO\;_VI/V=-/\
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M?#&N?#7X0>"/@%9:-\7M>\:> -2U'3OB'<>/M5O]8\"^#M5U3X@Z3K-O\O\
M[>_A7]K7QEIG_!4'X7> OA-^T_X'^)'Q1TB[_9U^&?PJ_9F_86^&'B+X0_'S
M]E&R^'/A?X<^!_C!^T!^VQ\1_@E\4-5^)<NA>&O&/C3R?A!\-?B[X"^+_@9]
M,U'PEX0^'5S?Q:CXWN@#^CWP]^TI'XD_;"^*/[)VE>#)[N'X0?L\_"'XX^,O
MB;#XAL7TZPUGXV>/OBMX4\'_  R3PZ-.:[34YM"^$7B#QC/K#ZHMLNEWFEV<
M.E^;.U[6Y\6OVQOV3?@;X_\ !7PI^,_[2/P.^$WQ-^(?]GMX&\ ?$+XH>#/"
M7C#Q3!JVJ/H6CW6D^'M9UBTU62PU;7H'T'2K^6TBL]1UV)]'L9YM23[-7RY_
MP3_^$GB+PG\7_P#@HA\6?&'P_P#%7@-?B/\ M2^%_A=\*++QAIUQ::CJ_P"S
MU^RI^SU\(?@?\//$>DM>E[F\\)>*O'.C_%SQKX;U!)6L]4M_%,^MVB0'5IHE
M^%;/1?$WACXB?M^?L]_%K]@#XI_M2?%/]N/]M;R?$'BGQ'\/-8M/V8/&?[%7
MB/0?AYX/^'7B#QU^U0_AW7/"'A7P7^SQ\%O#.MVG_"F8;N;XF)\8--OHO"/@
MVV7XA?\ ":2@'W]\6_VS/B_??'CQA^S1^QM^S1IG[27Q!^$%AX6NOV@?'OQ'
M^-%I\ /@-\$M2\=:+%XE\&_#[4O&MMX#^+/C+QI\5]>\(R6GC*Z\$^"?AU?Z
M;X5\)>(?"NL>,/$&D2>)=#L;_P T\<_\%(_B9\,?V,?CS^T%\1OV,/B7X6_:
M*^ GQ3\&? S4/V5;CQGI\FF?$WXJ?$CQI\-/"/PU_P"%*_'N/PTOAKX@?#;Q
MY)\5_"UYHGCNW\*6-QI=]!XA\*^)_".C^*O#U_8+\O>*+KQS^R[KW[?'P)^)
M_P )O^"B,OA?]J?]JZ\_:>^"7[37_!/KX9>(?B7XOUCP_P",O!?P>TZ7X9:G
MXC\%:3XGOO@OXS\"ZY\+K_X:74OQ&\.>&_!^L_"I_#-QIOC 276L36%[X(_!
MS]K_ %'X3?L'_#_X^V7[3'B8^/\ _@IG\1OVC/B'!\?/$OASXJ_$+X!?LT_!
M[P_\=/B[^RCX%^,OCWP)=W_A;2M=E\:> /V:)+NWM=5U2&U^(?B/5/"S7][,
MKRT68'NG[7/_  5T\)?LT?L,?LV_M:^$/@UKGQJ^(?[6G@_X4>,O@A^SIHOC
M6Q\/ZSKVG?$+PEX;\?>)]1U+QK)X<URUTSP[\.?#7B.T&J>(6\-W5GJ?B75/
M"7AB&VMK[Q98&'T[QE^V-^UCX@_:2^/'P!_9;_9$^%?QDT_]F[3?A#I_Q/\
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M2Q\J].GZMXB\%VGF7GC+PYI-]?:WX5M89KC7[#3X8I&3Y[^ /_!6G]C/XT?
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M;>\&SWOA/_@H5\7_ !?HW['OPC^"OQ4^/?P._:P_;6_:<_X7:MMX\^%?Q9\
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MXQ\':;J$2G0M8\<>#M/MKJ^\6^"M(U:^\5^&;6SOYM<TBP2QNS#Z!X:_:?\
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MNTGKMY'7L..1W],"JL<J%MDC-NS@ JP;)VXR4&WN>AQC&>0<*=VU@%8R#<J
M %FRNYU53M"G_;8L,'*C'%+_ #?YNP#F4 F0 [PN%(R2,9(VJ2%)R<A3C<<
MGN(L3.#EYB/O$*T;<\CYU=@48_W%SE>3S4PCG5=SCYL%B1@K$5RV%/#$-P">
M2#TV@ TPJ'VDK$7X.0SYW9;&<X!ZY&01ST[4UN@&QJK'!4,1AE"E5QC.2<!1
MQQC.<<],U90@$^=O(/(SDY;N1CVQU]/K32)%*[@ZD916+*V\DC+  87< .,8
MZX QS$2<+M1$X&\G<HW>B%%;*X&>>_0FFVW=:6^^WH_/J!(0KDHRAP0Q12HZ
MX!7G'!VM@DGJ33$"@)P 2H;( )X55R6 R.   3]T 8XQ5Y84PK;<,%'0MW4
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MC7O!7A;PYX]^&7Q2\/Z/XO\ #]IXQTFRU7Q?8^(7O]!M?#K0=Y\7/VH_VO\
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M$&HW7C6:P\%Z'X6OK_7O&WPS^'?AJ#XAZ#X=\+ZW-H7B#1M0MKVQU6YFU"0
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M/'&K>!/B%XI@\>+S:_M7_M9^+OA]^R%^S[\!?BI^UY\<;KX[^/?VX?&GQ/\
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M?_\ !6C]H7X_^.;CQ^?A_J=C9_LI_LX7_P"TQ\1]2US3/[-\ >&[JRTGXN_
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MX<TFQ^T)I'BOXY?L1_MX_M4ZG\1/C7\8?B)^V=^W!\9?V'?V&/@O:_M&>/-
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M/?#/PU\#Z9I>A^'K2]U75-5UWQQXQ\.Z)9QZ;%)(9;^"61OL\!DC?\-/C?\
M#+XM>)OC9X6\!:K=Z[JG[/?Q4A^#7Q0<Z+JFGZ1I'Q)_X0/P5\29]!T?4KZW
MCL]>?2_#/Q"\,2ZE<Z1<W5KINJZA+HTCKJEM=V\'\XW_  MK1_VS?VL[;5_"
MOQ*N?%?PC_:,_P""ROPI\(^"+)_$(U/P/J'[.?\ P2"_9:O_ -H#QYXR\+:5
M=R7.FV_AO7_VT/#T-K?:]I$?V7Q797WA>\N+][*XTC[;Y_X:_:%\4?LR? 3_
M ()_?\%+=-TKQYXNG_:__:I_X*0>)8_A%X5G\27,'QB\<?\ !0"/XD^.OV(_
MASJ.D62/!/?:YJ?P5_9[^&?AKQ'K-D+#P5:ZY?WXO-.T-=0N6.:2Z?*S^ZW]
M=P/ZU@0)"UQE, +;)M*RX4'$AG4DF,KOPV[+1"02$HCJKHP>%^R2;2=LCFUF
M0N%8_(BE%D"(K;@P7:Q&$<\ ?G-\,M&UW_@GM_P3Z^)/Q,^.OC"[^*?Q?^&G
MPL^-W[6?[3'C[5-9O[FQ\6_&2X\.Z]\7OB5;>%Y=6N+A-!^'NA:U9Q>!?AAX
M;M+>WT[P]X#\-^%=,AM&GMIFF_!'XF_LW:U^S)^S]_P2S^%GB[XC>"=/O?VJ
M/AOJOB?]O;XW?MD?M0_'?X/>#?C_ /$SX<?!ZW^(_P ,?V7O&_Q^\,S:WK7@
M7X;R>.OB[\1O%WACX5Z3'X9\/^/_  ]\%(?!&K+JD0U72-:;;LM%KTMTL^GS
MOU _JF_:(^.WPU_9@^#GC;XT_%!O$L7@SP2?#\-S9^#/!WB#QQXOUO7?%_B?
M0_ W@KP?X.\'>%[*_P#$'B7Q7XU\:>)?#_A/PWI&E6;SW^KZO:0F6W@+W,?#
M_ /]JWX7_M#>)?&W@3P=H/Q+\+_$'X9>!?@QXW^)7@3XG_#?7OA]XF^'\/QT
MTKQ+KW@7PIXHL=90PVGCFUT?P?=ZOXD\(V=U/?>%;#4- GU<1CQ!I2W7\R?P
MR^!G@3]IKPQ^Q5\ O$VI_##XI?L[?'3_ (*M>-/B/\#_  3\)?&7[2GB+X,?
M"SX#?LJ?LL>(O%7QPT+X&?$;XW6/P]\8?$?X,>-?VF?AGIFH^$_%7@>PUGX0
M6%Q\2M67X6ZV-/?36LN>^*WB#Q#XO\2RZ[>_$3X&_##]F3]MW_@I;^WE?^/-
M=^/OQ>\=?L]_ [XO>!/^"?WPS^&_[&?[+7[.WCCXT_#F&?7K+PAXMN_@C\0?
MC;IG@^YUS1=*^)UI\.=3\+:N^I:?J5UH5[*NO^&_KL!_9*\)G;8\<+NJ[0K0
MOO5=I(4(X'RA7WE-N!\C.H8)7EOQ?^+OPV^!>B^'O$7Q)U^30M/\6?$3X9_"
M+PP(=#UG7K_7?B)\6O&6E> _ 'A?3-(T.RO;V[GUOQ)J]I%--]F^PZ/813Z]
MJMQ8:9I]QJ$'\O/PRUCP]I/[/OP!\&?$7]H#P+X%_P"":W[4_P#P4G^(.C>*
M==^&'CSXZ^ OV;/!'P:^''[*WC.Y/[/W@3]H+XYR^$_%P_9T_:1_;"^%T_B#
M1/$7AW6]$^&'BW3-?UKX9_#C6K[PQXWM=)GZF_\ AC_P3F^,_P 4?^">OPG^
M$(US6?V/_C)_P4<_:3^+'@70_BEXNUC0O@-=:C^S7^RKXC^%E]H/[%US>ZS8
MW.N?"WXO?M'>(O ?Q%\)V^E>(M=T/Q9XR\._$;Q1\-[2+0Y72YI-OIIKT[:_
M@!_2U\8_B_\ #S]GSX>>(/BK\5M;DT#P5X?U'PQH=[?66BZWXBU"\UCQQXNT
M3X?^"O#>DZ)X?T_5M;U36/%?COQ5X=\-:-I>F64L][JNL0J8R)9)UR_"OQU^
M'_C/XY?&;]G?P[?:MJ/Q)^ WA/X3^,/B1$^A7J:!HME\:CXXF\$:5;:_O:SU
M+7[G3? .I:QJFC0AYM)TN\T.]G:.'6;>WA_-W_@L!X-^"GQ8M_\ @G3^SU\=
M5\'Q_#[XP_\ !1WX16FLMX^UVX\+^&WTKX5_"KXQ_%[_ (1IM3&KZ3:7.K^/
M]5\">'_AEH6B7MY)+K-]XP6UTFWFUH6)7\I_C1\#OAG\8?@#^W)^TY'I]Y<?
M%S]H?_@JM\)?V,?V)=9L?%GC73K#X,6_P8^./P,_X)\^#?B+\,].T34HK+1/
M&GAY_AA\5_'X\;V]A<:O?Z)9KH]UJ)T6YU6VNQMIO:R?;2]D!_6[:I+)(DTE
MO)A@1'((V*NC.T@91@[ YA\TA<,3Y)(R8S0(XKEB6C,L311H0H*Y90O[OG;C
M:JC=$0,#>C*-\BM_&/\ M7ZKK?QK^/7[=,_Q@^./[*GAW]IF3]JWQ/\ LP_L
ME^"/'/C3]J36_P!MS]F71H(_"'A?]EKQS^R+^SK\$=1L;T:AXNU:XTG]IN?X
MJ>"_#VHQ>*[;Q/K6G?$GQBW@_P ":QX?T+^RSPS8:Q8Z#H=GXEO[36=?L]&T
MRVU[5[6U:PM-8UZWTZWM]8U>*S$CI:)J6II<7MO;KN\NWG6-W+IDM2TNTNNR
MMV0&H(HQB-+>:-_+VQ-N$:!%)PB89<*I)/EIC&W(&0M3100@*S0Q!@ KDQ@+
MR2)2JMPJ-G'49555CL155&A+  M( &W>7$PCC/;[XPS#'S?-N^;(   K1BBB
M,8.#\O<R,S#&#][CI]..U3)IO1WTZ/U S6B5I8^%91(3G)+JS%,-D;T8# )!
M;)VX("A34S1H0P= ZC"$#EGVME3AB5PI&06&05#?PC%T-;]-V3GJ2Q(. >"1
M[@C'K3DCA+;U&6'!R6ZG)R03C/)/3'-)N]O("HEH8\^7&%W?.?FZ,R[2N2S'
MY1P3GYBQ8L7RQ=Y0D)"&0.,AB[!L@ <8Z<;AT'/OBK4)E.[S<_PXR%'KG[OX
M=:7$4.3G;N)Y))R>,^O7 S0W?M]P#M@9%5QNP!U]0,9XQ[U&&A5\ 8905R0<
M #DC)XQT/Y5(LB.<*P)QG'/3\O>F/!%('# G>"&PS D'MD$8Z#I@\=:0#F):
M,F,\G&#TZ,,]1QP#U%1B-]A9AF89"MD9'/'/ X!/:IU4* HZ 8'.>![FEH C
MC#A?WGWLGN#QVZ8J2BB@ HHHH **** "F"1"<!E)';--E=DVE1G)((P3QCKQ
MT_KFJJ1ARV]F0 ;MV A)).1E@1CV^G/% #'4-(SNX!02*J(V0P8YR3G&XXZ-
MC&2., TL)#MLD#*S[NZMZYR4^13CH!NSGJ,"G*@9BI9E4;L-P-V& 4[L;3N7
M)XX)Y'%/D4*F$G8,NW:%,9. PR,;22",YQ@XSSWIMM_U_7KZ@1N!&S'+F,DA
M?+.XJ6X8$8[OG&#P2.N*;O9?+:,%MK=9FV.25VDLN,XP>&Z'KVIAQ'O8LP#L
M#MPSJIW=47&3E^7/.W+;=N*=E,L/F+*J@$ A20H!!R/N\#//'/([M17?I?37
M>WY/_A@'O<-M<;@Q*$A=N"<@_*N#SGH#SDG SBH4D)4.4,F3D;7C385."K!B
M"QR,],XXP#4F Q9"N=R\'HPR'Z9X'W>,CJ23D4R,*LC,I!"_*8SRJ'&26QG+
ML/FXP.<$4225]7I;M:STOIZ 3NTCXW _*0PPN/H3D]#@\<'CM3., <X(Q^'
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M?$WQ-K5[J/BWP%XVD\0^ ]0$>G6?_"-QV6CZ3;V7P5X$_:L_:]TOP3XGT/\
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MZQXQ\>?$'Q]\3V^'-IKUCX-O_B%X[^)'B?Q=XO\ &&MZ-:>)]=A'B#7]:O\
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M7PV^+EO\/YM8^(?P9DN+CX5VRP1^#M*UY+_QEJO@N&2[\5:39'5 #[X\<_\
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MB?X ZQX(_9W\'V_A#XI_&#PE\0OV</%>M_$SX;_MC?"[X+>"=6\8:/\ #/\
M:MTJ#Q_IVG_#W]I+X1?%.71/!-Y=CX)Z<=*\%0?%70+(^//$^J>'?$%JH!^J
M7A_X _!KPIKGPS\2^&_AUX9T77O@S\+=3^"7PIU/3]/2&?X?_";69/!4FJ>
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M^.[OX=>+-/\ $VH?$KX@>//B/\%/ USIGCN/PS\,5MO%_P ?M%\0>&],\+>
M_AMJ>IRO9@'Z'W?[!?[&>H?'A/VFKW]F;X03_'X:_I_BY_B>_@S2U\17'C72
M[---TGQ_>QI$NE7OQ!TFPA2TTGQY=Z;-XMTRW@BAL-8MTAB"\5^TK^Q'X/\
MVK_CW\ /'7QFLO!GC_X'?!CX:?M%:!JOP4\6^$X?$4'BSXF?&I/A;H?ASQT]
M[>N]IHLOP\\&>%_B%IVDW=A;V_B*UU;QY'J>F:K8O8$R?CW\7/\ @HE\;_CQ
M^R'_ ,%+OV?Y?$_PY\0_%#1+3]E3]EWX0?'_ ."7PM^.G[.ND^)/'/\ P4GU
M>#X/Z!I&G_"KXZ>(/$OCGPYXZ^$-IXNTSQK#XG\._$CQ%HGC'PWXD\,>)-'/
MA?4$N]'MOV*_:K^.GBC]E3X>? #X3?L_^"-%\=_&7XZ_%/P9^RY^SYX?\>ZU
MK$7@G0M1L_ ?BOQAX@^(?Q3UK36OO%FH>"?A?\*/A?XQ\8>(;72(G\2>+-2T
M[2O"UMJ>D77B!]?TP ]E\'_LH_LV^ _!GPG^'G@KX'?#?PYX(^ _C";XC?![
MPUI7A738-,^'WQ%N-/\ %>EWOCWPZGDO+;>-]5L_'7C0:QXLDEF\0:M=>*=?
MU+4-0N=1U6\NYN1^*?["O[''QO\ B;HGQF^,G[,GP,^*'Q5\.QZ1%IWCWQW\
M//#OB7Q"8_#>H2:GX735KG5+*X37D\(ZG<SW_A!-=@U&/PE>W5Q<>'5TR6YF
M:3X]\>_M5?M]_!630_@3XW^&/[./CO\ :1^/W[1>A?!3]D3XF^%I_%O@'X&^
M-O!3?!+Q!\</BU\8/BK\*-0\??$GXH>"-*_9^T'P%X^T;4_#&F_$/5[_ .+&
MO_\ ""V7AW4_!EAXFU'5O#WDWC?]OG]N'X9>!?VS?AY?_"CX7_&;]H;]D7XL
M_LMZ!KOQ0^!GP>^,/B/X8O\  ?\ :3L= \0:[\;+O]E;1OB=XP^-WB+Q7\!?
M"S^+=>\<_ OP3\8M6\1>*]$L?#/B31/$NDZ=KS0Z< ?L1KGPK^&?BCQYX"^*
M7B;X?^#?$7Q+^%T'BRS^'/Q UGPSH^J>,?A]:>.["STOQM!X-\1W=E-JWAB#
MQ5I]C9Z;XA32+JS35+"WCM[X2P*5KD?$G[-_[/OBSPG\6?!'BCX(_"GQ-X-^
M/^OS>*/CAX3\0^!?#6I^&_BUXGFTGPWH/_"2?$32+[3)K'Q;KT6B^"O".EVV
MK:U#=ZC:V7AG0X[:XB.E6;0_@_XW_:0_:S_;!\$?\$\?!7PV_:B_8\UV?X[_
M /!0G4-3\-_&_P" 'A#XXW7PY^-O[.O[*/P<\3_M+RZ]XS^$L7QZ\/>/?A%J
M.E_%KX=Z?\$?C;\ =>^*GC)-3UV_T5M1\3Z9H-WJO@_4?I6T_;E_:]O?V_[W
M]F3Q&W[.OP<MO^%^WWA+X?\ [/GQL^$WQK\)>,OVF?V5]*T+3M6U_P#:/_9M
M_;$@\;7GP4^(GQ6T*SGU/Q1J?[-&E_"2[U[0O#_A_7-#\3^)=$GM'\96K3L!
M^C?A7]C;]DOP)\//&/PB\(?LO_L]>%OA=\1O#FF^$OB-\/M#^$?@2Q\&?$/P
MQH]I>V>FZ/X\\-6VAQZ;XRT^RLM0U&W@7Q+;ZFT<=[>N7:2YGD?N?@W\$/@Q
M^SQX&A^'/P&^$WPV^"G@"RU34M9MO _PH\&>'O OA*/6-5FCEU;5VT;PSI^G
M:=/J^HO!&^I7MQ%+?W!C7SYFCC1$^=?VQ?VIM5_98\7_ +(&IZI<^#M,^"'Q
M2^-OQ8\"?'WQ5XFLM1N;_P (^!_ ?[&G[3?[2MGXDT&\M=7M;33[BQUGX!QI
MK-UJFGZY"^@SWUC!:VU_);W</YG?"K_@JG^TSK?@[31\9? GPR^&'Q,\$_&+
M]I/XP_M(:/'HOB&_TSX&?\$_?V>/@!\.OVF+B+Q(UYXBMVMOC?-:_'_]GKX*
M:KK4T@T*P\::U\0/$%EH-]'X(O-*DKFT3LG?=Z]OGYW^X#]F/'?[,/[+?Q;^
M(7ASXI_$W]G[X ?$KXH^%="U;POX.^)7C[X7?#SQMX\\/:#*;^SUSP[H/BKQ
M#HFI:[IFCH=3U:SU'2K&]2R@_M34K>:WB_M"\6?VW2-"\.:5X8T[PGH6D:#8
M^#=/T*S\/Z3X=TO3=.MO#&G^&K2PCTRQT+3-(LH(]+M?#]GI445C9Z;;6PL8
M-.2.V@B%LL:#^0WXA>/?&5O\'/'7Q#D\ ?#CX=_%WX%?\$/O#UL? WPA\'MX
M#\)>#OV\_P#@N;\9C'?6/AWPC;WUS_9^OQ>._A=H-[J4S:G<:GJ>H?$#4-0O
M;J6ZUAI5_<+]NI(/V,_^"2/QL^'OP>M1:WOP[_93TK]ESX%6,4BPD>.?&WAS
MPY^S+\#["!O-@$<]QXX\6^$+>$(%#W+%25F?+0^X'V3\*_V7/V9?@>UI+\#/
MV?\ X&?",6UMXGLX9?A=\+? _@;9I_CO4M$U[QA:)<>&="TUC8^,-4\,^&]0
M\00+(;;6+C0=%ENUF.EV7D9_P?\ V,_V/_@)J/CG6?@?^S#^SQ\'-8^)EI+I
M_P 0]3^%_P '_A_X'O\ QKI=U<W=Y<:3XHN_#V@:?)KFBSWUW?7;Z/?^=I37
M=U=W!M&FN9V;\5_%_P"VI^T?_P $L=,^*'[,WCK1_A7^TQ8?!G]A_P#9:\8_
MLO>&_@Y\,OB!\/=6T+X@?$'X_P"C?L-_#G]G[Q;H\'BWXT>+?B-X7U_QI=>%
M/%7A?QAX?TRU^(_B#3-#^*=A8^"-7O=/T6VM?J_]AW]K_P#:<^)G[1NH?!CX
MKR7/QD^'.J_ GQ#\5O\ A>>B_L ?M=?L,^%_AA\4O"OCWP?X7U'X,7L7[3%W
MK>F_$?2_'&C>,[CQ'\-M;T+6;+Q99V_P[\9Q>+=)NX;W2;^W /MSP!^PK^Q/
M\)_!/Q&^&OPO_9)_9N^'?@/XOVR6?Q3\%^#O@Q\._#WAKXBV \XV^D^-]%T[
M0+>P\3:+;1W$\6GZ+JT%WIEC;3SV]E:0032(W=_%+]F7]G+X[>(_ _C'XV_
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M0F+5O!6K>(]'U&]\*ZF9XH3%>Z'/8W/G*A63>B;?Q\\(_&C_ (*2>&_V@O\
M@G-X5^*OQC^ >JVW[<NI^._B3\9/@OH/P1N-/O/V<OAQ\*?@GJOQ1UOP;\+/
MB)_PF]UJGCG1CXF\4_#'X8^,_'WQ!T.35I?%U[IGB7PO;>%])\22>#[#U?\
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MS?$O]L#]M+4_V3OCU_P4^^'?Q]\%?#OX%_"GXK>.?#_[.?['2_!GP1XA\/\
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M3>(+#1/B7\3OBE_PISP4O@%] \=:!XNT[[9#JUY8K#X<U7(_:X_;!_;K6/\
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MVGB:;4O/CUK0Q:VZ+JOAJ.75K=DBA>&/ZS_UV2Y*%<[<<97&22&Y/(^GUY-
M%H$,,@@C)&0<\BH9PQ";5+88DX&>QJO&QB4^4GR,25R&)]>2#C'/ P,<@] 3
M(9Y@2/*Q@<'E@W_?)X]?0^HYH (/]9_P!OS#(#^M6ZJ';%^\5@68X*L1A0WS
M'IR/F  SZX.20:L1OO4$XW<AE!^Z1U!&201W!Y'>@!]%!( R2 /4\"DW+C.1
MCUR,?GTH 6BF,WR,R$$@$C'() SCCU_/FF1R%@2^U3G '(XP.?FY.22.F.*
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M?P=8=4/^">GC;XL?#_\ :7\(?MA?M?\ Q5_:%E_:2^"&J_L_7FG>#/"_AKX
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MXG^+-K=?$;7_ (66&E:;XCU?5-4U7PKJ'Q&NOAS?/X);ZN_:-_9NTK]I"?\
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MQE\*M<^"Z:]KEM<(5OO#WA#X;:S!X>\!>& \5AX6A\.>&'M6D?1X"?DW7?\
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MK2;2RC^O(X@R'80FTL6Q\V<X(].@&.G7-1Y&,@CE2" VT\@>G<'IG_&FG;S
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M?_$7AI=1^*WPA\&_$[P%\./$DVJZRD'ACPS\8[CP->?$6VM/#\.H1^';F_\
M$,GPZ\(P/K-]I=SK%E9:;/I^G7UI::IJ<5UZ_*I $189PN&   &XA0!GD#DD
M]@>AQ1+&$18V&_"G#<+@ \\<]1C\OQ!S>2?FV_N]-P/'?BO\&?AO\;]#\/\
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M6(R$$,  ".1G.3G^@I 5T=T+%$W%L;LY4#&<84  9);..N 3S5B*5I"00H
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M^-='M=*TB&S^TKX0_:@^+/\ P4X^$NK_ +.NI_#[PS=_L6_LC>+/&/VCXV>
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M<L>]<*%SD')XXSD\@$\\Y]<G-+'&%5057<JE<@#H>N#@'!X)'<]: /PYO_\
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M:5XQ^'/CFQ\=ZWX6T32[;P#]NT_Q'H>H:W-^LT:E(T0G<54 L?XCCD]NIR>
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MYR2?KBE6-Q*7)&TYP-S'&0,<8QZ]^_M0 R.%U<,67 SD#=SD$=#QU.:L8'7
MSZXI:* "BHVE575"&);&" ,#<2HR<CN/2I* (I)1'MR"=V>X'3'KCUHCF$A(
M (P,\D'OCL34A /4 _4 _P Z JCH /H /Y4 +28'7 SZXI:@:=58KM<D'!(
M(_\ 0J )Z*:K!U# $ C(SU_K33*H<1X;)QR ,<^^<^O;L: )*@DB9W5@P
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MB*LQQA54E0' P2.OIU^GY4B31G:@)S@ 9#=0.A)[^Y/)[FIJ .:\1H'T^Y
MW*T;$G;G 0D#+<9ZCOUXP>1I:?&&TRU"C)^S1A2< G@$'Y0!UY' _K6=X@ -
ME=@\KN@W8_NXRW_CN>G/IS6II0 TVQ _Y]HOU4$]<]Z +42$(P<#YF/&<@@J
MH_7!J5551A0 ,YP/7_(I:* "BBB@ HHHH :S!%+'HH)./04JL& 8=#R,\4,H
M8%6&01@CU!H50H"@8 X H 6BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M.6UO(M/_ +1*W\%QID GU&"6U7U3XK?\%#/V;/@[\/O@C\5O%7B;5+OX<?M
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MV-P]7VCGBIX><:,/QX\<_M(^-_BU9_M8^"?'7QM\5_ #X@S^-_BA9:-^PO\
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M  3-ME#8B_9LU@Y:TEN4,B^ /BU'%.46)XM-(D"!I_M =EF\D_NE$DGL[?\
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M0DT:_N-(U;3)S;:/H?\ ;UK=:-+I%ROV?_P24\??&KQWX,^-%Q\0-4U;QO\
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MY+. H)!Q5/\ P6(^$:;1-^S!^W#&S%@%/P#A."$9P&/_  ERX8X"[,%@S#<
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MZG'<$WY)MVUM;43\7_#5;\5X7_PV<3]?3@YO^NA^N%%?DI_P]L\*DH$_8O\
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MIS_\%7;G:NW_ ()^?\%"I'EXB2'X%V$I8AE#A]GBEVAV@N09(P6"$KU4T?\
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MM\0W"66A>&?"_AK3+O5]>US5KV7$5M8:9IMG<75S</RL<1"AI&5&^7OV*_\
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M_@GX0^,O@;P/K5SX'U>;Q!XS\0:-J]UI&@?$WP=\/M2U>S96XIVOS.VWO/\
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M/BT@L(_#C'E]-_X**7'[*'PM_9R^"\G[1'P8_;V^+7QXM_B]\5/@-\=OB/\
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MKU[=344<&<^:@. H7)SZ[CQZ\?E51A"-[0B[]^:7W<TI6^5ORM7LX?RQ_P#
M(?Y&<8V,IC^T7B^A\Q=I;G(!(Z8&?NBE>WN%P?,E9"Z!"9R6*%6))'E$;@5&
M "1C(.*M"V=90RH N0S?-GG!W'!)/?H../>IS)"0L;G<R@$J 200-I/'OD9&
M1^E#I4M+0B[J[UDM?^W'#ST;?E83I0?1+TC%?HS/>S)7S!(XW 89G+': Q/
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M#H#\W&,\CT//Z5/0 4444 %%%% !5,_:<G!?J<<)TSQW_2KE(S*HRQ '3)H
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M^B?JK\0/VM/V5OA7\4?"?P0^)'[2/P-\ _&3QT^D1>#_ (5^-?BIX-\-^/\
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MR:18QVYAU.:9H.__ &"O^"@TO[?/BK]H+Q+\,=)^!M]^S1\*OBAXR^$GP_\
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M:%K=C\.M=\1>&?&-[X<^QV;7_BBSTS6_"NO6-G?^'8-0M]=>Q^T>'$U6QO\
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MG0 ZBOA;7?\ @HS^R;X;^-MM\ -8^).LVOC6Y^+.A? %O$D?PH^+=Y\%M/\
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M2TOP7XT^%GC[PE\!9[3]H+X$_M"^&;_P%\??B_K?@OPK\#-$^)?P!O\ PMX
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M\$UO#WP__93_ &I- _9^_P""97[!/QF^)&DZO\8/@MK/PN\1_%G]J3PO\"?
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ME^$KS^DGPA^UO\#?B%<_LZ?\(1XQD\3P?M6>#O%_Q$^ ]WIOAOQ4+3QI\/O
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M*=$N;'5[2SN9;??]CU;1-6@CDTSQ#X<U71_$.D75UIFJ6TS>N2Q@*KY+;F&
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MX/Z-XEM?B1I/B"S@\%^+/%OPS\%>$QXK']:%,E3S$*;F3)4AE^\"K!@1[Y%
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MT?#ZSBU'7--\2>*H?B/\0M;U+0H#[UXR_8X_:P\7_"_]KZT;X8:#J'Q&N_\
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MR1R0R+$T,L<B/$\,L4FZ-T:)V1U=65QE6 #$'G/!G@?P+\.](7P]X"\&^%/
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M'#:V>G.(;&PBB!:4Q6UA;VMO&J*3)%%&R(V54H#^=[XD?\%*OVFC\7] \?\
MP<^*&E_$[X(>+?VT_A#^S)\*?A[X+_8?^-D_[.OQ0\!^//VAM!^!7BC6+_\
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M>+PA>_$/7;OQ1K_AOP9-KT]S?:%X'B\1:CJ^LZ7X?6ZNH].O]8U(I</$\<:
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M:5X;A\2^(?%+S>%&L=4\3ZKJ-EJ/@S_A%[NVO;?3]4AE&H6L6HD _/S]G/\
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M>);"VU5?+_VB_P#@FGX2^,7Q0^%']DZ,MO\ "3Q5^V3XL_;<_:XN;KXF^/\
M2/B%XI^+WA?]E74_@)^SYJ?PUU71[C^U/"UU\//%-E\*_'/AX>'O$_A/3_ ^
MK_"30=:T>WU#5KJXDD /S[_;C^,O[8=E\,_^"D?["OBK]HKPM\0_%WBCX5?L
M/^$OA9\9_AY\$H/ OBGP+K?_  4H_:.\;_LGZW\!M1\(VWQ!UC2M0O;'0]&C
M\7_#WQBGB*V^(OA;PCXIOM:UN;Q3>Z!8^(-0_63]HCXD_%3]CG]C7PTO@U?
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M_C;H7AKXD? ?]D;P'^QK_P $V_@-^TU^T_K7@K]F'PQJ&KV_[:GQT\&?%_\
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M%I%EH%IKOC_XH?$C7?$WC;Q--I.A:?9Z'H&GWVL'1?#&C6R:3X;TW2].S;L
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MCD$CD?0]J %HHHH **** "BBB@ J"=78+M7=@DGD#MCO]:GIK.J8W,!G@9H
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MCXNO!XML[#1_'S_ N7X3>$_ACX+LO$MCHMOXMG\6+X7MM"TM-1.L262^:O\
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MGT[0?AIX5^$O@*R\9_#OX?\ @NVTWQ/JZ^$/%D%AKOCG7-0TVZU'6,WXA_\
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MEOC"UOM:\4:%^MVA_"C4/!'P$L?@OX#\:>(=-U/PW\*6^'?A+XE>(K/3=?\
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M@#P[+\0OB9KK0?$G6O%?A>_\12>*/%VOZZVH>"+%WURYT=]&\.^#P"+]H/\
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MOX5^.'B3]H#P?^ROX9;X>>#_  ]I7C'Q3\1-6^+.H>"=7^,7A/PKI/QD\2_
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M#KX>SWW[8OQ0\0?M5?"[]HRX_:C\"?M&>,O OA?Q!X(\,^/M4^%_BCX$ZKX
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M HR>">/H*%8,,@Y'T([ ]\=B*&4,I4]&&#]#UI%4(,#./<Y[ =?H* '4444
M,61')"G)'7AACG'<#O3Z8L:H25SD]<DGOGO[Y_,T^@ JLP*S>8PPBD?-D'JA
M4#:/F/S,1T/7T'%FFLH<%3T..AQT((Y^HH 56# ,IR#GL1T.#P<'J*6FJH0!
M1G SC)SU.3S]2:=0 4QI$0X8XR,]&/ ^@-/)P"3T')J$K%-SG=@8X)& >><>
MM $6+D@8SC'&63?GON(^4CTQD^^#5A'5OE!)91\W!ZC@\D 'D'I50S2X)W#
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M7 \OCCWZ'_\ 54.X#C)W!E4+\A!!]MP<^^!GGC-2,[N220 <94#IC&.2-PZ
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ME/0^H_0_2L3PN,::HW,V+J;ESN;E">N!P,X [ 8H Z9AN5ESC<",_48JL+8
M@[^A!^XO:K5% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M%LXQUQQ@?2JZ3I&FSJ5#':.21EFXXY^7GK^M.^U# .P@,.!GYL]/F7&57/\
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M#%4E1]S^6Y)R25^YC<Q).2/48QS[G@5:\^+^^/U_PI4C1260?>'7)Z'GH?\
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M #GD,O)P3S0!/YL8_C7\Z21FV;HN22,8&>._'^?ZU$D$055R00H!57X4@ $
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M!G[Z]^M %+H2#D$ D<,P;#[.!GUY[X'N*;)*L90.&P^2-@:0X7D[EC#,,C.
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MHHH :[A!N;.,@<#)R:%8.H89P<]>#P2#^HI656&&&1Z4*H4  8 Z"@!:***
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ )P"?09IJL'4,.AZ9IQ&00>AX-( %  & .
M* %HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH :R(QRR@D<<C-.HHH *8[B, D$@G' SS@GI] :?4<GE[1YF-N
M>,YZX/I[9H 9(^8@ZDKDK@]#@G%0A)9%SN)4[N"W<9 R,=F /4].,U9"QN@
M *=0.<?XT]5"@*HP!T'U.?YT 1PJR)M;KN8\'( )) 'L!QC I6D56"'.6QC
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M9[@>F>88BF#YQ0DC;P&SM!R 1CUYSC))XI 72%<#(#*<$9Y'3@_D:8Z';^[
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M]./>G/$KL&.[( '!P."2/U-24 98! (W!\@@8YQCL<*.N>I]*TU^ZOT'\JH
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M.0.1ANA&>XZXH LQDM&I;DD9/ [^WM2+$BL748)SW..0 >,X["DC(6)-WRX
M!W<8/OGI[9I6;Y&:,AB.FWYLGTXH DHJ.)G9<N"#D\%2O';@TXLJG!903T!(
M!_(F@!U%%% !1110 A('4@9Z9.,UEI+-"UP[!)%,C"%4BFW!%(Y<J9?,+,6(
MD2.)%QMVD\U<N,83(S\Q[9XQ_CC]*@64Q;F$;/PHVH/F/.. <#"@Y/? X!H
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MUH ;$Y=<L,')&.1T^O-(\0=@VX@@ 8&,?*21U'J:6*0R('( SV!SC@>H%24
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% #)'V*6QG&.,XZD#K^-"/O4-C&<\9
MST)'7\*>0",$ CT/(H  &  !Z#@4 %%%% !1110 4444 %%1R*SKA3@Y!SDC
MI].:CC?:PA;)89RV<CD%QU.[@''/>@"Q141F D\O!SD#.1CD ^N>A].M2T %
M02PF0@Y P,<@GO[$=*GHH .E4%B\QI "!SZ$]),]B/[N.,=<]JOU4,$F20RC
M))XW \DGG!'K0 NPPDR$AAD@*.#\[#N>./I42R_.\N. Q4J3M.3M'RY'S*,#
MYN!R>F.6/\C+&3D,23]TDN"0>0@8 \[69^.K$FG*P5@74':BH5)4X(!YY./X
ML<&@"WYH\KS=OX9'][;UZ>].C?S%W8QR1C(/3Z4(5= 0H"G/RX&."0>G'49J
M-Y5C)79TP>-H'/U(]#0!/13(Y!("0",''.#V![9'>GT 4'B>+&U$EW9SD'C;
MCWZMNYZ?=XIXMCE&W+P0WW2">/K@?E@>E7** (9(B\0C#!2 O)4,.!Z-_/J/
MS%0QJ%GQP3M<Y "]"%^Z.!WQC@^F:6 YE89)&'XR3T=0."?3I5K SG SZX&?
MSH J*!]I]][=_P#8.?UJT[;%+8S@9QTI=JYS@9]<#/Y]:4@'@C(]#0!66X#,
MJ[.I ^\IZG'059INU1T5?R'^%.H **** "BBB@ J%#$Y*A "O7*J.^/QYSTJ
M:HCY<7.W!;CY023W[4 $J%D4( "K @'@  $=OKP.*K1KB4*P!.2K#JIPI88S
MV!P1D9!J5696+N3Y;YV<[NIW+\H&1\H/7]*60(4,J##$J0P&&^9@#^8)% $K
M;$4E@H4=>!CK_C5&4J29%51$%;=(00HP,%LA@H P<DKP.@/<+MD R'YL@*64
MDXZY4@\=^>V#W%-<;@HPY;=@D,$4 G +#[K+CJH!)/;M0G;5 *3D_)C:VUD(
M\LH,X )!1L_,N3@C@#H>:B4.7D1L!V;&X$LN I(S&?D&0"1C=@_7-66C<AV0
MQ@*#MRH+ A0>#T'/3/0\]*8-N_;M9I 225;;@@G!)/#$*PZ=!QDG@'F!%&)%
M14PK*&4Y<[B1SD,2,D<]R2>A]:>?ODCY4VX R%YR.<,0,]?4]^AHX !(9\ 8
M56"JV>NXGC  &,CN:<0 '.  L@'(!P"J@#D$8#-3;N[]P!D* 2%5!8A047(V
MD$Y;RUY.0#G!!R<'&*E@^\4?YAR%!R5^5R>A'&T$ 9 QT%-<R)&-Y;!<@8.?
ME()4?+T& /\ )Q4T?EI&DA7G:!NP2>1CGO[4@)60%-@& <# P.,@D#C'3/:N
M-\-?:1?ZRDGD"-+O,016WM$6()D;Y1O!! X;Y=HR<<=HK!@&'0\C/%<=X?0G
M4]8;=(/WZ\!@$XE?.1UY[XQGGKG@ [*BD)"@D] "3]!R:1'5P2N< XY!'. >
MA]B* '444QY%CQNSSG& 3TQGI]10 ^B@'(!]1FB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *3:N<[1G.<X&<GCKUZ
M<?3CI4!6;<Y!.TAMOS#@\8XXQWID1E$K)(Q/WFP2"-IX7UQT;@>U %K:N<[1
MGKG SG&,YZ]./I2T44 5Y8Y&<%#@!0,;B.<D]!]1]>E02"2.(!F.X \AB>0K
MG(Z'TY_PJ_361'^\H;MS0!77="Q,A)#D*H!+#).,G.,#G]:L@Y (Z$ _G2,B
MOC<H.#D9['VIU $;[%!=E!Z G:">2!]3S@GZ=SBHXWA<A5C ^]U10/E)!Z>_
M\Q36CG9F&1M).-^&7&[(&WJ#TY[4U4:%@[8"@D' W;BV?N <H"2"0<]P,<9
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MO(B$!B>03P">!]*DH **** "HY!&0/,'&>/O=?\ @/-24QXTD #JK@'(#*K
M'&.C CO0 %$=%4C*  @9(X P.X/3U_'FJQ8!_+8XAR1MQV )'S#YN&4]\\<\
M4%Y4.T?*@)5/D&,#.T _[H]!TH= T2RYPYP=Q^[EB<Y P/XC]* !_(V@)C<
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M8!/)R<#\SQ3J *\"LN[<I'" 9QSC=GH3ZBFV\;(S94KE0,DYR03GN?7BK5%
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M5'10!^0Q0 M%%% ";ESC<,^F1GGIQ2U$8@9!)DY&.,#''X9_R/05+0 4444
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M[8DD8HN0 ?KG'0D=/< ?C51D)03%C\Y!*;00-QZ=,\#\R,GKB@"X&4\!E)]
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M"4)!RZ)M#?*^<X)XD/9, Y4@\9)X)%,9PLFPL(W9OW>[G VD#Y/4Y)1L]#C
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M5?V4?B1^UAI\WC_P?=WVE_MH?L,? #X@_!SX0>"=-TO3];NK+Q7:>-=9\4_
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MPQ\/Z=K>L^"OA=XCT.34O"_Q!L])UW0O$EI=ZC8S^)K"ROM*UFTO-.U"X@F
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M?YC%)/+$50^9QDX* -SC!R,C&,_SXJM%)*"P"",<D-G<6R1G(/ )X/'3& *
M- 2HSE ?F&01@]C@\U5E$DCM&#N&[.UF*K@ '[RC=D$C&#]:@>=HFC9!YA=G
M$A.0L>220<#J#QD ]^, 9?%(P E?)8A\E%SENP ('0+D\=!SZT[-J^G;?7Y
M64188P[J%9<Y*L[XRQ P6Y/![],GM4C/NB=XSR%;!QC! ST/I5!IIBA=]ZQ!
ME.2(\E!][>@0N,,.-IR>"?ES4@=MFU3\C)NQMY*LH+-EL,!DGJ,^U#5NWR L
MQ297#-EMQ'/7MC&/8C\<U/6>(RS*P#':R@D'@8()R,\\'T-6X3(5/F<-N;'
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M(F7#.S.-^"HZOU&2?N83K[CM5>;+.(PZQQHA>0'>&=V^[N:-=VW/7:=W!YZ
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MK3N<%6RWRD ]1S\P8^A[=\#K5V@ J%Y2LBH "#MR<\C<Q7@8[8S2/-L8J4)
M )((Z'V/T/&:@>169) " #@@]O+#29XSP1QTR.N#T(!9DB$C*V[&WM@'/.>_
M^?UI)9EC9$ZL^XJ.?X<9Z#W_ )GM4?VG/1,_1C_[,J_IFHWD\V2),;&._:?X
MAC9G:XSM_(Y('3'(!>HK/CC\QE(PNT*QXZY(/'_?/KW_ !JZ3Y:KG'&%YR!T
M]@Q[>GXT .R/4?F*A$Q,OEX&,D9!/0 G/3'MUZU78DLYVQG&UL[2<[R0.>.F
M.3CGT%3PRJV$ &5!W8& #UPHYSU]OZ4 6***B>38Z+MSN(&<XQE@O3';(^M
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MR,@:20*")(^JC! =3PI.2>A'(P:TMC.C2[ERH/5<\QDD<9Z' X].,]ZSGO\
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?N,'/]W/XT 6J*CCD\P'Y2N#CD@]L]JDH **** /_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
